var images_info;if (!images_info) images_info =[]; images_info["80"]={"80000":{"type":"graphic_table","displayName":"Radiation therapy for esophageal cancer","title":"Schema for definitive and palliative treatment for esophageal cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Schema for definitive and palliative treatment for esophageal cancer</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Suggested scheme for definitive treatment</td> </tr> <tr> <td class=\"subtitle2_single\">External beam radiotherapy (EBRT)</td> </tr> <tr> <td class=\"indent1\">45 to 50 Gy in 1.8 to 2.0 Gy fractions, five times a week with concurrent chemotherapy followed by brachytherapy</td> </tr> <tr> <td class=\"indent1\">Brachytherapy after EBRT and not concurrent with chemotherapy</td> </tr> <tr> <td class=\"indent1\">HDR: total dose of 10 Gy, 5 Gy fractions,&nbsp;one fraction per week starting&nbsp;two to three&nbsp;weeks following completion of EBRT</td> </tr> <tr> <td class=\"indent1\">LDR: total dose of 20 Gy single course, 0.4 to 1.0 Gy per hour starting&nbsp;two to three&nbsp;weeks after completion of EBRT</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Suggested scheme for palliative treatment</td> </tr> <tr> <td class=\"subtitle2_single\">Recurrence after EBRT or short life expectancy</td> </tr> <tr> <td class=\"indent1\">Brachytherapy* (HDR: 10 to 14 Gy in one to two fractions or LDR: 20 to 40 Gy in one to two fractions at 0.4 to 1.0 Gy per hour)</td> </tr> <tr> <td class=\"subtitle2_single\">No previous EBRT</td> </tr> <tr> <td class=\"indent1\">EBRT 30 to 40 Gy in two to three&nbsp;Gy fractions followed by brachytherapy* (HDR: 10 to 14 Gy in one to two fractions or LDR: 20 to 25 Gy in a single course at 0.4 to 1.0 Gy per hour)</td> </tr> <tr> <td class=\"subtitle2_single\">No previous EBRT and life expectancy &#62;6 months</td> </tr> <tr> <td class=\"indent1\">Guidelines similar to those for definitive therapy above</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Gy: gray; HDR: high-dose rate; LDR: low-dose rate.<BR>* All brachytherapy doses specified 1 cm from midsource/mid-dwell position. Applicator diameter of 6&nbsp;to 10 mm is recommended.</div><div class=\"graphic_reference\">Adapted from Gaspar LE, Nag S, Herskovic,A, et al. American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer. Int J Radiat Oncol Biol Phys 1997; 38:127.</div><div id=\"graphicVersion\">Graphic 80000 Version 5.0</div></div></div>"},"80001":{"type":"graphic_table","displayName":"Cambridge depersonalization scale","title":"Cambridge depersonalization scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cambridge depersonalization scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle2_left\">Name:</td> <td class=\"subtitle2_left\">Age:</td> <td class=\"subtitle2_left\"> <p>Sex: Male / female</p> <em>(please circle as required)</em></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\"> <p>Schooling: Primary / secondary / higher (eg, university)</p> <em>(please circle as required)</em></td> </tr> <tr> <td class=\"subtitle1\" colspan=\"3\">Please read instructions carefully:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\" colspan=\"3\">This questionnaire describes strange and 'funny' experiences that normal people may have in their daily life. We are interested in their: (a) <strong>frequency</strong>, ie, how often you have had these experiences <strong><em>over the last six months</em></strong> and (b) their approximate <strong>duration</strong>. For each question, please circle the answers that suit you best. If you are not sure, give your best guess.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">1. Out of the blue, I feel strange, as if I were not real or as if I were cut off from the world.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">2. What I see looks 'flat' or 'lifeless', as if I were looking at a picture.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">3. Parts of my body feel as if they didn't belong to me.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">4. I have found myself <em>not being frightened at all</em> in situations which normally I would find frightening or distressing.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">5. My favourite activities are no longer enjoyable.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">6. Whilst doing something I have the feeling of being a \"detached observer\" of myself.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">7. The flavour of meals no longer gives me a feeling of pleasure or distaste.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">8. My body feels very light, as if it were floating on air.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">9. When I weep or laugh, I do not seem <em>to feel</em> any emotions at all.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">10. I have the feeling of <em>not having any thoughts at all</em>, so that when I speak it feels as if my words were being uttered by an 'automaton'.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">11. Familiar voices (including my own) sound remote and unreal.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">12. I have the feeling that my hands or my feet have become larger or smaller.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">13. My surroundings feel detached or unreal, as if there was a veil between me and the outside world.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">14. It seems as if things that I have recently done had taken place a long time ago. For example anything which I have done this morning feels as if it were done weeks ago.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">15. Whilst fully awake I have \"visions\" in which I can <em>see</em> myself outside, as if I were looking my image in a mirror.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">16. I feel detached from memories of things that have happened to me - as if I had not been involved in them.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">17. When in a new situation, it feels as if I have been through it before.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">18. Out of the blue, I find myself not feeling any affection towards my family and close friends.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">19. Objects around me seem to look smaller or further away.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">20. I cannot feel properly the objects that I touch with my hands for, it feels <em>as if it were not me</em> who were touching it.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">21. I do not seem able to picture things in my mind, for example, the face of a close friend or a familiar place.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">22. When a part of my body hurts, I feel so detached from the pain that if feels as if it were 'somebody else's pain.'</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">23. I have the feeling of being outside my body.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">24. When I move it doesn't feel as if I were in charge of the movements, so that I feel 'automatic' and mechanical as if I were a 'robot'.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">25. The smell of things no longer gives me a feeling of pleasure or dislike.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">26. I feel so detached from my thoughts that they seem to have a 'life' of their own.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">27. I have to touch myself to make sure that I have a body or a real existence.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">28. <em>I seem to have lost</em> some bodily sensations (eg, of hunger and thirst) so that when I eat or drink, it feels an automatic routine.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">29. Previously familiar places look unfamiliar, as if I had never seen them before.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Frequency</strong></p> <p>0 = Never</p> <p>1 = Rarely</p> <p>2 = Often</p> <p>3 = Very often</p> <p>4 = All the time</p> </td> <td colspan=\"2\"> <p><strong>Duration</strong><br /> <strong>In general, it lasts:</strong></p> <p>1 = Few seconds</p> <p>2 = Few minutes</p> <p>3 = Few hours</p> <p>4 = About a day</p> <p>5 = More than a day</p> <p>6 = More than a week</p> </td> </tr> <tr> <td class=\"subtitle1\" colspan=\"3\">Thank you for answering all the questions!!</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Sierra M, Berrios GE. The Cambridge Depersonalization Scale: a new instrument for the measurement of depersonalization. Psychiatry Res 2000; 93:153. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 80001 Version 1.0</div></div></div>"},"80005":{"type":"graphic_picture","displayName":"Sexual maturity rating of pubic hair and genitalia in boys","title":"Sexual maturity rating (Tanner staging) of pubic hair and external genitalia development in boys","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Sexual maturity rating (Tanner staging) of pubic hair and external genitalia development in boys</div><div class=\"cntnt\"><img style=\"width:478px; height:764px;\" src=\"images/PEDS/80005_Pubic_hair_boys.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stages of pubic hair development in boys:&#xD;&#xA;<ul class=\"decimal_heading\">&#xD;&#xA;    <li>Stage 1: Prepubertal, with no pubic hair. </li>&#xD;&#xA;    <li>Stage 2: Sparse, straight pubic hair along the base of the penis.</li>&#xD;&#xA;    <li>Stage 3: Hair is darker, coarser, and curlier, extending over the mid-pubis.</li>&#xD;&#xA;    <li>Stage 4: Hair is adult-like in appearance, but does not extend to thighs. </li>&#xD;&#xA;    <li>Stage 5: Hair is adult in appearance, extending from thigh to thigh.</li>&#xD;&#xA;</ul>&#xD;&#xA;Stages of external genitalia development in boys:&#xD;&#xA;<ul class=\"decimal_heading\">&#xD;&#xA;    <li>Stage 1: Prepubertal.</li>&#xD;&#xA;    <li>Stage 2: Enlargement of testes and scrotum; scrotal skin reddens and changes in texture.</li>&#xD;&#xA;    <li>Stage 3: Enlargement of penis (length at first); further growth of testes.</li>&#xD;&#xA;    <li>Stage 4: Increased size of penis with growth in breadth and development of glans; testes and scrotum larger, scrotal skin darker.</li>&#xD;&#xA;    <li>Stage 5: Adult genitalia.</li>&#xD;&#xA;</ul></div><div class=\"graphic_reference\">Figure from: Roede MJ, van Wieringen JC. Growth diagrams 1980: Netherlands third nation-wide survey. Tijdschr Soc Gezondheids 1985; 63:1. Reproduced with permission from the author.</div><div id=\"graphicVersion\">Graphic 80005 Version 6.0</div></div></div>"},"80006":{"type":"graphic_table","displayName":"Liver test normal pregnancy","title":"Liver tests in normal pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Liver tests in normal pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">Liver tests affected by pregnancy (these tests are increased or decreased in relation to values in non-pregnant women)</td> </tr> <tr> <td class=\"indent1\">Albumin and total protein (decreased from the first trimester)</td> </tr> <tr> <td class=\"indent1\">Alkaline phophatase levels (increased in second and third trimester)</td> </tr> <tr> <td class=\"indent1\">Bilirubin levels (slightly decreased from the first trimester)</td> </tr> <tr> <td class=\"indent1\">Gamma glutamyltransferase levels (slightly decreased in late pregnancy)</td> </tr> <tr> <td class=\"subtitle2_left\">Liver tests not affected by pregnancy</td> </tr> <tr> <td class=\"indent1\">Serum aminotransferase levels (ALT, AST)</td> </tr> <tr> <td class=\"indent1\">Prothrombin time</td> </tr> <tr> <td class=\"indent1\">Serum concentration of total bile acids (fasting state)</td> </tr> <tr> <td class=\"indent1\">Lactate dehydrogenase (LDH)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80006 Version 3.0</div></div></div>"},"80011":{"type":"graphic_table","displayName":"Preoperative physical status","title":"Physical status classification, American Society of Anesthesiologists","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical status classification, American Society of Anesthesiologists</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Code</td>\n\n      <td class=\"subtitle1\">Patient's Preoperative\nPhysical Status</td>\n\n    </tr>\n\n    <tr>\n\n      <td>1</td>\n\n      <td>Normally healthy patient</td>\n\n    </tr>\n\n    <tr>\n\n      <td>2</td>\n\n      <td>Patient with mild systemic disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>3</td>\n\n      <td>Patient with severe systemic disease that is not\nincapacitating</td>\n\n    </tr>\n\n    <tr>\n\n      <td>4</td>\n\n      <td>Patient with an incapacitating systemic disease that is\na constant threat to life</td>\n\n    </tr>\n\n    <tr>\n\n      <td>5</td>\n\n      <td>Moribund patient who is not expected to survive for 24\nhours with or without operation</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">8.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=32365&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Preoperative_physical_statu.htm</title></head></div><div class=\"graphic_footnotes\">The above is the version of the ASA Physical Status Classification System that was current at the time of development of, and still is used in, the NNIS Risk Index. Meanwhile, the American Society of Anesthesiologists has revised their classification system; the most recent version is available at http://www.asahq.org/profinfo/physicalstatus.html.</div><div class=\"graphic_reference\">Anonymous. New classification of physical status. Anesthesiology 1963; 24:-111.</div><div id=\"graphicVersion\">Graphic 80011 Version 1.0</div></div></div>"},"80013":{"type":"graphic_figure","displayName":"ASO hybridization and dot blot","title":"Allele specific oligonucleotide (ASO) hybridization and dot-blot analysis","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Allele specific oligonucleotide (ASO) hybridization and dot-blot analysis</div><div class=\"cntnt\"><img style=\"width:499px; height:263px;\" src=\"images/PC/80013_ASO_hybridization_and_dot_b.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This representation of ASO hybridization with dot blot analysis shows how this technique can be used to distinguish between an individual who is homozygous for a normal gene from individuals homozygous or heterozygous for a mutation in this gene. Patient DNA is red, and probes are green. In this case a normal gene is detected by a probe with the normal sequence, and a mutant gene is detected by a probe with a mutant sequence. The point mutation is denoted by an \"X\".<br />Box 1: the normal probe is hybridized to spots of DNA \"dotted\" from a normal individual, an individual homozygous for the mutation, and an individual heterozygous for the mutation. The probe gives a signal for the normal and heterozygous individuals, but not the homozygous individual (who lacks the normal gene).<br />Box 2: the mutant probe is hybridized to spots of DNA \"dotted\" from a normal individual, an individual homozygous for the mutation, and an individual heterozygous for the mutation. The probe gives a signal for the homozygous and heterozygous individuals but not the normal individual (who lacks the mutant gene).</div><div class=\"graphic_footnotes\">ASO: allele specific oligonucleotide.</div><div id=\"graphicVersion\">Graphic 80013 Version 2.0</div></div></div>"},"80014":{"type":"graphic_figure","displayName":"CCK releasing factor regulation","title":"Model for regulation of CCK release by an intraluminal releasing factor","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Model for regulation of CCK release by an intraluminal releasing factor</div><div class=\"cntnt\"><img style=\"width:492px; height:308px;\" src=\"images/GAST/80014_CCK_releasing_factor_regula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A luminal cholecystokinin (CCK) releasing factor (LCRF) stimulates intestinal CCK secretion. LCRF is normally secreted in the intestinal lumen, where it is exposed to pancreatic enzymes, such as trypsin. Under basal conditions, LCRF is inactivated by even small amounts of pancreatic enzymes. However, following a meal, food competes for enzyme binding, allowing LCRF to interact with CCK cells to stimulate hormone secretion. CCK in the circulation stimulates pancreatic secretion that, upon digestion of food, restores LCRF and CCK secretion to basal levels.</div><div class=\"graphic_reference\">Adapted from: Liddle RA. Am J Physiol 1995; 269:G319.</div><div id=\"graphicVersion\">Graphic 80014 Version 2.0</div></div></div>"},"80015":{"type":"graphic_picture","displayName":"Fibrosing cholestatic hepatitis","title":"Fibrosing cholestatic hepatitis after liver transplantation for hepatitis B virus","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Fibrosing cholestatic hepatitis after liver transplantation for hepatitis B virus</div><div class=\"cntnt\"><img style=\"width:474px; height:346px;\" src=\"images/GAST/80015_Fibrosing_cholestatic_hepat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fibrosing cholestatic hepatitis in a patient six months after liver transplantation for cirrhosis due to hepatitis B virus.<br />(A) Balloon degeneration of hepatocytes, periportal fibrosis, and marked cholestasis but minimal inflammation.<br />(B) Immunohistochemical staining reveals intense and widespread accumulation of HBsAg and HBcAg.</div><div class=\"graphic_reference\">Courtesy Robert J Fontana, MD.</div><div id=\"graphicVersion\">Graphic 80015 Version 3.0</div></div></div>"},"80017":{"type":"graphic_waveform","displayName":"EP study tracings RBB ablation for BBRVT","title":"Intracardiac and surface ECG tracings during radiofrequency catheter ablation of the right bundle branch in a patient with BBRVT","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Intracardiac and surface ECG tracings during radiofrequency catheter ablation of the right bundle branch in a patient with BBRVT</div><div class=\"cntnt\"><img style=\"width:519px; height:364px;\" src=\"images/CARD/80017_Ablation_RBB_reentrant_VT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown are five surface ECG leads (I, II, aVF, V1, V6) and intracardiac recordings from the His bundle region (HBE2-3,1-2), the right ventricular apex (RVA3-4), and a mapping catheter (USER1) positioned distal to the His catheter along the RV septum. Application of radiofrequency (RF) energy to the tip of the mapping catheter causes two accelerated beats with a typical left bundle branch block (LBBB) morphology (black arrow), likely from heating and activating the right bundle branch. After these beats, complete right bundle branch block (RBBB) is present (red arrow), as evidenced by the change in QRS morphology, particularly in lead V1. Following right bundle branch ablation, the HV interval increased to 105 ms, though no infranodal A-V block was noted. Right bundle branch reentrant tachycardia was no longer inducible. A permanent pacemaker was placed becaued of the markedly prolonged HV interval.</div><div class=\"graphic_footnotes\">H: His bundle electrogram; A: atrial electrogram; V: ventricular electrogram.</div><div id=\"graphicVersion\">Graphic 80017 Version 5.0</div></div></div>"},"80018":{"type":"graphic_picture","displayName":"Chronic pancreatitis Light","title":"Chronic pancreatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic pancreatitis</div><div class=\"cntnt\"><img style=\"width:380px; height:259px;\" src=\"images/GAST/80018_Chronic_pancreatitis_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph from a patient with chronic pancreatitis. There are bands of fibrosis (stained in red) and scattered mononuclear cells.</div><div class=\"graphic_reference\">Courtesy of Steven D Freedman, MD, PhD.</div><div id=\"graphicVersion\">Graphic 80018 Version 2.0</div></div></div>"},"80019":{"type":"graphic_table","displayName":"Empiric intravenous antibiotic therapy for human bite wounds","title":"Empiric intravenous antibiotic therapy for human bite wounds","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Empiric intravenous antibiotic therapy for human bite wounds</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antibiotic</td> <td class=\"subtitle1\">Dosing for adults</td> <td class=\"subtitle1\">Dosing for children</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Agents of choice for empiric coverage include:</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Monotherapy with a beta-lactam/beta-lactamase inhibitor, such as one of the following:</td> </tr> <tr> <td class=\"sublist2\">Ampicillin-sulbactam</td> <td class=\"sublist_other\">3 g every&nbsp;6 hours</td> <td class=\"sublist_other\">50 mg/kg per dose (based on ampicillin component) every&nbsp;6 hours*</td> </tr> <tr> <td class=\"sublist2\">Piperacillin-tazobactam</td> <td class=\"sublist_other\">4.5 g every&nbsp;8 hours</td> <td class=\"sublist_other\">125 mg/kg per dose (based on piperacillin component) every&nbsp;8 hours*</td> </tr> <tr> <td class=\"sublist2\">Ticarcillin-clavulanate</td> <td class=\"sublist_other\">3.1 g every&nbsp;4 hours</td> <td class=\"sublist_other\">50 mg/kg per dose (based on ticarcillin component) every&nbsp;4 hours*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>A third-generation cephalosporin such as ceftriaxone</p> <p><strong>PLUS</strong> </p> Metronidazole</td> <td> <p>1 g every 24 hours</p> <p><strong>PLUS</strong> </p> 500 mg every&nbsp;8 hours</td> <td> <p>100 mg/kg per dose every 24 hours (maximum 1 g per dose) </p> <p><strong>PLUS</strong> </p> 10 mg/kg per dose every&nbsp;8 hours (maximum 500 mg per dose)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Alternative empiric regimens include:</td> </tr> <tr> <td class=\"indent1\"> <p>A fluoroquinolone such as levofloxacin</p> <p><strong>PLUS</strong> </p> Metronidazole</td> <td> <p>500 mg daily</p> <p><strong>PLUS</strong> </p> 500 mg every&nbsp;8 hours</td> <td>Use fluoroquinolones with caution in children &#60;18 years of age</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Monotherapy with a carbapenem<sup>&#182;</sup>, such as one of the following:</td> </tr> <tr> <td class=\"sublist2\">Imipenem-cilastatin</td> <td class=\"sublist_other\">500 mg every&nbsp;6 hours</td> <td class=\"sublist_other\">25 mg/kg per dose every&nbsp;6 hours (maximum 500 mg per dose)</td> </tr> <tr> <td class=\"sublist2\">Meropenem</td> <td class=\"sublist_other\">1 g every 8 hours</td> <td class=\"sublist_other\">20 mg/kg per dose every 8 hours (maximum 1 g per dose)</td> </tr> <tr> <td class=\"sublist2\">Ertapenem</td> <td class=\"sublist_other\">1 g daily</td> <td class=\"sublist_other\">15 mg/kg per dose every&nbsp;12 hours for children up to 12 years of age (maximum 500 mg per dose)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Maximum pediatric dose: see adult dose.<br />¶ Carbapenems should not be used for patients with history of immediate-type hypersensitivity to beta-lactams.</div><div id=\"graphicVersion\">Graphic 80019 Version 4.0</div></div></div>"},"80020":{"type":"graphic_figure","displayName":"Oxygen face masks","title":"Venturi face masks","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Venturi face masks</div><div class=\"cntnt\"><img style=\"width:451px; height:424px;\" src=\"images/PULM/80020_Oxygen_face_masks.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High flow Venturi oxygen masks yield a precise fraction of inspired oxygen by use of a Venturi valve. The size of the valve aperture ensures that specific proportions of oxygen and entrained air are mixed to obtain a fixed oxygen concentration in quantities that exceed the full ventilatory requirement. In contrast, low flow oxygen masks do not provide the entire ventilatory requirement because air is drawn in through the loosely fitting mask in an uncontrolled fashion to supplement the oxygen flow rate.</div><div class=\"graphic_reference\">Adapted from Bateman, NT, Leach, RM, BMJ 1998; 317:798.</div><div id=\"graphicVersion\">Graphic 80020 Version 1.0</div></div></div>"},"80021":{"type":"graphic_figure","displayName":"Equipment for LEEP","title":"Equipment for loop electrosurgical excision procedure (LEEP) of uterine cervix","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Equipment for loop electrosurgical excision procedure (LEEP) of uterine cervix</div><div class=\"cntnt\"><img style=\"width:486px; height:455px;\" src=\"images/OBGYN/80021_Equipment_for_LEEP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A-E) Loops of various sizes and (F) an electrosurgical generator.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 80021 Version 2.0</div></div></div>"},"80026":{"type":"graphic_figure","displayName":"Insulin plus oral hypoglycemics","title":"Combination insulin and oral hypoglycemic therapy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Combination insulin and oral hypoglycemic therapy</div><div class=\"cntnt\"><img style=\"width:334px; height:762px;\" src=\"images/ENDO/80026_Insulin_plus_oral_hypoglyce.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this study, 96 patients who were inadequately controlled with a sulfonylurea drug alone were randomly assigned to receive bedtime intermediate-acting insulin (BI) plus either glyburide, metformin, glyburide plus metformin, or a second injection of intermediate-acting insulin in the morning. After 12 months, the group receiving bedtime insulin plus metformin alone had significantly less weight gain (A) and lower A1C values (B) than the other three treatment groups.</div><div class=\"graphic_footnotes\">BI: bedtime intermediate-acting insulin; A1C: glycated hemoglobin.</div><div class=\"graphic_reference\">Redrawn from Yki-Jarvinen H, Ryysy L, Nikkila K, et al, Ann Intern Med 1999; 130:389.</div><div id=\"graphicVersion\">Graphic 80026 Version 3.0</div></div></div>"},"80029":{"type":"graphic_picture","displayName":"Vascular amyloidosis","title":"Vascular renal amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vascular renal amyloidosis</div><div class=\"cntnt\"><img style=\"width:378px; height:268px;\" src=\"images/NEPH/80029_Vascularamyloidosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph showing renal amyloidosis limited to the vasculature. Amorphous pink-staining material has infiltrated into the walls of multiple blood vessels (arrows), while the sole glomerulus in this section appears to be spared.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 80029 Version 2.0</div></div></div>"},"80031":{"type":"graphic_diagnosticimage","displayName":"Magnification view","title":"Magnification view","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Magnification view</div><div class=\"cntnt\"><img style=\"width:464px; height:317px;\" src=\"images/PC/80031_Magnification_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The routine CC view (Panel A) shows calcifications in the lateral aspect of the breast. The size, shape and the distribution of these calcifications are better seen on magnification view (Panel B). The pleomorphic appearance and segmental distribution of numerous calcifications oriented towards the nipple is a classic appearance of ductal carcinoma in situ.</div><div class=\"graphic_footnotes\">CC: craniocaudal.</div><div id=\"graphicVersion\">Graphic 80031 Version 2.0</div></div></div>"},"80032":{"type":"graphic_figure","displayName":"Automated platelet counting low","title":"Comparison between automated optical and immunologic platelet counts","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Comparison between automated optical and immunologic platelet counts</div><div class=\"cntnt\"><img style=\"width:511px; height:468px;\" src=\"images/HEME/80032_Automated_platelet_counting.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graph depicts simultaneously-obtained automated platelet counts using an optical method (y-axis) and an immunologic method (anti-CD61, y-axis) for counts in the range from zero to 30,000 platelets/microL. The least squares best-fit line for the data points is shown as the red line, while the 95 percent confidence limits are shown by the two dashed blue lines. Note that the majority of the data points well outside of the 95 percent confidence limits are above the best-fit line, suggesting that the optical method is more prone to overestimate platelet counts than the immunologic method in this range.</div><div class=\"graphic_reference\">Redrawn from: Kunz D1, Kunz WS, Scott CS, Gressner AM. Automated CD61 immunoplatelet analysis of thrombocytopenic samples. Br J Haematol 2001; 112:584.</div><div id=\"graphicVersion\">Graphic 80032 Version 2.0</div></div></div>"},"80033":{"type":"graphic_table","displayName":"Cumulative incidence of PVE","title":"Estimated cumulative incidence of prosthetic valve endocarditis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated cumulative incidence of prosthetic valve endocarditis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"3\" class=\"subtitle1\">Study (years)</td>\n\n      <td colspan=\"1\" rowspan=\"3\" class=\"subtitle1\">Initial number valve recipients</td>\n\n      <td colspan=\"4\" rowspan=\"1\" class=\"subtitle1\">Percent of patients with PVE</td>\n\n\n\n\n    </tr>\n\n    <tr>\n\n      \n\n      \n\n      <td class=\"subtitle2\" colspan=\"4\" rowspan=\"1\">Months after surgery</td>\n\n\n\n\n    </tr>\n\n    <tr>\n      \n      \n      <td class=\"subtitle3\">12</td>\n      <td class=\"subtitle3\">24</td>\n      <td class=\"subtitle3\">48</td>\n      <td class=\"subtitle3\">60</td>\n    </tr>\n    <tr>\n\n      <td>Rutledge, et al (1985)</td>\n\n      <td>1598</td>\n\n      <td>1.4</td>\n\n      <td>&nbsp;</td>\n\n      <td>&nbsp;</td>\n\n      <td>3.2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ivert, et al (1984)</td>\n\n      <td>1465</td>\n\n      <td>3.0</td>\n\n      <td>&nbsp;</td>\n\n      <td>4.1</td>\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Calderwood, et al (1985) </td>\n\n      <td>2608</td>\n\n      <td>3.1</td>\n\n      <td>&nbsp;</td>\n\n      <td>5.4</td>\n\n      <td>5.7</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Arvay &#38; Lengyel (1988) </td>\n\n      <td>912</td>\n\n      <td>&nbsp;</td>\n\n      <td>&nbsp;</td>\n\n      <td>&nbsp;</td>\n\n      <td>4.9</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Agnihotri, et al (1995)</td>\n\n      <td>2413*</td>\n\n      <td>1.0</td>\n\n      <td colspan=\"1\">1.5</td>\n      <td>&nbsp;</td>\n\n      <td>3.0</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">8.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=29691&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Cumulative_incidence_of_PVE.htm</title></head></div><div class=\"graphic_footnotes\">PVE: prosthetic valve endocarditis.<BR>* Aortic position only.</div><div class=\"graphic_reference\">Reproduced with permission from Karchmer AW. In: Principles and Practice of Infectious Diseases, 5th ed, Mandell GL, et al (Eds), Churchill Livingstone, Philadelphia 1999. p. 903.</div><div id=\"graphicVersion\">Graphic 80033 Version 3.0</div></div></div>"},"80035":{"type":"graphic_diagnosticimage","displayName":"Miliary sarcoidosis CT","title":"Miliary nodules in sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Miliary nodules in sarcoidosis</div><div class=\"cntnt\"><img style=\"width:342px; height:227px;\" src=\"images/PULM/80035_Miliary_sarcoidosis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sarcoidosis with multiple nodules, 1 to 2 mm in diameter, in a peribronchiolar location. Beading of the major fissures is characteristic of lymphatic involvement. Bilateral hilar lymph node enlargement is present.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 80035 Version 3.0</div></div></div>"},"80038":{"type":"graphic_picture","displayName":"Defibulation 6","title":"Defibulation (reversal of female genital infibulation)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Defibulation (reversal of female genital infibulation)</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/OBGYN/80038_Defibulation_6.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Step 6: Completed defibulation.</div><div id=\"graphicVersion\">Graphic 80038 Version 2.0</div></div></div>"},"80040":{"type":"graphic_table","displayName":"Differential diagnosis of GBS","title":"Differential diagnosis of Guillain-Barré syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of Guillain-Barr&eacute; syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Differential diagnosis</td> </tr> <tr> <td class=\"subtitle2_single\">Cerebral</td> </tr> <tr> <td class=\"indent1\">Acute disseminated encephalomyelitis (ADEM)</td> </tr> <tr> <td class=\"indent1\">Bilateral strokes</td> </tr> <tr> <td class=\"indent1\">Psychogenic symptoms</td> </tr> <tr> <td class=\"subtitle2_single\">Cerebellar</td> </tr> <tr> <td class=\"indent1\">Acute cerebellar ataxia syndrome</td> </tr> <tr> <td class=\"indent1\">Posterior fossa structural lesion</td> </tr> <tr> <td class=\"subtitle2_single\">Spinal</td> </tr> <tr> <td class=\"indent1\">Anterior spinal artery syndrome</td> </tr> <tr> <td class=\"indent1\">Compressive myelopathy</td> </tr> <tr> <td class=\"indent1\">Neuromyelitis optica</td> </tr> <tr> <td class=\"indent1\">Poliomyelitis</td> </tr> <tr> <td class=\"indent1\">Transverse myelitis</td> </tr> <tr> <td class=\"indent1\">Other infectious causes of acute myelitis (eg, West Nile virus, coxsackieviruses, echoviruses)</td> </tr> <tr> <td class=\"subtitle2_single\">Peripheral nervous system</td> </tr> <tr> <td class=\"sublist2_start\">Acute onset chronic inflammatory demyelinating neuropathy (CIDP)</td> </tr> <tr> <td class=\"indent1\">Critical illness polyneuropathy</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus-related radiculitis</td> </tr> <tr> <td class=\"indent1\">Diphtheria</td> </tr> <tr> <td class=\"indent1\">HIV-related radiculitis</td> </tr> <tr> <td class=\"indent1\">Leptomeningeal malignancy</td> </tr> <tr> <td class=\"indent1\">Lyme disease</td> </tr> <tr> <td class=\"indent1\">Metabolic and electrolyte disorders (eg, hypoglycemia, hypophosphatemia)</td> </tr> <tr> <td class=\"indent1\">Porphyria</td> </tr> <tr> <td class=\"indent1\">Thiamine deficiency (beriberi)</td> </tr> <tr> <td class=\"indent1\">Tick paralysis</td> </tr> <tr> <td class=\"indent1\">Toxic neuropathy</td> </tr> <tr> <td class=\"indent1\">Vasculitis</td> </tr> <tr> <td class=\"subtitle2_single\">Neuromuscular junction</td> </tr> <tr> <td class=\"indent1\">Botulism</td> </tr> <tr> <td class=\"indent1\">Myasthenia gravis</td> </tr> <tr> <td class=\"indent1\">Neuromuscular blocking agents</td> </tr> <tr> <td class=\"subtitle2_single\">Muscle disease</td> </tr> <tr> <td class=\"indent1\">Acute inflammatory myopathies (eg, dermatomyositis, polymyositis)</td> </tr> <tr> <td class=\"indent1\">Acute viral myositis</td> </tr> <tr> <td class=\"indent1\">Acute rhabdomyolysis</td> </tr> <tr> <td class=\"indent1\">Critical illness myopathy</td> </tr> <tr> <td class=\"indent1\">Metabolic myopathies (eg, hypokalemic, hyperkalemic)</td> </tr> <tr> <td class=\"indent1\">Mitochondrial myopathies</td> </tr> <tr> <td class=\"indent1\">Periodic paralysis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Evans OB. Guillain-Barré syndrome in children. Pediatr Rev 1986; 8:69.</LI>&#xD;&#xA;<LI>Jones HR. Childhood Guillain-Barré syndrome: clinical presentation, diagnosis, and therapy. J Child Neurol 1996; 11:4.</LI>&#xD;&#xA;<LI>Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med 2012; 366:2294.</LI>&#xD;&#xA;<LI>Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet 2016; 388:717.</LI></OL></div><div id=\"graphicVersion\">Graphic 80040 Version 7.0</div></div></div>"},"80042":{"type":"graphic_figure","displayName":"Flow volume loops","title":"Common patterns on flow-volume loops","html":"<div class=\"graphic\"><div style=\"width: 742px\" class=\"figure\"><div class=\"ttl\">Common patterns on flow-volume loops</div><div class=\"cntnt\"><img style=\"width:722px; height:548px;\" src=\"images/PULM/80042_Airflow_limitation_curves.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The flow-volume loops are plotted against absolute lung volume to show the influence of changes in lung volume. For both loops in each panel, the rightward intersection with the horizontal axis is at total lung capacity (TLC, maximal inhalation) and the leftward intersection is at residual volume (RV, maximal exhalation).<br />(Upper left panel) Patient with airflow limitation (solid lines) compared to predicted (dashed lines).<br />(Upper middle panel) Patient with mixed disease with reduced airflow and reduced lung volumes. It is important to note that if one only measures airflow, this mixed picture would have been missed.<br />(Upper right panel) The flow volume loop observed in a patient with restrictive disease where the increased recoil causes increased airflow.<br />(Bottom left panel) Consistent truncation of the inspiratory phase of the loop, characteristic of a variable extrathoracic obstruction, eg, tracheal collapse as might be due to intubation trauma.<br />(Bottom middle panel) Another extrathoracic process of a more transient nature characteristic of vocal cord dysfunction.<br />(Bottom right panel) Consistent truncation of both inspiration and expiration, characteristic of a fixed obstruction, eg, tracheal stenosis.</div><div class=\"graphic_footnotes\">PVFM: paradoxical vocal fold motion.</div><div id=\"graphicVersion\">Graphic 80042 Version 2.0</div></div></div>"},"80043":{"type":"graphic_table","displayName":"Important sources of allergens and route of exposure","title":"Important sources of allergens and route of exposure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important sources of allergens and route of exposure</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Allergen group</td> <td class=\"subtitle1\">Mode of exposure*</td> </tr> <tr> <td>Grass pollens</td> <td>Inhalation (outdoor)</td> </tr> <tr> <td>Weed pollens</td> <td>Inhalation (outdoor)</td> </tr> <tr> <td>Tree pollens</td> <td>Inhalation (outdoor)</td> </tr> <tr> <td>Mold (hyphae-spores)</td> <td>Inhalation (outdoor and indoor)</td> </tr> <tr> <td>Dust mite fecal material</td> <td>Inhalation (indoor)</td> </tr> <tr> <td>Animal proteins (epidermal and serum)</td> <td>Inhalation (indoor)</td> </tr> <tr> <td>Foods</td> <td>Ingestion </td> </tr> <tr> <td>Insects</td> <td>Inhalation or injection (indoor and outdoor)</td> </tr> <tr> <td>Hymenoptera venoms</td> <td>Injection</td> </tr> <tr> <td>Parasites</td> <td>Ingestion or injection</td> </tr> <tr> <td>Drugs</td> <td>Injection or ingestion</td> </tr> <tr> <td>Occupational</td> <td>Contact or inhalation or ingestion</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The principal location where the allergen source is encountered is specified in parentheses.</div><div id=\"graphicVersion\">Graphic 80043 Version 6.0</div></div></div>"},"80045":{"type":"graphic_picture","displayName":"Miller and Phillips laryngoscope blades","title":"Miller and Phillips laryngoscope blades","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Miller and Phillips laryngoscope blades</div><div class=\"cntnt\"><img style=\"width:432px; height:308px;\" src=\"images/EM/80045_Millerlaryngoscope.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Orebaugh SL. Retraction blades for direct laryngoscopy. In: Atlas of Airway Management: Techniques and Tools, 2nd Ed, Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 80045 Version 11.0</div></div></div>"},"80047":{"type":"graphic_diagnosticimage","displayName":"Proton plan EFT paranas sinus","title":"Proton beam radiation treatment plan for a young man with a Ewing's sarcoma involving the left paranasal sinuses and infratemporal fossa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proton beam radiation treatment plan for a young man with a Ewing's sarcoma involving the left paranasal sinuses and infratemporal fossa</div><div class=\"cntnt\"><img style=\"width:432px; height:437px;\" src=\"images/ONC/80047_Proton_plan_EFT_paranas_sin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The much higher degree of conformality and normal tissue sparing with protons can be seen by comparing this treatment plan to the corresponding photon beam treatment plan in Figure 1B.</div><div class=\"graphic_reference\">Courtesy of John A Jackson, Medical Dosimetrist, Massachusetts General Hospital.</div><div id=\"graphicVersion\">Graphic 80047 Version 2.0</div></div></div>"},"80048":{"type":"graphic_table","displayName":"NCHS vs WHO growth curves","title":"Comparison of National Center for Health Statistics and World Health Organization growth charts for children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of National Center for Health Statistics and World Health Organization growth charts for children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"45%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Year published</td> <td class=\"subtitle1\">NCHS/CDC</td> <td class=\"subtitle1\">WHO</td> </tr> <tr> <td class=\"subtitle2\">2000</td> <td class=\"subtitle2\">2006</td> </tr> <tr> <td>Population(s) from which curves were derived</td> <td>General US population (data from the National Health and Nutrition Survey between 1970s and 1990s); includes infants and children from a variety of socioeconomic and ethnic groups</td> <td>Multicentre Growth Reference study (Brazil, Ghana, India, Norway, Oman, United States); population chosen to reflect growth under ideal conditions</td> </tr> <tr class=\"divider_bottom\"> <td>Age groups</td> <td> <p>0 to 36 months (cross-sectional data; includes both breastfed and formula-fed infants)</p> 2 to 20 years (cross-sectional data)</td> <td> <p>0 to 2 years (longitudinal data); infants were exclusively/predominantly breastfed for 4 to 6 months and continued to breastfeed until at least 12 months</p> 2 to 5 years (cross-sectional data)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Estimated prevalence of overweight in US children*<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">0 to 23 months</td> <td>9.6 percent</td> <td>7.5 percent</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">24 to 59 months</td> <td>9.6 percent</td> <td>8.5 percent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Estimated prevalence of underweight in US children*<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Weight-for-age</td> </tr> <tr> <td class=\"indent2\">0 to 23 months</td> <td>6.8 percent</td> <td>2 percent</td> </tr> <tr> <td class=\"indent2\">24 to 59 months</td> <td>3.8 percent</td> <td>0.8 percent</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Weight-for-height</td> </tr> <tr> <td class=\"indent2\">0 to 23 months</td> <td>4 percent</td> <td>0.8 percent</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">24 to 59 months</td> <td>3 percent</td> <td>0.5 percent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Estimated prevalence of shortness in US children*<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">0 to 23 months</td> <td>4.9 percent</td> <td>5.2 percent</td> </tr> <tr> <td class=\"indent1\">24 to 59 months</td> <td>2.9 percent</td> <td>3.1 percent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NCHS: National Center for Health Statistics; CDC: Centers for Disease Control; WHO: World Health Organization.<br />* Using data from the National Health and Nutrition Examination Survey (1999-2004).<br />¶ On the NCHS curves, overweight is defined by weight-for-height &gt;95th percentile for children 0 to 23 months and BMI &gt;95th percentile for children 24 to 59 months. On the WHO curves, overweight is defined by weight-for-height &gt;97.7th percentile for children 0 to 23 months and BMI &gt;97.7th percentile for children 24 to 59 months.<br />Δ On the NCHS curves, underweight is defined by weight-for-age or weight-for-height &lt;5th percentile. On the WHO curves, underweight is defined by weight-for-age or weight-for-height &lt;2.3rd percentile.<br /><FONT class=lozenge>◊</FONT> On the NCHS curve, shortness defined by height-for-age &lt;5th percentile. On the WHO curve, shortness is defined by height-for-age &lt;2.3rd percentile.</div><div class=\"graphic_reference\">Data for prevalence estimates from: Mei Z, Ogden CL, Flegal KM, Grummer-Strawn LM. Comparison of the prevalence of shortness, underweight, and overweight among US children aged 0 to 59 months by using the CDC 2000 and the WHO 2006 growth charts. J Pediatr 2008; 153:622.</div><div id=\"graphicVersion\">Graphic 80048 Version 4.0</div></div></div>"},"80050":{"type":"graphic_picture","displayName":"Bilirubinate crystals","title":"Gallbladder bile microscopy","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Gallbladder bile microscopy</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/GAST/80050_Bilirubinate_crystals.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Amorphous brown bilirubinate crystals on microscopy.</div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD, FACP.</div><div id=\"graphicVersion\">Graphic 80050 Version 2.0</div></div></div>"},"80051":{"type":"graphic_figure","displayName":"Cervical hypoplasia","title":"Cervical hypoplasia with the presence of a vagina","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cervical hypoplasia with the presence of a vagina</div><div class=\"cntnt\"><img style=\"width:406px; height:338px;\" src=\"images/OBGYN/80051_Cervicalhypoplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from:&nbsp;Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012.&nbsp;Copyright © 2012 Lippincott Williams&nbsp;&amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 80051 Version 12.0</div></div></div>"},"80052":{"type":"graphic_figure","displayName":"Pathologic staging prostate CA","title":"Pathologic staging of prostate cancer","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Pathologic staging of prostate cancer</div><div class=\"cntnt\"><img style=\"width:510px; height:342px;\" src=\"images/ONC/80052_Pathologicstagingprostate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radical prostatectomy allows the determination of the extent of cancer in the prostate gland, prostate capsule, seminal vesicle, and lymph nodes because these tissues are removed and examined under the microscope. The likelihood of remaining disease free at&nbsp;10 years following prostatectomy is related to the extent of capsular penetration, whether the cancer is specimen confined, and whether there is evidence of positive margins.</div><div class=\"graphic_reference\">Adapted with permission from Garnick, M, Patient's Guide to Prostate Cancer, Penguin, New York, 1999, p. 45.</div><div id=\"graphicVersion\">Graphic 80052 Version 2.0</div></div></div>"},"80053":{"type":"graphic_figure","displayName":"Trim toenails PI","title":"Trim your toenails","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trim your toenails</div><div class=\"cntnt\"><img style=\"width:299px; height:222px;\" src=\"images/PI/80053_Trim_toenails_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 80053 Version 1.0</div></div></div>"},"80055":{"type":"graphic_picture","displayName":"Pancreatoscopy-directed stone fragmentation","title":"Pancreatoscopy-directed stone fragmentation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatoscopy-directed stone fragmentation</div><div class=\"cntnt\"><img style=\"width:360px; height:327px;\" src=\"images/GAST/80055_Pancreat_dir_stone_frag_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pancreatoscopy showing fragmentation of a pancreatic duct stone using a holmium laser.</div><div id=\"graphicVersion\">Graphic 80055 Version 2.0</div></div></div>"},"80056":{"type":"graphic_picture","displayName":"Erythema nodosum","title":"Erythema nodosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema nodosum</div><div class=\"cntnt\"><img style=\"width:238px; height:360px;\" src=\"images/ID/80056_Erythema_nodosum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Painful erythematous nodules of erythema nodosum are often found in a symmetric distribution on the legs. The nodules can also appear to be pigmented.</div><div class=\"graphic_reference\">Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore. 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 80056 Version 5.0</div></div></div>"},"80057":{"type":"graphic_figure","displayName":"Fecundability in healthy couples","title":"Fecundability in a cohort of healthy couples attempting to conceive","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fecundability in a cohort of healthy couples attempting to conceive</div><div class=\"cntnt\"><img style=\"width:435px; height:280px;\" src=\"images/OBGYN/80057_Fecundability_in_healthy_co.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Zinaman MJ, Clegg ED, Brown CC, et al. Estimates of human fertility and pregnancy loss. Fertil Steril 1996; 65:503.</div><div id=\"graphicVersion\">Graphic 80057 Version 3.0</div></div></div>"},"80058":{"type":"graphic_picture","displayName":"Vitiligo2","title":"Vulvar vitiligo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar vitiligo</div><div class=\"cntnt\"><img style=\"width:350px; height:228px;\" src=\"images/OBGYN/80058_Vitiligo2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 80058 Version 3.0</div></div></div>"},"80059":{"type":"graphic_figure","displayName":"Weaver curve","title":"Weaver curve","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Weaver curve</div><div class=\"cntnt\"><img style=\"width:447px; height:341px;\" src=\"images/PEDS/80059_Weaver_curve_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plotted above is an example of the use of the Weaver curve. The child's occipitofrontal circumference (OFC) was 49.5 cm at the age of&nbsp;nine months, placing him well above the 97th percentile on Nellhaus's head circumference chart. His standard score (SS) was calculated to be +2.93. The father had an OFC of 59.5 cm, and the mother's was 59.0 cm with SS of +2.65 and +2.90, respectively. Their average parental SS was +2.78. When plotted, the intercept (A) of lines from the SS falls below the +2 SD regression line. Thus, the child's head size in relationship to that of his parents is judged to be normal.</div><div class=\"graphic_reference\">Reproduced with permission from: Weaver DD, Christian JC. J Pediatr 1980; 96:993. Copyright © 1980 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 80059 Version 6.0</div></div></div>"},"80061":{"type":"graphic_diagnosticimage","displayName":"Angiogram coronary a fistula","title":"Angiogram coronary a fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Angiogram coronary a fistula</div><div class=\"cntnt\"><img style=\"width:419px; height:244px;\" src=\"images/PEDS/80061_Angiogram_coronary_a_fistul.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right anterior oblique view of left coronary angiogram showing fistulous connection of left anterior descending coronary artery to the right ventricle (left panel). This connection was occluded by transcatheter placement of occluding coils (right panel).</div><div class=\"graphic_reference\">Reproduced with permission from: Okubo, M, Nyaken, D, Benson, LN. Outcomes of transcatheter embolization in the treatment of coronary artery fistulas. Cathet Cardiovasc Intervent 2001; 52:510. Copyright © 2001 John Wiley &amp;Sons, Inc.</div><div id=\"graphicVersion\">Graphic 80061 Version 2.0</div></div></div>"},"80062":{"type":"graphic_diagnosticimage","displayName":"Upper airway anatomy","title":"Upper airway anatomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Upper airway anatomy</div><div class=\"cntnt\"><img style=\"width:432px; height:332px;\" src=\"images/PULM/80062_Upper_airway_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three dimensional surface, bony and airway reconstruction of contiguous axial CT images in a normal subject. Top row demonstrates surface reconstruction. Middle row demonstrates relationships between bony skeleton and airway. Bottom row demonstrates skeleton airway relationships in midsagittal plane. Note the relationship between hyoid bone and airway. Arrow: airway; Arrow head: hyoid bone.</div><div class=\"graphic_reference\">Courtesy of Richard J Schwab, MD</div><div id=\"graphicVersion\">Graphic 80062 Version 2.0</div></div></div>"},"80063":{"type":"graphic_picture","displayName":"Acute liver TPL rejection I","title":"Acute cellular hepatic allograft rejection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute cellular hepatic allograft rejection</div><div class=\"cntnt\"><img style=\"width:432px; height:285px;\" src=\"images/GAST/80063_Acute_liver_TPL_rejection_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power light micrograph of a liver biopsy from a patient with acute cellular hepatic allograft rejection shows an expanded portal triad containing mixed inflammatory cells. There is also evidence of ductulitis and endotheliitis.</div><div class=\"graphic_reference\">Courtesy of Donald Jensen, MD.</div><div id=\"graphicVersion\">Graphic 80063 Version 2.0</div></div></div>"},"80064":{"type":"graphic_diagnosticimage","displayName":"Angiogram coiled cerebral aneurysm","title":"Aneurysm before and after therapy","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Aneurysm before and after therapy</div><div class=\"cntnt\"><img style=\"width:530px; height:275px;\" src=\"images/NEURO/80064_Coil_embolization_of_aneury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Towne projection of an aneurysm of the right posterior cerebral artery before (left panel) and after (right panel) successful coil embolization.</div><div class=\"graphic_reference\">Courtesy of Guy Rordorf, MD.</div><div id=\"graphicVersion\">Graphic 80064 Version 3.0</div></div></div>"},"80068":{"type":"graphic_table","displayName":"Differential diagnosis of asthma in older adults","title":"Differential diagnosis of asthma in older adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of asthma in older adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Potentially helpful diagnostic tests, in addition to clinical assessment</td> </tr> <tr> <td>Asthma</td> <td>Spirometry pre and post-bronchodilator, methacholine inhalation challenge</td> </tr> <tr> <td>Atrial fibrillation</td> <td>Electrocardiogram</td> </tr> <tr> <td>Bronchiectasis</td> <td>History of &#62;1/4 cup of sputum per day, HRCT thorax</td> </tr> <tr> <td>Chronic obstructive pulmonary disease</td> <td>History of smoking, spirometry pre and post-bronchodilator, lung volumes, DLCO, CT thorax showing&nbsp;emphysema</td> </tr> <tr> <td>Coronary heart disease</td> <td>Electrocardiogram, stress test</td> </tr> <tr> <td>Deconditioning</td> <td>Ambulatory oximetry, cardiopulmonary exercise testing</td> </tr> <tr> <td>Heart failure</td> <td>BNP, echocardiogram</td> </tr> <tr> <td>Obesity</td> <td>Ambulatory oximetry, cardiopulmonary exercise testing</td> </tr> <tr> <td>Pulmonary embolism</td> <td>ABG, D-dimer, CT pulmonary angiogram, electrocardiogram</td> </tr> <tr> <td>Pulmonary vascular disease</td> <td>Echocardiogram, right heart catheterization</td> </tr> <tr> <td>Restrictive lung disease</td> <td>Lung volumes, DLCO, HRCT thorax</td> </tr> <tr> <td>Upper airway obstruction</td> <td>Flow volume loop, direct visualization</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ABG: arterial blood gas; BNP: brain natriuretic peptide; DLCO: diffusing capacity; CT: computed tomography; HRCT: high resolution computed tomography.</div><div id=\"graphicVersion\">Graphic 80068 Version 3.0</div></div></div>"},"80069":{"type":"graphic_picture","displayName":"Aponeurotic ptosis","title":"Patient with ptosis of the right upper lid secondary to levator dehiscence","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Patient with ptosis of the right upper lid secondary to levator dehiscence</div><div class=\"cntnt\"><img style=\"width:504px; height:211px;\" src=\"images/NEURO/80069_Aponeurotic_ptosis_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the absence of the right upper lid crease. The patient is raising the right eyebrow to try and compensate for the ptosis. The left lid shows pseudoretraction because of Hering's law of equal innervation.</div><div class=\"graphic_reference\">Courtesy of Michael S Lee, MD.</div><div id=\"graphicVersion\">Graphic 80069 Version 2.0</div></div></div>"},"80072":{"type":"graphic_diagnosticimage","displayName":"Magnetic resonance images of osteitis pubis A","title":"Magnetic resonance images of osteitis pubis A","html":"<div class=\"graphic\"><div style=\"width: 583px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance images of osteitis pubis A</div><div class=\"cntnt\"><img style=\"width:563px; height:264px;\" src=\"images/PC/80072_MRI_athletic_osteitis_pubis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal T1 and matching fat-suppressed coronal PD-weighted&nbsp;magnetic resonance&nbsp;images demonstrate subarticular marrow changes of symphyseal degeneration and athletic osteitis pubis. Note areas of subchondral sclerosis (arrow), fatty change (Modic Type 2 signal abnormality identified by arrowheads), and signal hyperintensity indicating 'osteitis' (Modic Type 1 signal abnormality identified by thick arrows). These changes are bilateral but asymmetric.</div><div class=\"graphic_reference\">Reproduced with permission from: Read JW. Groin disruption injury. Sports Medicine Imaging. For more information, visit <a href=\"http://www.sportsmedicineimaging.com/\" target=\"_blank\">http://www.sportsmedicineimaging.com/</a>. Copyright &copy; 2009 SportsMedicineImaging.com. All rights reserved.</div><div id=\"graphicVersion\">Graphic 80072 Version 6.0</div></div></div>"},"80073":{"type":"graphic_picture","displayName":"Mycosis fungoides patch","title":"Mycosis fungoides - patch stage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mycosis fungoides - patch stage</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/80073_Mycosis_fungoides_patch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subtle erythematous patches with slight scale are present on the buttocks of this patient with mycosis fungoides.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 80073 Version 4.0</div></div></div>"},"80075":{"type":"graphic_figure","displayName":"Cryos in chronic liver disease","title":"Incidence of cryoglobulins in chronic liver disease","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Incidence of cryoglobulins in chronic liver disease</div><div class=\"cntnt\"><img style=\"width:460px; height:255px;\" src=\"images/GAST/80075_Cryoschronicliverdisease.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incidence of circulating cryoglobulins in 136 healthy controls and in 226 patients with chronic liver disease due to hepatitis C, hepatitis B, or other liver diseases (such as autoimmune hepatitis and primary biliary cholangitis). Cryoglobulins were unusual in controls and most common in patients with hepatitis C virus infection, being detected in 54% of cases.</div><div class=\"graphic_reference\">Data from: Lunel F, Musset L, Cacoub P, et al. Cryoglobulinemia in chronic liver diseases: Role of hepatitis C virus and liver damage. Gastroenterology 1994; 106:1291.</div><div id=\"graphicVersion\">Graphic 80075 Version 5.0</div></div></div>"},"80076":{"type":"graphic_figure","displayName":"Second deg vag laceratio repair","title":"Repair of a second degree perineal laceration","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Repair of a second degree perineal laceration</div><div class=\"cntnt\"><img style=\"width:526px; height:298px;\" src=\"images/OBGYN/80076_Second_deg_vag_laceratio_re.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A first-degree laceration involves the fourchet, the perineal skin, and the vaginal mucous membrane. A second-degree laceration also includes the muscles of the perineal body. The rectal sphincter remains intact.</div><div class=\"graphic_reference\">Reproduced with permission from: Gabbe, SG, Niebyl, JR, Simpson, JL. Closure of 2nd degree laceration. In: Obstetrics: Normal &amp; problem pregnancies, 3rd ed, Churchill Livingstone Inc., New York 1996. Copyright &#169; 1996 Elsevier.</div><div id=\"graphicVersion\">Graphic 80076 Version 2.0</div></div></div>"},"80078":{"type":"graphic_table","displayName":"Neonatal pain assess tools","title":"Commonly used measures of pain in neonates","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly used measures of pain in neonates</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Measure</td> <td class=\"subtitle1\">Variables included</td> <td class=\"subtitle1\">Type of pain</td> <td class=\"subtitle1\">Psychometric testing</td> </tr> <tr> <td>PIPP (Premature Infant Pain Profile)</td> <td>Heart rate, oxygen saturation, facial actions; takes state and gestational age into account</td> <td>Procedural, postoperative (minor)</td> <td>Reliability, validity, clinical utility well established</td> </tr> <tr> <td>NIPS (Neonatal Infant Pain Score)</td> <td>Facial expression, crying, breathing patterns, arm and leg movements, arousal</td> <td>Procedural</td> <td>Reliability, validity</td> </tr> <tr> <td>NFCS (Neonatal Facial Coding System)</td> <td>Facial actions</td> <td>Procedural</td> <td>Reliability, validity, clinical utility, high degree of sensitivity to analgesia</td> </tr> <tr> <td>N-PASS (Neonatal Pain, Agitation, and Sedation Scale)</td> <td>Crying, irritability, behavioral state, facial expression, extremity tone, vital signs</td> <td>Postoperative, procedural, ventilated</td> <td>Reliability, validity, includes sedation end of scale, does not distinguish pain from agitation</td> </tr> <tr> <td>CRIES (Cry, Requires oxygen, Increased vital signs, Expression, Sleeplessness)</td> <td>Crying, facial expression, sleeplessness, requires oxygen to stay at &#62;95% saturation, increased vital signs</td> <td>Postoperative</td> <td>Reliability, validity</td> </tr> <tr> <td>COMFORT scale</td> <td>Movement, calmness, facial tension, alertness, respiration rate, muscle tone, heart rate, blood pressure</td> <td>Postoperative, critical care, developed for sedation, recently validated for postoperative pain in 0- to 3-year-old infants</td> <td>Reliability, validity, clinical utility</td> </tr> <tr> <td>Douleur Aigu&#235; Nouveau-n&#233; scale</td> <td>Facial and limb movements, vocal expression</td> <td>Procedural pain</td> <td>Reliability, validity</td> </tr> <tr> <td>Behavioral Infant Pain Profile</td> <td>Behavioral state, facial expression and hand movements</td> <td>Acute pain</td> <td>Reliability, validity</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 117, Pages S9-S22, Copyright &copy; 2006 by the AAP.</div><div id=\"graphicVersion\">Graphic 80078 Version 14.0</div></div></div>"},"80080":{"type":"graphic_picture","displayName":"Acanthocytes or spur cells","title":"Acanthocytes (spur cells)","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acanthocytes (spur cells)</div><div class=\"cntnt\"><img style=\"width:360px; height:246px;\" src=\"images/HEME/80080_Acanthocytes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear shows multiple acanthocytes (spur cells). These cells have prominent irregular protrusions scattered over the surface in an asymmetrical pattern. They are often confused with echinocytes in which the protrusions are smaller and more regular.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 80080 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"80082":{"type":"graphic_table","displayName":"90th percentile for waist circumference","title":"90th percentile for waist circumference for European-American, African-American, and Mexican-American children and adolescents, according to sex","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">90th percentile for waist circumference for European-American, African-American, and Mexican-American children and adolescents, according to sex</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Age (y)</td>\n\n      <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">Boys</td>\n\n\n\n      <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">Girls</td>\n\n\n\n    </tr>\n\n    <tr>\n\n\n      <td class=\"subtitle2\">European American</td>\n\n      <td class=\"subtitle2\">African American</td>\n\n      <td class=\"subtitle2\">Mexican American</td>\n\n      <td class=\"subtitle2\">European American </td>\n\n      <td class=\"subtitle2\">African American</td>\n\n      <td class=\"subtitle2\">Mexican American</td>\n\n    </tr>\n\n    <tr>\n\n      <td>6</td>\n\n      <td>64.2</td>\n\n      <td>62.8</td>\n\n      <td>67.1</td>\n\n      <td>64.0</td>\n\n      <td>64.8</td>\n\n      <td>66.2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>7</td>\n\n      <td>67.6</td>\n\n      <td>66.1</td>\n\n      <td>70.6</td>\n\n      <td>66.8</td>\n\n      <td>68.5</td>\n\n      <td>69.4</td>\n\n    </tr>\n\n    <tr>\n\n      <td>8</td>\n\n      <td>71.0</td>\n\n      <td>69.3</td>\n\n      <td>74.1</td>\n\n      <td>69.7</td>\n\n      <td>72.2</td>\n\n      <td>72.6</td>\n\n    </tr>\n\n    <tr>\n\n      <td>9</td>\n\n      <td>74.3</td>\n\n      <td>72.5</td>\n\n      <td>77.6</td>\n\n      <td>72.6</td>\n\n      <td>75.8</td>\n\n      <td>75.8</td>\n\n    </tr>\n\n    <tr>\n\n      <td>10</td>\n\n      <td>77.7</td>\n\n      <td>75.7</td>\n\n      <td>81.0</td>\n\n      <td>75.5</td>\n\n      <td>79.5</td>\n\n      <td>78.9</td>\n\n    </tr>\n\n    <tr>\n\n      <td>11</td>\n\n      <td>81.1</td>\n\n      <td>78.9</td>\n\n      <td>84.5</td>\n\n      <td>78.3</td>\n\n      <td>83.2</td>\n\n      <td>82.1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>12</td>\n\n      <td>84.5</td>\n\n      <td>82.1</td>\n\n      <td>88.0</td>\n\n      <td>81.2</td>\n\n      <td>86.9</td>\n\n      <td>85.3</td>\n\n    </tr>\n\n    <tr>\n\n      <td>13</td>\n\n      <td>87.9</td>\n\n      <td>85.3</td>\n\n      <td>91.5</td>\n\n      <td>84.1</td>\n\n      <td>90.5</td>\n\n      <td>88.5</td>\n\n    </tr>\n\n    <tr>\n\n      <td>14</td>\n\n      <td>91.3</td>\n\n      <td>88.5</td>\n\n      <td>95.0</td>\n\n      <td>86.9</td>\n\n      <td>94.2</td>\n\n      <td>91.7</td>\n\n    </tr>\n\n    <tr>\n\n      <td>15</td>\n\n      <td>94.7</td>\n\n      <td>91.7</td>\n\n      <td>98.4</td>\n\n      <td>89.8</td>\n\n      <td>97.9</td>\n\n      <td>94.8</td>\n\n    </tr>\n\n    <tr>\n\n      <td>16</td>\n\n      <td>98.1</td>\n\n      <td>94.9</td>\n\n      <td>101.9</td>\n\n      <td>92.7</td>\n\n      <td>101.6</td>\n\n      <td>98.0</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Fernandez JR, Redden DT, Pietrobelli A, Allison DB. J Pediatr 2004; 145:439.</div><div id=\"graphicVersion\">Graphic 80082 Version 3.0</div></div></div>"},"80083":{"type":"graphic_diagnosticimage","displayName":"Anorexia nervosa heart and lung changes","title":"Radiographic changes associated with anorexia nervosa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiographic changes associated with anorexia nervosa</div><div class=\"cntnt\"><img style=\"width:431px; height:428px;\" src=\"images/PULM/80083_Anorexia_lung_changes_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representative posterior-anterior &quot;locating scout&quot; and thin slice computed tomographic (CT) images from a control patient with a BMI of 19 kg/m2 (A and B), and from an anorexic patient with a BMI of 12 kg/m2 (C and D).</div><div class=\"graphic_reference\">Reproduced with permission from: Coxson, HO, et al. Am J Respir Crit Care Med 2004; 170:748.</div><div id=\"graphicVersion\">Graphic 80083 Version 4.0</div></div></div>"},"80085":{"type":"graphic_diagnosticimage","displayName":"Duplex pulsed doppler sonogram","title":"Duplex pulsed Doppler sonogram depicting umbilical arterial circulation","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Duplex pulsed Doppler sonogram depicting umbilical arterial circulation</div><div class=\"cntnt\"><img style=\"width:540px; height:371px;\" src=\"images/OBGYN/80085_Duplex_pulsed_doppler_sonog.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left panel shows pulsed Doppler interrogation of the umbilical artery in a two dimensional color Doppler image. The Doppler beam path is indicated by the cursor line and the Doppler sample volume is indicated by two horizontal lines. The right panel shows the spectral Doppler waveforms from the sampled umbilical artery location. Note the prominent end-diastolic flow typical of the last weeks of pregnancy reflecting declining flow impedance. The peak velocity is indicated by the blue margin of the waveform. The vertical lines are defining one cardiac cycle. The Doppler indices are shown in lower left corner.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Reproduced with permission from: Maulik D. Umbilical Doppler velocimetry: normative data and diagnostic efficacy. In Maulik D. (ed) Doppler Ultrasound in Obstetrics and Gynecology; Springer Verlag. Copyright &#169; 2005 Springer Verlag.</div><div id=\"graphicVersion\">Graphic 80085 Version 4.0</div></div></div>"},"80087":{"type":"graphic_picture","displayName":"Neuroendocrine tumor appendix","title":"Appendiceal neuroendocrine tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Appendiceal neuroendocrine tumor</div><div class=\"cntnt\"><img style=\"width:432px; height:294px;\" src=\"images/GAST/80087_Carcinoidtumorappendedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pathologic specimen of a neuroendocrine tumor of the distal appendix (arrow).</div><div class=\"graphic_reference\">Courtesy of Stephen E Goldfinger, MD.</div><div id=\"graphicVersion\">Graphic 80087 Version 5.0</div></div></div>"},"80091":{"type":"graphic_picture","displayName":"One hand bag mask ventilation technique","title":"One-hand bag mask ventilation technique","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">One-hand bag mask ventilation technique</div><div class=\"cntnt\"><img style=\"width:595px; height:337px;\" src=\"images/EM/80091_One_handed_tech.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To perform this technique, one hand is placed on the mask, with the web space between the thumb and index finger resting against the mask connector. The web space is placed in the center of the mask, allowing for a more even application of pressure. The correct technique is to lift the mandible up into the mask with the middle, ring, and little fingers, while holding the mask tightly against the patient's face with the thumb and index finger. Clinicians should take care to pull up only on the bony parts of the mandible; pressure to the soft tissues of the neck may occlude the airway.</div><div class=\"graphic_reference\">Courtesy of Kathleen Wittels, MD.</div><div id=\"graphicVersion\">Graphic 80091 Version 2.0</div></div></div>"},"80092":{"type":"graphic_picture","displayName":"Melioidosis ulcer","title":"Skin ulcer in melioidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin ulcer in melioidosis</div><div class=\"cntnt\"><img style=\"width:259px; height:394px;\" src=\"images/ID/80092_Melioidosis_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Solitary skin ulcer as a cutaneous manifestation of melioidosis.</div><div class=\"graphic_reference\">Courtesy of Bart Currie, FRACP.</div><div id=\"graphicVersion\">Graphic 80092 Version 2.0</div></div></div>"},"80093":{"type":"graphic_figure","displayName":"Urea mass transfer coefficient","title":"Figure showing the reduction in blood urea nitrogen during and immediately after hemodialysis among patients with a high versus low mass transfer coefficient for urea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Figure showing the reduction in blood urea nitrogen during and immediately after hemodialysis among patients with a high versus low mass transfer coefficient for urea</div><div class=\"cntnt\"><img style=\"width:378px; height:296px;\" src=\"images/NEPH/80093_Urea_mass_transfer_coeffici.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the changes in BUN occurring during four hours of hemodialysis and the hour after dialysis is discontinued. Patients with a low mass transfer coefficient for urea (MTCurea) have, when compared&nbsp;with those with a high MTCurea, a more rapid reduction in BUN due to delayed urea equilibration with intracellular stores. This defect is associated with a greater urea rebound when dialysis is stopped and less total urea removal.</div><div class=\"graphic_footnotes\">BUN: blood urea nitrogen.</div><div id=\"graphicVersion\">Graphic 80093 Version 4.0</div></div></div>"},"80097":{"type":"graphic_diagnosticimage","displayName":"CT appendicitis in pregnancy","title":"CT appendicitis in pregnancy","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">CT appendicitis in pregnancy</div><div class=\"cntnt\"><img style=\"width:506px; height:389px;\" src=\"images/OBGYN/80097_CT_appendicitis_in_pregnanc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The main findings of appendicitis on computed tomography (CT) are right lower quadrant inflammation, an enlarged nonfilling tubular structure, and/or an appendicolith.</div><div class=\"graphic_reference\">Courtesy of Joel Goldberg, MD, FACS.</div><div id=\"graphicVersion\">Graphic 80097 Version 2.0</div></div></div>"},"80098":{"type":"graphic_diagnosticimage","displayName":"Bone scan of skeletal metastases","title":"Bone scan of skeletal metastases","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bone scan of skeletal metastases</div><div class=\"cntnt\"><img style=\"width:196px; height:523px;\" src=\"images/ONC/80098_Bone_scan_skeltl_metastases.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skeletal metastases. A radionuclide technetium Tc-99m methylene diphosphonate bone scan posterior view demonstrates multiple sites of abnormally increased skeletal uptake (arrows).</div><div class=\"graphic_reference\">Courtesy of Daniel Rosenthal, MD.</div><div id=\"graphicVersion\">Graphic 80098 Version 5.0</div></div></div>"},"80099":{"type":"graphic_table","displayName":"Lung cancer TNM staging 7th edition","title":"TNM staging system for lung cancer (seventh edition)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">TNM staging system for lung cancer (seventh edition)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr> <td class=\"sublist1_start\">T1</td> <td class=\"sublist_other_start\" colspan=\"3\">Tumor &#8804;3 cm diameter, surrounded by lung or visceral pleura, without invasion more proximal than lobar bronchus*</td> </tr> <tr> <td class=\"sublist1\">T1a</td> <td class=\"sublist_other\" colspan=\"3\">Tumor &#8804;2 cm in diameter</td> </tr> <tr> <td class=\"sublist1\">T1b</td> <td class=\"sublist_other\" colspan=\"3\">Tumor &#62;2 cm but &#8804;3 cm in diameter</td> </tr> <tr> <td rowspan=\"4\">T2</td> <td class=\"sublist1_start\" colspan=\"3\">Tumor &#62;3 cm but &#8804;7 cm, or tumor with any of the following features:</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">Involves main bronchus, &#8805;2 cm distal to carina</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">Invades visceral pleura</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung</td> </tr> <tr> <td class=\"sublist1\">T2a</td> <td class=\"sublist_other\" colspan=\"3\">Tumor &#62;3 cm but &#8804;5 cm</td> </tr> <tr> <td class=\"sublist1\">T2b</td> <td class=\"sublist_other\" colspan=\"3\">Tumor &#62;5 cm but &#8804;7 cm</td> </tr> <tr> <td rowspan=\"4\">T3</td> <td class=\"sublist1_start\" colspan=\"3\">Tumor &#62;7 cm or any of the following:</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">Directly invades any of the following: chest wall, diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium, main bronchus &#60;2 cm from carina (without involvement of carina)</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">Atelectasis or obstructive pneumonitis of the entire lung</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">Separate tumor nodules in the same lobe</td> </tr> <tr> <td>T4</td> <td colspan=\"3\">Tumor of any size that invades the mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, or with separate tumor nodules in a different ipsilateral lobe</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr> <td>N0</td> <td colspan=\"3\">No regional lymph node metastases</td> </tr> <tr> <td>N1</td> <td colspan=\"3\">Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension</td> </tr> <tr> <td>N2</td> <td colspan=\"3\">Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)</td> </tr> <tr> <td>N3</td> <td colspan=\"3\">Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr> <td>M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr> <td class=\"sublist1_start\">M1</td> <td class=\"sublist_other_start\" colspan=\"3\">Distant metastasis</td> </tr> <tr> <td class=\"sublist1\">M1a</td> <td class=\"sublist_other\" colspan=\"3\">Separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural or pericardial effusion</td> </tr> <tr> <td class=\"sublist1\">M1b</td> <td class=\"sublist_other\" colspan=\"3\">Distant metastasis (in extrathoracic organs)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Stage groupings</td> </tr> <tr> <td>Stage IA</td> <td>T1a-T1b</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IB</td> <td>T2a</td> <td>N0</td> <td>M0</td> </tr> <tr> <td rowspan=\"2\">Stage IIA</td> <td>T1a,T1b,T2a</td> <td>N1</td> <td>M0</td> </tr> <tr> <td>T2b</td> <td>N0</td> <td>M0</td> </tr> <tr> <td rowspan=\"2\">Stage IIB</td> <td>T2b</td> <td>N1</td> <td>M0</td> </tr> <tr> <td>T3</td> <td>N0</td> <td>M0</td> </tr> <tr> <td rowspan=\"3\">Stage IIIA</td> <td>T1a,T1b,T2a,T2b</td> <td>N2</td> <td>M0</td> </tr> <tr> <td>T3</td> <td>N1,N2</td> <td>M0</td> </tr> <tr> <td>T4</td> <td>N0,N1</td> <td>M0</td> </tr> <tr> <td rowspan=\"2\">Stage IIIB</td> <td>T4</td> <td>N2</td> <td>M0</td> </tr> <tr> <td>Any T</td> <td>N3</td> <td>M0</td> </tr> <tr> <td>Stage IV</td> <td>Any T</td> <td>Any N</td> <td>M1a or M1b</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The uncommon superficial spreading tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.</div><div class=\"graphic_reference\">Adapted from: Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groups in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2:706.</div><div id=\"graphicVersion\">Graphic 80099 Version 6.0</div></div></div>"},"80101":{"type":"graphic_figure","displayName":"Triangular fibrocartilage complex","title":"Triangular fibrocartilage complex","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Triangular fibrocartilage complex</div><div class=\"cntnt\"><img style=\"width:535px; height:444px;\" src=\"images/EM/80101_Triangfibrocartcomplex.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Nagle DJ. Arthroscopically assisted triangular fibrocartilage complex débridement and ulnar shortening. In: Operative Techniques in Orthopaedic Surgery, Wiesel SW (Ed), Philadelphia: Lippincott Williams &amp; Wilkins, 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 80101 Version 8.0</div></div></div>"},"80102":{"type":"graphic_diagnosticimage","displayName":"Fluorescein angiogram","title":"Fluorescein angiogram","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Fluorescein angiogram</div><div class=\"cntnt\"><img style=\"width:526px; height:229px;\" src=\"images/ENDO/80102_Fluorescein.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Color fundus photograph and B) fluorescein angiogram showing early detection of significant neovascularization elsewhere (NVE) by angiography that is barely visible in the color photograph.</div><div id=\"graphicVersion\">Graphic 80102 Version 4.0</div></div></div>"},"80105":{"type":"graphic_picture","displayName":"Inspection for pelvic obliquity","title":"Inspection for pelvic obliquity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inspection for pelvic obliquity</div><div class=\"cntnt\"><img style=\"width:382px; height:265px;\" src=\"images/EM/80105_Inspection_for_pelvic_obliq.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This test is used as a screening maneuver for leg length discrepancy. The patient is asked to stand. The hands are placed on top of the iliac crests and the level of the pelvis is estimated. Asymetry of the iliac crests is seen with leg length discrepancy, pelvic fracture, scoliosis, and unilateral paraspinal muscle spasm.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 80105 Version 2.0</div></div></div>"},"80107":{"type":"graphic_figure","displayName":"Yale Brown OCD rating scale","title":"Yale-Brown obsessive-compulsive scale","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Yale-Brown obsessive-compulsive scale</div><div class=\"cntnt\"><img style=\"width:539px; height:598px;\" src=\"images/PC/80107_Yale_Brown_OCD_rating_scale.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted with permission from Goodman, WK, Price, LH, Rasmussen, SA, et al, Arch Gen Psychiatry 1989; 46:106.</div><div id=\"graphicVersion\">Graphic 80107 Version 3.0</div></div></div>"},"80110":{"type":"graphic_table","displayName":"Contraindications to exercise treadmill testing","title":"Absolute and relative contraindications to exercise treadmill testing<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Absolute and relative contraindications to exercise treadmill testing<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"divider_bottom\"><strong>Absolute contraindications</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Acute myocardial infarction (within two days) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Ongoing unstable angina </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Uncontrolled cardiac arrhythmia with hemodynamic compromise </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Active endocarditis </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Symptomatic severe aortic stenosis </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Decompensated heart failure </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Acute pulmonary embolism, pulmonary infarction, or deep vein thrombosis </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Acute myocarditis or pericarditis </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Acute aortic dissection </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Physical disability that precludes safe and adequate testing </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\"><strong>Relative contraindications</strong>*</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Known obstructive left main coronary artery stenosis </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Moderate to severe aortic stenosis with uncertain relation to symptoms </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Tachyarrhythmias with uncontrolled ventricular rates </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Acquired advanced or complete heart block </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Hypertrophic obstructive cardiomyopathy with severe resting gradient </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Recent stroke or transient ischemic attack </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Mental impairment with limited ability to cooperate </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Resting hypertension with systolic or diastolic blood pressures &#62;200/110 mmHg </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Uncorrected medical conditions, such as significant anemia, important electrolyte imbalance, and hyperthyroidism </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Relative contraindications can be superseded if benefits outweigh risks of exercise.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Fletcher GF, Ades PA, Kligfield P, et al. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation 2013; 128:873.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 80110 Version 5.0</div></div></div>"},"80111":{"type":"graphic_algorithm","displayName":"Natural hx occupational asthma","title":"Natural history of occupational asthma with a latency period","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Natural history of occupational asthma with a latency period</div><div class=\"cntnt\"><img style=\"width:540px; height:336px;\" src=\"images/PULM/80111_Natural_hx_occupational_ast.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 80111 Version 2.0</div></div></div>"},"80113":{"type":"graphic_picture","displayName":"Surgical treatment of septic arthritis of the wrist","title":"Surgical treatment of septic arthritis of the wrist","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Surgical treatment of septic arthritis of the wrist</div><div class=\"cntnt\"><img style=\"width:548px; height:412px;\" src=\"images/SURG/80113_Surg_tx_septic_arthr_wrist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Septic arthritis is a surgical emergency and early exploration is necessary to avoid joint damage from the disease process. The photographs show the surgical treatment of septic arthritis of the wrist. Panel A illustrates the surgical approach through the third dorsal compartment and panel B illustrates exposure of the joint and infective erosion of the carpal bones.</div><div id=\"graphicVersion\">Graphic 80113 Version 2.0</div></div></div>"},"80114":{"type":"graphic_diagnosticimage","displayName":"Lipoma terminal ileum SBFT","title":"Lipoma of the terminal ileum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lipoma of the terminal ileum</div><div class=\"cntnt\"><img style=\"width:321px; height:288px;\" src=\"images/GAST/80114_Lipoma_terminal_ileum_SBFT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small bowel follow through examination demonstrates a smooth, well-circumscribed mass arising from the wall of the terminal ileum. The appearance is consistent with a benign mesenchymal tumor, such as a lipoma or a carcinoid tumor.</div><div class=\"graphic_reference\">Courtesy of Norman Joffe, MD.</div><div id=\"graphicVersion\">Graphic 80114 Version 2.0</div></div></div>"},"80116":{"type":"graphic_figure","displayName":"Irbesartan in type 2 diabetes","title":"Irbesartan slows progression of nephropathy in type 2 diabetes","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Irbesartan slows progression of nephropathy in type 2 diabetes</div><div class=\"cntnt\"><img style=\"width:482px; height:309px;\" src=\"images/NEPH/80116_Irbesartan_in_type_2_diabet.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of irbesartan, amlodipine, and placebo on the course of hypertensive patients with nephropathy due to type 2 diabetes; the target blood pressure was similar in the three groups. Treatment with irbesartan was associated with a risk of the primary end point (doubling of the baseline serum creatinine, development of end-stage renal disease, or death from any cause) that was 20 percent lower than placebo and 23 percent lower than amlodipine.</div><div class=\"graphic_reference\">Adapted from data published in: Lewis EJ, Hunsicker LG, Clarke WR, et al. N Engl J Med 2001; 345:851.</div><div id=\"graphicVersion\">Graphic 80116 Version 2.0</div></div></div>"},"80117":{"type":"graphic_picture","displayName":"Hirsutism and acne in CAH","title":"Hirsutism in an 18-year-old woman with late-onset congenital adrenal hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hirsutism in an 18-year-old woman with late-onset congenital adrenal hyperplasia</div><div class=\"cntnt\"><img style=\"width:400px; height:303px;\" src=\"images/PC/80117_Hirsutism_and_acne_in_CAH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clinical features are similar to those of polycystic ovary syndrome: acne, hirsutism, menstrual irregularities, and obesity.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd ed. Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright ©2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80117 Version 3.0</div></div></div>"},"80118":{"type":"graphic_picture","displayName":"Intraocular foreign body","title":"Patient who suffered penetrating eye injury with residual intraocular nail","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patient who suffered penetrating eye injury with residual intraocular nail</div><div class=\"cntnt\"><img style=\"width:300px; height:395px;\" src=\"images/EM/80118_Intraocular_foreign_body.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Clinical photo.<br> (B) CT scan of the orbit showing extent of intraocular penetration.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 80118 Version 4.0</div></div></div>"},"80119":{"type":"graphic_figure","displayName":"Occlusal cant","title":"Occlusal cant due to a mandibular abnormality","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Occlusal cant due to a mandibular abnormality</div><div class=\"cntnt\"><img style=\"width:324px; height:205px;\" src=\"images/PEDS/80119_Occlusal_cant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Occlusal cant is demonstrated by having the child bite down on a tongue depressor to identify any angulation.</div><div id=\"graphicVersion\">Graphic 80119 Version 2.0</div></div></div>"},"80120":{"type":"graphic_waveform","displayName":"Transdiaphragmatic pressure","title":"Transdiaphragmatic pressure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transdiaphragmatic pressure</div><div class=\"cntnt\"><img style=\"width:360px; height:286px;\" src=\"images/PULM/80120_Transdiaphragmatic_pressure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Real-time tracing of esophageal pressure as a reflection of pleural pressure and abdominal pressure as a reflection of gastric pressure in a patient with bilateral diaphragmatic paralysis. Decreased intrathoracic pressure (more negative pleural pressure) on inspiration is associated with an abnormal decrease in gastric pressure (more negative gastric pressure). At the same time, there is outward displacement of the ribcage (upward deflection of ribcage) with a paradoxical decrease in abdominal volume (downward deflection of abdomen). The ribcage and abdomen tracings are obtained from inductance plethysmographic coils placed around the chest and abdomen to monitor movement.</div><div class=\"graphic_footnotes\">Ppl: pleural pressure; Pga: gastric pressure; RC: ribcage; AB: abdomen; Insp: inspiration; Exp: expiration.</div><div id=\"graphicVersion\">Graphic 80120 Version 3.0</div></div></div>"},"80123":{"type":"graphic_algorithm","displayName":"Triage radiation injury","title":"Triage for radiation injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Triage for radiation injury</div><div class=\"cntnt\"><img style=\"width:387px; height:428px;\" src=\"images/HEME/80123_Triage_radiation_injury.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This flow chart details the triage and therapy for persons exposed to radiation in a scenario in which there are a limited number of casualties. The degree of toxicity to the variously defined organ systems (ie, cutaneous, gastrointestinal cerebrovascular, and hematologic, see separate figures) determines whether the patient is admitted to the hospital or monitored in an ambulatory setting. Patients with hematologic toxicity of grades 2 to 4 may be treated with transfusion of blood components, those with grades 3 to 4 may receive colony-stimulating factors, and those with grade 4 hematologic toxicity are potential candiates for hematopoietic cell transplantation.</div><div class=\"graphic_footnotes\"><br>* The highest degree of toxicity to any of these three organ system indicates the physiologic &quot;response category&quot; for an individual patient. All patients with hematologic toxicity of grade 2 or more require hospitalization.</div><div class=\"graphic_reference\">Reproduced with permission from: Dainiak, N. Hematologic consequences of exposure to ionizing radiation. Exp Hematol 2002; 30:513. Copyright © 2004 Elsevier Inc</div><div id=\"graphicVersion\">Graphic 80123 Version 2.0</div></div></div>"},"80124":{"type":"graphic_diagnosticimage","displayName":"MAC short-axis","title":"Mitral annular calcification, parasternal short-axis view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral annular calcification, parasternal short-axis view</div><div class=\"cntnt\"><img style=\"width:380px; height:275px;\" src=\"images/CARD/80124_MACshortaxis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parasternal short-axis view of the left ventricle showing MAC along the posterior aspect of the mitral annulus.</div><div class=\"graphic_footnotes\">MV: mitral valve; MAC: mitral annular calcification.</div><div class=\"graphic_reference\">Courtesy of Rosario V. Freeman, MD, MS.</div><div id=\"graphicVersion\">Graphic 80124 Version 4.0</div></div></div>"},"80126":{"type":"graphic_figure","displayName":"Male pelvis - Sagittal section","title":"Male pelvis - Sagittal section","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Male pelvis - Sagittal section</div><div class=\"cntnt\"><img style=\"width:531px; height:398px;\" src=\"images/SURG/80126_Male-pelvis-sagittal-section.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the median sagittal section of the male pelvis. Note the close proximity of the prostate gland to the anterior surface of the rectum.</div><div id=\"graphicVersion\">Graphic 80126 Version 1.0</div></div></div>"},"80127":{"type":"graphic_figure","displayName":"Cochlear and vestibular anatomy","title":"Cochlear and vestibular anatomy","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Cochlear and vestibular anatomy</div><div class=\"cntnt\"><img style=\"width:525px; height:704px;\" src=\"images/PC/80127_Cochlear_vestibular_ant_edt.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 80127 Version 2.0</div></div></div>"},"80128":{"type":"graphic_diagnosticimage","displayName":"Greenstick fracture radius","title":"Greenstick fracture of distal radius","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Greenstick fracture of distal radius</div><div class=\"cntnt\"><img style=\"width:385px; height:489px;\" src=\"images/EM/80128_Greenstick_fx_radius.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Greenstick fracture of distal radius and complete fracture of ulna, with minimal angulation and no displacement in an 8-year-old child. Both are metaphyseal fractures. Note that the lateral view shows the complete cortical break on the volar aspect of the radial greenstick fracture with bulging of the periosteum dorsally.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 80128 Version 5.0</div></div></div>"},"80129":{"type":"graphic_movie","displayName":"Post bronchocscopic laser resection","title":"Bronchoscopic laser resection","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchoscopic laser resection</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/80129_postlaseconv.mp4\" style=\"width:240px;height:196px\"></div><img style=\"width:257px; height:176px;\" src=\"images/CARD/80129_postlase.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchoscopy shows restablishment of a patent airway following bronchoscopic laser resection.</div><div class=\"graphic_reference\">Courtesy of Henri G Colt, MD and Praveen Mathur, MD.</div><div id=\"graphicVersion\">Graphic 80129 Version 2.0</div></div></div>"},"80130":{"type":"graphic_diagnosticimage","displayName":"UPJ obstruct blood vessel","title":"Intermittent uteropelvic obstruction due to extrinsic compression by an accessory blood vessel","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Intermittent uteropelvic obstruction due to extrinsic compression by an accessory blood vessel</div><div class=\"cntnt\"><img style=\"width:501px; height:459px;\" src=\"images/PEDS/80130_UPJ_obstruct_blood_vessel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intermittent ureteropelvic junction obstruction due to an accessory crossing blood vessel (black arrow in panel D). Panels A and B show changes in renal pelvis dilatation, which corresponded to the timing of symptoms. Pain corresponded with increased renal dilatation and evidence of obstruction on sonography and at the time of surgery (yellow arrow in panels C and D).</div><div class=\"graphic_reference\">Courtesy of Dr. Laurence S Baskin.</div><div id=\"graphicVersion\">Graphic 80130 Version 3.0</div></div></div>"},"80135":{"type":"graphic_table","displayName":"Supine hypotensive syndrome","title":"Signs and symptoms attributed to supine hypotensive syndrome in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs and symptoms attributed to supine hypotensive syndrome in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Faintness</td>\n</tr>\n<tr>\n<td>Dyspnea</td>\n</tr>\n<tr>\n<td>Dizziness</td>\n</tr>\n<tr>\n<td>Restlessness</td>\n</tr>\n<tr>\n<td>Nausea</td>\n</tr>\n<tr>\n<td>Vomiting</td>\n</tr>\n<tr>\n<td>Chest pain</td>\n</tr>\n<tr>\n<td>Abdominal pain</td>\n</tr>\n<tr>\n<td>Visual disturbances</td>\n</tr>\n<tr>\n<td>Numbness</td>\n</tr>\n<tr>\n<td>Paresthesias</td>\n</tr>\n<tr>\n<td>Headache</td>\n</tr>\n<tr>\n<td>Cold, clammy skin</td>\n</tr>\n<tr>\n<td>Pallor</td>\n</tr>\n<tr>\n<td>Cyanosis</td>\n</tr>\n<tr>\n<td>Hypotension</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 80135 Version 1.0</div></div></div>"},"80136":{"type":"graphic_diagnosticimage","displayName":"Dental plate aspiration","title":"Dental plate fragment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dental plate fragment</div><div class=\"cntnt\"><img style=\"width:331px; height:308px;\" src=\"images/PULM/80136_Dental_plate_aspiration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Encased in the left main stem bronchus following facial trauma.</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 80136 Version 2.0</div></div></div>"},"80137":{"type":"graphic_picture","displayName":"Catalase test","title":"Test for production of catalase","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Test for production of catalase</div><div class=\"cntnt\"><img style=\"width:360px; height:132px;\" src=\"images/ID/80137_Catalasetest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Catalase splits hydrogen peroxide into water and oxygen. The streptococci (left) are catalase negative while organisms such as staphylococci (right) are catalase positive and produce bubbles when mixed with hydrogen peroxide.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 80137 Version 4.0</div></div></div>"},"80138":{"type":"graphic_figure","displayName":"Clopidogrel in CREDO one year","title":"Clopidogrel after PCI","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Clopidogrel after PCI</div><div class=\"cntnt\"><img style=\"width:491px; height:363px;\" src=\"images/CARD/80138_Clopidogrel_in_CREDO_one_ye.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data from the CREDO trial of more than 2100 patients undergoing elective percutaneous coronary intervention (PCI), almost all with stenting, who were treated with a loading dose of clopidogrel or placebo before the procedure and then clopidogrel for 28 days; clopidogrel or placebo, according to original randomization, was then given for the remainder of one year. The combined end point of death, myocardial infarction, or stroke at one year occurred significantly less often in those treated with clopidogrel (relative risk reduction 26.9 percent, 95 percent CI 3.9 to 44.4 percent).</div><div class=\"graphic_reference\">Data from Steinhubl SR, Berger PB, Mann JT 3rd, et al. JAMA 2002; 288:2411.</div><div id=\"graphicVersion\">Graphic 80138 Version 2.0</div></div></div>"},"80139":{"type":"graphic_picture","displayName":"Contact derm vulva2","title":"Contact dermatitis vulva","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Contact dermatitis vulva</div><div class=\"cntnt\"><img style=\"width:360px; height:273px;\" src=\"images/OBGYN/80139_Contact_derm_vulva2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 80139 Version 2.0</div></div></div>"},"80140":{"type":"graphic_picture","displayName":"Normal lung - High","title":"Normal lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal lung</div><div class=\"cntnt\"><img style=\"width:360px; height:330px;\" src=\"images/PULM/80140_Normal_lung_High.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph shows alveoli containing capillaries within a narrow interstitium. The alveoli are lined with thin, elongated type I pneumocytes (arrow) and smaller numbers of cuboidal type II pneumocytes (dashed arrow).</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 80140 Version 2.0</div></div></div>"},"80141":{"type":"graphic_diagnosticimage","displayName":"Solitary pulmonary granuloma","title":"Lamellated calcification in pulmonary nodule","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lamellated calcification in pulmonary nodule</div><div class=\"cntnt\"><img style=\"width:361px; height:279px;\" src=\"images/PULM/80141_Solitary_pulmonary_granulom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Benign pattern of calcification in a solitary pulmonary granuloma with lamellation at the periphery of the nodule. The digital computer printout of the same nodule shows a circular agglomeration of positive values above 200 Hounsfield Units surrounded peripherally and centrally by more negative values.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 80141 Version 2.0</div></div></div>"},"80144":{"type":"graphic_figure","displayName":"Misconstruction short Roux-en-Y limb misconstruction","title":"Short Roux limb misconstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Short Roux limb misconstruction</div><div class=\"cntnt\"><img style=\"width:347px; height:434px;\" src=\"images/SURG/80144_Short-limb-roux.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 80144 Version 1.0</div></div></div>"},"80146":{"type":"graphic_picture","displayName":"Abdominal and inguinal intertrigo","title":"Intertrigo","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Intertrigo</div><div class=\"cntnt\"><img style=\"width:453px; height:317px;\" src=\"images/PC/80146_Abd_and_inguinal_intertrigo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe intertrigo of the abdominal and inguinal folds in an&nbsp;older adult&nbsp;patient.</div><div class=\"graphic_reference\">Courtsey of Eva Rawlings Parker, MD.</div><div id=\"graphicVersion\">Graphic 80146 Version 4.0</div></div></div>"},"80147":{"type":"graphic_picture","displayName":"Major histologic patterns of invasive adenocarcinoma","title":"Major histologic patterns of invasive adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Major histologic patterns of invasive adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:435px; height:658px;\" src=\"images/ONC/80147_Maj_hist_patt_invas_adeno.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Lepidic predominant pattern with mostly lepidic growth (right) and a smaller area of invasive acinar adenocarcinoma (left).<br> (B) Lepidic pattern consists of a proliferation type II pneumocytes and Clara cells along the surface alveolar walls.<br> (C) Area of invasive acinar adenocarcinoma (same tumor as in A and B).<br> (D) Acinar adenocarcinoma consists of round to oval-shaped malignant glands invading a fibrous stroma.<br> (E) Papillary adenocarcinoma consists of malignant cuboidal to columnar tumor cells growing on the surface of fibrovascular cores.<br> (F) Micropapillary adenocarcinoma consists of small papillary clusters of glandular cells growing within this airspace, most of which do not show fibrovascular cores.<br> (G) Solid adenocarcinoma with mucin consisting of sheets of tumor cells with abundant cytoplasm and mostly vesicular nuclei with several conspicuous nucleoli. No acinar, papillary, or lepidic patterns are seen, but multiple cells have intracytoplasmic basophilic globules that suggest intracytoplasmic mucin.<br> (H) Solid adenocarcinoma with mucin. Numerous intracytoplasmic droplets of mucin are highlighted with this diastase-periodic acid Schiff stain.</div><div class=\"graphic_reference\">Reproduced with permission from: Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011; 6:244. Copyright © 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80147 Version 9.0</div></div></div>"},"80148":{"type":"graphic_algorithm","displayName":"Approach hepatic hydrothorax","title":"Treatments for hepatic hydrothorax","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Treatments for hepatic hydrothorax</div><div class=\"cntnt\"><img style=\"width:441px; height:415px;\" src=\"images/GAST/80148_Approach_hepatic_hydrothora.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">All patients with confirmed hepatic hydrothorax should be referred for evaluation for liver transplantation. The first step in management is therapy with low sodium diet (88 mEq [2000 mg] per day) and diuretics (see topic review on diuretic therapy for ascites). If there is no response to diuretics, therapeutic thoracentesis of approximately 2 liters can be attempted followed by diuretics. If patients do not respond to diuretics or develop complications, they can be considered to have refractory&nbsp;hepatic hydrothorax and should be considered for transjugular intrahepatic portosystemic shunt (TIPS) placement. This measure may help as a bridge to liver transplantation. However, patients should be carefully selected. TIPS is best considered in patients younger than 70 years of age, without hepatic encephalopathy, and/or those with Child A/B cirrhosis. For patients that cannot undergo TIPS placement, consideration for pleurodesis or diaphragmatic repair by thoracoscopy should be considered. Chest tube placement should be avoided as it is associated with severe complications.</div><div class=\"graphic_footnotes\"><br />* Furosemide 40 mg/day and spironolactone 100 mg/day, and if there is no response, diuretics may be increased in a stepwise fashion every&nbsp;three to five&nbsp;days by doubling doses (ratio of 40 mg:100 mg), furosemide up to 160 mg/day and spironolactone up to 400 mg/day.</div><div id=\"graphicVersion\">Graphic 80148 Version 4.0</div></div></div>"},"80151":{"type":"graphic_table","displayName":"ADHD drugs comparison","title":"Comparison of drugs used to treat attention deficit hyperactivity disorder in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of drugs used to treat attention deficit hyperactivity disorder in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Short-acting stimulants</strong></td> <td> <p>Extensive data efficacy and safety</p> <p>Generic formulations available</p> <p>Flavored oral suspension and chewable tablet available for methylphenidate</p> </td> <td>Must be taken two to three times per day if full-day coverage is desired</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Long-acting stimulants</strong></td> <td>Can be dosed once per day (can avoid administration at school)</td> <td> <p>Side effects may extend later in the day</p> <p>Increased cost</p> Fewer generic options</td> <td>Short-acting stimulant can be added in PM for afternoon boost when needed</td> </tr> <tr> <td class=\"indent1\">Single-pulse sustained release (eg, Metadate ER)</td> <td>Generic formulations available</td> <td>&nbsp;</td> <td> <p>Must be swallowed whole</p> <p>Preferably taken 30 to 45 minutes before meal</p> </td> </tr> <tr> <td class=\"indent1\">Extended release oral suspension (Dyanavel XR, Adzenys ER), extended-release chewable tablet (Quillichew ER), or orally disintegrating tablet (Adzenys XR-ODT, Cotempla XR-ODT)</td> <td> <p>May be used for children who have difficulty swallowing pills</p> <p>These preparations are&nbsp;flavored and may be more palatable</p> </td> <td> <p>No generic options</p> <p>Increased cost</p> </td> <td> <p>May be taken with or without food*</p> <p>Do not mix oral suspensions with food or other&nbsp;liquids before taking</p> </td> </tr> <tr> <td class=\"indent1\">Sustained release bead preparations (eg, Ritalin LA, Focalin XR, Adderall XR, Metadate CD, Aptensio XR, Mydayis<sup>&#182;</sup>)</td> <td> <p>Approximates a twice-per-day or three-times-per-day dosing schedule</p> <p>Can be sprinkled into soft foods for children who have difficulty swallowing pills</p> <p>Generic formulations are available for some products</p> </td> <td>&nbsp;</td> <td> <p>The beads should not be chewed</p> <p>Some products should not be taken with antacids or other drugs that decrease gastric acidity</p> Ingestion with a high-fat meal may delay time of onset and increase peak concentration</td> </tr> <tr> <td class=\"indent1\">Osmotic release (eg, Concerta)</td> <td> <p>Approximates a three-times-per-day dosing schedule</p> <p>Generic formulations available</p> </td> <td>Children with decreased GI absorption or intestinal resection may not receive the full benefit</td> <td> <p>Capsule should not be opened or chewed</p> Capsule is passed through the GI tract and into the stool intact</td> </tr> <tr> <td class=\"indent1\">Patch (Daytrana)</td> <td>Can be used for patients who cannot take oral medications</td> <td> <p>Patch must be applied two hours before needed effect</p> <p>Has been associated with permanent loss of pigmentation at the site of application</p> <p>No generic options</p> <p>Increased cost</p> </td> <td>Early removal of the patch permits controlled duration (effects last approximately two to three hours after patch is removed)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Prodrug (Lisdexamfetamine [Vyvanse])</td> <td> <p>May have lower risk for abuse</p> <p>Capsules can be opened and mixed with water for children who have difficulty swallowing capsules</p> <p>Chewable tablet available</p> </td> <td> <p>No generic options</p> <p>Increased cost</p> </td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Atomoxetine</strong></td> <td> <p>Can be dosed once per day</p> <p>Lower potential for abuse than stimulants</p> <p>Not a controlled substance</p> <p>Generic formulation available</p> </td> <td> <p>May be less efficacious than stimulants</p> <p>Potential increased risk of suicidal ideation</p> <p>More time to steady state (up to two weeks for initial response; up to eight weeks for maximal effect)</p> <p>\"Drug holidays\" are not an option</p> </td> <td> <p>Taking with food may prevent nausea</p> Requires dosing adjustment if administered with agents that inhibit the cytochrome P450 2D6 (CYP2D6) enzyme</td> </tr> <tr> <td><strong>Extended release alpha-2-adrenergic agonists</strong></td> <td> <p>Not a controlled substance</p> <p>May also treat coexisting conditions (eg, sleep disorders, tic disorders)</p> <p>Generic formulations available</p> </td> <td> <p>May be less efficacious than stimulants</p> <p>More time to steady state (up to two weeks for initial response)</p> <p>\"Drug holidays\" are not an option</p> <p>&nbsp;</p> </td> <td> <p>Must be swallowed whole, not crushed or chewed</p> May lead to hypotension and orthostasis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ER: extended release; XR: extended release; ODT: orally disintegrating tablets;&nbsp;LA: long-acting; CD: controlled dispense; GI: gastrointestinal.<br />* Although the prescribing information indicates that Cotempla XR-ODT should be taken consistently with or without food, we suggest that it be taken consistently with food – given the general stimulant effect of appetite suppression.<br />¶ <FONT color=red><FONT color=black>Mydayis is not approved by the US Food&nbsp;and Drug Administration for children &lt;13 years.</FONT></FONT></div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Daughton JM, Kratochvil CJ. Review of ADHD pharmacotherapies: Advantages, disadvantages, and clinical pearls. J Am Acad Child Adolesc Psychiatry 2009; 48:240. </LI>&#xD;&#xA;<LI>Harpin VA. Medication options when treating children and adolescents with ADHD: Interpreting the NICE guidance 2006. Arch Dis Child Educ Pract Ed 2008; 93:58. </LI>&#xD;&#xA;<LI>Drugs for ADHD.&nbsp;Med Lett Drugs Ther 2015; 57:37.&nbsp;</LI>&#xD;&#xA;<LI>Wigal SB. Efficacy and safety limitations of attention deficit hyperactivity disorder pharmacotherapy in pediatric patients. J Pediatr 2009; 154:S13. </LI>&#xD;&#xA;<LI>US Food and Drug Administration. FDA drug safety communication: FDA reporting permanent skin color changes associated with use of Daytrana patch (methylphenidate transdermal system) for treating ADHD. Available at:&nbsp;<A spellcheck=true href=\"http://www.fda.gov/Drugs/DrugSafety/ucm452244.htm\" target=_blank>www.fda.gov/Drugs/DrugSafety/ucm452244.htm</A> (Accessed on June 30, 2015).</LI></OL>Prepared with additional information from US Food&nbsp;and Drug Administration approved product information. Available at: <A spellcheck=true href=\"http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm \" target=_blank>www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm </A>(Accessed on September 19, 2017).<br /></div><div id=\"graphicVersion\">Graphic 80151 Version 20.0</div></div></div>"},"80155":{"type":"graphic_figure","displayName":"Bicycle helmet fit","title":"Bicycle helmet fit","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bicycle helmet fit</div><div class=\"cntnt\"><img style=\"width:197px; height:270px;\" src=\"images/PEDS/80155_Bicycle_helmet_fit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A properly fitting bicycle helmet should rest just above the eyebrows and not slide around on the head. The straps of the helmet should be adjusted to form a &quot;Y&quot; just under the ear of the child. The chin strap should be snug enough to pull down on the helmet when the child opens the mouth wide.</div><div id=\"graphicVersion\">Graphic 80155 Version 1.0</div></div></div>"},"80157":{"type":"graphic_table","displayName":"Complications of oophorectomy","title":"Complications of laparoscopic oophorectomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of laparoscopic oophorectomy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Injection of air into the vascular system</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Burns</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pneumomediastinum</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Perforation of viscera or blood vessels with the Verres needle or trocar</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Nerve injury</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ureteral injuries</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Infection</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Spillage of malignant cells</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Problems with bleeding from the infundibulopelvic ligament pedicle,&nbsp; along the mesoovarium, or in the broad ligament</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Infection</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 80157 Version 1.0</div></div></div>"},"80158":{"type":"graphic_table","displayName":"Favorable predict oral devices","title":"Factors reported to favor a better response with mandibular advancement splints","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors reported to favor a better response with mandibular advancement splints</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Younger age</td>\n</tr>\n\n<tr>\n<td>Female gender</td>\n</tr>\n\n<tr>\n<td>Lower body mass index</td>\n</tr>\n\n<tr>\n<td>Smaller neck circumference</td>\n</tr>\n\n<tr>\n<td>Less severe OSA</td>\n</tr>\n\n<tr>\n<td>Supine-dependent OSA</td>\n</tr>\n\n<tr>\n<td>Healthy dentition with good protrusive range</td>\n</tr>\n\n<tr>\n<td>Longer maxilla</td>\n</tr>\n\n<tr>\n<td>Smaller oropharynx</td>\n</tr>\n\n<tr>\n<td>Smaller overjet</td>\n</tr>\n\n<tr>\n<td>Shorter soft palate</td>\n</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 80158 Version 2.0</div></div></div>"},"80159":{"type":"graphic_figure","displayName":"Survival by recipient age","title":"Kaplan-Meier survival by age group for adult lung transplantations performed between January 1990 and June 2011","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Kaplan-Meier survival by age group for adult lung transplantations performed between January 1990 and June 2011</div><div class=\"cntnt\"><img style=\"width:580px; height:338px;\" src=\"images/PULM/80159_Survival_recipient_age_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adult lung transplant recipient Kaplan-Meier survival by age group (transplants: January 1990-June 2011).</div><div class=\"graphic_reference\">Reproduced from: Yusen RD, Christie JD, Edwards LB, et al. The registry of the international society for heart and lung transplantation: thirtieth adult lung and heart-lung transplant report-2013; focus theme: age. J Heart Lung Transplant 2013; 32:965. Illustration used with the permission of Elsevier Inc. All rights reserved.<br />For additional and updated information, please see the International Society for Heart and Lung Transplantation slide set \"Overall Lung and Adult Lung Transplantation Statistics,\" slide titled \"ADULT LUNG TRANSPLANTATION\" Kaplan-Meier Survival by Age Group (Transplants: January 1990 - June 2009)\" at: <a href=\"http://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry\" target=\"_blank\">http://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry</a>.</div><div id=\"graphicVersion\">Graphic 80159 Version 13.0</div></div></div>"},"80160":{"type":"graphic_diagnosticimage","displayName":"Complex complicated cysts","title":"Ultrasound appearance of complex and complicated cysts","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Ultrasound appearance of complex and complicated cysts</div><div class=\"cntnt\"><img style=\"width:472px; height:422px;\" src=\"images/SURG/80160_Complex_complicated_cysts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Complex cyst with nodule.<br />(B) Complex cyst.<br />(C) Cyst with thin septa and nodular portion.<br />(D) Complicated cyst with \"swirling\".</div><div id=\"graphicVersion\">Graphic 80160 Version 3.0</div></div></div>"},"80161":{"type":"graphic_picture","displayName":"Nevus central globular pattern","title":"Dermoscopic image of a nevus with a peripheral reticular and central globular pattern","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of a nevus with a peripheral reticular and central globular pattern</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/80161_Nevus_cent_globular_pattern.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 80161 Version 3.0</div></div></div>"},"80162":{"type":"graphic_picture","displayName":"Acute paronychia finger 1","title":"Acute paronychia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute paronychia</div><div class=\"cntnt\"><img style=\"width:432px; height:167px;\" src=\"images/DERM/80162_Acute_paronychia_finger_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Painful erythema and swelling with a purulent collection is present in this patient with an acute paronychia.</div><div class=\"graphic_reference\">Reproduced with permission from: Wolters Kluwer. Copyright &#169; 2008.</div><div id=\"graphicVersion\">Graphic 80162 Version 1.0</div></div></div>"},"80164":{"type":"graphic_table","displayName":"Laser and light sources for treating leg veins","title":"Laser and light sources for treating leg veins","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laser and light sources for treating leg veins</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Wavelength (nm)</td> <td class=\"subtitle1\">Vein diameter (mm)</td> <td class=\"subtitle1\">Skin type</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr> <td>Nd:YAG</td> <td>1064</td> <td>0.3 to 3</td> <td>I,II,III,IV</td> <td>Pain</td> </tr> <tr> <td>PDL</td> <td>595</td> <td>&#60;1.5</td> <td>&nbsp;</td> <td>Bruising</td> </tr> <tr> <td>Diode</td> <td>800 to 900</td> <td>to 4</td> <td>I,II,III,IV</td> <td>&nbsp;</td> </tr> <tr> <td>KTP</td> <td>532</td> <td>0.5 to 1.0</td> <td>&nbsp;</td> <td>Pigmentation changes</td> </tr> <tr> <td>Alexandrite</td> <td>755</td> <td>&#62;0.4</td> <td>I,II,III</td> <td>Bruising, telangiectatic matting</td> </tr> <tr> <td>IPLS*</td> <td>500 to 1000</td> <td>&#60;1 (red)</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Nd:YAG: neodymium-doped yttrium aluminum garnet; PDL: pulse dye laser; KTP: potassium titanyl phosphate; IPLS: intense pulsed light system.<br />* Not a laser.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Kunishige JH, Goldberg LH, Friedman PM. Laser therapy for leg veins. Clin Dermatol 2007; 25:454.</li>&#xD;&#xA;    <li>Eremia S, Li C, Umar SH. A side-by-side comparative study of 1064 nm Nd:YAG, 810 nm diode and 755 nm alexandrite lasers for treatment of 0.3-3 mm leg veins. Dermatol Surg 2002; 28:224.</li>&#xD;&#xA;    <li>Chen JZ, Alexiades-Armenakas MR, Bernstein LJ, et al. Two randomized, double-blind, placebo-controlled studies evaluating the S-Caine Peel for induction of local anesthesia before long-pulsed Nd:YAG laser therapy for leg veins. Dermatol Surg 2003; 29:1012.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 80164 Version 5.0</div></div></div>"},"80165":{"type":"graphic_picture","displayName":"Lichenoid drug eruption","title":"Lichenoid drug eruption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichenoid drug eruption</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/80165_Lichenoid_drug_eruption.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous to violaceous papules with fine scale are present in this patient with a lichenoid drug eruption.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 80165 Version 3.0</div></div></div>"},"80167":{"type":"graphic_diagnosticimage","displayName":"Duct of Luschka leak","title":"Bile leak from duct of Luschka after cholecystectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bile leak from duct of Luschka after cholecystectomy</div><div class=\"cntnt\"><img style=\"width:261px; height:356px;\" src=\"images/GAST/80167_Duct_of_Luschka_leak.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiopancreatography reveals extravasation in the gallbladder bed (arrow) from a duct of Luschka.</div><div class=\"graphic_reference\">Courtesy of Michael J Bourke, MBBS, FRACP.</div><div id=\"graphicVersion\">Graphic 80167 Version 5.0</div></div></div>"},"80168":{"type":"graphic_figure","displayName":"Lyme disease map US","title":"Reported cases of Lyme disease - United States, 2014","html":"<div class=\"graphic\"><div style=\"width: 760px\" class=\"figure\"><div class=\"ttl\">Reported cases of Lyme disease - United States, 2014</div><div class=\"cntnt\"><img style=\"width:740px; height:544px;\" src=\"images/ID/80168_Lyme_disease_map_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">One dot is placed randomly within the county of residence for each confirmed case. Though Lyme disease cases have been reported in nearly every state, cases are reported based on the county of residence, not necessarily the county of infection.</div><div class=\"graphic_reference\">Reproduced from: Lyme Disease: Lyme Disease Maps, 2015. United States Centers for Disease Control and Prevention. Available at: <a href=\"http://www.cdc.gov/lyme/stats/maps.html\" target=\"_blank\">http://www.cdc.gov/lyme/stats/maps.html</a> (Accessed July 27, 2016).</div><div id=\"graphicVersion\">Graphic 80168 Version 5.0</div></div></div>"},"80169":{"type":"graphic_table","displayName":"Rapid overview of epiglottitis in children","title":"Rapid overview: Epiglottitis (supraglottitis) in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid overview: Epiglottitis (supraglottitis) in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical findings</td> </tr> <tr> <td>Respiratory distress: stridor, tachypnea, anxiety, refusal to lie down, \"sniffing\" or \"tripod\" posture</td> </tr> <tr> <td>Sore throat, dysphagia, drooling, anterior neck pain (at the level of the hyoid)</td> </tr> <tr> <td>Muffled \"hot potato\" voice or aphonia</td> </tr> <tr> <td>Marked retractions and labored breathing indicate impending respiratory failure</td> </tr> <tr> <td>Verbal patients with pain out of proportion to oropharyngeal examination</td> </tr> <tr> <td>Unimmunized or under-immunized&nbsp;patients</td> </tr> <tr> <td class=\"subtitle1_single\">Immediate management</td> </tr> <tr> <td><strong>&nbsp;Defer</strong> <strong>attempts at visualizing the epiglottis (tongue blade or any other instrument)&nbsp;or invasive procedures (eg, IV placement, phlebotomy, or any other painful or frightening intervention) until after airway assessment and managemen</strong>t</td> </tr> <tr> <td><strong>&nbsp;Prepare to manage the airway and immediately involve airway specialists (anesthesiologist or critical care physician and otolaryngologist) whenever available</strong></td> </tr> <tr> <td>&nbsp;<strong>Patient not able to maintain the airway:</strong> Attempt bag-valve mask ventilation&nbsp;</td> </tr> <tr> <td>&nbsp;&nbsp;<strong> Unable to oxygenate (pulse oximetry&nbsp;lower than high 80s or falling):</strong> Attempt endotracheal intubation by rapid sequence intubation&nbsp;first but be prepared to establish a surgical airway (eg, needle cricothyrotomy or surgical cricothyrotomy)*&nbsp;</td> </tr> <tr> <td><strong>&nbsp;&nbsp;&nbsp;Able to oxygenate&nbsp;(pulse oximetry high 80s and steady or improving)</strong>: &nbsp;Endotracheal intubation by the most capable provider, preferably&nbsp;in the operating with an otolaryngologist present<sup>&#182;</sup></td> </tr> <tr> <td> <li><strong>&nbsp;Patient able to maintain the airway</strong> </li> </td> </tr> <tr> <td>&nbsp; Provide supplemental humidified oxygen and maintain the child in a position of comfort with the parent present (eg, sitting on the parent's lap on the stretcher)</td> </tr> <tr> <td>&nbsp; Keep the patient in a setting where the airway can be rapidly managed if necessary with capable personnel and specialized airway equipment constantly available</td> </tr> <tr> <td>&nbsp; Soft-tissue radiograph of the lateral neck (portable if possible) may be helpful but necessary personnel and equipment to manage an acute airway event must remain with the patient at <strong>all </strong>times during the imaging process. </td> </tr> <tr> <td>&nbsp; Do <strong>not </strong>image&nbsp;patients with severe respiratory distress in whom it will delay definitive airway management</td> </tr> <tr> <td>&nbsp;&nbsp;&nbsp;&nbsp; Radiographic findings of epiglottitis: Enlarged epiglottis (\"thumb\" sign), loss of vallecular air space, thickened aryepiglottic folds, and/or distended hypopharynx</td> </tr> <tr> <td>&nbsp;Attempts at direct visualization are <strong>only </strong>appropriate&nbsp;in patients with no stridor or stridor without significant distress, no increase in symptoms with agitation, and no cyanosis<sup></sup>&#916; </td> </tr> <tr> <td>&nbsp;&nbsp;In children &#60;6 years of age with confirmed epiglottitis or older children who are toxic-appearing or have &#62;50 percent obstruction of the lumen by direct visualization, perform endotracheal intubation in the operating room with an otolaryngologist present</td> </tr> <tr> <td class=\"subtitle1_single\">&nbsp;Additional management</td> </tr> <tr> <td class=\"subtitle2_single\">Laboratory studies: only obtain after the airway is assessed and managed</td> </tr> <tr> <td class=\"indent1\">Epiglottal cultures after establishment of artificial airway</td> </tr> <tr> <td class=\"indent1\">Blood cultures after the airway is secured</td> </tr> <tr> <td class=\"subtitle2_single\">Antimicrobial therapy</td> </tr> <tr> <td class=\"subtitle3_single\">Administer empiric antimicrobial therapy (ceftriaxone OR cefotaxime AND an antistaphylococcal agent [eg, vancomycin or clindamycin&nbsp;as&nbsp;&nbsp;determined by the local prevalence of methicillin-resistant <em>Staphylococcus aureus </em>and, if prevalent,&nbsp;its local sensitivity profile])&#9674;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Needle cricothyroidotomy may be performed on children of any age. The age at which one can safely perform a surgical cricothyroidotomy on a child is not well established, and recommendations vary from 5 to 12 years old. Surgical cricothyroidotomy is best performed in children in whom external landmarks of the neck (eg, the cricothyroid membrane) are easily palapable.&nbsp;Refer to UpToDate topics on&nbsp;needle cricothyroidotomy with percutaneous transtracheal ventilation and emergent surgical cricothyroidotomy (cricothyrotomy).<br />​¶ Refer to UpToDate topics on the management of epiglottitis, endotracheal intubation in the pediatric patient with a difficult airway and devices for difficult endotracheal intubation in children. <br />​Δ&nbsp;Refer to UpToDate topics on the diagnosis of epiglottitis for an approach to examining the oropharynx of children with epiglottitis. <br />◊For antibiotic regimens refer to UpToDate tables on intravenous antimicrobial treatment regimens for epiglottitis and UpToDate topics on the management of epiglottitis.</div><div id=\"graphicVersion\">Graphic 80169 Version 11.0</div></div></div>"},"80170":{"type":"graphic_table","displayName":"Examples of medications associated with hair loss","title":"Examples of medications associated with telogen hair loss","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of medications associated with telogen hair loss</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td>Acitretin</td> <td>Heavy metals</td> </tr> <tr> <td>Amantadine</td> <td>Hormones</td> </tr> <tr> <td>Amiodarone</td> <td>Isotretinoin</td> </tr> <tr> <td>Anticoagulants</td> <td>Ketoconazole</td> </tr> <tr> <td>Anticonvulsants</td> <td>Lithium</td> </tr> <tr> <td>Captopril</td> <td>Penicillamine</td> </tr> <tr> <td>Cholesterol lowering drugs</td> <td>Propanolol</td> </tr> <tr> <td>Cimetidine</td> <td>Valproic acid</td> </tr> <tr> <td>Colchicine</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data adapted and modified from: Litt JZ. Litt's Pocketbook of Drug Eruptions and Interactions, 3rd ed, The Parthenon Publishing Group, New York 2004.</div><div id=\"graphicVersion\">Graphic 80170 Version 5.0</div></div></div>"},"80171":{"type":"graphic_diagnosticimage","displayName":"Relapsing polychondritis CT","title":"CT scan of the chest in relapsing polychondritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan of the chest in relapsing polychondritis</div><div class=\"cntnt\"><img style=\"width:377px; height:230px;\" src=\"images/RHEUM/80171_Relapsing_polychondritis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest CT during inspiration (panel A) and expiration (panel B) in a patient with relapsing polychondritis. The trachea (panel A) and the proximal bronchi (arrow in B) show mild diffuse wall thickening and luminal narrowing.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jerome H Herman, MD.</div><div id=\"graphicVersion\">Graphic 80171 Version 3.0</div></div></div>"},"80175":{"type":"graphic_figure","displayName":"Postop nomogram sarcoma","title":"Postoperative nomogram for 12-year sarcoma-specific death based upon data from 2163 patients treated at Memorial Sloan Kettering Cancer Center","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Postoperative nomogram for 12-year sarcoma-specific death based upon data from 2163 patients treated at Memorial Sloan Kettering Cancer Center</div><div class=\"cntnt\"><img style=\"width:517px; height:412px;\" src=\"images/ONC/80175_Postop_nomogram_sarcoma.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>Instructions for physician:</strong> Locate the patient's tumor size on the Size axis. Draw a line straight upwards to the Points axis to determine how many points towards sarcoma-specific death the patient receives for tumor size. Repeat this process for the other axes, each time drawing straight upward to the Points axis. Sum the points achieved for each predictor, and locate this sum on the Total Points axis. Draw a line straight down to either the Low Grade or High Grade axis to find the patient's probability of dying from sarcoma within 12 years assuming he or she does not die of another cause first. <strong>Instructions to patient:</strong> &quot;If we had 100 patients exactly like you, we would expect between (predicted percentage from nomogram - 8 percent) and (predicted percentage + 8 percentage) to die of sarcoma within 12 years if they did not die of another cause first. Death from sarcoma after 12 years is still possible.&quot;</div><div class=\"graphic_footnotes\">Fibro: fibrosarcoma; Lipo: liposarcoma; Leiomyo: leiomyosarcoma; MFH: malignant fibrous histiocytoma; MPNT: malignant peripheral-nerve tumor; SSD: sarcoma-specific death.</div><div class=\"graphic_reference\">Reproduced with permission from: Kattan MW, Leung DHY, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Onc 2002; 20:791. Copyright © 2002 American Society of Clinical Oncology.</div><div id=\"graphicVersion\">Graphic 80175 Version 3.0</div></div></div>"},"80177":{"type":"graphic_table","displayName":"Pertussis CDC case definitions","title":"Centers for Disease Control and Prevention case definition for pertussis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Centers for Disease Control and Prevention case definition for pertussis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical criteria</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cough illness lasting &#8805;2 weeks, without a more likely diagnosis and at least one of the following: <ul class=\"decimal_heading\"> <li>Paroxysms of coughing, <strong>or</strong> </li> <li>Inspiratory whoop, <strong>or</strong> </li> <li>Posttussive vomiting, <strong>or</strong> </li> <li>For infants &#60;1 year, apnea (with or without cyanosis) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory criteria</td> </tr> <tr> <td class=\"indent1\">Isolation of <em>B. pertussis</em> from a clinical specimen</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Positive PCR for pertussis</td> </tr> <tr> <td class=\"subtitle1_single\">Epidemiologic linkage</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Contact with a laboratory-confirmed case of pertussis*</td> </tr> <tr> <td class=\"subtitle1_single\">Case classification</td> </tr> <tr> <td class=\"indent1\"><strong>Confirmed</strong></td> </tr> <tr> <td class=\"indent2\">Acute cough illness of any duration, with isolation of <em>B. pertussis</em> from a clinical specimen, <strong>or</strong></td> </tr> <tr> <td class=\"indent2\">Clinical criteria (as above) and PCR positive for pertussis, <strong>or</strong></td> </tr> <tr> <td class=\"indent2\">Clinical criteria (as above) and contact with a laboratory-confirmed case of pertussis*</td> </tr> <tr> <td class=\"indent1\"><strong>Probable</strong></td> </tr> <tr> <td class=\"indent2\">Clinical criteria (as above) <strong>and</strong> absence of laboratory confirmation <strong>and</strong> no epidemiologic linkage, <strong>or</strong></td> </tr> <tr> <td class=\"indent2\">For infants &#60;1 year, acute cough illness of <strong>any duration</strong> with at least one of the following: <ul class=\"decimal_heading\"> <li>Paroxysms of coughing </li> <li>Inspiratory whoop </li> <li>Posttussive vomiting </li> <li>Apnea (with or without cyanosis) </li> </ul> <strong>And:</strong> <ul class=\"decimal_heading\"> <li>PCR positive for pertussis or contact with a laboratory confirmed case </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PCR: polymerase chain reaction.<br />* An illness meeting the clinical case definition should be classified as \"probable\" rather than \"confirmed\" if it occurs in a patient who has contact with an infant aged &lt;1 year who is PCR positive for pertussis and has &ge;1 sign or symptom and cough duration &lt;14 days.</div><div class=\"graphic_reference\">Source: National Notifiable Diseases Surveillance System (NNDSS). Pertussis (Whooping Cough) (Bordetella pertussis): 2014 Case Definition. Centers for Disease Control and Prevention. Available at: <a href=\"http://wwwn.cdc.gov/nndss/conditions/pertussis/case-definition/2014/\" target=\"_blank\">http://wwwn.cdc.gov/nndss/conditions/pertussis/case-definition/2014/</a> (Accessed on October 1, 2014).</div><div id=\"graphicVersion\">Graphic 80177 Version 8.0</div></div></div>"},"80179":{"type":"graphic_picture","displayName":"Urethral caruncle","title":"Urethral caruncle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urethral caruncle</div><div class=\"cntnt\"><img style=\"width:300px; height:399px;\" src=\"images/OBGYN/80179_Urethral_caruncle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urethral caruncles are soft pink or red, sessile or pedunculated, lesions protruding from the urethral meatus.</div><div class=\"graphic_reference\">Courtesy of Toby Chai, MD, University of Maryland School of Medicine.</div><div id=\"graphicVersion\">Graphic 80179 Version 2.0</div></div></div>"},"80180":{"type":"graphic_table","displayName":"Causes false positive pheo","title":"Medications that may increase measured levels of catecholamines and metanephrines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications that may increase measured levels of catecholamines and metanephrines</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Tricyclic antidepressants</td> </tr> <tr> <td>Levodopa</td> </tr> <tr> <td>Drugs containing adrenergic receptor agonists (eg, decongestants)</td> </tr> <tr> <td>Amphetamines</td> </tr> <tr> <td>Buspirone and most psychoactive agents</td> </tr> <tr> <td>Prochlorperazine</td> </tr> <tr> <td>Reserpine</td> </tr> <tr> <td>Withdrawal from clonidine and other drugs</td> </tr> <tr> <td>Ethanol</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80180 Version 2.0</div></div></div>"},"80182":{"type":"graphic_table","displayName":"Dietary counseling tips","title":"Tips for dietary counseling in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tips for dietary counseling in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Challenge</td> <td class=\"subtitle1\">Possible solutions</td> </tr> <tr> <td rowspan=\"4\">Family has little or no structure to dietary patterns (few family meals, meals are not eaten at the table, television on during meals, etc...)</td> <td>Encourage family to eat meals together.</td> </tr> <tr> <td>Emphasize scheduling of meals and snacks.</td> </tr> <tr> <td>Avoid skipping meals.</td> </tr> <tr> <td>Limit meal-time distractions (eg, television).</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Child is motivated by sports and activity, but has little interest in making dietary changes</td> <td>Emphasize physical activity as primary goal; frame dietary recommendations as tools to be stronger and improve athletic performance.</td> </tr> <tr> <td>Discuss energy in versus energy out; emphasize the importance of achieving proper balance between nutrition and activity.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Family frequently eats meals away from home</td> <td>Identify barriers that prevent families from eating at home more often.</td> </tr> <tr> <td>Provide meal-planning resources, initially using recipes that are familiar to them; begin the process of cooking more at home using these recipes.</td> </tr> <tr> <td>Assess the type of restaurant, usual selections, and discuss alternatives.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Large portion sizes</td> <td>Emphasize structured (pre-planned and timed) meals and snacks.</td> </tr> <tr> <td>Provide tools and education to help child learn to pay attention to bodily cues for hunger and fullness.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Fast eating pace</td> <td>Emphasize that eating slowly is important in recognizing fullness.</td> </tr> <tr> <td>Provide family with strategies to slow down eating pace.</td> </tr> <tr> <td>Discuss \"mindful eating\" and encourage all family members to practice slow, mindful eating.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Poor dietary quality (lack of fruits/vegetables and whole grains, consumption of whole milk, etc...)</td> <td>Provide education about food groups, discussing the importance of each food group as part of the daily diet.</td> </tr> <tr> <td>One approach is to discuss the concept of a \"balanced plate,\" focusing on supplying ample vegetables, fruits and fiber (approximately 1/4 plate each for vegetables, grains, fruits, and protein). Guidance available at <a href=\"http://www.choosemyplate.gov/\" target=\"_blank\">www.choosemyplate.gov</a>.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Lacks nutritional knowledge (no label reading, does not make shopping list, etc...)</td> <td>Assess family's level of nutritional knowledge, and start by helping them set small goals, such as balancing their plates or providing a variety of foods.</td> </tr> <tr> <td>When the family is ready, increase goals gradually by discussing which foods should be eaten most often, which foods should be eaten sparingly, and teaching the family how to read food labels.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Excessive refined grains (white bread) and simple carbohydrates (sugars)</td> <td>Emphasize the importance of including fiber in the diet as a means of decreasing hunger and feeling full after eating.</td> </tr> <tr> <td>Explain that whole grains are digested and absorbed at a slower rate than refined gains and sugars, resulting in a more stable blood sugar which reduces hunger and is healthier.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">High-fat dairy intake</td> <td>Compare nutritional information in high fat dairy products to low fat dairy products.</td> </tr> <tr> <td>Discuss types of fat: which fats are healthier, and which fats should be avoided (ie, trans fats and saturated fats).</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Skipping meals</td> <td>Emphasize the importance of eating three regularly-scheduled meals a day to have a healthy weight and metabolism.</td> </tr> <tr> <td>Explain that meal-skipping can lead to increased hunger and excessive eating later.</td> </tr> <tr> <td>Start by establishing a small goal to eat just one food group at the time that they would usually skip a meal.</td> </tr> <tr> <td>Increase goal gradually by introducing other food groups as the child is ready; encouraging them to achieve a balanced meal.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Excessive snacking</td> <td>Set a snack schedule between meals to encourage less grazing.</td> </tr> <tr> <td>Outline several choices for healthy snacks.</td> </tr> <tr> <td>Emphasize the importance of eating a single portion of food from two different food groups to encourage fullness until the next meal.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">High intake of sugar-sweetened beverages</td> <td>Discuss empty calories from sugar-containing beverages (which include 100 percent fruit juice).</td> </tr> <tr> <td>Estimate the number of calories that the child is currently taking from beverages.</td> </tr> <tr> <td>Suggest low-sugar alternatives for family to try.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Low fruit and vegetable intake</td> <td>Provide education regarding serving sizes of vegetables and fruits.</td> </tr> <tr> <td>Discuss the importance of fiber from vegetables and fruits.</td> </tr> <tr> <td>Have the family try new vegetables and fruits to increase variety.</td> </tr> <tr> <td>Provide quick and easy recipes or products.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Picky eating</td> <td>Introduce child to new foods gradually.</td> </tr> <tr> <td>Provide the same foods for each family member; no \"special orders.\"</td> </tr> <tr> <td>Eat meals and snacks together as a family.</td> </tr> <tr> <td>Structure meals and snacks.</td> </tr> <tr> <td>Encourage, but do not pressure child to eat a specific food. Continue to offer the same food on multiple occasions.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80182 Version 9.0</div></div></div>"},"80183":{"type":"graphic_picture","displayName":"Cold sore PI","title":"Cold sores (fever blisters)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cold sores (fever blisters)</div><div class=\"cntnt\"><img style=\"width:396px; height:228px;\" src=\"images/PI/80183_ColdsorePI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cold sores are caused by an infection with a herpes virus. They start out as blisters that break open and then form a scab.</div><div class=\"graphic_reference\">Reproduced with permission from: Neville B, et al: Color Atlas of Clinical Oral Pathology. Philadelphia: Lea &amp; Febiger, 1991. Copyright © 1991 Wolters Kluwer Health.</div><div id=\"graphicVersion\">Graphic 80183 Version 7.0</div></div></div>"},"80185":{"type":"graphic_figure","displayName":"Causes maternal death","title":"Global causes of maternal mortality","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Global causes of maternal mortality</div><div class=\"cntnt\"><img style=\"width:518px; height:410px;\" src=\"images/OBGYN/80185_Causes_maternal_death.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: The World Health Report 2005: Make every mother and child count. World Health Organization, Geneva 2005. Copyright &#169;2005 World Health Organization.</div><div id=\"graphicVersion\">Graphic 80185 Version 1.0</div></div></div>"},"80186":{"type":"graphic_picture","displayName":"Mechanical triggering PI","title":"Trigger finger","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trigger finger</div><div class=\"cntnt\"><img style=\"width:369px; height:275px;\" src=\"images/PI/80186_Mechanical_triggering.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When a person with trigger finger straightens the fingers, the condition causes a finger to &quot;catch&quot; or &quot;lock&quot; in the bent position.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 80186 Version 1.0</div></div></div>"},"80188":{"type":"graphic_table","displayName":"Bacteriology of SBP","title":"Bacteria isolated from ascitic fluid in 519 patients with spontaneous bacterial peritonitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bacteria isolated from ascitic fluid in 519 patients with spontaneous bacterial peritonitis</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Organism\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Percent of isolates\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Escherichia coli</td>\r\n  \r\n   <td>43</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Klebsiella pneumoniae</td>\r\n  \r\n   <td>11</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Streptococcus pneumoniae</td>\r\n  \r\n   <td>9</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Other streptococcal species</td>\r\n  \r\n   <td>19</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Enterobacteriaceae</td>\r\n  \r\n   <td>4</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Staphylococcus</td>\r\n  \r\n   <td>3</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pseudomonas</td>\r\n  \r\n   <td>1</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Miscellaneous*</td>\r\n  \r\n   <td>10</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">*In some regions of the world, such as Korea, Aeromonas hydrophila infection is an important cause of SBP, particularly in warm weather months. Affected patients commonly also have diarrhea. [Choi JP, et al. Clin Infect Dis 2008; 47:67.]</div><div class=\"graphic_reference\">Data from McHutchison JG, Runyon BA. Spontaneous bacterial peritonitis. In: Gastrointestinal and Hepatic Infections, Surawicz CM, Owen RL (Eds), WB Saunders, Philadelphia 1995. p.455.</div><div id=\"graphicVersion\">Graphic 80188 Version 3.0</div></div></div>"},"80190":{"type":"graphic_figure","displayName":"Humeral ulnar angle","title":"Anteroposterior radiograph angles of the elbow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anteroposterior radiograph angles of the elbow</div><div class=\"cntnt\"><img style=\"width:202px; height:516px;\" src=\"images/EM/80190_Humeralulnarangle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The humeral-ulnar angle.</div><div class=\"graphic_reference\">Reproduced with permission from: Beaty JH, Kasser JR. The elbow region: General concepts in the pediatric patient. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 80190 Version 12.0</div></div></div>"},"80193":{"type":"graphic_figure","displayName":"Macula lutea with AMD","title":"Macula lutea and ocular structures with age-related macular degeneration (AMD)","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Macula lutea and ocular structures with age-related macular degeneration (AMD)</div><div class=\"cntnt\"><img style=\"width:500px; height:509px;\" src=\"images/PC/80193_MaculaluteawithAMD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Fundus photograph of normal retina. The macula is the central part of the retina. The fovea is about the size of the optic nerve (diameter, 1500 micrometer) and is centered on the foveola. The foveola is the thinnest part of the retina. It&nbsp;is responsible for the most acute detailed vision.<br />(B) Cross section of normal retina, choroid, and sclera. A photon of light must penetrate all of the layers of the retina before being absorbed and converted into a neural signal by the photoreceptor outer segments.&nbsp;The retinal photoreceptors and retinal pigment epithelium (RPE) are metabolically active cells that depend on the choroidal vasculature to supply oxygen and nutrients and remove metabolic waste.<br />(C) <STRONG>Dry AMD or nonneovascular AMD</STRONG> is characterized by nodular, hard drusen (localized deposits of extracellular material), with sharp edges, diffuse soft drusen, and RPE hyperplasia and hyperpigmentation. The risk for progression to wet or neovascular AMD increases with increasing number and size of drusen and the presence of RPE pigmentary abnormalities. <STRONG>Wet AMD or neovascular AMD</STRONG> is characterized by the intrusion of abnormal new vessels from the choroid into the subretinal (type 2) or sub-RPE (type 1) space. In some cases, neovascularization may originate from the retinal vessels (not shown), with or without a choroidal component. Choroidal neovascularization often exudes fluid or hemorrhage into the subretinal or sub-RPE space.</div><div class=\"graphic_reference\">Reproduced with permission from: Arroyo JG. A 76-Year Old Man With Macular Degeneration. JAMA 2006; 295:2394. Copyright © 2006 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 80193 Version 17.0</div></div></div>"},"80194":{"type":"graphic_picture","displayName":"Tumor embolus Gross","title":"Pulmonary tumor embolism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary tumor embolism</div><div class=\"cntnt\"><img style=\"width:319px; height:231px;\" src=\"images/PULM/80194_Tumor_embolus_Gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Autopsy photograph shows a serpiginous tumor embolus (arrow) at the bifurcation of the pulmonary artery.</div><div class=\"graphic_reference\">From: Colby TV, Koss MN, Travis WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.</div><div id=\"graphicVersion\">Graphic 80194 Version 2.0</div></div></div>"},"80195":{"type":"graphic_table","displayName":"CKD factors that affect hemostasis","title":"Chronic kidney disease factors that affect hemostasis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chronic kidney disease factors that affect hemostasis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Factors predisposing to bleeding</td> </tr> <tr> <td>Platelet abnormalities including subnormal dense granule content</td> </tr> <tr> <td>Reduction in intracellular ADP and serotonin</td> </tr> <tr> <td>Impaired release of the platelet alpha-granule protein and beta-thromboglobulin</td> </tr> <tr> <td>Enhanced intracellular cAMP and abnormal mobilization of platelet Ca2+</td> </tr> <tr> <td>Abnormal platelet arachidonic acid metabolism</td> </tr> <tr> <td>Defective cyclo-oxygenase activity</td> </tr> <tr> <td>Abnormality of the activation-dependent binding activity of GPIIb/IIIa</td> </tr> <tr> <td>Increased formation of vascular PGI2</td> </tr> <tr> <td>Altered von Willebrand factor</td> </tr> <tr> <td class=\"subtitle2_left\">Indirectly</td> </tr> <tr> <td class=\"indent1\">Presence of uremic toxins, especially parathyroid hormone</td> </tr> <tr> <td class=\"indent1\">Anemia/altered blood rheology</td> </tr> <tr> <td class=\"indent1\">Erythropoietin deficiency</td> </tr> <tr> <td class=\"indent1\">Specific drug treatment (eg, nonsteroidal anti-inflammatory drugs)</td> </tr> <tr> <td class=\"subtitle1_single\">Procoagulant factors</td> </tr> <tr> <td>The high prevalence of systemic inflammation, atherosclerosis, and diffuse endothelial damage may provide a substrate for hypercoagulability</td> </tr> <tr> <td>Dysfunctional activated protein C metabolism, possibly through multiple mechanisms</td> </tr> <tr> <td>The fibrinolytic system is also dysfunctional because of both elevated plasminogen activator inhibitor-1 to tissue-type plasminogen activator ratios and inhibition of plasmin by increased levels of lipoprotein(a)</td> </tr> <tr> <td>Defects in the expression of glycoprotein GPIb (the receptor for von Willebrand factor)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADP: adenosine diphosphate; cAMP: cyclic adenosine diphosphate; CKD: chronic kidney disease; GP: glycoprotein; PG: prostaglandin.</div><div class=\"graphic_reference\">Reproduced with permission from: Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20:705. Copyright © 2009 American Society of Nephrology.</div><div id=\"graphicVersion\">Graphic 80195 Version 7.0</div></div></div>"},"80196":{"type":"graphic_figure","displayName":"Effect of weight loss in OHS","title":"Weight loss lowers arterial carbon dioxide (PaCO<SUB>2</SUB>) in OHS","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Weight loss lowers arterial carbon dioxide (PaCO<SUB>2</SUB>) in OHS</div><div class=\"cntnt\"><img style=\"width:492px; height:280px;\" src=\"images/PULM/80196_Effect_of_weight_loss_in_OH.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Weight loss in patients with the obesity hypoventilation syndrome (OHS) lowers the arterial PaCO<sub>2</sub>. Each line represents a different patient.</div><div class=\"graphic_reference\">Original figure modified for this publication. Rochester DF, Enson Y. Current concepts in the pathogenesis of the obesity-hypoventilation syndrome. Am J Med 1974; 57:402. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 80196 Version 3.0</div></div></div>"},"80197":{"type":"graphic_picture","displayName":"Four cuff segmental pressures","title":"Four cuff segmental pressures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Four cuff segmental pressures</div><div class=\"cntnt\"><img style=\"width:432px; height:243px;\" src=\"images/SURG/80197_Four_cuff_seg_pressures.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cuffs are placed on the high thigh, low thigh, below the knee and at the ankle.</div><div class=\"graphic_reference\">Courtesy of the Division of Vascular Surgery at OHSU.</div><div id=\"graphicVersion\">Graphic 80197 Version 1.0</div></div></div>"},"80198":{"type":"graphic_picture","displayName":"Staphylococcal scalded skin syndrome close view","title":"Staphylococcal scalded skin syndrome","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Staphylococcal scalded skin syndrome</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/80198_Staphylococcal_syndro_close.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A wrinkled appearance to the skin, bullae, and desquamation are present in this patient with staphylococcal scalded skin syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 80198 Version 1.0</div></div></div>"},"80199":{"type":"graphic_picture","displayName":"Vulva trauma","title":"Major vuvlar trauma from motor vehicle accident","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Major vuvlar trauma from motor vehicle accident</div><div class=\"cntnt\"><img style=\"width:342px; height:504px;\" src=\"images/OBGYN/80199_Vulva_trauma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive laceration with abrasion and debris from road.</div><div class=\"graphic_reference\">Courtesy of Marc Laufer, MD.</div><div id=\"graphicVersion\">Graphic 80199 Version 2.0</div></div></div>"},"80200":{"type":"graphic_picture","displayName":"AML FAB M2 and t8 21","title":"Acute myeloid leukemia with t(8;21)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute myeloid leukemia with t(8;21)</div><div class=\"cntnt\"><img style=\"width:395px; height:287px;\" src=\"images/HEME/80200_AML_FAB_M2_and_t8_21.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow smear from a 23-year-old female with acute myeloid leukemia with maturation (FAB-M2) associated with a t(8;21) chromosomal aabnormality. The myeloblasts have abundant cytoplasm and cytoplasmic vacuoles (black arrows). One myeloblast contains a prominent Auer rod (red arrow). (Wright-Giemsa stain).</div><div class=\"graphic_reference\">From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 80200 Version 1.0</div></div></div>"},"80201":{"type":"graphic_diagnosticimage","displayName":"Vertebral artery flow in subclavian steal syndrome","title":"Vertebral artery flow in subclavian steal syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vertebral artery flow in subclavian steal syndrome</div><div class=\"cntnt\"><img style=\"width:374px; height:225px;\" src=\"images/CARD/80201_Vertebral_flow_subclavian_s.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pulse-waved Doppler spectral display shows retrograde flow in the left vertebral artery in a patient with a hemodynamically significant left subclavian artery stenosis.</div><div class=\"graphic_reference\">Courtesy of Peter Spittell, MD.</div><div id=\"graphicVersion\">Graphic 80201 Version 3.0</div></div></div>"},"80202":{"type":"graphic_figure","displayName":"Components energy expenditure","title":"Components of energy expenditure","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Components of energy expenditure</div><div class=\"cntnt\"><img style=\"width:454px; height:261px;\" src=\"images/ENDO/80202_Components_energy_expenditu.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The components of energy expenditure are basal metabolic activities (such as heat production for maintenance of body temperature, maintenance of ionic gradients across cells, cardiac and respiratory function), the thermic effect of food (thermogenesis), and physical activity.</div><div class=\"graphic_reference\">Courtesy of George A Bray, MD.</div><div id=\"graphicVersion\">Graphic 80202 Version 1.0</div></div></div>"},"80205":{"type":"graphic_picture","displayName":"BAL in alveolar proteinosis with eosinophilic bodies","title":"PAS stain of bronchoalveolar lavage fluid in pulmonary alveolar proteinosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">PAS stain of bronchoalveolar lavage fluid in pulmonary alveolar proteinosis</div><div class=\"cntnt\"><img style=\"width:429px; height:281px;\" src=\"images/PULM/80205_PAP_eosinophilic_bodies_Hig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microscopy of bronchoalveolar lavage fluid from a patient with pulmonary alveolar proteinosis shows large acellular eosinophilic bodies in a background of eosinophilic granules.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King, Jr, MD.</div><div id=\"graphicVersion\">Graphic 80205 Version 3.0</div></div></div>"},"80206":{"type":"graphic_figure","displayName":"Sites associated with pressure-induced injury","title":"Sites associated with pressure-induced injury","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Sites associated with pressure-induced injury</div><div class=\"cntnt\"><img style=\"width:570px; height:444px;\" src=\"images/SURG/80206_Pressure_ulcer_sites.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Common sites for development of pressure-induced skin and soft tissue injury.</div><div class=\"graphic_reference\">Reproduced with permission from: Taylor CR, Lillis C, LeMone P, Lynn P. Fundamentals of Nursing: The Art And Science Of Nursing Care, Sixth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80206 Version 3.0</div></div></div>"},"80210":{"type":"graphic_figure","displayName":"Meta analysis ACEI in HF","title":"ACE inhibitors reduce mortality in patients with left ventricular dysfunction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">ACE inhibitors reduce mortality in patients with left ventricular dysfunction</div><div class=\"cntnt\"><img style=\"width:336px; height:245px;\" src=\"images/CARD/80210_Meta_analysis_ACEI_in_HF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A meta-analysis of five trials involving 12,763 patients with left ventricular dysfunction who were followed for 35 months found that therapy with an angiotensin converting enzyme (ACE) inhibitor significantly reduced mortality (23 versus 26.8 percent, odds ratio 0.80, p &lt;0.0001). There is continuing divergence in the mortality curves during the follow-up that exceeds four years.</div><div class=\"graphic_reference\">Data from Flather MD, Yusuf S, Kober L, et al. Lancet 2000; 355:1575.</div><div id=\"graphicVersion\">Graphic 80210 Version 2.0</div></div></div>"},"80211":{"type":"graphic_waveform","displayName":"M mode Chagasic cardiomyopathy","title":"Chagas' cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chagas' cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:433px; height:245px;\" src=\"images/CARD/80211_M_mode_Chagasic_cardiomyopa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The M mode echocardiographic scan (from the left ventricular apex to aortic root) from a patient with Chagas' cardiomopathy shows a dilated left ventricle (LV) and left atrium (LA) and the posterior wall (PW) shows very little systolic thickening while the septal (S) motion is exaggerated. There is significant mitral valve (MV)-S separation. This picture is somewhat similar to that encountered in patients with inferior infarction and mitral regurgitation.</div><div class=\"graphic_footnotes\">Ao: aortic root.</div><div id=\"graphicVersion\">Graphic 80211 Version 3.0</div></div></div>"},"80212":{"type":"graphic_picture","displayName":"Iridodialysis II","title":"Iridodialysis II","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Iridodialysis II</div><div class=\"cntnt\"><img style=\"width:407px; height:273px;\" src=\"images/EM/80212_Iridodialysis_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph showing an iridodialysis (iris torn away from the iris root) resulting from blunt trauma.</div><div class=\"graphic_reference\">Photo courtesy of Kathryn A Colby, MD, PhD, Massachusetts Eye and Ear Infirmary, Boston.</div><div id=\"graphicVersion\">Graphic 80212 Version 3.0</div></div></div>"},"80214":{"type":"graphic_table","displayName":"Sources dietary fat","title":"Sources of dietary fat","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sources of dietary fat</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type of fat </td> <td class=\"subtitle1\">Food sources </td> </tr> <tr> <td>Monounsaturated fatty acids</td> <td>Vegetable oils (canola, olive, sunflower, safflower), peanut, tree nuts, seeds, avocado</td> </tr> <tr> <td>Polyunsaturated fatty acids; n-3 or omega-3</td> <td> <p>ALA - Vegetable oils (canola, soybean, walnut), flax/linseed/hemp/chia seed, wheat germ; also vegetables of the cabbage family and some fortified eggs</p> <p>EPA and DHA - Seafood (especially fatty fish); some infant formulas and fortified eggs</p> </td> </tr> <tr> <td>Polyunsaturated fatty acids; n-6 or omega-6</td> <td>LA - Vegetable oils (soybean, corn, cottonseed), peanut, tree nuts, seeds, other vegetable sources, poultry</td> </tr> <tr> <td>Saturated fatty acids</td> <td>Full-fat or fat-reduced dairy products, meat, poultry, vegetable oils (coconut, palm kernel, palm)</td> </tr> <tr> <td>Trans fatty acids</td> <td>Partially hydrogenated vegetable oils (stick and full-fat margarine, commercial baked goods, deep fried foods)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALA: alpha-linolenic acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; LA: linoleic acid.</div><div id=\"graphicVersion\">Graphic 80214 Version 7.0</div></div></div>"},"80215":{"type":"graphic_picture","displayName":"Barretts esophagus with high grade dysplasia CPC Light","title":"Barrett's esophagus with high grade dysplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Barrett's esophagus with high grade dysplasia</div><div class=\"cntnt\"><img style=\"width:360px; height:269px;\" src=\"images/GAST/80215_Barretts_high-grade_CPC_Lig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power of a biopsy specimen with high grade glandular dysplasia. Compared to low grade dysplasia, the cells here have higher nuclear-cytoplasmic ratios, are more hyperchromatic, and demonstrate a lack of maturation at the mucosal surface.</div><div class=\"graphic_reference\">Courtesy of Donald Antonioli, MD.</div><div id=\"graphicVersion\">Graphic 80215 Version 2.0</div></div></div>"},"80216":{"type":"graphic_table","displayName":"AML prognostic value European LeukemiaNet classification","title":"Prognostic value of European LeukemiaNet classification in acute myeloid leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prognostic value of European LeukemiaNet classification in acute myeloid leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup span=\"3\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Genetic group</td> <td class=\"subtitle1\">Subsets</td> <td class=\"subtitle1\">CR (%)</td> <td class=\"subtitle1\">DFS (%)</td> <td class=\"subtitle1\">OS (%)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Favorable</td> <td>t(8;21)(q22;q22); <em>RUNX1-RUNX1T1</em></td> <td class=\"divider_bottom\" rowspan=\"4\"> <p>Younger adults: 96</p> Older adults: 83</td> <td class=\"divider_bottom\" rowspan=\"4\"> <p>Younger adults: 55</p> Older adults: 24</td> <td class=\"divider_bottom\" rowspan=\"4\"> <p>Younger adults: 66</p> Older adults: 33</td> </tr> <tr> <td>inv(16)(p13.1q22) or t(16;16)(p13.1;q22); <em>CBFB-MYH11</em></td> </tr> <tr> <td>Mutated <em>NPM1</em> without <em>FLT3</em>-ITD (normal karyotype)</td> </tr> <tr class=\"divider_bottom\"> <td>Mutated <em>CEBPA</em> (normal karyotype)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Intermediate-I*</td> <td>Mutated <em>NPM1</em> and <em>FLT3</em>-ITD (normal karyotype)</td> <td class=\"divider_bottom\" rowspan=\"3\"> <p>Younger adults: 76</p> Older adults: 61</td> <td class=\"divider_bottom\" rowspan=\"3\"> <p>Younger adults: 23</p> Older adults: 10</td> <td class=\"divider_bottom\" rowspan=\"3\"> <p>Younger adults: 28</p> Older adults: 11</td> </tr> <tr> <td>Wild-type <em>NPM1</em> and <em>FLT3</em>-ITD (normal karyotype)</td> </tr> <tr class=\"divider_bottom\"> <td>Wild-type <em>NPM1</em> without <em>FLT3</em>-ITD (normal karyotype)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Intermediate-II</td> <td>t(9;11)(p22;q23); <em>MLLT3-MLL</em></td> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Younger adults: 79</p> Older adults: 63</td> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Younger adults: 34</p> Older adults: 11</td> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Younger adults: 45</p> Older adults: 16</td> </tr> <tr class=\"divider_bottom\"> <td>Cytogenetic abnormalities not classified as favorable or adverse<sup>&#182;</sup></td> </tr> <tr> <td rowspan=\"4\">Adverse</td> <td>inv(3)(q21q26.2) or t(3;3)(q21;q26.2); <em>RPN1-EVI1</em></td> <td rowspan=\"4\"> <p>Younger adults: 50</p> Older adults: 39</td> <td rowspan=\"4\"> <p>Younger adults: 10</p> Older adults: 6</td> <td rowspan=\"4\"> <p>Younger adults: 12</p> Older adults: 3</td> </tr> <tr> <td>t(6;9)(p23;q34); <em>DEK-NUP214</em></td> </tr> <tr> <td>t(v;11)(v;q23); <em>MLL</em> rearranged</td> </tr> <tr> <td>&ndash;5 or del(5q); &ndash;7; abnl(17p); complex karyotype<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The European LeukemiaNet classification in AML uses cytogenetic and molecular data to identify four prognostic groups. When applied to 818 younger adults (&lt;60 years) and 732 older adults with primary AML treated within cooperative group trials, the prognostic groups had significantly different rates of CR, DFS, and OS at three years.</div><div class=\"graphic_footnotes\">AML: acute myeloid leukemia; WHO: World Health Organization; CR: complete remission; DFS: disease-free survival; OS: overall survival.<br />* Includes all AMLs with normal karyotype except for those included in the favorable subgroup.<br />&#182; For most abnormalities, adequate numbers have not been studied to draw firm conclusions regarding their prognostic significance.<br />&Delta; Three or more chromosome abnormalities in the absence of one of the WHO designated recurring translocations or inversions, that is, t(15;17), t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23), t(6;9), inv(3) or t(3;3).</div><div class=\"graphic_reference\">Additional data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Mr&oacute;zek K, Marcucci G, Nicolet DJ, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol 2012; 30:4515.</li>&#xD;&#xA;</ol>&#xD;&#xA;This research was originally published in Blood. D&ouml;hner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115:453. Copyright &copy; 2010 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 80216 Version 8.0</div></div></div>"},"80218":{"type":"graphic_movie","displayName":"Stand on one foot video","title":"Balance exercise video: Stand on one foot","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Balance exercise video: Stand on one foot</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PC/80218_Standononefootmovie.mp4\" style=\"width:480px;height:336px\"></div><img style=\"width:369px; height:297px;\" src=\"images/PC/80218_StandononefootimgPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">You can do this exercise while waiting for the bus or standing in line at the grocery. For an added challenge, you can modify the exercise to improve your balance.<br> <ol> <li>Stand on one foot behind a sturdy chair, holding on for balance. </li> <li>Hold position for up to 10 seconds. </li> <li>Repeat 10 to 15 times. </li> <li>Repeat 10 to 15 times with other leg. </li> <li>Repeat 10 to 15 more times with each leg. </li> </ol></div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 80218 Version 1.0</div></div></div>"},"80219":{"type":"graphic_diagnosticimage","displayName":"CT of a pulmonary hamartoma","title":"CT of a pulmonary hamartoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT of a pulmonary hamartoma</div><div class=\"cntnt\"><img style=\"width:306px; height:278px;\" src=\"images/PULM/80219_Hamartoma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulmonary hamartoma. CT of the chest without contrast shows a solid pulmonary nodule with characteristic popcorn calcifications.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 80219 Version 3.0</div></div></div>"},"80220":{"type":"graphic_diagnosticimage","displayName":"Traction tracheomegaly","title":"Traction tracheomegaly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traction tracheomegaly</div><div class=\"cntnt\"><img style=\"width:360px; height:414px;\" src=\"images/PULM/80220_Traction_tracheomegaly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph from a patient with post-primary tuberculosis demonstrates tracheomegaly, upper lobe fibrosis with volume loss, bronchiectasis, emphysema, and bibasal pleural scarring.</div><div id=\"graphicVersion\">Graphic 80220 Version 3.0</div></div></div>"},"80221":{"type":"graphic_picture","displayName":"Mastocytoma solitary","title":"Solitary mastocytoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Solitary mastocytoma</div><div class=\"cntnt\"><img style=\"width:391px; height:367px;\" src=\"images/DERM/80221_Mastocytoma_solitary.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Solitary mastocytoma presents as a pink-yellowish plaque that typically urticates and becomes erythematous after rubbing.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. Kate P&#252;ttgen.</div><div id=\"graphicVersion\">Graphic 80221 Version 1.0</div></div></div>"},"80222":{"type":"graphic_figure","displayName":"Check rein ligaments","title":"Check rein ligaments","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Check rein ligaments</div><div class=\"cntnt\"><img style=\"width:592px; height:405px;\" src=\"images/SURG/80222_Check_rein_ligament_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The volar plate is a fibrocartilagenous thickening that stabilizes the proximal interphalangeal (PIP) joint&nbsp;and prevents hyperextension. The proximal end of the volar plate is free and attached to the proximal phalanx by the check rein ligaments.</div><div id=\"graphicVersion\">Graphic 80222 Version 5.0</div></div></div>"},"80227":{"type":"graphic_diagnosticimage","displayName":"IDUS distal CBD","title":"Intraductal ultrasound demonstrating a polypoid mass in the common bile duct","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraductal ultrasound demonstrating a polypoid mass in the common bile duct</div><div class=\"cntnt\"><img style=\"width:360px; height:287px;\" src=\"images/GAST/80227_IDUS_distal_CBD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Polypoid mass within the distal common bile duct as seen by endoscopic ultrasound.</div><div class=\"graphic_reference\">Courtesy of Drs. Michael J Levy, Enrique Vazquez-Sequeiros, and Maurits J Wiersema.</div><div id=\"graphicVersion\">Graphic 80227 Version 5.0</div></div></div>"},"80228":{"type":"graphic_algorithm","displayName":"Field management algorithm for C-spine injury","title":"Management of suspected cervical spine injuries in the unconscious athlete","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Management of suspected cervical spine injuries in the unconscious athlete</div><div class=\"cntnt\"><img style=\"width:532px; height:647px;\" src=\"images/EM/80228_Field_mgmt_C-spine_injury.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from Athletic Injuries in the Head, Neck, and Face. Torg, JS (Ed), Lea &amp; Febiger, Philadelphia, 1982, p43.</div><div id=\"graphicVersion\">Graphic 80228 Version 2.0</div></div></div>"},"80229":{"type":"graphic_table","displayName":"Adverse effects of methotrexate","title":"Major adverse effects of methotrexate*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major adverse effects of methotrexate*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Bone marrow toxicity</td> </tr> <tr> <td>Neutropenia (most common, usually reversible)</td> </tr> <tr> <td>Thrombocytopenia (dose related, usually reversible)</td> </tr> <tr> <td>Anemia (rare)</td> </tr> <tr> <td class=\"subtitle1_single\">Hepatic toxicity</td> </tr> <tr> <td>Cirrhosis &#38; fibrosis</td> </tr> <tr> <td class=\"subtitle1_single\">Pulmonary toxicity</td> </tr> <tr> <td class=\"sublist1_start\">Opportunistic infections</td> </tr> <tr> <td class=\"sublist1\">PCP, CMV, Herpes zoster, fungal, mycobacterial, etc</td> </tr> <tr> <td class=\"sublist1_start\">Noninfectious conditions</td> </tr> <tr> <td class=\"sublist1\">Hypersensitivity pneumonitis</td> </tr> <tr> <td class=\"sublist1\">Organizing pneumonia (previously called bronchiolitis obliterans with organizing pneumonia or BOOP)</td> </tr> <tr> <td class=\"sublist1\">Acute lung injury (noncardiogenic pulmonary edema)</td> </tr> <tr> <td class=\"sublist1\">Pulmonary fibrosis </td> </tr> <tr> <td class=\"sublist1\">Asthma/hyperreactive airways disease</td> </tr> <tr> <td class=\"sublist1\">Pleuritis and/or pleural effusion</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td>Oligospermia</td> </tr> <tr> <td>Teratogenicity</td> </tr> <tr> <td>Malignancy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PCP: Pneumocystis pneumonia; CMV: cytomegalovirus.<br />* Major adverse effects are defined as potentially life-threatening (incidence &lt;1 percent) or requiring withdrawal of treatment (incidence 3 to 15 percent).</div><div id=\"graphicVersion\">Graphic 80229 Version 4.0</div></div></div>"},"80232":{"type":"graphic_figure","displayName":"Muscle compartments of the foot","title":"Muscle compartments of the foot","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Muscle compartments of the foot</div><div class=\"cntnt\"><img style=\"width:532px; height:415px;\" src=\"images/SURG/80232_Right-foot-compartments.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Compartments of the foot: <ul> <li>Interosseous (turqoise) &#8212; Interosseus muscles, each in its own compartment. </li> <li>Calcaneal (pink) &#8212; Flexor digitorum brevis, quadratus plantae and adductor hallucis. </li> <li>Lateral (green) &#8212; Flexor digiti minimi and abductor digiti quinti. </li> <li>Medial (red) &#8212; Abductor hallucis and flexor hallucis brevis muscles. </li> <li>Superficial (blue) &#8212; Flexor digitorum brevis, lumbricals, flexor digitorum longus tendons. </li> </ul></div><div id=\"graphicVersion\">Graphic 80232 Version 4.0</div></div></div>"},"80233":{"type":"graphic_figure","displayName":"Neural pathways in syncope","title":"Pathways in neurally mediated syncope","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Pathways in neurally mediated syncope</div><div class=\"cntnt\"><img style=\"width:566px; height:327px;\" src=\"images/CARD/80233_Neural_pathways_in_syncope.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the specific syndromes, the suspected peripheral receptors (triggers), the afferent neural pathways, and the efferent pathways responsible for the clincial manifestations of bradycardia and hypotension in specific syncopal syndromes.</div><div class=\"graphic_footnotes\">NTS: nucleus tractus solitarius; V, VII, VIII, IX, and X: cranial nerves.</div><div id=\"graphicVersion\">Graphic 80233 Version 3.0</div></div></div>"},"80234":{"type":"graphic_picture","displayName":"Larynx appearance with videolaryngoscope","title":"Larynx appearance with videolaryngoscope","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Larynx appearance with videolaryngoscope</div><div class=\"cntnt\"><img style=\"width:482px; height:516px;\" src=\"images/EM/80234_LarynxanatomyVLphoto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Several photographs of the larynx obtained with a videolaryngoscope: (A) preintubation view of an adult airway; (B) preintubation view of a pediatric airway; (C) endotracheal tube passing between the vocal cords; (D) view of the larynx and hypopharynx (note the horizontally oriented space below the laryngeal inlet, which is the esophagus).</div><div class=\"graphic_reference\">Reproduced with permission from: Nagdev A. Airway, breathing, circulation: Normal airway. In: Greenberg's Text-Atlas of Emergency Medicine, Greenberg MI, Hendrickson RG, Silverberg M, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 80234 Version 13.0</div></div></div>"},"80236":{"type":"graphic_table","displayName":"Asperger syndrome DDx","title":"Differential diagnosis of Asperger syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of Asperger syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Features that may help to distinguish the condition from Asperger syndrome (ICD-10 terminology) or ASD without intellectual or language impairment (DSM-5 terminology)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pervasive developmental disorders (this section applies only if the ICD-10 is used for diagnosis)*</td> </tr> <tr> <td class=\"indent1\">Childhood autism and atypical autism</td> <td>Significant abnormalities in language and cognitive skills</td> </tr> <tr> <td class=\"indent1\">Pervasive developmental disorder, unspecified</td> <td>Some, but not all, of the criteria for childhood autism are present (may have late age of presentation, or atypical or subthreshold symptoms; or may meet only some of the criteria for childhood autism)</td> </tr> <tr> <td class=\"indent1\">Rett disorder</td> <td>Female predominance; head growth deceleration; loss of skills; impaired language skills</td> </tr> <tr> <td class=\"indent1\">Childhood disintegrative disorder</td> <td>Marked intellectual disability and language impairment; loss of skills</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other disorders</td> </tr> <tr> <td class=\"indent1\">Attention deficit hyperactivity disorder<sup>&#916;</sup></td> <td>Less impairment in social skills and pragmatic language than in individuals on the autism spectrum; absence of restricted, repetitive patterns of behavior, interests, and activities; normal pragmatic language skills</td> </tr> <tr> <td class=\"indent1\">Schizophrenia<sup>&#916;</sup></td> <td>Hallucinations; delusions; disorganized speech</td> </tr> <tr> <td class=\"indent1\">Social phobia/anxiety<sup>&#916;</sup></td> <td>Lack of pervasive impairments in social development; lack of circumscribed interests; subjective distress about social interactions and about specific situations</td> </tr> <tr> <td class=\"indent1\">Selective mutism</td> <td>Lack of impairment in social interaction; normal ability for communication in some settings; absence of restricted, repetitive patterns of behavior, interests, or activities</td> </tr> <tr> <td class=\"indent1\">Obsessive compulsive disorder<sup>&#916;</sup></td> <td>Normal social skills; normal pragmatic language; restricted/repetitive behaviors are a source of anxiety rather than a pleasure (as they are in autistic disorder or Asperger syndrome)</td> </tr> <tr> <td class=\"indent1\">Developmental coordination disorder</td> <td>Absence of restricted, repetitive patterns of behavior, interests, or activities; normal pragmatic language</td> </tr> <tr> <td class=\"indent1\">Oppositional defiant disorder</td> <td>Absence of restricted, repetitive patterns of behavior, interests, or activities; normal pragmatic language</td> </tr> <tr> <td class=\"indent1\">Language disorder</td> <td>Normal social skills; absence of restricted, repetitive patterns of behavior, interests, or activities; lack of stereotypies</td> </tr> <tr> <td class=\"indent1\">Social (pragmatic) communication disorder<sup>&#9674;</sup></td> <td>Absence of restricted, repetitive patterns of behavior, interests, or activities</td> </tr> <tr> <td class=\"indent1\">Nonverbal learning disorder<sup>&#916;</sup></td> <td>Less impairment in social skills and pragmatic language than for individuals on the autism spectrum; verbal skills typically stronger than nonverbal skills; lack of restricted, repetitive patterns of behavior, interests, or activities</td> </tr> <tr> <td class=\"indent1\">Social awkwardness related to intellectual giftedness</td> <td>Normal pragmatic language skills; intense interests are functional, varied, and can be explained by the child; generally enjoy social interaction</td> </tr> <tr> <td class=\"indent1\">Normal social awkwardness</td> <td>Normal age-appropriate interests and hobbies; normal pragmatic language skills</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICD-10: International Classification of Diseases, 10th Revision; DSM-5: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; ASD: autism spectrum disorder.<br />* The DSM-5 does not recognize diagnostic subtypes of autism spectrum disorder; Asperger syndrome and pervasive developmental disorder-not otherwise specified have been encompassed within the single diagnostic category of autism spectrum disorder.<br />&Delta; May occur comorbidly with Asperger disorder.<br /><span class=\"lozenge\">&loz;</span> This is a new disorder, recognized for the first time in DSM-5; it is not included in ICD-10.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Johnson CP, Myers SM. Autism spectrum disorders. In: Developmental-Behavioral Pediatrics. Evidence and Practice. Wolraich ML, Drotar DD, Dworkin PH, Perrin EC (Eds). Mosby Elsevier, Philadelphia 2008. p.519. </li>&#xD;&#xA;    <li>World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Clinical descriptions and diagnostic guidelines. <a href=\"http://www.who.int/classifications/icd/en/bluebook.pdf\" target=\"_blank\">www.who.int/classifications/icd/en/bluebook.pdf</a>. (Accessed on June 04, 2013).</li>&#xD;&#xA;    <li>World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Diagnostic criteria for research. <a href=\"http://www.who.int/classifications/icd/en/GRNBOOK.pdf\" target=\"_blank\">www.who.int/classifications/icd/en/GRNBOOK.pdf</a>. (Accessed on June 11, 2013).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 80236 Version 6.0</div></div></div>"},"80239":{"type":"graphic_picture","displayName":"Laser-skin position","title":"Correct positioning of laser during treatment of the skin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Correct positioning of laser during treatment of the skin</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/80239_Laser_skin_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Treatment should be performed with the laser perpendicular to the skin so that light is delivered directly to the target.</div><div id=\"graphicVersion\">Graphic 80239 Version 1.0</div></div></div>"},"80241":{"type":"graphic_figure","displayName":"Thromboelastography (TEG) tracing interpretation","title":"Thromboelastography (TEG) tracing interpretation","html":"<div class=\"graphic\"><div style=\"width: 635px\" class=\"figure\"><div class=\"ttl\">Thromboelastography (TEG)&nbsp;tracing interpretation</div><div class=\"cntnt\"><img style=\"width:615px; height:576px;\" src=\"images/SURG/80241_TEG_tracing_interpretation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">TEG: thromboelastograph</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">TEG® Hemostasis Analyzer Tracing Image and TEG® LY30 Clot Breakdown Diagram reproduced with permission of Haemonetics Corporation. TEG® and Thromboelastograph® are registered trademarks of Haemonetics Corporation in the US, other countries, or both.</div><div id=\"graphicVersion\">Graphic 80241 Version 4.0</div></div></div>"},"80242":{"type":"graphic_picture","displayName":"Erythrasma in axilla","title":"Erythrasma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythrasma</div><div class=\"cntnt\"><img style=\"width:292px; height:504px;\" src=\"images/DERM/80242_Erythrasma_axilla1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 24-year-old male presented with erythematous plaques in the axillae. A Wood's lamp examination was positive for coral-red fluorescence.</div><div class=\"graphic_reference\">Copyright © Kosman Sadek Zikry, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 80242 Version 8.0</div></div></div>"},"80243":{"type":"graphic_picture","displayName":"Epidemic keratoconjunctivitis infection","title":"Epidemic keratoconjunctivitis infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epidemic keratoconjunctivitis infection</div><div class=\"cntnt\"><img style=\"width:396px; height:276px;\" src=\"images/EM/80243_EKC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with right epidemic keratoconjunctivitis infection. Note the lid swelling, red eye, and absence of purulent discharge. Patient also has right preauricular adenopathy (not visible). Note the early injection of left eye, representing sequential involvement.</div><div class=\"graphic_reference\">Reproduced with permission from: Levin AV. Ophthalmic emergencies. In: Textbook of Pediatric Emergency Medicine, 6th ed, Fleisher GR, Ludwig S (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 80243 Version 15.0</div></div></div>"},"80244":{"type":"graphic_figure","displayName":"Growth in familial short stature","title":"Growth in familial (genetic) short stature","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Growth in familial (genetic) short stature</div><div class=\"cntnt\"><img style=\"width:302px; height:390px;\" src=\"images/ENDO/80244_Growth_in_intrinsic_shortne.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Growth curve in a male with familial short stature. The growth velocity is normal from&nbsp;five years of age&nbsp;onward, with the height being below, but parallel to, the third percentile.</div><div class=\"graphic_reference\">Data from Rogol, AD, Lawton, EL. Body measurements. In: Pediatric Outpatient Procedures, Lohr, J (Ed), JB Lippincott, Philadelphia 1990, p.1.</div><div id=\"graphicVersion\">Graphic 80244 Version 3.0</div></div></div>"},"80245":{"type":"graphic_table","displayName":"PHACE syndrome","title":"Characteristics of PHACE syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of PHACE syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\">P</td> <td>Posterior fossa brain malformations, most commonly the Dandy-Walker variant</td> </tr> <tr> <td class=\"subtitle1_left\">H</td> <td>Hemangiomas, particularly large, segmental facial lesions</td> </tr> <tr> <td class=\"subtitle1_left\">A</td> <td>Arterial anomalies</td> </tr> <tr> <td class=\"subtitle1_left\">C</td> <td>Cardiac anomalies and coarctation of the aorta</td> </tr> <tr> <td class=\"subtitle1_left\">E</td> <td>Eye abnormalities and endocrine abnormalities</td> </tr> <tr> <td class=\"subtitle1_left\">S*</td> <td>Sternal cleft, supraumbilical raphe, or both</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The term &quot;PHACE(S)&quot; is sometimes used in the presence of ventral developmental defects.</div><div id=\"graphicVersion\">Graphic 80245 Version 3.0</div></div></div>"},"80246":{"type":"graphic_diagnosticimage","displayName":"PA stump thrombus CT","title":"Postpneumonectomy complication: Thrombus in the pulmonary artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postpneumonectomy complication: Thrombus in the pulmonary artery</div><div class=\"cntnt\"><img style=\"width:360px; height:227px;\" src=\"images/PULM/80246_PA_stump_thrombus_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest CT after right-sided pneumonectomy shows a thrombus in the right pulmonary artery stump (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Richard Irwin, MD.</div><div id=\"graphicVersion\">Graphic 80246 Version 4.0</div></div></div>"},"80248":{"type":"graphic_picture","displayName":"Disseminated superficial actinic porokeratosis 2","title":"Disseminated superficial actinic porokeratosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Disseminated superficial actinic porokeratosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/80248_Dis_sup_actinic_porokera_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous macules with peripheral keratotic rims are present on the extremity.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 80248 Version 3.0</div></div></div>"},"80250":{"type":"graphic_picture","displayName":"SLE mesangial","title":"Light micrograph showing mesangial proliferative glomerulonephritis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light micrograph showing mesangial proliferative glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:396px; height:252px;\" src=\"images/NEPH/80250_SLE_Mesangial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a mesangial glomerulonephritis showing segmental areas of increased mesangial matrix and cellularity (arrows). This finding alone can be seen in many diseases, including lupus nephritis and IgA nephropathy.</div><div class=\"graphic_footnotes\">IgA: immunoglobulin A.</div><div class=\"graphic_reference\">Courtesy of Helmut G&nbsp;Rennke, MD.</div><div id=\"graphicVersion\">Graphic 80250 Version 5.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"80251":{"type":"graphic_figure","displayName":"Diabetes increases mortality from coronary heart disease","title":"Diabetes increases coronary heart disease mortality with and without a prior myocardial infarction (MI)","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Diabetes increases coronary heart disease mortality with and without a prior myocardial infarction (MI)</div><div class=\"cntnt\"><img style=\"width:539px; height:256px;\" src=\"images/CARD/80251_Death_MI_diabetes_no_diabet.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a seven-year follow-up of 1059 subjects with type 2 diabetes and 1378 patients without diabetes, persons with diabetes, with or without a prior myocardial infarction (MI), had a greater mortality from coronary disease compared to those without diabetes (42 versus 16 percent for those with a prior MI and 15 versus 2 percent for those without a prior MI). The rate of coronary death and fatal and nonfatal MI in persons with diabetes without a prior MI was the same as in those without diabetes with a prior MI, providing part of the rationale for considering type 2 diabetes a coronary heart disease equivalent.</div><div class=\"graphic_reference\">Data from: Haffner SM, Lehto S, Ronnemaa T, et al. N Engl J Med 1998; 339:229.</div><div id=\"graphicVersion\">Graphic 80251 Version 6.0</div></div></div>"},"80254":{"type":"graphic_picture","displayName":"Prost CA extraprost extension","title":"Prostate adenocarcinoma with extraprostatic extension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prostate adenocarcinoma with extraprostatic extension</div><div class=\"cntnt\"><img style=\"width:369px; height:278px;\" src=\"images/ONC/80254_Prost_CA_extraprost_extensi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power photomicrograph of an hematoxylin- and eosin-stained section from a prostate core needle biopsy. Evidence of extraprostatic extension of the tumor is suggested by the presence of tumor cells infiltrating fat (arrows).</div><div class=\"graphic_reference\">Courtesy of Ximing Yang, MD.</div><div id=\"graphicVersion\">Graphic 80254 Version 2.0</div></div></div>"},"80255":{"type":"graphic_figure","displayName":"Audiogram presbycusis","title":"Audiograms of an individual with normal hearing and individuals with presbycusis","html":"<div class=\"graphic\"><div style=\"width: 627px\" class=\"figure\"><div class=\"ttl\">Audiograms of an individual with normal hearing and individuals with presbycusis</div><div class=\"cntnt\"><img style=\"width:607px; height:787px;\" src=\"images/PC/80255_Audiogram_presby_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three typical audiograms of an individual with normal hearing, an individual age 60 years old, and an individual age 80 years old.</div><div class=\"graphic_footnotes\">%: percent.</div><div id=\"graphicVersion\">Graphic 80255 Version 5.0</div></div></div>"},"80257":{"type":"graphic_figure","displayName":"Limits of the dissection for mastectomy","title":"Limits of the dissection for mastectomy","html":"<div class=\"graphic\"><div style=\"width: 597px\" class=\"figure\"><div class=\"ttl\">Limits of the dissection for mastectomy</div><div class=\"cntnt\"><img style=\"width:577px; height:441px;\" src=\"images/SURG/80257_Limitsdissectionmastect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Inset) Limits of the modiﬁed radical mastectomy are delineated laterally by the anterior margin of the latissimus dorsi muscle, medially by the sternal border, superiorly by the subclavius muscle, and inferiorly by the caudal extension of the breast approximately 3 to 4 cm inferior to the inframammary fold. Skin ﬂaps for the modiﬁed radical technique are planned with relation to the quadrant in which the primary neoplasm is located. Adequate margins are ensured by developing skin edges 3 to 5 cm from the tumor margin. Skin incisions are made perpendicular to the subcutaneous plane. Flap thickness should vary with patient body habitus but ideally should be 7 to 8 mm thick. Flap tension should be perpendicular to the chest wall with ﬂap elevation deep to the cutaneous vasculature, which is accentuated by ﬂap retraction.</div><div class=\"graphic_reference\">Reproduced with permission from: Bland KI. Modified radical mastectomy and total (simple) mastectomy. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 80257 Version 7.0</div></div></div>"},"80258":{"type":"graphic_waveform","displayName":"ECG Ebstein anomaly WPW","title":"Electrocardiogram of preexcitation associated with Ebstein anomaly","html":"<div class=\"graphic\"><div style=\"width: 578px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram of preexcitation associated with Ebstein anomaly</div><div class=\"cntnt\"><img style=\"width:558px; height:343px;\" src=\"images/CARD/80258_ECG_Ebstein_anomaly_WPW.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The electocardiogram of a 13-year-old with Ebstein anomaly shows preexcitation with a left bundle branch block pattern and predominant S waves in V1 and V2.</div><div id=\"graphicVersion\">Graphic 80258 Version 3.0</div></div></div>"},"80259":{"type":"graphic_table","displayName":"Antiem drugs opioid nausea","title":"Antiemetic drugs used to manage opioid-induced nausea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antiemetic drugs used to manage opioid-induced nausea</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Class</td>\r\n                    <td class=\"subtitle1\">Mechanism</td>\r\n                    <td class=\"subtitle1\">Examples</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"7\">Neuroleptics</td>\r\n                    <td rowspan=\"7\">Dopamine receptor blockade in lower brainstem (chemoreceptor trigger zone)</td>\r\n                    <td class=\"sublist1_start\">Phenothiazines:</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Prochlorperazine</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Chlorpromazine</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1_start\">Butyrophenones:</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Haloperidol</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1_start\">Atypical:</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Olanzepine</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Prokinetic drugs</td>\r\n                    <td>Peripheral effects to increase peristalsis; metaclopramide also has central dopamine antagonist</td>\r\n                    <td>Metoclopramide</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>5-HT3 receptor antagonists</td>\r\n                    <td>Block serotonin receptor (chronic use may cause constipation)</td>\r\n                    <td>\r\n                    <p>Palonosetron</p>\r\n                    <p>Ondansetron</p>\r\n                    <p>Granisetron</p>\r\n                    <p>Dolasetron</p>\r\n                    </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Anticholinergic drugs</td>\r\n                    <td>Block acetylcholine release in lower brainstem</td>\r\n                    <td>\r\n                    <p>Trimethobenzamide</p>\r\n                    <p>Scopolamine</p>\r\n                    <p>Promethazine</p>\r\n                    </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Antihistamines</td>\r\n                    <td>Block histamine receptors in lower brainstem</td>\r\n                    <td>\r\n                    <p>Meclizine</p>\r\n                    <p>Diphenhydramine</p>\r\n                    <p>Dimenhydrinate</p>\r\n                    <p>Hydroxyzine</p>\r\n                    </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Corticosteroids</td>\r\n                    <td>Multiple effects</td>\r\n                    <td>Dexamethasone</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Benzodiazepines</td>\r\n                    <td>Reduce anxiety; direct effect on lower brainstem</td>\r\n                    <td>Lorazepam</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Cannabinoids</td>\r\n                    <td>Binds to cannabinoid receptors to exert direct effect in the lower brainstem</td>\r\n                    <td>\r\n                    <p>Dronabinol</p>\r\n                    <p>Nabilone</p>\r\n                    </td>\r\n                </tr>\r\n            </tbody>\r\n        </table>\r\n        <!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=45275&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div id=\"graphicVersion\">Graphic 80259 Version 3.0</div></div></div>"},"80261":{"type":"graphic_algorithm","displayName":"Approach to postmenarcheal bleeding","title":"Approach to vaginal bleeding in the postmenarcheal adolescent","html":"<div class=\"graphic\"><div style=\"width: 637px\" class=\"figure\"><div class=\"ttl\">Approach to vaginal bleeding in the postmenarcheal adolescent</div><div class=\"cntnt\"><img style=\"width:617px; height:618px;\" src=\"images/EM/80261_Approachpostmenbleeded.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Refer to UpToDate topics on abnormal uterine bleeding in the adolescent.</div><div class=\"graphic_reference\">Reproduced with permission from: Zinns LE, Chuang JH, Posner JC, Paradise J. Vaginal bleeding. In: Fleisher and Ludwig's Textbook of Pediatric Emergency Medicine, 7th edition, Bachur RG, Shaw KN (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2016. Copyright © 2016 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 80261 Version 15.0</div></div></div>"},"80262":{"type":"graphic_figure","displayName":"Hand-sewn colorectal anastomosis with running sutures","title":"Hand-sewn colorectal anastomosis with running sutures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hand-sewn colorectal anastomosis with running sutures</div><div class=\"cntnt\"><img style=\"width:323px; height:343px;\" src=\"images/SURG/80262_Hand-sewn-colorectal-running.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts an anastomosis of the proximal colon and upper rectum using a &#160;single layer closure with a running silk suture. One suture is placed on the mesenteric border and another is placed on the antimesenteric border. The posterior wall is anastomosed first, the bowel is turned, and the anterior portion is completed. Sutures are placed in the seromuscular layer.</div><div id=\"graphicVersion\">Graphic 80262 Version 1.0</div></div></div>"},"80263":{"type":"graphic_figure","displayName":"Cervico-vaginal agenesis","title":"Vaginal agenesis with agenesis of the cervix","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vaginal agenesis with agenesis of the cervix</div><div class=\"cntnt\"><img style=\"width:406px; height:318px;\" src=\"images/OBGYN/80263_Cervicovaginalagenesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 80263 Version 13.0</div></div></div>"},"80265":{"type":"graphic_diagnosticimage","displayName":"Nocardia pneumonia CXR CT","title":"Nocardia infection","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Nocardia infection</div><div class=\"cntnt\"><img style=\"width:515px; height:262px;\" src=\"images/ID/80265_Nocardia_pneum_CXR_CT_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 43-year-old man who, after bone marrow transplantation for acute leukemia, developed fever and dyspnea with a clear chest radiograph while neutropenic. Following bone marrow engraftment (absolute neutrophil count&nbsp;&gt;500/mm<SUP>3</SUP>), an infiltrate appeared on chest radiograph (panel A), which was more apparent by chest&nbsp;computed tomography&nbsp;(panel B). Cultures revealed<EM> Nocardia asteroide</EM>s.</div><div class=\"graphic_reference\">Courtesy of Jay Fishman, MD.</div><div id=\"graphicVersion\">Graphic 80265 Version 5.0</div></div></div>"},"80267":{"type":"graphic_diagnosticimage","displayName":"Plain chest radiograph of HAPE","title":"Plain chest radiograph of HAPE","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plain chest radiograph of HAPE</div><div class=\"cntnt\"><img style=\"width:361px; height:344px;\" src=\"images/EM/80267_HAPE_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain chest radiography is useful in HAPE and reveals characteristic patchy alveolar infiltrates, predominantly in the right central hemithorax, which become more confluent and bilateral as the illness progresses. In a few cases, HAPE may not take this classic radiographic appearance.</div><div class=\"graphic_footnotes\">HAPE: High altitude pulmonary edema.</div><div class=\"graphic_reference\">Courtesy of Scott A Gallagher, MD.</div><div id=\"graphicVersion\">Graphic 80267 Version 3.0</div></div></div>"},"80268":{"type":"graphic_table","displayName":"Accuracy of US in Crohn disease","title":"Sensitivity and specificity of ultrasonography in the detection of Crohn disease (with respect to endoscopic, radiologic and operative findings)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sensitivity and specificity of ultrasonography in the detection of Crohn disease (with respect to endoscopic, radiologic and operative findings)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Sensitivity</td> <td class=\"subtitle1\">Specificity</td> <td class=\"subtitle1\">PPV</td> <td class=\"subtitle1\">NPV</td> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">Author</td> <td class=\"subtitle1\">Year</td> </tr> <tr> <td class=\"centered\">181 (89)</td> <td class=\"centered\">81</td> <td class=\"centered\">79</td> <td class=\"centered\">79</td> <td class=\"centered\">81</td> <td class=\"centered\">[1]</td> <td class=\"centered\">Pera A, et al</td> <td class=\"centered\">1988</td> </tr> <tr> <td class=\"centered\">61 (26)</td> <td class=\"centered\">77</td> <td class=\"centered\">96</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[2]</td> <td class=\"centered\">Stiatti A, et al</td> <td class=\"centered\">1990</td> </tr> <tr> <td class=\"centered\">36</td> <td class=\"centered\">86</td> <td class=\"centered\">97</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[3]</td> <td class=\"centered\">Hata J, et al</td> <td class=\"centered\">1992</td> </tr> <tr> <td class=\"centered\">127 (46)</td> <td class=\"centered\">78 (87)*</td> <td class=\"centered\">91</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[4]</td> <td class=\"centered\">Sheridan MB, et al</td> <td class=\"centered\">1993</td> </tr> <tr> <td class=\"centered\">(31)</td> <td class=\"centered\">73</td> <td class=\"centered\">93</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[5]</td> <td class=\"centered\">Brignola C, et al</td> <td class=\"centered\">1993</td> </tr> <tr> <td class=\"centered\">41</td> <td class=\"centered\">96</td> <td class=\"centered\">100</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[6]</td> <td class=\"centered\">Limberg B, et al</td> <td class=\"centered\">1994</td> </tr> <tr> <td class=\"centered\">59</td> <td class=\"centered\">95</td> <td class=\"centered\">93</td> <td class=\"centered\">90</td> <td class=\"centered\">95</td> <td class=\"centered\">[7]</td> <td class=\"centered\">Solvig J, et al</td> <td class=\"centered\">1995</td> </tr> <tr> <td class=\"centered\">(115)</td> <td class=\"centered\">89</td> <td class=\"centered\">94</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[8]</td> <td class=\"centered\">Maconi G, et al</td> <td class=\"centered\">1996</td> </tr> <tr> <td class=\"centered\">227 (69)</td> <td class=\"centered\">84</td> <td class=\"centered\">NE</td> <td class=\"centered\">98</td> <td class=\"centered\">76</td> <td class=\"centered\">[9]</td> <td class=\"centered\">Hollerbach S, et al</td> <td class=\"centered\">1998</td> </tr> <tr> <td class=\"centered\">(47)</td> <td class=\"centered\">81</td> <td class=\"centered\">86</td> <td class=\"centered\">96</td> <td class=\"centered\">57</td> <td class=\"centered\">[10]</td> <td class=\"centered\">Andreoli A, et al</td> <td class=\"centered\">1998</td> </tr> <tr> <td class=\"centered\">30</td> <td class=\"centered\">87</td> <td class=\"centered\">100</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[11]</td> <td class=\"centered\">Miao YM, et al</td> <td class=\"centered\">2002</td> </tr> <tr> <td class=\"centered\">296</td> <td class=\"centered\">93</td> <td class=\"centered\">97</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[12]</td> <td class=\"centered\">Parente F, et al</td> <td class=\"centered\">2002</td> </tr> <tr> <td class=\"centered\">296 (211)</td> <td class=\"centered\">79</td> <td class=\"centered\">98</td> <td class=\"centered\">95</td> <td class=\"centered\">NE</td> <td class=\"centered\">[12]</td> <td class=\"centered\">Parente F, et al</td> <td class=\"centered\">2002</td> </tr> <tr> <td class=\"centered\">296 (85)</td> <td class=\"centered\">90</td> <td class=\"centered\">100</td> <td class=\"centered\">100</td> <td class=\"centered\">NE</td> <td class=\"centered\">[12]</td> <td class=\"centered\">Parente F, et al</td> <td class=\"centered\">2002</td> </tr> <tr> <td class=\"centered\">46</td> <td class=\"centered\">76</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[13]</td> <td class=\"centered\">Potthast S, et al</td> <td class=\"centered\">2002</td> </tr> <tr> <td class=\"centered\">46</td> <td class=\"centered\">31</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[13]</td> <td class=\"centered\">Potthast S, et al</td> <td class=\"centered\">2002</td> </tr> <tr> <td class=\"centered\">46</td> <td class=\"centered\">58</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[13]</td> <td class=\"centered\">Potthast S, et al</td> <td class=\"centered\">2002</td> </tr> <tr> <td class=\"centered\">46</td> <td class=\"centered\">89</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[13]</td> <td class=\"centered\">Potthast S, et al</td> <td class=\"centered\">2002</td> </tr> <tr> <td class=\"centered\">78</td> <td class=\"centered\">77</td> <td class=\"centered\">83</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[14]</td> <td class=\"centered\">Haber HP, et al</td> <td class=\"centered\">2002</td> </tr> <tr> <td class=\"centered\">48</td> <td class=\"centered\">56</td> <td class=\"centered\">97</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[15]</td> <td class=\"centered\">Schmidt T, et al</td> <td class=\"centered\">2003</td> </tr> <tr> <td class=\"centered\">48</td> <td class=\"centered\">56</td> <td class=\"centered\">97</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[15]</td> <td class=\"centered\">Schmidt T, et al</td> <td class=\"centered\">2003</td> </tr> <tr> <td class=\"centered\">48</td> <td class=\"centered\">67</td> <td class=\"centered\">100</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[15]</td> <td class=\"centered\">Schmidt T, et al</td> <td class=\"centered\">2003</td> </tr> <tr> <td class=\"centered\">625 (128)</td> <td class=\"centered\">87</td> <td class=\"centered\">96</td> <td class=\"centered\">93</td> <td class=\"centered\">81</td> <td class=\"centered\">[16]</td> <td class=\"centered\">Maconi G, et al</td> <td class=\"centered\">2003</td> </tr> <tr> <td class=\"centered\">625 (128)</td> <td class=\"centered\">91</td> <td class=\"centered\">85</td> <td class=\"centered\">77</td> <td class=\"centered\">94</td> <td class=\"centered\">[16]</td> <td class=\"centered\">Maconi G, et al</td> <td class=\"centered\">2003</td> </tr> <tr> <td class=\"centered\">102</td> <td class=\"centered\">91/96<sup>&#182;</sup></td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[17]</td> <td class=\"centered\">Parente F, et al</td> <td class=\"centered\">2004</td> </tr> <tr> <td class=\"centered\">102</td> <td class=\"centered\">74/89<sup>&#182;</sup></td> <td class=\"centered\">97</td> <td class=\"centered\">92</td> <td class=\"centered\">96</td> <td class=\"centered\">[17]</td> <td class=\"centered\">Parente F, et al</td> <td class=\"centered\">2004</td> </tr> <tr> <td class=\"centered\">84 (50)</td> <td class=\"centered\">92</td> <td class=\"centered\">97</td> <td class=\"centered\">98</td> <td class=\"centered\">88</td> <td class=\"centered\">[18]</td> <td class=\"centered\">Rispo A, et al</td> <td class=\"centered\">2005</td> </tr> <tr> <td class=\"centered\">48</td> <td class=\"centered\">81<sup>&#916;</sup></td> <td class=\"centered\">63<sup>&#916;</sup></td> <td class=\"centered\">63<sup>&#916;</sup></td> <td class=\"centered\">81<sup>&#916;</sup></td> <td class=\"centered\">[19]</td> <td class=\"centered\">Serra C, et al</td> <td class=\"centered\">2007</td> </tr> <tr> <td class=\"centered\">53</td> <td class=\"centered\">85<sup>&#9674;</sup></td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[20]</td> <td class=\"centered\">Maconi G, et al</td> <td class=\"centered\">2007</td> </tr> <tr> <td class=\"centered\">119</td> <td class=\"centered\">91</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[21]</td> <td class=\"centered\">Martinez MJ, et al</td> <td class=\"centered\">2009</td> </tr> <tr> <td class=\"centered\">119</td> <td class=\"centered\">80</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[21]</td> <td class=\"centered\">Martinez MJ, et al</td> <td class=\"centered\">2009</td> </tr> <tr> <td class=\"centered\">58</td> <td class=\"centered\">86</td> <td class=\"centered\">90</td> <td class=\"centered\">83</td> <td class=\"centered\">92</td> <td class=\"centered\">[22]</td> <td class=\"centered\">Neye H, et al</td> <td class=\"centered\">2010</td> </tr> <tr> <td class=\"centered\">58</td> <td class=\"centered\">78</td> <td class=\"centered\">95</td> <td class=\"centered\">86</td> <td class=\"centered\">91</td> <td class=\"centered\">[22]</td> <td class=\"centered\">Neye H, et al</td> <td class=\"centered\">2010</td> </tr> <tr> <td class=\"centered\">58</td> <td class=\"centered\">90</td> <td class=\"centered\">99</td> <td class=\"centered\">90</td> <td class=\"centered\">99</td> <td class=\"centered\">[22]</td> <td class=\"centered\">Neye H, et al</td> <td class=\"centered\">2010</td> </tr> <tr> <td class=\"centered\">143</td> <td class=\"centered\">93</td> <td class=\"centered\">99</td> <td class=\"centered\">98</td> <td class=\"centered\">&nbsp;95&nbsp;</td> <td class=\"centered\">[23]</td> <td class=\"centered\">Chatu S, et al</td> <td class=\"centered\">2012</td> </tr> <tr> <td class=\"centered\">15</td> <td class=\"centered\">92<sup>&#167;</sup>/100<sup>&#165;</sup>/60<sup>&#135;</sup>/100<sup>&#134;</sup></td> <td class=\"centered\">0<sup>&#167;</sup>/50<sup>&#165;</sup>/88<sup>&#135;</sup>/80<sup>&#134;</sup></td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[24]</td> <td class=\"centered\">Onali S, et al</td> <td class=\"centered\">2012</td> </tr> <tr> <td class=\"centered\">49&nbsp;</td> <td class=\"centered\">96<sup>&#135;</sup>/100<sup>&#134;</sup>&nbsp;</td> <td class=\"centered\">91<sup>&#135;</sup>/95<sup>&#134;</sup></td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[25]</td> <td class=\"centered\">Pallotta N, et al&nbsp;</td> <td class=\"centered\">2012</td> </tr> <tr> <td class=\"centered\">59</td> <td class=\"centered\">98**/83<sup>&#182;&#182;</sup>&nbsp;</td> <td class=\"centered\">67**/98<sup>&#182;&#182;</sup></td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[26]</td> <td class=\"centered\">Calabrese E, et al</td> <td class=\"centered\">&nbsp;2013&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PPV: positive predictive value; NPV: negative predictive value; NE: not evaluable. Parentheses indicate the number of patients with proven Crohn disease, if noted.<br />* Learning curve.<br />¶ Oral contrast-enhanced ultrasound.<br />Δ Contrast-enhanced ultrasound.<br /><FONT class=lozenge>◊</FONT> Transperineal ultrasound.<br />§ Strictures.<br />¥ Dilation.<br />‡ Fistulas.<br />† Abscesses.<br />** Small bowel.<br />¶¶ Colon.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Pera A, Cammarota T, Comino E, Caldera D, Ponti V, Astegiano M et al. Ultrasonography in the detection of Crohn's disease and in the differential diagnosis of inflammatory bowel disease. Digestion 1988; 41:180.</LI>&#xD;&#xA;<LI>Stiatti A, Martinuzzi A, Bartolini M, Lascialfari L, Trallori G, Morettini A. Ultrasonography in the diagnosis of chronic inflammatory intestinal disease. Radiol Med (Torino) 1990; 80:301.</LI>&#xD;&#xA;<LI>Hata J, Haruma K, Suenaga K, Yoshihara M, Yamamoto G, Tanaka S et al. Ultrasonographic assessment of inflammatory bowel disease. Am J Gastroenterol 1992; 87:443.</LI>&#xD;&#xA;<LI>Sheridan MB, Nicholson DA, Martin DF. Transabdominal ultrasonography as the primary investigation in patients with suspected Crohn's disease or recurrence: a prospective study. Clin Radiol 1993; 48:402.</LI>&#xD;&#xA;<LI>Brignola C, Belloli C, Iannone P, De Simone G, Corbelli C, Levorato M et al. Comparison of scintigraphy with indium-111 leukocyte scan and ultrasonography in assessment of X-ray-demonstrated lesions of Crohn's disease. Dig Dis Sci 1993; 38:433.</LI>&#xD;&#xA;<LI>Limberg B, Osswald B. Diagnosis and differential diagnosis of ulcerative colitis and Crohn's disease by hydrocolonic sonography. Am J Gastroenterol 1994; 89:1051.</LI>&#xD;&#xA;<LI>Solvig J, Ekberg O, Lindgren S, Floren CH, Nilsson P. Ultrasound examination of the small bowel: comparison with enteroclysis in patients with Crohn disease. Abdom Imaging 1995; 20:323.</LI>&#xD;&#xA;<LI>Maconi G, Parente F, Bollani S, Cesana B, Bianchi PG. Abdominal ultrasound in the assessment of extent and activity of Crohn's disease: clinical significance and implication of bowel wall thickening. Am J Gastroenterol 1996; 91:1604.</LI>&#xD;&#xA;<LI>Hollerbach S, Geissler A, Schiegl H, Kullmann F, Lock G, Schmidt J et al. The accuracy of abdominal ultrasound in the assessment of bowel disorders. Scand J Gastroenterol 1998; 33:1201.</LI>&#xD;&#xA;<LI>Andreoli A, Cerro P, Falasco G, Giglio LA, Prantera C. Role of ultrasonography in the diagnosis of postsurgical recurrence of Crohn's disease. Am J Gastroenterol 1998; 93:1117.</LI>&#xD;&#xA;<LI>Miao YM, Koh DM, Amin Z, Healy JC, Chinn RJ, Zeegen R et al. Ultrasound and magnetic resonance imaging assessmentof active bowel segments in Crohn's disease. Clin Radiol 2002; 57:913.</LI>&#xD;&#xA;<LI>Parente F, Maconi G, Bollani S, Anderloni A, Sampietro G, Cristaldi M et al. Bowel ultrasound in assessment of Crohn's disease and detection of related small bowel strictures: a prospective comparative study versus x ray and intraoperative findings. Gut 2002; 50:490.</LI>&#xD;&#xA;<LI>Potthast S, Rieber A, Von Tirpitz C, Wruk D, Adler G, Brambs HJ. Ultrasound and magnetic resonance imaging in Crohn's disease: a comparison. Eur Radiol 2002; 12:1416.</LI>&#xD;&#xA;<LI>Haber HP, Busch A, Ziebach R, Dette S, Ruck P, Stern M. Ultrasonographic findings correspond to clinical, endoscopic, and histologic findings in inflammatory bowel disease and other enterocolitides. J Ultrasound Med 2002; 21:375.</LI>&#xD;&#xA;<LI>Schmidt T, Reinshagen M, Brambs HJ, Adler G, Rieber A, Tirpitz V et al. Comparison of conventional enteroclysis, intestinal ultrasound and MRI-enteroclysis for determining changes in the small intestine and complications in patients with Crohn's disease. Z Gastroenterol 2003; 41:641.</LI>&#xD;&#xA;<LI>Maconi G, Sampietro GM, Parente F, Pompili G, Russo A, Cristaldi M et al. Contrast radiology, computed tomography and ultrasonography in detecting internal fistulas and intra-abdominal abscesses in Crohn's disease: a prospective comparative study. Am J Gastroenterol 2003; 98:1545.</LI>&#xD;&#xA;<LI>Parente F, Greco S, Molteni M, Anderloni A, Sampietro GM, Danelli PG et al. Oral contrast enhanced bowel ultrasonography in the assessment of small intestine Crohn's disease. A prospective comparison with conventional ultrasound, x ray studies, and ileocolonoscopy. Gut 2004; 53:1652.</LI>&#xD;&#xA;<LI>Rispo A, Imbriaco M, Celentano L, Cozzolino A, Camera L, Mainenti PP et al. Noninvasive diagnosis of small bowel Crohn's disease: combined use of bowel sonography and Tc-99m-HMPAO leukocyte scintigraphy. Inflamm Bowel Dis 2005; 11:376.</LI>&#xD;&#xA;<LI>Serra C, Menozzi G, Labate AM, Giangregorio F, Gionchetti P, Beltrami M, Robotti D, Fornari F, Cammarota T. Ultrasound assessment of vascularization of the thickened terminal ileum wall in Crohn's disease patients using a low-mechanical index real-time scanning technique with a second generation ultrasound contrast agent. Eur J Radiol. 2007; 62:114.</LI>&#xD;&#xA;<LI>Maconi G, Ardizzone S, Greco S, Radice E, Bezzio C, Bianchi Porro G. Transperineal ultrasound in the detection of perianal and rectovaginal fistulae in Crohn's disease. Am J Gastroenterol. 2007; 102:2214.</LI>&#xD;&#xA;<LI>Martínez MJ, Ripollés T, Paredes JM, Blanc E, Martí-Bonmatí L. Assessment of the extension and the inflammatory activity in Crohn's disease: comparison of ultrasound and MRI. Abdom Imaging. 2009; 34:141.</LI>&#xD;&#xA;<LI>Neye H, Ensberg D, Rauh P, Peitz U, Mönkemüller K, Treiber G, Klauck S, Malfertheiner P, Rickes S. Impact of high-resolution transabdominal ultrasound in the diagnosis of complications of Crohn's disease. Scand J Gastroenterol. 2010; 45: 690.</LI>&#xD;&#xA;<LI>Chatu S, Pilcher J, Saxena Sk, et al. Diagnostic accuracy of small intestine ultrasonography using an oral contrast agent in Crohn's disease: comparative study from the UK. Clin Radiol 2012; 67:553.</LI>&#xD;&#xA;<LI>Onali S, Calabrese E, Petruzziello C, et al. Small intestine contrast ultrasonography vs computed tomography enteroclysis for assessing ileal Crohn's disease. World J Gastroenterol 2012; 18:6088.</LI>&#xD;&#xA;<LI>Pallotta N, Vincoli G, Montesani C, et al. Small intestine contrast ultrasonography (SICUS) for the detection of small bowel complications in crohn's disease: a prospective comparative study versus intraoperative findings. Inflamm Bowel Dis 2012; 18:74.</LI>&#xD;&#xA;<LI>Calabrese E, Zorzi F, Onali S, et al. Accuracy of small-intestine contrast ultrasonography, compared with computed tomography enteroclysis, in characterizing lesions in patients with Crohn's disease. Clin Gastroenterol Hepatol 2013; 11:950.</LI></OL></div><div id=\"graphicVersion\">Graphic 80268 Version 4.0</div></div></div>"},"80270":{"type":"graphic_figure","displayName":"Targets for antithrombotic therapy","title":"Targets for antithrombics","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Targets for antithrombics</div><div class=\"cntnt\"><img style=\"width:552px; height:726px;\" src=\"images/CARD/80270_Trgts_antithrombotic_thrpy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Antithrombotic drugs for non-ST-elevation acute coronary syndromes. The figure depicts the targets of available antithrombotic drugs that can be used to inhibit blood coagulation and platelet aggregation during and after thrombus formation. Vorapaxar is a protease-activated receptor 1 (PAR-1) blocker.</div><div class=\"graphic_footnotes\">ADP: adenosine diphosphate; GP: glycoprotein; LMWH: low molecular weight heparin; UFH: unfractionated heparin; Tx: thromboxane.</div><div class=\"graphic_reference\">Reproduced from: Roffi M, Patrono C, Collet J-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal Jan 2016; 37(3):267-315, by permission of the Oxford University Press on behalf of the European Society of Cardiology. Copyright © 2015 Oxford University Press. Available at:&nbsp;<A spellcheck=true href=\"http://www.escardio.org/\" target=_blank>www.escardio.org</A>.</div><div id=\"graphicVersion\">Graphic 80270 Version 13.0</div></div></div>"},"80271":{"type":"graphic_figure","displayName":"Female anatomy PI","title":"Female reproductive anatomy","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Female reproductive anatomy</div><div class=\"cntnt\"><img style=\"width:545px; height:497px;\" src=\"images/OBGYN/80271_FemanatPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These are the internal organs that make up a woman's reproductive system.</div><div id=\"graphicVersion\">Graphic 80271 Version 5.0</div></div></div>"},"80272":{"type":"graphic_diagnosticimage","displayName":"GB adenomyomatosis OCG","title":"Gallbladder adenomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gallbladder adenomyomatosis</div><div class=\"cntnt\"><img style=\"width:360px; height:388px;\" src=\"images/GAST/80272_GB_adenomyomatosis_OCG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oral cholecystogram showing localized adenomyomatosis in the fundus of the gallbladder. Note the appearance of Rokitansky-Aschoff sinuses (arrow).</div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD, FACP.</div><div id=\"graphicVersion\">Graphic 80272 Version 2.0</div></div></div>"},"80273":{"type":"graphic_figure","displayName":"Allopurinol hyperuricosuria","title":"Allopurinol prevents stones in hyperuricosuria","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Allopurinol prevents stones in hyperuricosuria</div><div class=\"cntnt\"><img style=\"width:413px; height:241px;\" src=\"images/NEPH/80273_Allopurinol_hyperuricosuria.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When compared to placebo, allopurinol protects against new stone formation in hyperuricosuric calcium oxalate stone formers.</div><div class=\"graphic_reference\">Data from Ettinger, B, Tang, A, Citron, JT, et al, N Engl J Med 1986; 315:1386.</div><div id=\"graphicVersion\">Graphic 80273 Version 1.0</div></div></div>"},"80275":{"type":"graphic_diagnosticimage","displayName":"Echocardiogram apical 4-chamber with contrast showing dilated RV","title":"Echocardiogram apical 4-chamber with and without saline contrast showing enlargement of the right heart chambers","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiogram apical 4-chamber with and without saline contrast showing enlargement of the right heart chambers</div><div class=\"cntnt\"><img style=\"width:321px; height:352px;\" src=\"images/CARD/80275_4_chamber_RV_volume_overloa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A: Apical four-chamber view from a patient with&nbsp;severe idiopathic pulmonary arterial hypertension associated with tricuspid regurgitation. There is a large apex-forming right ventricle (RV), large right atrium (RA), and small left ventricle (LV) and left atrium (LA).<br />Panel B: Agitated saline contrast is injected intravenously and results in RA and RV opacification; four bubbles are seen in the LV (arrow), possibly due to right-to-left flow across a patent foramen ovale.<br />Panel C: Similar echocardiographic findings can be seen in patients with primary volume overload of the right ventricle. This panel shows&nbsp;an apical four chamber view from a patient with a large left-to-right shunt due to an atrial septal defect (ASD). The RV is apex-forming but the RV and RA are not as large as in panel A.<br />Panel D: Contrast is injected intravenously and a few bubbles are seen in the LV; more importantly, there is a prominent negative contrast (nc) effect due to opacified atrial blood.</div><div id=\"graphicVersion\">Graphic 80275 Version 4.0</div></div></div>"},"80277":{"type":"graphic_table","displayName":"Features of ectopic pregnancy","title":"Significance of features associated with ectopic pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Significance of features associated with ectopic pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Features</td> <td class=\"subtitle1\">SN (percent)</td> <td class=\"subtitle1\">SP (percent)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Clinical features</td> </tr> <tr> <td class=\"indent1\">Estimated gestational age &#60;70 days</td> <td>95</td> <td>27</td> </tr> <tr> <td class=\"indent1\">Vaginal bleeding</td> <td>69</td> <td>26</td> </tr> <tr> <td class=\"indent1\">Abdominal pain</td> <td>97</td> <td>15</td> </tr> <tr> <td class=\"indent1\">Abdominal tenderness</td> <td>85</td> <td>50</td> </tr> <tr> <td class=\"indent1\">Peritoneal signs</td> <td>23</td> <td>95</td> </tr> <tr> <td class=\"indent1\">Cervical motion tenderness</td> <td>33</td> <td>91</td> </tr> <tr> <td class=\"indent1\">Adnexal tenderness</td> <td>69</td> <td>62</td> </tr> <tr> <td class=\"indent1\">Adnexal mass</td> <td>5</td> <td>96</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Transvaginal ultrasound</td> </tr> <tr> <td class=\"indent1\">No intrauterine gestational sac</td> <td>100</td> <td>89</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Adnexal mass</td> </tr> <tr> <td class=\"sublist2\">Separate from ovary</td> <td class=\"sublist_other\">93</td> <td class=\"sublist_other\">99</td> </tr> <tr> <td class=\"sublist2\">Cardiac activity</td> <td class=\"sublist_other\">20</td> <td class=\"sublist_other\">100</td> </tr> <tr> <td class=\"sublist2\">Yolk sac or embryo</td> <td class=\"sublist_other\">37</td> <td class=\"sublist_other\">100</td> </tr> <tr> <td class=\"sublist2\">Tubal ring/yolk sac or embryo</td> <td class=\"sublist_other\">65</td> <td class=\"sublist_other\">99</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Fluid in pouch of Douglas</td> </tr> <tr> <td class=\"sublist2\">Any</td> <td class=\"sublist_other\">63</td> <td class=\"sublist_other\">69</td> </tr> <tr> <td class=\"sublist2\">Echogenic</td> <td class=\"sublist_other\">56</td> <td class=\"sublist_other\">96</td> </tr> <tr> <td class=\"indent1\">Color-flow Doppler</td> <td>95</td> <td>98</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Beta-hCG combined with transvaginal ultrasound</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Empty uterus</td> </tr> <tr> <td class=\"sublist2\">&#8805;1000 milli-international units/mL</td> <td class=\"sublist_other\">43 to 96</td> <td class=\"sublist_other\">86 to 100</td> </tr> <tr> <td class=\"sublist2\">&#8805;1500 milli-international units/mL</td> <td class=\"sublist_other\">40 to 99</td> <td class=\"sublist_other\">84 to 96</td> </tr> <tr> <td class=\"sublist2\">&#8805;2000 milli-international units/mL</td> <td class=\"sublist_other\">38 to 48</td> <td class=\"sublist_other\">80 to 98</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Adnexal mass*</td> </tr> <tr> <td class=\"sublist2\">&#8805;1000 milli-international units/mL</td> <td class=\"sublist_other\">73</td> <td class=\"sublist_other\">85</td> </tr> <tr> <td class=\"sublist2\">&#8805;1500 milli-international units/mL</td> <td class=\"sublist_other\">46 to 64</td> <td class=\"sublist_other\">92 to 96</td> </tr> <tr> <td class=\"sublist2\">&#8805;2000 milli-international units/mL</td> <td class=\"sublist_other\">55</td> <td class=\"sublist_other\">96</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SN: sensitivity; SP: specificity; beta-hCG: beta human chorionic gonadotropin.<br />* Mass or fluid in cul de sac for beta-hCG ≥1500 milli-international units/mL and ≥2000 milli-international units/mL.</div><div class=\"graphic_reference\">Data from: Ramakrishnan, K, Scheid, DC. Ectopic pregnancy: Forget the &quot;classic presentation&quot; if you want to catch it sooner: A new algorithm to improve detection. Journal of Family Practice 2006; 55:388.</div><div id=\"graphicVersion\">Graphic 80277 Version 4.0</div></div></div>"},"80278":{"type":"graphic_figure","displayName":"Transverse vaginal septum","title":"Transverse vaginal septum with microperforation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse vaginal septum with microperforation</div><div class=\"cntnt\"><img style=\"width:341px; height:325px;\" src=\"images/OBGYN/80278_Transversevaginalseptum.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 80278 Version 13.0</div></div></div>"},"80280":{"type":"graphic_table","displayName":"Zoonoses from dogs A","title":"Zoonoses dogs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Zoonoses dogs</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Transmission</td>\n<td class=\"subtitle1\">Organism</td>\n<td class=\"subtitle1\">Human symptoms</td>\n<td class=\"subtitle1\">Canine symptoms</td>\n<td class=\"subtitle1\">Geographic distribution</td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"4\">Infectious saliva</td>\n<td>Rabies</td>\n<td>Acute progressive encephalitis</td>\n<td>Stages: prodromal, furious, and paralytic</td>\n<td>Worldwide</td>\n</tr>\n<tr>\n\n<td>Pasteurella </td>\n<td>Skin and soft-tissue infections, septic arthritis, osteomyelitis</td>\n<td>Normal flora of oral cavity</td>\n<td>Worldwide</td>\n</tr>\n<tr>\n\n<td>Capnocytophaga</td>\n<td>Skin and soft-tissue infections, sepsis, meningitis</td>\n<td>Normal flora of oral cavity</td>\n<td>Worldwide</td>\n</tr>\n\n<tr>\n\n<td>Brucella</td>\n<td colspan=\"1\">Fever of unknown origin; varied and nonspecific symptoms</td><td>Similar to human disease</td>\n<td>Worldwide</td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"6\">Fecal</td>\n<td>Salmonella Cryptosporidium Giardia</td>\n<td>Asymptomatic or gastroenteritis</td>\n<td>Asymptomatic or gastroenteritis</td>\n<td>Worldwide</td>\n</tr>\n<tr>\n\n<td>Campylobacter</td>\n<td>Abdominal pain and diarrhea</td>\n<td>Asymptomatic or gastroenteritis</td>\n<td>Worldwide</td>\n</tr>\n<tr>\n\n<td>Toxocara canis</td>\n<td>Visceral larva migrans and ocular larva migrans</td>\n<td>Asymptomatic</td>\n<td>Worldwide</td>\n</tr>\n<tr>\n\n<td>Ancylostoma caninum</td>\n<td>Cutaneous larva migrans</td>\n<td>Asymptomatic</td>\n<td>Worldwide</td>\n</tr>\n<tr>\n\n<td>Echinococcus granulosus</td>\n<td>Hydatid cysts, echinococcosis</td>\n<td>Hydatid cysts, echinococcosis</td>\n<td>Most common in ranching areas of the Mediterranean, South America, and Australia</td>\n</tr>\n<tr>\n\n<td>Dipylidium caninum</td>\n<td>Asymptomatic to abdominal pain, diarrhea, pruritus ani, and urticaria</td>\n<td>Similar to human disease</td>\n<td>Worldwide</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 80280 Version 1.0</div></div></div>"},"80282":{"type":"graphic_picture","displayName":"Phase-contrast micrograph showing monomorphic red cells in urine","title":"Phase-contrast micrograph showing monomorphic red cells in urine sediment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Phase-contrast micrograph showing monomorphic red cells in urine sediment</div><div class=\"cntnt\"><img style=\"width:378px; height:251px;\" src=\"images/NEPH/80282_Red_cells.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urine sediment viewed by phase-contrast microscopy showing many red cells and an occasional larger white cell with a granular cytoplasm (arrows). The red cells have a uniform size and shape, suggesting that they are of nonglomerular origin.</div><div class=\"graphic_reference\">Courtesy of Harvard Medical School.</div><div id=\"graphicVersion\">Graphic 80282 Version 4.0</div></div></div>"},"80283":{"type":"graphic_figure","displayName":"Sacroiliac tenderness II","title":"Testing for sacroiliac pain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Testing for sacroiliac pain</div><div class=\"cntnt\"><img style=\"width:360px; height:226px;\" src=\"images/RHEUM/80283_Sacroiliac_tenderness_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the patient lying on the side, pressure is exerted by the examiner to compress the pelvis. This maneuver will elicit sacroiliac pain in patients with active sacroiliitis.</div><div class=\"graphic_reference\">Courtesy of Craig W Wiesenhutter, MD.</div><div id=\"graphicVersion\">Graphic 80283 Version 2.0</div></div></div>"},"80284":{"type":"graphic_table","displayName":"Properties of hyaluronic acid fillers","title":"Properties of hyaluronic acid fillers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Properties of hyaluronic acid fillers</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Hylaform</td> <td class=\"subtitle1\">Hylaform Plus</td> <td class=\"subtitle1\">Prevelle Silk</td> <td class=\"subtitle1\">Restylane</td> <td class=\"subtitle1\">Perlane</td> <td class=\"subtitle1\">Juv&#233;derm Ultra*</td> <td class=\"subtitle1\">Juv&#233;derm Ultra Plus*</td> <td class=\"subtitle1\">Elevess<sup>&#182;</sup></td> </tr> <tr> <td>Total HA concentration (mg/mL)</td> <td>5.5</td> <td>5.5</td> <td>5.5</td> <td>20</td> <td>20</td> <td>24</td> <td>24</td> <td>28</td> </tr> <tr> <td>Percent cross-linked HA</td> <td>12</td> <td>12</td> <td>12</td> <td>&#60;1</td> <td>&#60;1</td> <td>6</td> <td>8</td> <td>N/A</td> </tr> <tr> <td>Gel/fluid ratio</td> <td>98/2</td> <td>98/2</td> <td>98/2</td> <td>75/25</td> <td>75/25</td> <td>90/10</td> <td>90/10</td> <td>100/0</td> </tr> <tr> <td>HA gel concentration (mg/mL)</td> <td>5.4</td> <td>5.4</td> <td>5.4</td> <td>15</td> <td>15</td> <td>17.3</td> <td>17.3</td> <td>28</td> </tr> <tr> <td><em>G&#8242;</em> modulus (Pa)</td> <td>140-220</td> <td>140-220</td> <td>230-260</td> <td>660</td> <td>588</td> <td>170</td> <td>200</td> <td>329</td> </tr> <tr> <td>Average particulate size (mcm)</td> <td>500</td> <td>700</td> <td>350</td> <td>300</td> <td>650</td> <td>-</td> <td>-</td> <td>200</td> </tr> <tr> <td>Anesthetic included</td> <td>No</td> <td>No</td> <td>Yes</td> <td>No</td> <td>No</td> <td>No</td> <td>No</td> <td>Yes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">N/A: data not available.<br />* Data provided by Allergan.<br />¶ Data provided by Anika Therapeutics.</div><div class=\"graphic_reference\">Reproduced with permission from: Beasley KL, Weiss MA, Weiss RA. Hyaluronic acid fillers: A comprehensive review. Facial Plast Surg 2009; 25:86. Copyright &copy; 2009 Thieme Medical Publishers, Inc.</div><div id=\"graphicVersion\">Graphic 80284 Version 4.0</div></div></div>"},"80285":{"type":"graphic_diagnosticimage","displayName":"Nondisplaced tuberosity avulsion fracture","title":"Nondisplaced tuberosity avulsion fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nondisplaced tuberosity avulsion fracture</div><div class=\"cntnt\"><img style=\"width:253px; height:540px;\" src=\"images/EM/80285_Min_displaced_tuberosity_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fracture (arrow) extends into the joint between the cuboid and the fifth metatarsal but does not involve the intermetatarsal joint. Such fractures generally heal well with conservative management. Note the presence of an accessory ossicle (arrowhead) just lateral to the proximal portion of the cuboid. Like most accessory ossicles, it is rounded, corticated, and located far from the fifth metatarsal.</div><div class=\"graphic_reference\">Reproduced with permission: Eiff MP, Hatch RL, Calmbach W. Fracture Management for Primary Care, 2nd ed, W.B. Saunders, Philadelphia 2002.</div><div id=\"graphicVersion\">Graphic 80285 Version 5.0</div></div></div>"},"80286":{"type":"graphic_diagnosticimage","displayName":"Cecal bascule barium enema","title":"Cecal bascule","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Cecal bascule</div><div class=\"cntnt\"><img style=\"width:499px; height:290px;\" src=\"images/GAST/80286_Cecal_bascule_barium_enema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A plain film of the abdomen (left panel) demonstrates marked dilatation of a stool-filled cecal bascule (arrows). Following the administration of barium (right panel), the site of torsion is evident as marked narrowing of the lumen in the midascending colon (arrow). These features are consistent with a cecal bascule.</div><div class=\"graphic_reference\">Courtesy of Jonathan B Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 80286 Version 3.0</div></div></div>"},"80287":{"type":"graphic_algorithm","displayName":"Evaluation of lung rejection","title":"Evaluation of possible chronic lung transplant rejection","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Evaluation of possible chronic lung transplant rejection</div><div class=\"cntnt\"><img style=\"width:587px; height:318px;\" src=\"images/PULM/80287_Evaluation_of_lung_rejectio.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 80287 Version 2.0</div></div></div>"},"80288":{"type":"graphic_algorithm","displayName":"OSA diagnosis algorithm","title":"Diagnosis of obstructive sleep apnea (OSA) algorithm","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Diagnosis of obstructive sleep apnea (OSA) algorithm</div><div class=\"cntnt\"><img style=\"width:496px; height:630px;\" src=\"images/SLEEP/80288_OSAH_diagnosis_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">OSA: obstructive sleep apnea; AHI: apnea-hypopnea index.<br />* Excessive daytime sleepiness is a common complaint with multiple potential causes. For additional information, refer to UpToDate topic text on the evaluation of excessive daytime sleepiness.<br />¶ Mission-critical workers should only have in-laboratory polysomnography (not&nbsp;home&nbsp;sleep apnea&nbsp;testing).<br />Δ Such as resistant hypertension, unexplained pulmonary hypertension, or secondary polycythemia.</div><div id=\"graphicVersion\">Graphic 80288 Version 9.0</div></div></div>"},"80289":{"type":"graphic_figure","displayName":"Fusarium diagnostic clues","title":"Diagnostic clues for invasive fusariosis","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Diagnostic clues for invasive fusariosis</div><div class=\"cntnt\"><img style=\"width:517px; height:722px;\" src=\"images/ID/80289_Fusarium_diag_tools_edit2.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 80289 Version 4.0</div></div></div>"},"80290":{"type":"graphic_picture","displayName":"Oral papillomas in Cowden syndrome patient","title":"Oral papillomas on the lips and tongue of a Cowden syndrome patient","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Oral papillomas on the lips and tongue of a Cowden syndrome patient</div><div class=\"cntnt\"><img style=\"width:548px; height:241px;\" src=\"images/ONC/80290_Oral_papill_Cowden_synd_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">From: Stanich PP, Francis DL, Sweetser S. The spectrum of findings in Cowden syndrome. Clin Gastroenterol Hepatol 2011; 9:e2. Illustrations used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 80290 Version 1.0</div></div></div>"},"80292":{"type":"graphic_table","displayName":"Mech opioids may red dys","title":"Mechanisms by which opioids may reduce dyspnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mechanisms by which opioids may reduce dyspnea</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td>Decreased metabolic rate and ventilatory requirements</td>\n\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Reduced medullary sensitivity to hypercarbia or hypoxia</td>\n\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Blunted medullary response to hypercarbia or hypoxia</td>\n\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Alteration of neurotransmission within medullary respiratory centre</td>\n\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Cortical sedation (suppression of respiratory awareness)</td>\n\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Analgesia  -  reduction of pain-induced respiratory drive</td>\n\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Anxiolytic effects</td>\n\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Blunted afferent transmission from pulmonary mechanoreceptor to the CNS</td>\n\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Vasodilation (improved cardiac function)</td>\n\n\t\t\t\t</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 80292 Version 1.0</div></div></div>"},"80293":{"type":"graphic_figure","displayName":"Tympanogram in otitis media with effusion","title":"Tympanogram in otitis media with effusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tympanogram in otitis media with effusion</div><div class=\"cntnt\"><img style=\"width:428px; height:260px;\" src=\"images/PEDS/80293_TympanograminOME.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tympanogram A depicts middle ear compliance (bold black line) within the normal range (light blue area). Tympanogram B, which is flat and without a peak, depicts the reduced middle ear compliance characteristic of middle ear effusion.</div><div class=\"graphic_reference\">Adapted from: Acoustic Impedance and Admittance:&nbsp;The Measurement of Middle Ear Function, Feldman AS, Wilber LA (Eds), Williams &amp; Wilkins, Baltimore 1976. p.103.</div><div id=\"graphicVersion\">Graphic 80293 Version 3.0</div></div></div>"},"80294":{"type":"graphic_picture","displayName":"Circuvent device for delivery of MDI or nebulized medication","title":"Circuvent® device for delivery of MDI or nebulized medication during mechanical ventilation","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Circuvent&#174; device for delivery of MDI or nebulized medication during mechanical ventilation</div><div class=\"cntnt\"><img style=\"width:465px; height:193px;\" src=\"images/PULM/80294_Circ_dev_deliv_MDI_nebu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CircuVent<sup>&reg;</sup> device allows delivery of aerosolized medications (MDI or nebulized) to mechanically ventilated patients without removing the heat and moisture exchanger (HME). Using a valve system, air bypasses the HME during delivery of the aerosol.</div><div class=\"graphic_reference\">Reproduced with permission from: Smiths Medical. Copyright &copy; 2012. All rights reserved.</div><div id=\"graphicVersion\">Graphic 80294 Version 1.0</div></div></div>"},"80295":{"type":"graphic_table","displayName":"Causes decr RBC production","title":"Causes of anemia with decreased red cell production","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of anemia with decreased red cell production</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Bone marrow failure</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Congenital pure red cell aplasia</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Blackfan Diamond anemia*</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Aase syndrome*</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">Aquired pure red cell aplasia</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Autoimmune processes</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Infections</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Drugs</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Transient erythroblastopenia of childhood*</td>\n    </tr>\n    <tr>\n\n      <td>Malignancy</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Bone marrow failure syndromes</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Aplastic anemia</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Fanconi's anemia</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Others</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">Mylelofibrosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Renal failure</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Vitamin D deficiency</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Hypoparathyroidism</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">Bone diseases</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Osteopetrosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Impaired erythropoietin production</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hypothyroidism</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Starvation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Chronic renal disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Anemia of chronic disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Disorders of erythroid maturation/ineffective erythropoiesis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Iron deficiency</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sideroblastic anemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lead toxicity</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Megaloblastic anemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Congenital dyserythropoietic anemias</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Causes unique to the pediatric age group.</div><div id=\"graphicVersion\">Graphic 80295 Version 1.0</div></div></div>"},"80296":{"type":"graphic_figure","displayName":"Plasmodium blood smears","title":"Red blood cell morphology in various forms of <em>Plasmodium</em> infections","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Red blood cell morphology in various forms of <em>Plasmodium</em> infections</div><div class=\"cntnt\"><img style=\"width:564px; height:532px;\" src=\"images/ID/80296_Plasmodiumbloodsmears.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Identification of a schizont with &gt;12 merozoites in the peripheral circulation is an important diagnostic clue for <em>P. vivax</em>. In general, schizonts of <em>P. falciparum</em> are very rarely seen in blood films; they are generally absent from the peripheral circulation except in cases of severe infection with overwhelming parasitemia.</div><div id=\"graphicVersion\">Graphic 80296 Version 8.0</div></div></div>"},"80297":{"type":"graphic_figure","displayName":"Digoxin and total mortality","title":"Digoxin has no effect on total mortality in heart failure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Digoxin has no effect on total mortality in heart failure</div><div class=\"cntnt\"><img style=\"width:396px; height:279px;\" src=\"images/CARD/80297_Digoxin_and_total_mortality.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 6800 patients with symptomatic heart failure and a left ventricular ejection fraction &#8804;45 percent who were randomized to digoxin or placebo, there was no difference in total mortality.</div><div class=\"graphic_reference\">Data from: The Digitalis Investigation Group. N Engl J Med 1997; 336:525.</div><div id=\"graphicVersion\">Graphic 80297 Version 1.0</div></div></div>"},"80298":{"type":"graphic_table","displayName":"Analgesic routes admin","title":"Routes of administration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Routes of administration</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Route\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Comments\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Oral (PO)</td>\r\n  \r\n   <td>Requires functioning GI tract</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Rectal (PR)</td>\r\n  \r\n   <td>Absorption may be unpredictable</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Intramuscular (IM)</td>\r\n  \r\n   <td>Not recommended due to painful injections and fluctuations in drug levels</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Intravenous (IV)</td>\r\n  \r\n   <td>Single, repetitive bolus, continuous infusion, or patient-controlled analgesia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Subcutaneous (SC)</td>\r\n  \r\n   <td>Single, repetitive bolus, continuous infusion, or patient-controlled analgesia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Transdermal (TD)</td>\r\n  \r\n   <td>Noninvasive; delayed onset of action with first dose</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Oral transmucosal (OT)</td>\r\n  \r\n   <td>Includes sublingual and several rapid onset formulations</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Epidural analgesia (EA)</td>\r\n  \r\n   <td>Indwelling catheter is tunneled under the skin and left percutaneous or connected to a port</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Intrathecal analgesia (IA)</td>\r\n  \r\n   <td>An indwelling intrathecal catheter is placed for long-term analgesia</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 80298 Version 1.0</div></div></div>"},"80299":{"type":"graphic_figure","displayName":"Metacarpophalangeal joint","title":"Metacarpophalangeal joint","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Metacarpophalangeal joint</div><div class=\"cntnt\"><img style=\"width:521px; height:639px;\" src=\"images/EM/80299_MCP_lig_volar_plate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The metacarpophalangeal joint is more prone to dislocation when the joint is in extension because the fibers of the collateral ligaments are lax, making the joint less stable.</div><div id=\"graphicVersion\">Graphic 80299 Version 2.0</div></div></div>"},"80301":{"type":"graphic_algorithm","displayName":"Breast biopsy algorithm for indeterminate or suspicious lesions","title":"Breast biopsy algorithm for solid lesions, indeterminate or suspicious","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">Breast biopsy algorithm for solid lesions, indeterminate or suspicious</div><div class=\"cntnt\"><img style=\"width:555px; height:481px;\" src=\"images/ONC/80301_Bx_solid_lesions_Ed2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LCIS: lobular carcinoma in situ.<br />* Not all high-risk breast lesions identified by core needle biopsy require excision. Refer to related UpToDate topics for details on the management of high-risk breast lesions (excision versus observation).</div><div class=\"graphic_reference\">Adapted from: Esserman LJ, Wolverton D, Hylton N. Integration of breast imaging into cancer management. Curr Oncol Rep 2000; 2:572.</div><div id=\"graphicVersion\">Graphic 80301 Version 5.0</div></div></div>"},"80302":{"type":"graphic_figure","displayName":"Variations of Billroth II reconstruction","title":"Variations of Billroth II reconstruction","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Variations of Billroth II reconstruction</div><div class=\"cntnt\"><img style=\"width:518px; height:597px;\" src=\"images/PC/80302_Billroth_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Sedgwick, CE. Gastrectomy. In: Atlas of Abdominal Surgery, Braasch, JW, Sedgwick, CE, Veidenheimer, MC, Ellis, FH (Eds), WB Saunders Company, Philadelphia 1991. p. 33.</div><div id=\"graphicVersion\">Graphic 80302 Version 2.0</div></div></div>"},"80304":{"type":"graphic_picture","displayName":"Postinfectious GN with low-power LM","title":"Postinfectious glomerulonephritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postinfectious glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:396px; height:265px;\" src=\"images/NEPH/80304_Postinfectious_GN_Light_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power light micrograph showing diffuse, proliferative glomerulonephritis, as may be seen in postinfectious glomerulonephritis. The glomeruli are so hypercellular (arrows) that open capillary lumens cannot be seen, and the glomeruli may be hard to distinguish from the surrounding interstitium.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 80304 Version 3.0</div></div></div>"},"80305":{"type":"graphic_picture","displayName":"Oral aphthae PI","title":"Oral aphthae","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Oral aphthae</div><div class=\"cntnt\"><img style=\"width:530px; height:285px;\" src=\"images/PI/80305_Oral_aphthae_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shallow ulcers are evident on the buccal mucosa.</div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 80305 Version 1.0</div></div></div>"},"80306":{"type":"graphic_figure","displayName":"Estimates of the benefits and risks of tamoxifen","title":"Estimates of the benefits and risks of tamoxifen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Estimates of the benefits and risks of tamoxifen</div><div class=\"cntnt\"><img style=\"width:398px; height:322px;\" src=\"images/PC/80306_Varying_effects_of_tamoxife.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tamoxifen decreased the average annual rate of breast cancer in the Breast Cancer Prevention Trial, but increased the rate of endometrial cancer and vascular events such as stroke, pulmonary embolism, and deep vein thrombosis.</div><div class=\"graphic_reference\">Data from Fisher B, Costantino JP, Wikerham DL. J Natl Cancer Inst 1998; 90:1371.</div><div id=\"graphicVersion\">Graphic 80306 Version 2.0</div></div></div>"},"80307":{"type":"graphic_diagnosticimage","displayName":"Preoperative deformities in SSc","title":"Severe subluxation and contractures in scleroderma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe subluxation and contractures in scleroderma</div><div class=\"cntnt\"><img style=\"width:389px; height:262px;\" src=\"images/RHEUM/80307_Preoperative_deformities_in.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Preoperative radiograph showing metacarpophalangeal hyperextension deformities combined with fixed proximal interphalangeal joint flexion contractures. This patient with scleroderma subsequently underwent resection arthroplasty and proximal interphalangeal joint fusion.</div><div class=\"graphic_reference\">Reproduced with permission from: Nalebuff EA. Surgery in patients with systemic sclerosis of the hand. Clin Orthop Rel Res 1999; 91:366. Copyright © 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80307 Version 8.0</div></div></div>"},"80308":{"type":"graphic_figure","displayName":"Elevation of uterus","title":"Elevating the uterus prior to dividing from the adnexa during abdominal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Elevating the uterus prior to dividing from the adnexa during abdominal hysterectomy</div><div class=\"cntnt\"><img style=\"width:478px; height:512px;\" src=\"images/OBGYN/80308_Elevation_of_uterus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The uterus is elevated using broad ligament clamps which incorporate the utero-ovarian and round ligaments.</div><div id=\"graphicVersion\">Graphic 80308 Version 2.0</div></div></div>"},"80309":{"type":"graphic_table","displayName":"Dosing and administration of tetracyclines","title":"Dosing and administration of tetracyclines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosing and administration of tetracyclines</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Drug</td> </tr> <tr> <td>Doxycycline</td> <td>100 mg IV/PO every 12 hours; No adjustment in renal dysfunction</td> </tr> <tr> <td rowspan=\"3\">Tetracycline</td> <td>250-500 mg PO every 6 hours with normal renal function.</td> </tr> <tr> <td>250-500 mg PO every 12 to 24 hours with CrCl 10-50 mL/min.</td> </tr> <tr> <td>Not recommended when CrCl &#60;10 mL/min</td> </tr> <tr> <td>Minocycline</td> <td>100 mg PO every 12 hours; 100-200 mg IV every 12 hours; No adjustment in renal dysfunction</td> </tr> <tr> <td>Demeclocycline</td> <td>150-300 mg PO every 12 to 24 hours; Avoid use in renal dysfunction</td> </tr> <tr> <td>Tigecycline</td> <td>100 mg initial dose then 50 mg IV every 12 hours; No adjustment in renal dysfunction</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80309 Version 3.0</div></div></div>"},"80310":{"type":"graphic_diagnosticimage","displayName":"Post fossa ependymoma MRIproton","title":"Posterior fossa ependymoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior fossa ependymoma</div><div class=\"cntnt\"><img style=\"width:324px; height:311px;\" src=\"images/ONC/80310_Post_fossa_ependymoma_MRIpr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Proton image of the same posterior fossa ependymoma as seen in the previous images.</div><div class=\"graphic_reference\">Courtesy of Mark Kieran, MD.</div><div id=\"graphicVersion\">Graphic 80310 Version 4.0</div></div></div>"},"80314":{"type":"graphic_table","displayName":"Genetic diseases with increased frequency in Ashkenazi Jews","title":"Frequency of genetic diseases in the Eastern European or Ashkenazi Jewish population","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of genetic diseases in the Eastern European or Ashkenazi Jewish population</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disease or syndrome</td> <td class=\"subtitle1\">Incidence</td> <td class=\"subtitle1\">Carrier frequency</td> <td class=\"subtitle1\">&nbsp;Percent of carriers with recessive mutations detected by the test</td> <td class=\"subtitle1\">Carrier screening recommended by ACOG&nbsp;</td> <td class=\"subtitle1\">&nbsp;Carrier screening recommended by ACMG</td> <td class=\"subtitle1\">&nbsp;Screening panel used by author, Dr. Roman</td> </tr> <tr> <td>Cystic fibrosis</td> <td>1/2500 to 1/3300</td> <td>1/19 to 1/29</td> <td>97</td> <td>x</td> <td>x</td> <td>x</td> </tr> <tr> <td>Familial dysautonomia</td> <td>1/3600 to 1/5000</td> <td>1/30 to 1/32</td> <td>99</td> <td>x</td> <td>x</td> <td>x</td> </tr> <tr> <td>Canavan </td> <td>1/3000 to 1/6000</td> <td>1/40</td> <td>98</td> <td>x</td> <td>x</td> <td>x</td> </tr> <tr> <td>Tay-Sachs </td> <td>1/3000 to 1/3600</td> <td>1/25 to 1/30</td> <td>96 by enzyme, 94 by DNA</td> <td>x</td> <td>x</td> <td>x</td> </tr> <tr> <td>Gaucher </td> <td>1/900</td> <td>1/15</td> <td>95</td> <td>&nbsp;x</td> <td>x</td> <td>x</td> </tr> <tr> <td>Mucolipidosis type IV</td> <td>1/40,000 to 1/62,500</td> <td>1/100 to 1/127</td> <td>95</td> <td>&nbsp;x</td> <td>x</td> <td>x</td> </tr> <tr> <td>Niemann-Pick&nbsp; SMPD-1 related (type A and B)</td> <td>1/32,000</td> <td>1/90</td> <td>95</td> <td>&nbsp;x</td> <td>x</td> <td>x</td> </tr> <tr> <td>Fanconi anemia group C</td> <td>1/32,000</td> <td>1/89</td> <td>99</td> <td>&nbsp;x</td> <td>x</td> <td>x</td> </tr> <tr> <td>Bloom </td> <td>1/40,000 to 1/48,000</td> <td>1/100</td> <td>95 to 97</td> <td>&nbsp;x</td> <td>x</td> <td>x</td> </tr> <tr> <td>Lipoamide dehydrogenase deficiency</td> <td>1/46,000</td> <td>1/107</td> <td>&#62;95</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>x</td> </tr> <tr> <td>ABCC8-related familial hyperinsulinism</td> <td>1/18,000</td> <td>1/68</td> <td>90</td> <td>&nbsp;x</td> <td>&nbsp;</td> <td>x</td> </tr> <tr> <td>NEB-related nemaline myopathy type 2</td> <td>1/113,000</td> <td>1/120</td> <td>&#62;95</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>x</td> </tr> <tr> <td>Joubert</td> <td>1/34,000</td> <td>1/102</td> <td>&#62;99</td> <td>&nbsp;x</td> <td>&nbsp;</td> <td>x</td> </tr> <tr> <td>Usher type 1F</td> <td>1/86,000</td> <td>1/165</td> <td>&#62;75</td> <td>&nbsp;x</td> <td>&nbsp;</td> <td>x</td> </tr> <tr> <td>Usher type 3</td> <td>1/57,000</td> <td>1/107</td> <td>&#62;95</td> <td>&nbsp;x</td> <td>&nbsp;</td> <td>x</td> </tr> <tr> <td>Glycogen storage&nbsp;type I</td> <td>1/16,000</td> <td>1/64</td> <td>98</td> <td>&nbsp;x</td> <td>&nbsp;</td> <td>x</td> </tr> <tr> <td>Maple syrup urine </td> <td>1/50,000</td> <td>1/81</td> <td>&#62;99</td> <td>&nbsp;x</td> <td>&nbsp;</td> <td>x</td> </tr> <tr> <td>Walker-Warburg </td> <td>1/60,500</td> <td>1/149</td> <td>&#62;95</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>x</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80314 Version 5.0</div></div></div>"},"80316":{"type":"graphic_picture","displayName":"Noninflammatory acne PI","title":"Noninflammatory lesions of acne","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Noninflammatory lesions of acne</div><div class=\"cntnt\"><img style=\"width:396px; height:305px;\" src=\"images/PI/80316_Noninflammatory_lesions_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The combination of open and closed comedones, as seen here, is most common in younger patients.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80316 Version 5.0</div></div></div>"},"80318":{"type":"graphic_picture","displayName":"Target cells","title":"Target cells","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Target cells</div><div class=\"cntnt\"><img style=\"width:360px; height:239px;\" src=\"images/HEME/80318_Targetcells.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral smear shows multiple target cells that have an area of central density surrounded by a halo of pallor (arrows). These cells are characteristic of liver disease and certain hemoglobinopathies (most notably hemoglobin C disease).</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 80318 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"80320":{"type":"graphic_table","displayName":"Mgmt interleukin 2 toxicity II","title":"Management of IL-2 toxicity, continued","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of IL-2 toxicity, continued</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Dyspnea </td> </tr> <tr> <td>1. Rare. May reflect fluid overload. Check oxygen saturation and withhold IL-2 until oxygen saturation is above 95%. Diuretics as clinically indicated.</td> </tr> <tr> <td>2. Clarify that serum bicarbonate is greater than 18 mEq/L.</td> </tr> <tr> <td class=\"subtitle1_single\">Peripheral edema </td> </tr> <tr> <td>1. Usually not clinically significant and will reverse once IL-2 is discontinued.</td> </tr> <tr> <td>2. Diuretics may be indicated upon discharge if weight is greatly increased or peripheral edema is clinically detectable (ie, rings too tight, pitting edema, unable to fully close hand or put on usual shoes).</td> </tr> <tr> <td class=\"subtitle1_single\">Oliguria, rising creatinine </td> </tr> <tr> <td>1. Increase in serum creatinine is usually not clinically significant and will reverse once IL-2 is discontinued.</td> </tr> <tr> <td>2. However, oliguria, if significant fluid overload, may provide an indication to hold or delay IL-2 until urine output is improved.</td> </tr> <tr> <td>3. Some centers set an upper limit of creatinine, at which point IL-2 is discontinued.</td> </tr> <tr> <td class=\"subtitle1_single\">Transminase elevations </td> </tr> <tr> <td>1. Usually not clinically significant and will reverse once IL-2 is discontinued.</td> </tr> <tr> <td class=\"subtitle1_single\">Neurotoxicity </td> </tr> <tr> <td>1. This can be a significant toxicity.</td> </tr> <tr> <td>2. IL-2 should be held for persistent confusion, disorientation, hallucinations, progressive agitation, or somnolence unrelated to concomitant medication.</td> </tr> <tr> <td>3. If not grade 4 neurotoxicity, IL-2 can be resumed with resolution of symptoms.</td> </tr> <tr> <td>4. If symptoms recur, IL-2 should be stopped.</td> </tr> <tr> <td class=\"subtitle1_single\">Skin rash, pruritus </td> </tr> <tr> <td>1. Rash is common during treatment and is treated symptomatically with emollients and antihistamines.</td> </tr> <tr> <td>2. For pruitis that does not respond to antihistamines such as diphenhydramine or hydroxyzine, gabapentin may be helpful, as it affects peripheral nerve fibers.</td> </tr> <tr> <td>3. Pruritis may persist long after IL-2 treatment is discontinued.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Dutcher J, Atkins MB, Margolin K, et al for the Cytokine Working Group. Kidney Cancer: The Cytokine Working Group Experience (1986-2001), part II. Management of IL-2 toxicity and studies with other cytokines. Med Oncol 2001; 18:209. Copyright © 2001 Humana Press.</div><div id=\"graphicVersion\">Graphic 80320 Version 3.0</div></div></div>"},"80322":{"type":"graphic_table","displayName":"Normal creatinine excretion rate for children based upon age","title":"Normal creatinine excretion rate for children based upon age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal creatinine excretion rate for children based upon age</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age (years)</td> <td class=\"subtitle1\" colspan=\"2\">Normative values</td> <td class=\"subtitle1\" colspan=\"2\">Range (mean &#177; 1 SD)</td> </tr> <tr> <td class=\"subtitle2\">mg/kg/day</td> <td class=\"subtitle2\">mmol/kg/day</td> <td class=\"subtitle2\">mg/kg/day</td> <td class=\"subtitle2\">mmol/kg/day</td> </tr> <tr> <td>3 to 5</td> <td>15 to 17</td> <td>0.13 to 0.15</td> <td>12 to 20</td> <td>0.01 to 0.18</td> </tr> <tr> <td>6 to 13</td> <td>18 to 20</td> <td>0.16 to 0.17</td> <td>15 to 25</td> <td>0.16 to 0.22</td> </tr> <tr> <td class=\"subllist1_start\" colspan=\"5\">14 to 18</td> </tr> <tr> <td class=\"sublist1\">Boys</td> <td class=\"sublist_other\">23</td> <td class=\"sublist_other\">0.20</td> <td class=\"sublist_other\">18 to 27</td> <td class=\"sublist_other\">0.16 to 0.24</td> </tr> <tr> <td class=\"sublist1\">Girls</td> <td class=\"sublist_other\">20</td> <td class=\"sublist_other\">0.18</td> <td class=\"sublist_other\">17 to 24</td> <td class=\"sublist_other\">0.15 to 0.21</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Remer T, Neubert A, Maser-Gluth C. Anthropometry-based reference values for 24-h urinary creatinine excretion during growth and their use in endocrine and nutritional research. Am J Clin Nutr 2002; 75:561.</div><div id=\"graphicVersion\">Graphic 80322 Version 4.0</div></div></div>"},"80323":{"type":"graphic_picture","displayName":"Kaposis sarcoma eyelid","title":"Kaposi's sarcoma eyelid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kaposi's sarcoma eyelid</div><div class=\"cntnt\"><img style=\"width:407px; height:251px;\" src=\"images/PC/80323_Kaposis_sarcoma_eyelid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaposi sarcoma presenting as violaceous nodules on the upper and lower eyelid.</div><div class=\"graphic_reference\">With permission from Slomovits, TL (Ed), Basic and clinical science courses section, American Academy of Ophthalmology, San Francisco 1996.</div><div id=\"graphicVersion\">Graphic 80323 Version 3.0</div></div></div>"},"80325":{"type":"graphic_figure","displayName":"Fixed effects model","title":"Fixed effects model","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Fixed effects model</div><div class=\"cntnt\"><img style=\"width:507px; height:417px;\" src=\"images/PC/80325_Fixed_effects_model.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This model assumes there is a single true treatment effect and that all trials provide estimates of this one true effect.</div><div class=\"graphic_footnotes\">RD: risk difference; OR: odds ratio; RR: relative risk.</div><div class=\"graphic_reference\">Courtesy of: Joseph Lau, MD.</div><div id=\"graphicVersion\">Graphic 80325 Version 3.0</div></div></div>"},"80327":{"type":"graphic_picture","displayName":"Ankle foot orthosis1","title":"Ankle-foot orthosis","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Ankle-foot orthosis</div><div class=\"cntnt\"><img style=\"width:530px; height:369px;\" src=\"images/PEDS/80327_Ankle_foot_orthosis1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of: Drs. Vineeta Swaroop and Luciano Dias.</div><div id=\"graphicVersion\">Graphic 80327 Version 2.0</div></div></div>"},"80329":{"type":"graphic_table","displayName":"Morphology gastritis or gastropathy","title":"Morphologic classification of gastritis or gastropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Morphologic classification of gastritis or gastropathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Location of process:</td> <td>Antral predominant, corpus predominant, or pangastritis</td> </tr> <tr> <td>Type of inflammation:</td> <td>Acute, chronic, mixed, eosinophilic, lymphocytic, or granulomatous</td> </tr> <tr> <td>Topography of inflammation:</td> <td> <p>Diffuse or focal</p> <p>Gastric site</p> </td> </tr> <tr> <td>Atrophy:</td> <td>Present or absent, graded*</td> </tr> <tr> <td>Intestinal metaplasia:</td> <td>Present or absent, graded*</td> </tr> <tr> <td>Infectious agent:</td> <td>Helicobacter pylori, Helicobacter heilmannii, virus, other</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Mild, moderate, or marked.</div><div id=\"graphicVersion\">Graphic 80329 Version 2.0</div></div></div>"},"80331":{"type":"graphic_diagnosticimage","displayName":"Bacterial tracheitis - Lateral neck radiograph","title":"Bacterial tracheitis: Lateral neck radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bacterial tracheitis: Lateral neck radiograph</div><div class=\"cntnt\"><img style=\"width:360px; height:293px;\" src=\"images/PEDS/80331_Bacterial_tracheitis_x-ray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral neck radiograph showing intraluminal membranes and tracheal wall irregularity consistent with bacterial tracheitis.</div><div class=\"graphic_reference\">Courtesy of R. Paul Guillerman, MD, Department of Radiology, Baylor College of Medicine.</div><div id=\"graphicVersion\">Graphic 80331 Version 5.0</div></div></div>"},"80333":{"type":"graphic_algorithm","displayName":"Algorithm for diagnosis of IPH","title":"Diagnostic approach to idiopathic pulmonary hemosiderosis (IPH)","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to idiopathic pulmonary hemosiderosis (IPH)</div><div class=\"cntnt\"><img style=\"width:506px; height:616px;\" src=\"images/PULM/80333_Algorithm_for_diagnosis_of.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 80333 Version 2.0</div></div></div>"},"80334":{"type":"graphic_picture","displayName":"Enlargement of the great auricular nerve in leprosy","title":"Enlargement of the great auricular nerve in leprosy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Enlargement of the great auricular nerve in leprosy</div><div class=\"cntnt\"><img style=\"width:370px; height:409px;\" src=\"images/ID/80334_Enlargement_auricular_lep.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Gorbach SL, Bartlett JG, Blacklow NR. Infectious Diseases, 3rd Ed. Philadelphia, Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80334 Version 1.0</div></div></div>"},"80335":{"type":"graphic_table","displayName":"Common causes of out-toeing","title":"Clinical features of common causes of out-toeing in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of common causes of out-toeing in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">External rotation contracture of the hip</td> <td class=\"subtitle1\">External tibial torsion</td> <td class=\"subtitle1\">Femoral retroversion</td> </tr> <tr> <td><strong>Description</strong></td> <td>Physiologic contracture related to intrauterine positioning</td> <td>External (lateral) rotation of the tibia relative to the transcondylar axis of the femur</td> <td>Decreased angle of rotation between the axis of the femoral neck and the transcondylar axis of the femur</td> </tr> <tr> <td><strong>Most common age group</strong></td> <td>Birth to one year</td> <td>Late childhood, early adolescence</td> <td>Older than three years</td> </tr> <tr> <td><strong>Foot progression angle</strong></td> <td>External</td> <td>External</td> <td>External</td> </tr> <tr> <td><strong>Patellar progression angle</strong></td> <td>External</td> <td>Neutral or external</td> <td>External</td> </tr> <tr> <td><strong>Evaluation</strong></td> <td>Increased external hip rotation; decreased internal hip rotation*</td> <td>Thigh foot angle<sup>&#182;</sup> is external (positive)</td> <td>Increased external hip rotation; decreased internal hip rotation*</td> </tr> <tr> <td><strong>Laterality</strong></td> <td>Usually bilateral and symmetrical</td> <td>Often unilateral with the right side more often affected</td> <td>Usually bilateral and symmetrical; when unilateral, the right side is more often affected</td> </tr> <tr> <td><strong>Other clinical features</strong></td> <td>&nbsp;</td> <td> <p>Medial malleolus anterior to lateral malleolus when seated with thigh directly in front of hip joint and the knee pointed straight ahead</p> <p>May be associated with knock-knees</p> May be associated with prematurity and prone positioning</td> <td> <p>Rare</p> <p>More commonly seen in obese children</p> May be associated with slipped capital femoral epiphysis</td> </tr> <tr> <td><strong>Natural history</strong></td> <td>Usually resolves by 12 months</td> <td>Usually does not correct spontaneously; may worsen over time, but rarely causes problems or sequelae (eg, patellofemoral pain or instability, arthritis of the knee)</td> <td> <p>Does not improve spontaneously</p> May be associated with hip or knee arthritis, stress fractures, and slipped capital femoral epiphysis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Hip rotation is measured with the child prone and the knees flexed. To assess external hip rotation, the lower leg is rotated toward the axis of the body; to assess internal rotation, the lower leg is rotated away from the axis of the body. Refer to UpToDate content on out-toeing in children for details. <br />¶ The thigh-foot angle is measured with the child prone, the knee flexed, and the ankle dorsiflexed so that the plantar surface of the foot is parallel to the ceiling. A visual line is approximated along the long axis of the thigh and a second line along the long axis of the heel. The angle between these two lines is the thigh-foot angle. Refer to UpToDate content on out-toeing in children for details. </div><div id=\"graphicVersion\">Graphic 80335 Version 5.0</div></div></div>"},"80336":{"type":"graphic_figure","displayName":"Kidney anatomy PI","title":"Anatomy of the kidney","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Anatomy of the kidney</div><div class=\"cntnt\"><img style=\"width:540px; height:421px;\" src=\"images/PI/80336_Kidney_anatomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the structure of a kidney. The outer portion (the cortex) contains the glomeruli. The tubules are located in the cortex and medulla. The collecting tubules form a large portion of the inner medulla (the papilla). Urine travels from the collecting tubules into the caylces, and then to the renal pelvis, ureter, and bladder.</div><div id=\"graphicVersion\">Graphic 80336 Version 2.0</div></div></div>"},"80340":{"type":"graphic_picture","displayName":"Acute fatty liver Trichrome","title":"Acute fatty liver of pregnancy","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Acute fatty liver of pregnancy</div><div class=\"cntnt\"><img style=\"width:526px; height:215px;\" src=\"images/GAST/80340_Acute_fatty_liver_Trichrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trichrome stain of a liver biopsy from a patient with acute fatty liver of pregnancy. Left panel: Low power view shows pallor of the hepatocytes surrounding the central vein (CV). Right panel: High power view reveals disruption of the plate pattern with &quot;dropped out&quot; hepatocytes, lobular disarray, and vacuolated, pale hepatocytes (microvesicular fat).</div><div class=\"graphic_reference\">Courtesy of Caroline A. Riely, MD.</div><div id=\"graphicVersion\">Graphic 80340 Version 2.0</div></div></div>"},"80342":{"type":"graphic_picture","displayName":"Surgical treatment of human bite","title":"Surgical treatment of human bite","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Surgical treatment of human bite</div><div class=\"cntnt\"><img style=\"width:360px; height:540px;\" src=\"images/SURG/80342_Surgical_tx_human_bite.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Human bite injuries require hospital admission, antibiotics, debridement in the operating room, and delayed primary wound closure. A wide exposure of the wound is required and the joint should be opened and inspected, even if the joint capsule appears intact. As shown in the photograph, exposure of the metacarpophalangeal joint is required to demonstrate the true extent of the injury.</div><div id=\"graphicVersion\">Graphic 80342 Version 3.0</div></div></div>"},"80343":{"type":"graphic_picture","displayName":"Cutaneobiliary fistula","title":"Cutaneobiliary fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneobiliary fistula</div><div class=\"cntnt\"><img style=\"width:360px; height:246px;\" src=\"images/GAST/80343_Cutaneobiliary_fistula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cutaneobiliary fistula as seen through the cholangioscope. The guidewire can be seen in the upper portion.</div><div class=\"graphic_reference\">Courtesy of Jurgen F Riemann, MD, PhD.</div><div id=\"graphicVersion\">Graphic 80343 Version 1.0</div></div></div>"},"80344":{"type":"graphic_figure","displayName":"Development of a metanephric excretory unit","title":"Development of a metanephric excretory unit","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Development of a metanephric excretory unit</div><div class=\"cntnt\"><img style=\"width:522px; height:426px;\" src=\"images/OBGYN/80344_Excretory_unit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrows, the place where the excretory unit (blue) establishes an open communication with the collecting system (yellow), allowing flow of urine from the glomerulus into the collecting ducts.</div><div class=\"graphic_reference\">Reproduced with permission from: Sadler, T, PhD. Langman's Medical Embryology, Ninth Edition Image Bank. Baltimore: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169;2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80344 Version 2.0</div></div></div>"},"80345":{"type":"graphic_table","displayName":"Diet during therapeutic use of monoamine oxidase inhibitors","title":"Diet during therapeutic use of monoamine oxidase inhibitors (MAOIs)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diet during therapeutic use of monoamine oxidase inhibitors (MAOIs)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Food</td> <td class=\"subtitle1\">Allowed (not allowed if spoiled or improperly stored)*</td> <td class=\"subtitle1\">Minimize intake<sup>&#182;</sup></td> <td class=\"subtitle1\">Not allowed</td> </tr> <tr class=\"divider_bottom\"> <td>Beverages</td> <td>Decaffeinated beverages (eg, coffee, tea, soda); milk</td> <td> <p>Caffeine-containing drinks</p> <p>Clear alcoholic spirits (eg, gin, vodka, rum)</p> <p>Red or white wine (no more than two 4-ounce servings per day)</p> <p>Bottled/canned beer, including nonalcoholic (no more than two 12-ounce servings per day)</p> Soy milk</td> <td>Tap (draft) beer, Korean beer, vermouth</td> </tr> <tr class=\"divider_bottom\"> <td>Breads, cereals, crackers</td> <td>Commercial yeast breads, hot and cold cereals, most crackers (ie, containing no aged cheese)</td> <td>None</td> <td>Sourdough bread; crackers and breads that contain aged cheese</td> </tr> <tr class=\"divider_bottom\"> <td>Dairy, eggs, cheeses</td> <td>Butter, cottage cheese, eggs, farmers or pot cheese, cream cheese, ricotta cheese, pasteurized milk, pasteurized cream, ice cream, pudding, yogurt</td> <td>American processed cheese, mozzarella, parmesan, Romano, sour cream (limit these to one serving of &#189; cup)</td> <td><strong>All aged cheeses are absolutely not allowed</strong><sup>&#916;</sup>, including: Blue/bleu, camembert, cheddar, gorgonzola, gouda, gruyere, provolone, Roquefort, Stilton, Swiss</td> </tr> <tr class=\"divider_bottom\"> <td>Meat, fish, and poultry</td> <td>All fresh packaged, fresh frozen, or fresh processed (not aged or smoked) meats, fish, and poultry; fresh breakfast sausage</td> <td>Pepperoni, hot dogs, bologna</td> <td><strong>All aged, smoked, pickled, or cured meats/fish/poultry are absolutely not allowed</strong>, including: Aged, smoked, pickled or dried meats (eg, bacon, aged or dried sausage, all types of salami, Genoa, mortadella, corned beef, pastrami); aged chicken and beef liver; dried, pickled or smoked fish (eg, pickled herring, lox, smoked salmon, smoked trout, shrimp paste); liverwurst; meat extracts; meat alternatives that contain soy product (eg, meatless hot dogs made from tofu)</td> </tr> <tr class=\"divider_bottom\"> <td>Starches&nbsp;<span style=\"font-size: 12pt; font-family: 'Times New Roman',serif;\">&ndash;</span>&nbsp;potatoes/rice</td> <td>Potatoes, rice, noodles, pasta, and most stuffings</td> <td>None</td> <td>Soy products (eg, tofu, tempeh)</td> </tr> <tr class=\"divider_bottom\"> <td>Vegetables and beans</td> <td>Most fresh, frozen, canned, or dried vegetables, leafy salad greens, lentils, and beans (except fava and soy beans); most veggie burgers (ie, containing no soy product)</td> <td>Chili peppers</td> <td>Fava or broad beans (Italian green beans) and their pods, Kim chee (Kimchi), sauerkraut, snow peas, soy beans, bean pastes, edamame beans</td> </tr> <tr class=\"divider_bottom\"> <td>Fruit and fruit juices</td> <td>Most fresh, frozen, or canned fruits and fruit juices</td> <td>Avocado (not over-ripened), canned figs, raspberries</td> <td>Avocado (over-ripened), banana (over-ripened), banana peel, dried fruit, any kind of fruit that is over-ripened</td> </tr> <tr class=\"divider_bottom\"> <td>Soups, gravies, casseroles, pizza</td> <td>Home prepared (not prepackaged) soups, gravies, casseroles that contain <strong>no</strong> aged cheese, bouillons, flavoring cubes, or meat extracts</td> <td>Occasional consumption of&nbsp;one to two&nbsp;slices of pizza from large chain commercial outlets appears safe (ie, generally made with low tyramine cheese); avoid: larger quantities, extra cheese, or pizzas containing aged cheese</td> <td>Soups, gravies, casseroles, pizzas that contain aged cheese; soups or casseroles with flavoring meat extracts (eg, flavor cubes, bouillon), miso, broad or fava beans and their pods, tofu, tempeh, soy products (eg, soy sauce, teriyaki sauce) or yeast extracts</td> </tr> <tr class=\"divider_bottom\"> <td>Fats and oils</td> <td>Butter, cream cheese, margarine, mayonnaise, olive oil, vegetable oils</td> <td>Moderate amount (eg, 2 to 4 ounces) of peanut butter is considered safe</td> <td>Fats and oils included in fermented, aged, cured, smoked, pickled, or other foods that are not allowed</td> </tr> <tr class=\"divider_bottom\"> <td>Snacks</td> <td>Potato chips, popcorn, most nuts, most crackers (ie, containing no aged cheese)</td> <td>Moderate consumption of peanuts is considered safe</td> <td>Snack foods containing aged cheeses</td> </tr> <tr class=\"divider_bottom\"> <td>Sweets</td> <td>Sugar, hard candy, honey, molasses, syrups</td> <td>One serving of chocolate (eg, 2 ounces) is considered safe</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Desserts</td> <td>Cakes, cookies, gelatin, pastries, pies, sherbets, sorbets</td> <td>One serving of chocolate-containing dessert (eg 4 ounces) is considered safe</td> <td>None</td> </tr> <tr> <td>Condiments and miscellaneous</td> <td>Ketchup, mustard, mayonnaise, non-cheese salad dressings, salt, spices, herbs, Worcestershire sauce</td> <td>None</td> <td>All aged or fermented soy and yeast products (eg, soy sauce, teriyaki sauce, soy paste, Thai or Vietnamese fish sauce, marmite/vegemite and other concentrated yeast extracts), sauerkraut</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>Foods and beverages listed as \"not allowed\" often contain significant amounts of tyramine that can interact with nonselective monoamine oxidase inhibitors (MAOIs), or potentially with selective MAOI-b inhibitors at high doses, and may result in elevated blood pressure or hypertensive crisis.</li>&#xD;&#xA;    <li>The ingredients of all foods and beverages (including those listed in this table as \"allowed\") should be reviewed prior to consumption to confirm they do not also include ingredients that are not allowed.</li>&#xD;&#xA;    <li>Tyramine avoidance should be continued for two weeks following discontinuation of a MAOI.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">* <STRONG>No leftover, improperly stored, handled, or spoiled foods of any type should be consumed.</STRONG> It is important to purchase and consume only fresh meats, poultry, and fish that are properly wrapped and stored under refrigeration and eaten the same day or frozen right away. Fresh produce should be consumed within 48 hours of purchase and not eaten if overripe. Use canned or frozen foods immediately upon opening or thawing.<br />¶ Eat these foods occasionally; no more than one serving (eg, ½ cup) of one to three of these foods or beverages each day.<br />Δ The majority of cases of food-related hypertensive crisis during treatment with MAOIs are associated with consumption of aged cheeses.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Hirsch M, Birnbaum RJ. An Approach to psychopharmacological treatment. In: The Ten-Minute guide to psychiatric diagnosis and treatment, Stern TA (Ed). New York: Professional Publishing Group, Ltd, 2005. p.355. Copyright © 2005 Castle Connolly Graduate Medical Publishing, Ltd.</LI>&#xD;&#xA;<LI>McCabe-Sellers BJ, Staggs CG, and Bogle ML. Tyramine in foods and monoamine oxidase inhibitor drugs: A crossroad where medicine, nutrition, pharmacy and food industry converge; J Food Comp Anal. 2006; 19:S58.</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 80345 Version 8.0</div></div></div>"},"80346":{"type":"graphic_waveform","displayName":"M-mode echocardiography in cardiac tamponade","title":"M-mode echocardiography in cardiac tamponade","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">M-mode echocardiography in cardiac tamponade</div><div class=\"cntnt\"><img style=\"width:512px; height:392px;\" src=\"images/CARD/80346_Mmodecardiactamponade.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The M-mode sweep in panel A is from the left ventricular (LV) cavity to the aortic root (Ao) in a patient with a large pericardial effusion (EFF) and cardiac tamponade. Right ventricular (RV) narrowing is seen in the minor axis; only minimal cavitary expansion occurs with inspiration (IN), although it becomes more marked toward the right ventricular outflow tract (RVOT). With inspiration there is a reduction in the dimension of the LV cavity, seen by the more posterior position of the interventricular septum (IVS) (black arrow); there is also a reduction in the E to F slope of mitral valve (MV) movement during inspiration, a result of reduced volume and flow from left atrium to ventricle (red arrows). After pericardiotomy (panel B), the pericardial effusion has disappeared, the RV is decompressed, and there are no changes in LV or RV volume with respiration. Note that the M-mode sweep after pericardiectomy goes from Ao to LV cavity.</div><div class=\"graphic_footnotes\">ARVW: anterior right ventricular wall; CW: chest wall; PLVW: posterior left ventricular wall; LA: left atrium.</div><div id=\"graphicVersion\">Graphic 80346 Version 6.0</div></div></div>"},"80348":{"type":"graphic_diagnosticimage","displayName":"Cavernous malformation MRI","title":"MRI of a cerebral cavernous malformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI of a cerebral cavernous malformation</div><div class=\"cntnt\"><img style=\"width:271px; height:347px;\" src=\"images/NEURO/80348_Cavernous_malformation_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cavernous malformations appear characteristically on MRI as a \"popcorn\" pattern of variable image intensities.</div><div class=\"graphic_reference\">Courtesy of Guy Rordorf, MD.</div><div id=\"graphicVersion\">Graphic 80348 Version 4.0</div></div></div>"},"80349":{"type":"graphic_table","displayName":"Presumptive eligibility SSI","title":"Presumptive eligibility for supplemental security income in children*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Presumptive eligibility for supplemental security income in children*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Amputation of two limbs</td> </tr> <tr> <td>Amputation of a leg at the hip</td> </tr> <tr> <td>Diabetes with amputation of a foot</td> </tr> <tr> <td>Cerebral palsy, muscular dystrophy, or muscular atrophy and marked difficulty in walking, speaking, or coordinating the hands</td> </tr> <tr> <td>Total blindness</td> </tr> <tr> <td>Total deafness</td> </tr> <tr> <td>Down syndrome</td> </tr> <tr> <td>Bed confinement or immobility because of a longstanding condition</td> </tr> <tr> <td>Severe mental deficiency in a child older than&nbsp;seven years of age</td> </tr> <tr> <td>Stroke or cerebral vascular accident that occurred more than&nbsp;three months ago, with continued marked difficulty in walking or using a hand or arm</td> </tr> <tr> <td>Symptomatic human immunodeficiency virus infection</td> </tr> <tr> <td>Birth weight less than 1200 g in a child younger than 12 months of age</td> </tr> <tr> <td>Birth weight between 1200 and 2000 g combined with specific gestational ages</td> </tr> <tr> <td>Terminal cancer with a life expectancy of&nbsp;six months or less or in hospice care (physician confirmation required)</td> </tr> <tr> <td>Inability to ambulate without a walker or equivalent device&nbsp;two weeks after a spinal cord injury</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SSI: supplemental security income.<BR>* Children with these conditions can receive SSI benefits for up to six months while formal eligibility is being determined. Pediatric health care providers should provide parents with a statement about the diagnosis and severity of the child's condition.</div><div class=\"graphic_reference\">Data from: American Academy of Pediatrics: Policy statements--Supplemental Security Income (SSI) for children and youth with disabilities. Pediatrics 2009; 124:1702.</div><div id=\"graphicVersion\">Graphic 80349 Version 3.0</div></div></div>"},"80351":{"type":"graphic_picture","displayName":"Thick joints in MCTD","title":"Swollen digits in mixed connective tissue disease (MCTD)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Swollen digits in mixed connective tissue disease (MCTD)</div><div class=\"cntnt\"><img style=\"width:441px; height:291px;\" src=\"images/RHEUM/80351_Thick_joints_in_MCTD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Puffy hands are a common early clinical feature of mixed connective tissue disease. This patient with early MCTD presented with swollen fingers and the Raynaud phenomenon.</div><div class=\"graphic_reference\">Courtesy of Robert M Bennett, MD.</div><div id=\"graphicVersion\">Graphic 80351 Version 2.0</div></div></div>"},"80352":{"type":"graphic_diagnosticimage","displayName":"Bleeding tumor b","title":"Angiogram of the left cervicovaginal artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Angiogram of the left cervicovaginal artery</div><div class=\"cntnt\"><img style=\"width:331px; height:497px;\" src=\"images/OBGYN/80352_Bleeding_tumor_b.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angiogram of the left cervicovaginal artery shows occlusion of the artery. Previously seen opacification of neovascularity is no longer present. Note that there is residual tumor staining from contrast injections during the procedure. There was significant improvement in her vaginal bleeding after the embolization procedure.</div><div id=\"graphicVersion\">Graphic 80352 Version 3.0</div></div></div>"},"80353":{"type":"graphic_table","displayName":"Molecular test encephalitis","title":"Molecular tests for encephalitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Molecular tests for encephalitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Etiology</td> <td class=\"subtitle1\">Availability<sup>*</sup></td> <td class=\"subtitle1\">When inclusion of NAT is indicated</td> <td class=\"subtitle1\">Preferred testing method(s)<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Bacteria</td> </tr> <tr> <td class=\"indent1\"><em>Coxiella burnetti</em> (Q fever)</td> <td>Yes</td> <td>When clinically suspected</td> <td>NAT, serology</td> </tr> <tr> <td class=\"indent1\"><em>Listeria</em> spp</td> <td>Yes<sup>&#916;</sup></td> <td>Rarely</td> <td>Culture +/&ndash; NAT, serology</td> </tr> <tr> <td class=\"indent1\"><em>Mycobacterium tuberculosis<sup></sup></em><sup>&#9674;</sup></td> <td>Yes</td> <td>Potentially</td> <td>AFB stain, culture, histologic exam, and NAT</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Fastidious organisms (<em>Mycoplasma</em> spp, <em>Bartonella</em> spp)</td> <td>Yes</td> <td>When clinically suspected, especially in children</td> <td>Serology, NAT including alternative sites where appropriate (eg, respiratory)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Viruses</td> </tr> <tr> <td class=\"indent1\">Adenoviruses</td> <td>Yes</td> <td>Rarely</td> <td>Testing of alternative sites (eg, respiratory) +/&ndash; CSF</td> </tr> <tr> <td class=\"indent1\">Arboviruses</td> <td>Limited</td> <td>When clinically suspected</td> <td>Serology and NAT</td> </tr> <tr> <td class=\"indent1\">Epstein-Barr virus</td> <td>Yes</td> <td>When clinically suspected</td> <td>Serology and NAT, preferably quantitative</td> </tr> <tr> <td class=\"indent1\">Enteroviruses</td> <td>Widespread<sup>&#916;</sup></td> <td>When clinically suspected</td> <td>NAT</td> </tr> <tr> <td class=\"indent1\">Human herpesvirus 6</td> <td>Yes<sup>&#916;</sup></td> <td>When clinically suspected</td> <td>NAT, preferably quantitative</td> </tr> <tr> <td class=\"indent1\">Herpes simplex virus</td> <td>Widespread<sup>&#916;</sup></td> <td>When clinically suspected</td> <td>NAT</td> </tr> <tr> <td class=\"indent1\">Influenza</td> <td>Yes</td> <td>Rarely</td> <td>Testing of alternative sites (eg, respiratory) +/&ndash; CSF</td> </tr> <tr> <td class=\"indent1\">Lymphocytic choriomeningitis virus</td> <td>Limited</td> <td>Rarely</td> <td>Serology</td> </tr> <tr> <td class=\"indent1\">Mumps</td> <td>Limited</td> <td>Rarely</td> <td>History, culture, serology, and NAT</td> </tr> <tr> <td class=\"indent1\">Parechovirusus<sup>&#167;</sup></td> <td>Yes<sup>&#916;</sup></td> <td>Primarily in young children (&#60;5 years old)</td> <td>NAT</td> </tr> <tr> <td class=\"indent1\">Rabies<sup>&#165;</sup></td> <td>Limited (CDC)</td> <td>When clinically suspected</td> <td>Combination of serology, biopsy, NAT</td> </tr> <tr> <td class=\"indent1\">Varicella-zoster virus</td> <td>Yes<sup>&#916;</sup></td> <td>When clinically suspected</td> <td>NAT</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">West Nile virus<sup>&#135;</sup></td> <td>Yes</td> <td>Rarely (unless immunodeficient)</td> <td>Serology</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Fungal</td> </tr> <tr> <td class=\"indent1\"><em>Cryptococcus</em></td> <td>Yes<sup>&#916;</sup></td> <td>No</td> <td>Antigen detection, culture</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other fungi</td> <td>Limited</td> <td>No</td> <td>Culture, serology, histologic exam</td> </tr> <tr> <td class=\"subtitle2_left\">Rickettsia<sup>&#134;</sup></td> <td class=\"divider_bottom\">Limited</td> <td class=\"divider_bottom\">Occasionally</td> <td class=\"divider_bottom\">Serology</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Spirochetes</td> </tr> <tr> <td class=\"indent1\"><em>Borrelia burgdorferi</em> (the agent of Lyme disease)</td> <td>Yes</td> <td>Rarely</td> <td>Serology, NAT</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>Treponema pallidum</em> (syphilis)</td> <td>Limited</td> <td>When clinically suspected</td> <td>Serology, CSF VDRL</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Parasites</td> </tr> <tr> <td class=\"indent1\">Microsporidia</td> <td>Limited</td> <td>Rarely</td> <td>Serology, stains, histologic exam</td> </tr> <tr> <td class=\"indent1\">Free-living amebae (eg, <em>Naegleria fowleri</em>)</td> <td>Limited</td> <td>When clinically suspected</td> <td>CSF wet mount and NAT</td> </tr> <tr> <td class=\"indent1\">Other parasites (<em>Baylisascaris </em>spp, <em>Balamuthia mandrillaris</em>)</td> <td>Limited</td> <td>Rarely (eg, CSF eosinophilia)</td> <td>Histologic exam, serology +/&ndash; NAT</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PPV: positive predictive value; CDC: Centers for Disease Control and Prevention; NAT: nucleic acid amplification testing; CSF: cerebrospinal fluid; AFB: acid-fast bacilli; VDRL: Venereal Disease Research Laboratories; FDA: US Food and Drug Administration.<br />* Widespread: readily available; Yes: consistently available, but not yet common; Limited: one or two specialized laboratories (eg, CDC or research groups).<br />¶ Test on CSF except where noted.<br />Δ Also available as part of FDA-cleared &nbsp;multiplex NAT at some centers and referral laboratories.<br />◊ Limited experience, presumably poor sensitivity, high PPV.<br />§&nbsp;Not detected by most enterovirus assays.<br />¥&nbsp;In conjunction with other modalities.<br />‡&nbsp;Virus is usually cleared from blood and CSF prior to symptom onset.<br />† Limited experience from CSF.</div><div id=\"graphicVersion\">Graphic 80353 Version 10.0</div></div></div>"},"80354":{"type":"graphic_figure","displayName":"Cervical remodeling","title":"Cervical remodeling","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Cervical remodeling</div><div class=\"cntnt\"><img style=\"width:578px; height:449px;\" src=\"images/OBGYN/80354_Cervical_remodeling.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stages of cervical function during pregnancy and the puerperium. Although the process occurs as a continuum, each stage is characterized by unique biochemical and cellular events.</div><div class=\"graphic_footnotes\">iNOS: induced nitric oxide synthase; IL-8: interleukin-8; HA: hyaluronan; GAGs: glycosaminoglycans.</div><div class=\"graphic_reference\">Reproduced with permission from: Word RA, Li X-H, Hnat M, Carrick K. Dynamics of cervical remodeling during pregnancy and parturition: Mechanisms and current concepts. Semin Reprod Med 2007; 25:69. Copyright &#169; 2007 Thieme Medical Publishers, Inc.</div><div id=\"graphicVersion\">Graphic 80354 Version 5.0</div></div></div>"},"80355":{"type":"graphic_waveform","displayName":"Equalization of pressures","title":"Equalization of pressures in severe constrictive pericarditis","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Equalization of pressures in severe constrictive pericarditis</div><div class=\"cntnt\"><img style=\"width:461px; height:163px;\" src=\"images/CARD/80355_Equalization_of_pressures.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tracing from a patient with severe constrictive pericarditis shows that the wedge and right atrial pressures are equal during inspiration, but that the wedge pressure is higher during expiration.</div><div class=\"graphic_reference\">Courtesy of Ralph Shabetai, MD.</div><div id=\"graphicVersion\">Graphic 80355 Version 2.0</div></div></div>"},"80358":{"type":"graphic_table","displayName":"Abnormal red cell ion transport","title":"Hematologic diseases characterized by abnormal red cell ion transport","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hematologic diseases characterized by abnormal red cell ion transport</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Disease</td>\n<td class=\"subtitle1\">Transport abnormality</td>\n</tr>\n<tr>\n<td>Sickle cell syndromes</td>\n<td>Cellular dehydration mediated by increases in K-Cl cotransport and activity of the calcium-activated (Gardos) potassium channel</td>\n</tr>\n<tr>\n<td>Beta thalassemia</td>\n<td>Relative cellular dehydration mediated by K-Cl cotransport</td>\n</tr>\n<tr>\n<td>Hemoglobin C disease</td>\n<td>Cellular dehydration mediated by increased K-Cl cotransport</td>\n</tr>\n<tr>\n<td>Hereditary spherocytosis</td>\n<td>Increased sodium and potassium permeability</td>\n</tr>\n<tr>\n<td>Hereditary stomatocytosis</td>\n<td>Hyperhydration due to increased sodium permeability or dehydration (xerocytosis) associated with enhanced potassium loss</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 80358 Version 1.0</div></div></div>"},"80359":{"type":"graphic_figure","displayName":"Fascial spaces mouth and face","title":"Fascial spaces around the mouth and face","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Fascial spaces around the mouth and face</div><div class=\"cntnt\"><img style=\"width:534px; height:217px;\" src=\"images/ID/80359_Fascial_spaces_mouth_and_fa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: Horizontal section at the level of the occlusal surface of the mandibular teeth. <br />Right panel: Frontal view of the face.</div><div class=\"graphic_reference\">Reproduced with permission from Chow AW, Roser SM, Brady FA, Ann Intern Med 1978; 88:392.</div><div id=\"graphicVersion\">Graphic 80359 Version 3.0</div></div></div>"},"80360":{"type":"graphic_movie","displayName":"Mitral valve prolapse with patient squatting","title":"Mitral valve prolapse as heard with the patient squatting","html":"<div class=\"graphic normal\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Mitral valve prolapse as heard with the patient squatting</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/80360_mvpsquatconv.mp4\" style=\"width:566px;height:296px\"></div><img style=\"width:572px; height:287px;\" src=\"images/CARD/80360_mvpsquat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram and phonocardiogram of mitral valve prolapse as heard at the apex. S1 (mitral and tricuspid valve closure) is followed by a mid systolic click resulting from the prolapsing mitral valve after which there is a systolic murmur of mitral regurgitation. With squatting there is an increase in systemic vascular resistance or afterload and an increase in left ventricular pressure and volume. As a result, there is a delay in mitral valve closure and the prolapse (and click) are delayed, occurring late in systole. Consequently, the mitral regurgitation murmur is late and shortened.</div><div class=\"graphic_reference\">Provided by John M Criley, MD, The Physiological Origins of Heart Sounds and Murmurs, Little, Brown, Boston, 1996, 1-800-527-0145. This program contains a complete interactive tutorial integrating over 200 heart sounds and murmurs with cineangiographic, echo-Doppler, and hemodynamic motion picture sequences.</div><div id=\"graphicVersion\">Graphic 80360 Version 5.0</div></div></div>"},"80361":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound of unilateral MCDK","title":"Prenatal ultrasound of unilateral multicystic dysplastic kidney","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound of unilateral multicystic dysplastic kidney</div><div class=\"cntnt\"><img style=\"width:416px; height:282px;\" src=\"images/OBGYN/80361_Unilateral_MCDK.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Tulin Ozcan, MD.</div><div id=\"graphicVersion\">Graphic 80361 Version 3.0</div></div></div>"},"80362":{"type":"graphic_diagnosticimage","displayName":"Osteochondroma proximal femur","title":"\"Cauliflower\" osteochondroma of the lesser trochanter of the femur","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">&quot;Cauliflower&quot; osteochondroma of the lesser trochanter of the femur</div><div class=\"cntnt\"><img style=\"width:300px; height:422px;\" src=\"images/PEDS/80362_Osteochondroma_prox_femur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Observe the cauliflower exostosis arising from the lesser trochanter of the proximal femur. There are areas of increased density scattered throughout the osteochondroma, representing calcified islands of cartilage.</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80362 Version 3.0</div></div></div>"},"80366":{"type":"graphic_figure","displayName":"Acid load and NH4 excretion","title":"Dietary acid load increases ammonium excretion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dietary acid load increases ammonium excretion</div><div class=\"cntnt\"><img style=\"width:416px; height:229px;\" src=\"images/NEPH/80366_AcidloadandNH4excretion.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of a dietary acid load on the plasma bicarbonate (HCO3)&nbsp;concentration (dashed line; in mEq/L) and urinary ammonium (NH4)&nbsp;excretion (solid line; in mEq/day) in normal subjects. Ammonium excretion increased almost fourfold despite a minimal fall in the plasma bicarbonate concentration.</div><div class=\"graphic_reference\">Data from Welbourne T, Weber M, Bank N. The effect of glutamine administration on urinary ammonium excretion in normal subjects and patients with renal disease. J Clin Invest 1972; 51:1852.</div><div id=\"graphicVersion\">Graphic 80366 Version 2.0</div></div></div>"},"80367":{"type":"graphic_table","displayName":"Geriatric trauma risks","title":"Potential pitfalls in the management of the elderly trauma patient","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential pitfalls in the management of the elderly trauma patient</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">What the injured elderly would tell you (if they could)</td> <td class=\"subtitle1\">Related physiology and rationale</td> </tr> <tr> <td>\"I can go from normotensive to hypotensive in a heartbeat.\"</td> <td>Profound, life-threatening hypovolemia may occur in the setting of normal blood pressure. Physiologic reserve is minimal, and hemodynamic decompensation can occur quickly.</td> </tr> <tr> <td>\"I respond poorly to too much or too little fluid.\"</td> <td>The therapeutic window for cardiac preload is narrow, and inadequate preload monitoring may lead to errors in volume resuscitation.</td> </tr> <tr> <td>\"My subdural hematoma hasn't expanded enough yet to really affect my level of consciousness.\"</td> <td>Cortical atrophy, common in the elderly, may act to delay the clinical manifestations of serious intracranial hemorrhage. This hemorrhage may be clinically occult.</td> </tr> <tr> <td>\"Trauma is not really my major problem.\"</td> <td>Stroke, myocardial infarction, and seizures may result from falls or motor vehicle crashes and delayed diagnosis of the principal underlying problem.</td> </tr> <tr> <td>\"I only look like I have adequate ventilatory reserve.\"</td> <td>Ventilatory failure and respiratory arrest may occur suddenly in conjunction with chest or abdominal injuries despite a benign outward clinical appearance.</td> </tr> <tr> <td>\"I get demand ischemia if I have too much pain or my hematocrit drops below 29.\"</td> <td>Myocardial (demand) ischemia may result from severe or prolonged pain or from transfusion thresholds that have not been appropriately liberalized in the setting of coronary artery disease.</td> </tr> <tr> <td>\"I can't stand even a little shock or hypoxia...and neither can my myocardium.\"</td> <td>Even minor perturbations in perfusion, oxygenation, or vasoconstriction may lead to major cardiac complications.</td> </tr> <tr> <td>\"My connective tissue just ain't what it used to be...\"</td> <td>Decrease in connective tissue integrity with less \"tamponade effect\" for hemorrhage into soft tissues. Blood loss into soft tissue spaces, including subcutaneous loss, may be excessive and is often overlooked.</td> </tr> <tr> <td>\"The sensitivity of my abdominal examination is better than flipping a coin...but not much.\"</td> <td>Clinical manifestations of serious abdominal injury in elderly patients are often minimal. Reliance on the abdominal examination often leads to missed abdominal injuries.</td> </tr> <tr> <td>\"My bones are brittle...my hip bone, my shin bone, and my aortic bone!\"</td> <td>BAI may occur in the elderly in the absence of conventional signs or symptoms. A low threshold for CT imaging should exist.</td> </tr> <tr> <td>\"A little medication goes a long way with me...\"</td> <td>Failure to adjust medication dosage, particularly sedative-hypnotics and analgesics, may result in serious complications.</td> </tr> <tr> <td>\"I just haven't been eating so well lately.\"</td> <td>Chronic malnutrition is common and often undiagnosed.</td> </tr> <tr> <td>\"My injuries weren't accidental.\"</td> <td>Elder abuse is common and often unreported and undiagnosed.</td> </tr> <tr> <td>\"Major trauma? Heck, I wouldn't even tolerate a brisk haircut...\"</td> <td>Underestimating and undermanaging comorbidities (eg, chronic obstructive pulmonary disease, coronary artery disease, smoking, ethyl alcohol [ETOH] consumption) may result in preventable morbidity/mortality.</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">3</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=80809&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n<mso:Media_Notes msdt:dt=\"string\"></mso:Media_Notes>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Reproduced from: Mackersie, RC. Pitfalls in the evaluation and resuscitation of the trauma patient. Emerg Med Clin North Am 2010; 28:1. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 80367 Version 3.0</div></div></div>"},"80368":{"type":"graphic_figure","displayName":"T-shaped uterus 2","title":"Diethylstilbestrol-related anomalies: T-shaped uterus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diethylstilbestrol-related anomalies: T-shaped uterus</div><div class=\"cntnt\"><img style=\"width:352px; height:208px;\" src=\"images/OBGYN/80368_Tshapeduterusdilatedhor.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 80368 Version 17.0</div></div></div>"},"80369":{"type":"graphic_movie","displayName":"Echocardiogram five chamber view of AS","title":"Five chamber echocardiographic view of a calcified aortic valve","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Five chamber echocardiographic view of a calcified aortic valve</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/80369_5chambasconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:266px; height:413px;\" src=\"images/CARD/80369_5chambas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Five chamber view from a 2-D echocardiogram in a patient with aortic stenosis shows significant calcification of the aortic valve and lack of leaflet mobility. Moderate left ventricular hypertrophy is also present.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 80369 Version 4.0</div></div></div>"},"80370":{"type":"graphic_table","displayName":"Morbidity in IDM","title":"Perinatal mortality and neonatal morbidity in infants of diabetic mothers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Perinatal mortality and neonatal morbidity in infants of diabetic mothers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Rate, percent</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Perinatal mortality</td> <td>0.6 to 4.8</td> <td>Lowest rates reflect very good prenatal care and strict glycemic control</td> </tr> <tr> <td>Cesarean delivery</td> <td>32 to 45</td> <td>Highest rates are associated with lowest perinatal mortality</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Prematurity</td> </tr> <tr> <td class=\"sublist1\">&#60;37 weeks gestation</td> <td class=\"sublist_other\">24 to 36</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">&#60;34 weeks gestation</td> <td class=\"sublist_other\">14 to 16</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td>Congenital anomalies</td> <td>1.7 to 9.4</td> <td>Lowest rates are associated with strict glycemic control preconception and in early pregnancy</td> </tr> <tr> <td>Perinatal asphyxia, including fetal distress during labor, low 1-minute Apgar score, and intrauterine death</td> <td>9 to 27</td> <td>Lowest rates are seen with close monitoring during labor and appropriate intervention</td> </tr> <tr> <td>Macrosomia</td> <td>9 to 47</td> <td>Lowest rates are seen with strict glycemic control during pregnancy; strong association with neonatal hypoglycemia</td> </tr> <tr> <td>Intrauterine growth restriction</td> <td>2 to 8</td> <td>&nbsp;</td> </tr> <tr> <td>Respiratory distress syndrome</td> <td>2 to 6</td> <td>&nbsp;</td> </tr> <tr> <td>Hypoglycemia</td> <td>5 to 25</td> <td>Strong correlation with macrosomia, lower rates seen with strict glycemic control during pregnancy</td> </tr> <tr> <td>Hypocalcemia</td> <td>4</td> <td>Mostly asymptomatic</td> </tr> <tr> <td>Polycythemia (hematocrit &#62;65 percent)</td> <td>5</td> <td>&nbsp;</td> </tr> <tr> <td>Hyperbilirubinemia</td> <td>11 to 29</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Cardiomyopathy</td> </tr> <tr> <td class=\"sublist1\">Symptomatic</td> <td class=\"sublist_other\">5 to 10</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Asymptomatic</td> <td class=\"sublist_other\">30 to 50</td> <td class=\"sublist_other\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Note: The wide range cited for some complications is due to the inclusion of several studies, which were performed at different times, places in the world, and in different study groups (infants of all diabetic mothers, or those of gestational diabetic mothers or pregestational type 1 or 2 diabetic mothers). In many cases, different definitions of symptoms or findings were also used. In general, the lowest rates of complications are associated with improved obstetric care that resulted in better maternal glycemic control and neonatal management.</div><div id=\"graphicVersion\">Graphic 80370 Version 4.0</div></div></div>"},"80371":{"type":"graphic_picture","displayName":"Continuous nasal NPPV","title":"Continuous nasal NPPV","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Continuous nasal NPPV</div><div class=\"cntnt\"><img style=\"width:409px; height:432px;\" src=\"images/PULM/80371_Continuous_nasal_NPPV.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of John R Bach, MD.</div><div id=\"graphicVersion\">Graphic 80371 Version 3.0</div></div></div>"},"80373":{"type":"graphic_picture","displayName":"Complex atyp hyperplas endometr","title":"Atypical endometrial hyperplasia (complex)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Atypical endometrial hyperplasia (complex)</div><div class=\"cntnt\"><img style=\"width:504px; height:375px;\" src=\"images/OBGYN/80373_Complex_atyp_hyperplas_en1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The irregularly shaped glands in this case are very closely packed bu are still separated by residual endometrial stroma.</div><div class=\"graphic_reference\">Reproduced with permission from: Silverberg SG, Kurman RJ. Tumors of the Uterine Corpus and Gestational Trophoblastic Disease. AFIP Atlas of Tumor Pathology, version 2.0, American Registry of Pathology, Washington DC 1995.</div><div id=\"graphicVersion\">Graphic 80373 Version 3.0</div></div></div>"},"80375":{"type":"graphic_picture","displayName":"Normal urothelium","title":"Normal urothelium","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Normal urothelium</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ONC/80375_Normal_urothelium.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal urothelium is composed of three to seven cell layers; the thickness varies depending on the extent of bladder distension. Normal urothelial cells are approximately two to three times the size of stromal lymphocytes.</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 80375 Version 1.0</div></div></div>"},"80376":{"type":"graphic_figure","displayName":"Bullard laryngoscope insertion","title":"Bullard laryngoscope insertion","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Bullard laryngoscope insertion</div><div class=\"cntnt\"><img style=\"width:562px; height:554px;\" src=\"images/EM/80376_Bullardlaryngoscopeinsert.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The body of the device is initially held horizontally to insert the blade into the mouth.<br> (B) The blade is then rotated over the back of the tongue to seat the device. The tip of the blade usually picks up the epiglottis.<br> (C) The entire device may need to be lifted to enable passage of the endotracheal tube into the trachea.</div><div class=\"graphic_reference\">Reproduced with permission from: King BR, Hagberg CA. Management of the difficult airway. In: Textbook of Pediatric Emergency Medicine Procedures, 2nd edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 80376 Version 7.0</div></div></div>"},"80378":{"type":"graphic_table","displayName":"Etiology fourth nerve palsy","title":"Etiology of fourth nerve palsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of fourth nerve palsy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Anatomic localization</td> <td class=\"subtitle1\">Specific cause</td> <td class=\"subtitle1\">Common associated clinical features</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Midbrain (nuclear/fascicular)</td> <td>Aplasia of the nucleus</td> <td class=\"divider_bottom\" rowspan=\"6\">Hemisensory loss, hemiparesis, central Horner syndrome, other brainstem cranial neuropathies.</td> </tr> <tr> <td>Vascular lesions (eg, brainstem arteriovenous malformations)</td> </tr> <tr> <td>Demyelination (multiple sclerosis)</td> </tr> <tr> <td>Brainstem hemorrhage, ischemia, or infarction</td> </tr> <tr> <td>Trauma (including surgical)</td> </tr> <tr class=\"divider_bottom\"> <td>Neoplasm (eg, glioma, metastasis)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Subarachnoid space</td> <td>Aneurysms (eg, superior cerebellar artery)</td> <td class=\"divider_bottom\" rowspan=\"6\">Headache, stiff neck, and other cranial nerve abnormalities. Focal lesions (aneurysms, schwannomas) may produce isolated fourth nerve palsies.</td> </tr> <tr> <td>Increased intracranial pressure and hydrocephalus</td> </tr> <tr> <td>Infections (eg, mastoiditis, encephalitis meningitis)</td> </tr> <tr> <td>Postlumbar puncture or spinal anesthesia</td> </tr> <tr> <td>Trauma</td> </tr> <tr class=\"divider_bottom\"> <td>Neoplasm (eg, carcinomatous meningitis, cerebellar hemangioblastoma, ependymoma, meningioma, metastasis, neurilemmoma, pineal tumors, or trochlear nerve sheath tumors)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Cavernous sinus</td> <td>Neoplasm (eg, meningioma, metastasis)</td> <td class=\"divider_bottom\" rowspan=\"4\">Third, fifth, or sixth nerve dysfunction, or Horner syndrome.</td> </tr> <tr> <td>Infection (eg, syphilis, tuberculosis, herpes zoster)</td> </tr> <tr> <td>Inflammation (eg, sarcoid, granulomatosis with polyangiitis [Wegener], or the Tolosa-Hunt syndrome)</td> </tr> <tr class=\"divider_bottom\"> <td>Vascular lesions (eg, carotid-cavernous fistulas, internal carotid artery aneurysm)</td> </tr> <tr> <td rowspan=\"5\">Orbital</td> <td>Neoplasm (eg, hemangioma, metastasis)</td> <td rowspan=\"5\">Third, fifth, and sixth cranial nerves as well as the optic nerve. Orbital involvement may also produce such signs as proptosis, chemosis, and orbital or conjunctival edema.</td> </tr> <tr> <td>Infection (orbital cellulitis)</td> </tr> <tr> <td>Infiltration (eg, sarcoid)</td> </tr> <tr> <td>Inflammation (eg, orbital inflammatory pseudotumor)</td> </tr> <tr> <td>Trauma</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80378 Version 6.0</div></div></div>"},"80379":{"type":"graphic_table","displayName":"Pacing in multifascicular block","title":"Indications for pacing in multifascicular block","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for pacing in multifascicular block</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Pacemaker necessary</td>\n<td class=\"subtitle1\">Pacemaker probably necessary</td>\n<td class=\"subtitle1\">Pacemaker not necessary</td>\n</tr>\n<tr>\n<td>Symptomatic patients with fascicular block and significantly prolonged H-V interval by electrophysiologic study</td>\n<td>Patients with syncope and bifascicular or trifascicular block with other etiologies of syncope excluded</td>\n<td>Asymptomatic fascicular block without AV block</td>\n</tr>\n<tr>\n<td>Symptomatic patients with block distal to His at atrial paced rates of less than 100-120 bpm</td>\n<td>Pacing-induced block distal to His at atrial paced rates of less than 130 bpm</td>\n<td>Asymptomatic fascicular block and first degree AV block</td>\n</tr>\n<tr>\n<td>Symptomatic patients with bifascicular block and intermittent type II second degree AV block or third degree AV block</td>\n<td>Asymptomatic patients with fascicular block and intermittent type II second degree or third degree AV block</td>\n<td>&nbsp;</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 80379 Version 1.0</div></div></div>"},"80380":{"type":"graphic_table","displayName":"IV medications for pediatric hypertensive emergencies","title":"Intravenous drugs for treatment of hypertensive emergencies and urgencies in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intravenous drugs for treatment of hypertensive emergencies and urgencies in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug*</td> <td class=\"subtitle1\">Route</td> <td class=\"subtitle1\">Dose range<sup>&#182;</sup></td> <td class=\"subtitle1\">Onset of action</td> <td class=\"subtitle1\">Duration of action</td> <td class=\"subtitle1\">Mechanism of action</td> <td class=\"subtitle1\">Comments<sup>&#916;</sup></td> </tr> <tr> <td><strong>Labetalol</strong></td> <td>Intravenous infusion or bolus</td> <td> <p>Bolus: 0.2- 1 mg/kg per dose up to&nbsp; maximum 40 mg/dose</p> Infusion: 0.25-3 mg/kg per hour</td> <td>2-5 min</td> <td>2-6 hr</td> <td>&#945;- and <sub>&#946; </sub>- adrenergic blocker</td> <td>Relatively contraindicated in asthma, BPD, HF and may mask symptoms of hypoglycemia</td> </tr> <tr> <td><strong>Nicardipine</strong></td> <td>Intravenous infusion</td> <td> <p>Bolus: 30 mcg/kg up to maximum 2 mg per dose&nbsp;</p> <p>Infusion:&nbsp;0.5- 4 mcg/kg per minute</p> </td> <td>2-5 min</td> <td>30 min - 4 hr (increases with time of infusion)</td> <td>Calcium channel blocker</td> <td>May cause reflex tachycardia</td> </tr> <tr> <td>Hydralazine</td> <td>Intravenous bolus</td> <td> <p>IV: 0.1-0.2 mg/kg per dose up to 0.4 mg/kg per dose</p> Maximum single dose: 20 mg</td> <td>10 min (max effect may take up to 80 min)</td> <td>4-6 hours</td> <td>Direct vasodilator</td> <td> <p>May cause reflex tachycardia</p> Variable response with potential for prolonged hypotension</td> </tr> <tr> <td>Esmolol</td> <td>Intravenous infusion</td> <td>100-500 mcg/kg loading dose then 100-500 mcg/kg per minute</td> <td>Immediate</td> <td>10-30 min</td> <td><sub>&#946; </sub>- adrenergic blocker</td> <td>Relatively contraindicated in asthma, BPD, HF and may cause profound bradycardia</td> </tr> <tr> <td>Fenoldopam</td> <td>Intravenous infusion</td> <td>0.2 mcg/kg/minute per minute up to 0.8 mcg/kg per minute</td> <td>5-40 min</td> <td>60 min</td> <td>Peripheral dopamine receptor agonist</td> <td>Limited experience in children</td> </tr> <tr> <td>Nitroprusside</td> <td>Intravenous infusion</td> <td> <p>&nbsp;0.5-3 mcg/kg/minute starting dose</p> <p>Maximum dose 10 mcg/kg/minute</p> <p>&nbsp;</p> </td> <td>Seconds</td> <td>Effect requires continuous infusion</td> <td>Venodilator with some arteriolar dilation</td> <td> <p>Monitor cyanide levels with prolonged (&#62;72 hr) use or in renal failure; or coadminister sodium thiosulfate</p> May increase ICP</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICP: intracranial pressure; BPD: bronchopulmonary dysplasia; HF: heart failure.<br />* Bolded medications are most commonly used for hypertensive emergencies in children.<br />¶ See text for specific drug information about starting dose and recommended titration intervals.<br />Δ All agents may cause excessive hypotension.</div><div class=\"graphic_reference\">Adapted from: Flynn, JT, Tullus, K. Severe hypertension in children and adolescents: pathophysiology and treatment. Pediatr Nephrol 2009; 24:1101.</div><div id=\"graphicVersion\">Graphic 80380 Version 4.0</div></div></div>"},"80381":{"type":"graphic_picture","displayName":"Laser lithotripsy","title":"Laser lithotripsy of a gallstone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laser lithotripsy of a gallstone</div><div class=\"cntnt\"><img style=\"width:374px; height:272px;\" src=\"images/GAST/80381_Laser_lithotripsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large stone grasped with a basket under direct exposure of the laser beam. A greenish &quot;plasma&quot; is seen generating shock-waves to break up the surface of the stone.</div><div class=\"graphic_reference\">Reproduced with permission from Berlien, Laser und Medizin-Technologie gGmbH (LMTB), Berlin from H, Muller, G. Angewandte Lasermedizin: Lehr- und Handbuch fur Praxis und Klinik, ecomed verlagsgesellschaft 1990.</div><div id=\"graphicVersion\">Graphic 80381 Version 2.0</div></div></div>"},"80383":{"type":"graphic_picture","displayName":"Cutaneous sarcoidosis - histopathology","title":"Cutaneous sarcoidosis - histopathology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous sarcoidosis - histopathology</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/80383_Cutaneous_sarcoidosis_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This histologic specimen from a nodular lesion demonstrates a granulomatous infiltrate throughout the dermis. Circumscribed &quot;naked,&quot; epithelioid granulomas are present.</div><div class=\"graphic_reference\">Courtesy of Shane A Meehan, MD.</div><div id=\"graphicVersion\">Graphic 80383 Version 1.0</div></div></div>"},"80384":{"type":"graphic_figure","displayName":"Esophageal perforation buttressed with intercostal muscle flap","title":"Esophageal perforation buttressed with intercostal muscle flap","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal perforation buttressed with intercostal muscle flap</div><div class=\"cntnt\"><img style=\"width:427px; height:465px;\" src=\"images/SURG/80384_Repair-muscle-flap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the repair of an esophageal perforation with an intercostal muscle patch.</div><div id=\"graphicVersion\">Graphic 80384 Version 2.0</div></div></div>"},"80385":{"type":"graphic_picture","displayName":"Bullous pemphigoid eczematous","title":"Eczematous lesions in bullous pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Eczematous lesions in bullous pemphigoid</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/80385_Eczematous_lesions_in_bullous_pemphigoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eczematous and erythematous, urticarial plaques with eroded blisters and excoriations on posterior trunk and extremity skin.</div><div class=\"graphic_reference\">&nbsp; Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 80385 Version 5.0</div></div></div>"},"80387":{"type":"graphic_table","displayName":"Therapeutic goals","title":"Therapeutic goals for management of metabolic syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Therapeutic goals for management of metabolic syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Goals</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Lifestyle risk factors</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Abdominal obesity</td> <td>Year 1: reduce body weight 7 to 10 percent</td> </tr> <tr> <td>Continue weight loss thereafter with ultimate goal BMI &#60;25 kg/m2</td> </tr> <tr> <td class=\"indent1\">Physical inactivity</td> <td>At least 30 min (and preferably &#8805;60 min) continuous or intermittent moderate intensity exercise 5X/wk, but preferably daily</td> </tr> <tr> <td class=\"indent1\">Atherogenic diet</td> <td>Reduced intake saturate fat, trans fat, cholesterol</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Metabolic risk factors</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Dyslipidemia</td> </tr> <tr> <td class=\"sublist2\" rowspan=\"3\">Primary target elevated LDL-C</td> <td class=\"sublist_other\">High risk*: &#60;100 mg/dL (2.6 mmol/&#62;L); optional &#60;70 mg/dL</td> </tr> <tr> <td class=\"sublist_other\">Moderate risk: &#60;130 mg/dL (3.4 mmol/L)</td> </tr> <tr> <td class=\"sublist_other\">Lower risk: &#60;160 mg/dL (4.9 mmol/L)</td> </tr> <tr> <td class=\"sublist2\" rowspan=\"3\">Secondary target elevated non-HDL-C</td> <td class=\"sublist_other\">High risk*: &#60;130 mg/dL (3.4 mmol/L); optional &#60;100 mg/dL (2.6 mmol/L) very high risk</td> </tr> <tr> <td class=\"sublist_other\">Moderate risk: &#60;160 mg/dL (4.1 mmol/L)</td> </tr> <tr> <td class=\"sublist_other\">Lower risk: &#60;190 mg/dL (4.9 mmol/L)</td> </tr> <tr> <td class=\"sublist2\">Tertiary target reduced HDL-C</td> <td class=\"sublist_other\">Raise to extent possible w/weight reduction and exercise</td> </tr> <tr> <td class=\"indent1\">Elevated bp</td> <td>Reduce to at least &#60;140/90 (&#60;130/80 if diabetic)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Elevated glucose</td> <td>For IFG, encourage weight reduction and exercise</td> </tr> <tr> <td>For type 2 DM, target A1C &#60;7 percent</td> </tr> <tr> <td class=\"indent1\">Prothrombotic state</td> <td>Low dose aspirin for high risk patients</td> </tr> <tr> <td class=\"indent1\">Proinflammatory state</td> <td>Lifestyle therapies; no specific interventions</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DM: diabetes mellitus; IFG: impaired fasting glucose; bp: blood pressure.<br />* High risk: diabetes, known coronary artery disease.</div><div class=\"graphic_reference\">Data from: Grundy S, Cleeman J, Daniels S, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005; 112:2735.</div><div id=\"graphicVersion\">Graphic 80387 Version 3.0</div></div></div>"},"80389":{"type":"graphic_figure","displayName":"Pediatric Dyspnea Scale","title":"Pediatric Dyspnea Scale","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Pediatric Dyspnea Scale</div><div class=\"cntnt\"><img style=\"width:526px; height:224px;\" src=\"images/PEDS/80389_Pediatric_Dyspnea_Scale.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Each patient is asked to answer the question, \"How much difficulty are you having breathing?\" by choosing the column that best corresponds to his or her perceived symptoms.</div><div class=\"graphic_reference\">Reproduced with permission from: Khan Fl, Reddy RC, Baptist AP. Pediatric Dyspnea Scale for use in hospitalized patients with asthma. J Allergy Clin Immunol 2009; 123:660. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 80389 Version 2.0</div></div></div>"},"80390":{"type":"graphic_diagnosticimage","displayName":"Endstage sarcoidosis PA","title":"Endstage sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endstage sarcoidosis</div><div class=\"cntnt\"><img style=\"width:348px; height:347px;\" src=\"images/PULM/80390_Endstage_sarcoidosis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows a destructive pattern with marked loss of volume in both upper lobes, retraction of both hilar regions cephalad, distortion, and hyperexpansion of the lung bases. Bilateral upper lobe cavities containing mycetomas are present.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 80390 Version 3.0</div></div></div>"},"80392":{"type":"graphic_picture","displayName":"Colposcope on rolling stand","title":"Colposcope on a rolling stand","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Colposcope on a rolling stand</div><div class=\"cntnt\"><img style=\"width:177px; height:303px;\" src=\"images/OBGYN/80392_Colposcope_on_rolling_stand.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Apgar BS, Rubin MM, Brotzman GL. Principles and technique of the colposcopic examination. In: Colposcopy Principles and Practice, Apgar BS, Brotzman GL, Spitzer M (Eds), W.B. Saunders Company, Philadelphia 2002. p. 115. Copyright © 2002 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 80392 Version 2.0</div></div></div>"},"80394":{"type":"graphic_picture","displayName":"Optic pit","title":"Optic pit","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Optic pit</div><div class=\"cntnt\"><img style=\"width:274px; height:371px;\" src=\"images/PEDS/80394_Optic_pit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the oval gray excavation nasally (arrows). This nasal location is unusual because most optic pits are inferior or temporal.</div><div class=\"graphic_reference\">Courtesy of Karl C Golnik, MD.</div><div id=\"graphicVersion\">Graphic 80394 Version 1.0</div></div></div>"},"80395":{"type":"graphic_picture","displayName":"Acute angle-closure glaucoma","title":"Acute angle-closure glaucoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute angle-closure glaucoma</div><div class=\"cntnt\"><img style=\"width:322px; height:239px;\" src=\"images/PC/80395_Angleclosureglaucoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The conjunctival vessels are dilated, especially near the cornea (ciliary flush) and the cornea is slightly hazy (edematous).</div><div class=\"graphic_reference\">Reproduced with permission from: Trobe JD, Hackel RE. Field Guide to the Eyes. Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 80395 Version 14.0</div></div></div>"},"80396":{"type":"graphic_table","displayName":"Spine instability score","title":"Classification system for Spine Instability Neoplastic Score (SINS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification system for Spine Instability Neoplastic Score (SINS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Component scores for clinical and radiographic findings</td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Spine location</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Junctional (occiput-C2, C7-T2, T11-L1, L5-S1)</td> <td>3</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Mobile spine (C3-C6, L2-L4)</td> <td>2</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Semi-rigid (T3-T10)</td> <td>1</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Rigid (S2-S5)</td> <td>0</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"3\">Pain relief with recumbence and/or pain with movement/loading of the spine</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Yes</td> <td>3</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">No (occasional pain but not mechanical)</td> <td>1</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Pain-free lesion</td> <td>0</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"3\">Bone lesion quality</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Lytic</td> <td>2</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Mixed lytic/blastic</td> <td>1</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Blastic</td> <td>0</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"3\">Radiographic spinal alignment</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Subluxation/translation present</td> <td>4</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">De novo deformity (kyphosis/scoliosis)</td> <td>2</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Normal alignment</td> <td>0</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"3\">Vertebral body collapse</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">&#62;50% collapse</td> <td>3</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">&#60;50% collapse</td> <td>2</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">No collapse with &#62;50% body involved</td> <td>1</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">None of the above</td> <td>0</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"3\">Posterolateral involvement of spinal elements (facet, pedicle, or&nbsp;costovertebral joint fracture or replacement with tumor)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Bilateral</td> <td>3</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Unilateral</td> <td>1</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">None of the above</td> <td>0</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\" colspan=\"3\">The SINS score is generated by adding all of the scores from the six individual components (minimal score is 0, maximal score is 18)</td> </tr> <tr> <td class=\"subtitle2\">Score</td> <td class=\"subtitle2\">Classification</td> <td class=\"subtitle2\">Action</td> </tr> <tr> <td>0 to 6</td> <td>Stable spine</td> <td>&nbsp;</td> </tr> <tr> <td>7 to 12</td> <td>Indeterminant</td> <td>Possible impending instability, warrants surgical consultation</td> </tr> <tr> <td>13 to 18</td> <td>Instability</td> <td>Warrants surgical consultation</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80396 Version 2.0</div></div></div>"},"80397":{"type":"graphic_figure","displayName":"Hymenoptera taxonomy","title":"Overview of taxonomy of common Hymenoptera (stinging insects)","html":"<div class=\"graphic\"><div style=\"width: 723px\" class=\"figure\"><div class=\"ttl\">Overview of taxonomy of common Hymenoptera (stinging insects)</div><div class=\"cntnt\"><img style=\"width:703px; height:757px;\" src=\"images/ALLRG/80397_Hymenoptera_taxonomy_ed1.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 80397 Version 5.0</div></div></div>"},"80398":{"type":"graphic_diagnosticimage","displayName":"ACL full thickness tear","title":"Full thickness tear of the anterior cruciate ligament","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Full thickness tear of the anterior cruciate ligament</div><div class=\"cntnt\"><img style=\"width:371px; height:371px;\" src=\"images/RHEUM/80398_ACL_full_thickness_tear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This sagittal proton density magnetic resonance image of the knee demonstrates complete discontinuity of the proximal fibers of the anterior cruciate ligament (arrow) consistent with a full thickness tear.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 80398 Version 2.0</div></div></div>"},"80400":{"type":"graphic_table","displayName":"Frequency of laboratory tests following kidney transplantation","title":"Suggested frequency of laboratory tests following kidney transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested frequency of laboratory tests following kidney transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Frequency</td> </tr> <tr> <td>Basic chemistry panel (including eGFR), magnesium, and phosphorus</td> <td>Every visit</td> </tr> <tr> <td>Complete blood count and differential</td> <td>Every visit</td> </tr> <tr> <td>Tacrolimus/cyclosporine/everolimus/sirolimus level</td> <td>Every visit</td> </tr> <tr> <td>Urinalysis with sediment examination</td> <td>Every visit</td> </tr> <tr> <td>Spot urine protein-to-creatinine ratio</td> <td>Every visit</td> </tr> <tr> <td>Fasting blood glucose&nbsp;</td> <td>Weekly for the first&nbsp;four weeks, then at&nbsp;three and&nbsp;six months, then every year&nbsp;</td> </tr> <tr> <td>HbA1C</td> <td>Every three months or every visit if less frequent</td> </tr> <tr> <td>Fasting lipid profile</td> <td>Every three months or every&nbsp;visit if less frequent</td> </tr> <tr> <td>PTH and 25-hydroxyvitamin D</td> <td>Immediately posttransplant and then every 6 to 12 months</td> </tr> <tr> <td>BK virus blood and/or&nbsp;urine PCR testing</td> <td>Monthly for the first&nbsp;six months, and then at 9, 12, 18, and 24 months</td> </tr> <tr> <td>CMV blood PCR testing&nbsp;(in patients not receiving CMV prophylaxis therapy)&nbsp;</td> <td>Weekly for the&nbsp;first&nbsp;three months </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">eGFR: estimated glomerular filtration rate; PTH: parathyroid hormone; PCR: polymerase chain reaction; CMV: cytomegalovirus.</div><div class=\"graphic_reference\">Courtesy of Anil Chandraker, MD.</div><div id=\"graphicVersion\">Graphic 80400 Version 6.0</div></div></div>"},"80401":{"type":"graphic_table","displayName":"Lesion-specific characteristics outcome balloon angioplasty","title":"Lesion-specific characteristics and outcome after balloon angioplasty","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lesion-specific characteristics and outcome after balloon angioplasty</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Type A lesions: High success (&#62;85%); low risk</td> </tr> <tr> <td>Discrete, &#60;10 mm in length</td> </tr> <tr> <td>Concentric</td> </tr> <tr> <td>Readily accessible</td> </tr> <tr> <td>Nonangulated segment, &#60;45 degrees</td> </tr> <tr> <td>Smooth contour</td> </tr> <tr> <td>Little or no calcification</td> </tr> <tr> <td>Less than totally occlusive</td> </tr> <tr> <td>Not ostial in location</td> </tr> <tr> <td>No major branch involvement</td> </tr> <tr> <td>Absence of thrombus</td> </tr> <tr> <td class=\"subtitle1_single\">Type B lesions: Moderate success (60 to 85%); moderate risk (Type B1: One type B characteristic; Type B2: More than one type B characteristic)</td> </tr> <tr> <td>Tubular, 10 to 20 mm in length</td> </tr> <tr> <td>Eccentric</td> </tr> <tr> <td>Moderate tortuosity of proximal segment</td> </tr> <tr> <td>Moderately angulated segment (&#62;45 degrees, &#60;90 degrees)</td> </tr> <tr> <td>Irregular contour</td> </tr> <tr> <td>Moderate-to-heavy calcification</td> </tr> <tr> <td>Total occlusions less than three months old and/or bridging collaterals</td> </tr> <tr> <td>Ostial in location</td> </tr> <tr> <td>Bifurcation lesions requiring double guide wires</td> </tr> <tr> <td>Some thrombus present</td> </tr> <tr> <td class=\"subtitle1_single\">Type C lesions: Low success (&#60;60%); high risk</td> </tr> <tr> <td>Diffuse, &#62;20 mm in length</td> </tr> <tr> <td>Excessive tortuosity of proximal segment</td> </tr> <tr> <td>Extremely angulated segments &#62;90 degrees</td> </tr> <tr> <td>Total occlusion more than three months old</td> </tr> <tr> <td>Inability to protect major side branches</td> </tr> <tr> <td>Degenerated vein grafts with friable lesions</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Although the risk of abrupt vessel closure is moderate, in certain instances the likelihood of a major complication may be low with dilation of total occlusions less than three months old or when abundant collateral channels supply the distal vessel.</div><div class=\"graphic_reference\">From Ryan TO, Axon DP, Gunnar RM, et al. J Am Coll Cardiol 1988; 12:529.</div><div id=\"graphicVersion\">Graphic 80401 Version 4.0</div></div></div>"},"80402":{"type":"graphic_figure","displayName":"Tissue factor generate thrombin","title":"Tissue factor generates thrombin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tissue factor generates thrombin</div><div class=\"cntnt\"><img style=\"width:439px; height:183px;\" src=\"images/OBGYN/80402_Tissue_factor_generate_thro.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Charles Lockwood, MD.</div><div id=\"graphicVersion\">Graphic 80402 Version 1.0</div></div></div>"},"80403":{"type":"graphic_figure","displayName":"C peptide in prolonged fast","title":"Plasma C-peptide concentrations after a prolonged fast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plasma C-peptide concentrations after a prolonged fast</div><div class=\"cntnt\"><img style=\"width:261px; height:314px;\" src=\"images/ENDO/80403_C_peptide_in_prolonged_fast.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relation between plasma glucose and C-peptide concentrations in normal subjects and patients with an insulinoma after a prolonged fast. In patients who become hypoglycemic, a plasma C-peptide concentration above 0.2 nmol/L is suggestive of an insulinoma. To convert plasma glucose values to mmol/L, multiply by 0.056.</div><div class=\"graphic_reference\">Redrawn from Service FJ. Hypoglycemic disorders. N Engl J Med 1995; 332:1144.</div><div id=\"graphicVersion\">Graphic 80403 Version 2.0</div></div></div>"},"80405":{"type":"graphic_picture","displayName":"NSCLC pos cytotology","title":"Squamous cell carcinoma of the lung in lymph node","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Squamous cell carcinoma of the lung in lymph node</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PULM/80405_NSCLC_pos_cytotology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 54-year-old man presented with shortness of breath. Endobronchial ultrasound-guided needle aspirate revealed squamous cell carcinoma involving the 4R (N2) node and establishing stage IIIA disease.</div><div class=\"graphic_reference\">Courtesy of Marie Christine Aubry, MD.</div><div id=\"graphicVersion\">Graphic 80405 Version 3.0</div></div></div>"},"80406":{"type":"graphic_picture","displayName":"Otoscopic view of right ear with large congenital cholesteatoma","title":"Otoscopic view of right ear with large congenital cholesteatoma causing hearing loss","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Otoscopic view of right ear with large congenital cholesteatoma causing hearing loss</div><div class=\"cntnt\"><img style=\"width:342px; height:370px;\" src=\"images/ALLRG/80406_Otoscopic_cong_cholest.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 80406 Version 1.0</div></div></div>"},"80408":{"type":"graphic_table","displayName":"Oral abx paronychia","title":"Empiric therapy for paronychia due to presumed oral flora","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Empiric therapy for paronychia due to presumed oral flora</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Agent of choice\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Amoxicillin - clavulanate (875/125 mg twice daily)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Alternate empiric regimens include:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   One of the following agents with activity against <em>Eikenella</em>:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Doxycycline* (100 mg twice daily)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Trimethoprim-sulfamethoxazole* (1 double strength tablet twice daily)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Penicillin VK (500 mg four times daily)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Cefuroxime (500 mg twice daily)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   \t<p>Fluoroquinolones (one of the following):</p>\n\t<p>\t\t\t\t&#8226; Ciprofloxacin (500 to 750 mg twice daily)</p>\n\t<p>\t\t\t\t&#8226; Moxifloxacin (400 mg once daily)</p>\n\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   <span class=\"red\"><strong>PLUS</strong></span>\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   One of the following agents with anaerobic activity:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Metronidazole (500 mg three times daily)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Clindamycin* (450 mg three times daily)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   The following agents have poor activity against <em>Eikenella</em> and should be avoided:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Cephalexin</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Dicloxacillin</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Erythromycin</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">8.00000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=31950&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Oral_abx_paronychia.htm</title></head></div><div class=\"graphic_footnotes\">* Also active against MRSA (check susceptibility testing).</div><div id=\"graphicVersion\">Graphic 80408 Version 2.0</div></div></div>"},"80409":{"type":"graphic_figure","displayName":"ACEI delays moderately increased albuminuria ","title":"Captopril delays progression of moderately increased albuminuria (formerly called microalbuminuria) in diabetes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Captopril delays progression of moderately increased albuminuria (formerly called microalbuminuria) in diabetes</div><div class=\"cntnt\"><img style=\"width:377px; height:250px;\" src=\"images/NEPH/80409_ACEIdelaysmicroalbuminuri.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of captopril or placebo in 225 patients with type 1 diabetes mellitus, normal blood pressure, and moderately increased albuminuria (formerly called microalbuminuria). At two years, captopril slowed the rate of progression to overt, dipstick-positive proteinuria and lowered the&nbsp;AER compared with placebo.</div><div class=\"graphic_footnotes\">AER: albumin excretion rate.</div><div class=\"graphic_reference\">Data from:&nbsp;Captopril reduces the risk of&nbsp;nephropathy in IDDM&nbsp;patients with microalbuminuria. The Microalbuminuria Captopril Study Group.&nbsp;Diabetologia 1996; 39:587.</div><div id=\"graphicVersion\">Graphic 80409 Version 6.0</div></div></div>"},"80410":{"type":"graphic_table","displayName":"Duration illness prior to ILD","title":"Duration of interstitial lung disease prior to diagnosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Duration of interstitial lung disease prior to diagnosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Acute (days to weeks)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Acute idiopathic interstitial pneumonia (AIP, Hamman-Rich syndrome)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Eosinophilic pneumonia</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Hypersensitivity pneumonitis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Cryptogenic organizing pneumonia</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Subacute (weeks to months)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Sarcoidosis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Some drug-induced ILDs</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Alveolar hemorrhage syndromes</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Cryptogenic organizing pneumonia</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Connective tissue disease (systemic lupus erythematosus or polymyositis)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Chronic (months to years)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Idiopathic pulmonary fibrosis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Sarcoidosis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Pulmonary Langerhans cell histiocytosis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Chronic hypersensitivity pneumonitis</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 80410 Version 2.0</div></div></div>"},"80411":{"type":"graphic_picture","displayName":"Vespula nest","title":"Vespula nest","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Vespula nest</div><div class=\"cntnt\"><img style=\"width:504px; height:391px;\" src=\"images/ALLRG/80411_Vespula_nest.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.</div><div id=\"graphicVersion\">Graphic 80411 Version 1.0</div></div></div>"},"80412":{"type":"graphic_figure","displayName":"Rectal exam PI","title":"Rectal exam","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Rectal exam</div><div class=\"cntnt\"><img style=\"width:540px; height:396px;\" src=\"images/PI/80412_Rectal_exam_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During a rectal exam, the doctor or nurse puts a finger inside your rectum and feels your prostate gland. That way he or she can see how big it is and whether it has bumps or dents or anything unusual.</div><div id=\"graphicVersion\">Graphic 80412 Version 5.0</div></div></div>"},"80413":{"type":"graphic_table","displayName":"Meds that worsen UI","title":"Medications that may cause or worsen urinary incontinence","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications that may cause or worsen urinary incontinence</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Effect on continence</td> </tr> <tr> <td>Alcohol</td> <td>Frequency, urgency, sedation, delirium, immobility</td> </tr> <tr> <td>&#945;-Adrenergic agonists</td> <td>Outlet obstruction (men)</td> </tr> <tr> <td>&#945;-Adrenergic blockers</td> <td>Stress leakage (women)</td> </tr> <tr> <td>Angiotensin-converting enzyme inhibitors</td> <td>Associated cough worsens stress and possibly urge leakage in persons with impaired sphincter function</td> </tr> <tr> <td>Anticholinergics</td> <td>Impaired emptying, retention, delirium, sedation, constipation, fecal impaction</td> </tr> <tr> <td>Antipsychotics</td> <td>Anticholinergic effects plus rigidity and immobility</td> </tr> <tr> <td>Calcium channel blockers</td> <td>Impaired detrusor contractility and retention; the dihydropyridine agents can cause pedal edema, leading to nocturnal polyuria</td> </tr> <tr> <td>Estrogen</td> <td>Worsens stress and mixed leakage in women</td> </tr> <tr> <td>GABAnergic agents (gabapentin, pregablin)</td> <td>Pedal edema causing nocturia and nighttime incontinence</td> </tr> <tr> <td>Latanoprost</td> <td>Urge incontinence</td> </tr> <tr> <td>Loop diuretics</td> <td>Polyuria, frequency, urgency</td> </tr> <tr> <td>Narcotic analgesics</td> <td>Urinary retention, fecal impaction, sedation, delirium</td> </tr> <tr> <td>Nonsteroidal anti-inflammatory drugs</td> <td>Pedal edema causing nocturnal polyuria</td> </tr> <tr> <td>Oral contraceptives<sup>[1]</sup></td> <td>Stress, urge, and mixed incontinence</td> </tr> <tr> <td>Sedative hypnotics</td> <td>Sedation, delirium, immobility</td> </tr> <tr> <td>Thiazolidinediones</td> <td>Pedal edema causing nocturnal polyuria</td> </tr> <tr> <td>Tricylic antidepressants</td> <td>Anticholinergic effects, sedation</td> </tr> <tr> <td>Cholinesterase inhibitors</td> <td>Alone may increase incontinence; increased functional impairment when combined with antiincontinence antimuscarinic agents</td> </tr> <tr> <td>Beta blockers</td> <td>Urge incontinence</td> </tr> <tr> <td>Opioid analgesics</td> <td>Sedation, anticholinergic effects</td> </tr> <tr> <td>Histamine 1 receptor antagonists</td> <td>Confusion</td> </tr> <tr> <td>Lithium</td> <td>Polyuria</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reference:<br> <ol> <li>Townsend MK, Curhan GC, Resnick NM, Grodstein F. Oral contraceptive use and incident urinary incontinence in premenopausal women. J Urol 2009; 181:2170. </li> </ol> <br> Reprinted with permission: DuBeau CE. Urinary Incontinence. In: Pompei P, Murphy JB, eds. Geriatrics Review Syllabus: A Core Curriculum in Geriatric Medicine, 6th ed. New York, NY: American Geriatrics Society; 2006: 185. Table based on data from Resnick NM. Geriatric medicine. In: Principles of Internal Medicine, Isselbacher JK, Braunwald E, Wilson JD, et al (Eds), McGraw-Hill, New York 1994. p.34.</div><div id=\"graphicVersion\">Graphic 80413 Version 3.0</div></div></div>"},"80414":{"type":"graphic_picture","displayName":"Dilated episcleral vessels","title":"Dilated episcleral vessels in a patient with a cavernous dural fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dilated episcleral vessels in a patient with a cavernous dural fistula</div><div class=\"cntnt\"><img style=\"width:359px; height:360px;\" src=\"images/NEURO/80414_Dilated_episcleral_vessels.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Jeffrey L Bennett, MD, PhD.</div><div id=\"graphicVersion\">Graphic 80414 Version 1.0</div></div></div>"},"80415":{"type":"graphic_picture","displayName":"Endometriosis posterior vaginal fornix","title":"Endometriotic lesion of the posterior vaginal fornix","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endometriotic lesion of the posterior vaginal fornix</div><div class=\"cntnt\"><img style=\"width:298px; height:432px;\" src=\"images/OBGYN/80415_Endo_post_vaginal_fornix.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These endometriotic lesions (dark lesions) infiltrate the vaginal mucosa and are visible on speculum examination of the posterior vaginal fornix.</div><div id=\"graphicVersion\">Graphic 80415 Version 1.0</div></div></div>"},"80416":{"type":"graphic_figure","displayName":"Mobilization of the upper rectum","title":"Mobilization of the upper rectum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mobilization of the upper rectum</div><div class=\"cntnt\"><img style=\"width:332px; height:329px;\" src=\"images/SURG/80416_Mobilize-rectum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The upper rectum&#160;is mobilized with the sigmoid colon &#160;in the avascular plane, gently sweeping the bowel anteriorly.</div><div id=\"graphicVersion\">Graphic 80416 Version 2.0</div></div></div>"},"80418":{"type":"graphic_table","displayName":"Causes of membranous nephropathy","title":"Major causes of membranous nephropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of membranous nephropathy</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td>Idiopathic - may represent autoantibody against a podocyte antigen such as PLA2R</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Systemic lupus erythematosus (WHO Class V)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1_start\">Drugs:</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Penicillamine</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Bucillamine</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Gold salts</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Anti-TNF therapy</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">Tiopronin</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">NSAIDs</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Hepatitis B virus</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Hepatitis C virus (rare)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Malignancy (may not be causative)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Hematopoietic cell transplant / GVHD</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Status post renal transplantation</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Sarcoidosis (uncommon)</td>\r\n                </tr>\r\n            </tbody>\r\n        </table>\r\n        <!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">9.00000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=35257&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_footnotes\">PLA2R: phospholipase-A2-receptor; WHO: World Health Organization; anti-TNF: antitumor necrosis factor; NSAIDs: nonsteroidal anti-inflammatory drugs; GVHD: graft-versus-host disease.</div><div id=\"graphicVersion\">Graphic 80418 Version 3.0</div></div></div>"},"80419":{"type":"graphic_picture","displayName":"Lichen planus nails","title":"Lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen planus</div><div class=\"cntnt\"><img style=\"width:432px; height:360px;\" src=\"images/DERM/80419_Lichen_planus_nails.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lichen planus of the nail may present with nail plate thinning, longitudinal ridging (trachyonychia), fissuring, and rarely, pterygium. Nail plate thinning and longitudinal ridging are visible on this patient's nails.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80419 Version 1.0</div></div></div>"},"80421":{"type":"graphic_table","displayName":"Binet staging system CLL","title":"Binet staging system for chronic lymphocytic leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Binet staging system for chronic lymphocytic leukemia</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Stage\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Description\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A</td>\r\n  \r\n   <td  >\r\n  \r\n   Two or less lymphoid bearing areas enlarged*\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>B</td>\r\n  \r\n   <td  >\r\n  \r\n   Three or more lymphoid bearing areas enlarged*\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>C</td>\r\n  \r\n   <td  >\r\n  \r\n   Presence of anemia (Hgb &#60;10.0 g/dL) or thrombocytopenia (platelet count &#60;100,000/microL)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">7.00000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=24882&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Binet_staging_system_CLL.htm</title></head></div><div class=\"graphic_footnotes\">* Five lymphoid bearing areas are possible: cervical, axillary, inguino-femoral, spleen, and liver.</div><div class=\"graphic_reference\">Revised from: Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48:198.</div><div id=\"graphicVersion\">Graphic 80421 Version 2.0</div></div></div>"},"80422":{"type":"graphic_table","displayName":"Detsky cardiac risk index","title":"Detsky modified cardiac risk index","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Detsky modified cardiac risk index</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Variable</td> <td class=\"subtitle1\">Number of points</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Coronary artery disease</td> </tr> <tr> <td class=\"sublist1\">Myocardial infarction &#60;six months earlier</td> <td class=\"sublist_other\">10</td> </tr> <tr> <td class=\"sublist1\">Myocardial infarction &#62;six months earlier</td> <td class=\"sublist_other\">5</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Canadian Cardiovascular Society angina classification*</td> </tr> <tr> <td class=\"sublist1\">Class III</td> <td class=\"sublist_other\">10</td> </tr> <tr> <td class=\"sublist1\">Class IV</td> <td class=\"sublist_other\">20</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Alveolar pulmonary edema</td> </tr> <tr> <td class=\"sublist1\">Within&nbsp;one week</td> <td class=\"sublist_other\">10</td> </tr> <tr> <td class=\"sublist1\">Ever</td> <td class=\"sublist_other\">5</td> </tr> <tr> <td>Suspected critical aortic stenosis</td> <td>20</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Arrhythmias</td> </tr> <tr> <td class=\"sublist1\">Rhythm other than sinus or sinus plus atrial premature beats on electrocardiogram</td> <td>5</td> </tr> <tr> <td class=\"sublist1\">&#62;Five premature ventricular contractions on electrocardiogram</td> <td>5</td> </tr> <tr> <td class=\"sublist1\">Poor general medical status, defined as any of the following:</td> <td rowspan=\"2\">5</td> </tr> <tr> <td class=\"sublist2\">PO2 &#60;60 mm Hg, PCO2 &#62;50 mm Hg, serum potassium &#60;3.0 meq/L, blood urea nitrogen &#62;50 mg/dL (17.9 mmol/L), serum creatinine &#62;2.9 mg/dL (260 &#181;mol/L), bedridden</td> </tr> <tr> <td>Age &#62;70 years</td> <td>5</td> </tr> <tr> <td>Emergency surgery</td> <td>10</td> </tr> <tr> <td colspan=\"2\"><strong>Class I:</strong> 0 to 15 points</td> </tr> <tr> <td colspan=\"2\"><strong>Class II:</strong> 20 to 30 points</td> </tr> <tr> <td colspan=\"2\"><strong>Class III:</strong> more than 30 points</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Canadian Cardiovascular Society classification of angina:<BR>0: Asymptomatic.<BR>I: Angina with strenuous exercise.<BR>II: Angina with moderate exertion.<BR>III: Angina with walking&nbsp;one to&nbsp;two level blocks or climbing&nbsp;one flight of stairs or less at a normal pace.<BR>IV: Inability to perform any physical activity without development of angina.</div><div class=\"graphic_reference\">Modified from Detsky AS, Abrams HB, Forbath N, et al. Arch Intern Med 1986; 146:2121.</div><div id=\"graphicVersion\">Graphic 80422 Version 4.0</div></div></div>"},"80423":{"type":"graphic_table","displayName":"Adj analgesics cancer pain","title":"Adjuvant analgesics used for cancer pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adjuvant analgesics used for cancer pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Category based on conventional use </td> <td class=\"subtitle1\">Class </td> <td class=\"subtitle1\">Subclass </td> <td class=\"subtitle1\">Drugs </td> </tr> <tr> <td rowspan=\"9\">Multipurpose analgesics </td> <td>Glucocorticoids</td> <td>-</td> <td>Dexamethasone, prednisone, methylprednisone</td> </tr> <tr> <td rowspan=\"4\">Antidepressants </td> <td>Tricyclic</td> <td>Amitriptyline, desipramine, nortriptyline</td> </tr> <tr> <td>SNRIs</td> <td>Duloxetine, minalcipran, desvenlafaxine</td> </tr> <tr> <td>SSRIs</td> <td>Paroxetine, citalopram</td> </tr> <tr> <td>Other</td> <td>Buproprion</td> </tr> <tr> <td>Alpha-2 adrenergic agonists</td> <td>-</td> <td>Tizanidine, clonidine</td> </tr> <tr> <td>Cannabinoids</td> <td>-</td> <td>Dronabinol, nabilone, nabiximols</td> </tr> <tr> <td>Topical analgesics</td> <td>-</td> <td>Local anesthetics, lidocaine, capsaicin, tricyclic antidepressants, NSAIDs, others</td> </tr> <tr> <td>Botulinum toxin&nbsp;injections</td> <td>-</td> <td>-</td> </tr> <tr> <td rowspan=\"7\">Used for neuropathic pain </td> <td>All multipurpose analgesics</td> <td>See above</td> <td>See above</td> </tr> <tr> <td>Anticonvulsants</td> <td>-</td> <td>Gabapentin, pregabalin, valproate, phenytoin, carbamazepine, oxcarbazepine, topiramate, lamotrigine</td> </tr> <tr> <td rowspan=\"2\">Sodium channel blockers </td> <td>Sodium channel modulator</td> <td>Lacosamide</td> </tr> <tr> <td>Sodium channel blocker</td> <td>Mexiletine,&nbsp;intravenous lidocaine</td> </tr> <tr> <td>NMDA&nbsp;receptor antagonists</td> <td>-</td> <td>Ketamine, memantine, dextromethorphan, amantadine</td> </tr> <tr> <td rowspan=\"2\">GABA agonists </td> <td>GABA<sub>a</sub> agonists</td> <td>Clonazepam</td> </tr> <tr> <td>GABA<sub>b</sub> agonists</td> <td>Baclofen</td> </tr> <tr> <td rowspan=\"5\">Used for bone pain </td> <td rowspan=\"3\">Osteoclast inhibitors </td> <td>Bisphosphonates</td> <td>Pamidronate, zolendronate, ibandronate</td> </tr> <tr> <td>-</td> <td>Calcitonin</td> </tr> <tr> <td>RANKL inhibitor</td> <td>Denosumab</td> </tr> <tr> <td>Radiopharmaceuticals</td> <td>-</td> <td>Strontium-89, samarium-153, radium-223</td> </tr> <tr> <td>NSAIDs, glucocorticoids</td> <td>-</td> <td>-</td> </tr> <tr> <td rowspan=\"3\">Used for bowel obstruction </td> <td>Anticholinergic drugs</td> <td>-</td> <td>Scopolamine, atropine, glycopyrrolate</td> </tr> <tr> <td>Somatostatin analog</td> <td>-</td> <td>Octreotide</td> </tr> <tr> <td>Glucocorticoids</td> <td>-</td> <td>-</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SNRI: serotonin-norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor;&nbsp;NSAID: Nonsteroidal antiinflammatory drugs; NMDA: N-methyl-D-aspartate; GABA: gamma-aminobutyric acid; RANKL: receptor activator of nuclear factor kappa B ligand.</div><div id=\"graphicVersion\">Graphic 80423 Version 2.0</div></div></div>"},"80424":{"type":"graphic_figure","displayName":"End of life care in ICU","title":"End of life care in intensive care units","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">End of life care in intensive care units</div><div class=\"cntnt\"><img style=\"width:452px; height:382px;\" src=\"images/PALC/80424_End_of_life_care.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histogram showing the relative proportions of different types of end of life care of 5910 patients in 131 intensive care units. Less than one-half of all deaths were preceded by full resuscitative efforts.</div><div class=\"graphic_reference\">Reprinted with permission of: the American Thoracic Society. Copyright © 1998 American Thoracic Society. Prendergast TJ, Claessens MT, Luce JM, 1998, A national survey of end-of-life care for critically ill patients, American Journal of Respiratory and Critical Care Medicine, Volume 158, Pages 1163-7. Official journal of the American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 80424 Version 3.0</div></div></div>"},"80426":{"type":"graphic_picture","displayName":"Nocardia on Gram stain","title":"Gram stain of <EM>Nocardia</EM>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gram stain of <EM>Nocardia</EM></div><div class=\"cntnt\"><img style=\"width:370px; height:244px;\" src=\"images/ID/80426_Nocardia_in_Gram_stain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Nocardia </EM>appear as delicate, filamentous, branching gram-positive rods that are indistinguishable from <EM>Actinomyces</EM>.</div><div class=\"graphic_reference\">Courtesy of Stanley W Chapman, MD.</div><div id=\"graphicVersion\">Graphic 80426 Version 5.0</div></div></div>"},"80428":{"type":"graphic_table","displayName":"Energy requirements children","title":"Estimated caloric needs per day by age, gender, and physical activity level","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated caloric needs per day by age, gender, and physical activity level</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"12%\"></colgroup><colgroup span=\"4\" width=\"22%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Age (y)</td> <td class=\"subtitle1\" colspan=\"4\">Activity level</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Males</td> <td class=\"subtitle2\" colspan=\"2\">Females</td> </tr> <tr> <td class=\"subtitle3\">Sedentary*</td> <td class=\"subtitle3\">Moderately active<sup>&#182;</sup></td> <td class=\"subtitle3\">Sedentary* </td> <td class=\"subtitle3\">Moderately active<sup>&#182;</sup></td> </tr> <tr class=\"centered\"> <td>2</td> <td>1000</td> <td>1000</td> <td>1000</td> <td>1000</td> </tr> <tr class=\"centered\"> <td>3</td> <td>1000</td> <td>1400<sup>&#916;</sup></td> <td>1000</td> <td>1200<sup>&#916;</sup></td> </tr> <tr class=\"centered\"> <td>4</td> <td>1200</td> <td>1400<sup>&#916;</sup></td> <td>1200</td> <td>1400<sup>&#916;</sup></td> </tr> <tr class=\"centered\"> <td>5</td> <td>1200</td> <td>1400<sup>&#916;</sup></td> <td>1200</td> <td>1400<sup>&#916;</sup></td> </tr> <tr class=\"centered\"> <td>6</td> <td>1400</td> <td>1600</td> <td>1200</td> <td>1400</td> </tr> <tr class=\"centered\"> <td>7</td> <td>1400</td> <td>1600</td> <td>1200</td> <td>1600</td> </tr> <tr class=\"centered\"> <td>8</td> <td>1400</td> <td>1600</td> <td>1400</td> <td>1600</td> </tr> <tr class=\"centered\"> <td>9</td> <td>1600</td> <td>1800</td> <td>1400</td> <td>1600</td> </tr> <tr class=\"centered\"> <td>10</td> <td>1600</td> <td>1800</td> <td>1400</td> <td>1800</td> </tr> <tr class=\"centered\"> <td>11</td> <td>1800</td> <td>2000</td> <td>1600</td> <td>1800</td> </tr> <tr class=\"centered\"> <td>12</td> <td>1800</td> <td>2200</td> <td>1600</td> <td>2000</td> </tr> <tr class=\"centered\"> <td>13</td> <td>2000</td> <td>2200</td> <td>1600</td> <td>2000</td> </tr> <tr class=\"centered\"> <td>14</td> <td>2000</td> <td>2400</td> <td>1800</td> <td>2000</td> </tr> <tr class=\"centered\"> <td>15</td> <td>2200</td> <td>2600</td> <td>1800</td> <td>2000</td> </tr> <tr class=\"centered\"> <td>16</td> <td>2400</td> <td>2800</td> <td>1800</td> <td>2000</td> </tr> <tr class=\"centered\"> <td>17</td> <td>2400</td> <td>2800</td> <td>1800</td> <td>2000</td> </tr> <tr class=\"centered\"> <td>18</td> <td>2400</td> <td>2800</td> <td>1800</td> <td>2000</td> </tr> <tr class=\"centered\"> <td>19 to 20</td> <td>2600</td> <td>2800</td> <td>2000</td> <td>2200</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These estimates are based on Estimated Energy Requirements (EER) equations, using reference heights (average) and reference weights (healthy) for each age-gender group.<sup>[1]</sup> For children and adolescents, reference height and weight vary. The estimates are rounded to the nearest 200 calories. An individual's energy needs may be higher or lower than these average estimates.</div><div class=\"graphic_footnotes\">* Sedentary means a lifestyle that includes only the light physical activity associated with typical day-to-day life.<br />&#182; Moderately active means a lifestyle that includes physical activity equivalent to walking about 1.5 to 3 miles per day at 3 to 4 miles per hour, in addition to the light physical activity associated with typical day-to-day life.<br />&Delta; Data published in 2014 suggests that estimates for energy requirements of active preschool-aged children are too high. This is because new data suggests that physical activity levels for this age group are narrower than previously thought.<sup>[2]</sup></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>​Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington (DC): The National Academies Press; 2002. </LI>&#xD;&#xA;<LI>Butte NF, et al. Revision of dietary reference intakes for energy in preschool-aged children. Am J Clin Nutr 2014; 100:161.</LI></OL>Table data from: U.S. Department of Health and Human Services and U.S. Department of Agriculture.2015 – 2020 Dietary Guidelines for Americans. 8th&nbsp;Edition. December 2015, appendix 2. Available at: http://health.gov/dietaryguidelines/2015/guidelines/</div><div id=\"graphicVersion\">Graphic 80428 Version 4.0</div></div></div>"},"80429":{"type":"graphic_picture","displayName":"Intralesional steroid injection","title":"Intralesional corticosteroids","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intralesional corticosteroids</div><div class=\"cntnt\"><img style=\"width:432px; height:343px;\" src=\"images/PC/80429_Intralesional_steroid_injec.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Triamcinolone is injected into the upper subcutis&nbsp;of the scalp in areas affected by alopecia areata.</div><div class=\"graphic_reference\">Courtesy of Andrew G Messenger, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 80429 Version 3.0</div></div></div>"},"80431":{"type":"graphic_table","displayName":"General ways to save your energy PI","title":"General ways to save your energy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">General ways to save your energy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Planning and organizing</td> </tr> <tr> <td>Switch between tasks that take a lot of energy and those that take less energy.</td> </tr> <tr> <td>Try to plan ahead so that you aren't doing too many things that take a lot of energy every day or week.</td> </tr> <tr> <td>Have others help you as much as possible. It helps you get tasks done, and it makes those who want to help feel useful.</td> </tr> <tr> <td>Combine chores or errands to lower the number of tasks you need to do.</td> </tr> <tr> <td>Arrange your household so that most activities can be done on 1 floor.</td> </tr> <tr> <td>Organize ahead of time so that you don't have to rush.</td> </tr> <tr> <td class=\"subtitle1_single\">Pacing</td> </tr> <tr> <td>Be sure to get enough rest. Try to rest in between activities. You can also stop to rest before you get tired, even if it means stopping in the middle of a task.</td> </tr> <tr> <td>Try to avoid bursts of activity, because they can drain your energy.</td> </tr> <tr> <td>Follow a routine and pace your activities on good days as well as bad days.</td> </tr> <tr> <td class=\"subtitle1_single\">Positioning</td> </tr> <tr> <td>Sit to do things when possible.</td> </tr> <tr> <td>Use assistive devices, which are devices that can help you do things without bending, reaching, or using too much energy. Assistive devices include walkers, scooters, canes, handrails, crutches, and grab bars.</td> </tr> <tr> <td>Avoid heavy lifting (such as children, pots and pans, and laundry).</td> </tr> <tr> <td>Use carts or wagons to move things from room to room and place to place.</td> </tr> <tr> <td>Wear a fanny pack, carpenter's belt, jacket, or sweater with pockets to carry things.</td> </tr> <tr> <td class=\"subtitle1_single\">Prioritizing</td> </tr> <tr> <td>Focus on things you enjoy doing.</td> </tr> <tr> <td>Be realistic with yourself.</td> </tr> <tr> <td class=\"subtitle1_single\">When you're too tired to eat or shop for groceries</td> </tr> <tr> <td>Let others help prepare or bring food. Family or friends usually like to help!</td> </tr> <tr> <td>Shop at less busy times.</td> </tr> <tr> <td class=\"subtitle1_single\">Meal preparation</td> </tr> <tr> <td>Have all your ingredients on hand before you prepare a meal.</td> </tr> <tr> <td>Use mixes or pre-packaged foods.</td> </tr> <tr> <td>Use cookware that you can serve from.</td> </tr> <tr> <td>Use small, lightweight appliances.</td> </tr> <tr> <td>Buy utensils that fit comfortably in your hand.</td> </tr> <tr> <td>Store items that you use a lot at chest level so that you don't have to bend and reach.</td> </tr> <tr> <td>Line ovens and drip pans with foil for easier cleanup.</td> </tr> <tr> <td>Let dishes air dry or use a dishwasher.</td> </tr> <tr> <td class=\"subtitle1_single\">Childcare</td> </tr> <tr> <td>Plan activities or outings at places where you can sit or lie down.</td> </tr> <tr> <td>Use daycare programs.</td> </tr> <tr> <td>Have your children help with household chores by making a game out of the chores.</td> </tr> <tr> <td class=\"subtitle1_single\">Work</td> </tr> <tr> <td>Plan work around your best times of the day.</td> </tr> <tr> <td>Organize work areas so that your equipment is within easy reach.</td> </tr> <tr> <td>Take rest breaks.</td> </tr> <tr> <td>Work part time, if possible.</td> </tr> <tr> <td class=\"subtitle1_single\">Leisure</td> </tr> <tr> <td>Plan activities that allow you to sit or lie down.</td> </tr> <tr> <td>Plan social events for times of the day when you have the most energy.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80431 Version 2.0</div></div></div>"},"80434":{"type":"graphic_table","displayName":"Antiseizure drugs in children part II","title":"Oral drug maintenance therapy for seizures in children (continued)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral drug maintenance therapy for seizures in children (continued)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Drug</td> <td class=\"subtitle1\" colspan=\"3\">Dose*</td> <td class=\"subtitle1\" rowspan=\"2\">Blood level</td> <td class=\"subtitle1\" rowspan=\"2\">Laboratory<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2\">Starting</td> <td class=\"subtitle2\">Maintenance</td> <td class=\"subtitle2\">Frequency</td> </tr> <tr class=\"divider_bottom\"> <td>Oxcarbazepine</td> <td>8 to 10 mg/kg/day (maximum 600 mg/day)</td> <td>30 to 40 mg/kg/day (maximum 2400 mg/day as monotherapy)</td> <td>Dosed three times daily (for IR in children &#60;5 years) or twice daily (for school-aged children) or once daily (for ER)</td> <td>Not well established; 8-35 mcg/mL has been proposed</td> <td> <p>HLA-B*1502 screening before starting if of Asian descent; CBC/plts every 3 months for first 6 months.</p> <p>Serum sodium prior to initiation, at maintenance dose, and as needed in patients at risk for, or&nbsp;with symptoms of, hyponatremia.</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Phenytoin</td> <td>5 mg/kg/day (maximum 300 mg/day)</td> <td>4 to 8 mg/kg/day (300 mg/day for older children, adolescents; maximum 600 mg/day)</td> <td>Dosed three times daily (for IR) or once to twice daily (for ER)</td> <td>10-20 mcg/mL (40-80 micromol/L)</td> <td>Routine lab tests not recommended</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Phenobarbital</td> <td class=\"divider_bottom\" rowspan=\"2\">3 to 4 mg/kg/day</td> <td>Infants: 5 to 6 mg/kg/day</td> <td class=\"divider_bottom\" rowspan=\"2\">Dosed once or twice daily</td> <td class=\"divider_bottom\" rowspan=\"2\">10-40 mcg/mL (43-172 micromol/L)</td> <td class=\"divider_bottom\" rowspan=\"2\">Routine lab tests not recommended</td> </tr> <tr class=\"divider_bottom\"> <td>Children 1-5 years: 6 to 8 mg/kg/day</td> </tr> <tr class=\"divider_bottom\"> <td>Primidone</td> <td>1 to 2 mg/kg/day (maximum 125 mg/day)</td> <td>10 to 25 mg/kg/day (maximum 2000 mg/day)</td> <td>Starting dose given at bedtime; maintenance dose in 3-4 divided doses</td> <td>5-12 mcg/mL (23-55 micromol/L) (monitor both primidone and phenobarbital level, which is 1.2 times higher)</td> <td>Routine lab tests not recommended</td> </tr> <tr class=\"divider_bottom\"> <td>Rufinamide</td> <td>10 mg/kg/day (maximum 400 mg/day)</td> <td>45 mg/kg/day (maximum 3200 mg/day)</td> <td>Dosed twice daily</td> <td>Not well established; 3-30 mcg/mL has been proposed</td> <td>Routine lab tests not recommended</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Tiagabine<sup>&#916;</sup> (doses based on combination with enzyme-inducing AED)</td> <td>&#60;12 years: 0.25 mg/kg/day (maximum 4 mg/day)</td> <td>Weekly increase 0.5 to 1 mg/kg/day with maximum 4 to 8 mg/kg/day</td> <td>Dosed three to four times daily</td> <td class=\"divider_bottom\" rowspan=\"2\">Not useful</td> <td class=\"divider_bottom\" rowspan=\"2\">Routine lab tests not recommended</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;12 years: 4 mg/day</td> <td>&#8805;12 years: Increase 4 mg/week to maximum 32 mg/day</td> <td>Dosed two to four times daily</td> </tr> <tr class=\"divider_bottom\"> <td>Topiramate</td> <td>1 to 3 mg/kg/day (maximum 25 mg/day)</td> <td>5 to 9 mg/kg/day (usual maximum 500 mg/day; higher doses in adults have not provided added benefit)</td> <td>Dosed twice daily (for IR) or once daily (for ER)</td> <td>5-20 mcg/mL (15-59 micromol/L)&nbsp;</td> <td>Serum electrolytes, CBC/plts, and hepatic transaminases when maximum dose reached or at 3-6 months</td> </tr> <tr class=\"divider_bottom\"> <td>Valproate</td> <td>10 to 15 mg/kg/day</td> <td>30 to 60 mg/kg/day</td> <td>Dosed three times daily (for IR), twice daily (for enteric coated), or once daily (for ER)</td> <td>50-150 mcg/mL (346-1040 micromol/L)</td> <td> <p>VPA level 1-2 weeks after initial dose; hepatic transaminases every 1-2 months.</p> Recommendations for baseline metabolic screening if used in children &#60;3 years are provided in accompanying text.</td> </tr> <tr> <td>Zonisamide</td> <td>1 to 2 mg/kg/day (maximum 100 mg/day)</td> <td>5 to 8 mg/kg/day (usual maximum 500 mg/day; higher doses in adults have not provided added benefit)</td> <td>Dosed once or twice daily</td> <td>Not well established; 10-20 mcg/mL has been proposed</td> <td>Serum electrolytes at&nbsp;baseline and&nbsp;when maximum dose is reached or at 3-6 months</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Usual range of initial and maintenance doses of antiepileptic drugs (AEDs) in children with seizures (continued). Dose adjustment and additional monitoring may be needed when therapy is altered (particularly in combination regimens including enzyme-inducing AEDs or valproate) and in children with organ dysfunction. Refer to accompanying text and Lexicomp pediatric drug-specific monographs included within UpToDate.</div><div class=\"graphic_footnotes\">IR: immediate release; ER: extended release; CBC: complete blood count; plts: platelets; AED: antiepileptic drug; VPA: valproate.<br />*&nbsp;In general, the pediatric dose should not exceed the higher end of the adult dose range (shown in parentheses as the maximum dose). On a milligram per kilogram basis, doses of some of the antiepileptic drugs needed to obtain a similar blood concentration in children are greater than those for adolescents and adults.<br />¶ Additional laboratory monitoring recommendations may be contained in the approved product information in some countries; consult local product information.<br />Δ&nbsp;Tiagabine dose recommendations are based on US available product and limited experience in children &lt;12 years old. Tiagabine preparations available in countries other than the US are labeled differently and recommendations may not be comparable; consult local product information.</div><div id=\"graphicVersion\">Graphic 80434 Version 6.0</div></div></div>"},"80437":{"type":"graphic_picture","displayName":"Iliac aneurysm repair with iliac branched endograft","title":"Iliac aneurysm repair with iliac branched endograft","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Iliac aneurysm repair with iliac branched endograft</div><div class=\"cntnt\"><img style=\"width:432px; height:432px;\" src=\"images/SURG/80437_Iliac_aneu_rep_bran_endogr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Common iliac artery aneurysm repair with an iliac branched endograft device (Zenith&#174;). The endograft extends into the internal and external iliac arteries.</div><div id=\"graphicVersion\">Graphic 80437 Version 1.0</div></div></div>"},"80439":{"type":"graphic_diagnosticimage","displayName":"Pulmonary embolism IE","title":"Chest radiograph of a patient with tricuspid valve endocarditis due to <EM>Staphylococcus aureus</EM>","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of a patient with tricuspid valve endocarditis due to <EM>Staphylococcus aureus</EM></div><div class=\"cntnt\"><img style=\"width:504px; height:413px;\" src=\"images/ID/80439_Pulmonary_embolism_IE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note multiple cavitating lung nodules due to septic pulmonary emboli.</div><div class=\"graphic_reference\">Courtesy of Phillip Goodman, MD. Duke University Medical Center.</div><div id=\"graphicVersion\">Graphic 80439 Version 3.0</div></div></div>"},"80441":{"type":"graphic_waveform","displayName":"ECG peaked T waves in hyperkalemia","title":"ECG showing peaked T waves in hyperkalemia","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">ECG showing peaked T waves in hyperkalemia</div><div class=\"cntnt\"><img style=\"width:505px; height:125px;\" src=\"images/CARD/80441_Peaked_T_waves_hyperkalemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A tall peaked and symmetrical T wave is the first change seen on the electrocardiogram (ECG) in a patient with hyperkalemia.</div><div id=\"graphicVersion\">Graphic 80441 Version 5.0</div></div></div>"},"80443":{"type":"graphic_algorithm","displayName":"Compensated cirrhosis","title":"Pathogenic mechanisms of compensated cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathogenic mechanisms of compensated cirrhosis</div><div class=\"cntnt\"><img style=\"width:427px; height:466px;\" src=\"images/GAST/80443_Compensated_cirrhosis.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 80443 Version 2.0</div></div></div>"},"80445":{"type":"graphic_diagnosticimage","displayName":"Parapneumonic effusion CT","title":"Parapneumonic effusion chest CT scan","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parapneumonic effusion chest CT scan</div><div class=\"cntnt\"><img style=\"width:360px; height:251px;\" src=\"images/PULM/80445_Parapneumonic_effusion_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan showing a loculated parapneumonic effusion (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Charlie Strange, MD.</div><div id=\"graphicVersion\">Graphic 80445 Version 4.0</div></div></div>"},"80447":{"type":"graphic_picture","displayName":"Triatoma","title":"<em>Triatoma sanguisuga</em> or kissing bug","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Triatoma sanguisuga</em> or kissing bug</div><div class=\"cntnt\"><img style=\"width:235px; height:382px;\" src=\"images/ALLRG/80447_Triatoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Moffitt JE, Venarske D, Goddard J, et al. Allergic reactions to Triatoma bites. Ann Allergy Asthma Immunol 2003; 91:122. Copyright ©2003 American College of Allergy, Asthma, and Immunology.</div><div id=\"graphicVersion\">Graphic 80447 Version 3.0</div></div></div>"},"80448":{"type":"graphic_movie","displayName":"TTE two ASDs","title":"Transthoracic echocardiogram with color Doppler showing two atrial septal defects","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transthoracic echocardiogram with color Doppler showing two atrial septal defects</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/80448_asdcdop2conv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:273px; height:236px;\" src=\"images/CARD/80448_asdcdop2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two-dimensional echocardiogram (parasternal short axis view at the level of the aortic valve) with color flow Doppler shows significant left to right atrial flow through two atrial septal defects.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 80448 Version 5.0</div></div></div>"},"80450":{"type":"graphic_picture","displayName":"Achondroplasia","title":"Achondroplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Achondroplasia</div><div class=\"cntnt\"><img style=\"width:202px; height:421px;\" src=\"images/PEDS/80450_Achondroplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three-month-old infant with achondroplasia. Note the large head, short extremities, and protruding abdomen.</div><div class=\"graphic_reference\">Reproduced with permission from: Sadler T, PhD. Langman's Medical Embryology, Ninth Edition Image Bank. Baltimore: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169;2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80450 Version 1.0</div></div></div>"},"80452":{"type":"graphic_picture","displayName":"Hypertrophic osteoarthropathy 1","title":"Hypertrophic osteoarthropathy - digital clubbing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypertrophic osteoarthropathy - digital clubbing</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/80452_Hypertrophic_osteoarthr_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bulbous swelling of the distal phalanx of the finger with increased nail curvature is present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 80452 Version 4.0</div></div></div>"},"80453":{"type":"graphic_diagnosticimage","displayName":"SMA syndrome ultrasound","title":"Ultrasound in superior mesenteric artery syndrome","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Ultrasound in superior mesenteric artery syndrome</div><div class=\"cntnt\"><img style=\"width:543px; height:416px;\" src=\"images/SURG/80453_SMA_syndrome_ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal ultrasonography image shows SMA-aortic angle of 12° (white constructed angle). A normal angle should be between 38 and 65°.<BR>Inset: Transverse ultrasonography image showing SMA-aorta distance of 4.4 mm.</div><div class=\"graphic_footnotes\">SMA: superior mesenteric artery; COELA: celiac artery.</div><div class=\"graphic_reference\">Reproduced with permission from: Saha SB, Mandal A, Deoghuria D. Superior mesenteric artery syndrome: an unusual cause of duodenal obstruction--a case report and literature review. Jurnalul de Chirurgie, Iasi [ISSN: 1584-9341] 2009; 5(2):172-174. Copyright &copy; 2009.</div><div id=\"graphicVersion\">Graphic 80453 Version 2.0</div></div></div>"},"80454":{"type":"graphic_waveform","displayName":"ECG Ventricular fibrillation tutorial","title":"Single lead electrocardiogram (ECG) showing ventricular fibrillation","html":"<div class=\"graphic normal\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Single lead electrocardiogram (ECG) showing ventricular fibrillation</div><div class=\"cntnt\"><img style=\"width:460px; height:121px;\" src=\"images/CARD/80454_Ventric_fibrillation_tutori.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is a complete absence of properly formed QRS complexes and no obvious P waves. A recent onset (eg, within minutes) of the arrhythmia is suggested by the coarse morphology of the fibrillatory waves.</div><div id=\"graphicVersion\">Graphic 80454 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"80455":{"type":"graphic_algorithm","displayName":"Pathways of fever production","title":"Pathways of fever production","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Pathways of fever production</div><div class=\"cntnt\"><img style=\"width:522px; height:443px;\" src=\"images/ID/80455_Pathwaysfeverprodedt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Starting from the top left, infectious agents and/or microbial products, as well as cytokines and other inflammatory processes, induce macrophages, endothelial cells, and the reticuloendothelial system to produce and secrete pyrogenic cytokines into the circulation. These pyrogenic cytokines induce the synthesis of PGE2 in the hypothalamus. In addition, microbial toxins, acting as ligands to the toll-like receptors in the hypothalamus, stimulate the synthesis of PGE2 by the hypothalamus. PGE2 raises the thermostatic set point in the hypothalamus to febrile levels. The vasomotor center sends signals for heat conservation (vasoconstriction) and heat production (shivering). Corticosteroids reduce the peripheral synthesis of pyrogenic cytokines, whereas antipyretics reduce PGE2 levels in the brain.</div><div class=\"graphic_footnotes\">TLR: toll-like receptor; IL-1: interleukin-1; IL-6: interleukin-6; TNF: tumor necrosis factor; IFN: interferon; PGE2: prostaglandin E2.</div><div class=\"graphic_reference\">Courtesy of Reuven Porat, MD, and Charles A Dinarello, MD.</div><div id=\"graphicVersion\">Graphic 80455 Version 4.0</div></div></div>"},"80456":{"type":"graphic_table","displayName":"Pharmacotherapy ASD","title":"Selected pharmacotherapeutic agents used for symptom management in children and adolescents with autism spectrum disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected pharmacotherapeutic agents used for symptom management in children and adolescents with autism spectrum disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Targeted symptom(s)</td> <td class=\"subtitle1\">Potential adverse effects</td> </tr> <tr> <td><strong>Atypical antipsychotic agents</strong> (eg, risperidone*, aripiprazole*, olanzapine)</td> <td> <p>Aggression</p> <p>Hyperactivity/inattention</p> <p>Repetitive behavior</p> <p>Sleep disturbance</p> </td> <td> <p>Weight gain</p> <p>Metabolic syndrome</p> <p>Tremor</p> <p>Extrapyramidal symptoms</p> <p>Increased salivation</p> <p>Sedation</p> </td> </tr> <tr> <td><strong>Stimulants</strong> (eg, methylphenidate, dextroamphetamine, dexmethylphenidate)</td> <td>Hyperactivity/inattention/impulsivity</td> <td> <p>Decreased appetite</p> <p>Difficulty falling asleep</p> <p>Irritability</p> <p>Social withdrawal</p> </td> </tr> <tr> <td><strong>Selective serotonin reuptake inhibitors</strong> (eg, fluoxetine, fluvoxamine, sertraline, paroxetine, etc)</td> <td> <p>Aggression</p> <p>Anxiety</p> <p>Depression</p> <p>Repetitive behavior</p> </td> <td> <p>Potential increased risk of suicidal ideation</p> <p>Behavioral activation</p> <p>Irritability</p> </td> </tr> <tr> <td><strong>Alpha-2-adrenergic agonists</strong> (eg, guanfacine, clonidine)</td> <td> <p>Aggression</p> <p>Hyperactivity/inattention</p> <p>Sleep disturbance</p> </td> <td> <p>Sedation</p> <p>Fatigue</p> <p>Irritability</p> <p>Constipation</p> <p>Hypotension</p> <p>Rebound hypertension if discontinued abruptly</p> </td> </tr> <tr> <td><strong>Anticonvulsant mood stabilizers</strong> (eg, valproic acid)</td> <td> <p>Aggression</p> <p>Hyperactivity/inattention</p> <p>Repetitive behaviors</p> <p>Sleep disturbance</p> </td> <td> <p>Mood lability</p> <p>Fatigue</p> <p>Insomnia</p> <p>Diarrhea</p> <p>Weight gain</p> <p>Increased appetite</p> </td> </tr> <tr> <td><strong>Atomoxetine</strong></td> <td>Hyperactivity/inattention</td> <td> <p>Potential increased risk of suicidal ideation</p> <p>Irritability</p> <p>Gastrointestinal symptoms</p> <p>Fatigue</p> </td> </tr> <tr> <td><strong>Melatonin</strong></td> <td>Sleep disturbance</td> <td> <p>Difficulty waking</p> <p>Daytime sleepiness</p> <p>Enuresis</p> </td> </tr> <tr> <td><strong>Mood stabilizer</strong> (eg, lithium)</td> <td>Aggression</td> <td> <p>Weight gain</p> <p>Nausea</p> <p>Frequent urination</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Approved by the&nbsp;US Food and Drug Administration for the treatment of aggression and irritability in children with autism spectrum disorders.</div><div class=\"graphic_reference\">Data from:<br> <ol> <li>Hollander E, Phillips AT, Yeh CC. Targeted treatments for symptom domains in child and adolescent autism. Lancet 2003; 362:732. </li> <li>Myers SM, Johnson CP, American Academy of Pediatrics Council on Children with Disabilities. Management of children with autism spectrum disorders. Pediatrics 2007; 120:1162. </li> <li>Leskovec TJ, Rowles BM, Findling RL. Pharmacological treatment options for autism spectrum disorders in children and adolescents. Harv Rev Psychiatry 2008; 16:97. </li> </ol></div><div id=\"graphicVersion\">Graphic 80456 Version 4.0</div></div></div>"},"80458":{"type":"graphic_table","displayName":"Noninvasive methods for arrhythmia risk stratification after MI","title":"Incidence of sustained ventricular arrythmias or sudden cardiac death in patients after myocardial infarction (MI)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of sustained ventricular arrythmias or sudden cardiac death in patients after myocardial infarction (MI)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Test</td> <td class=\"subtitle1\" colspan=\"2\">Percent adverse outcome</td> </tr> <tr> <td class=\"subtitle2\">For normal test results</td> <td class=\"subtitle2\">For abnormal test results</td> </tr> <tr> <td>Holter monitor</td> <td>7 to 9</td> <td>14 to 23</td> </tr> <tr> <td>LV ejection fraction</td> <td>5 to 6</td> <td>16 to 24</td> </tr> <tr> <td>Signal-averaged ECG</td> <td>1 to 3</td> <td>17 to 29</td> </tr> <tr> <td>Programmed stimulation</td> <td>0 to 4</td> <td>12 to 32</td> </tr> <tr> <td>Heart rate variability</td> <td>1 to 23</td> <td>16 to 17</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LV: left ventricular; ECG: electrocardiogram.</div><div class=\"graphic_reference\">Adapted from: Cain ME, Anderson JL, Arnsdorf MF, et al. Signal-averaged electrocardiography. J Am Coll Cardiol 1996; 27:238.</div><div id=\"graphicVersion\">Graphic 80458 Version 5.0</div></div></div>"},"80459":{"type":"graphic_picture","displayName":"Skin biopsy MCTD IF","title":"Skin lesion in mixed connective tissue disease (MCTD)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin lesion in mixed connective tissue disease (MCTD)</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/RHEUM/80459_Skin_biopsy_MCTD_IF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Indirect immunofluorescence microscopy for Cb5-9 from a skin lesion in mixed connective tissue disease, showing granular nuclear staining in the epidermis.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 80459 Version 2.0</div></div></div>"},"80460":{"type":"graphic_picture","displayName":"Contact lens-associated fungal keratitis","title":"Contact lens-associated fungal keratitis","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Contact lens-associated fungal keratitis</div><div class=\"cntnt\"><img style=\"width:514px; height:175px;\" src=\"images/ID/80460_Contact_lens_fungal_kerat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fungal keratitis in a 30-year-old female who wore daily disposable soft contact lenses.<br> (A) The central corneal infiltrate progressed dispite intensive antifungal therapy.<br> (B) A central 7 mm corneal transplant (penetrating keratoplasty) was performed 8 days after diagnosis to control the fungal infection.</div><div class=\"graphic_reference\">Reproduced with permission from: Jurkunas U, Behlau I, Colby K. Fungal keratitis: Changing pathogens and risk factors. Cornea 2009; 28:638. Copyright © 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80460 Version 9.0</div></div></div>"},"80461":{"type":"graphic_algorithm","displayName":"Eval of pituitary incidentaloma","title":"Approach to the patient with an incidental signal abnormality on MRI of the pituitary gland","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Approach to the patient with an incidental signal abnormality on MRI of the pituitary gland</div><div class=\"cntnt\"><img style=\"width:472px; height:302px;\" src=\"images/ENDO/80461_Eval_of_pituitary_incidenta.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 80461 Version 3.0</div></div></div>"},"80462":{"type":"graphic_picture","displayName":"Cutaneous necrosis warfarin","title":"Cutaneous necrosis: warfarin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous necrosis: warfarin</div><div class=\"cntnt\"><img style=\"width:351px; height:264px;\" src=\"images/HEME/80462_Cutaneous_necrosis_warfarin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral areas of cutaneous infarction with purple-to-black coloration of both breasts, surrounded by an area of erythema, occurred on the fifth day of warfarin therapy.</div><div class=\"graphic_reference\">Reproduced with permission from: Fitzpatrick, TB, Johnson, AB, Wolff, K, Suurmond, D. Color Atlas and Synopsis of Clinical Dermatology: Common and Serious Diseases, 4th edition. McGraw-Hill, New York 2001. Copyright &#169; 2001 The McGraw-Hill Companies.</div><div id=\"graphicVersion\">Graphic 80462 Version 1.0</div></div></div>"},"80464":{"type":"graphic_table","displayName":"Benign EEG variants","title":"Benign EEG variants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Benign EEG variants</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle1\">\r\n \r\n &nbsp;\r\n \r\n </td>\r\n \r\n <td class=\"subtitle1\">\r\n \r\n Patient: age / state\r\n \r\n </td>\r\n \r\n <td class=\"subtitle1\">\r\n \r\n Waveform: morphology / frequency\r\n \r\n </td>\r\n \r\n <td class=\"subtitle1\">\r\n \r\n Duration\r\n \r\n </td>\r\n \r\n <td class=\"subtitle1\">\r\n \r\n Distribution\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle2_left\" colspan=\"5\">\r\n \r\n Benign spike-like patterns\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent1\">\r\n \r\n Small sharp spikes\r\n \r\n </td>\r\n \r\n <td>Adults / drowsiness and light sleep</td>\r\n \r\n <td>Monophasic or diphasic spikes</td>\r\n \r\n <td>Phase &#60;50 msecs</td>\r\n \r\n <td>Bi-hemispheric maximal-anterior / mid temporal</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent1\">\r\n \r\n Wicket spikes\r\n \r\n </td>\r\n \r\n <td>Adults / drowsiness and light sleep</td>\r\n \r\n <td>Sharply contoured arch shaped / 6 to 11 Hz</td>\r\n \r\n <td>Few seconds</td>\r\n \r\n <td>Bilateral anterior / mid temporal</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent1\">\r\n \r\n 14- and 6-Hz positive bursts\r\n \r\n </td>\r\n \r\n <td>Children and adolescents / drowsiness and light sleep</td>\r\n \r\n <td>Arch shaped positive sharp component / 4-7 Hz and 13-17 Hz range</td>\r\n \r\n <td>Less than 1 to 2 seconds</td>\r\n \r\n <td>Bilateral posterior temporal / parietal</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent1\">\r\n \r\n 6 Hz spike and wave\r\n \r\n </td>\r\n \r\n <td>Adolescents and young adults / relaxed wakefulness and drowsiness</td>\r\n \r\n <td>\r\n \r\n Low voltage spike-high amplitude slow wave / 5 to 7 Hz\r\n \r\n </td>\r\n \r\n <td>\r\n \r\n 1 to 2 seconds\r\n \r\n </td>\r\n \r\n <td>Generalized / at times maximal anterior or posterior</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle2_left\" colspan=\"5\">\r\n \r\n Rhythmic patterns with an epileptiform morphology\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent1\">\r\n \r\n Rhythmic temporal theta bursts of drowsiness\r\n \r\n </td>\r\n \r\n <td>Adolescents and young adults / relaxed wakefulness and drowsiness</td>\r\n \r\n <td>Notched flat topped / 5 to 7 Hz</td>\r\n \r\n <td>Seconds</td>\r\n \r\n <td>Bilateral temporal</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent1\">\r\n \r\n Subclinical rhythmic EEG discharge in adults\r\n \r\n </td>\r\n \r\n <td>Adults &#62;50 / hyperventilation, drowsiness</td>\r\n \r\n <td>Rhythmic sharply contoured / 5 to 6 Hz</td>\r\n \r\n <td>40 to 80 seconds</td>\r\n \r\n <td>Bilateral parietal / posterior temporal</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent1\">\r\n \r\n Midline theta rhythm\r\n \r\n </td>\r\n \r\n <td>Children and adults / awake, drowsy</td>\r\n \r\n <td>Sinusoidal, arciform / 5 to 7 Hz</td>\r\n \r\n <td>4 to 20 seconds</td>\r\n \r\n <td>Midline, maximal centrally</td>\r\n \r\n </tr>\r\n </table></div><div class=\"graphic_reference\">Reproduced with permission from: Mushtaq, R, Van Cott, AC, Benign EEG variants. Am J Electroneurodiagnostic Technol 2005; 45:88. Copyright &#169;2005 American Society of Electroneurodiagnostic Technologists.</div><div id=\"graphicVersion\">Graphic 80464 Version 1.0</div></div></div>"},"80466":{"type":"graphic_table","displayName":"Gell and Coombs classification of immunologic drug reactions","title":"Gell and Coombs classification of immunologic drug reactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gell and Coombs classification of immunologic drug reactions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Mechanism</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr class=\"divider_bottom\"> <td> <p>I</p> Immediate reaction (within one hour)</td> <td>IgE-mediated, immediate-type hypersensitivity</td> <td>Antigen exposure causes IgE-mediated activation of mast cells and basophils, with release of vasoactive substances, such as histamine, prostaglandins, and leukotrienes.</td> <td> <p>Anaphylaxis</p> <p>Angioedema</p> <p>Bronchospasm</p> <p>Urticaria (hives)</p> <p>Hypotension</p> </td> </tr> <tr class=\"divider_bottom\"> <td>II</td> <td>Antibody-dependent cytotoxicity</td> <td>An antigen or hapten that is intimately associated with a cell binds to antibody, leading to cell or tissue injury.</td> <td> <p>Hemolytic anemia</p> <p>Thrombocytopenia</p> Neutropenia</td> </tr> <tr class=\"divider_bottom\"> <td>III</td> <td>Immune complex disease</td> <td>Damage is caused by formation or deposition of antigen-antibody complexes in vessels or tissue. Deposition of immune complexes causes complement activation and/or recruitment of neutrophils by interaction of immune complexes with Fc IgG receptors.</td> <td> <p>Serum sickness</p> Arthus reaction</td> </tr> <tr> <td>IV</td> <td>Cell-mediated or delayed hypersensitivity</td> <td>Antigen exposure activates T cells, which then mediate tissue injury. Depending upon the type of T cell activation and the other effector cells recruited, different subtypes can be differentiated (ie, types IVa to IVd).</td> <td> <p>Contact dermatitis</p> <p>Some morbilliform reactions</p> <p>Severe exfoliative dermatoses (eg, SJS/TEN)</p> <p>AGEP </p> <p>DRESS/DiHS</p> <p>Interstitial nephritis</p> <p>Drug-induced hepatitis</p> <p>Other presentations</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E; Fc IgG: Fc portion of immunoglobulin G; SJS/TEN: Stevens-Johnson syndrome/toxic epidermal necrolysis; AGEP: acute generalized exanthematous pustulosis; DRESS/DiHS: drug rash with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome.</div><div class=\"graphic_reference\">Adapted from: Weiss ME, Adkinson NF. Immediate hypersensitivity reactions to penicillin and related antibiotics. Clin Allergy 1988; 18:515.</div><div id=\"graphicVersion\">Graphic 80466 Version 18.0</div></div></div>"},"80469":{"type":"graphic_movie","displayName":"Left atrial myxoma long axis","title":"Left atrial myxoma","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left atrial myxoma</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/80469_laxmyxomconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:320px; height:240px;\" src=\"images/CARD/80469_laxmyxom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long axis view from a two-dimensional echocardiogram shows a large myxoma in the left atrium.</div><div class=\"graphic_reference\">Courtesy of Neil Weisman, MD.</div><div id=\"graphicVersion\">Graphic 80469 Version 2.0</div></div></div>"},"80471":{"type":"graphic_table","displayName":"Common causes of viral gastroenteritis children","title":"Epidemiologic and clinical features of common causes of acute viral gastroenteritis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Epidemiologic and clinical features of common causes of acute viral gastroenteritis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Virus</td> <td class=\"subtitle1\">Predominant season</td> <td class=\"subtitle1\">Incubation period</td> <td class=\"subtitle1\">Common modes of transmission in order of frequency</td> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Duration</td> <td class=\"subtitle1\">Lactose intolerance</td> <td class=\"subtitle1\">Other features</td> </tr> <tr class=\"divider_bottom\"> <td>Rotavirus</td> <td>Fall/winter</td> <td>1 to 3 days</td> <td> <ul> <li>Fecal-oral </li> <li>Respiratory? </li> </ul> </td> <td>6 to 24 months</td> <td>5 to 7 days</td> <td>Yes</td> <td> <ul> <li>Causes severe childhood diarrhea </li> <li>Endemic; season broadened by mass immunization </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Norovirus</td> <td>All year (winter)</td> <td>12 to 48 hours</td> <td> <ul> <li>Fecal-oral </li> <li>Water </li> <li>Shellfish </li> <li>Other foods </li> <li>Respiratory? </li> </ul> </td> <td>All ages</td> <td>1 to 4 days</td> <td>No</td> <td> <ul> <li>Vomiting is prominent symptom </li> <li>Causes most outbreaks of nonbacterial gastroenteritis </li> <li>Endemic and epidemic </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Sapovirus</td> <td>All year</td> <td>1 to 2 days</td> <td> <ul> <li>Fecal-oral </li> </ul> </td> <td>Infants and toddlers</td> <td>3 to 4 days</td> <td>&nbsp;</td> <td> <ul> <li>Endemic and epidemic </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Astrovirus</td> <td>Winter</td> <td>4 to 5 days</td> <td> <ul> <li>Fecal-oral </li> <li>Water </li> </ul> </td> <td>All ages</td> <td>5 to 6 days</td> <td>Yes</td> <td> <ul> <li>Endemic and epidemic </li> </ul> </td> </tr> <tr> <td>Enteric adenovirus (types 40 and 41)</td> <td>Summer</td> <td>3 to 10 days</td> <td> <ul> <li>Fecal-oral </li> </ul> </td> <td>Children</td> <td>6 to 9 days</td> <td>Yes</td> <td> <ul> <li>Endemic </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Dennehy PH. Viral gastroenteritis in children. Pediatr Infect Dis J 2011; 30:63.</li>&#xD;&#xA;    <li>Lee RM, Lessler J, Lee RA, et al. Incubation periods of viral gastroenteritis: A systematic review. BMC Infect Dis 2013; 13:446.</li>&#xD;&#xA;    <li>Public Health Agency of Canada. Adenovirus (serotypes 40 &amp; 41). Available at: <a href=\"http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/adenovirus-eng.php\" target=\"_blank\">www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/adenovirus-eng.php</a> (Accessed on August 5, 2015).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 80471 Version 5.0</div></div></div>"},"80472":{"type":"graphic_figure","displayName":"Yield of repeat screening","title":"The decreasing yield of a screening test after the first round of screening","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The decreasing yield of a screening test after the first round of screening</div><div class=\"cntnt\"><img style=\"width:415px; height:530px;\" src=\"images/PC/80472_Yieldofrepeatscreening.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The first round (prevalence screening) detects prevalent cases. The second and third rounds (incidence screenings) detect incident cases. In this figure, it is assumed that the test detects all cases and that all people in the population are screened. When this is not so, cases missed in the first round are available for detection in subsequent rounds - and the yield would be higher.</div><div class=\"graphic_footnotes\">O: onset of disease; Dx: diagnosis time, if screening were not carried out.</div><div class=\"graphic_reference\">Reproduced with permission from: Fletcher RH, Fletcher SW, Fletcher GS. Clinical Epidemiology: The Essentials, 5th Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 80472 Version 11.0</div></div></div>"},"80473":{"type":"graphic_figure","displayName":"Mortality diabetes in HF","title":"Cumulative mortality from all causes in patients with heart failure with and without diabetes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cumulative mortality from all causes in patients with heart failure with and without diabetes</div><div class=\"cntnt\"><img style=\"width:318px; height:349px;\" src=\"images/CARD/80473_Mortality_diabetes_in_HF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of diabetes on HF mortality. In the DIAMOND-CHF trial of 5491 patients with heart failure (HF), 900 (16 percent) had diabetes mellitus. Mortality for patients with diabetes was significantly higher than for those without diabetes (31 versus 23 percent at one year, adjusted risk ratio 1.5, 95% CI 1.3 to 1.6).</div><div class=\"graphic_footnotes\">+DM: diabetic patients; -DM: non-diabetic patients.</div><div class=\"graphic_reference\">Reproduced with permission from: Gustafsson I, Brendorp B, Seibaek M, et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 2004; 43:771. Copyright © 2004 American College of Cardiology Foundation.</div><div id=\"graphicVersion\">Graphic 80473 Version 2.0</div></div></div>"},"80475":{"type":"graphic_table","displayName":"Occupational asthma vs RADS","title":"Comparison of occupational asthma with a latency period and reactive airways dysfunction syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of occupational asthma with a latency period and reactive airways dysfunction syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Occupational asthma with a latency period</td> <td class=\"subtitle1\">Reactive airways dysfunction syndrome and irritant-induced asthma</td> </tr> <tr> <td>Latency period</td> <td>Present</td> <td>Absent</td> </tr> <tr class=\"divider_top\"> <td>Diagnosis</td> <td>Various - eg, peak expiratory flow monitoring, specific inhalation challenges; IgE-mediated allergy if suspected agent is of a high-molecular-weight nature</td> <td>History; pulmonary function testing</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Pathology</td> <td rowspan=\"2\">Similar to asthma</td> <td>Acute: epithelial shedding and hemorrhage</td> </tr> <tr> <td>Chronic: regeneration of epithelial cells; few lymphocytes and neutrophils; increased collagen deposition and thickness of basement membrane</td> </tr> <tr class=\"divider_top\"> <td>Pulmonary function testing</td> <td>Better reversibility to bronchodilator</td> <td>Less reversibility to bronchodilator</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80475 Version 4.0</div></div></div>"},"80478":{"type":"graphic_figure","displayName":"Ultrasonogram diagram hip","title":"Ultrasonographic findings of the normal hip of an infant","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Ultrasonographic findings of the normal hip of an infant</div><div class=\"cntnt\"><img style=\"width:583px; height:398px;\" src=\"images/PEDS/80478_Ultrasonogram_diagram_hip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Diagrammatic representation of an ultrasonographic landmark of a normal right hip.<br />(B) Diagram demonstrating alpha and beta angles. The alpha angle is the angle formed by the ossified lateral wall of the ilium (line 1 above) and the bony roof line (line 3 above). The beta angle is the angle formed by the ossified lateral wall of the ilium (line 1 above) and the cartilaginous roof line (line 2 above).</div><div id=\"graphicVersion\">Graphic 80478 Version 3.0</div></div></div>"},"80481":{"type":"graphic_picture","displayName":"Severe atopic dermatitis 2","title":"Severe atopic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe atopic dermatitis</div><div class=\"cntnt\"><img style=\"width:380px; height:477px;\" src=\"images/DERM/80481_Severeatopicdermatitis2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Widespread, eczematous papules and plaques are present on the back of this adult with severe atopic dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80481 Version 2.0</div></div></div>"},"80482":{"type":"graphic_picture","displayName":"Meth mouth","title":"Meth mouth","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Meth mouth</div><div class=\"cntnt\"><img style=\"width:321px; height:453px;\" src=\"images/EM/80482_Meth_mouth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These photographs demonstrate the extensive tooth decay (&quot;meth-mouth&quot;) common in chronic methamphetamine abuse due to bruxism, decreased saliva production, and poor dental hygiene.</div><div class=\"graphic_reference\">Reproduced with permission from: Stephen Wagner DDS Albuquerque, NM.</div><div id=\"graphicVersion\">Graphic 80482 Version 2.0</div></div></div>"},"80483":{"type":"graphic_figure","displayName":"Diabetogenic genes","title":"Association of type 1 diabetes with diabetogenic genes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Association of type 1 diabetes with diabetogenic genes</div><div class=\"cntnt\"><img style=\"width:289px; height:262px;\" src=\"images/ENDO/80483_Diabetogenic_genes.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Direct correlation in different populations between the gene frequency of &quot;diabetogenic&quot; HLA-DQ&#946; genotypes (which lack aspartate at position 57 on the beta chain) and the predicted and observed incidence of type 1 diabetes mellitus (per 100,000 population).</div><div class=\"graphic_reference\">Data from: Dorman JS, LaPorte RE, Stone RA, Trucco M,&nbsp;Worldwide differences in the incidence of type I diabetes are associated with amino acid variation at position 57 of the HLA-DQ beta chain. Proc Natl Acad Sci USA 1990; 87:7370.</div><div id=\"graphicVersion\">Graphic 80483 Version 2.0</div></div></div>"},"80484":{"type":"graphic_table","displayName":"Fetal echogenic bowel outcome","title":"Adverse pregnancy outcomes with second trimester fetal echogenic bowel","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adverse pregnancy outcomes with second trimester fetal echogenic bowel</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td colspan=\"1\" class=\"subtitle1\">Outcome</td><td class=\"subtitle1\">Range reported in the literature, percent</td>\n</tr>\n<tr>\n<td>Chromosomal abnormalities</td>\n<td>4 to 25</td>\n</tr>\n<tr>\n<td>Fetal growth restriction*</td>\n<td>0 to 19</td>\n</tr>\n<tr>\n<td>Perinatal death*</td>\n<td>0 to 17</td>\n</tr>\n<tr>\n<td>Congenital infection</td>\n<td>0 to 10</td>\n</tr>\n<tr>\n<td>Cystic fibrosis</td>\n<td>0 to 5</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">* Excludes chromosomally abnormal fetuses.</div><div class=\"graphic_reference\">Adapted from: Sepulveda, W, Sebire, NJ. Ultrasound Obstet Gynecol 2000; 16:510.</div><div id=\"graphicVersion\">Graphic 80484 Version 2.0</div></div></div>"},"80485":{"type":"graphic_figure","displayName":"Radiosurg radiother","title":"Radiotherapy and radiosurgery","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Radiotherapy and radiosurgery</div><div class=\"cntnt\"><img style=\"width:545px; height:294px;\" src=\"images/ONC/80485_Radiosurg_radiother.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) In radiotherapy, radiation is delivered to both normal and cancer tissues. The therapeutic efficacy is derived from the increased DNA repair capacity of normal cells relative to tumor cells when repeatedly exposed to small doses of radiation. In the illustration, the dashed line represents the radiation field. The solid square represents the intracranial space. The striped circle represents the tumor volume. In this theoretical illustration, both the tumor and the normal tissue receive 2 Gy of ionization radiation. B) In radiosurgery, multiple, non-parallel radiation beams are converged on the tumor volume. The radiation received by the normal tissue in each beam path is minimal relative to the point of beam convergence. In this illustration, the dashed line represents the radiation field. The solid square represents the intracranial space. The striped circle represents the tumor volume. The tumor volume receives 8 Gy of radiation from four radiation sources while the surrounding tissues receive significantly lower doses of radiation.</div><div id=\"graphicVersion\">Graphic 80485 Version 1.0</div></div></div>"},"80487":{"type":"graphic_table","displayName":"ACC AHA HRS prevent tachy","title":"ACC/AHA/HRS guideline summary: Indications for pacing to prevent tachycardia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA/HRS guideline summary: Indications for pacing to prevent tachycardia</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td   class=\"subtitle1_single\">\r\n  \r\n   Class I - There is evidence and/or general agreement that pacing should be used to prevent tachycardia in the following setting:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226;  Sustained pause-dependent ventricular tachycardia (VT), with or without QT prolongation. (Level of Evidence: C)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td   class=\"subtitle1_single\">\r\n  \r\n   Class IIa - The weight of evidence or opinion is in favor of the usefulness of pacing to prevent tachycardia in the following setting:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226;  High-risk patients with congenital long QT syndrome. (Level of Evidence: C)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td   class=\"subtitle1_single\">\r\n  \r\n   Class IIb - The weight of evidence or opinion is less well established for the usefulness of pacing to prevent tachycardia in the following setting:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226;  Prevention of symptomatic, drug-refractory, recurrent atrial fibrillation in patients with coexisting sinus node dysfunction. (Level of Evidence: B)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td   class=\"subtitle1_single\">\r\n  \r\n   Class III - There is evidence and/or general agreement that pacing to prevent tachycardia is not useful in the following settings:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226;  Frequent or complex ventricular ectopic activity without sustained VT in the absence of the long QT syndrome. (Level of Evidence: C)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226;  Torsade de pointes VT due to reversible causes. (Level of Evidence: A)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">2.00000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=1924&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>ACC_AHA_HRS_prevent_tachy.htm</title></head></div><div class=\"graphic_reference\">Adapted from Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.</div><div id=\"graphicVersion\">Graphic 80487 Version 2.0</div></div></div>"},"80488":{"type":"graphic_picture","displayName":"Osteo in patella","title":"Osteomyelitis of the patella","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteomyelitis of the patella</div><div class=\"cntnt\"><img style=\"width:433px; height:437px;\" src=\"images/ID/80488_Osteo_in_patella.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial T1-weighted image demonstrates signal changes and cortical interruption overlying the anterior and lateral patella (white arrow). Incidental note is made of an enchondroma (asterisk). (B) Axial short inversion time inversion recovery (STIR) image demonstrates high signal edema in the marrow of the anterior and lateral patella with overlying soft tissue loss representing osteomyelitis. A small knee joint effusion is also present. (C,D) Pre- and post-contrast axial images demonstrate enhancement in the distribution of edema in the patella and overlying soft tissues (white arrow).</div><div class=\"graphic_reference\">Courtesy of Perry Horwich, MD.</div><div id=\"graphicVersion\">Graphic 80488 Version 2.0</div></div></div>"},"80490":{"type":"graphic_diagnosticimage","displayName":"Photon plan EFT paranas sinus","title":"Conformal photon beam radiation treatment plans for a young man with a Ewing's sarcoma involving the left paranasal sinuses and infratemporal fossa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Conformal photon beam radiation treatment plans for a young man with a Ewing's sarcoma involving the left paranasal sinuses and infratemporal fossa</div><div class=\"cntnt\"><img style=\"width:432px; height:436px;\" src=\"images/ONC/80490_Photon_plan_EFT_paranas_sin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast this treatment plan with the proton beam treatment plan illustrated in Figure 1A to see the much higher degree of conformality and normal tissue sparing with protons.</div><div class=\"graphic_reference\">Courtesy of John A Jackson, Medical Dosimetrist, Massachusetts General Hospital.</div><div id=\"graphicVersion\">Graphic 80490 Version 2.0</div></div></div>"},"80492":{"type":"graphic_picture","displayName":"Clostridia in muscle","title":"Clostridia in muscle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clostridia in muscle</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/ID/80492_Clostridia_in_muscle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tissue Gram stain of muscle biopsy (x400) from a patient with gas gangrene shows numerous gram-positive bacilli. <EM>Clostridium perfringens</EM> grew from this specimen.</div><div class=\"graphic_reference\">Courtesy of Stephen Calderwood, MD.</div><div id=\"graphicVersion\">Graphic 80492 Version 4.0</div></div></div>"},"80495":{"type":"graphic_table","displayName":"Vaginal cancer survival","title":"Survival by FIGO stage for patients with vaginal cancer: 1999 to 2001 FIGO statistics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Survival by FIGO stage for patients with vaginal cancer: 1999 to 2001 FIGO statistics</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Stage</td> <td class=\"subtitle1\" rowspan=\"2\">Patients (n)</td> <td class=\"subtitle1\" colspan=\"3\">Overall survival (percent) at</td> </tr> <tr> <td class=\"subtitle2\">1 year</td> <td class=\"subtitle2\">2 years</td> <td class=\"subtitle2\">5 years</td> </tr> <tr> <td class=\"centered\">0</td> <td class=\"centered\">31</td> <td class=\"centered\">93.5</td> <td class=\"centered\">90.3</td> <td class=\"centered\">90.3</td> </tr> <tr> <td class=\"centered\">I</td> <td class=\"centered\">59</td> <td class=\"centered\">91.3</td> <td class=\"centered\">87.7</td> <td class=\"centered\">77.6</td> </tr> <tr> <td class=\"centered\">II</td> <td class=\"centered\">76</td> <td class=\"centered\">78.7</td> <td class=\"centered\">64.9</td> <td class=\"centered\">52.2</td> </tr> <tr> <td class=\"centered\">III</td> <td class=\"centered\">43</td> <td class=\"centered\">75.3</td> <td class=\"centered\">58.9</td> <td class=\"centered\">42.5</td> </tr> <tr> <td class=\"centered\">IVa</td> <td class=\"centered\">22</td> <td class=\"centered\">72.7</td> <td class=\"centered\">45.5</td> <td class=\"centered\">20.5</td> </tr> <tr> <td class=\"centered\">IVb</td> <td class=\"centered\">14</td> <td class=\"centered\">71.4</td> <td class=\"centered\">42.9</td> <td class=\"centered\">12.9</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Original table modified for this publication. From: Beller U, Benedet JL, Creasman WT, et al. Carcinoma of the vagina. Int J Gynaecol Obstet 2006; 95:S29. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 80495 Version 14.0</div></div></div>"},"80498":{"type":"graphic_movie","displayName":"Apical 4 chamber echocardiogram with color Doppler TR","title":"Apical 4 chamber echocardiogram with color Doppler showing tricuspid regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apical 4 chamber echocardiogram with color Doppler showing tricuspid regurgitation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/80498_4chcotr2conv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:255px; height:218px;\" src=\"images/CARD/80498_4chcotr2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The four chamber view from a 2-D echocardiogram with color flow Doppler shows significant tricuspid regurgitation with a dilated right atrium. There is a prosthetic mitral valve suggesting that the etiology for tricuspid regurgitation is pulmonary hypertension resulting from previous mitral valve disease.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 80498 Version 3.0</div></div></div>"},"80501":{"type":"graphic_figure","displayName":"Extraocular muscles","title":"Extraocular muscles","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Extraocular muscles</div><div class=\"cntnt\"><img style=\"width:532px; height:321px;\" src=\"images/PEDS/80501_Extraocular_muscles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three pairs of extraocular muscles move each eye. The superior rectus and inferior oblique muscles primarily move the eye upward. The inferior rectus and superior oblique muscles primarily move the eye downward. The lateral rectus moves the eye horizontally laterally (abduction). The medial rectus muscle moves the eye horizontally medially (adduction). The superior oblique muscle incyclotorts the eye, and the inferior oblique muscle excyclotorts the eye.</div><div id=\"graphicVersion\">Graphic 80501 Version 2.0</div></div></div>"},"80502":{"type":"graphic_figure","displayName":"Islets of Langerhans","title":"Islets of Langerhans","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">Islets of Langerhans</div><div class=\"cntnt\"><img style=\"width:724px; height:620px;\" src=\"images/ENDO/80502_Islets_of_Langerhans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the anatomic relationships in an islet of Langerhans. The insulin-producing beta cells (in blue) are in the center closest to the systemic blood supply from pancreatic arterioles and are surrounded by the glucagon-producing alpha cells (in orange). On the outside are the delta cells (in yellow), which make somatostatin, and the PP cells (in green), which make pancreatic polypeptide. Periportal blood flow within the islet is from beta to alpha to delta cells.</div><div id=\"graphicVersion\">Graphic 80502 Version 2.0</div></div></div>"},"80503":{"type":"graphic_table","displayName":"Classification of neutrophilia","title":"Classification of neutrophilia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of neutrophilia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Spurious</td> </tr> <tr> <td class=\"indent1\">Platelet clumping</td> </tr> <tr> <td class=\"indent1\">Mixed cryoglobulinemia</td> </tr> <tr> <td class=\"subtitle1_single\">Primary (no other evident associated disease)</td> </tr> <tr> <td class=\"indent1\"><strong>Myeloproliferative disorders (eg, CML, PV, ET)</strong></td> </tr> <tr> <td class=\"indent1\">Hereditary neutrophilia</td> </tr> <tr> <td class=\"indent1\">Chronic idiopathic neutrophilia</td> </tr> <tr> <td class=\"indent1\">Familial myeloproliferative disease</td> </tr> <tr> <td class=\"indent1\">Congenital anomalies and leukemoid reaction</td> </tr> <tr> <td class=\"indent1\">Down syndrome</td> </tr> <tr> <td class=\"indent1\">Leukocyte adhesion factor deficiency</td> </tr> <tr> <td class=\"indent1\">Familial cold urticaria and leukocytosis</td> </tr> <tr> <td class=\"subtitle1_single\">Secondary</td> </tr> <tr> <td class=\"indent1\"><strong>Infection</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Stress (physical or emotional stress, vigorous exercise)</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Cigarette smoking</strong></td> </tr> <tr> <td class=\"sublist2_start\">Drugs</td> </tr> <tr> <td class=\"sublist2\"><strong>Glucocorticoids</strong></td> </tr> <tr> <td class=\"sublist2\"><strong>Recombinant G-CSF or GM-CSF</strong>*</td> </tr> <tr> <td class=\"sublist2\">Catecholamines (epinephrine)</td> </tr> <tr> <td class=\"sublist2\">Lithium</td> </tr> <tr> <td class=\"sublist2\">All-trans retinoic acid</td> </tr> <tr> <td class=\"sublist2\">Isolated case reports for occasional other drugs</td> </tr> <tr> <td class=\"indent1\">Nonhematologic malignancy</td> </tr> <tr> <td class=\"indent1\">Heatstroke</td> </tr> <tr> <td class=\"indent1\">Generalized bone marrow stimulation (as in hemolysis)</td> </tr> <tr> <td class=\"indent1\">Asplenia and hyposplenism</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Most commonly encountered causes of neutrophilia are shown in <strong>bold</strong>.</div><div class=\"graphic_footnotes\">CML: chronic myelogenous leukemia; PV: polycythemia vera; ET: essential thrombocythemia; G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte-macrophage colony-stimulating factor.<br />* These agents are used therapeutically to raise the neutrophil count.</div><div id=\"graphicVersion\">Graphic 80503 Version 3.0</div></div></div>"},"80504":{"type":"graphic_table","displayName":"Donor-derived infections","title":"Donor-derived infections in organ transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Donor-derived infections in organ transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Virus</td> </tr> <tr> <td>Herpes viruses - cytomegalovirus (CMV)&nbsp;Epstein-Barr virus (EBV), human herpesvirus (HHV)-6, herpes simplex virus (HSV), varicella-zoster virus (VZV)</td> </tr> <tr> <td>Human T lymphotropic virus (HTLV) I and II </td> </tr> <tr> <td>HIV</td> </tr> <tr> <td>West Nile Virus</td> </tr> <tr> <td>Rabies</td> </tr> <tr> <td>Lymphocytic choriomeningitis virus (LCMV)</td> </tr> <tr> <td class=\"subtitle1_single\">Bacteria</td> </tr> <tr> <td>Tuberculosis</td> </tr> <tr> <td>Nontuberculous mycobacteria</td> </tr> <tr> <td>Meningococcus</td> </tr> <tr> <td>Syphilis</td> </tr> <tr> <td>Bacteremia at the time of donation (many organisms)</td> </tr> <tr> <td class=\"subtitle1_single\">Fungi</td> </tr> <tr> <td><em>Candida</em> species (often central venous catheter related)</td> </tr> <tr> <td><em>Aspergillus</em></td> </tr> <tr> <td>Endemic mycoses (<em>Histoplasma capsulatum</em>, <em>Coccidoides </em>spp, <em>Cryptococcus gattii</em>)</td> </tr> <tr> <td><em>Cryptococcus neoformans</em></td> </tr> <tr> <td class=\"subtitle1_single\">Parasite</td> </tr> <tr> <td><em>Toxoplasma gondii</em></td> </tr> <tr> <td><em>Trypanosoma cruzi</em></td> </tr> <tr> <td>Malaria</td> </tr> <tr> <td>Babesia</td> </tr> <tr> <td><em>Strongyloides stercoralis</em></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">List includes examples of potential pathogens in transplant recipients; additional donor-derived pathogens continue to be identified.</div><div id=\"graphicVersion\">Graphic 80504 Version 4.0</div></div></div>"},"80506":{"type":"graphic_picture","displayName":"Aural atresia","title":"Aural atresia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aural atresia</div><div class=\"cntnt\"><img style=\"width:307px; height:377px;\" src=\"images/PEDS/80506_Aural_atresia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Failure of recanalization of the external auditory canal results in aural atresia. This child has aural atresia with a normal pinna.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 80506 Version 1.0</div></div></div>"},"80507":{"type":"graphic_table","displayName":"Questions to identify asthma triggers","title":"Questions to identify asthma triggers*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Questions to identify asthma triggers*</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Inhalant allergens</td> </tr> <tr> <td class=\"subtitle2_single\">Does the patient have symptoms year-round? (If \"yes,\" ask the following questions. If \"no,\" see next set of questions).</td> </tr> <tr> <td class=\"indent1\">Does the patient keep pets indoors? What type?</td> </tr> <tr> <td class=\"indent1\">Does the patient have moisture, dampness, or a moldy odor in any room of his or her home (eg, basement)? (Suggests house dust mites, molds).</td> </tr> <tr> <td class=\"indent1\">Does the patient have mold visible in any part of his or her home? (Suggests molds).</td> </tr> <tr> <td class=\"indent1\">Has the patient seen cockroaches or rodents in his or her home in the past month? (Suggests significant exposure).</td> </tr> <tr> <td class=\"indent1\">Assume exposure to house dust mites unless patient lives in a semiarid region. However, if a patient living in a semiarid region uses a swamp cooler, exposure to house dust mites must still be assumed.</td> </tr> <tr> <td class=\"subtitle2_single\">Do symptoms get worse at certain times of the year? (If \"yes,\" ask when symptoms occur).</td> </tr> <tr> <td class=\"indent1\">Early spring? (Trees).</td> </tr> <tr> <td class=\"indent1\">Late spring? (Grasses).</td> </tr> <tr> <td class=\"indent1\">Late summer to autumn? (Weeds).</td> </tr> <tr> <td class=\"indent1\">Summer and fall? (<em>Alternaria</em>, <em>Cladosporium</em>, mites).</td> </tr> <tr> <td class=\"indent1\">Cold months in temperate climates? (Suggests indoor allergens, such as animal dander).</td> </tr> <tr> <td class=\"subtitle1_single\">Tobacco smoke</td> </tr> <tr> <td class=\"indent1\">Does the patient smoke?</td> </tr> <tr> <td class=\"indent1\">Does anyone smoke at home or work?</td> </tr> <tr> <td class=\"indent1\">Does anyone smoke at the child's daycare?</td> </tr> <tr> <td class=\"subtitle1_single\">Indoor/outdoor pollutants and irritants</td> </tr> <tr> <td class=\"indent1\">Is a wood burning stove or fireplace used in the patient's home?</td> </tr> <tr> <td class=\"indent1\">Are there unvented stoves or heaters in the patient's home?</td> </tr> <tr> <td class=\"indent1\">Does the patient have contact with other smells or fumes from perfumes, cleaning agents, or sprays?</td> </tr> <tr> <td class=\"indent1\">Have there been recent renovations or painting in the home?</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Workplace exposures</td> </tr> <tr> <td class=\"indent1\">Does the patient cough or wheeze during the week but not on weekends when away from work?</td> </tr> <tr> <td class=\"indent1\">Do the patient's eyes and nasal passages get irritated soon after arriving at work?</td> </tr> <tr> <td class=\"indent1\">Do coworkers have similar symptoms?</td> </tr> <tr> <td class=\"indent1\">What substances are used in the patient's worksite? (Assess for sensitizers).</td> </tr> <tr> <td class=\"subtitle1_single\">Rhinitis</td> </tr> <tr> <td class=\"indent1\">Does the patient have constant or seasonal nasal congestion, runny nose, and/or postnasal drip?</td> </tr> <tr> <td class=\"subtitle1_single\">Gastroesophageal reflux disease (GERD)</td> </tr> <tr> <td class=\"indent1\">Does the patient have heartburn?</td> </tr> <tr> <td class=\"indent1\">Does food sometimes come up into the patient's throat?</td> </tr> <tr> <td class=\"indent1\">Has the patient had coughing, wheezing, or shortness of breath at night in the past four weeks?</td> </tr> <tr> <td class=\"indent1\">Does the infant vomit, followed by cough or have wheezy cough at night? Are symptoms worse after feeding?</td> </tr> <tr> <td class=\"subtitle1_single\">Sulfite sensitivity<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Does the patient have wheezing, coughing, or shortness of breath after eating shrimp, dried fruit, or processed potatoes or after drinking beer or wine?</td> </tr> <tr> <td class=\"subtitle1_single\">Medication sensitivities and contraindications</td> </tr> <tr> <td class=\"indent1\">What medications does the patient use now (prescription and nonprescription)?</td> </tr> <tr> <td class=\"indent1\">Does the patient use eye drops<sup>&#182;</sup>? What type?</td> </tr> <tr> <td class=\"indent1\">Does the patient use any medications that contain beta-blockers or&nbsp;angiotensin-converting enzyme (ACE)&nbsp;inhibitors<sup>&#182;</sup>?</td> </tr> <tr> <td class=\"indent1\">Does the patient ever take aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs)?</td> </tr> <tr> <td class=\"indent1\">Has the patient ever had symptoms of asthma after starting or taking any of these medications?</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These questions are examples and do not represent a standardized assessment or diagnostic instrument. The validity and reliability of these questions have not been assessed.<br />¶&nbsp;Rare issue in children.</div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 80507 Version 11.0</div></div></div>"},"80508":{"type":"graphic_picture","displayName":"Mature cystic teratoma Gross","title":"Mature cystic teratoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mature cystic teratoma</div><div class=\"cntnt\"><img style=\"width:360px; height:235px;\" src=\"images/PULM/80508_Mature_cystic_teratoma_Gros.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mediastinal cystic mass filled with cheesy, sebum-like material and hair, forming a &quot;hair-ball.&quot;</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 80508 Version 1.0</div></div></div>"},"80511":{"type":"graphic_figure","displayName":"WHO length for age girls 0 to 24 months","title":"Length-for-age percentiles, girls 0 to 24 months, WHO growth standards","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Length-for-age percentiles, girls 0 to 24 months, WHO growth standards</div><div class=\"cntnt\"><img style=\"width:567px; height:459px;\" src=\"images/PEDS/80511_WHO_leng_girls_0_to_24.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">WHO: World Health Organization.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.</div><div id=\"graphicVersion\">Graphic 80511 Version 3.0</div></div></div>"},"80512":{"type":"graphic_table","displayName":"Genetic causes hypopituitarism","title":"Genetic disorders of hypothalamopituitary development in humans","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic disorders of hypothalamopituitary development in humans</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Phenotype</td> <td class=\"subtitle1\">Inheritance</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Isolated hormone abnormalities</td> </tr> <tr> <td class=\"indent1\"><em>GH1</em></td> <td>Isolated GH deficiency</td> <td>AR, AD</td> </tr> <tr> <td class=\"indent1\"><em>GHRHR</em></td> <td>Isolated GH deficiency</td> <td>AR</td> </tr> <tr> <td class=\"indent1\"><em>TSHB</em></td> <td>Isolated TSH deficiency</td> <td>AR</td> </tr> <tr> <td class=\"indent1\"><em>TRHR</em></td> <td>Isolated TSH deficiency</td> <td>AR</td> </tr> <tr> <td class=\"indent1\"><em>TPIT</em></td> <td>Isolated ACTH deficiency</td> <td>AR</td> </tr> <tr> <td class=\"indent1\"><em>GnRHR</em></td> <td>HH</td> <td>AR</td> </tr> <tr> <td class=\"indent1\"><em>PC1</em></td> <td>ACTH deficiency, hypoglycemia, HH, obesity</td> <td>AR</td> </tr> <tr> <td class=\"indent1\"><em>POMC</em></td> <td>ACTH deficiency, obesity, red hair</td> <td>AR</td> </tr> <tr> <td class=\"indent1\"><em>DAX1</em></td> <td>Adrenal hypoplasia congenital and HH</td> <td>XL</td> </tr> <tr> <td class=\"indent1\"><em>CRH</em></td> <td>CRH deficiency</td> <td>AR</td> </tr> <tr> <td class=\"indent1\"><em>KAL1</em></td> <td>Kallman syndrome, renal agenesis, synkinesia</td> <td>XL</td> </tr> <tr> <td class=\"indent1\"><em>FGFR1</em></td> <td>Kallman syndrome, cleft lip and palate, facial dysmorphism</td> <td>AD, AR</td> </tr> <tr> <td class=\"indent1\">Leptin</td> <td>HH, obesity</td> <td>AR</td> </tr> <tr> <td class=\"indent1\">Leptin-R</td> <td>HH, obesity</td> <td>AR</td> </tr> <tr> <td class=\"indent1\"><em>GPR54</em></td> <td>HH</td> <td>AR</td> </tr> <tr> <td class=\"indent1\">Kisspeptin</td> <td>HH</td> <td>AR</td> </tr> <tr> <td class=\"indent1\"><em>FSHB</em></td> <td>Primary amenorrhea, defective spermatogenesis</td> <td>AR</td> </tr> <tr> <td class=\"indent1\"><em>LHB</em></td> <td>Delayed puberty</td> <td>AR</td> </tr> <tr> <td class=\"indent1\"><em>PROK2</em></td> <td>Kallman syndrome, severe sleep disorder, obesity</td> <td>AD</td> </tr> <tr> <td class=\"indent1\"><em>PROKR2</em></td> <td>Kallman syndrome</td> <td>AD, AR</td> </tr> <tr> <td class=\"indent1\"><em>AVP-NPII</em></td> <td>Diabetes insipidus</td> <td>AR, AD</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Combined pituitary hormone deficiency</td> </tr> <tr> <td class=\"indent1\"><em>POU1F1</em></td> <td>GH, TSH, and prolactin deficiencies</td> <td>AR, AD</td> </tr> <tr> <td class=\"indent1\"><em>PROP1</em></td> <td>GH, TSH, LH, FSH, prolactin, and evolving ACTH deficiencies</td> <td>AR</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Specific syndrome</td> </tr> <tr> <td class=\"indent1\"><em>HESX1</em></td> <td>Septo-optic dysplasia</td> <td>AR, AD</td> </tr> <tr> <td class=\"indent1\"><em>LHX3</em></td> <td>GH, TSH, LH, FSH, prolactin deficiencies, limited neck rotation</td> <td>AR</td> </tr> <tr> <td class=\"indent1\"><em>LHX4</em></td> <td>GH, TSH, ACTH deficiencies with cerebellar abnormalities</td> <td>AD</td> </tr> <tr> <td class=\"indent1\"><em>SOX3</em></td> <td>Hypopituitarism and mental retardation</td> <td>XL</td> </tr> <tr> <td class=\"indent1\"><em>GLI2</em></td> <td>Holoprosencephaly and multiple midline defects</td> <td>AD</td> </tr> <tr> <td class=\"indent1\"><em>SOX2</em></td> <td>Anophthalmia, hypopituitarism, oesophageal atresia</td> <td>AD</td> </tr> <tr> <td class=\"indent1\"><em>GLI3</em></td> <td>Pallister-Hall syndrome</td> <td>AD</td> </tr> <tr> <td class=\"indent1\"><em>PITX2</em></td> <td>Rieger syndrome</td> <td>AD</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GH: growth hormone; AR: autosomal recessive; AD: autosomal dominant; TSH: thyroid-stimulating hormone;&nbsp;ACTH: corticotropin; HH: hypogonadotropic hypogonadism; XL: X-linked; CRH: corticotropin-releasing hormone; R: receptor; LH: luteinizing hormone; FSH: follicle-stimulating hormone.</div><div class=\"graphic_reference\">Reproduced from: Mehta A, Dattani MT. Developmental disorders of the hypothalamus and pituitary gland associated with congenital hypopituitarism. Best Pract Res Clin Endocrinol Metab 2008; 22:191. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 80512 Version 4.0</div></div></div>"},"80515":{"type":"graphic_figure","displayName":"Uncomplicated cesarean delivery of fetus cephalic presentation","title":"Uncomplicated cesarean delivery of fetus in cephalic presentation","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Uncomplicated cesarean delivery of fetus in cephalic presentation</div><div class=\"cntnt\"><img style=\"width:521px; height:401px;\" src=\"images/OBGYN/80515_Delivery_of_vertex.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 80515 Version 2.0</div></div></div>"},"80517":{"type":"graphic_figure","displayName":"Abnormal CFTR function in CF","title":"Defects in the CFTR gene in cystic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Defects in the CFTR gene in cystic fibrosis</div><div class=\"cntnt\"><img style=\"width:351px; height:306px;\" src=\"images/PULM/80517_Abnormal_CFTR_function_in_C.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the biosynthesis and function of CFTR in an epithelial cell and of mechanisms of dysfunction associated with different cystic fibrosis mutations.</div><div class=\"graphic_footnotes\">CFTR: cystic fibrosis transmembrane conductance regulator; ER: endoplasmic reticulum; PKA: phosphokinase A; NB01 and NB02: nuclear binding folds.</div><div class=\"graphic_reference\">Adapted from Welsh, MJ, Tsui, L-C, Boat, T, Beaudet, AL. Cystic fibrosis. In: The Metabolic and Molecular Basis of Inherited Disease, Scriver, CR, Beaudet, AL, Sly, WS, et al (Eds), McGraw-Hill, New York, 1995, p. 3801.</div><div id=\"graphicVersion\">Graphic 80517 Version 2.0</div></div></div>"},"80518":{"type":"graphic_picture","displayName":"Barretts esoph goblet cells","title":"Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:273px; height:324px;\" src=\"images/GAST/80518_Barretts_esoph_goblet_cells.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Biopsy specimen of a patient with Barrett's esophagus shows intestinalized columnar epithelium with goblet cells.</div><div class=\"graphic_reference\">From: Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 80518 Version 3.0</div></div></div>"},"80520":{"type":"graphic_picture","displayName":"Zipper fastener release with screwdriver","title":"Zipper fastener penile entrapment release with a screwdriver","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Zipper fastener penile entrapment release with a screwdriver</div><div class=\"cntnt\"><img style=\"width:504px; height:318px;\" src=\"images/EM/80520_Zipper_fastener_release.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To release the entrapped penile tissue, place the edge of a flathead screwdriver between the face plates of the zipper fastener on the side opposite of the entrapped tissue and rotate the tip towards the median bar of the fastener. These steps will widen the face plates and allow the tissue to be freed.</div><div class=\"graphic_reference\">Reproduced with permission from: Raveenthiran V. Releasing of zipper-entrapped foreskin: a novel nonsurgical technique. Pediatr Emerg Care 2007; 23:463. Copyright © 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80520 Version 7.0</div></div></div>"},"80521":{"type":"graphic_picture","displayName":"Dissection of the fatty nodal bundle","title":"Right groin node dissection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right groin node dissection</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/OBGYN/80521_Fat_dissection_vulvectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dissection of the fatty nodal bundle. The fatty bundle has been detached from the fascia laterally and dissected off the fascia lata.</div><div class=\"graphic_reference\">Courtesy of C William Helm, MD.</div><div id=\"graphicVersion\">Graphic 80521 Version 5.0</div></div></div>"},"80522":{"type":"graphic_diagnosticimage","displayName":"Gallstone ileus on computed tomography of the abdomen","title":"Gallstone ileus seen on computed tomography (CT) scan","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Gallstone ileus seen on computed tomography (CT) scan</div><div class=\"cntnt\"><img style=\"width:529px; height:255px;\" src=\"images/GAST/80522_Gallstone_ileus_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan in a 75-year-old woman with small bowel obstruction due to gallstone ileus. Left panel: Free air is seen in the biliary tree and gallbladder (arrow). Right panel: Dilated loops of small bowel with large gallstone with a calcified rim (arrow) impacted in the terminal ileum.</div><div class=\"graphic_reference\">Courtesy of Nezam Afdhal, MD.</div><div id=\"graphicVersion\">Graphic 80522 Version 5.0</div></div></div>"},"80523":{"type":"graphic_table","displayName":"Survival rates following resection of a pancreatic NET","title":"Five- and ten-year survival rates for patients who underwent resection of a pancreatic neuroendocrine tumor<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Five- and ten-year survival rates for patients who underwent resection of a pancreatic neuroendocrine tumor<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Stage</td> <td class=\"subtitle1\" colspan=\"2\">Observed survival*</td> <td class=\"subtitle1\" colspan=\"2\">Relative survival<sup>&#182;</sup></td> <td class=\"subtitle1\" rowspan=\"2\">Median survival<br /> (months)</td> </tr> <tr> <td class=\"subtitle2\">5-year<br /> (percent)</td> <td class=\"subtitle2\">10-year<br /> (percent)</td> <td class=\"subtitle2\">5-year<br /> (percent)</td> <td class=\"subtitle2\">10-year<br /> (percent)</td> </tr> <tr> <td class=\"centered\">I</td> <td class=\"centered\">61.0</td> <td class=\"centered\">46.0</td> <td class=\"centered\">75.6</td> <td class=\"centered\">71.1</td> <td class=\"centered\">112</td> </tr> <tr> <td class=\"centered\">II</td> <td class=\"centered\">52.0</td> <td class=\"centered\">28.8</td> <td class=\"centered\">64.3</td> <td class=\"centered\">45.8</td> <td class=\"centered\">63</td> </tr> <tr> <td class=\"centered\">III</td> <td class=\"centered\">41.4</td> <td class=\"centered\">18.5</td> <td class=\"centered\">60.5</td> <td class=\"centered\">33.1</td> <td class=\"centered\">46</td> </tr> <tr> <td class=\"centered\">IV</td> <td class=\"centered\">15.5</td> <td class=\"centered\">5.1</td> <td class=\"centered\">19.9</td> <td class=\"centered\">8.9</td> <td class=\"centered\">14</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Comparisons between each stage group are significant to p&lt;0.0001.<br />&para; Survival adjusted for patient age by matching against 1990 United States Census Bureau data.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Bilimoria KY, Bentrem DJ, Merkow RP, et al: Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg 2007; 205:558. </li>&#xD;&#xA;</ol>&#xD;&#xA;Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 80523 Version 15.0</div></div></div>"},"80525":{"type":"graphic_picture","displayName":"Hysteroscopy tamoxifen pt","title":"Hysteroscopic view of a patient on tamoxifen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hysteroscopic view of a patient on tamoxifen</div><div class=\"cntnt\"><img style=\"width:392px; height:262px;\" src=\"images/OBGYN/80525_Hysteroscopy_tamoxifen_pt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This hysteroscopic view of the uterine cavity of a patient on tamoxifen shows atrophic surface epithelium and microcystic fluid blebs under the surface epithelium.</div><div class=\"graphic_reference\">Courtesy of Steven Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 80525 Version 2.0</div></div></div>"},"80526":{"type":"graphic_table","displayName":"Causes of sixth nerve palsy","title":"Causes of sixth nerve palsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of sixth nerve palsy</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Nuclear lesions</td> </tr> <tr> <td class=\"indent1\">Congenital (eg, Mobius syndrome)</td> </tr> <tr> <td class=\"indent1\">Demyelinating</td> </tr> <tr> <td class=\"indent1\">Ischemic</td> </tr> <tr> <td class=\"indent1\">Neoplastic</td> </tr> <tr> <td class=\"indent1\">Traumatic</td> </tr> <tr> <td class=\"indent1\">Metabolic (Wernicke's disease)</td> </tr> <tr> <td class=\"subtitle1_single\">Fascicular lesions</td> </tr> <tr> <td class=\"indent1\">Demyelination</td> </tr> <tr> <td class=\"indent1\">Infarction</td> </tr> <tr> <td class=\"indent1\">Neoplasm</td> </tr> <tr> <td class=\"indent1\">Traumatic</td> </tr> <tr> <td class=\"subtitle1_single\">Subarachnoid space lesions</td> </tr> <tr> <td class=\"indent1\">Aneurysm or other vascular abnormalities</td> </tr> <tr> <td class=\"indent1\">Carcinomatous meningitis</td> </tr> <tr> <td class=\"sublist2_start\">Damage following procedures</td> </tr> <tr> <td class=\"sublist2\">Cervical traction</td> </tr> <tr> <td class=\"sublist2\">Shunting for hydrocephalus</td> </tr> <tr> <td class=\"sublist2\">Spinal or epidural anesthesia</td> </tr> <tr> <td class=\"sublist2\">Lumbar puncture</td> </tr> <tr> <td class=\"sublist2\">Myelography, radiculography</td> </tr> <tr> <td class=\"sublist2_start\">Inflammatory lesions</td> </tr> <tr> <td class=\"sublist2\">Vasculitis</td> </tr> <tr> <td class=\"sublist2\">Sarcoidosis </td> </tr> <tr> <td class=\"sublist2\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"sublist2_start\">Infectious</td> </tr> <tr> <td class=\"sublist2\">Lyme disease</td> </tr> <tr> <td class=\"sublist2\">Syphilis</td> </tr> <tr> <td class=\"sublist2\">Tuberculosis</td> </tr> <tr> <td class=\"sublist2\">Cryptococcal and other meningitis</td> </tr> <tr> <td class=\"sublist2\">Cysticercosis</td> </tr> <tr> <td class=\"sublist2\">HIV-CMV encephalitis</td> </tr> <tr> <td class=\"sublist2_start\">Neoplastic</td> </tr> <tr> <td class=\"sublist2\">Abducens nerve tumor</td> </tr> <tr> <td class=\"sublist2\">Leukemia</td> </tr> <tr> <td class=\"sublist2\">Metastatic</td> </tr> <tr> <td class=\"sublist2\">Trigeminal nerve tumor</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Petrous apex lesions</td> </tr> <tr> <td class=\"sublist2_start\">Neoplasm</td> </tr> <tr> <td class=\"sublist2\">Nasopharyngeal carcinoma</td> </tr> <tr> <td class=\"sublist2_start\">Infection or inflammatory</td> </tr> <tr> <td class=\"sublist2\">Complicated otitis media or mastoiditis</td> </tr> <tr> <td class=\"indent1\">Thrombosis of inferior petrosal sinus</td> </tr> <tr> <td class=\"sublist2_start\">Traumatic</td> </tr> <tr> <td class=\"sublist2\">Basilar skull fracture</td> </tr> <tr> <td class=\"subtitle1_single\">Cavernous sinus lesions</td> </tr> <tr> <td class=\"indent1\">Cavernous sinus thrombosis</td> </tr> <tr> <td class=\"indent1\">Cavernous sinus fistula</td> </tr> <tr> <td class=\"sublist2_start\">Neoplasm</td> </tr> <tr> <td class=\"sublist2\">Nasopharyngeal cancer</td> </tr> <tr> <td class=\"sublist2\">Pituitary adenoma</td> </tr> <tr> <td class=\"sublist2\">Plasmacytoma</td> </tr> <tr> <td class=\"sublist2\">Sixth nerve neuroma</td> </tr> <tr> <td class=\"sublist2\">Skull base tumors</td> </tr> <tr> <td class=\"sublist2\">Sphenoid sinus tumors</td> </tr> <tr> <td class=\"sublist2\">Squamous cell cancer of the pterygopalatine fossa</td> </tr> <tr> <td class=\"indent1\">Ischemic lesions</td> </tr> <tr> <td class=\"indent1\">Inflammatory or infectious</td> </tr> <tr> <td class=\"indent1\">Internal carotid artery aneurysm or dissection</td> </tr> <tr> <td class=\"subtitle1_single\">Orbital lesions</td> </tr> <tr> <td class=\"indent1\">Neoplastic</td> </tr> <tr> <td class=\"indent1\">Inflammatory</td> </tr> <tr> <td class=\"indent1\">Infectious</td> </tr> <tr> <td class=\"indent1\">Traumatic</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified from: Lee AG, Brazis PW. Clinical pathways in Neuro-ophthalmology: An evidence-based approach, Theime, New York, 1999.</div><div id=\"graphicVersion\">Graphic 80526 Version 4.0</div></div></div>"},"80527":{"type":"graphic_diagnosticimage","displayName":"DIP CT scan","title":"Desquamative interstitial pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Desquamative interstitial pneumonia</div><div class=\"cntnt\"><img style=\"width:416px; height:314px;\" src=\"images/PULM/80527_DIP_CT_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High resolution computed tomographic scan shows diffuse ground glass abnormality, with some associated cystic changes.</div><div class=\"graphic_reference\">Courtesy of Jess Mandel, MD.</div><div id=\"graphicVersion\">Graphic 80527 Version 2.0</div></div></div>"},"80528":{"type":"graphic_table","displayName":"Causes of esophageal dysphagia","title":"Causes of esophageal dysphagia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of esophageal dysphagia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Mechanical lesions</td> </tr> <tr> <td class=\"subtitle2_single\">Intrinsic</td> </tr> <tr> <td class=\"indent1\">Benign tumors</td> </tr> <tr> <td class=\"indent1\">Caustic esophagitis/stricture</td> </tr> <tr> <td class=\"indent1\">Diverticula</td> </tr> <tr> <td class=\"indent1\">Malignancy</td> </tr> <tr> <td class=\"indent1\">Peptic stricture</td> </tr> <tr> <td class=\"indent1\">Eosinophilic esophagitis</td> </tr> <tr> <td class=\"indent1\">Infectious esophagitis</td> </tr> <tr> <td class=\"indent1\">Pill esophagitis</td> </tr> <tr> <td class=\"indent1\">Postsurgery (laryngeal, esophageal, gastric)</td> </tr> <tr> <td class=\"indent1\">Radiation esophagitis/stricture</td> </tr> <tr> <td class=\"indent1\">Rings and webs</td> </tr> <tr> <td class=\"indent1\">Lymphocytic esophagitis</td> </tr> <tr> <td class=\"subtitle2_single\">Extrinsic</td> </tr> <tr> <td class=\"indent1\">Aberrant subclavian artery</td> </tr> <tr> <td class=\"indent1\">Cervical osteophytes</td> </tr> <tr> <td class=\"indent1\">Enlarged aorta</td> </tr> <tr> <td class=\"indent1\">Enlarged left atrium</td> </tr> <tr> <td class=\"indent1\">Mediastinal mass (lymphadenopathy, lung cancer, etc)</td> </tr> <tr> <td class=\"indent1\">Postsurgery (laryngeal, spinal)</td> </tr> <tr> <td class=\"subtitle1_single\">Motility disorders</td> </tr> <tr> <td class=\"indent1\">Achalasia</td> </tr> <tr> <td class=\"indent1\">Chagas disease</td> </tr> <tr> <td class=\"indent1\">Primary motility disorders</td> </tr> <tr> <td class=\"indent1\">Secondary motility disorders</td> </tr> <tr> <td class=\"subtitle1_single\">Functional</td> </tr> <tr> <td class=\"indent1\">Functional dysphagia</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80528 Version 5.0</div></div></div>"},"80529":{"type":"graphic_movie","displayName":"TEE bicuspid aortic valve","title":"Bicuspid aortic valve","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bicuspid aortic valve</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/80529_teebicavconv.mp4\" style=\"width:431px;height:322px\"></div><img style=\"width:422px; height:302px;\" src=\"images/CARD/80529_teebicav.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram shows an aortic valve that has only two leaflets. Both leaflets have a moderate amount of calcium.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 80529 Version 3.0</div></div></div>"},"80530":{"type":"graphic_diagnosticimage","displayName":"25 year old woman with moyamoya","title":"25-year-old woman with presumed moyamoya disease","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">25-year-old woman with presumed moyamoya disease</div><div class=\"cntnt\"><img style=\"width:521px; height:558px;\" src=\"images/NEURO/80530_25_yr_old_woman_MMD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) MRA shows almost no flow related enhancement in the distal supraclinoid internal carotid arteries or the proximal anterior and middle cerebral arteries. B) Source image from the MRA shows multiple collateral arterial vessels in the basal ganglia (white arrow). C) Right internal carotid artery injection from a conventional angiogram, lateral projection, shows multiple collateral vessels arising around the occluded proximal anterior and cerebral arteries (black arrow). D) Right external carotid artery injection from a conventional angiogram, lateral projection, shows collaterals to the middle cerebral artery distribution (black arrow).</div><div class=\"graphic_reference\">Courtesy of Eric D Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 80530 Version 3.0</div></div></div>"},"80533":{"type":"graphic_table","displayName":"Musculoskeletal disease in DM","title":"Musculoskeletal diseases associated with diabetes mellitus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Musculoskeletal diseases associated with diabetes mellitus</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle2_left\">Hand</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Carpal tunnel syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Dupuytren's contracture</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Flexor tenosynovitis</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Diabetic sclerodactyly</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Limited joint mobility</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\">Shoulder</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Adhesive capsulitis</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Calcific periarthritis</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Limited joint mobility</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\">Lower limb</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Neuropathic arthropathy (foot and ankle)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Diabetic muscle infarction (thigh and calf)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Osteoarthritis (knee)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\">Spine</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Diffuse idiopathic skeletal hyperostosis</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 80533 Version 2.0</div></div></div>"},"80534":{"type":"graphic_picture","displayName":"Laron syndrome","title":"Laron syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laron syndrome</div><div class=\"cntnt\"><img style=\"width:246px; height:504px;\" src=\"images/PEDS/80534_Laronsyndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral view of a five-year-old girl with Laron syndrome. Note dwarfism, obesity, and typical facial features.</div><div class=\"graphic_reference\">Reproduced with permission from: Laron Z. Biologic and clinical aspects of molecular defects along the growth hormone-insulin-like growth factor I axis. In: Pediatric Endocrinology: Mechanisms, Manifestations, and Management, 1st ed, Eugster E, Pescovitz O (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 80534 Version 8.0</div></div></div>"},"80535":{"type":"graphic_table","displayName":"Treatment regimens for CMV retinitis","title":"Treatment regimens for adult patients with cytomegalovirus (CMV) retinitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment regimens for adult patients with cytomegalovirus (CMV) retinitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Induction</td> <td class=\"subtitle1\">Maintenance*</td> <td class=\"subtitle1\">Laboratory monitoring<sup><span style=\"font-size: 13px;\">&#182;</span></sup></td> <td class=\"subtitle1\">Dose-limiting toxicity<br /> (percent of patients)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Primary regimen</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Oral valganciclovir<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> <td>900 mg every 12 hours with food for 14-21 days</td> <td>900 mg once per day with food</td> <td>Complete blood count (CBC) twice/week during induction, weekly during maintenance; Serum creatinine monthly</td> <td>Neutropenia<sup>&#9674;</sup>, thrombocytopenia<sup>&#167;</sup>, diarrhea</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">If retinal lesions are immediately sight-threatening&nbsp;ADD intravitreal ganciclovir or foscarnet<sup>&#165;</sup></td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"5\">Ganciclovir</td> </tr> <tr> <td class=\"indent2\">Intraocular implants</td> <td colspan=\"4\">Ganciclovir surgically implanted reservoir is an effective treatment, but is no longer available</td> </tr> <tr> <td class=\"indent2\">Intravitreal injection<sup>&#165;</sup></td> <td> <p>Single injection<sup>&#135;</sup>: 2.5 mg per injection (in 0.05 mL volume) in combination with oral valganciclovir<sup>&#134;</sup></p> <p><strong>OR</strong></p> <p>Repeated injections: 2.5 mg per injection (in 0.05 mL volume) weekly for two to three weeks in combination with oral valganciclovir<sup><span style=\"font-size: 13px;\">&#134;</span></sup></p> </td> <td> <p>Oral valganciclovir<sup><span style=\"font-size: 13px;\">&#134;</span></sup></p> <p><strong>OR</strong></p> Intravitreal ganciclovir 2.5 mg (in 0.05 mL volume) per week in settings where systemic therapy is unavailable<sup>**</sup></td> <td>Not applicable</td> <td>Direct retinal toxicity if doses are excessively high</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"5\">Foscarnet</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Intravitreal injection<sup><span style=\"font-size: 13px;\">&#165;</span></sup></td> <td> <p>Single injection<sup><span style=\"font-size: 13px;\">&#135;</span></sup>: 2.4 mg per injection in combination with oral valganciclovir<sup><span style=\"font-size: 13px;\">&#134;</span></sup></p> <p><strong>OR</strong></p> Repeated injections: 2.4 mg per injection given twice weekly for&nbsp;up to 4 doses over a period of 7 to 14 days in combination with oral valganciclovir<sup><span style=\"font-size: 13px;\">&#134;</span></sup></td> <td> <p>Oral valganciclovir<sup><span style=\"font-size: 13px;\">&#134;</span></sup></p> </td> <td>Not applicable</td> <td>Direct retinal toxicity if doses are excessively high</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Alternate systemic regimens for patients unable to take oral valganciclovir. If retinal lesions are sight-threatening,&nbsp;ADD intravitreal ganciclovir or foscarnet, as above<sup><span style=\"font-size: 13px;\">&#165;</span></sup></td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"5\">Intravenous (IV) ganciclovir<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> </tr> <tr> <td class=\"indent2\">Standard dose</td> <td>5 mg/kg IV every 12 hours for 14-21 days</td> <td> <p>5 mg/kg IV per day</p> <p><strong>OR</strong></p> Oral valganciclovir as above</td> <td rowspan=\"2\">Complete blood count (CBC), serum electrolytes twice per week during induction and once weekly during maintenance; serum creatinine monthly</td> <td rowspan=\"2\">Neutropenia (15-50)<sup><span style=\"font-size: 13px;\">&#9674;</span></sup>, thrombocytopenia (5-20)<sup><span style=\"font-size: 13px;\">&#167;</span></sup></td> </tr> <tr> <td class=\"indent2\">High dose (salvage therapy)</td> <td>5 to 7.5 mg/kg IV every 12 hours for 14-21 days</td> <td>10 mg/kg IV per day</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"5\">Intravenous (IV) foscarnet<span style=\"font-size: 13px;\"><sup>&#182;&#182;</sup></span></td> </tr> <tr> <td class=\"indent2\">Standard dose</td> <td>60 mg/kg IV every 8 hours or 90 mg/kg IV every 12 hours for 14-21 days</td> <td> <p>90 mg/kg IV per day</p> <p><strong>OR</strong></p> Oral valganciclovir as above</td> <td>CBC with differential, platelet count, serum creatinine, potassium, magnesium, ionized calcium, phosphorous twice per week during induction, weekly during maintenance; hemoglobin</td> <td rowspan=\"2\">Nephrotoxicity (10-20), infusion-related decreased ionized serum calcium<sup>&#916;&#916;</sup>, other electrolyte abnormalities, genital ulcers, fluid overload, anemia</td> </tr> <tr> <td class=\"indent2\">High dose (salvage therapy)</td> <td>90 mg/kg IV every 12 hours for 14-21 days</td> <td>120 mg/kg IV per day</td> <td>Same as for standard dose foscarnet</td> </tr> <tr> <td class=\"indent1\">Ganciclovir<sup><span style=\"font-size: 13px;\">&#916;</span></sup> and foscarnet<sup>&#182;&#182;</sup> (salvage therapy)</td> <td> <p>90 mg foscarnet/kg IV every 12 hours <strong>PLUS either</strong> 5 mg ganciclovir/kg IV per day <strong>or</strong> oral valganciclovir 900 mg per day for 14-21 days</p> <p><strong>OR</strong></p> 5 mg ganciclovir/kg IV every 12 hours (<strong>OR</strong> oral valganciclovir 900 mg twice daily) plus 90 mg foscarnet/kg IV per day for 14-21 days</td> <td>5 mg ganciclovir/kg IV per day (<strong>OR</strong> oral valganciclovir 900 mg daily) plus 90 mg foscarnet/kg IV per day</td> <td>Refer to individual agents above</td> <td>Refer to individual agents above</td> </tr> <tr> <td class=\"indent1\">Cidofovir (IV)<sup>&#9674;&#9674;</sup></td> <td>5 mg/kg IV once per week for 2 weeks</td> <td>5 mg/kg IV once every other week</td> <td>Serum creatinine, urinary protein CBC with differential, platelets, and hepatic transaminases before each infusion</td> <td>Nephrotoxicity (50), proteinuria, neutropenia<sup><span style=\"font-size: 13px;\">&#9674;</span></sup>, decreased intraocular pressure<span style=\"font-size: 13px;\"><sup>&#167;&#167;</sup></span>, iritis<span style=\"font-size: 13px;\"><sup>&#167;&#167;</sup></span>, uveitis<sup><span style=\"font-size: 13px;\">&#167;<span style=\"font-size: 13px;\">&#167;</span></span></sup>, neuropathy; nausea, fever, rash (associated with probenecid)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">CMV retinitis should be managed in consultation with an experienced ophthalmologist.</div><div class=\"graphic_footnotes\">* Maintenance with oral valganciclovir is preferred. Considerations for decision to stop maintenance are reviewed in the topic on the treatment of CMV retinitis.<br />¶<SUP> </SUP>Monitoring may be less frequent in resource-limited settings. Refer to the topic on treatment of CMV retinitis for a discussion.<br />Δ&nbsp;The dose of oral valganciclovir or IV ganciclovir should be adjusted for renal insufficiency; for detail, refer to Lexicomp drug monograph included within UpToDate.<br />◊&nbsp;Neutropenia is reversible with granulocyte colony-stimulating factor (GCSF) given as adjunctive treatment. Refer to the topic on the treatment of CMV retinitis.&nbsp;<br />§ Ganciclovir should be stopped for platelet counts &lt;20,000 per microL. Avoid or use caution with other myelosuppressive agents.<br />¥&nbsp;The preferred use of intravitreal injections is in the setting of immediately sight threatening lesions in conjunction with systemic therapy. In resource-limited settings, where systemic therapy may not be available, the frequency of dosing is described in the table. A detailed discussion of intravitreal therapy for CMV retinitis is found in the topic on treatment of CMV retinitis.<br />‡&nbsp;If systemic therapy is initiated within 24 hours of the initial intravitreal injection, subsequent injections are probably unnecessary.<br />†<SUP>&nbsp;</SUP>For patients who cannot take oral valganciclovir, an alternate systemic therapy should be used as described in the table.<br />**&nbsp;Local treatment alone will not prevent involvement of other eye or additional systems.&nbsp;Refer to&nbsp;the topic on treatment of CMV retinitis.<br />¶¶&nbsp;Precise adjustment of foscarnet dose for renal insufficiency is necessary. An infusion pump is used to assure appropriate (ie, 2 hour) infusion time. (For detail refer to Lexicomp drug monograph included with UpToDate). Hydration is recommended to reduce the risk of nephrotoxicity. Infuse 750-1000 mL of normal saline prior to the first infusion of foscarnet to establish diuresis. With subsequent infusions, 750-1000 mL of hydration fluid should be given concurrently with each 90-120 mg/kg infusion of foscarnet.<br />ΔΔ&nbsp;Symptoms of infusion-related ionized hypocalcemia include tetany, paresthesias, arrhythmia, mental status changes, and headache. If this occurs, the infusion should be slowed. Avoid co-treatment with other nephrotoxic drugs and drugs that can alter serum calcium concentrations (ie, pentamidine). Severe additive toxicity and deaths have been reported.<br />◊◊&nbsp;Cidofovir use is contraindicated in patients with pre-existing renal insufficiency or proteinuria. In addition, cidofovir should be avoided in patients with a sulfa allergy because of cross hypersensitivity with probenecid. To decrease cidofovir associated nephrotoxicity, administer 2 g probenecid orally 3 hours before cidofovir infusion and hydrate with 1 L normal saline 1 hour prior to infusion. Administer 1 L normal saline with or immediately after cidofovir infusion. Administer 1 g probenecid orally 2 and 8 hours after infusion is completed. Probenecid is associated with hypersensitivity reactions and intolerance (ie, nausea, vomiting, fever). Dose should be reduced from 5 to 3 mg/kg if serum creatinine level increases by 0.3 to 0.4 mg/dL (26.5 to 35.4 micromol/L) over baseline value. Drug must be discontinued if serum creatinine level increases by &gt;0.5 mg/dL (44 micromol/L) over baseline value or if urinary protein level is &gt;3+. Cidofovir should not be administered concurrently with or within 7 days of other nephrotoxins.<br />§§&nbsp;Discontinue cidofovir if intraocular pressure is below 50 percent of baseline value or if uveitis develops that is unresponsive to topical corticosteroids and cycloplegics.</div><div class=\"graphic_reference\">Adapted&nbsp;from:<br /><OL>&#xD;&#xA;<LI>Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed (November 4, 2015) [pages N9].</LI></OL></div><div id=\"graphicVersion\">Graphic 80535 Version 8.0</div></div></div>"},"80536":{"type":"graphic_picture","displayName":"Acne open comedones","title":"Noninflammatory acne","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Noninflammatory acne</div><div class=\"cntnt\"><img style=\"width:396px; height:280px;\" src=\"images/PC/80536_Acne_open_comedones.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous open comedones are present on the chin.</div><div class=\"graphic_reference\">Reproduced with permission: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80536 Version 3.0</div></div></div>"},"80537":{"type":"graphic_diagnosticimage","displayName":"Tension hemothorax PA","title":"Chest radiograph of tension hemothorax after pneumonectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of tension hemothorax after pneumonectomy</div><div class=\"cntnt\"><img style=\"width:308px; height:258px;\" src=\"images/PULM/80537_Tension_hemothorax_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph 12 hours after a left pleuropneumonectomy demonstrates a tension hemothorax. The postpneumonectomy space is completely opacified, with contralateral shifting of the mediastinum.</div><div class=\"graphic_reference\">Courtesy of Richard Irwin, MD.</div><div id=\"graphicVersion\">Graphic 80537 Version 3.0</div></div></div>"},"80538":{"type":"graphic_waveform","displayName":"EPS tracing intra-Hisian block","title":"Electrophysiologic study (EPS) in advanced conduction disease showing intra-Hisian block","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Electrophysiologic study (EPS)&nbsp;in advanced conduction disease showing intra-Hisian block</div><div class=\"cntnt\"><img style=\"width:534px; height:273px;\" src=\"images/CARD/80538_ElectrogramsintraHisianb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tracing, obtained during an electophysiologic study, records three surface electrocardiogram (ECG) leads (1, 2, and V1) and the bundle of His electrogram (HBE). The first two sinus beats (SB) are conducted normally from the atrium to the ventricle, but the HBE manifests a split bundle of His electrograms (H and H'). The proximal component (H) is present following a nonconducted P wave (P*), but the distal bundle of His (H') is not activated. The level of atrioventricular block is sharply defined as being intra-Hisian, indicated advanced conduction system disease.</div><div class=\"graphic_footnotes\">A: atrial electrogam; V: ventricular electrogram.</div><div id=\"graphicVersion\">Graphic 80538 Version 6.0</div></div></div>"},"80539":{"type":"graphic_picture","displayName":"Pediculosis corporis louse","title":"Pediculus humanus humanus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pediculus humanus humanus</div><div class=\"cntnt\"><img style=\"width:380px; height:266px;\" src=\"images/DERM/80539_Pediculosis_corporis_louse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Human body louse.</div><div class=\"graphic_reference\">Reproduced with permission from: Koneman's Color Atlas and Textbook of Diagnostic Microbiology, Fifth Edition, Lippincott-Raven, Philadelphia 1997. Copyright &#169; 1997 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80539 Version 1.0</div></div></div>"},"80542":{"type":"graphic_table","displayName":"BMI table","title":"Body mass index from weight (pounds) and height (inches)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Body mass index from weight (pounds) and height (inches)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\t\n\t<tr>\n\t\t<td rowspan=\"2\" class=\"subtitle1\">&nbsp;</td>\n\t\t<td colspan=\"14\" class=\"subtitle1\">BMI, kg/m2</td>\n\t\t</tr>\n\n\t\t\t\t\t\n\t\t\t\t\t<tr>\n\t\t\t\t\t\n\t\t\t\t\t<td class=\"subtitle2\">19</td>\n\t\t\t\t\t<td class=\"subtitle2\">20</td>\n\t\t\t\t\t<td class=\"subtitle2\">21</td>\n\t\t\t\t\t<td class=\"subtitle2\">22</td>\n\t\t\t\t\t<td class=\"subtitle2\">23</td>\n\t\t\t\t\t<td class=\"subtitle2\">24</td>\n\t\t\t\t\t<td class=\"subtitle2\">25</td>\n\t\t\t\t\t<td class=\"subtitle2\">26</td>\n\t\t\t\t\t<td class=\"subtitle2\">27</td>\n\t\t\t\t\t<td class=\"subtitle2\">28</td>\n\t\t\t\t\t<td class=\"subtitle2\">29</td>\n\t\t\t\t\t<td class=\"subtitle2\">30</td>\n\t\t\t\t\t<td class=\"subtitle2\">35</td>\n\t\t\t\t\t<td class=\"subtitle2\">40</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle3_left\">Height, inches</td>\n\t\t\t\t\t<td class=\"subtitle3_left\" colspan=\"14\">Weight, pounds</td>\n\t\t\t\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">58</td>\n\t\t\t\t\t<td class=\"indent2\">91</td>\n\t\t\t\t\t<td>96</td>\n\t\t\t\t\t<td>100</td>\n\t\t\t\t\t<td>105</td>\n\t\t\t\t\t<td>110</td>\n\t\t\t\t\t<td>115</td>\n\t\t\t\t\t<td>119</td>\n\t\t\t\t\t<td>124</td>\n\t\t\t\t\t<td>129</td>\n\t\t\t\t\t<td>134</td>\n\t\t\t\t\t<td>138</td>\n\t\t\t\t\t<td>142</td>\n\t\t\t\t\t<td>167</td>\n\t\t\t\t\t<td>191</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">59</td>\n\t\t\t\t\t<td class=\"indent2\">94</td>\n\t\t\t\t\t<td>99</td>\n\t\t\t\t\t<td>104</td>\n\t\t\t\t\t<td>109</td>\n\t\t\t\t\t<td>114</td>\n\t\t\t\t\t<td>119</td>\n\t\t\t\t\t<td>124</td>\n\t\t\t\t\t<td>128</td>\n\t\t\t\t\t<td>133</td>\n\t\t\t\t\t<td>138</td>\n\t\t\t\t\t<td>143</td>\n\t\t\t\t\t<td>148</td>\n\t\t\t\t\t<td>173</td>\n\t\t\t\t\t<td>198</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">60</td>\n\t\t\t\t\t<td class=\"indent2\">97</td>\n\t\t\t\t\t<td>102</td>\n\t\t\t\t\t<td>107</td>\n\t\t\t\t\t<td>112</td>\n\t\t\t\t\t<td>118</td>\n\t\t\t\t\t<td>123</td>\n\t\t\t\t\t<td>128</td>\n\t\t\t\t\t<td>133</td>\n\t\t\t\t\t<td>138</td>\n\t\t\t\t\t<td>143</td>\n\t\t\t\t\t<td>148</td>\n\t\t\t\t\t<td>153</td>\n\t\t\t\t\t<td>179</td>\n\t\t\t\t\t<td>204</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">61</td>\n\t\t\t\t\t<td class=\"indent2\">100</td>\n\t\t\t\t\t<td>106</td>\n\t\t\t\t\t<td>111</td>\n\t\t\t\t\t<td>116</td>\n\t\t\t\t\t<td>122</td>\n\t\t\t\t\t<td>127</td>\n\t\t\t\t\t<td>132</td>\n\t\t\t\t\t<td>137</td>\n\t\t\t\t\t<td>143</td>\n\t\t\t\t\t<td>148</td>\n\t\t\t\t\t<td>153</td>\n\t\t\t\t\t<td>158</td>\n\t\t\t\t\t<td>185</td>\n\t\t\t\t\t<td>211</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">62</td>\n\t\t\t\t\t<td class=\"indent2\">104</td>\n\t\t\t\t\t<td>109</td>\n\t\t\t\t\t<td>115</td>\n\t\t\t\t\t<td>120</td>\n\t\t\t\t\t<td>126</td>\n\t\t\t\t\t<td>131</td>\n\t\t\t\t\t<td>136</td>\n\t\t\t\t\t<td>142</td>\n\t\t\t\t\t<td>147</td>\n\t\t\t\t\t<td>153</td>\n\t\t\t\t\t<td>158</td>\n\t\t\t\t\t<td>164</td>\n\t\t\t\t\t<td>191</td>\n\t\t\t\t\t<td>218</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">63</td>\n\t\t\t\t\t<td class=\"indent2\">107</td>\n\t\t\t\t\t<td>113</td>\n\t\t\t\t\t<td>118</td>\n\t\t\t\t\t<td>124</td>\n\t\t\t\t\t<td>130</td>\n\t\t\t\t\t<td>135</td>\n\t\t\t\t\t<td>141</td>\n\t\t\t\t\t<td>146</td>\n\t\t\t\t\t<td>152</td>\n\t\t\t\t\t<td>158</td>\n\t\t\t\t\t<td>163</td>\n\t\t\t\t\t<td>169</td>\n\t\t\t\t\t<td>197</td>\n\t\t\t\t\t<td>225</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">64</td>\n\t\t\t\t\t<td class=\"indent2\">110</td>\n\t\t\t\t\t<td>116</td>\n\t\t\t\t\t<td>122</td>\n\t\t\t\t\t<td>128</td>\n\t\t\t\t\t<td>134</td>\n\t\t\t\t\t<td>140</td>\n\t\t\t\t\t<td>145</td>\n\t\t\t\t\t<td>151</td>\n\t\t\t\t\t<td>157</td>\n\t\t\t\t\t<td>163</td>\n\t\t\t\t\t<td>168</td>\n\t\t\t\t\t<td>174</td>\n\t\t\t\t\t<td>204</td>\n\t\t\t\t\t<td>232</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">65</td>\n\t\t\t\t\t<td class=\"indent2\">114</td>\n\t\t\t\t\t<td>120</td>\n\t\t\t\t\t<td>126</td>\n\t\t\t\t\t<td>132</td>\n\t\t\t\t\t<td>138</td>\n\t\t\t\t\t<td>144</td>\n\t\t\t\t\t<td>150</td>\n\t\t\t\t\t<td>156</td>\n\t\t\t\t\t<td>162</td>\n\t\t\t\t\t<td>168</td>\n\t\t\t\t\t<td>174</td>\n\t\t\t\t\t<td>180</td>\n\t\t\t\t\t<td>210</td>\n\t\t\t\t\t<td>240</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">66</td>\n\t\t\t\t\t<td class=\"indent2\">118</td>\n\t\t\t\t\t<td>124</td>\n\t\t\t\t\t<td>130</td>\n\t\t\t\t\t<td>136</td>\n\t\t\t\t\t<td>142</td>\n\t\t\t\t\t<td>148</td>\n\t\t\t\t\t<td>155</td>\n\t\t\t\t\t<td>161</td>\n\t\t\t\t\t<td>167</td>\n\t\t\t\t\t<td>173</td>\n\t\t\t\t\t<td>179</td>\n\t\t\t\t\t<td>186</td>\n\t\t\t\t\t<td>216</td>\n\t\t\t\t\t<td>247</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">67</td>\n\t\t\t\t\t<td class=\"indent2\">121</td>\n\t\t\t\t\t<td>127</td>\n\t\t\t\t\t<td>134</td>\n\t\t\t\t\t<td>140</td>\n\t\t\t\t\t<td>146</td>\n\t\t\t\t\t<td>153</td>\n\t\t\t\t\t<td>159</td>\n\t\t\t\t\t<td>166</td>\n\t\t\t\t\t<td>172</td>\n\t\t\t\t\t<td>178</td>\n\t\t\t\t\t<td>185</td>\n\t\t\t\t\t<td>191</td>\n\t\t\t\t\t<td>223</td>\n\t\t\t\t\t<td>255</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">68</td>\n\t\t\t\t\t<td class=\"indent2\">125</td>\n\t\t\t\t\t<td>131</td>\n\t\t\t\t\t<td>138</td>\n\t\t\t\t\t<td>144</td>\n\t\t\t\t\t<td>151</td>\n\t\t\t\t\t<td>158</td>\n\t\t\t\t\t<td>164</td>\n\t\t\t\t\t<td>171</td>\n\t\t\t\t\t<td>177</td>\n\t\t\t\t\t<td>184</td>\n\t\t\t\t\t<td>190</td>\n\t\t\t\t\t<td>197</td>\n\t\t\t\t\t<td>230</td>\n\t\t\t\t\t<td>262</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">69</td>\n\t\t\t\t\t<td class=\"indent2\">128</td>\n\t\t\t\t\t<td>135</td>\n\t\t\t\t\t<td>142</td>\n\t\t\t\t\t<td>149</td>\n\t\t\t\t\t<td>155</td>\n\t\t\t\t\t<td>162</td>\n\t\t\t\t\t<td>169</td>\n\t\t\t\t\t<td>176</td>\n\t\t\t\t\t<td>182</td>\n\t\t\t\t\t<td>189</td>\n\t\t\t\t\t<td>196</td>\n\t\t\t\t\t<td>203</td>\n\t\t\t\t\t<td>236</td>\n\t\t\t\t\t<td>270</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">70</td>\n\t\t\t\t\t<td class=\"indent2\">132</td>\n\t\t\t\t\t<td>139</td>\n\t\t\t\t\t<td>146</td>\n\t\t\t\t\t<td>153</td>\n\t\t\t\t\t<td>160</td>\n\t\t\t\t\t<td>167</td>\n\t\t\t\t\t<td>174</td>\n\t\t\t\t\t<td>181</td>\n\t\t\t\t\t<td>188</td>\n\t\t\t\t\t<td>195</td>\n\t\t\t\t\t<td>202</td>\n\t\t\t\t\t<td>209</td>\n\t\t\t\t\t<td>243</td>\n\t\t\t\t\t<td>278</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">71</td>\n\t\t\t\t\t<td class=\"indent2\">136</td>\n\t\t\t\t\t<td>143</td>\n\t\t\t\t\t<td>150</td>\n\t\t\t\t\t<td>157</td>\n\t\t\t\t\t<td>165</td>\n\t\t\t\t\t<td>172</td>\n\t\t\t\t\t<td>179</td>\n\t\t\t\t\t<td>186</td>\n\t\t\t\t\t<td>193</td>\n\t\t\t\t\t<td>200</td>\n\t\t\t\t\t<td>208</td>\n\t\t\t\t\t<td>215</td>\n\t\t\t\t\t<td>250</td>\n\t\t\t\t\t<td>286</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">72</td>\n\t\t\t\t\t<td class=\"indent2\">140</td>\n\t\t\t\t\t<td>147</td>\n\t\t\t\t\t<td>154</td>\n\t\t\t\t\t<td>162</td>\n\t\t\t\t\t<td>169</td>\n\t\t\t\t\t<td>177</td>\n\t\t\t\t\t<td>184</td>\n\t\t\t\t\t<td>191</td>\n\t\t\t\t\t<td>199</td>\n\t\t\t\t\t<td>206</td>\n\t\t\t\t\t<td>213</td>\n\t\t\t\t\t<td>221</td>\n\t\t\t\t\t<td>258</td>\n\t\t\t\t\t<td>294</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">73</td>\n\t\t\t\t\t<td class=\"indent2\">144</td>\n\t\t\t\t\t<td>151</td>\n\t\t\t\t\t<td>159</td>\n\t\t\t\t\t<td>166</td>\n\t\t\t\t\t<td>174</td>\n\t\t\t\t\t<td>182</td>\n\t\t\t\t\t<td>189</td>\n\t\t\t\t\t<td>197</td>\n\t\t\t\t\t<td>204</td>\n\t\t\t\t\t<td>212</td>\n\t\t\t\t\t<td>219</td>\n\t\t\t\t\t<td>227</td>\n\t\t\t\t\t<td>265</td>\n\t\t\t\t\t<td>302</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">74</td>\n\t\t\t\t\t<td class=\"indent2\">148</td>\n\t\t\t\t\t<td>155</td>\n\t\t\t\t\t<td>163</td>\n\t\t\t\t\t<td>171</td>\n\t\t\t\t\t<td>179</td>\n\t\t\t\t\t<td>186</td>\n\t\t\t\t\t<td>194</td>\n\t\t\t\t\t<td>202</td>\n\t\t\t\t\t<td>210</td>\n\t\t\t\t\t<td>218</td>\n\t\t\t\t\t<td>225</td>\n\t\t\t\t\t<td>233</td>\n\t\t\t\t\t<td>272</td>\n\t\t\t\t\t<td>311</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">75</td>\n\t\t\t\t\t<td class=\"indent2\">152</td>\n\t\t\t\t\t<td>160</td>\n\t\t\t\t\t<td>168</td>\n\t\t\t\t\t<td>176</td>\n\t\t\t\t\t<td>184</td>\n\t\t\t\t\t<td>192</td>\n\t\t\t\t\t<td>200</td>\n\t\t\t\t\t<td>208</td>\n\t\t\t\t\t<td>216</td>\n\t\t\t\t\t<td>224</td>\n\t\t\t\t\t<td>232</td>\n\t\t\t\t\t<td>240</td>\n\t\t\t\t\t<td>279</td>\n\t\t\t\t\t<td>319</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent2\">76</td>\n\t\t\t\t\t<td class=\"indent2\">156</td>\n\t\t\t\t\t<td>164</td>\n\t\t\t\t\t<td>172</td>\n\t\t\t\t\t<td>180</td>\n\t\t\t\t\t<td>189</td>\n\t\t\t\t\t<td>197</td>\n\t\t\t\t\t<td>205</td>\n\t\t\t\t\t<td>213</td>\n\t\t\t\t\t<td>221</td>\n\t\t\t\t\t<td>230</td>\n\t\t\t\t\t<td>238</td>\n\t\t\t\t\t<td>246</td>\n\t\t\t\t\t<td>287</td>\n\t\t\t\t\t<td>328</td>\n\t\t\t\t</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Data from: Center for health statistics in collaboration with the National center for chronic disease prevention and health promotion, 2000.</div><div id=\"graphicVersion\">Graphic 80542 Version 1.0</div></div></div>"},"80543":{"type":"graphic_picture","displayName":"Villous chorangiosis","title":"Villous chorangiosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Villous chorangiosis</div><div class=\"cntnt\"><img style=\"width:396px; height:298px;\" src=\"images/OBGYN/80543_Chorioangiosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Terminal villi show an increase in the number of capillaries per villous cross-section (more than capillaries in more than 10 contiguous villi in several areas of the placenta).</div><div class=\"graphic_reference\">Courtesy of Raymond W. Redline, MD.</div><div id=\"graphicVersion\">Graphic 80543 Version 2.0</div></div></div>"},"80544":{"type":"graphic_table","displayName":"Chemotherapy erythema multiforme SJS/TEN","title":"Cytotoxic chemotherapy agents associated with erythema multiforme or Stevens-Johnson syndrome/toxic epidermal necrolysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cytotoxic chemotherapy agents associated with erythema multiforme or Stevens-Johnson syndrome/toxic epidermal necrolysis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Erythema multiforme </td> </tr> <tr> <td>Amifostine</td> </tr> <tr> <td>Busulfan</td> </tr> <tr> <td>Cladribine</td> </tr> <tr> <td>Chlorambucil</td> </tr> <tr> <td>Cyclophosphamide</td> </tr> <tr> <td>Docetaxel</td> </tr> <tr> <td>Etoposide</td> </tr> <tr> <td>Hydroxyurea</td> </tr> <tr> <td>Mechlorethamine</td> </tr> <tr> <td>Methotrexate</td> </tr> <tr> <td>Mitomycin C</td> </tr> <tr> <td>Mitotane</td> </tr> <tr> <td>Paclitaxel</td> </tr> <tr> <td>Tamoxifen</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">SJS/TEN </td> </tr> <tr> <td>Amifostine</td> </tr> <tr> <td>Asparaginase</td> </tr> <tr> <td>Bleomycin</td> </tr> <tr> <td>Bortezomib</td> </tr> <tr> <td>Capecitabine</td> </tr> <tr> <td>Chlorambucil</td> </tr> <tr> <td>Cladribine</td> </tr> <tr> <td>Cyclophosphamide</td> </tr> <tr> <td>Cytarabine</td> </tr> <tr> <td>Docetaxel</td> </tr> <tr> <td>Doxorubicin</td> </tr> <tr> <td>Etoposide</td> </tr> <tr> <td>Lenalidomide</td> </tr> <tr> <td>Letrozole</td> </tr> <tr> <td>Levamisole</td> </tr> <tr> <td>Methotrexate</td> </tr> <tr> <td>Paclitaxel</td> </tr> <tr> <td>Procarbazine</td> </tr> <tr> <td>Rituximab</td> </tr> <tr> <td>Thalidomide</td> </tr> <tr> <td>5-Fluorouracil</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SJS/TEN: Stevens-Johnson syndrome/toxic epidermal necrolysis.</div><div id=\"graphicVersion\">Graphic 80544 Version 3.0</div></div></div>"},"80545":{"type":"graphic_table","displayName":"Americans with Disabilities Act","title":"Americans with Disabilities Act","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Americans with Disabilities Act</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Title I of the <strong>Americans with Disabilities Act of 1990</strong>, which took effect July 26, 1992, prohibits private employers, state and local governments, employment agencies, and labor unions from discriminating against qualified individuals with disabilities in job application procedures; hiring; firing; advancement; compensation; job training; and other terms, conditions, and privileges of employment. An individual with a disability is a person who:</td> </tr> <tr> <td class=\"sublist1\">Has a physical or mental impairment that substantially limits one or more major life activities</td> </tr> <tr> <td class=\"sublist1\">Has a record of such an impairment</td> </tr> <tr> <td class=\"sublist1\">Is regarded as having such an impairment</td> </tr> <tr> <td class=\"sublist1_start\">A qualified employee or applicant with a disability is an individual who, with or without reasonable accommodation, can perform the essential functions of the job in question. Reasonable accommodation may include, but is not limited to:</td> </tr> <tr> <td class=\"sublist1\">Making existing facilities used by employees readily accessible to and usable by persons with disabilities</td> </tr> <tr> <td class=\"sublist1\">Job restructuring</td> </tr> <tr> <td class=\"sublist1\">Modifying work schedules </td> </tr> <tr> <td class=\"sublist1\">Reassignment to a vacant position</td> </tr> <tr> <td class=\"sublist1\">Acquiring or modifying equipment or devices </td> </tr> <tr> <td class=\"sublist1\">Adjusting modifying examinations, training materials, or policies, and providing qualified readers or interpreters</td> </tr> <tr> <td>An employer is required to make an accommodation to the known disability of a qualified applicant or employee if it would not impose an \"undue hardship\" on the operation of the employer's business. Undue hardship is defined as an action requiring significant difficulty or expense when considered in light of factors such as an employer's size, financial resources, and the nature and structure of its operation.</td> </tr> <tr> <td>An employer is not required to lower quality or production standards to make an accommodation, nor is an employer obligated to provide personal use items such as glasses or hearing aids.</td> </tr> <tr> <td class=\"subtitle1_single\">Medical examinations and inquiries</td> </tr> <tr> <td>Employers may not ask job applicants about the existence, nature, or severity of a disability. Applicants may be asked about their ability to perform specific job functions. A job offer may be conditioned on the results of a medical examination but only if the examination is required for all entering employees in similar jobs. Medical examinations of employees must be job related and consistent with the employer's business needs.</td> </tr> <tr> <td class=\"subtitle1_single\">Drug and alcohol abuse</td> </tr> <tr> <td>Employees and applicants currently engaging in the illegal use of drugs are not covered by the ADA when an employer acts on the basis of such use. Tests for illegal drugs are not subject to the ADA's restrictions on medical examinations. Employers may hold illegal drug users and alcoholics to the same performance standards as other employees.</td> </tr> <tr> <td class=\"subtitle1_single\">EEOC enforcement of the ADA</td> </tr> <tr> <td>The EEOC issued regulations to enforce the provisions of Title I of the ADA on July 26, 1991. The provisions originally took effect on July 26, 1992 and covered employers with 25 or more employees. On July 26, 1994, the threshold dropped to include employers with 15 or more employees.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADA: Americans with Disabilities Act; EEOC: U.S. Equal Employment Opportunity Commission.</div><div class=\"graphic_reference\">Americans with Disabilities Act of 1990. Available at: <A href=\"http://www.ada.gov/pubs/ada.htm\">www.ada.gov/pubs/ada.htm</A>&nbsp;(Accessed on April 14, 2015).</div><div id=\"graphicVersion\">Graphic 80545 Version 3.0</div></div></div>"},"80546":{"type":"graphic_picture","displayName":"Mucinous cyst","title":"Mucinous cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mucinous cyst</div><div class=\"cntnt\"><img style=\"width:255px; height:249px;\" src=\"images/RHEUM/80546_Mucinous_cyst_new.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dorsum of the hand is inspected for the presence of a cyst, which, in this case, is appreciated distally near the nail bed. The size, shape, and compressibility of the cyst are determined by physical measurement and palpation.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 80546 Version 6.0</div></div></div>"},"80548":{"type":"graphic_picture","displayName":"Fistulotomy photograph","title":"Intraoperative fistulotomy of an anal fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraoperative fistulotomy of an anal fistula</div><div class=\"cntnt\"><img style=\"width:423px; height:317px;\" src=\"images/SURG/80548_AUfistulotomyphoto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This intraoperative photograph shows the fistula tract between the primary internal opening and the secondary external opening.</div><div class=\"graphic_reference\">Courtesy of Bradley J Champagne, MD.</div><div id=\"graphicVersion\">Graphic 80548 Version 4.0</div></div></div>"},"80549":{"type":"graphic_picture","displayName":"Congenital toxoplasmosis chorioretinitis","title":"Congenital toxoplasmosis chorioretinitis","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Congenital toxoplasmosis chorioretinitis</div><div class=\"cntnt\"><img style=\"width:530px; height:498px;\" src=\"images/PEDS/80549_Congenital_toxo_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Severe, active retinochoroiditis.<br> (B) Peripheral retinochoroiditis.<br> (C) Central, healed retinochoroiditis.<br> (D) Multiple chorioretinal scars.</div><div class=\"graphic_reference\">Panels A, B, and C reproduced from: Centers for Disease Control and Prevention. Parasite Image Library. Available at: <A href=\"http://www.cdc.gov/dpdx\" target=_blank>www.cdc.gov/dpdx</A>. Accessed on December 15, 2010. <br />Panel D reproduced from: Gold DH, Weingeist TA. Color Atlas of the Eye in Systemic Disease. Baltimore: Lippincott Williams &amp; Wilkins, 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80549 Version 2.0</div></div></div>"},"80552":{"type":"graphic_movie","displayName":"Left ventricular hypertrophy short axis echocardiogram","title":"Left ventricular hypertrophy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ventricular hypertrophy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/80552_shaxlvhyconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:237px; height:376px;\" src=\"images/CARD/80552_shaxlvhy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The short axis view from a 2-D echocardiogram shows concentric hypertrophy of entire left ventricular myocardium and the papillary muscle.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 80552 Version 2.0</div></div></div>"},"80553":{"type":"graphic_table","displayName":"Diseases of myelin","title":"Diseases of myelin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diseases of myelin</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Dysmyelinating</td> </tr> <tr> <td class=\"indent1\">Adrenoleukodystrophy</td> </tr> <tr> <td class=\"indent1\">Metachromatic leukodystrophy</td> </tr> <tr> <td class=\"indent1\">Krabbe disease</td> </tr> <tr> <td class=\"indent1\">Alexander disease</td> </tr> <tr> <td class=\"indent1\">Canavan van Bogaert disease</td> </tr> <tr> <td class=\"indent1\">Pelizaeus-Merzbacher disease</td> </tr> <tr> <td class=\"indent1\">Phenylketonuria</td> </tr> <tr> <td class=\"subtitle1_single\">Demyelinating</td> </tr> <tr> <td class=\"subtitle2_single\">Autoimmune</td> </tr> <tr> <td class=\"indent1\">Acute disseminated encephalomyelitis</td> </tr> <tr> <td class=\"indent1\">Acute hemorrhagic leukoencephalopathy</td> </tr> <tr> <td class=\"indent1\">Multiple sclerosis</td> </tr> <tr> <td class=\"indent1\">Neuromyelitis optica </td> </tr> <tr> <td class=\"subtitle2_single\">Infectious</td> </tr> <tr> <td class=\"indent1\">Progressive multifocal leukoencephalopathy</td> </tr> <tr> <td class=\"subtitle2_single\">Toxic/metabolic</td> </tr> <tr> <td class=\"indent1\">Carbon monoxide</td> </tr> <tr> <td class=\"indent1\">Vitamin B12 deficiency</td> </tr> <tr> <td class=\"indent1\">Mercury intoxication (Minamata disease)</td> </tr> <tr> <td class=\"indent1\">Alcohol/tobacco amblyopia</td> </tr> <tr> <td class=\"indent1\">Central pontine myelinolysis</td> </tr> <tr> <td class=\"indent1\">Marchiafava-Bignami syndrome</td> </tr> <tr> <td class=\"indent1\">Hypoxia</td> </tr> <tr> <td class=\"indent1\">Radiation</td> </tr> <tr> <td class=\"subtitle2_single\">Vascular</td> </tr> <tr> <td class=\"indent1\">Binswanger disease</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80553 Version 4.0</div></div></div>"},"80557":{"type":"graphic_table","displayName":"Interferon induced diseases","title":"Interferon-induced or exacerbated diseases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interferon-induced or exacerbated diseases</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n\t\n   <tr>\n   <td  class=\"sublist1_start\">Thyroid diseases</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Asymptomatic thyroid peroxidase antibodies</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Hashimoto thyroiditis and hypothyroidism</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Thyrotoxicosis (Graves' disease)</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Destructive thyroiditis without thyroid antibodies</td>\n   </tr>\n\n   <tr>\n   <td>Autoimmune hepatitis</td>\n   </tr>\n\n   <tr>\n   <td>Diabetes mellitus</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1_start\">Rheumatic disorders</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Polyarthropathy</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Rheumatoid arthritis-like syndrome</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Systemic lupus erythematosus-like syndrome</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Psoriatic arthritis</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1_start\">Skin diseases</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Psoriasis</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Sarcoidosis</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Lichenoid and eczematous eruptions</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Fixed drug eruption</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Leukocytoclastic vasculitis</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1_start\">Pulmonary diseases</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Interstitional pneumonitis</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Bronchiolitis obliterans</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Sarcoidosis</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Pleural effusions</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Asthma</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1_start\">Hematologic disorders</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Autoimmune hemolytic anemia</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Autoimmune thrombocytopenia</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Antiphospholipid antibody syndrome</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1_start\">Neuromuscular diseases</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Sensory and sensorimotor neuropathy</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Mononeuritis multiplex</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Axonal neuropathies</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Demyelinating nervous diseases</td>\n   </tr>\n\n   <tr>\n   <td  class=\"sublist1\">Myasthenia gravis</td>\n   </tr>\n\n\n </table></div><div id=\"graphicVersion\">Graphic 80557 Version 1.0</div></div></div>"},"80558":{"type":"graphic_figure","displayName":"Perfluorochemical structures","title":"Perfluorochemical structures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perfluorochemical structures</div><div class=\"cntnt\"><img style=\"width:242px; height:215px;\" src=\"images/PULM/80558_Perfluorochemical_structure.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The structure of two perfluorochemicals used for liquid ventilation is shown.</div><div id=\"graphicVersion\">Graphic 80558 Version 1.0</div></div></div>"},"80559":{"type":"graphic_table","displayName":"Systemic sclerosis","title":"Classification of systemic sclerosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of systemic sclerosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Limited cutaneous scleroderma</td> </tr> <tr> <td class=\"indent1\">Raynaud phenomenon for years, occasionally decades</td> </tr> <tr> <td class=\"indent1\">Skin involvement limited to hands, face, feet, and forearms (acral distribution)</td> </tr> <tr> <td class=\"indent1\">Nailfold capillary pattern typical of scleroderma predominantly nailfold capillary loops with capillary dropout</td> </tr> <tr> <td class=\"indent1\">A significant (10 to 15%) late incidence of pulmonary hypertension, with or without skin calcification, gastrointestinal disease, telangiectasias (CREST syndrome), or interstitial lung disease</td> </tr> <tr> <td class=\"indent1\">Renal disease rarely occurs</td> </tr> <tr> <td class=\"indent1\">Anticentromere antibody (ACA) in 50 to 60%, but other patterns also occurring in 5 to 10% (especially anti-PM/Scl and anti-Scl-70)</td> </tr> <tr> <td class=\"subtitle1_single\">Diffuse cutaneous scleroderma</td> </tr> <tr> <td class=\"indent1\">Raynaud phenomenon followed, within one year, by puffy or hidebound skin changes</td> </tr> <tr> <td class=\"indent1\">Truncal and acral skin involvement; tendon friction rubs</td> </tr> <tr> <td class=\"indent1\">Nailfold capillary pattern typical of scleroderma with dilatation (early), dilatation and dropout (active), and tortuosity with dropout (late)</td> </tr> <tr> <td class=\"indent1\">Early and significant incidence of renal, interstitial lung, diffuse gastrointestinal, and myocardial disease</td> </tr> <tr> <td class=\"indent1\">Anti-Scl-70 (30%) and anti-RNA polymerase-I, II, or III (12 to 15%) antibodies</td> </tr> <tr> <td class=\"subtitle1_single\">Scleroderma sine scleroderma</td> </tr> <tr> <td class=\"indent1\">Presentation with pulmonary fibrosis or renal, cardiac, or gastrointestinal disease</td> </tr> <tr> <td class=\"indent1\">No skin involvement</td> </tr> <tr> <td class=\"indent1\">Raynaud phenomenon may be present</td> </tr> <tr> <td class=\"indent1\">Antinuclear antibodies may be present (anti-Scl-70, ACA, or anti-RNA polymerase-I, II, or III)</td> </tr> <tr> <td class=\"subtitle1_single\">Environmentally induced scleroderma</td> </tr> <tr> <td class=\"indent1\">Generally diffuse distribution of skin sclerosis and a history of exposure to an environmental agent suspected of causing scleroderma</td> </tr> <tr> <td class=\"subtitle1_single\">Overlap syndromes</td> </tr> <tr> <td class=\"indent1\">Features of systemic sclerosis that coexist with those of another autoimmune rheumatic disease, such as systemic lupus erythematosus, rheumatoid arthritis, dermatomyositis, vasculitis, or Sj&#246;gren's syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Prescleroderma</td> </tr> <tr> <td class=\"indent1\">Raynaud phenomenon</td> </tr> <tr> <td class=\"indent1\">Nailfold capillary changes (early or active pattern typical) and evidence of digital ischemia</td> </tr> <tr> <td class=\"indent1\">Specific circulating autoantibodies - antitopoisomerase-I (Scl-70), anticentromere (ACA), or anti-RNA polymerase-I, II, or III or other hallmark scleroderma reactivity</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CREST syndrome: calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia syndrome, also called limited scleroderma or limited cutaneous form of systemic sclerosis; anti-PM/Scl: anti-polymyositis/scleroderma antinuclear antibodies, also called anti-exosome antibodies; anti-Scl-70: antinuclear autoantibody to the scleroderma 70 kD antigen fragment, also called the anti-topoisomerase I antibody; RNA: ribonucleic acid; ACA: anticentromere antibody.</div><div id=\"graphicVersion\">Graphic 80559 Version 7.0</div></div></div>"},"80561":{"type":"graphic_table","displayName":"Empiric oral rx pneumonia child","title":"Initial oral empiric antibiotics for outpatient treatment of pediatric community-acquired pneumonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial oral empiric antibiotics for outpatient treatment of pediatric community-acquired pneumonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age group</td> <td class=\"subtitle1\">Empiric regimen</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">1 to 6 months</td> </tr> <tr> <td class=\"indent1\">Bacterial (not <em>Chlamydia trachomatis</em>)</td> <td><strong>Infants &#60;3 to 6 months of age with suspected bacterial pneumonia should be hospitalized</strong></td> </tr> <tr> <td class=\"indent1\"><em>C. trachomatis</em></td> <td>Refer to UpToDate topic on <em>C. trachomatis</em> infections in the newborn</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">6 months to 5 years</td> </tr> <tr> <td class=\"indent1\" rowspan=\"13\">Typical bacterial*</td> <td>Amoxicillin<sup>&#182;</sup> 90 mg/kg per day in 2 or 3 divided doses (MAX 4 g/day), <strong>or</strong></td> </tr> <tr> <td>Amoxicillin-clavulanate 90 mg/kg per day of the amoxicillin component in 2 or 3 divided doses (MAX 4 g/day amoxicillin component), <strong>or</strong></td> </tr> <tr> <td class=\"sublist1_start\"><strong>For patients with non-type 1 hypersensitivity to penicillins:</strong></td> </tr> <tr> <td class=\"indent1\">- Cefdinir 14 mg/kg per day in 2 divided doses (MAX 600 mg/day), <strong>or</strong></td> </tr> <tr> <td class=\"sublist1_start\"><strong>For patients with type 1 hypersensitivity to penicillins:</strong></td> </tr> <tr> <td class=\"indent1\">- Levofloxacin<sup>&#916;</sup>16 to 20 mg/kg per day in 2 divided doses (MAX 750 mg/day), <strong>or</strong></td> </tr> <tr> <td class=\"indent1\">- Clindamycin 30 to 40 mg/kg per day in 3 or 4 divided doses (MAX 1.8 g/day), <strong>or</strong></td> </tr> <tr> <td class=\"indent1\">- Erythromycin 30 to 50 mg/kg per day in 4 divided doses (MAX 2 g/day as base, 3.2 g/day as ethylsuccinate), <strong>or</strong></td> </tr> <tr> <td class=\"indent1\">- Azithromycin 10 mg/kg on Day 1 followed by 5 mg/kg daily for 4 more days (MAX 500 mg on Day 1 and 250 mg thereafter), <strong>or</strong></td> </tr> <tr> <td class=\"indent1\">- Clarithromycin 15 mg/kg per day in 2 divided doses (MAX 1 g/day), <strong>or</strong></td> </tr> <tr> <td class=\"sublist1_start\"><strong>In communities with a high rate of pneumococcal resistance to penicillin:</strong></td> </tr> <tr> <td class=\"indent1\">- Levofloxacin<sup>&#916;</sup> 16 to 20 mg/kg per day in 2 divided doses (MAX 750 mg/day), <strong>or</strong></td> </tr> <tr> <td class=\"indent1\">- Linezolid 30 mg/kg per day in 3 divided doses (MAX 1800 mg/day)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">&#8805;5 years</td> </tr> <tr> <td class=\"indent1\" rowspan=\"7\"><em>Mycoplasma pneumoniae</em> or <em>Chlamydia pneumoniae</em></td> <td>Erythromycin 40 to 50 mg/kg per day in 4 divided doses (MAX 2 g/day as base, 3.2 g/day as ethylsuccinate), <strong>or</strong></td> </tr> <tr> <td>Azithromycin 10 mg/kg on Day 1 followed by 5 mg/kg daily for 4 more days (MAX 500 mg on Day 1 and 250 mg thereafter), <strong>or</strong></td> </tr> <tr> <td>Clarithromycin 15 mg/kg per day in 2 divided doses (MAX 1 g/day), <strong>or</strong></td> </tr> <tr> <td>Doxycycline 4 mg/kg per day in 2 divided doses (MAX 200 mg/day), <strong>or</strong></td> </tr> <tr> <td class=\"sublist1_start\"><strong>For patients &#8805;18 years:</strong></td> </tr> <tr> <td class=\"indent1\">- Levofloxacin<sup>&#916;</sup><sup>&#167;</sup> 8 to 10 mg/kg once daily for children 5 to 16 years (MAX 500 mg/day); 500 mg once per day for children for children &#8805;16 years, <strong>or</strong></td> </tr> <tr> <td class=\"indent1\">- Moxifloxacin<sup>&#916;&#9674;</sup> 400 mg once per day</td> </tr> <tr> <td class=\"indent1\" rowspan=\"13\">Typical bacterial*</td> <td>Amoxicillin<sup>&#182;</sup> 90 mg/kg per day in 2 or 3 divided doses (MAX 4 g/day), <strong>or</strong></td> </tr> <tr> <td class=\"sublist1_start\"><strong>For patients with non-type 1 hypersensitivity to penicillins:</strong></td> </tr> <tr> <td class=\"indent1\">- Cefdinir 14 mg/kg per day in 2 divided doses (MAX 600 mg/day), <strong>or</strong></td> </tr> <tr> <td class=\"indent1\">- Cefpodoxime 10 mg/kg per day in 2 divided doses (MAX 400 mg/day), <strong>or</strong></td> </tr> <tr> <td class=\"sublist1_start\"><strong>For patients with type 1 hypersensitivity to penicillins:</strong></td> </tr> <tr> <td class=\"indent1\">- Levofloxacin<sup>&#916;</sup> 8 to 10 mg/kg once daily for children 5 to 16 years (MAX 750 mg/day); 750 mg once daily for children &#8805;16 years</td> </tr> <tr> <td class=\"indent1\">- Clindamycin 30 to 40 mg/kg per day in 3 or 4 divided doses (MAX 1.8 g/day), <strong>or</strong></td> </tr> <tr> <td class=\"indent1\">- Erythromycin 40 to 50 mg/kg per day in 4 divided doses (MAX 2 g/day as base, 3.2 g/day as ethyl succinate), <strong>or</strong></td> </tr> <tr> <td class=\"indent1\">- Azithromycin 10 mg/kg on Day 1 followed by 5 mg/kg daily for 4 more days (MAX 500 mg on Day 1 and 250 mg thereafter), <strong>or</strong></td> </tr> <tr> <td class=\"indent1\">- Clarithromycin 15 mg/kg per day in 2 divided doses (MAX 1 g/day), <strong>or</strong></td> </tr> <tr> <td class=\"sublist1_start\"><strong>In communities with a high rate of pneumococcal resistance to penicillin:</strong></td> </tr> <tr> <td class=\"indent1\">- Levofloxacin<sup>&#916;</sup> 8 to 10 mg/kg once daily for children 5 to 16 years (MAX 750 mg/day); 750 mg once daily for children &#8805;16 years, <strong>or</strong></td> </tr> <tr> <td class=\"indent1\">- Linezolid 30 mg/kg per day divided in 3 doses (MAX 1800 mg/day) for children &#60;12 years; 20 mg/kg per day divided in 2 doses (MAX 1200 mg/day) for children &#8805;12 years</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Aspiration pneumonia</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Community-acquired</td> <td>Amoxicillin-clavulanate 40 to 50 mg/kg per day in 2 or 3 divided doses (MAX 1750 mg/day amoxicillin component), <strong>or</strong></td> </tr> <tr> <td class=\"sublist1_start\"><strong>For patients with type 1 hypersensitivity to beta-lactam antibiotics:</strong></td> </tr> <tr> <td class=\"indent1\">- Clindamycin 30 to 40 mg/kg per day, divided in 3 or 4 doses (MAX 1.8 g/day)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CAP: community-acquired pneumonia; MAX: maximum.<br />* For the infant or child who is suspected to have bacterial CAP and is unable to tolerate liquids at the time of presentation, a single initial dose of ceftriaxone (50 to 75 mg/kg) may be administered intramuscularly or intravenously before starting oral antibiotics.<br />¶ Preferred agent.<br />Δ In the United States, fluoroquinolones (eg, levofloxacin and moxifloxacin) are approved by the Food and Drug Administration for community-acquired pneumonia for patients ≥18 years of age. However, they may be used in younger children if other antibiotics are inappropriate (eg, due to hypersensitivity or local antimicrobial resistance patterns).<br /><FONT class=lozenge>◊</FONT> Also covers typical bacterial pathogens.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>McIntosh K. Community-acquired pneumonia in children. N Engl J Med 2002; 346:429. </LI>&#xD;&#xA;<LI>Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25. </LI>&#xD;&#xA;<LI>American Academy of Pediatrics. Antibacterial drugs for pediatric patients beyond the newborn period. In:&nbsp;Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015 p.884.</LI></OL></div><div id=\"graphicVersion\">Graphic 80561 Version 23.0</div></div></div>"},"80563":{"type":"graphic_waveform","displayName":"M mode mitral valve prolapse","title":"M-mode echocardiogram of mitral valve prolapse","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">M-mode echocardiogram of mitral valve prolapse</div><div class=\"cntnt\"><img style=\"width:576px; height:175px;\" src=\"images/CARD/80563_Mmodemitralvalveprolaps.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The M-mode echocardiograms and phonocardiograms are from three patients with mitral prolapse. In all three examples, the valve leaflets are thickened. In panel A, there is posterior displacement of the C-D segment that begins in early systole and persists throughout (pansystolic prolapse). In panels B and C, the prolapse begins roughly in mid-systole (late or mid-systolic prolapse). The phonocardiographic findings are not predicted by the morphologic appearance. In particular, the pansystolic prolapse in panel A has only a click (arrow) and no murmur, the example in panel B has a late systolic murmur (arrow) and no click, and the example panel C has both a click (CL) and a late systolic murmur (LSM).</div><div id=\"graphicVersion\">Graphic 80563 Version 4.0</div></div></div>"},"80564":{"type":"graphic_picture","displayName":"Saddle nose in RPC","title":"Saddle nose deformity in relapsing polychondritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Saddle nose deformity in relapsing polychondritis</div><div class=\"cntnt\"><img style=\"width:185px; height:343px;\" src=\"images/RHEUM/80564_Saddle_nose_RPC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Saddle nose deformity (arrow) due to cartilage damage in a patient with relapsing polychondritis.</div><div class=\"graphic_reference\">Courtesy of Clement J Michet, MD.</div><div id=\"graphicVersion\">Graphic 80564 Version 3.0</div></div></div>"},"80566":{"type":"graphic_picture","displayName":"Nuclear cataract 2","title":"Nuclear cataract","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nuclear cataract</div><div class=\"cntnt\"><img style=\"width:286px; height:396px;\" src=\"images/PEDS/80566_Nuclear_cataract_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nuclear cataract of congenital rubella syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: Gold DH, MD, and Weingeist TA, MD, PhD. Color Atlas of the Eye in Systemic Disease. Baltimore: Lippincott Williams &amp; Wilkins, 2001. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80566 Version 1.0</div></div></div>"},"80567":{"type":"graphic_figure","displayName":"Pulp space infection felon","title":"Pulp space infection (felon)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulp space infection (felon)</div><div class=\"cntnt\"><img style=\"width:388px; height:733px;\" src=\"images/SURG/80567_Pulp_space_infection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The digital pulp is the fleshy mass at the fingertips and is divided into multiple compartments by fibrous septae that provide structural support.<br />(A) A transverse section through the distal fingertip showing septae that divides the pulp space into compartments.<br />(B) An abscess involving multiple compartments of the pulp space. An infection of the pulp space is also called a felon.<br />(C) An example of a tense pulp abscess.</div><div id=\"graphicVersion\">Graphic 80567 Version 4.0</div></div></div>"},"80568":{"type":"graphic_figure","displayName":"Diurnal testosterone pattern","title":"Diurnal pattern of testosterone secretion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diurnal pattern of testosterone secretion</div><div class=\"cntnt\"><img style=\"width:414px; height:288px;\" src=\"images/ENDO/80568_Diurnal_testosterone_patter.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hourly serum testosterone levels in normal young (n = 17) and old (n = 12) men. The circadian rhythm is lost in old men. Blood samples were obtained using an indwelling peripheral venous cannula, which allowed free movement and normal sleep.</div><div class=\"graphic_reference\">Data from: Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian&nbsp;rhythmicity in blood&nbsp;testosterone levels with aging in normal men.&nbsp;J Clin Endocrinol Metab 1983; 56:1278.</div><div id=\"graphicVersion\">Graphic 80568 Version 4.0</div></div></div>"},"80569":{"type":"graphic_picture","displayName":"Anal fissure and ulcer Crohn disease","title":"Perianal Crohn disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perianal Crohn disease</div><div class=\"cntnt\"><img style=\"width:364px; height:194px;\" src=\"images/GAST/80569_Anal_fiss_ulcer_Crohns_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Perineum in a woman with Crohn disease shows a large posterior ulcer (arrow) with anterior edematous fissure (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Alain Bitton, MD, FRCPC.</div><div id=\"graphicVersion\">Graphic 80569 Version 4.0</div></div></div>"},"80570":{"type":"graphic_picture","displayName":"Nodular lymphoid hyperplasia","title":"Nodular lymphoid hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nodular lymphoid hyperplasia</div><div class=\"cntnt\"><img style=\"width:266px; height:223px;\" src=\"images/GAST/80570_Lymphoid_hyperplasia_TI_End.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodular mucosa of the terminal ileum seen at colonoscopy in a patient later proven to have common variable immunodeficiency (CVID). Nodularity was also visible in the proximal colon.</div><div class=\"graphic_reference\">Reproduced with permission from: Eric D Libby, MD.</div><div id=\"graphicVersion\">Graphic 80570 Version 3.0</div></div></div>"},"80571":{"type":"graphic_picture","displayName":"Veress needle for insufflation","title":"Veress needle for insufflation","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Veress needle for insufflation</div><div class=\"cntnt\"><img style=\"width:712px; height:232px;\" src=\"images/SURG/80571_Vrss_ndl_insfflt.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 80571 Version 5.0</div></div></div>"},"80574":{"type":"graphic_table","displayName":"Peak systolic velocity ratios arterial duplex","title":"Peak systolic velocity ratios arterial duplex","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Peak systolic velocity ratios arterial duplex</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Ratio PSV* at stenotic segment/normal segment</td> <td class=\"subtitle1\">Degree of stenosis</td> </tr> <tr> <td>1.5-2.0</td> <td>30-49 percent</td> </tr> <tr> <td>2.0-4.0</td> <td>50-75 percent</td> </tr> <tr> <td>&#62;4.0</td> <td>&#62;75 percent</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Measuring the degree of stenosis using duplex ultrasound.</div><div class=\"graphic_footnotes\">* PSV: peak systolic velocity.</div><div class=\"graphic_reference\">Courtesy of the Division of Vascular Surgery at OHSU.</div><div id=\"graphicVersion\">Graphic 80574 Version 2.0</div></div></div>"},"80575":{"type":"graphic_picture","displayName":"Dermatofibroma dimple","title":"Dermatofibroma \"dimple sign\"","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermatofibroma &quot;dimple sign&quot;</div><div class=\"cntnt\"><img style=\"width:366px; height:320px;\" src=\"images/DERM/80575_Dermatofibroma_dimple.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A &quot;dimple&quot; is elicited on compression of this dermatofibroma.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80575 Version 2.0</div></div></div>"},"80576":{"type":"graphic_table","displayName":"AAST kidney injury scale","title":"American Association for the Surgery of Trauma organ injury severity scale for the kidney","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Association for the Surgery of Trauma organ injury severity scale for the kidney</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td class=\"centered\" rowspan=\"2\">I</td> <td>Contusion</td> <td>Microscopic or gross hematuria, urologic studies normal</td> </tr> <tr> <td>Hematoma</td> <td>Subcapsular, nonexpanding hematoma without parenchymal laceration</td> </tr> <tr class=\"divider_top\"> <td class=\"centered\" rowspan=\"2\">II</td> <td>Hematoma</td> <td>Nonexpanding perirenal hematoma confined to renal retroperitoneum</td> </tr> <tr> <td>Laceration</td> <td>Laceration &#60;1 cm depth of renal cortex without urinary extravasation</td> </tr> <tr class=\"divider_top\"> <td class=\"centered\">III</td> <td>Laceration</td> <td>Laceration &#62;1 cm depth of renal cortex without collecting system rupture or urinary extravasation</td> </tr> <tr class=\"divider_top\"> <td class=\"centered\" rowspan=\"2\">IV</td> <td>Laceration</td> <td>Parenchymal laceration extending through renal cortex, medulla, and collecting system</td> </tr> <tr> <td>Vascular</td> <td>Main renal artery or vein injury with contained hemorrhage</td> </tr> <tr class=\"divider_top\"> <td class=\"centered\" rowspan=\"2\">V</td> <td>Laceration</td> <td>Completely shattered kidney</td> </tr> <tr> <td>Vascular</td> <td>Avulsion of renal hilum, devascularizing the kidney</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Santucci RA, McAninch JW, Safir M, et al. Validation of the American Association for the Surgery of Trauma organ injury severity scale for the kidney. J Trauma 2001; 50:195. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80576 Version 4.0</div></div></div>"},"80578":{"type":"graphic_picture","displayName":"Xanthogranulomatous PN gross","title":"Xanthogranulomatous PN gross","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Xanthogranulomatous PN gross</div><div class=\"cntnt\"><img style=\"width:360px; height:196px;\" src=\"images/NEPH/80578_Xanthogranulomatous_PN_gros.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross specimen of a kidney with a segmental area of xanthogranulomatous pyelonephritis (arrow) surrounding a calcium stone (S). The yellow tissue in this area represents an inflammatory reaction with lipid-filled macrophages.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 80578 Version 2.0</div></div></div>"},"80580":{"type":"graphic_picture","displayName":"Manual testing grip strength","title":"Manual testing of grip strength","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Manual testing of grip strength</div><div class=\"cntnt\"><img style=\"width:310px; height:329px;\" src=\"images/EM/80580_Manual_testing_grip_strengt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Manual gripping of the examiner's fingers provides a crude estimate of grip strength.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 80580 Version 2.0</div></div></div>"},"80581":{"type":"graphic_figure","displayName":"Progression of human coronary atherosclerosis II","title":"Progression of human coronary atherosclerosis II","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Progression of human coronary atherosclerosis II</div><div class=\"cntnt\"><img style=\"width:327px; height:583px;\" src=\"images/CARD/80581_Prog_coronary_athero_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathology of human coronary plaque progression, 2 of 2. The thrombus of a plaque erosion occurs in the absence of rupture and may overlie a substrate of pathologic intimal thickening (top left) or fibrous cap atheroma (top right). Eruptive calcified nodules represent a rare form of coronary thrombus. Acute rupture may progress to healing (healed plaque rupture) with resolution of the luminal occlusion.</div><div class=\"graphic_footnotes\">Ca<sup>2+</sup>: calcification; NC: necrotic core; FC: fibrous cap; Th: thrombus.</div><div class=\"graphic_reference\">Reproduced with permission from: Virmani R, Kolodgie FD, Burke AP. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20:1262. Copyright © 2000 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80581 Version 7.0</div></div></div>"},"80582":{"type":"graphic_picture","displayName":"Ecthyma gangrenosum","title":"Ecthyma gangrenosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ecthyma gangrenosum</div><div class=\"cntnt\"><img style=\"width:259px; height:394px;\" src=\"images/ID/80582_Ecthyma_gangrenosum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Necrotic skin lesion due to <EM>Pseudomonas aeruginosa</EM> at the exit site of a Hickman catheter in a neutropenic patient with acute leukemia.</div><div class=\"graphic_reference\">Courtesy of Charles V Sanders, MD.</div><div id=\"graphicVersion\">Graphic 80582 Version 3.0</div></div></div>"},"80584":{"type":"graphic_table","displayName":"Black box antidepressants","title":"List of antidepressant drugs receiving a boxed warning, other product labeling changes, and a medication guide pertaining to pediatric suicidality","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">List of antidepressant drugs receiving a boxed warning, other product labeling changes, and a medication guide pertaining to pediatric suicidality</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Anafranil (clomipramine HCl)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\t\t\n\t\t\t\t\t\t\t<td>Asendin (amoxapine)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Aventyl (nortriptyline HCl)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Celexa (citalopram HBr)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Cymbalta (duloxetine HCl)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Desyrel (trazodone HCl)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Effexor (venlafaxine HCl)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Elavil (amitriptyline HCl)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Etrafon (perphenazine/amitriptyline)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Lexapro (escitalopram oxalate)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Limbitrol (chlordiazepoxide/amitriptyline)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Ludiomil (Maprotiline HCl)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Luvox (fluvoxamine maleate)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Marplan (isocarboxazid)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Nardil (phenelzine sulfate)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Norpramin (desipramine HCl)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Pamelor (nortriptyline HCl)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Parnate (tranylcypromine sulfate)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Paxil (paroxetine HCl)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Pexeva (paroxetine mesylate)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Prozac (fluoxetine HCl)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Remeron (mirtazapine)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Sarafem (fluoxetine HCl)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Serzone (nefazodone HCl)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Sinequan (doxepin HCl)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Surmontil (trimipramine)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Symbyax (olanzapine/fluoxetine)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Tofranil (imipramine HCl)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Tofranil-PM (impiramine pamoate)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Triavil (Perphenaine/Amitriptyline)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Vivactil (protriptyline HCl)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Wellbutrin (bupropion HCl)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Zoloft (sertraline HCl)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Zyban (bupropion HCl)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n  </tbody>\n</table></div><div class=\"graphic_reference\">Available at: www.fda.gov/cder/drug/antidepressants (Accessed January 9, 2007).</div><div id=\"graphicVersion\">Graphic 80584 Version 1.0</div></div></div>"},"80586":{"type":"graphic_figure","displayName":"X-linked recessive pedigree","title":"Example of a pedigree demonstrating X-linked recessive inheritance","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Example of a pedigree demonstrating X-linked recessive inheritance</div><div class=\"cntnt\"><img style=\"width:458px; height:318px;\" src=\"images/PEDS/80586_X-linked_recessive_pedigree.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note that there are no affected females and that there is no male-to-male transmission.</div><div class=\"graphic_reference\">Courtesy of V Reid Sutton, MD.</div><div id=\"graphicVersion\">Graphic 80586 Version 1.0</div></div></div>"},"80587":{"type":"graphic_picture","displayName":"Dermatofibroma - shin","title":"Dermatofibroma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermatofibroma</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/80587_Dermatofibroma_shin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This firm, hyperpigmented papule on the shin is a dermatofibroma.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 80587 Version 3.0</div></div></div>"},"80588":{"type":"graphic_table","displayName":"Antibody screening for celiac","title":"Positive predictive value of serum tests for celiac disease based upon 4615 adults in Northern Italy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Positive predictive value of serum tests for celiac disease based upon 4615 adults in Northern Italy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Serum test</td>\n<td class=\"subtitle1\">Probability*, percent</td>\n</tr>\n<tr>\n<td>IgA antiendomysium</td>\n<td>100</td>\n</tr>\n<tr>\n<td>IgG antigliadin</td>\n<td>2</td>\n</tr>\n<tr>\n<td>IgA antigliadin</td>\n<td>12</td>\n</tr>\n<tr>\n<td>IgG and IgA antigliadin</td>\n<td>33</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">* Indicates probability that the disease is present when the test is positive.</div><div class=\"graphic_reference\">Adapted from: Pittschieler K, Ladinser B. Coeliac disease: screened by a new strategy. Acta Paediatr 1996; 412(Suppl):42.</div><div id=\"graphicVersion\">Graphic 80588 Version 2.0</div></div></div>"},"80590":{"type":"graphic_diagnosticimage","displayName":"Normal resting myocardial perfusion imaging ","title":"Normal acute rest technetium 99m sestamibi myocardial perfusion imaging","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Normal acute rest technetium 99m sestamibi myocardial perfusion imaging</div><div class=\"cntnt\"><img style=\"width:473px; height:209px;\" src=\"images/CARD/80590_Normal_resting_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal acute myocardial perfusion scan was obtained on a 44-year-old female admitted with typical chest pain and nonspecific electrographic abnormalities. Serial enzymes were negative for myocardial infarction and cardiac catheterization revealed normal coronary arteries.</div><div class=\"graphic_reference\">Courtesy of Gary Heller, MD.</div><div id=\"graphicVersion\">Graphic 80590 Version 4.0</div></div></div>"},"80591":{"type":"graphic_table","displayName":"Laboratories features of selective IgM deficiency","title":"Laboratory features of selective IgM deficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory features of selective IgM deficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">Complete blood count</td> </tr> <tr> <td class=\"indent1\">Total lymphocyte number may be normal or low</td> </tr> <tr> <td class=\"indent1\">Other cell types normal</td> </tr> <tr> <td class=\"subtitle2_left\">Total hemolytic complement (CH50) normal</td> </tr> <tr> <td class=\"subtitle2_left\">Antibodies</td> </tr> <tr> <td class=\"indent1\">IgM low or absent</td> </tr> <tr> <td class=\"indent1\">IgG and IgA normal</td> </tr> <tr> <td class=\"indent1\">IgE may be normal or mildly elevated (elevations may indicate presence of associated allergic diseases)</td> </tr> <tr> <td class=\"subtitle2_left\">Flow cytometry of lymphocytes</td> </tr> <tr> <td class=\"indent1\">CD4+ T cells may be low or normal</td> </tr> <tr> <td class=\"indent1\">CD8+ T cells may be low or normal</td> </tr> <tr> <td class=\"indent1\">B cells and NK cells normal</td> </tr> <tr> <td class=\"subtitle2_left\">HIV testing negative</td> </tr> <tr> <td class=\"subtitle2_left\">Response to vaccination</td> </tr> <tr> <td class=\"indent1\">Response to pneumococcal polysaccharide vaccine (T cell independent carbohydrate antigens) may be normal or impaired</td> </tr> <tr> <td class=\"indent1\">Response to diphtheria/tetanus vaccine (T cell-dependent protein antigens) may be normal or impaired</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgM: immunoglobulin M; IgG: immunoglobulin G; IgA: immunoglobulin A; IgE: immunoglobulin E; NK: natural killer; HIV: human immunodeficiency virus.</div><div id=\"graphicVersion\">Graphic 80591 Version 11.0</div></div></div>"},"80593":{"type":"graphic_picture","displayName":"Squamous cell cancer and lichen sclerosus","title":"Vulvar squamous cell cancer and lichen sclerosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar squamous cell cancer and lichen sclerosus</div><div class=\"cntnt\"><img style=\"width:321px; height:359px;\" src=\"images/OBGYN/80593_SSC_and_LS.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 80593 Version 4.0</div></div></div>"},"80595":{"type":"graphic_table","displayName":"Genes associated with nonsyndromic dilated cardiomyopathy","title":"Genes associated with nonsyndromic dilated cardiomyopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genes associated with nonsyndromic dilated cardiomyopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"25%\"></colgroup><colgroup span=\"3\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gene*</td> <td class=\"subtitle1\">Protein</td> <td class=\"subtitle1\">Function</td> <td class=\"subtitle1\">OMIM</td> <td class=\"subtitle1\">Estimated fraction*<sup>&#182;</sup></td> <td class=\"subtitle1\">References</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Autosomal</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"6\">DCM phenotype</td> </tr> <tr> <td class=\"indent2\">TTN</td> <td>Titin</td> <td>Sarcomere structure/extensible scaffold for other proteins</td> <td>188840</td> <td>0.20</td> <td>42, 43, 67</td> </tr> <tr> <td class=\"indent2\">MYH7</td> <td>&#946;-myosin heavy chain</td> <td>Sarcomeric protein; muscle contraction</td> <td>160760</td> <td>0.042</td> <td>1-4</td> </tr> <tr> <td class=\"indent2\">MYH6</td> <td>&#945;-myosin heavy chain</td> <td>Sarcomeric protein; muscle contraction</td> <td>160710</td> <td>0.043</td> <td>5, 6</td> </tr> <tr> <td class=\"indent2\">MYPN</td> <td>Myopalladin</td> <td>Sarcomeric protein, Z-disc</td> <td>608517</td> <td>0.035</td> <td>7</td> </tr> <tr> <td class=\"indent2\">TNNT2</td> <td>Cardiac troponin T</td> <td>Sarcomeric protein; muscle contraction</td> <td>191045</td> <td>0.029</td> <td>1, 3, 4, 8-11</td> </tr> <tr> <td class=\"indent2\">BAG3</td> <td>BCL2-associated athanogene 3</td> <td>Co-chaperone for heat shock proteins</td> <td>603883</td> <td>0.025</td> <td>68</td> </tr> <tr> <td class=\"indent2\">MYBPC3</td> <td>Myosin-binding protein C</td> <td>Sarcomeric protein; muscle contraction</td> <td>600958</td> <td>0.02</td> <td>2, 6</td> </tr> <tr> <td class=\"indent2\">RBM20</td> <td>RNA binding protein 20</td> <td>RNA binding protein of the spliceosome</td> <td>613171</td> <td>0.019</td> <td>12, 13</td> </tr> <tr> <td class=\"indent2\">TMPO</td> <td>Thymopoietin</td> <td>Also LAP2; a lamin-associated nuclear protein</td> <td>188380</td> <td>0.011</td> <td>14</td> </tr> <tr> <td class=\"indent2\">LAMA4</td> <td>Laminin a-4</td> <td>Extracellular matrix protein</td> <td>600133</td> <td>0.011</td> <td>15</td> </tr> <tr> <td class=\"indent2\">VCL</td> <td>Metavinculin</td> <td>Sarcomere structure; intercalated discs</td> <td>193065</td> <td>0.01</td> <td>3, 16</td> </tr> <tr> <td class=\"indent2\">LDB3</td> <td>Cypher</td> <td>Cytoskeletal assembly; targeting/clustering of membrane proteins</td> <td>605906</td> <td>0.01</td> <td>4, 17</td> </tr> <tr> <td class=\"indent2\">TCAP</td> <td>Titin-cap or telethonin</td> <td>Z-disc protein that associates with titin; aids sarcomere assembly</td> <td>604488</td> <td>0.01</td> <td>4, 18</td> </tr> <tr> <td class=\"indent2\">PSEN1/2</td> <td>Presenilin 1/2</td> <td>Transmembrane proteins, gamma secretase activity</td> <td>104311/600759</td> <td>0.01</td> <td>19</td> </tr> <tr> <td class=\"indent2\">ACTN2</td> <td>&#945;-actinin-2</td> <td>Sarcomere structure; anchor for myofibrillar actin</td> <td>102573</td> <td>0.009</td> <td>20</td> </tr> <tr> <td class=\"indent2\">CRYAB</td> <td>Alpha B crystallin</td> <td>Cytoskeletal protein</td> <td>123590</td> <td>0.007</td> <td>21</td> </tr> <tr> <td class=\"indent2\">TPM1</td> <td>&#945;-tropomyosin</td> <td>Sarcomeric protein; muscle contraction</td> <td>191010</td> <td>0.006</td> <td>6, 22, 23</td> </tr> <tr> <td class=\"indent2\">ABCC9</td> <td>SUR2A</td> <td>Kir6.2 regulatory subunit, inwardly rectifying cardiac KATP channel</td> <td>601439</td> <td>0.006</td> <td>24</td> </tr> <tr> <td class=\"indent2\">ACTC</td> <td>Cardiac actin</td> <td>Sarcomeric protein; muscle contraction</td> <td>102540</td> <td>0.005</td> <td>25-30</td> </tr> <tr> <td class=\"indent2\">PDLIM3</td> <td>PDZ LIM domain protein 3</td> <td>Cytoskeletal protein</td> <td>605889</td> <td>0.005</td> <td>31</td> </tr> <tr> <td class=\"indent2\">ILK</td> <td>Integrin-linked kinase</td> <td>Intracellular serine-threonine kinase; interacts with integrins</td> <td>602366</td> <td>0.005</td> <td>15</td> </tr> <tr> <td class=\"indent2\">TNNC1</td> <td>Cardiac troponin C</td> <td>Sarcomeric protein; muscle contraction</td> <td>191040</td> <td>0.004</td> <td>6, 10</td> </tr> <tr> <td class=\"indent2\">TNNI3</td> <td>Cardiac troponin I</td> <td>Sarcomeric protein, muscle contraction; also seen as recessive</td> <td>191044</td> <td>0.004</td> <td>6, 32</td> </tr> <tr> <td class=\"indent2\">PLN</td> <td>Phospholamban</td> <td>Sarcoplasmic reticulum Ca++ regulator; inhibits SERCA2 pump</td> <td>172405</td> <td>0.004</td> <td>3, 33-36</td> </tr> <tr> <td class=\"indent2\">DES</td> <td>Desmin</td> <td>DAGC; transduces contractile forces</td> <td>125660</td> <td>0.003</td> <td>28, 37, 38</td> </tr> <tr> <td class=\"indent2\">SGCD</td> <td>&#948;-sarcoglycan</td> <td>DAGC; transduces contractile forces</td> <td>601411</td> <td>0.003</td> <td>38-40</td> </tr> <tr> <td class=\"indent2\">CSRP3</td> <td>Muscle LIM protein</td> <td>Sarcomere stretch sensor/Z discs</td> <td>600824</td> <td>0.003</td> <td>4, 41</td> </tr> <tr> <td class=\"indent2\">EYA4</td> <td>Eyes-absent 4</td> <td>Transcriptional coactivators (Six and Dach)</td> <td>603550</td> <td>?</td> <td>44</td> </tr> <tr> <td class=\"indent2\">ANKRD1</td> <td>Ankyrin repeat domain-containing protein 1</td> <td>Cardiac ankyrin repeat protein (CARP); localized to myopalladin/titin complex</td> <td>609599</td> <td>?</td> <td>45</td> </tr> <tr> <td class=\"indent2\">NEBL</td> <td>Nebulette</td> <td>Binds actin; Z-disc protein</td> <td>605491</td> <td>?</td> <td>46</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"6\">DCM with prominent conduction system disease</td> </tr> <tr> <td class=\"indent2\">LMNA</td> <td>Lamin A/C</td> <td>Structure/stability of inner nuclear membrane; gene expression</td> <td>150330</td> <td>0.06</td> <td>47-60</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">SCN5A</td> <td>Sodium channel</td> <td>Controls sodium ion flux</td> <td>600163</td> <td>0.026</td> <td>4, 61, 62</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">X-linked</td> </tr> <tr> <td class=\"indent1\">DMD</td> <td>Dystrophin</td> <td>DAGC; transduces contractile force</td> <td>300377</td> <td>?</td> <td>63, 64</td> </tr> <tr> <td class=\"indent1\">TAZ/G4.5</td> <td>Tafazzin</td> <td>Unknown; causes Barth syndrome</td> <td>300394</td> <td>?</td> <td>65, 66</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DAGC: dystrophin-associated glycoprotein complex.<br />* Genes ordered by the fraction of DCM probands carrying mutations based upon primary and secondary reports; all are autosomal except as indicated.<br />&para; ? denotes estimate &lt;0.01 or inadequate data for estimate.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Kamisago M, Sharma SD, DePalma SR, et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 2000; 343:1688. </li>&#xD;&#xA;    <li>Daehmlow S, Erdmann J, Knueppel T, et al. Novel mutations in sarcomeric protein genes in dilated cardiomyopathy. Biochem Biophys Res Commun. 2002; 298:116-20. </li>&#xD;&#xA;    <li>Villard E, Duboscq-Bidot L, Charron P, et al. Mutation screening in dilated cardiomyopathy: prominent role of the beta myosin heavy chain gene. Eur Heart J 2005; 26:794. </li>&#xD;&#xA;    <li>Hershberger RE, Parks SB, Kushner JD, et al. Coding sequence mutations identified in MYH7, TNNT2, SCN5A, CSRP3, LBD3, and TCAP from 313 patients with familial or idiopathic dilated cardiomyopathy. Clin Translational Science 2008; 1:21. </li>&#xD;&#xA;    <li>Carniel E, Taylor MR, Sinagra G, et al. Alpha-myosin heavy chain: a sarcomeric gene associated with dilated and hypertrophic phenotypes of cardiomyopathy. Circulation 2005; 112:54. </li>&#xD;&#xA;    <li>Hershberger RE, Norton N, Morales A, et al. Coding sequence rare variants identified in MYBPC3, MYH6, TPM1, TNNC1, and TNNI3 from 312 patients with familial or idiopathic dilated cardiomyopathy. Circ Cardiovasc Genet 2010; 3:155. </li>&#xD;&#xA;    <li>Duboscq-Bidot L, Xu P, Charron P, et al. Mutations in the Z-band protein myopalladin gene and idiopathic dilated cardiomyopathy. Cardiovasc Res 2008; 77:118. </li>&#xD;&#xA;    <li>Hanson E, Jakobs P, Keegan H, et al. Cardiac troponin T lysine-210 deletion in a family with dilated cardiomyopathy. J Card Fail 2002; 8:28. </li>&#xD;&#xA;    <li>Li D, Czernuszewicz GZ, Gonzalez O, et al. Novel cardiac troponin T mutation as a cause of familial dilated cardiomyopathy. Circulation 2001; 104:2188. </li>&#xD;&#xA;    <li>Mogensen J, Murphy RT, Shaw T, et al. Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2004; 44:2033. </li>&#xD;&#xA;    <li>Moller DV, Andersen PS, Hedley P, et al. The role of sarcomere gene mutations in patients with idiopathic dilated cardiomyopathy. Eur J Hum Genet 2009; 17:1241. </li>&#xD;&#xA;    <li>Brauch KM, Karst ML, Herron KJ, et al. Mutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopathy. J Am Coll Cardiol 2009; 54:930. </li>&#xD;&#xA;    <li>Li D, Morales A, Gonzalez Quintana J, et al. Identification of novel mutations In RBM20 in patients with dilated cardiomyopathy. Clin Trans Sci 2010; 3:90. </li>&#xD;&#xA;    <li>Taylor MR, Slavov D, Gajewski A, et al. Thymopoietin (lamina-associated polypeptide 2) gene mutation associated with dilated cardiomyopathy. Hum Mutat 2005; 26:566. </li>&#xD;&#xA;    <li>Knoll R, Postel R, Wang J, et al. Laminin-alpha4 and integrin-linked kinase mutations cause human cardiomyopathy via simultaneous defects in cardiomyocytes and endothelial cells. Circulation 2007; 116:515. </li>&#xD;&#xA;    <li>Olson TM, Illenberger S, Kishimoto NY, et al. Metavinculin mutations alter actin interaction in dilated cardiomyopathy. Circulation 2002; 105:431. </li>&#xD;&#xA;    <li>Vatta M, Mohapatra B, Jimenez S, et al. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J Am Coll Cardiol 2003; 42:2014. </li>&#xD;&#xA;    <li>Hayashi T, Arimura T, Itoh-Satoh M, et al. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J Am Coll Cardiol 2004; 44:2192. </li>&#xD;&#xA;    <li>Li D, Parks SB, Kushner JD, et al. Mutations of presenilin genes in dilated cardiomyopathy and heart failure. Am J Hum Genet 2006; 79:1030. </li>&#xD;&#xA;    <li>Mohapatra B, Jimenez S, Lin JH, et al. Mutations in the muscle LIM protein and alpha-actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis. Mol Genet Metab 2003; 80:207. </li>&#xD;&#xA;    <li>Inagaki N, Hayashi T, Arimura T, et al. Alpha B-crystallin mutation in dilated cardiomyopathy. Biochem Biophys Res Commun 2006; 342:379. </li>&#xD;&#xA;    <li>Olson TM, Kishimoto NY, Whitby FG, Michels VV. Mutations that alter the surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy. J Mol Cell Cardiol 2001; 33:723. </li>&#xD;&#xA;    <li>Lakdawala NK, Dellefave L, Redwood CS, et al. Familial dilated cardiomyopathy caused by an alpha-tropomyosin mutation: the distinctive natural history of sarcomeric dilated cardiomyopathy. J Am Coll Cardiol 2010; 55:320. </li>&#xD;&#xA;    <li>Bienengraeber M, Olson TM, Selivanov VA, et al. ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. Nat Genet 2004; 36:382. </li>&#xD;&#xA;    <li>Olson TM, Michels VV, Thibodeau SN, et al. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 1998; 280:750. </li>&#xD;&#xA;    <li>Mayosa B, Khogali S, Zhang B, Watkins H. Cardiac and skeletal actin gene mutations are not a common cause of dilated cardiomyopathy. J Med Genet 1999; 36:796. </li>&#xD;&#xA;    <li>Takai E, Akita H, Shiga N, et al. Mutational analysis of the cardiac actin gene in familial and sporadic dilated cardiomyopathy. Am J Med Genet 1999; 86:325. </li>&#xD;&#xA;    <li>Tesson F, Sylvius N, Pilotto A, et al. Epidemiology of desmin and cardiac actin gene mutations in a european population of dilated cardiomyopathy. Eur Heart J 2000; 21:1872. </li>&#xD;&#xA;    <li>Zolty R, Brodsky G, Perryman B, et al. Epidemiology of cardiac actin gene mutations in dilated cardiomyopathy. J Cardiac Failure 1999; 5:Supple 1:23. </li>&#xD;&#xA;    <li>Taylor MR, Slavov D, Ku L, et al. Prevalence of desmin mutations in dilated cardiomyopathy. Circulation 2007; 115:1244. </li>&#xD;&#xA;    <li>Arola AM, Sanchez X, Murphy RT, et al. Mutations in PDLIM3 and MYOZ1 encoding myocyte Z line proteins are infrequently found in idiopathic dilated cardiomyopathy. Mol Genet Metab 2007; 90:435. </li>&#xD;&#xA;    <li>Murphy RT, Mogensen J, Shaw A, et al. Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy. Lancet 2004; 363:371. </li>&#xD;&#xA;    <li>Schmitt JP, Kamisago M, Asahi M, et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 2003; 299:1410. </li>&#xD;&#xA;    <li>Haghighi K, Kolokathis F, Pater L, et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest 2003; 111:869. </li>&#xD;&#xA;    <li>DeWitt MM, MacLeod HM, Soliven B, McNally EM. Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy. J Am Coll Cardiol 2006; 48:1396. </li>&#xD;&#xA;    <li>Medin M, Hermida-Prieto M, Monserrat L, et al. Mutational screening of phospholamban gene in hypertrophic and idiopathic dilated cardiomyopathy and functional study of the PLN -42 C&gt;G mutation. Eur J Heart Fail 2007; 9:37. </li>&#xD;&#xA;    <li>Li D, Tapscoft T, Gonzalez O, et al. Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circ 1999; 100:461. </li>&#xD;&#xA;    <li>Karkkainen S, Miettinen R, Tuomainen P, et al. A novel mutation, Arg71Thr, in the delta-sarcoglycan gene is associated with dilated cardiomyopathy. J Mol Med 2003; 15:15. </li>&#xD;&#xA;    <li>Tsubata S, Bowles KR, Vatta M, et al. Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J Clin Invest 2000; 106:655. </li>&#xD;&#xA;    <li>Sylvius N, Duboscq-Bidot L, Bouchier C, et al. Mutational analysis of the beta- and delta-sarcoglycan genes in a large number of patients with familial and sporadic dilated cardiomyopathy. Am J Med Genet 2003; 120A:8. </li>&#xD;&#xA;    <li>Knoll R, Hoshijima M, Hoffman HM, et al. The Cardiac Mechanical Stretch Sensor Machinery Involves a Z Disc Complex that Is Defective in a Subset of Human Dilated Cardiomyopathy Cell 2002; 111:943. </li>&#xD;&#xA;    <li>Gerull B, Gramlich M, Atherton J, et al. Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat Genet 2002; 14:14. </li>&#xD;&#xA;    <li>Gerull B, Atherton J, Geupel A, et al. Identification of a novel frameshift mutation in the giant muscle filament titin in a large Australian family with dilated cardiomyopathy. J Mol Med 2006; 84:478. </li>&#xD;&#xA;    <li>Schonberger J, Wang L, Shin JT, et al. Mutation in the transcriptional coactivator EYA4 causes dilated cardiomyopathy and sensorineural hearing loss. Nat Genet 2005; 37:418. </li>&#xD;&#xA;    <li>Duboscq-Bidot L, Charron P, Ruppert V, et al. Mutations in the ANKRD1 gene encoding CARP are responsible for human dilated cardiomyopathy. Eur Heart J 2009; 30:2128. </li>&#xD;&#xA;    <li>Purevjav E, Varela J, Morgado M, et al. Nebulette mutations are associated with dilated cardiomyopathy and endocardial fibroelastosis. J Am Coll Cardiol 2010; 56:1493. </li>&#xD;&#xA;    <li>Fatkin D, MacRae C, Sasaki T, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 1999; 341:1715. </li>&#xD;&#xA;    <li>Brodsky G, Muntoni F, Miocic S, et al. Lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement. Circulation 2000; 101:473. </li>&#xD;&#xA;    <li>Becane HM, Bonne G, Varnous S, et al. High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation. Pacing Clin Electrophysiol 2000; 23:1661. </li>&#xD;&#xA;    <li>Jakobs PM, Hanson E, Crispell KA, et al. Novel lamin A/C mutations in two families with dilated cardiomyopathy and conduction system disease. J Card Fail 2001; 7:249. </li>&#xD;&#xA;    <li>Arbustini E, Pilotto A, Repetto A, et al. Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/C defect-related disease. J Am Coll Cardiol 2002; 39:981. </li>&#xD;&#xA;    <li>Hershberger RE, Hanson E, Jakobs PM, et al. A novel lamin A/C mutation in a family with dilated cardiomyopathy, prominent conduction system disease, and need for permanent pacemaker implantation. Am Heart J 2002; 144:1081. </li>&#xD;&#xA;    <li>Taylor MR, Fain PR, Sinagra G, et al. Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol 2003; 41:771. </li>&#xD;&#xA;    <li>Sebillon P, Bouchier C, Bidot LD, et al. Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations. J Med Genet 2003; 40:560. </li>&#xD;&#xA;    <li>MacLeod HM, Culley MR, Huber JM, McNally EM. Lamin A/C truncation in dilated cardiomyopathy with conduction disease. BMC Med Genet 2003; 4:4. </li>&#xD;&#xA;    <li>Sylvius N, Bilinska ZT, Veinot JP, et al. In vivo and in vitro examination of the functional significances of novel lamin gene mutations in heart failure patients. J Med Genet 2005; 42:639. </li>&#xD;&#xA;    <li>Pethig K, Genschel J, Peters T, et al. LMNA mutations in cardiac transplant recipients. Cardiology 2005; 103:57. </li>&#xD;&#xA;    <li>Karkkainen S, Reissell E, Helio T, et al. Novel mutations in the lamin A/C gene in heart transplant recipients with end stage dilated cardiomyopathy. Heart 2006; 92:524. </li>&#xD;&#xA;    <li>Parks SB, Kushner JD, Nauman D, et al. Lamin A/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy. Am Heart J 2008; 156:161. </li>&#xD;&#xA;    <li>Pasotti M, Klersy C, Pilotto A, et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol 2008; 52:1250. </li>&#xD;&#xA;    <li>McNair WP, Ku L, Taylor MR, et al. SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. Circulation 2004; 110:2163. </li>&#xD;&#xA;    <li>Olson TM, Michels VV, Ballew JD, et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA. 2005; 293:447. </li>&#xD;&#xA;    <li>Towbin JA, Hejtmancik JF, Brink P, et al. X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 1993; 87:1854. </li>&#xD;&#xA;    <li>Muntoni F, Cau M, Ganau A, et al. Brief report: Deletion of the dystrophin muscle-promoter region associated with x-linked dilated cardiomyopathy. N Engl J Med 1993; 329:921. </li>&#xD;&#xA;    <li>D'Adamo P, Fassone L, Gedeon A, et al. The X-linked gene G4.5 is responsible for different infantile dilated cardiomyopathies. Am J Hum Genet 1997; 61:862. </li>&#xD;&#xA;    <li>Bione S, D'Adamo P, Maestrini E, et al. A novel X-linked gene, G4.5, is responsible for Barth syndrome. Nat Genet 1996; 12:385. </li>&#xD;&#xA;    <li>Herman DS, Lam L, Taylor MRG, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med 2012; 36:619. </li>&#xD;&#xA;    <li>Norton N, Li D, Rieder MJ, et al. Genome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as cause for dilated cardiomyopathy. Am J Human Genetics 2011; 88:273.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Hershberger RE, Morales MS, Siegfried MS. Clinical and genetic issues in dilated cardiomyopathy: A review for genetics professionals. Genet Med 2010; 12:655. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. Additional data added for this publication from References 67 and 68.</div><div id=\"graphicVersion\">Graphic 80595 Version 14.0</div></div></div>"},"80597":{"type":"graphic_table","displayName":"Rituximab desens","title":"Rituximab desensitization","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rituximab desensitization</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n \r\n <tr>\r\n\t\t<td class=\"subtitle1_left\" colspan=\"8\">Desensitization protocol instructions:</td>\r\n\t</tr>\r\n\t<tr>\r\n\t\t<td class=\"indent1\" colspan=\"8\">1. Confirm written consent is in medical record. Initial desensitization is performed in the medical ICU.</td>\r\n\t</tr>\r\n\t<tr>\r\n\t\t<td class=\"indent1\" colspan=\"8\">2. Please ensure preceding dose of beta-blockers was held, unless otherwise advised by supervising physician.</td>\r\n\t</tr>\r\n\t<tr>\r\n\t\t<td class=\"indent1\" colspan=\"8\">3. Obtain IV access, and vital signs (temperature, HR, BP, RR, oxygen saturation, peak flow).</td>\r\n\t</tr>\r\n\t<tr>\r\n\t\t<td class=\"indent1\" colspan=\"8\">4. Have at bedside: Epinephrine 0.3 mg (for adult) for IM injection, peak flow meter, and BP cuff.</td>\r\n\t</tr>\r\n\t<tr>\r\n\t\t<td class=\"indent1\" colspan=\"8\">5. A nurse must closely observe the patient throughout the protocol (one-to-one).</td>\r\n\t</tr>\r\n\t<tr>\r\n\t\t<td colspan=\"8\"><strong>Premedicate</strong> 20 minutes before starting infusion with diphenhydramine (25 mg IV) and ranitidine (50 mg IV)</td>\r\n\t</tr>\r\n\t<tr>\r\n\t\t<td colspan=\"8\"><strong>Administration:</strong> Hang each solution successively, changing the rate every 15 minutes, per protocol. The IV tubing should be pre-flushed with the appropriate solution (1, 2, or 3) and attached at the IV hub, prior to starting infusion with each bag. There is no reason to wait between bags. Vital signs should be taken and recorded every 15 minutes, and every 30 minutes during the last step (step 12).</td>\r\n\t</tr>\r\n\r\n<tr>\r\n \r\n <td class=\"subtitle1_left\" colspan=\"5\">\r\n \r\n Name of medication:\r\n \r\n </td>\r\n \r\n <td colspan=\"3\">\r\n \r\n <strong>Rituximab</strong>\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle1_left\" colspan=\"5\">\r\n \r\n Target dose, mg\r\n \r\n </td>\r\n \r\n <td colspan=\"3\">\r\n \r\n <strong>600</strong>\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle1_left\" colspan=\"5\">\r\n \r\n Standard volume per bag, mL\r\n \r\n </td>\r\n \r\n <td colspan=\"3\">\r\n \r\n <strong>250</strong>\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle1_left\" colspan=\"5\">\r\n \r\n Final rate of infusion, mL/hr\r\n \r\n </td>\r\n \r\n <td colspan=\"3\">\r\n \r\n <strong>75</strong>\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"sublist_other\" colspan=\"8\">&nbsp;</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle1_left\" colspan=\"5\">\r\n \r\n Calculated target concentration, mg/mL\r\n \r\n </td>\r\n \r\n <td colspan=\"3\">\r\n \r\n <strong>2.4</strong>\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle1_left\" colspan=\"5\">\r\n \r\n Standard time of infusion, minutes\r\n \r\n </td>\r\n \r\n <td colspan=\"3\">\r\n \r\n <strong>200</strong>\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"sublist_other\" colspan=\"8\">&nbsp;</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle1_left\" colspan=\"6\">&nbsp;</td>\r\n \r\n <td class=\"subtitle1_left\">\r\n \r\n Total mg per bag\r\n \r\n </td>\r\n \r\n <td class=\"subtitle1_left\">\r\n \r\n Amount of bag infused, mL\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle2_left\" colspan=\"3\">\r\n \r\n Solution 1\r\n \r\n </td>\r\n \r\n <td>250</td>\r\n \r\n <td>mL of</td>\r\n \r\n <td>0.024 mg/mL</td>\r\n \r\n <td>6.000</td>\r\n \r\n <td>8.67</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle2_left\" colspan=\"3\">\r\n \r\n Solution 2\r\n \r\n </td>\r\n \r\n <td>250</td>\r\n \r\n <td>mL of</td>\r\n \r\n <td>0.240 mg/mL</td>\r\n \r\n <td>60.000</td>\r\n \r\n <td>17.58</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle2_left\" colspan=\"3\">\r\n \r\n Solution 3\r\n \r\n </td>\r\n \r\n <td>250</td>\r\n \r\n <td>mL of</td>\r\n \r\n <td><strong>2.382 mg/mL</strong></td>\r\n \r\n <td>595.573</td>\r\n \r\n <td>250.00</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td colspan=\"8\">\r\n \r\n <strong>PLEASE NOTE:</strong> The total volume and dose dispensed are more than the final dose given to patient because the initial solutions are <em>not completely infused</em>\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle1\">\r\n \r\n Step\r\n \r\n </td>\r\n \r\n <td class=\"subtitle1\">\r\n \r\n Solution\r\n \r\n </td>\r\n \r\n <td class=\"subtitle1\">\r\n \r\n Rate, mL/hr\r\n \r\n </td>\r\n \r\n <td class=\"subtitle1\">\r\n \r\n Time, min\r\n \r\n </td>\r\n \r\n <td class=\"subtitle1\">\r\n \r\n Volume infused per step, mL\r\n \r\n </td>\r\n \r\n <td class=\"subtitle1\">\r\n \r\n Dose administered with this step, mg\r\n \r\n </td>\r\n \r\n <td class=\"subtitle1\">\r\n \r\n Cumulative dose, mg\r\n \r\n </td>\r\n \r\n <td class=\"subtitle1\">\r\n \r\n Fold increase per step\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>1</td>\r\n \r\n <td>1</td>\r\n \r\n <td>1.9</td>\r\n \r\n <td>15</td>\r\n \r\n <td>0.47</td>\r\n \r\n <td>0.0113</td>\r\n \r\n <td>0.0113</td>\r\n \r\n <td>-</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>2</td>\r\n \r\n <td>1</td>\r\n \r\n <td>4.7</td>\r\n \r\n <td>15</td>\r\n \r\n <td>1.17</td>\r\n \r\n <td>0.0281</td>\r\n \r\n <td>0.0394</td>\r\n \r\n <td>2.5</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>3</td>\r\n \r\n <td>1</td>\r\n \r\n <td>9.4</td>\r\n \r\n <td>15</td>\r\n \r\n <td>2.34</td>\r\n \r\n <td>0.0563</td>\r\n \r\n <td>0.0956</td>\r\n \r\n <td>2</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>4</td>\r\n \r\n <td>1</td>\r\n \r\n <td>18.8</td>\r\n \r\n <td>15</td>\r\n \r\n <td>4.69</td>\r\n \r\n <td>0.1125</td>\r\n \r\n <td>0.2081</td>\r\n \r\n <td>2</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>5</td>\r\n \r\n <td>2</td>\r\n \r\n <td>4.7</td>\r\n \r\n <td>15</td>\r\n \r\n <td>1.17</td>\r\n \r\n <td>0.2813</td>\r\n \r\n <td>0.4894</td>\r\n \r\n <td>2.5</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>6</td>\r\n \r\n <td>2</td>\r\n \r\n <td>9.4</td>\r\n \r\n <td>15</td>\r\n \r\n <td>2.34</td>\r\n \r\n <td>0.5625</td>\r\n \r\n <td>1.0519</td>\r\n \r\n <td>2</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>7</td>\r\n \r\n <td>2</td>\r\n \r\n <td>18.8</td>\r\n \r\n <td>15</td>\r\n \r\n <td>4.69</td>\r\n \r\n <td>1.1250</td>\r\n \r\n <td>2.1769</td>\r\n \r\n <td>2</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>8</td>\r\n \r\n <td>2</td>\r\n \r\n <td>37.5</td>\r\n \r\n <td>15</td>\r\n \r\n <td>9.38</td>\r\n \r\n <td>2.2500</td>\r\n \r\n <td>4.4269</td>\r\n \r\n <td>2</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>9</td>\r\n \r\n <td>3</td>\r\n \r\n <td>9.4</td>\r\n \r\n <td>15</td>\r\n \r\n <td>2.34</td>\r\n \r\n <td>5.5835</td>\r\n \r\n <td>10.0104</td>\r\n \r\n <td>2.481554688</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>10</td>\r\n \r\n <td>3</td>\r\n \r\n <td>18.8</td>\r\n \r\n <td>15</td>\r\n \r\n <td>4.69</td>\r\n \r\n <td>11.1670</td>\r\n \r\n <td>21.1774</td>\r\n \r\n <td>2</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>11</td>\r\n \r\n <td>3</td>\r\n \r\n <td>37.5</td>\r\n \r\n <td>15</td>\r\n \r\n <td>9.38</td>\r\n \r\n <td>22.3340</td>\r\n \r\n <td>43.5114</td>\r\n \r\n <td>2</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>12</td>\r\n \r\n <td>3</td>\r\n \r\n <td><strong>75.0</strong></td>\r\n \r\n <td>186.875</td>\r\n \r\n <td>233.59</td>\r\n \r\n <td>556.4886</td>\r\n \r\n <td>600.0000</td>\r\n \r\n <td>2</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td colspan=\"8\">\r\n \r\n <strong>Total time: 351.875 minutes = 5.86 hours</strong>\r\n \r\n </td>\r\n \r\n </tr>\r\n\r\n<tr>\r\n\t<td class=\"subtitle1_left\" colspan=\"8\">Monitoring and charting during desensitization:</td>\r\n</tr>\r\n<tr>\r\n\t<td class=\"indent1\" colspan=\"8\">Please clearly document any reaction, including:</td>\r\n</tr>\r\n<tr>\r\n\t<td class=\"indent2\" colspan=\"8\">a. Patient's symptoms, vital signs, and physical findings;</td>\r\n</tr>\r\n<tr>\r\n\t<td class=\"indent2\" colspan=\"8\">b. Exactly when the reaction occurred (ie, what step, how many minutes into that step);</td>\r\n</tr>\r\n<tr>\r\n\t<td class=\"indent2\" colspan=\"8\">c. Treatment administered, how and when the reaction resolved, and when the protocol was restarted.</td>\r\n</tr>\r\n<tr>\r\n\t<td class=\"subtitle1_left\" colspan=\"8\">Treatment of allergic reactions:</td>\r\n</tr>\r\n<tr>\r\n\t<td class=\"indent1\" colspan=\"8\">1. <strong>For mild reactions:</strong> In case of isolated itching, flushing, hives, mild chest tightness, nausea, abdominal pain, or back pain, with normal vital signs, stop the infusion and treat with IV Benadryl. Observe patient until the reaction subsides, and then resume the protocol at the point where the infusion was stopped.</td>\r\n</tr>\r\n<tr>\r\n\t<td class=\"indent1\" colspan=\"8\">2. <strong>For severe reactions:</strong> In case of hypotension, throat swelling, wheezing/respiratory distress, or decreased oxygen saturation, stop the infusion and treat with Epinephrine 0.3 mg IM x 1, Benadryl and Solumedrol IV, oxygen, nebulized albuterol for bronchospasm, and IV fluids (normal saline), per AHA guidelines. Place patient in a recumbent position if hypotensive. Consider glucagon 1-2 mg IV bolus if patient has taken beta-blockers, followed by infusion at 1-5 mg/hr. <strong>Immediately alert the housestaff and supervising physician.</strong> When the patient is stable, the protocol will be resumed as instructed by the supervising physician. <em>Patient should be discharged with prescription for an Epipen.</em></td>\r\n</tr>\r\n<tr>\r\n\t<td class=\"indent1\" colspan=\"8\"><strong>Contact the supervising physician for ANY severe or prolonged reaction, or any questions regarding the protocol, reactions, and appropriate management.</strong></td>\r\n</tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=47898&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Rituximab_desens.htm</title></head></div><div class=\"graphic_reference\">Courtesy of Mariana C Castells, MD, PhD.</div><div id=\"graphicVersion\">Graphic 80597 Version 1.0</div></div></div>"},"80598":{"type":"graphic_diagnosticimage","displayName":"Osteoid osteoma xray","title":"Osteoid osteoma plain radiograph","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Osteoid osteoma plain radiograph</div><div class=\"cntnt\"><img style=\"width:465px; height:483px;\" src=\"images/PEDS/80598_Osteoid_osteoma_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Full and B) coned views of the midshaft of the femur demonstrate a dense sclerotic zone of cortical thickening laterally, which contains a small oval lucent nidus (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Eisenberg RL. An Atlas of Differential Diagnosis, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80598 Version 3.0</div></div></div>"},"80599":{"type":"graphic_diagnosticimage","displayName":"MRI of femoral osteomyelitis","title":"MRI of femoral osteomyelitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">MRI of femoral osteomyelitis</div><div class=\"cntnt\"><img style=\"width:504px; height:504px;\" src=\"images/RADIOL/80599_Trochanteric_osteomyelitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Femoral osteomyelitis. Coronal inversion recovery MRI of the pelvis shows bright signal of bone marrow edema of the left femoral greater trochanter and intertrochanteric region (arrow) with extensive surrounding muscle edema consistent with osteomyelitis.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging. </div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD.</div><div id=\"graphicVersion\">Graphic 80599 Version 4.0</div></div></div>"},"80601":{"type":"graphic_table","displayName":"Classification porphyrias","title":"Classification of the human porphyrias as hepatic or erythropoietic and as acute or cutaneous, the affected enzymes, patterns of inheritance and their major biochemical features","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of the human porphyrias as hepatic or erythropoietic and as acute or cutaneous, the affected enzymes, patterns of inheritance and their major biochemical features</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"7%\"></colgroup><colgroup span=\"4\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Disease</td> <td class=\"subtitle1\" colspan=\"2\">Classification</td> <td class=\"subtitle1\" rowspan=\"2\">Enzyme affected</td> <td class=\"subtitle1\" rowspan=\"2\">Inheritance</td> <td class=\"subtitle1\" colspan=\"4\">Major biochemical findings*</td> </tr> <tr> <td class=\"subtitle2\">Tissue site</td> <td class=\"subtitle2\">Clinical features</td> <td class=\"subtitle2\">Urine</td> <td class=\"subtitle2\">Plasma</td> <td class=\"subtitle2\">Erythrocytes</td> <td class=\"subtitle2\">Feces</td> </tr> <tr> <td>ADP</td> <td>Hepatic<sup>&#182;</sup></td> <td>Acute</td> <td>ALAD</td> <td>Autosomal recessive</td> <td>ALA, coproporphyrin III</td> <td>ALA, coproporphyrin III</td> <td>Zinc protoporphyrin and low ALAD activity</td> <td>&nbsp;</td> </tr> <tr> <td>AIP</td> <td>Hepatic</td> <td>Acute</td> <td>PBGD</td> <td>Autosomal dominant</td> <td>ALA, PBG, coproporphyrin</td> <td>&nbsp;</td> <td>Low PBGD activity</td> <td>&nbsp;</td> </tr> <tr> <td>HCP</td> <td>Hepatic</td> <td>Acute and cutaneous</td> <td>CPOX</td> <td>Autosomal dominant</td> <td>ALA, PBG, coproporphyrin III</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Coproporphyrin III</td> </tr> <tr> <td>VP</td> <td>Hepatic</td> <td>Acute and cutaneous</td> <td>PPOX</td> <td>Autosomal dominant</td> <td>ALA, PBG, coproporphyrin III</td> <td>Fluorescence peak at 626 nm</td> <td>&nbsp;</td> <td>Coproporphyrin III and protoporphyrin</td> </tr> <tr> <td>PCT</td> <td>Hepatic</td> <td>Cutaneous</td> <td>UROD</td> <td>Autosomal dominant<sup>&#916;</sup></td> <td>Uroporphyrin and hepta-carboxyl-porphyrin</td> <td>Uroporphyrin and hepta-carboxyl-porphyrin</td> <td>&nbsp;</td> <td>Isocoproporphyrin</td> </tr> <tr> <td>HEP</td> <td>Hepatic<sup>&#182;</sup></td> <td>Cutaneous</td> <td>UROD</td> <td>Autosomal recessive</td> <td>Uroporphyrin and hepta-carboxyl-porphyrin</td> <td>Uroporphyrin and hepta-carboxyl-porphyrin</td> <td>Zinc protoporphyrin and low UROD activity</td> <td>Isocoproporphyrin</td> </tr> <tr> <td>CEP</td> <td>Erythropoietic</td> <td>Cutaneous</td> <td>UROS</td> <td>Autosomal recessive</td> <td>Uroporphyrin I and coproporphyrin I</td> <td>Uroporphyrin I and coproporphyrin I</td> <td>Uroporphyrin I and coproporphyrin I</td> <td>Coproporphyrin I</td> </tr> <tr> <td>EPP &#8212; classic form</td> <td>Erythropoietic</td> <td>Cutaneous</td> <td>FECH</td> <td>Autosomal dominant</td> <td>&nbsp;</td> <td>Protoporphyrin</td> <td>Free protoporphyrin</td> <td>Protoporphyrin</td> </tr> <tr> <td>EPP&nbsp;&#8212; variant form</td> <td>Erythropoietic</td> <td>Cutaneous</td> <td>ALAS2</td> <td>X-linked recessive</td> <td>&nbsp;</td> <td>Protoporphyrin</td> <td>Free and zinc protoporphyrin</td> <td>Protoporphyrin</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADP: ALA dehydratase porphyria; AIP: acute intermittent porphyria; HCP: hereditary coproporphyria; VP: variegate porphyria; PCT: porphyria cutanea tarda; HEP: hepatoerythropoietic porphyria; CEP: congenital erythropoietic porphyria; EPP: erythropoietic protoporphyria; ALAD: ALA dehydratase; PBGD: porphobilinogen deaminase; CPOX: coproporphyrinogen oxidase; PPOX: protoporphyrinogen oxidase; UROD: uroporphyrinogen decarboxylase; UROS: uroporphyrinogen III synthase; FECH: ferrochelatase; ALAS2: ALA-synthase 2; ALA: delta-aminolevulinic acid; PBG: porphobilinogen.<br />* Increases of importance for diagnosis in most cases.<br />¶ These hepatic porphyrias also have erythropoietic features, including increases in erythrocyte zinc protoporphyrin.<br />Δ UROD inhibition in PCT is mostly acquired, but an inherited deficiency of the enzyme predisposes in familial (type 2) disease.</div><div class=\"graphic_reference\">Karl Anderson, MD, FACP.</div><div id=\"graphicVersion\">Graphic 80601 Version 8.0</div></div></div>"},"80602":{"type":"graphic_algorithm","displayName":"Approach to calcipenic rickets","title":"Diagnostic approach to calcipenic (hypocalcemic) rickets","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to calcipenic (hypocalcemic) rickets</div><div class=\"cntnt\"><img style=\"width:550px; height:322px;\" src=\"images/PEDS/80602_Approach_hypocalcemic_ricke.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Calcipenic rickets is sometimes termed \"hypocalcemic rickets,\" but this term is not completely accurate because serum calcium is not always low in this disorder. Calcipenic rickets is most commonly caused by vitamin D deficiency. Calcipenic rickets also may be caused by a mixed deficiency of vitamin D and calcium.</div><div class=\"graphic_footnotes\">* 1-alpha-hydroxylase deficiency (previously called vitamin D dependent rickets type I or pseudo-vitamin D deficiency), is characterized by defective conversion of 25-hydroxyvitamin D to 1,25 dihydroxyvitamin D.<br />&para; Hereditary resistance to vitamin D (previously called vitamin D dependent rickets type II) is a rare disorder characterized by end-organ resistance to vitamin D, usually caused by a defect in the vitamin D receptor.</div><div id=\"graphicVersion\">Graphic 80602 Version 7.0</div></div></div>"},"80604":{"type":"graphic_figure","displayName":"Commisural calcium in MS","title":"Commissural calcium predicts outcome after mitral valvuloplasty","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Commissural calcium predicts outcome after mitral valvuloplasty</div><div class=\"cntnt\"><img style=\"width:422px; height:272px;\" src=\"images/CARD/80604_Commisural_calcium_in_MS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In patients undergoing valvuloplasty for mitral stenosis, the presence or absence of commissural calcium on an echocardigram was predictive of survival with freedom from death, mitral valve replacement, or repeat valvuloplasty (p</div><div class=\"graphic_reference\">Data from Cannan CR, Nishimura R, Reeder GS, et al. J Am Coll Cardiol 1997; 29:175.</div><div id=\"graphicVersion\">Graphic 80604 Version 2.0</div></div></div>"},"80605":{"type":"graphic_picture","displayName":"Noncholinergic neurotransmitter","title":"Noncholinergic neurotransmitters","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Noncholinergic neurotransmitters</div><div class=\"cntnt\"><img style=\"width:522px; height:359px;\" src=\"images/PULM/80605_Noncholinergic_neurotransmi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Noncholinergic neurotransmitters are localized to nerve fibers and neurons of human airway parasympathetic ganglia. In addition to acetylcholine, many noncholinergic neurotransmitters have been localized to nerves and ganglia neurons of the human airways. In this ganglion, nerve fibers stain for substance P while a subset of the ganglia neurons stain for nitric oxide synthase (NOS). Photomicrographs in panels B and D (1000x) are higher magnification of ganglia depicted in panels A and C (400x), respectively. Calibration bars: 50 µm in panels A and C, 20 µm in panels B and D.</div><div id=\"graphicVersion\">Graphic 80605 Version 2.0</div></div></div>"},"80606":{"type":"graphic_algorithm","displayName":"Algorithm ectopic pregnancy diagnosis","title":"Algorithm: Diagnosis of ectopic pregnancy","html":"<div class=\"graphic\"><div style=\"width: 978px\" class=\"figure\"><div class=\"ttl\">Algorithm: Diagnosis of ectopic pregnancy</div><div class=\"cntnt\"><img style=\"width:958px; height:793px;\" src=\"images/OBGYN/80606_Algo_ectopic_pregnancy_DX.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">hCG: human chorionic gonadotropin; TVUS: transvaginal ultrasound; FAST: Focused Assessment with Sonography for Trauma; IUP: intrauterine pregnancy.<br />* Nondiagnostic findings on ultrasound include no findings in the uterus or adnexa, a potential gestational sac in the uterus with no yolk sac or embryo, or an adnexal mass with no yolk sac or embryo. An intrauterine sac and an adnexal mass suspicious for an ectopic pregnancy may both be present. If so, this may be an intrauterine pseudosac, but a rare heterotopic pregnancy must be excluded.<br />¶ The discriminatory zone is the serum hCG level above which a gestational sac should be visualized by TVUS if an IUP is present. Typically an IUP is seen when the hCG is 2000 international units/L or higher, but since fibroids, body habitus, and multiple gestations can occur, no single value of hCG should be used to treat a stable patient with a pregnancy of unknown location.<br />Δ Other etiologies of elevated hCG include trophoblastic or nontrophoblastic tumors (eg, testicular cancer), pituitary hCG, false positive, or exogenous hCG.</div><div id=\"graphicVersion\">Graphic 80606 Version 3.0</div></div></div>"},"80614":{"type":"graphic_picture","displayName":"Incorrect laryngoscope motion","title":"Incorrect laryngoscope motion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incorrect laryngoscope motion</div><div class=\"cntnt\"><img style=\"width:429px; height:322px;\" src=\"images/EM/80614_Laryngoscopeincorrect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When performing direct laryngoscopy, do not &quot;lever&quot; back on the handle, as in the photo above. This impairs the view and can damage teeth. Instead, pull in the direction of the handle.</div><div class=\"graphic_reference\">Reproduced with permission from: Orebaugh SL. Direct laryngoscopy. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 80614 Version 11.0</div></div></div>"},"80615":{"type":"graphic_figure","displayName":"Vessel occlusion sickle cell","title":"Proposed mechanisms of vascular occlusion in sickle cell disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proposed mechanisms of vascular occlusion in sickle cell disease</div><div class=\"cntnt\"><img style=\"width:391px; height:362px;\" src=\"images/HEME/80615_Vessel_occlusion_sickle_cel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A (on left) illustrates adhesion of sickle cells to the vascular endothelium in post-capillary venules and venules. Panel B (on right) illustrates the subsequent trapping of dense red cells (in blue) in the partially obstructed post-capillary venules, followed by retrograde obstruction.</div><div id=\"graphicVersion\">Graphic 80615 Version 1.0</div></div></div>"},"80616":{"type":"graphic_picture","displayName":"Arteriovenous anastomosis postablation 2","title":"Arteriovenous anastomosis postablation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arteriovenous anastomosis postablation</div><div class=\"cntnt\"><img style=\"width:288px; height:292px;\" src=\"images/OBGYN/80616_Tx_TTTS5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ablated area between the recipient vein and donor artery. The laser fiber is at 12 o'clock.</div><div class=\"graphic_reference\">Courtesy of Kenneth J Moise, Jr, MD and Anthony Johnson, DO.</div><div id=\"graphicVersion\">Graphic 80616 Version 4.0</div></div></div>"},"80617":{"type":"graphic_table","displayName":"Markers of risk in HCM","title":"The recognised markers of risk in HCM and their sensitivity, specificity, and positive and negative predictive accuracy (PPA and NPA)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The recognised markers of risk in HCM and their sensitivity, specificity, and positive and negative predictive accuracy (PPA and NPA)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Risk factor </td> <td class=\"subtitle1\">Sensitivity, percent </td> <td class=\"subtitle1\">Specificity, percent </td> <td class=\"subtitle1\">PPA, percent </td> <td class=\"subtitle1\">NPA, percent </td> </tr> <tr> <td>Abnormal blood pressure response: &#60;40 years old<sup>[1]</sup></td> <td>75</td> <td>66</td> <td>15</td> <td>97</td> </tr> <tr> <td>NSVT: adult &#60;45 years old<sup>[2]</sup></td> <td>69</td> <td>80</td> <td>22</td> <td>97</td> </tr> <tr> <td>NSVT: &#8804;21 years old<sup>[3]</sup></td> <td>&#60;10</td> <td>89</td> <td>&#60;10</td> <td>85</td> </tr> <tr> <td>Inducible VT/VF: high risk population<sup>[4]</sup></td> <td>82</td> <td>68</td> <td>17</td> <td>98</td> </tr> <tr> <td>Syncope: &#60;45 years old*<sup>[5]</sup></td> <td>35</td> <td>82</td> <td>25</td> <td>86</td> </tr> <tr> <td>Family history: at least one unexplained sudden death &#177; HCM*<sup>[5]</sup></td> <td>42</td> <td>79</td> <td>28</td> <td>88</td> </tr> <tr> <td>LVH &#8805;3 cm<sup>&#182;[6]</sup></td> <td>26</td> <td>88</td> <td>13</td> <td>95</td> </tr> <tr> <td>Two or more risk factors<sup>&#182;&#916;[7]</sup></td> <td>45</td> <td>90</td> <td>23</td> <td>96</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HCM: hypertrophic cardiomyopathy; LVH: left ventricular hypertrophy; ICD: implantable cardioverter-defibrillator; NPA: negative predictive accuracy; NSVT: nonsustained ventricular tachycardia; PPA: positive predictive accuracy; VF: ventricular fibrillation; VT: ventricular tachycardia.<br />* Figures provided are for the risk of death from all causes rather than sudden death only.<br />¶&nbsp;Figures provided are for risk of sudden death and/or appropriate ICD discharge.<br />Δ In this data set from Elliott and colleagues, family history and syncope were combined in order to achieve statistical significance of relative risk.</div><div class=\"graphic_reference\">1. McKenna WJ, Franklin RC, Nihoyannopoulos P, et al. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 1988; 11:147.<br />2. Maron BJ, Savage DD, Wolfson JK, et al. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol 1981; 48:252.<br />3. McKenna WJ, Oakley CM, Krikler DM, et al. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985; 53:412.<br />4. Fananapazir L, Chang AC, Epstein SE, McAreavey D. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation 1992; 86:730.<br />5. McKenna W, Deanfield J, Faruqui A, et al. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981; 47:532.<br />6. Elliott PM, Gimeno BJ, Mahon NG, et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001; 357:420.<br />7. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000; 36:2212.<br />Reproduced with permission from: McKenna, WJ, Behr, ER. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart 2002; 87:169. Copyright © 2002 BMJ Publishing Group, Ltd.</div><div id=\"graphicVersion\">Graphic 80617 Version 2.0</div></div></div>"},"80618":{"type":"graphic_table","displayName":"Drug and toxin induced mental status changes","title":"Drug- and toxin-induced mental status alterations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug- and toxin-induced mental status alterations</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Central nervous system depression</td> </tr> <tr> <td class=\"sublist1_start\">Anticholinergics</td> </tr> <tr> <td class=\"sublist1\">Antihistamines</td> </tr> <tr> <td class=\"sublist1\">Belladonna alkaloids</td> </tr> <tr> <td class=\"sublist1\">Phenothiazines</td> </tr> <tr> <td class=\"sublist1_start\">Antidepressants</td> </tr> <tr> <td class=\"sublist1\">Cyclic antidepressants</td> </tr> <tr> <td class=\"sublist1\">Selective serotonin reuptake inhibitors</td> </tr> <tr> <td class=\"sublist1\">Monoamine oxidase inhibitors</td> </tr> <tr> <td>Antipsychotics</td> </tr> <tr> <td class=\"sublist1_start\">Simple asphyxiants</td> </tr> <tr> <td class=\"sublist1\">Carbon dioxide</td> </tr> <tr> <td class=\"sublist1\">Inert gases</td> </tr> <tr> <td class=\"sublist1_start\">Cellular asphyxiants</td> </tr> <tr> <td class=\"sublist1\">Carbon monoxide</td> </tr> <tr> <td class=\"sublist1\">Cyanide</td> </tr> <tr> <td class=\"sublist1\">Hydrogen sulfide</td> </tr> <tr> <td class=\"sublist1\">Methemoglobinemia</td> </tr> <tr> <td>Lithium</td> </tr> <tr> <td class=\"sublist1_start\">Cholinergics</td> </tr> <tr> <td class=\"sublist1\">Organophosphates</td> </tr> <tr> <td class=\"sublist1\">Carbamates</td> </tr> <tr> <td class=\"sublist1_start\">Sympatholytics</td> </tr> <tr> <td class=\"sublist1\">Beta blockers</td> </tr> <tr> <td class=\"sublist1\">Clonidine</td> </tr> <tr> <td class=\"sublist1_start\">Sedative-hypnotics</td> </tr> <tr> <td class=\"sublist1\">Benzodiazepines</td> </tr> <tr> <td class=\"sublist1\">Barbiturates</td> </tr> <tr> <td>Muscle relaxants</td> </tr> <tr> <td>Hypoglycemic agents</td> </tr> <tr> <td>Heavy metals</td> </tr> <tr> <td>Opiates</td> </tr> <tr> <td>Antiepileptics</td> </tr> <tr> <td>Mushrooms</td> </tr> <tr> <td>Salicylates</td> </tr> <tr> <td>Gamma-hydroxybutyrate</td> </tr> <tr> <td>Volatile inhalants</td> </tr> <tr> <td>Alcohols</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Agitation</td> </tr> <tr> <td>Amantadine</td> </tr> <tr> <td class=\"sublist1_start\">Sympathomimetics</td> </tr> <tr> <td class=\"sublist1\">Amphetamines</td> </tr> <tr> <td class=\"sublist1\">Cocaine</td> </tr> <tr> <td class=\"sublist1\">Caffeine</td> </tr> <tr> <td class=\"sublist1\">Phenylpropanolamine</td> </tr> <tr> <td class=\"sublist1\">Theophylline</td> </tr> <tr> <td class=\"sublist1\">Cathinones</td> </tr> <tr> <td class=\"sublist1_start\">Anticholinergics</td> </tr> <tr> <td class=\"sublist1\">Antihistamines</td> </tr> <tr> <td class=\"sublist1\">Atropine</td> </tr> <tr> <td class=\"sublist1\">Scopolamine</td> </tr> <tr> <td class=\"sublist1\">Antiparkinson agents</td> </tr> <tr> <td class=\"sublist1\">Antispasmodics</td> </tr> <tr> <td class=\"sublist1\">Muscle relaxants</td> </tr> <tr> <td class=\"sublist1\">Plants containing belladonna alkaloids</td> </tr> <tr> <td class=\"sublist1\">Phenothiazines</td> </tr> <tr> <td class=\"sublist1\">Tricyclic antidepressants</td> </tr> <tr> <td>Salicylates</td> </tr> <tr> <td class=\"sublist1_start\">Central hallucinogens</td> </tr> <tr> <td class=\"sublist1\">Lysergic acid diethylamide (LSD)</td> </tr> <tr> <td class=\"sublist1\">Phencyclidine</td> </tr> <tr> <td class=\"sublist1\">Mescaline</td> </tr> <tr> <td class=\"sublist1\">Psilocybin</td> </tr> <tr> <td class=\"sublist1\">Ketamine</td> </tr> <tr> <td class=\"sublist1\">Designer amphetamines</td> </tr> <tr> <td class=\"sublist1\">Synthetic cannabinoids</td> </tr> <tr> <td>Drug withdrawal states</td> </tr> <tr> <td>Lithium</td> </tr> <tr> <td>Carbon monoxide</td> </tr> <tr> <td>Hypoglycemic agents</td> </tr> <tr> <td>Heavy metals</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80618 Version 8.0</div></div></div>"},"80619":{"type":"graphic_picture","displayName":"PKDL macules","title":"Post-kala-azar dermal leishmaniasis (PKDL) macules","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Post-kala-azar dermal leishmaniasis (PKDL) macules</div><div class=\"cntnt\"><img style=\"width:360px; height:583px;\" src=\"images/ID/80619_PKDL_macules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive hypopigmented macular PKDL in an eight-year-old girl in Bangladesh. She had a history of kala-azar that resolved with sodium stibogluconate treatment 28 months prior to the onset of the rash.</div><div class=\"graphic_reference\">Reproduced with permission from: Caryn Bern, MD.</div><div id=\"graphicVersion\">Graphic 80619 Version 3.0</div></div></div>"},"80620":{"type":"graphic_figure","displayName":"Digoxin level and survival","title":"Serum digoxin in HF is correlated with survival","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Serum digoxin in HF is correlated with survival</div><div class=\"cntnt\"><img style=\"width:511px; height:336px;\" src=\"images/CARD/80620_Digoxin_level_and_survival.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 3782 patients with heart failure (HF) receiving digoxin or placebo in the DIG trial, there was a significant association between serum digoxin concentration (SDC) and all-cause mortality. Compared&nbsp;with placebo, survival was significantly better for patients with SDC 0.5 to 0.8 ng/mL, and significantly worse for patients with SDC ≥1.2 ng/mL.</div><div class=\"graphic_reference\">Data from Rathore SS, Curtis JP, Wang Y, et al. JAMA 2003; 289:871.</div><div id=\"graphicVersion\">Graphic 80620 Version 4.0</div></div></div>"},"80621":{"type":"graphic_algorithm","displayName":"Neonatal resuscitation algorithm","title":"Neonatal resuscitation algorithm: 2010 guidelines","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Neonatal resuscitation algorithm: 2010 guidelines</div><div class=\"cntnt\"><img style=\"width:550px; height:638px;\" src=\"images/PEDS/80621_Neonatal_resuscitation_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CPAP: continuous positive airway pressure; HR: heart rate; IV: intravenous; min: minute; PPV: positive pressure ventilation; SpO<sub>2</sub>: oxygen saturation measured by pulse oximetry.</div><div class=\"graphic_reference\">Reprinted with permission. Neonatal Resuscitation: 2010. American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. © 2010 American Heart Association, Inc.</div><div id=\"graphicVersion\">Graphic 80621 Version 14.0</div></div></div>"},"80623":{"type":"graphic_figure","displayName":"Horner syndrome due to internal carotid artery dissection","title":"Horner syndrome due to internal carotid artery dissection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Horner syndrome due to internal carotid artery dissection</div><div class=\"cntnt\"><img style=\"width:426px; height:655px;\" src=\"images/NEURO/80623_Horn_synd_int_caro_art_diss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Horner syndrome (miosis and ptosis).<br> (B) Multiple left frontoparietal acute ischemic lesions on diffusion-weighted MRI.<br> (C) Carotid angiography with evidence of left extracranial internal carotid artery occlusion.<br> (D) Internal carotid artery mural hematoma due to dissection evident on MRI scan.<br> (E) Intimal flap (arrows) appearance on Duplex scan, a pathognomonic sign of dissection.</div><div class=\"graphic_reference\">Reproduced with permission from: Mazzucco S, Rizzuto N. Teaching NeuroImage: Horner syndrome due to internal carotid artery dissection. Neurology 2006; 66:E19. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80623 Version 5.0</div></div></div>"},"80624":{"type":"graphic_table","displayName":"Histologic idiopathic HTN","title":"Histologic findings in patients with idiopathic noncirrhotic portal hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histologic findings in patients with idiopathic noncirrhotic portal hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Histologic feature*</td> <td class=\"subtitle1\">Frequency (percent)</td> </tr> <tr> <td>Irregular intimal thickening of portal veins</td> <td>75-100<sup>&#182;</sup></td> </tr> <tr> <td>Organizing thrombus and/or recanalization of portal veins</td> <td>20-100<sup>&#182;</sup></td> </tr> <tr> <td>Intralobular fibrous septa</td> <td>95</td> </tr> <tr> <td>Abnormal blood vessels in the lobules</td> <td>75</td> </tr> <tr> <td>Subcapsular atrophy</td> <td>70</td> </tr> <tr> <td>Dense portal fibrosis and portal venous obliteration</td> <td>32-52</td> </tr> <tr> <td>Periductal fibrosis of interlobular bile ducts</td> <td>50</td> </tr> <tr> <td>Portal inflammation</td> <td>47</td> </tr> <tr> <td>Nodular hyperplasia of parenchyma</td> <td>25-40</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Needle biopsies from patients with idiopathic noncirrhotic portal hypertension are typically normal or show only nonspecific morphologic changes. Specific abnormalities are more commonly seen in larger wedge biopsies or autopsy specimens.<br />&#182; Studies showing findings in 100 percent of patients were based upon autopsy specimens.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Sarin SK, Kapoor D. Non-cirrhotic portal fibrosis: current concepts and management. J Gastroenterol Hepatol 2002; 17:526.</li>&#xD;&#xA;    <li>Hillaire S, Bonte E, Denninger MH, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut 2002; 51:275.</li>&#xD;&#xA;    <li>Ludwig J, Hashimoto E, Obata H, Baldus WP. Idiopathic portal hypertension; a histopathological study of 26 Japanese cases. Histopathology 1993; 22:227.</li>&#xD;&#xA;    <li>Nakanuma Y, Hoso M, Sasaki M, et al. Histopathology of the liver in non-cirrhotic portal hypertension of unknown aetiology. Histopathology 1996; 28:195.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 80624 Version 5.0</div></div></div>"},"80626":{"type":"graphic_figure","displayName":"Spectrum growth hormone sensitivity","title":"The clinical spectrum of growth hormone sensitivity","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">The clinical spectrum of growth hormone sensitivity</div><div class=\"cntnt\"><img style=\"width:494px; height:456px;\" src=\"images/PEDS/80626_Spectrum-growth-sens.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A two-dimensional diagram of the different degrees of growth hormone sensitivity among disorders characterized by short stature. Approximate relative levels of growth hormone secretion are shown on the vertical axis and relative growth hormone sensitivity on the horizontal axis.</div><div class=\"graphic_reference\">Reproduced with permission from: Cohen P. Problems with reclassification of insulin-like growth factor I production and action disorders. J Clin Endocrinol Metab 2006; 91:4235. Copyright &#169; 2006 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 80626 Version 5.0</div></div></div>"},"80627":{"type":"graphic_figure","displayName":"Rib and chest anatomy","title":"Rib and chest anatomy","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Rib and chest anatomy</div><div class=\"cntnt\"><img style=\"width:581px; height:537px;\" src=\"images/EM/80627_Rib_chest_anat.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company. Copyright © 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80627 Version 2.0</div></div></div>"},"80628":{"type":"graphic_figure","displayName":"Countercurrent mechanism III","title":"Countercurrent multiplication and the excretion of a concentrated urine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Countercurrent multiplication and the excretion of a concentrated urine</div><div class=\"cntnt\"><img style=\"width:360px; height:245px;\" src=\"images/NEPH/80628_Countercurrent_mechanism_1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transport of NaCl from the ascending limb results in the formation of an interstitial osmalal gradient from 285 mosmol/kg in the cortext to 1200 mosmol/kg at the papillary tip. In the presence of ADH, the urine becomes concentrated as it equilibrates with the interstitium in the medullary collecting tubule. The contribution of urea to the concentrating process is discussed&nbsp;in UpToDate topics on renal manifestations of&nbsp;sickle cell disease&nbsp;and has been omitted from the diagram.</div><div class=\"graphic_footnotes\">ADH: antidiuretic hormone.</div><div id=\"graphicVersion\">Graphic 80628 Version 2.0</div></div></div>"},"80629":{"type":"graphic_table","displayName":"Causes of low QRS voltage","title":"Causes of low voltage QRS complexes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of low voltage QRS complexes</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Adrenal insufficiency</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Anasarca</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Artifactual or spurious, eg, unrecognized standardization of ECG at one-half the usual gain (ie, 5 mm/mV)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiac infiltration or replacement (eg, amyloidosis, tumor)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiac transplantation, especially with acute or chronic rejection</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiomyopathy, idiopathic or secondary*</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Chronic obstructive pulmonary disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Constrictive pericarditis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hypothyroidism, usually with sinus bradycardia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Left pneumothorax (mid-left chest leads)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Myocardial infarction, extensive</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Myocarditis, acute or chronic</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Normal variant</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Obesity</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pericardial effusion</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pericardial tamponade, usually with sinus tachycardia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pleural effusions</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Dilated cardiomyopathy may be associated with the combination of relatively low limb lead voltages and prominent precordial voltages.</div><div id=\"graphicVersion\">Graphic 80629 Version 1.0</div></div></div>"},"80630":{"type":"graphic_figure","displayName":"Dose response to diltiazem for rate control in AF","title":"Dose response to diltiazem for rate control in atrial fibrillation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dose response to diltiazem for rate control in atrial fibrillation</div><div class=\"cntnt\"><img style=\"width:406px; height:245px;\" src=\"images/CARD/80630_Dose_response_to_IV_dilt_in.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier analysis of the percentage of patients maintaining a therapeutic rate control response to each dose level of intravenous diltiazem infusion in patients who initially responded to bolus diltiazem. Maintenance of rate control was greater at doses of 10 to 15 mg/h.</div><div class=\"graphic_reference\">Data from Ellenbogen KA, Dias VC, Cardello FP, et al. Am J Cardiol 1995; 75:45.</div><div id=\"graphicVersion\">Graphic 80630 Version 3.0</div></div></div>"},"80631":{"type":"graphic_diagnosticimage","displayName":"PCP in pediatric AIDS CXR","title":"Chest radiograph of an HIV-infected 2-year-old boy with Pneumocystis jiroveci pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of an HIV-infected 2-year-old boy with Pneumocystis jiroveci pneumonia</div><div class=\"cntnt\"><img style=\"width:329px; height:288px;\" src=\"images/PEDS/80631_PCP_in_pediatric_AIDS_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the presence of bilateral interstitial lung disease, pneumomediastinum, and subcutaneous emphysema.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Courtesy of Meg Ferris, MD.</div><div id=\"graphicVersion\">Graphic 80631 Version 4.0</div></div></div>"},"80632":{"type":"graphic_table","displayName":"Definition and criteria for CKD","title":"Definition and criteria for chronic kidney disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definition and criteria for chronic kidney disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Definition:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">Chronic kidney disease is defined based on the presence of either kidney damage or decreased kidney function for three or more months, irrespective of cause.</td> </tr> <tr> <td class=\"subtitle1\">Criteria</td> <td class=\"subtitle1\">Comment</td> </tr> <tr class=\"divider_bottom\"> <td>Duration &#8805;3 months, based on documentation or inference</td> <td>Duration is necessary to distinguish chronic from acute kidney diseases. <ul class=\"decimal_heading\"> <li>Clinical evaluation can often suggest duration </li> <li>Documentation of duration is usually not available in epidemiologic studies </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Glomerular filtration rate (GFR) &#60;60 mL/min/1.73 m<sup>2</sup></td> <td>GFR is the best overall index of kidney function in health and disease. <ul class=\"decimal_heading\"> <li>The normal GFR in young adults is approximately 125 mL/min/1.73 m<sup>2</sup>; GFR &#60;15 mL/min/1.73 m<sup>2</sup> is defined as kidney failure </li> <li>Decreased GFR can be detected by current estimating equations for GFR based on serum creatinine (estimated GFR) but not by serum creatinine alone </li> <li>Decreased estimated GFR can be confirmed by measured GFR<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">, measured creatinine clearance, or estimated GFR using cystatin C</span></li> </ul> </td> </tr> <tr> <td rowspan=\"5\">Kidney damage, as defined by structural abnormalities or functional abnormalities other than decreased GFR</td> <td>Pathologic abnormalities (examples). Cause is based on underlying illness and pathology. Markers of kidney damage may reflect pathology. <ul class=\"decimal_heading\"> <li>Glomerular diseases (diabetes, autoimmune diseases, systemic infections, drugs, neoplasia) </li> <li>Vascular diseases (atherosclerosis, hypertension, ischemia, vasculitis, thrombotic microangiopathy) </li> <li>Tubulointerstitial diseases (urinary tract infections, stones, obstruction, drug toxicity) </li> <li>Cystic disease (polycystic kidney disease) </li> </ul> </td> </tr> <tr> <td>History of kidney transplantation. In addition to pathologic abnormalities observed in native kidneys, common pathologic abnormalities include the following: <ul class=\"decimal_heading\"> <li>Chronic allograft nephropathy (non-specific findings of tubular atrophy, interstitial fibrosis, vascular and glomerular sclerosis) </li> <li>Rejection </li> <li>Drug toxicity (calcineurin inhibitors) </li> <li>BK virus nephropathy </li> <li>Recurrent disease (glomerular disease, oxalosis, Fabry disease) </li> </ul> </td> </tr> <tr> <td>Albuminuria as a marker of kidney damage (increased glomerular permeability, urine albumin-to-creatinine ratio [ACR] &#62;30 mg/g).* <ul class=\"decimal_heading\"> <li>The normal urine ACR in young adults is &#60;10 mg/g. Urine ACR categories 10-29, 30-300 and &#62;300 mg are termed \"mildly increased, moderately increased, and severely increased\" respectively. Urine ACR &#62;2200 mg/g is accompanied by signs and symptoms of nephrotic syndrome (low serum albumin, edema and high serum cholesterol). </li> <li>Threshold value corresponds approximately to urine dipstick values of trace or 1+, depending on urine concentration </li> <li>High urine ACR can be confirmed by urine albumin excretion in a timed urine collection </li> </ul> </td> </tr> <tr> <td>Urinary sediment abnormalities as markers of kidney damage, for example:&nbsp; <ul class=\"decimal_heading\"> <li>RBC casts in proliferative glomerulonephritis </li> <li>WBC casts in pyelonephritis or interstitial nephritis </li> <li>Oval fat bodies or fatty casts in diseases with proteinuria </li> <li>Granular casts and renal tubular epithelial cells in many parenchymal diseases (non-specific) </li> </ul> </td> </tr> <tr> <td>Imaging abnormalities as markers of kidney damage (ultrasound, computed tomography and magnetic resonance imaging with or without contrast, isotope scans, angiography). <ul class=\"decimal_heading\"> <li>Polycystic kidneys </li> <li>Hydronephrosis due to obstruction </li> <li>Cortical scarring due to infarcts, pyelonephritis or vesicoureteral reflux </li> <li>Renal masses or enlarged kidneys due to infiltrative diseases </li> <li>Renal artery stenosis </li> <li>Small and echogenic kidneys (common in later stages of CKD due to many parenchymal diseases) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Albumin-to-creatinine ratio (ACR) conversion factor 1.0 mg/g = 0.113 mg/mmol.</div><div class=\"graphic_reference\">Reproduced from: Levey A, Coresh J. Chronic kidney disease. Lancet 2011. DOI: 10.1016/S0140-6736(11)60178-5. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 80632 Version 3.0</div></div></div>"},"80633":{"type":"graphic_picture","displayName":"Mental crease","title":"Mental crease","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Mental crease</div><div class=\"cntnt\"><img style=\"width:504px; height:365px;\" src=\"images/DERM/80633_Mental_crease_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A horizontal groove is present on the chin.</div><div id=\"graphicVersion\">Graphic 80633 Version 2.0</div></div></div>"},"80635":{"type":"graphic_figure","displayName":"Stocking donner PI","title":"Using a stocking donner to put on compression stockings","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Using a stocking donner to put on compression stockings</div><div class=\"cntnt\"><img style=\"width:345px; height:498px;\" src=\"images/PI/80635_Stocking_donner_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 80635 Version 2.0</div></div></div>"},"80637":{"type":"graphic_picture","displayName":"Optic disc swelling","title":"Optic disc swelling","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Optic disc swelling</div><div class=\"cntnt\"><img style=\"width:288px; height:445px;\" src=\"images/PEDS/80637_Optic_disc_swelling.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Top: Fully developed optic disc swelling, in this case papilledema. Note the absence of distinct disc margins, obstruction of blood vessels as they cross the disc margin, hemorrhages, and cotton wool spots. The blood vessels change course abruptly as they approach the disc because they are running up and over the elevated disc substance. Bottom: Mild optic disc swelling. Note the concentric lines (Paton's lines) in the retina next to the disc (arrow). This occurs because the swollen disc pushes the retina aside.</div><div class=\"graphic_reference\">Courtesy of Karl C Golnik, MD.</div><div id=\"graphicVersion\">Graphic 80637 Version 1.0</div></div></div>"},"80638":{"type":"graphic_table","displayName":"Enuresis examination","title":"Important aspects of the physical examination of a child with enuresis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the physical examination of a child with enuresis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Examination finding</td> <td class=\"subtitle1\">Possible significance</td> </tr> <tr> <td>Poor growth</td> <td>Renal disease</td> </tr> <tr> <td>Hypertension</td> <td>Renal disease</td> </tr> <tr> <td>Wetness in the undergarments</td> <td>Daytime incontinence</td> </tr> <tr> <td>Palpation of stool in abdomen</td> <td>Constipation</td> </tr> <tr> <td>Perianal excoriation or vulvovaginitis</td> <td>Pinworms</td> </tr> <tr> <td>Abnormalities of lumbosacral spine (midline hair tuft, abnormal gluteal fold)</td> <td>Spinal dysraphism</td> </tr> <tr> <td>Incomplete bladder emptying (by percussion or palpation)</td> <td>Urologic abnormality</td> </tr> <tr> <td>Observation of slow urinary stream, straining, dribbling, intermittent stream</td> <td>Urologic abnormality</td> </tr> <tr> <td>Abnormal neurologic examination of the perineum and lower extremities</td> <td>Spinal cord abnormality</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80638 Version 4.0</div></div></div>"},"80640":{"type":"graphic_table","displayName":"Novel rx food allergy","title":"Novel immunomodulatory therapies for food allergy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Novel immunomodulatory therapies for food allergy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Therapy</td> <td class=\"subtitle1\">Mechanisms of action</td> <td class=\"subtitle1\">Effects</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Human data</td> </tr> <tr> <td class=\"subtitle2_left indent1\" colspan=\"43\">Allergen-specific immunotherapy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Oral IT</td> <td> <ul> <li>Decreased skin test reactivity. </li> <li>Food-specific IgE increases during the first year of oral IT then decreases. </li> <li>Increased food-specific IgG and IgA. </li> <li>FOXP3+ T cells are increased until 12 months and then decrease thereafter. </li> <li>Increased peanut-induced Treg function and hypomethylation of <em>FOXP3</em>. </li> <li>Decreased basophil reactivity to food allergen. </li> <li>Increased CD4+CD23<sup>high</sup> T cells. </li> <li>Increased IL-10, IL-5, IFN-gamma, and TNF-alpha and decreased IL-4 production by food-specific PBMCs. </li> <li>Genes in the apoptotic pathways are downregulated. </li> </ul> </td> <td> <ul> <li>Sustained unresponsiveness (a surrogate term for oral food tolerance) or increased threshold dose of food for clinical reactions up to six months after stopping oral IT can be attained in 30 to 50% after three to five years of oral IT. </li> <li>Short-term success rate (a temporary state of desensitization) up to 75%, depending upon the food and treatment protocol. </li> </ul> </td> <td> <ul> <li>Limited long-term follow-up data. </li> <li>Some patients experience recurrence of symptoms if food not ingested on daily basis. </li> <li>Generally local reactions with occasional serious systemic reactions and a high rate of gastrointestinal side effects (abdominal pain, nausea, vomiting) in up to 30% of subjects; 2.4 to 8% risk of treatment-emergent eosinophilic esophagitis. </li> <li>Convenience of home administration of maintenance doses but requires lifestyle modifications. </li> <li>The risk of an allergic reaction to a previously tolerated dose of food is associated with physical exertion within one to two hours after dosing, dosing on an empty stomach, dosing during menses, concurrent febrile illness, seasonal allergies, and suboptimally controlled asthma. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Sublingual IT</td> <td> <ul> <li>Serum food-specific IgG4 and total IL-10 increased in treated group. </li> </ul> </td> <td> <ul> <li>Increased threshold dose on oral challenge. Efficacy lower than oral IT and limited by the low dose of allergen that can be held under the tongue. </li> </ul> </td> <td> <ul> <li>Systemic side effects rate 0.2% during rush build-up phase. </li> <li>One peanut sublingual IT study found a&nbsp;sustained unresponsiveness&nbsp;rate of 10% after three years of therapy, although 65% of the original 40 subjects did not continue therapy during the extended phase of this study. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Epicutaneous IT</td> <td> <ul> <li>Serum food-specific IgE decreased; IgG1 and IgG4 increased; decreased reactivity of blood basophils and tissue mast cells. </li> </ul> </td> <td> <ul> <li>Increased threshold dose on oral challenge; in one multicenter clinical trial, desensitization (defined as 10-fold increase in successfully consumed dose) was observed in 40% of treated subjects. </li> </ul> </td> <td> <ul> <li>Low rate of systemic side effects; no gastrointestinal side effects. </li> <li>Up to 100% with local skin irritation under the patch; no long-term follow-up. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Subcutaneous IT with chemically modified, aluminum hydroxide-adsorbed allergen</td> <td> <ul> <li>Increased specific IgG and IgG4 levels for whole peanut, Ara h1, Ara h2, Ara h3, and Ara h6. </li> <li>Trend for decreased basophil reactivity. </li> </ul> </td> <td> <ul> <li>Pilot study in 17 adults with peanut allergy reported good safety and tolerability. </li> </ul> </td> <td> <ul> <li>A chemically modified, aluminum hydroxide adsorbed peanut extract for weekly subcutaneous administration is under investigation in subjects with peanut allergy (5 to 50 years) in a safety and tolerability randomized trial (NCT02991885). </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Intradermal/intramuscular immunotherapy with LAMP-DNA vaccine</td> <td> <ul> <li>LAMP-DNA vaccines use the natural biochemistry of LAMP to intersect with the process that APCs use to internalize, digest, and present exogenously derived antigens to the immune system as part of the lysosomal/MHC II complex and activate CD4+ helper T cells, as well as CD8+ cytotoxic T cells. </li> </ul> </td> <td> <ul> <li>In peanut-allergic C3H/HeJ mice, intradermal injection of LAMP peanut vaccine attenuated allergic symptoms during peanut challenge, reduced peanut-specific IgE levels, and increased peanut-specific IgG2a levels compared with vector control. </li> </ul> </td> <td> <ul> <li>There is an ongoing phase-I, randomized trial to evaluate safety, tolerability, and immune response in adults allergic to peanut after receiving intradermal or intramuscular administration of a single multivalent peanut (Ara h1, h2, h3)-LAMP DNA plasmid vaccine (NCT02851277). </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Rectal IT with heat-killed bacteria and modified proteins</td> <td> <ul> <li>Potentiation of Th1 and T regulatory cytokine responses. </li> </ul> </td> <td> <ul> <li>Protection against peanut anaphylaxis in mice, lasting up to 10 weeks after treatment. </li> </ul> </td> <td> <ul> <li>Concern for toxicity of bacterial adjuvants, excessive Th1 stimulation, and potential for autoimmunity. </li> <li>Heat-killed <em>Escherichia coli</em> expressing modified peanut allergens administered rectally caused allergic reactions in a subset of adults allergic to peanut in a phase-I clinical trial. No active studies. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left indent1\" colspan=\"4\">Allergen nonspecific</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Monoclonal anti-IgE (omalizumab, talizumab)</td> <td> <ul> <li>Binds to circulating IgE and prevents IgE deposition on mast cells and blocks degranulation. </li> </ul> </td> <td> <ul> <li>Improves symptoms of asthma and allergic rhinitis; provides protection against peanut anaphylaxis in 75% of treated patients. </li> </ul> </td> <td> <ul> <li>Subcutaneous at monthly intervals; unknown long-term consequences of IgE elimination. Food nonspecific. Not used as a monotherapy for food allergy but as a pretreatment for oral IT to decrease adverse reactions during up-dosing. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Traditional Chinese Medicine (TCM)</td> <td> <ul> <li>Downregulation of Th2 cytokines (IL-4, IL-5, IL-13), upregulation of Th1 cytokines (IFN-gamma, IL-12), decreased allergen specific-IgE, decreased T cell proliferation to peanut. Decreased basophil activation by food allergen. </li> </ul> </td> <td> <ul> <li>Reverses allergic inflammation in the airways; protects mice from peanut anaphylaxis. No clinical protection in human studies when used as a monotherapy. </li> </ul> </td> <td> <ul> <li>Oral, generally safe, and well tolerated; ongoing studies focus on identification of the crucial active herbal components in the multi-herb formulas and establishing optimal dosing. Ongoing multicenter clinical trial in combination with oral IT and anti-IgE. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Animal data</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Peptide IT</td> <td> <ul> <li>Overlapping peptides (10 to 20 amino-acid long) that represent the entire sequence of allergen. Binding to mast cells eliminated; T cell responses preserved. </li> </ul> </td> <td> <ul> <li>Protection against peanut anaphylaxis in mice; no human studies. </li> </ul> </td> <td> <ul> <li>Improved safety profile compared with conventional IT; does not require identification of IgE-binding epitopes. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Engineered recombinant protein IT</td> <td> <ul> <li>Binding to mast cells eliminated; T cell responses comparable with native peanut allergens. </li> </ul> </td> <td> <ul> <li>Protection against peanut anaphylaxis in mice. </li> </ul> </td> <td> <ul> <li>Improved safety profile compared with conventional IT; requires identification of IgE binding sites. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">IT with immunostimulatory sequences (ISS-ODN)</td> <td> <ul> <li>Potent stimulation of Th1 cells via activation of APCs, natural killer cells, and B cells. </li> <li>Increased Th1 cytokines. </li> </ul> </td> <td> <ul> <li>Protection against peanut sensitization in mice; no human studies. </li> </ul> </td> <td> <ul> <li>Not shown to reverse established peanut allergy. </li> <li>Concern for excessive Th1 stimulation and potential for autoimmunity. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Human immunoglobulin Fc-Fc fusion protein</td> <td> <ul> <li>Fusion protein crosslinks the high-affinity Fc&#949;RI and low-affinity Fc&#947;RIIb receptors on mast cells and basophils. </li> </ul> </td> <td> <ul> <li>Fusion protein inhibits degranulation of mast cells and basophils. No human studies. </li> </ul> </td> <td> <ul> <li>A human gamma-allergen fusion protein, the Fc-Fel d 1 fusion protein inhibited Fel d 1-mediated degranulation in purified human basophils from cat-allergic patients and blocked the allergic responses in a mouse model. A similar approach can be used for food allergy. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sugar-conjugated BSA</td> <td> <ul> <li>Mannoside-conjugated BSA (Man<sub>51</sub>-BSA) targeted lamina propria dendritic cells expressing SIGNR-1 and promoted CD4+ type 1 Treg cells. </li> </ul> </td> <td> <ul> <li>Mice sensitized with Man<sub>51</sub>-BSA were protected from anaphylaxis during an oral challenge with BSA and Man<sub>51</sub>-BSA. No human studies. </li> </ul> </td> <td> <ul> <li>Sugar-modified food allergens might be used to induce oral tolerance by targeting SIGNR-1 and lamina propria dendritic cells. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><em>Trichuris suis</em> ova therapy</td> <td> <ul> <li>Stimulation of IL-10 synthesis. </li> </ul> </td> <td> <ul> <li>In a mouse model of food allergy protected against food IgE sensitization and anaphylaxis; no published human studies in food allergy. </li> </ul> </td> <td> <ul> <li>Safe and afforded clinical improvement in Crohn disease and ulcerative colitis; no beneficial effect in adults with allergic rhinitis. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IT: immunotherapy; IgE: immunoglobulin E; IgG: immunoglobulin G; IgA: immunoglobulin A; <EM>FOXP3</EM>: forkhead box P3; Treg: T regulatory cell; CD: cluster of differentiation; IL: interleukin; IFN: interferon; TNF: tumor necrosis factor; PBMC: peripheral blood mononuclear cells; LAMP: lysosome-associated membrane protein; APC: antigen-presenting cell; MHC: major histocompatibility complex; Th1: T helper cell type 1; Th2: T helper cell type 2; Fc: fragment, crystallizable; FcεRI: high affinity receptor (RI) that binds to the Fc fragment of IgE (Fc-epsilon); FCγRIIb: Fc fragment of IgG receptor IIb; Fel d 1: Felis domesticus (cat) allergen I; BSA: bovine serum albumin; SIGN-R1: the mouse homologue of a human C-type lectin receptor, DCSIGN (dendritic cell-specific ICAM3-grabbing nonintegrin).</div><div id=\"graphicVersion\">Graphic 80640 Version 11.0</div></div></div>"},"80642":{"type":"graphic_table","displayName":"Skin testing protocol for patients - Local anesthetics","title":"Skin testing protocol for patients with histories of possible IgE-mediated reactions to local anesthetics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Skin testing protocol for patients with histories of possible IgE-mediated reactions to local anesthetics</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Step</td> <td class=\"subtitle1\">Route</td> <td class=\"subtitle1\">Volume (mL)</td> <td class=\"subtitle1\">Dilution</td> </tr> <tr> <td class=\"centered\">1</td> <td>Puncture</td> <td>&ndash;</td> <td>Undiluted*</td> </tr> <tr> <td class=\"centered\">2</td> <td>Intradermal</td> <td>0.02 cc</td> <td>1:100</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Prick (epicutaneous) testing is performed initially, with appropriate positive (histamine) and negative (diluent) controls. Results are assessed at 20 minutes. A positive result consists of a wheal 3 mm greater than the negative control. If prick tests are negative, then intradermal testing is performed by injecting 0.02 mL of a 1:100 dilution of the local anesthetic in question.</div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.<br />* The concentration of the local anesthetic (usually 1 to 2%) to be used for the procedure.</div><div id=\"graphicVersion\">Graphic 80642 Version 5.0</div></div></div>"},"80644":{"type":"graphic_figure","displayName":"Microbes in odontogenic infx","title":"Microbial specificity and odontogenic infections*","html":"<div class=\"graphic\"><div style=\"width: 665px\" class=\"figure\"><div class=\"ttl\">Microbial specificity and odontogenic infections*</div><div class=\"cntnt\"><img style=\"width:645px; height:482px;\" src=\"images/ID/80644_Micrbs_odontogenic_infx_ed1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* A unifying hypothesis demonstrating a microbial shift from a plaque-free tooth surface and progression to supragingival and subgingival organisms.</div><div class=\"graphic_reference\">Modified with permission from Chow, AW. Odontogenic infections. In: Infections of the Head and Neck, Schlossberg, D (Ed), Springer-Verlag, New York 1987, p.149.</div><div id=\"graphicVersion\">Graphic 80644 Version 2.0</div></div></div>"},"80646":{"type":"graphic_algorithm","displayName":"Diagnosis in the prepubertal male with dysuria","title":"Diagnostic approach to the prepubertal male with dysuria","html":"<div class=\"graphic\"><div style=\"width: 757px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to the prepubertal male with dysuria</div><div class=\"cntnt\"><img style=\"width:737px; height:1003px;\" src=\"images/EM/80646_Dysuriaprepubmale.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">UTI may coexist with noninfectious etiologies. Unless the cause of dysuria is obvious on physical examination (eg, balanoposthitis, chemical irritation, diaper dermatitis, obvious local trauma, or viral exanthem) a urine specimen for rapid dipstick should be obtained in all patients. Urinalysis and urine culture should also be obtained if the urine dipstick suggests a UTI (refer to UpToDate topics on diagnosis of UTI in children).</div><div class=\"graphic_footnotes\">PCR: polymerase chain reaction; UTI: urinary tract infection.<br />* In boys, self-manipulation and masturbation are common causes of local injury.<br />&para; Sexual abuse should be suspected in prepubertal males with genital herpes infection or urethritis and testing for <em>Neisseria gonorrhea</em> and <em>Chlamydia trachomatis</em> is warranted.<br />&Delta; In addition to Stevens-Johnson, varicella infection, Beh&ccedil;et syndrome, and reactive arthritis with urethritis and conjunctivitis, potential causes include Kawasaki disease, other inflammatory disorders, and urinary tuberculosis. Refer to appropriate UpToDate topics.<br /><span class=\"lozenge\">&loz;</span> Refer to UpToDate topics and algorithms on the evaluation of symptomatic microscopic hematuria in children.</div><div id=\"graphicVersion\">Graphic 80646 Version 5.0</div></div></div>"},"80647":{"type":"graphic_figure","displayName":"Lesion location","title":"Lesion location","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lesion location</div><div class=\"cntnt\"><img style=\"width:357px; height:389px;\" src=\"images/PC/80647_Lesion_location.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of CC and MLO views. The breast is divided into anterior, middle and posterior depths to aid lesion localization.</div><div class=\"graphic_footnotes\">CC: craniocaudal; MLO: mediolateral oblique; Ant: anterior; Mid: middle; Post: posterior; Axill: axillary.</div><div id=\"graphicVersion\">Graphic 80647 Version 1.0</div></div></div>"},"80650":{"type":"graphic_figure","displayName":"Int and ext hemorrhoids PI","title":"Hemorrhoids","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Hemorrhoids</div><div class=\"cntnt\"><img style=\"width:485px; height:373px;\" src=\"images/PI/80650_Int_and_ext_hemorrhoids_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dentate line divides the anal canal into two parts. Internal hemorrhoids originate from above the dentate line; external hemorrhoids originate from below the dentate line. </div><div id=\"graphicVersion\">Graphic 80650 Version 5.0</div></div></div>"},"80651":{"type":"graphic_table","displayName":"Etiology aseptic meningitis","title":"Major causes of aseptic meningitis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of aseptic meningitis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Common</td> <td class=\"subtitle1\">Uncommon</td> <td class=\"subtitle1\">Rare</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Infectious causes</td> </tr> <tr> <td class=\"subtitle3_left\" rowspan=\"10\">Viruses</td> <td class=\"sublist1_start\">Enteroviruses:</td> <td rowspan=\"10\"> <p>Mumps</p> <p>HIV</p> </td> <td class=\"sublist1_start\">Respiratory viruses:</td> </tr> <tr> <td class=\"sublist1\"> <p>Polioviruses</p> <p>Echoviruses</p> <p>Coxsackieviruses</p> <p>Numbered enteroviruses</p> </td> <td class=\"sublist1\"> <p>Adenovirus</p> <p>Influenza</p> <p>Parainfluenza</p> </td> </tr> <tr> <td>Herpes simplex virus type 2*</td> <td>Lymphocytic choriomeningitis virus</td> </tr> <tr> <td class=\"sublist1_start\">Arboviruses:</td> <td>Measles</td> </tr> <tr> <td class=\"sublist1\" rowspan=\"6\"> <p>Eastern and Western equine encephalitis</p> <p>St. Louis encephalitis</p> <p>La Crosse (California) encephalitis</p> <p>West Nile</p> </td> <td>Parvovirus B19</td> </tr> <tr> <td>Rotavirus</td> </tr> <tr> <td class=\"sublist1_start\">Herpes viruses:</td> </tr> <tr> <td class=\"sublist1\"> <p>Herpes simplex virus type 1</p> <p>Human herpes virus 6</p> <p>Epstein-Barr virus</p> <p>Varicella zoster</p> <p>Cytomegalovirus</p> </td> </tr> <tr> <td class=\"sublist1_start\">Arboviruses:</td> </tr> <tr> <td class=\"sublist1\"> <p>Powassan virus</p> </td> </tr> <tr> <td class=\"subtitle3_left\">Bacteria</td> <td> <p><em>Borrelia burgdorferi</em> (Lyme disease)*</p> <p>Partially treated bacterial meningitis*</p> </td> <td> <p><em>Mycobacterium tuberculosis</em>*</p> <p>Parameningeal infection (epidural, subdural abscess)*</p> </td> <td> <p><em>Bartonella</em> sp (cat scratch disease)*</p> <p>Syphilis*</p> <p><em>Leptospira</em> sp*</p> <p><em>Brucella</em>*</p> <p><em>Mycoplasma pneumoniae</em>*</p> <p><em>Rickettsia</em>*</p> </td> </tr> <tr> <td class=\"subtitle3_left\">Fungi</td> <td>&nbsp;</td> <td> <p><em>Cryptococcus</em>*</p> <p><em>Coccidioides</em>*</p> <p><em>Histoplasma</em>*</p> <p><em>Blastomyces</em>*</p> </td> <td> <p><em>Candida</em> spp*</p> <p><em>Aspergillus</em> spp*</p> <p><em>Sporothrix schenckii</em>*</p> </td> </tr> <tr> <td class=\"subtitle3_left\">Parasites</td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p><em>Taenia solium</em> (cysticercosis)*</p> <p><em>Trichinella spiralis</em>*</p> <p><em>Toxoplasma gondii</em>*</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Noninfectious causes</td> </tr> <tr> <td class=\"subtitle3_left\">Drugs</td> <td colspan=\"3\"> <p>Ibuprofen</p> <p>Trimethoprim-sulfamethoxazole</p> <p>Other NSAIDS</p> <p>Pyridium (phenazopyridine)</p> <p>Anti-CD3 monoclonal antibody</p> <p>Azathioprine</p> </td> </tr> <tr> <td class=\"subtitle3_left\">Malignancy</td> <td colspan=\"3\"> <p>Lymphoma*</p> <p>Leukemia*</p> </td> </tr> <tr> <td class=\"subtitle3_left\">Autoimmune</td> <td colspan=\"3\"> <p>Sarcoid*</p> <p>Beh<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">&#231;</span>et syndrome*</p> <p>Systemic lupus erythematosus*</p> </td> </tr> <tr> <td class=\"subtitle3_left\">Other causes</td> <td colspan=\"3\"> <p>Epidermoid cyst*</p> <p>Postvaccination</p> <p>Heavy metal poisoning*</p> <p>Intracranial hemorrhage*</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Treatable cause.</div><div class=\"graphic_reference\">Reproduced with permission from: Sawyer MH, Rotbart HA. Aseptic and viral meningitis. In: Principles and Practice of Pediatric Infectious Diseases, 3rd ed, Long SS, Pickering LK, Prober CG (Eds), Churchill Livingstone, New York 2008. Copyright &copy; 2008 Elsevier.</div><div id=\"graphicVersion\">Graphic 80651 Version 7.0</div></div></div>"},"80652":{"type":"graphic_picture","displayName":"Gangrene of breast","title":"Gangrene of breast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gangrene of breast</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/PC/80652_Gangrene_of_breast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gangrene of the breast is rare but can occur in women with diabetes and renal failure.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 80652 Version 2.0</div></div></div>"},"80653":{"type":"graphic_picture","displayName":"Histopathology of pulmonary alveolar proteinosis","title":"Histopathology of pulmonary alveolar proteinosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histopathology of pulmonary alveolar proteinosis</div><div class=\"cntnt\"><img style=\"width:297px; height:196px;\" src=\"images/PULM/80653_Alveolar_proteinosis_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Open lung biopsy specimen shows that the alveolar septa are only slightly thickened due to type II epithelial cell hyperplasia, and the alveolar architecture is preserved. There is no inflammatory cell infiltration. The alveoli are filled with a flocculent and granular lipoproteinaceous material that stains pink with PAS stain.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King, Jr, MD.</div><div id=\"graphicVersion\">Graphic 80653 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lung</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/PULM/54820_Normal_lung_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph of normal lung tissue shows open alveoli with thin, capillary- containing interstitial spaces. An artery (A) is identifiable by its thick, muscular wall; the accompanying bronchus (B) contains mucoid material and is lined by columnar respiratory epithelial cells.</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 54820 Version 1.0</div></div></div>"},"80654":{"type":"graphic_picture","displayName":"Macroglossia in a patient with Beckwith-Wiedemann syndrome","title":"Macroglossia in a patient with Beckwith-Wiedemann syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Macroglossia in a patient with Beckwith-Wiedemann syndrome</div><div class=\"cntnt\"><img style=\"width:264px; height:504px;\" src=\"images/ALLRG/80654_Macroglossia_BW_syndr.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 80654 Version 1.0</div></div></div>"},"80656":{"type":"graphic_figure","displayName":"Circadian pattern SCD II","title":"Circadian pattern of cardiac arrest","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Circadian pattern of cardiac arrest</div><div class=\"cntnt\"><img style=\"width:410px; height:362px;\" src=\"images/CARD/80656_Circadian_pattern_SCD_II.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distribution of sudden death in 3690 patients with a witnessed cardiac arrest. Top panel: There is a diurnal pattern with a first arrest, with a peak occurrence during the morning hours. Bottom panel: There is also a diurnal pattern of sudden death in the 597 patients with a second cardiac arrest although, for the individual patient, there was no association between the time for the first and second event.</div><div class=\"graphic_reference\">Data from Peckova, M, Fahrenbruch, CE, Cobb, CE, et al, Circulation 1998; 98:31.</div><div id=\"graphicVersion\">Graphic 80656 Version 1.0</div></div></div>"},"80657":{"type":"graphic_table","displayName":"Methods of summarizing studies in systematic reviews","title":"Methods of summarizing studies in systematic reviews","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Methods of summarizing studies in systematic reviews</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Approach</td> <td class=\"subtitle1\">Main model</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Qualitative systematic review</td> <td>Qualitative description of evidence</td> <td>May be most appropriate if large degree of heterogeneity among studies.</td> </tr> <tr> <td rowspan=\"2\">Meta-analysis overall estimate</td> <td>Fixed effects model</td> <td>Assumes a single truth across populations and homogeneity among studies.</td> </tr> <tr> <td>Random effects model</td> <td>Incorporates between-study heterogeneity. Wider confidence interval than fixed effects model when heterogeneity is present.</td> </tr> <tr> <td>Meta-analysis of multiple interventions simultaneously</td> <td>Network meta-analysis (mixed or multiple treatment comparison)</td> <td>Estimates relative effects of multiple interventions against each other, even if no individual study analyzed a comparison between 2 or more specific interventions.</td> </tr> <tr> <td>Meta-analysis subgroup analyses</td> <td>Fixed or random effects models</td> <td>Estimates treatment effects for each group. May explain heterogeneity. Subject to ecological fallacy. May not be possible due to limited reported data. Arbitrary selection of subgroups may result in spurious findings. </td> </tr> <tr> <td>Meta-regression</td> <td>Regression across studies</td> <td>Tests interaction between subgroup and treatment effects. Can test continuous or categorical variables singly or in a multivariable analysis. May explain heterogeneity. Subject to ecological fallacy. May not be possible due to limited reported data. Arbitrary selection of subgroups may reult in spurious findings.</td> </tr> <tr> <td>Individual patient data meta-analysis</td> <td>Multivariate regression across individuals</td> <td>Allows most complete analysis of data and evaluation of heterogeneity. Costly and resource-intensive.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80657 Version 3.0</div></div></div>"},"80658":{"type":"graphic_picture","displayName":"AML FAB M0","title":"Acute myeloid leukemia (AML FAB M0)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute myeloid leukemia (AML FAB M0)</div><div class=\"cntnt\"><img style=\"width:425px; height:288px;\" src=\"images/HEME/80658_AML_FAB_M0.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate from a patient with AML (FAB classification M0). (Wright-Giemsa stain). The blasts lack differentiating features and were nonreactive to Sudan Black B and myeloperoxidase staining. More than 20 percent of the blasts expressed myeloid antigens CD13 and CD33. The blasts were terminal transferase negative and nonreactive with antibodies to lymphocytes. Auer rods were not found.</div><div class=\"graphic_reference\">From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 80658 Version 1.0</div></div></div>"},"80659":{"type":"graphic_picture","displayName":"Calcaneus","title":"Calcaneus foot deformity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calcaneus foot deformity</div><div class=\"cntnt\"><img style=\"width:350px; height:352px;\" src=\"images/PEDS/80659_Calcaneus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of: Drs. Vineeta Swaroop and Luciano Dias.</div><div id=\"graphicVersion\">Graphic 80659 Version 2.0</div></div></div>"},"80660":{"type":"graphic_diagnosticimage","displayName":"TEE pulmonic valve and pulmonary artery color Doppler","title":"Pulmonary valve and main pulmonary artery on transesophageal echocardiogam","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Pulmonary valve and main pulmonary artery on transesophageal echocardiogam</div><div class=\"cntnt\"><img style=\"width:480px; height:180px;\" src=\"images/CARD/80660_TEE_pulmonary_valve_artery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vertical (90º) imaging plane demonstrates the pulmonary valve (PV), main pulmonary artery (MPA), and transverse aorta (Ao) (Panel A). Panel B shows color Doppler flow within these structures.</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 80660 Version 3.0</div></div></div>"},"80661":{"type":"graphic_figure","displayName":"CDC SSI classification","title":"Cross-section of abdominal wall depicting CDC classifications of surgical site infection","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Cross-section of abdominal wall depicting CDC classifications of surgical site infection</div><div class=\"cntnt\"><img style=\"width:458px; height:363px;\" src=\"images/SURG/80661_CDC_SSI_classification.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection. In: Infection Control and Hospital Epidemiology, CDC 1999; 20:247.</div><div id=\"graphicVersion\">Graphic 80661 Version 4.0</div></div></div>"},"80662":{"type":"graphic_table","displayName":"Complications associated with multiple cesareans","title":"Risk of complications associated with cesarean delivery according to the number of previous cesarean deliveries","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk of complications associated with cesarean delivery according to the number of previous cesarean deliveries</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\" rowspan=\"2\">\n   Number of previous cesarean deliveries\n   </td>\n   <td  class=\"subtitle1\" colspan=\"6\">\n   Risk of complications, percent\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2\">\n   Placenta accreta\n   </td>\n   <td  class=\"subtitle2\">\n   Hysterectomy\n   </td>\n   <td  class=\"subtitle2\">\n   Transfusion\n   </td>\n   <td  class=\"subtitle2\">\n   Cystotomy\n   </td>\n   <td  class=\"subtitle2\">\n   Bowel injury\n   </td>\n   <td  class=\"subtitle2\">\n   Maternal death*\n   </td>\n   </tr>\n   <tr>\n   <td>1</td>\n   <td>0.24</td>\n   <td>0.65</td>\n   <td>4.05</td>\n   <td>0.13</td>\n   <td>0.11</td>\n   <td>0.19</td>\n   </tr>\n   <tr>\n   <td>2</td>\n   <td>0.31</td>\n   <td>0.42</td>\n   <td>1.53</td>\n   <td>0.09</td>\n   <td>0.06</td>\n   <td>0.07</td>\n   </tr>\n   <tr>\n   <td>3</td>\n   <td>0.57</td>\n   <td>0.90</td>\n   <td>2.26</td>\n   <td>0.28</td>\n   <td>0.13</td>\n   <td>0.05</td>\n   </tr>\n   <tr>\n   <td>4</td>\n   <td>2.13</td>\n   <td>2.41</td>\n   <td>3.65</td>\n   <td>1.17</td>\n   <td>0.34</td>\n   <td>0.07</td>\n   </tr>\n   <tr>\n   <td>5</td>\n   <td>2.33</td>\n   <td>3.49</td>\n   <td>4.26</td>\n   <td>1.94</td>\n   <td>0.00</td>\n   <td>0.00</td>\n   </tr>\n   <tr>\n   <td>6</td>\n   <td>6.74</td>\n   <td>8.99</td>\n   <td>15.73</td>\n   <td>4.49</td>\n   <td>1.12</td>\n   <td>0.00</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">* Only&nbsp;2 of the 27 maternal deaths were potentially related to the cesarean delivery itself. Both occurred in women having their second cesarean delivery. This study did not have adequate power to determine whether rare but serious events, such as maternal death, increased as the number of cesarean deliveries increased.</div><div class=\"graphic_reference\">Data from: Silver, RM, Landon, MB, Rouse, DJ, et al. Maternal Morbidity Associated With Multiple Repeat Cesarean Deliveries. Obstet Gynecol 2006; 107:1226.</div><div id=\"graphicVersion\">Graphic 80662 Version 3.0</div></div></div>"},"80663":{"type":"graphic_waveform","displayName":"ECG WPW left posterior path","title":"WPW syndrome with a left posterior accessory pathway","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">WPW syndrome with a left posterior accessory pathway</div><div class=\"cntnt\"><img style=\"width:435px; height:171px;\" src=\"images/CARD/80663_ECG_WPW_left_posterior_path.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 12 lead ECG from a patient with Wolff-Parkinson-White syndrome (WPW) shows a short PR interval and a delta wave which results in a widened QRS complex. The delta wave is positive in leads I, avL, and V1 to V6 and negative in leads II, III, and avF, compatible with a left posterior accessory pathway.</div><div id=\"graphicVersion\">Graphic 80663 Version 2.0</div></div></div>"},"80664":{"type":"graphic_picture","displayName":"Newborn testicular torsion","title":"Neonatal testicular torsion","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Neonatal testicular torsion</div><div class=\"cntnt\"><img style=\"width:504px; height:311px;\" src=\"images/PEDS/80664_Newborn_testicular_torsion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a newborn male, a clinical diagnosis of prenatal testicular torsion was made based upon the physical finding of a firm, enlarged, nontender right testicle. Surgical exploration through an inguinal incision confirmed extravaginal testicular torsion and an ischemic testicle.</div><div class=\"graphic_reference\">Courtesy of Laurence S Baskin, MD.</div><div id=\"graphicVersion\">Graphic 80664 Version 5.0</div></div></div>"},"80665":{"type":"graphic_diagnosticimage","displayName":"Usual interstitial pneumonia CT","title":"Usual interstitial pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Usual interstitial pneumonia</div><div class=\"cntnt\"><img style=\"width:371px; height:270px;\" src=\"images/PULM/80665_Usual_interstitial_pneumoni.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Exudative phase of UIP with ground glass and consolidative changes. No definite honeycombing is present. Subpleural curvilinear lines and mild traction bronchiectasis are visible.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 80665 Version 2.0</div></div></div>"},"80666":{"type":"graphic_figure","displayName":"Carpal tunnel PI","title":"Carpal tunnel syndrome ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Carpal tunnel syndrome </div><div class=\"cntnt\"><img style=\"width:448px; height:625px;\" src=\"images/PI/80666_Carpal-tunnel-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The carpal tunnel is a tunnel in the wrist that is formed by the bones of the wrist and a tough band of tissue called a &quot;ligament.&quot; Carpal tunnel syndrome happens when a nerve that goes through that tunnel, called the &quot;median nerve,&quot; gets pinched or squeezed. Carpal tunnel syndrome causes pain and numbness most often in the areas shaded here in blue.</div><div id=\"graphicVersion\">Graphic 80666 Version 2.0</div></div></div>"},"80667":{"type":"graphic_table","displayName":"Association of CVS migraines","title":"Profile of symptoms in cyclic vomiting syndrome, abdominal migraine, and migraine headaches","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Profile of symptoms in cyclic vomiting syndrome, abdominal migraine, and migraine headaches</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td>\r\n                    <td class=\"subtitle1\" colspan=\"3\">Percentage of patients with symptom</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2\">CVS</td>\r\n                    <td class=\"subtitle2\">Abdominal migraine</td>\r\n                    <td class=\"subtitle2\">Migraine headache</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\" colspan=\"4\">Core symptoms</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Vomiting</td>\r\n                    <td>100</td>\r\n                    <td>39 to 72</td>\r\n                    <td>40 to 69</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Abdominal pain</td>\r\n                    <td>3 to 81</td>\r\n                    <td>100</td>\r\n                    <td>10 to 55</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Headache</td>\r\n                    <td>38 to 59</td>\r\n                    <td>31 to 50</td>\r\n                    <td>100</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\" colspan=\"4\">Associated symptoms</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Lethargy</td>\r\n                    <td>91</td>\r\n                    <td>&nbsp;</td>\r\n                    <td>&nbsp;</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Pallor</td>\r\n                    <td>87</td>\r\n                    <td>90 to 100</td>\r\n                    <td>23 to 88</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Anorexia</td>\r\n                    <td>74</td>\r\n                    <td>91 to 98</td>\r\n                    <td>13 to 93</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Nausea</td>\r\n                    <td>72</td>\r\n                    <td>73 to 91</td>\r\n                    <td>46 to 100</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Photophobia</td>\r\n                    <td>32</td>\r\n                    <td>1 to 42</td>\r\n                    <td>27 to 81</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_reference\">Adapted from: Li BU, Balint JP. Cyclic vomiting syndrome: Evolution in understanding of a brain-gut disorder. Adv Pediatr 2000; 47:117.</div><div id=\"graphicVersion\">Graphic 80667 Version 3.0</div></div></div>"},"80669":{"type":"graphic_table","displayName":"Classification parkinsonism","title":"Etiologic classification of parkinsonism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologic classification of parkinsonism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">I. Parkinson disease </td> </tr> <tr> <td>Parkinson disease - sporadic</td> </tr> <tr> <td>Parkinson disease - hereditary</td> </tr> <tr> <td class=\"subtitle1_single\">II. Multisystem degenerations (\"parkinsonism plus\") </td> </tr> <tr> <td>Progressive supranuclear palsy</td> </tr> <tr> <td>Multiple system atrophy</td> </tr> <tr> <td>Lytico-Bodig or parkinsonism-dementia-ALS complex of Guam</td> </tr> <tr> <td>Corticobasal degeneration</td> </tr> <tr> <td>Progressive pallidal atrophy</td> </tr> <tr> <td>Parkinsonism-dementia complex</td> </tr> <tr> <td>Pallidopyramidal disease</td> </tr> <tr> <td class=\"subtitle1_single\">III. Heredodegenerative parkinsonism </td> </tr> <tr> <td>Dopa-responsive dystonia</td> </tr> <tr> <td>Huntington disease</td> </tr> <tr> <td>Wilson disease</td> </tr> <tr> <td>Hereditary ceruloplasmin deficiency</td> </tr> <tr> <td>Neurodegeneration with brain iron accumulation (NBIA), including pantothenate kinase-associated neurodegeneration, infantile neuroaxonal dystrophy, neuroferritinopathy, and aceruloplasminemia</td> </tr> <tr> <td>Olivopontocerebellar and spinocerebellar atrophies including Machado-Joseph disease</td> </tr> <tr> <td>Frontotemporal dementia with parkinsonism</td> </tr> <tr> <td>Gerstmann-Str&#228;ussler-Scheinker disease</td> </tr> <tr> <td>Familial progressive subcortical gliosis</td> </tr> <tr> <td>Lubag (X-linked dystonia-parkinsonism)</td> </tr> <tr> <td>Familial basal ganglia calcification</td> </tr> <tr> <td>Mitochondrial cytopathies with striatal necrosis</td> </tr> <tr> <td>Ceroid lipofuscinosis</td> </tr> <tr> <td>Familial parkinsonism with peripheral neuropathy</td> </tr> <tr> <td>Parkinsonian-pyramidal syndrome</td> </tr> <tr> <td>Neuroacanthocytosis</td> </tr> <tr> <td>Hereditary hemochromatosis</td> </tr> <tr> <td>Neuroferritinopathy</td> </tr> <tr> <td class=\"subtitle1_single\">IV. Secondary (acquired, symptomatic) parkinsonism </td> </tr> <tr> <td class=\"subtitle2_single\">Infectious </td> </tr> <tr> <td class=\"indent1\">Postencephalitic </td> </tr> <tr> <td class=\"indent1\">Acquired immunodeficiency syndrome </td> </tr> <tr> <td class=\"indent1\">Subacute sclerosing panencephalitis </td> </tr> <tr> <td class=\"indent1\">Creutzfeldt-Jakob disease </td> </tr> <tr> <td class=\"indent1\">Prion diseases </td> </tr> <tr> <td class=\"subtitle2_single\">Drugs </td> </tr> <tr> <td class=\"indent1\">Dopamine receptor blocking drugs (antipsychotic, antiemetic drugs) </td> </tr> <tr> <td class=\"indent1\">Reserpine </td> </tr> <tr> <td class=\"indent1\">Tetrabenazine </td> </tr> <tr> <td class=\"indent1\">Alpha-methyldopa </td> </tr> <tr> <td class=\"indent1\">Lithium </td> </tr> <tr> <td class=\"indent1\">Flunarizine </td> </tr> <tr> <td class=\"indent1\">Cinnarizine </td> </tr> <tr> <td class=\"indent1\">Valproate</td> </tr> <tr> <td class=\"subtitle2_single\">Toxins </td> </tr> <tr> <td class=\"indent1\">MPTP </td> </tr> <tr> <td class=\"indent1\">Carbon monoxide </td> </tr> <tr> <td class=\"indent1\">Manganese </td> </tr> <tr> <td class=\"indent1\">Mercury </td> </tr> <tr> <td class=\"indent1\">Carbon disulfide </td> </tr> <tr> <td class=\"indent1\">Cyanide </td> </tr> <tr> <td class=\"indent1\">Methanol </td> </tr> <tr> <td class=\"indent1\">Ethanol </td> </tr> <tr> <td class=\"subtitle2_single\">Vascular </td> </tr> <tr> <td class=\"indent1\">Multiinfarct </td> </tr> <tr> <td class=\"indent1\">Binswanger disease </td> </tr> <tr> <td class=\"subtitle2_single\">Trauma </td> </tr> <tr> <td class=\"indent1\">Pugilistic encephalopathy disease </td> </tr> <tr> <td class=\"subtitle2_single\">Other </td> </tr> <tr> <td class=\"indent1\">Parathyroid abnormalities </td> </tr> <tr> <td class=\"indent1\">Hypothyroidism </td> </tr> <tr> <td class=\"indent1\">Hepatocerebral degeneration </td> </tr> <tr> <td class=\"indent1\">Brain tumor </td> </tr> <tr> <td class=\"indent1\">Paraneoplastic </td> </tr> <tr> <td class=\"indent1\">Normal pressure hydrocephalus </td> </tr> <tr> <td class=\"indent1\">Noncommunicating hydrocephalus </td> </tr> <tr> <td class=\"indent1\">Syringomesencephalia </td> </tr> <tr> <td class=\"indent1\">Hemiatrophy-hemiparkinsonism </td> </tr> <tr> <td class=\"indent1\">Peripherally induced tremor and parkinsonism, and psychogenic </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified from: Jankovic, J, Lang, AE. Movement disorders: Diagnosis and Assessment. In: Bradley, WG, Daroff, RB, Fenichel, GM, Jankovic, J, eds. Neurology in Clinical Practice, 5th Edition, Butterworth-Heinemann, Philadelphia, PA, 2007. Copyright ©2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 80669 Version 3.0</div></div></div>"},"80671":{"type":"graphic_picture","displayName":"Vespula worker","title":"Vespula worker","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vespula worker</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ALLRG/80671_Vespula_worker.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.</div><div id=\"graphicVersion\">Graphic 80671 Version 1.0</div></div></div>"},"80672":{"type":"graphic_diagnosticimage","displayName":"Maisonneuve fracture","title":"Maisonneuve fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Maisonneuve fracture</div><div class=\"cntnt\"><img style=\"width:220px; height:516px;\" src=\"images/RHEUM/80672_Maisonneuve_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior radiograph shows an oblique proximal fibular fracture (arrows). When this results from an ankle injury with concomitant rupture of the tibiofibular syndesmosis, it is referred to as a Maisonneuve fracture.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 80672 Version 3.0</div></div></div>"},"80674":{"type":"graphic_picture","displayName":"Penicillium marneffei - papules","title":"Penicillium marneffei infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Penicillium marneffei infection</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/80674_Penic_marn_papules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous, umbilicated papules are present on the skin of this patient with <EM>Penicillium marneffei</EM> infection.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 80674 Version 4.0</div></div></div>"},"80675":{"type":"graphic_diagnosticimage","displayName":"Infant humeral fracture healing","title":"Infant humeral fracture","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Infant humeral fracture</div><div class=\"cntnt\"><img style=\"width:520px; height:339px;\" src=\"images/EM/80675_Infant_humeral_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Fracture, shaft of the humerus in newborn. <br />(B) Four weeks later, large mass of callus, varus angulation of 45 degrees. <br />(C) At age 14 months, fracture remodeled to normal alignment.</div><div class=\"graphic_reference\">Reprinted with permission from: Beaty JH. Fractures of the proximal humerus and shaft in children, in Eilert RE (ed): Instructional Course Lectures 41. Rosemont, IL, American Academy of Orthopaedic Surgeons, 1992, pp 369-372.</div><div id=\"graphicVersion\">Graphic 80675 Version 3.0</div></div></div>"},"80676":{"type":"graphic_table","displayName":"Autoimmune hepatitis variants","title":"Autoimmune hepatitis overlap syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Autoimmune hepatitis overlap syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Autoimmune hepatitis-primary biliary cholangitis overlap</td> </tr> <tr> <td>a. AMA-positive with histological evidence suggesting autoimmune hepatitis but not primary biliary cholangitis</td> </tr> <tr> <td>b. ANA and/or SMA-positive with histologic changes suggestive of primary biliary cholangitis (autoimmune cholangitis) </td> </tr> <tr> <td class=\"subtitle1_single\">Autoimmune hepatitis-primary sclerosing cholangitis overlap</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AMA: antimitochondrial antibodies; ANA: antinuclear antibodies; SMA: smooth muscle antibodies.</div><div id=\"graphicVersion\">Graphic 80676 Version 2.0</div></div></div>"},"80677":{"type":"graphic_table","displayName":"Diagnostic criteria for the 100-gram three-hour GTT","title":"Diagnostic criteria for the 100-gram three-hour GTT to diagnose gestational diabetes mellitus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for the 100-gram three-hour GTT to diagnose gestational diabetes mellitus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\"> <p>Plasma or serum glucose level</p> Carpenter/Coustan</td> <td class=\"subtitle1\" colspan=\"2\"> <p>Plasma level</p> National Diabetes Data Group</td> </tr> <tr> <td class=\"subtitle2\">mg/dL</td> <td class=\"subtitle2\">mmol/L</td> <td class=\"subtitle2\">mg/dL</td> <td class=\"subtitle2\">mmol/L</td> </tr> <tr> <td><strong>Fasting</strong></td> <td class=\"centered\">95</td> <td class=\"centered\">5.3</td> <td class=\"centered\">105</td> <td class=\"centered\">5.8</td> </tr> <tr> <td><strong>One hour</strong></td> <td class=\"centered\">180</td> <td class=\"centered\">10.0</td> <td class=\"centered\">190</td> <td class=\"centered\">10.6</td> </tr> <tr> <td><strong>Two hours</strong></td> <td class=\"centered\">155</td> <td class=\"centered\">8.6</td> <td class=\"centered\">165</td> <td class=\"centered\">9.2</td> </tr> <tr> <td><strong>Three hours</strong></td> <td class=\"centered\">140</td> <td class=\"centered\">7.8</td> <td class=\"centered\">145</td> <td class=\"centered\">8.0</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">100-gram oral glucose load is given in the morning&nbsp;to a patient who has fasted overnight&nbsp;for at least 8 hours. Glucose concentration greater than or equal to these values at&nbsp;two or more time points&nbsp;are generally considered&nbsp;a positive test, but in 2017,&nbsp;an American College of Obstetricians and Gynecologists practice bulletin stated that clinicians may reasonably&nbsp;consider one elevated value&nbsp;diagnostic of a positive test<SUP>1</SUP>. Two different classification schemes of GDM based upon results of the three-hour GTT results have been proposed. The Fourth International Workshop-Conference on Gestational Diabetes GTT values cited above are based upon the Carpenter and Coustan modification of earlier values. They are lower than those proposed by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus and the National Diabetes Data Group, which used cutoff values of 105, 190, 165, and 145 mg/dL (5.8, 10.6, 9.2, and 8.0 mmol/L), respectively. The values are lower because the thresholds derived from the older Somogyi-Nelson method of glucose analysis were corrected to account for the enzymatic assays currently in use.</div><div class=\"graphic_footnotes\">GTT: glucose tolerance test.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 180: Gestational diabetes mellitus. Obstet Gynecol 2017; 130:e17.</LI></OL>&#xD;&#xA;<P><br />Data from: VanDorsten JP, Dodson WC, Espeland MA, et al. National Institutes of Health consensus development conference statement: Diagnosing gestational diabetes mellitus. NIH Consens State Sci Statements 2013; 29:1.<br />​<br /></div><div id=\"graphicVersion\">Graphic 80677 Version 14.0</div></div></div>"},"80679":{"type":"graphic_picture","displayName":"Single-stage breast reconstruct","title":"Single-stage breast reconstruction in a patient with prior bilateral augmentation mammoplasty","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Single-stage breast reconstruction in a patient with prior bilateral augmentation mammoplasty</div><div class=\"cntnt\"><img style=\"width:546px; height:280px;\" src=\"images/ONC/80679_Single_stage_breast_reconst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left immediate single-stage breast reconstruction following mastectomy, utilizing a double lumen normal saline/silicone gel implant. Left panel: preoperative appearance; right panel, postoperative appearance.</div><div class=\"graphic_reference\">Courtesy of Jorge de la Pedraja, MD.</div><div id=\"graphicVersion\">Graphic 80679 Version 3.0</div></div></div>"},"80680":{"type":"graphic_table","displayName":"Feeding intolerance premature","title":"Clinical criteria of feeding intolerance in preterm infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical criteria of feeding intolerance in preterm infants</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Abdominal examination</td> </tr> <tr> <td class=\"indent1\">Distension</td> </tr> <tr> <td class=\"indent1\">Tenderness</td> </tr> <tr> <td class=\"indent1\">Change in bowel sounds (eg, increased or absent)</td> </tr> <tr> <td class=\"subtitle1_single\">Emesis</td> </tr> <tr> <td class=\"subtitle1_single\">Gastric residual volume</td> </tr> <tr> <td class=\"indent1\">Greater than 2 mL/kg of body weight</td> </tr> <tr> <td class=\"indent1\">Greater than half the volume of feeds over prior three hours</td> </tr> <tr> <td class=\"indent1\">Any change in quantity of fluid volume (usually increase)</td> </tr> <tr> <td class=\"subtitle1_single\">Gastric residual fluid characteristics</td> </tr> <tr> <td class=\"sublist2_start\">Change in color</td> </tr> <tr> <td class=\"sublist2\">Green: Bile</td> </tr> <tr> <td class=\"sublist2\">Red or brown: Blood</td> </tr> <tr> <td class=\"subtitle1_single\">Stools</td> </tr> <tr> <td class=\"indent1\">Any change in frequency</td> </tr> <tr> <td class=\"indent1\">Presence of blood or guaiac positive stools</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical status</td> </tr> <tr> <td class=\"indent1\">Any change in clinical status, eg, i<span style=\"font-size: 13px; font-family: Verdana;\">ncreased episodes of apnea and bradycardia, diminished oxygen saturation (desaturation events), and lethargy</span></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80680 Version 4.0</div></div></div>"},"80683":{"type":"graphic_picture","displayName":"Skin biopsy lupus profundus I","title":"Lupus profundus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lupus profundus</div><div class=\"cntnt\"><img style=\"width:360px; height:244px;\" src=\"images/RHEUM/80683_Skin_biopsy_lupus_profundus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Biopsy of a patient with lupus profundus showing expansion of the interstices of the fat lobule with disintegrating leukocytes and fibrin.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 80683 Version 1.0</div></div></div>"},"80688":{"type":"graphic_table","displayName":"Classification of gastric bezoars","title":"Classification of gastric bezoars","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of gastric bezoars</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Phytobezoar</td>\n</tr>\n<tr>\n<td>Persimmon (diospyrobezoar)</td>\n</tr>\n<tr>\n<td>Psyllium</td>\n</tr>\n<tr>\n<td>Fruit</td>\n</tr>\n<tr>\n<td>Vegetables</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Trichobezoar</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Pharmacobezoar</td>\n</tr>\n<tr>\n<td>Enteric coated aspirin</td>\n</tr>\n<tr>\n<td>Extended release capsules (nifedipine, theophylline)</td>\n</tr>\n<tr>\n<td>Sucralfate</td>\n</tr>\n<tr>\n<td>Others</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Other</td>\n</tr>\n<tr>\n<td>Styrofoam</td>\n</tr>\n<tr>\n<td>Fungi (candida)</td>\n</tr>\n<tr>\n<td>Lactobezoar</td>\n</tr>\n<tr>\n<td>Cement</td>\n</tr>\n<tr>\n<td>Furniture polish</td>\n</tr>\n<tr>\n<td>Shellac</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 80688 Version 2.0</div></div></div>"},"80689":{"type":"graphic_diagnosticimage","displayName":"Late lye esophageal stricture","title":"Esophageal stricture due to lye ingestion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal stricture due to lye ingestion</div><div class=\"cntnt\"><img style=\"width:413px; height:451px;\" src=\"images/GAST/80689_Late_lye_esophageal_strictu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiographic appearance of lye stricture 25 years after ingestion in a patient with dysphagia. Panel A: Barium esophagram reveals a smooth proximal esophageal body stricture. Panel B: Barium tablet radiogram demonstrates stagnation of a barium tablet (measuring 13 mm in diameter) proximal to the lye stricture.</div><div class=\"graphic_reference\">Courtesy of George Triadafilopoulos, MD.</div><div id=\"graphicVersion\">Graphic 80689 Version 3.0</div></div></div>"},"80690":{"type":"graphic_figure","displayName":"Duck bill weighted retractor","title":"Duck-billed or Steinert weighted retractor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Duck-billed&nbsp;or Steinert weighted retractor</div><div class=\"cntnt\"><img style=\"width:258px; height:441px;\" src=\"images/OBGYN/80690_Duck_bill_weighted_retracto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This retractor can be inserted into the opened posterior cul-de-sac during vaginal hysterectomy.</div><div id=\"graphicVersion\">Graphic 80690 Version 2.0</div></div></div>"},"80691":{"type":"graphic_movie","displayName":"Correction of myopia","title":"Myopia corrected with refractive divergent lens","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Myopia corrected with refractive divergent lens</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/80691_myoprefconv.mp4\" style=\"width:338px;height:228px\"></div><img style=\"width:336px; height:210px;\" src=\"images/CARD/80691_myopref.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Myopia is corrected with divergent (concave) lenses which move the focus onto the retina from a point of focus in front of the retina.</div><div class=\"graphic_reference\">Reproduced with permission from: The University of Michigan Kellogg Eye Center, www.kellogg.umich.edu.</div><div id=\"graphicVersion\">Graphic 80691 Version 3.0</div></div></div>"},"80692":{"type":"graphic_table","displayName":"Genetic testing in DMD and BMD","title":"Molecular genetic testing used in Duchenne and Becker muscular dystrophy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Molecular genetic testing used in Duchenne and Becker muscular dystrophy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Gene symbol</td> <td class=\"subtitle1\" rowspan=\"3\">Test method</td> <td class=\"subtitle1\" rowspan=\"3\">Mutations detected</td> <td class=\"subtitle1\" colspan=\"4\">Mutation detection rate by test method*</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">DMD</td> <td class=\"subtitle2\" colspan=\"2\">BMD</td> </tr> <tr> <td class=\"subtitle3\">Affected males</td> <td class=\"subtitle3\">Heterozygous females<sup>&#182;</sup></td> <td class=\"subtitle3\">Affected males</td> <td class=\"subtitle3\">Heterozygous females<sup>&#182;</sup></td> </tr> <tr> <td rowspan=\"3\"><em>DMD</em></td> <td class=\"divider_bottom\" rowspan=\"2\">Deletion/duplication analysis<sup>&#916;</sup></td> <td>Deletion of one or more exons or the whole gene</td> <td>~50-65%</td> <td>~50-65%</td> <td>~65-70%</td> <td>Unknown</td> </tr> <tr class=\"divider_bottom\"> <td>Duplication of one or more exons</td> <td>~5-10%</td> <td>~5-10%</td> <td>~5-10%</td> <td>Unknown</td> </tr> <tr> <td>Sequence analysis/mutation scanning<sup>&#9674;</sup></td> <td>Point mutations (sequence variants)<sup>&#167;</sup></td> <td>~20-35%<sup>&#165;</sup></td> <td>~25-35%<sup>&#135;</sup></td> <td>~20-30%<sup>&#165;</sup></td> <td>Unknown</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DMD: Duchenne muscular dystrophy; BMD: Becker muscular dystrophy; CGH: comparative genomic hybridization;&nbsp;PCR: polymerase chain reaction.<br />* The ability of the test method used to detect a mutation that is present in the indicated gene. The mutation detection rates reflect approximate values.<br />¶ The mutation spectrum for females heterozygous for a <EM>DMD</EM> mutation resulting in BMD has not been well documented, but is presumed to be similar to the spectrum for males with BMD. Similarly, there are less data about females heterozygous for a <EM>DMD</EM> mutation resulting in DMD, but it is also presumed to be similar to that seen in males with DMD.<br />Δ Testing that identifies deletions/duplications not readily detectable by sequence analysis of genomic DNA; a variety of methods including quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification, or targeted array CGH (gene/segment-specific) may be used. A full array CGH analysis that detects deletions/duplications across the genome may also include this gene/segment.<br /><FONT class=lozenge>◊</FONT> Sequence analysis and mutation scanning of the entire gene can have similar detection frequencies; however, detection rates for mutation scanning may vary considerably between laboratories based on specific protocol used.<br />§ Examples of mutations detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site mutations.<br />¥ Lack of amplification by PCR prior to sequence analysis can suggest a putative deletion of one or more exons or the entire X-linked gene in a male; confirmation may require additional testing by deletion/duplication analysis.<br />‡ Sequence analysis of genomic DNA cannot detect deletion of one or more exons or the entire X-linked gene in a heterozygous female.</div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Darras BT, Menache-Stroninki CC, Hinton V, Kunkel LM. Dystrophinopathies. In: Neuromuscular Disorders of Infancy, Childhood and Adolescence: A Clinician’s Approach, 2nd ed, Darras BT, Jones HR Jr, Ryan MM, De Vivo DC (Eds), Academic Press, San Diego 2015.</LI></OL>Modified from: Darras BT, Miller DR, Urion DK. Dystrophinopathies, September 2000 [Updated November 26, 2014]. GeneReviews at GeneTests: Medical Genetics Information Resource. Available at: <A href=\"http://www.ncbi.nlm.nih.gov/books/NBK1119/\" target=_blank>www.ncbi.nlm.nih.gov/books/NBK1119/</A> (Accessed on June 23, 2015). Copyright © 1993-2015, University of Washington, Seattle. All rights reserved.</div><div id=\"graphicVersion\">Graphic 80692 Version 3.0</div></div></div>"},"80693":{"type":"graphic_table","displayName":"Clinical designation of genital herpes simplex virus infection","title":"Clinical designation of genital herpes simplex virus infection (HSV)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical designation of genital herpes simplex virus infection (HSV)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"35%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Direct viral test result*</td> <td class=\"subtitle1\" colspan=\"2\">Type-specific serologic status<sup>&#182;</sup></td> <td class=\"subtitle1\" rowspan=\"2\">Classification of genital HSV infection</td> </tr> <tr> <td class=\"subtitle2\">HSV-1 antibodies</td> <td class=\"subtitle2\">HSV-2 antibodies</td> </tr> <tr> <td class=\"centered divider_bottom\" rowspan=\"3\"><strong>HSV-1 detected</strong></td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td>Primary HSV-1 infection</td> </tr> <tr> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td>Nonprimary first episode HSV-1 infection<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">+</td> <td class=\"centered\">&ndash; or +</td> <td>Recurrent HSV-1 infection</td> </tr> <tr> <td class=\"centered\" rowspan=\"3\"><strong>HSV-2 detected</strong></td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td>Primary HSV-2 infection</td> </tr> <tr> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td>Nonprimary first episode HSV-2 infection</td> </tr> <tr> <td class=\"centered\">&ndash; or +</td> <td class=\"centered\">+</td> <td>Recurrent HSV-2 infection</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Testing of the ulcerative lesion with culture, polymerase chain reaction, or direct fluorescent antibody.<br />&para; Performed at the time of initial presentation with the ulcerative lesion.<br />&Delta; Nonprimary first episode genital HSV-1 infection is rare.</div><div id=\"graphicVersion\">Graphic 80693 Version 4.0</div></div></div>"},"80697":{"type":"graphic_table","displayName":"C. difficile clinical manifestations","title":"Clinical manifestations of <EM>Clostridium difficile </EM>infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical&nbsp;manifestations of <EM>Clostridium difficile </EM>infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type of infection </td> <td class=\"subtitle1\">Diarrhea </td> <td class=\"subtitle1\">Other symptoms </td> <td class=\"subtitle1\">Physical examination </td> <td class=\"subtitle1\">Sigmoidoscopic examination </td> </tr> <tr> <td>Diarrhea with colitis</td> <td> <p>&#8226; Multiple loose bowel movements per day</p> <p>&#8226;&nbsp;Occult bleeding may be seen</p> <p>&#8226; Hematochezia rare</p> </td> <td>Nausea, anorexia, fever, malaise, dehydration, leukocytosis with left shift</td> <td>Abdominal distention, tenderness</td> <td>Diffuse or patchy nonspecific colitis</td> </tr> <tr> <td>Fulminant colitis</td> <td> <p>&#8226; Diarrhea may be severe OR diminished (due to paralytic ileus and colonic dilatation)</p> <p>&#8226; Surgical consult required; colectomy can be life saving</p> </td> <td>Lethargy, fever, tachycardia, abdominal pain; dilated colon/paralytic ileus may be demonstrated on plain abdominal film</td> <td>May present as acute abdomen; peritoneal signs suggest perforation</td> <td>Sigmoidoscopy and colonoscopy contraindicated; flexible proctoscopy with minimal air insufflation may be diagnostic</td> </tr> <tr> <td>Asymptomatic carriage</td> <td>Absent</td> <td>Absent</td> <td>Normal</td> <td>Normal</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80697 Version 7.0</div></div></div>"},"80699":{"type":"graphic_picture","displayName":"Wessley immune ring","title":"Wessley immune ring in contact lens wearer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wessley immune ring in contact lens wearer</div><div class=\"cntnt\"><img style=\"width:324px; height:244px;\" src=\"images/PC/80699_Wessley_immune_ring.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sterile immune infiltrate in the corneal stroma.</div><div id=\"graphicVersion\">Graphic 80699 Version 2.0</div></div></div>"},"80704":{"type":"graphic_figure","displayName":"Securing endotracheal tube","title":"Securing the endotracheal tube","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Securing the endotracheal tube</div><div class=\"cntnt\"><img style=\"width:313px; height:536px;\" src=\"images/EM/80704_SecuringETT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Securing the endotracheal tube. A) The tape is split into a Y and the base is applied to the cheek. B) One strip of tape is then applied to the skin above or below the lips while the other secures the tube. A second piece of tape may be applied from the other side in a similar manner for greater stability. Tincture of benzoin also may be used to increase adhesion.</div><div class=\"graphic_reference\">Reproduced with permission from: King C, Rappaport LD. Emergent endotracheal intubation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 80704 Version 10.0</div></div></div>"},"80705":{"type":"graphic_figure","displayName":"Elevated PD pressure manometry","title":"Sphincter of Oddi manometry","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Sphincter of Oddi manometry</div><div class=\"cntnt\"><img style=\"width:573px; height:237px;\" src=\"images/GAST/80705_Elevated_PD_pressure_manome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of elevated basal sphincter of Oddi (SO) pressure in the pancreatic segment (PD) of the SO.</div><div class=\"graphic_reference\">Courtesy of Walter J Hogan, MD.</div><div id=\"graphicVersion\">Graphic 80705 Version 1.0</div></div></div>"},"80707":{"type":"graphic_diagnosticimage","displayName":"Gallbladder adenomyomatosis US","title":"Gallbladder adenomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gallbladder adenomyomatosis</div><div class=\"cntnt\"><img style=\"width:360px; height:320px;\" src=\"images/GAST/80707_Gallbladder_adenomyomatosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound image of localized adenomyomatosis in the gallbladder fundus (arrow) producing a polypoid appearance.</div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD, FACP.</div><div id=\"graphicVersion\">Graphic 80707 Version 2.0</div></div></div>"},"80708":{"type":"graphic_table","displayName":"Dx of PVE by echocardiography","title":"Transthoracic and transesophageal echocardiography in the diagnosis of prosthetic valve endocarditis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Transthoracic and transesophageal echocardiography in the diagnosis of prosthetic valve endocarditis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Prosthesis type and position (number studied)</td> <td class=\"subtitle1\" colspan=\"4\">Number of valves (percent)</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Transthoracic</td> <td class=\"subtitle2\" colspan=\"2\">Transesophageal</td> </tr> <tr> <td class=\"subtitle3\">Nondiagnostic</td> <td class=\"subtitle3\">Diagnostic</td> <td class=\"subtitle3\">Nondiagnostic</td> <td class=\"subtitle3\">Diagnostic</td> </tr> <tr> <td class=\"subtitle2_left\">Aortic position (34)</td> <td>16</td> <td>18 (53)</td> <td>5</td> <td>29 (85)</td> </tr> <tr> <td class=\"indent1\">Bioprosthesis (12)</td> <td>6</td> <td>6 (50)</td> <td>1 </td> <td>11 (92) </td> </tr> <tr> <td class=\"indent1\">Mechanical valve (22)</td> <td>10</td> <td>12 (55)</td> <td>4</td> <td>18 (82)</td> </tr> <tr> <td class=\"subtitle2_left\">Mitral position (37)</td> <td>32</td> <td>5 (14)</td> <td>4</td> <td>33 (89)</td> </tr> <tr> <td class=\"indent1\">Bioprosthesis (10)</td> <td>8 </td> <td>2 (25) </td> <td>2 </td> <td>8 (80)</td> </tr> <tr> <td class=\"indent1\">Mechanical valve (27)</td> <td>24</td> <td>3 (11)</td> <td>2</td> <td>25 (93)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Patients had pathoanatomic or clinically confirmed (von Reyn criteria) prosthetic valve endocarditis.</div><div class=\"graphic_reference\">Reproduced with permission from Karchmer AW. In: Principles and Practice of Infectious Diseases, 5th ed, Mandell GL, et al (Eds), Churchill Livingstone, Philadelphia 1999. p. 907.</div><div id=\"graphicVersion\">Graphic 80708 Version 3.0</div></div></div>"},"80709":{"type":"graphic_picture","displayName":"Renal allograft biopsy showing ATN light microscopy","title":"Renal allograft biopsy showing acute tubular necrosis by light microscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Renal allograft biopsy showing acute tubular necrosis by light microscopy</div><div class=\"cntnt\"><img style=\"width:404px; height:288px;\" src=\"images/NEPH/80709_ATN_in_renal_allograft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Renal allograft biopsy showing acute tubular necrosis with sloughed and swollen epithelial cells (arrow) and, in the upper tubule, scalloping of the epithelial cells and an intratubular cast.</div><div class=\"graphic_reference\">Courtesy of Ann Crosson, MD.</div><div id=\"graphicVersion\">Graphic 80709 Version 2.0</div></div></div>"},"80710":{"type":"graphic_waveform","displayName":"Fetal complete AV block","title":"Simultaneous tricuspid valve Doppler waveform and M-mode tracing in a fetus with complete heart block","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Simultaneous tricuspid valve Doppler waveform and M-mode tracing in a fetus with complete heart block</div><div class=\"cntnt\"><img style=\"width:478px; height:269px;\" src=\"images/OBGYN/80710_Fetal_complete_AV_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrial rate is 120 bpm (long arrows) and ventricular rate is 50 bpm (short arrows).</div><div id=\"graphicVersion\">Graphic 80710 Version 2.0</div></div></div>"},"80711":{"type":"graphic_diagnosticimage","displayName":"Radiograph nonossifying fibroma","title":"Non-ossifying fibroma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Non-ossifying fibroma</div><div class=\"cntnt\"><img style=\"width:407px; height:446px;\" src=\"images/ONC/80711_Radiograph_nonossifying_fib.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A non-ossifying fibroma can usually be diagnosed with confidence from imaging studies alone, and seldom requires either biopsy or operative intervention. The lesion is recognized by its eccentric (cortical) origin, &quot;polycyclic&quot; outline, well-formed thin sclerotic wall, and progressive ossification, beginning with the portion of the lesion furthest from the growth plate.</div><div class=\"graphic_reference\">Courtesy of Daniel Rosenthal, MD.</div><div id=\"graphicVersion\">Graphic 80711 Version 2.0</div></div></div>"},"80712":{"type":"graphic_table","displayName":"Benefits strength training","title":"Potential benefits of strength training for children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential benefits of strength training for children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td>Adds variety to an overall exercise and conditioning program.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>May increase the likelihood that a child will participate in other activities, thereby developing positive physical activity behaviors.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Increased strength of muscles, tendons, and ligaments.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Increased stability of a joint.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Increased bone density and bone mass.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Improved muscle balance between agonist and antagonist muscle groups.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Improved body composition.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Increased motor unit recruitment and synchronization.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Improved motor coordination and performance.</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 80712 Version 1.0</div></div></div>"},"80714":{"type":"graphic_figure","displayName":"Outcome Brugada Syndrome by presentation","title":"Outcome of patients with Brugada Syndrome depends upon the clinical presentation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Outcome of patients with Brugada Syndrome depends upon the clinical presentation</div><div class=\"cntnt\"><img style=\"width:385px; height:324px;\" src=\"images/CARD/80714_Outcome_Brugada_by_presenta.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 334 patients with the Brugada Syndrome, the incidence of arrhythmic events (sudden cardiac death or documented ventricular fibrillation) during follow-up depended upon the clinical presentation. The outcome was best for those who were asymptomatic and presented with an abnormal ECG, intermediate for those presenting with syncope, and worst in patients with aborted sudden cardiac death.</div><div class=\"graphic_reference\">Data from: Brugada J, Brugada R, Antzelevitch C, et al. Circulation 2002; 105:73.</div><div id=\"graphicVersion\">Graphic 80714 Version 3.0</div></div></div>"},"80715":{"type":"graphic_picture","displayName":"Erythema multiforme palm","title":"Erythema multiforme","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema multiforme</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/80715_Erythema_multiforme_palm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Target lesions are present on the palm of this patient with erythema multiforme.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 80715 Version 4.0</div></div></div>"},"80716":{"type":"graphic_figure","displayName":"Glycosylation of proteins","title":"Formation of advanced glycosylation end products","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Formation of advanced glycosylation end products</div><div class=\"cntnt\"><img style=\"width:582px; height:217px;\" src=\"images/ENDO/80716_Glycosylation_of_proteins.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the formation of advanced glycosylation end products in the presence of persistent hyperglycemia.</div><div class=\"graphic_reference\">Adapted from: Bucala R, Vlassara H, Cerami A.&nbsp;Advanced glycosylated endproducts: role in diabetic and nondiabetic vascular disease. Drug Develop Res 1994; 32:77.</div><div id=\"graphicVersion\">Graphic 80716 Version 2.0</div></div></div>"},"80719":{"type":"graphic_table","displayName":"Oral Rx sexual dysfunction","title":"Oral treatments for male sexual dysfunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral treatments for male sexual dysfunction</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Mechanism and clinical use</td> <td class=\"subtitle1\">Adverse effects and precautions</td> <td class=\"subtitle1\">Drug interactions*</td> <td class=\"subtitle1\">Usual dosing<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Phosphodiesterase type 5 (PDE5) inhibitors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sildenafil</td> <td> <p>Inhibits enzyme phosphodiesterase 5, allowing cyclic GMP to accumulate within penis.</p> Effective for as-needed treatment of organic, psychogenic, or mixed type ED.</td> <td>Applies to <strong>all </strong>PDE5 inhibitors: <ul class=\"decimal_heading\"> <li>Headaches, dyspepsia, vasodilation, diarrhea, rhinitis, epistaxis, blue tinge to vision, other visual disturbances. </li> <li><strong>Contraindicated if using nitrates or riociguat<sup>&#916;</sup></strong> due to risk of severe hypotension and syncope. </li> <li>Co-administration with alpha-1 blockers may cause symptomatic hypotension. If co-administered, we suggest first stabilizing patient on alpha-1 blocker dose prior to starting PDE5 inhibitor at a reduced dose. Tamsulosin and silodosin may be better tolerated than other alpha-1 blockers. </li> <li>Safety is uncertain in patients with severe renal or hepatic impairment, coagulopathy, hypotension, unstable or advanced cardiovascular disease, or retinal disorders<sup>&#9674;</sup>.</li> </ul> </td> <td> <p>Sildenafil is metabolized by CYP3A4.</p> <p>Strong inhibitors of CYP3A4 (eg, protease inhibitors<sup>&#167;</sup>, systemic-azole antifungals, certain macrolide antibiotics) elevate sildenafil concentrations.</p> <p>Inducers of CYP3A4 may reduce sildenafil concentrations.</p> <p>A list of CYP3A4 inhibitors and inducers is provided in a separate table*.</p> <p>We suggest avoidance of large amounts of grapefruit and its juice (a CYP3A4 inhibitor) and alcohol which may enhance hypotensive effect.</p> <p>Use with nitrates and guanylate cyclase stimulators (eg, riociguat) is contraindicated (refer to adverse effects/precautions in this table and accompanying text)</p> </td> <td> <p>Taken one hour before sex and effective up to four hours.</p> <p>Dose: 50 to 100 mg on empty stomach.</p> <p>Administration with a high-fat meal may delay absorption.</p> <p>A reduced dose of 25 mg is recommended if coadministered with a strong inhibitor of CYP3A4 or an alpha-1 blocker and in patients with renal impairment (Crcl &#60;30 mL/minute) or moderate hepatic impairment<sup>&#182;</sup>.</p> Applies to <strong>all </strong>PDE5 inhibitors: Stimulation needed for erection.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vardenafil</td> <td>Same as sildenafil.</td> <td> <p>Similar efficacy, adverse effects, and precautions to sildenafil, EXCEPT visual color distortions reported much less frequently<sup>&#9674;</sup>.</p> Use not recommended in hemodialysis or severe hepatic impairment.</td> <td>Same as sildenafil.</td> <td> <p>Similar onset and duration of action as sildenafil.</p> <p>Dose: 10 to 20 mg on empty stomach about 60 minutes before sexual activity.</p> <p>Patients &#8805;65 years old: 5 mg initially.</p> <p>Orally disintegrating tablet (ODT): 10 mg on empty stomach (no titration).</p> <p>Administration with a high-fat meal may delay absorption.</p> <p>A reduced dose of 2.5 or 5 mg is recommended if coadministered with a strong inhibitor of CYP3A4 or an alpha-1 blocker, respectively*.</p> Dose adjustment for moderate hepatic impairment needed<sup>&#182;</sup>.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tadalafil</td> <td> <p>Similar onset of action as sildenafil.</p> <p>Duration of action up to 36 hours.</p> Effective for as-needed <strong>or</strong> daily treatment of organic, psychogenic, or mixed type ED.</td> <td> <p>Similar efficacy, side effects, and precautions to sildenafil, EXCEPT visual color distortions reported much less frequently<sup>&#9674;</sup>.</p> Daily use not recommended in severe renal or hepatic impairment.</td> <td>Same as sildenafil.</td> <td> <p>Tadalafil has a much longer duration of action than sildenafil.</p> <p>Dose for as-needed treatment: 10 to 20 mg about 60 minutes before sexual activity.</p> <p>10 mg not more than once every 72 hours is recommended if coadministered with a strong inhibitor of CYP3A4.</p> <p>Dose adjustment for renal or hepatic impairment is necessary when used as-needed<sup>&#182;</sup>.</p> <p><strong>or</strong></p> <p>Daily treatment: 2.5 to 5 mg once daily (assumes normal renal and hepatic function).</p> <p>2.5 mg once daily is recommended if coadministered with a strong inhibitor of CYP3A4 or alpha-1 blocker*.</p> Administration with a high-fat meal does not alter absorption.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Avanafil</td> <td>Onset of action of 15 to 30 minutes is more rapid than sildenafil.</td> <td> <p>Similar efficacy, adverse effects, and precautions to sildenafil, EXCEPT visual color distortions reported much less frequently<sup>&#9674;</sup>.</p> Use not recommended in severe renal or hepatic impairment.</td> <td> <p>Same as sildenafil, EXCEPT use of avanafil with medications that are strong inhibitors of CYP3A4 is not recommended.</p> <p>A list of strong inhibitors of CYP3A4 (to be <strong>avoided</strong> with avanafil) is provided separately*.</p> Grapefruit and grapefruit juice should be avoided within 24 hours of use.</td> <td> <p>100 to 200 mg as early as 15 minutes before sexual activity.</p> <p>Administration with a high-fat meal may delay absorption.</p> <p>A reduced dose of 50 mg is recommended if coadministered with an alpha-1 blocker or moderate inhibitor of CYP3A4*.</p> 50 mg dose should be taken about 30 minutes before sexual activity.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Other therapies</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Yohimbine</p> In United States yohimbine is available as an ingredient in some non-prescription dietary supplements (yohimbe)<sup>&#165;</sup>.</td> <td> <p>Blocks presynaptic alpha-2 receptors.</p> <p>Stimulates mid-brain, increases libido.</p> <p>Might increase local blood flow or decrease outflow.</p> <p>Used for psychogenic ED.</p> <p>May have placebo effect.</p> Alternative to testosterone for libido.</td> <td> <p>Dizziness, flushing, nausea, headache, anxiety, insomnia, elevated blood pressure, and increased heart rate; avoid with benign prostatic hyperplasia.</p> <p>Potency and purity of dietary supplements may not be assured.</p> Long-term use is not recommended.</td> <td>May interact with antihypertensives, antidepressants, or stimulant medications*.</td> <td>15 to 30 mg daily in two or three divided doses.</td> </tr> <tr> <td class=\"indent1\">Trazodone</td> <td> <p>Serotonin modulation and alpha-1 antagonism.</p> <p>Used for psychogenic ED.</p> <p>May benefit men suffering from premature ejaculation.</p> Low dose for psychogenic ED may not be effective for treatment of depression.</td> <td> <p>Dizziness, lethargy, sedation.</p> <p>Dose-related orthostatic hypotension, gastrointestinal toxicity, QTc prolongation, and weight gain.</p> May cause priapsim.</td> <td>Trazodone is metabolized by CYP1A2, 2D6, and 3A4; it is an inducer of P-gp*.</td> <td>25 to 100 mg before sleep.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CYP: cytochrome P450 drug metabolism; ED: erectile dysfunction; NAION: non-arteritic anterior ischemic optic neuropathy; P-gp: P-glycoprotein efflux transporters; SSRI: selective serotonin reuptake inhibitor; UDP-GT: glucuronyltransferase drug metabolism (glucuronidation).<br />* A list of strong inhibitors and inducers of CYP3A4 that can interact with PDE5 inhibitors is provided separately. This table does <strong>not</strong> provide a complete list of drug interactions. Specific drug interactions and management suggestions may be determined by using Lexi-Interact, the drug interactions program included with UpToDate.<br />&para; One-half of the usual PDE5 dose shown above may have adequate effect and better tolerability in some patients. The co-administration of more than one PDE5 inhibitor or use more than once per day is not recommended. Dose recommendations are based upon product information approved in United States and assume normal renal and hepatic function. Specific recommendations for use in setting of renal or hepatic impairment may be found in the Lexicomp drug monographs. Dose recommendations approved in other countries may differ. Consult locally approved product information.<br />&Delta; Riociguat is used in treatment of pulmonary arterial hypertension.<br /><span class=\"lozenge\">&loz;</span> Rarely, vision loss and non-arteritic anterior ischemic optic neuropathy (NAION) described in temporal association with PDE5 inhibitor in post-marketing reports. Precise causality (ie, PDE5 and/or patient-specific risk factors) not determined.<br />&sect; Protease inhibitors include atazanavir, boceprevir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, telaprevir and tipranavir. Interaction is of greater significance in ritonavir- or cobicistat-boosted regimens.<br />&yen; Additional information on yohimbe-containing supplements is available from the US National Library of Medicine <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/natural/759.html\" target=\"_blank\">MedlinePlus database</a>.</div><div class=\"graphic_reference\">Data courtesy of authors with additional data from The Medical Letter; 56 (1442):34 May, 2014 and United States approved prescribing information available at National Library of Medicine <a href=\"http://dailymed.nlm.nih.gov/dailymed/index.cfm\" spellcheck=\"true\" target=\"_blank\">DailyMed</a> website.</div><div id=\"graphicVersion\">Graphic 80719 Version 17.0</div></div></div>"},"80720":{"type":"graphic_diagnosticimage","displayName":"Pseudocyst of pancreas","title":"Pancreatic pseudocyst","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Pancreatic pseudocyst</div><div class=\"cntnt\"><img style=\"width:466px; height:405px;\" src=\"images/GAST/80720_Pseudocyst_chron_pan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic scan showing a massive pancreatic pseudocyst compressing the stomach and obliterating the pancreas.</div><div id=\"graphicVersion\">Graphic 80720 Version 5.0</div></div></div>"},"80723":{"type":"graphic_picture","displayName":"Pseudohyphae","title":"<EM>Candida</EM> pseudohyphae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Candida</EM> pseudohyphae</div><div class=\"cntnt\"><img style=\"width:389px; height:252px;\" src=\"images/ID/80723_Pseudohyphae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pseudohyphae (as opposed to true hyphae) are formed when buds elongate with differential rates of wall synthesis at various points along the cell wall. Elongation then stops, and the cell produces a new apical bud, which elongates. This repeated process of budding and elongation can result in extensive filamentation. Side branches initiate as buds and develop in the same manner. In most cases, a constriction remains and can be seen at the origin of each bud.</div><div class=\"graphic_reference\">Courtesy of Wiley Schell, MS.</div><div id=\"graphicVersion\">Graphic 80723 Version 3.0</div></div></div>"},"80724":{"type":"graphic_table","displayName":"Axillary nodes Paget dz","title":"Axillary node metastasis in patients with Paget disease of the breast with or without a palpable mass","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Axillary node metastasis in patients with Paget disease of the breast with or without a palpable mass</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp; </td> <td class=\"subtitle1\">Number of patients </td> <td class=\"subtitle1\">Percent node-positive with a palpable mass </td> <td class=\"subtitle1\">Percent node-positive in absence of a palpable mass </td> </tr> <tr> <td>Paone, 1981</td> <td>50</td> <td>64</td> <td>0</td> </tr> <tr> <td>Chaudary, 1986</td> <td>35</td> <td>45</td> <td>12</td> </tr> <tr> <td>Eusebio, 1992</td> <td>45</td> <td>45</td> <td>0</td> </tr> <tr> <td>Kollmorgen, 1998</td> <td>68</td> <td>57</td> <td>21</td> </tr> <tr> <td>Sukumvanich P; 2007</td> <td>39</td> <td>45</td> <td>11</td> </tr> </tbody></table></div><div class=\"graphic_reference\"><OL>&#xD;&#xA;<LI>Paone JF, Baker RR. Pathogenesis and treatment of Paget's disease of the breast. Cancer 1981; 48:825. </LI>&#xD;&#xA;<LI>Chaudary MA, Millis RR, Lane EB, Miller NA. Paget's disease of the nipple: a ten year review including clinical, pathological, and immunohistochemical findings.&nbsp;Breast Cancer Res Treat 1986; 8:139. </LI>&#xD;&#xA;<LI>Eusebio RB, Deckers PJ. Paget's disease of the nipple-areola complex: A plea for conservatism. Contemp Surg 1992; 40:13.</LI>&#xD;&#xA;<LI>Kollmorgen DR, Varanasi JS, Edge SB, Carson WE 3rd. J Am Coll Surg 1998; 187:171. </LI>&#xD;&#xA;<LI>Sukumvanich P, Bentrem DJ, Cody HS 3rd, et al. The role of sentinel lymph node biopsy in Paget's disease of the breast. Ann Surg Oncol 2007; 14:1020.</LI></OL></div><div id=\"graphicVersion\">Graphic 80724 Version 3.0</div></div></div>"},"80725":{"type":"graphic_picture","displayName":"Atypical nevi size","title":"Atypical nevi size","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atypical nevi size</div><div class=\"cntnt\"><img style=\"width:444px; height:381px;\" src=\"images/PEDS/80725_Atypical_nevi_size.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atypical nevus with size greater than 6 mm.</div><div class=\"graphic_reference\">Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.</div><div id=\"graphicVersion\">Graphic 80725 Version 1.0</div></div></div>"},"80726":{"type":"graphic_table","displayName":"FTT tips for parents","title":"Behavioral tips for parents of children with poor weight gain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Behavioral tips for parents of children with poor weight gain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Dietary advice</td> </tr> <tr> <td class=\"indent1\">Consumption of excessive fluid reduces the intake of solid foods. At mealtimes, offer solids before liquids. (Liquids are filling and provide fewer calories.)</td> </tr> <tr> <td class=\"indent1\">Fruit juices should not be offered to children before&nbsp;12 months of age. After 12 months, give only 100% fruit juice and limit to 4 ounces (120 mL)&nbsp;per day. Limit all sweetened or carbonated beverages. Breast milk, formula, or milk (over one year of age) is best.</td> </tr> <tr> <td class=\"indent1\">Don't worry if your child wants to eat the same food every day. Variety is not important. Total calories and protein are.</td> </tr> <tr> <td class=\"indent1\">Junk foods have little protein and fewer calories than some other food choices. Junk foods will not help growth; they only take up valuable space in the stomach.</td> </tr> <tr> <td class=\"indent1\">Offer foods that are easy for your child to handle (eg, cereal, slices of banana, or green beans).</td> </tr> <tr> <td class=\"indent1\">Add margarine, mayonnaise, gravies, and grated cheese. For snacks, use cheese, pudding, bananas, or dried fruit.</td> </tr> <tr> <td class=\"subtitle1_single\">Feeding times</td> </tr> <tr> <td class=\"indent1\">Children need to eat often, not constantly. Offer something every two to three hours, to allow three meals and two to three snacks per day. Avoid snacks right after an unfinished meal.</td> </tr> <tr> <td class=\"indent1\">Children work well with schedules. Try to keep mealtimes and snack times about the same each day.</td> </tr> <tr> <td class=\"indent1\">Allow one hour without food or drink (except water) before a meal to stimulate the appetite.</td> </tr> <tr> <td class=\"indent1\">Do not make mealtime too long for your child. (Fifteen minutes is probably long enough for a toddler.)</td> </tr> <tr> <td class=\"subtitle1_single\">Feeding behavior</td> </tr> <tr> <td class=\"indent1\">Try to relax; feeding/eating and mealtimes should be pleasant for everyone.</td> </tr> <tr> <td class=\"indent1\">Recognize your child's cues indicating hunger, satiety, and food preferences.</td> </tr> <tr> <td class=\"indent1\">You are responsible for deciding what food your child is offered (with consideration for your child's preferences); your child decides how much to eat.</td> </tr> <tr> <td class=\"indent1\">Avoid battles over eating. Encourage your child, but avoid forced feeding, threatening, bribing, or punitive approaches. Instead, use positive reinforcement (eg, praise for eating well).</td> </tr> <tr> <td class=\"indent1\">Do not withhold food as a form of punishment.</td> </tr> <tr> <td class=\"indent1\">Allow your child to feed himself or herself. Try very small amounts at first. Offer seconds later. Expect messiness and be prepared for easy clean-up (bibs, newspaper under high chair, etc).</td> </tr> <tr> <td class=\"indent1\">Some babies want to control the spoon - for such babies, use two spoons, one for the baby to control and one for you to use to feed.</td> </tr> <tr> <td class=\"subtitle1_single\">Feeding environment</td> </tr> <tr> <td class=\"indent1\">Try to eat together as a family. Good eating behavior can be modeled, and young children like to mimic older siblings and parents.</td> </tr> <tr> <td class=\"indent1\">Limit possible distractions during meals (eg, television).</td> </tr> <tr> <td class=\"indent1\">Make sure your child can reach the food. (Use a high chair, booster seat, or small table.)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Bithoney WG, Dubowitz H, Egan H. Failure to thrive/growth deficiency. Pediatr Rev 1992; 13:453. </LI>&#xD;&#xA;<LI>Frank DA, Zeisel SH. Failure to thrive. Pediatr Clin North Am 1988; 35:1187. </LI>&#xD;&#xA;<LI>Frank D, Silva M, Needlman R. Failure to thrive: Mystery, myth and method. Contemp Pediatr 1993; 10:114. </LI>&#xD;&#xA;<LI>Heyman MB, Abrams SA, Section on Gastroenterology, Hepatology, and Nutrition, Committee on Nutrition. Fruit juice in infants, children, and adolescents: Current recommendations. Pediatrics 2017; 139.</LI></OL></div><div id=\"graphicVersion\">Graphic 80726 Version 9.0</div></div></div>"},"80728":{"type":"graphic_figure","displayName":"Middle phalanx fracture displacement","title":"Middle phalanx fracture displacement","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Middle phalanx fracture displacement</div><div class=\"cntnt\"><img style=\"width:454px; height:391px;\" src=\"images/EM/80728_Mid_phal_fx_displace_mech.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A lateral view, showing the prolonged insertion of the flexor superficialis tendon into the middle phalanx. <br />(B) A fracture through the neck of the middle phalanx is likely to have a volar angulation because the proximal fragment is flexed by the strong pull of the superficialis. <br />(C) A fracture through the base of the middle phalanx is more likely to have a dorsal angulation because of the extension force of the central slip on the proximal fragment and a flexion force on the distal fragment by the superficialis.</div><div class=\"graphic_reference\">Reproduced with permission from: Rockwood CA Jr, Green DP, Bucholz RW, Heckman JD, eds. Rockwood and Green's Fractures in Adults, 4th ed. Philadelphia: Lippincott-Raven, 1996: Copyright © 1996 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80728 Version 3.0</div></div></div>"},"80729":{"type":"graphic_diagnosticimage","displayName":"CBD stones MRCP II","title":"Common bile duct stones","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Common bile duct stones</div><div class=\"cntnt\"><img style=\"width:247px; height:288px;\" src=\"images/GAST/80729_CBD_stones_MRCP_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance cholangiopancreatography study, obtained in a 60-year-old woman with recurrent right upper quadrant pain and an unremarkable ultrasound examination, shows small stones (arrows) in the GB and the CBD.</div><div class=\"graphic_footnotes\">CBD: common bile duct; GB: gallbladder.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 80729 Version 3.0</div></div></div>"},"80731":{"type":"graphic_figure","displayName":"Marshall Marchetti Krantz","title":"Marshall-Marchetti-Krantz procedure","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Marshall-Marchetti-Krantz procedure</div><div class=\"cntnt\"><img style=\"width:453px; height:392px;\" src=\"images/OBGYN/80731_Marshall_Marchetti_Krantz.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">In: Gynecologic Surgery. Mann, WM, Stovall, TG (Eds), Churchill Livingstone, New York 1996. p.716.</div><div id=\"graphicVersion\">Graphic 80731 Version 1.0</div></div></div>"},"80733":{"type":"graphic_figure","displayName":"Survival autoimmune hepatitis","title":"Survival in classic autoimmune hepatitis","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Survival in classic autoimmune hepatitis</div><div class=\"cntnt\"><img style=\"width:475px; height:277px;\" src=\"images/GAST/80733_Survival_autoimmune_hepatit.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comparison of survival, using death and liver transplantation as endpoints, in patients with autoimmune hepatitis according to the presence or absence of cirrhosis. Survival is excellent in both groups at 10 years but falls off substantially in the patients with cirrhosis between 10 and 20 years.</div><div class=\"graphic_reference\">Data from Roberts SK, Therneau TM, Czaja AJ. Gastroenterology 1996; 110:848.</div><div id=\"graphicVersion\">Graphic 80733 Version 2.0</div></div></div>"},"80734":{"type":"graphic_figure","displayName":"Salmonellosis risk factors","title":"Pathogenic bacterial properties and host factors conferring increased susceptibility to Salmonella infection","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Pathogenic bacterial properties and host factors conferring increased susceptibility to Salmonella infection</div><div class=\"cntnt\"><img style=\"width:559px; height:508px;\" src=\"images/ID/80734_Salmonellosis_risk_factors.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Infections of the Gastrointestinal Tract, Blaser, Smith, Ravdin, et al (Eds), Lippincott Williams &amp; Wilkins, Phildadelphia 1995. Copyright © 1995 Lippincott Williams &amp; Wilkins.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 80734 Version 8.0</div></div></div>"},"80736":{"type":"graphic_figure","displayName":"DLBCL pathogenesis I","title":"Schematic overview of potential mechanisms for the development of germinal center B cell-like and activated B cell-like diffuse large B cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Schematic overview of potential mechanisms for the development of germinal center B cell-like and activated B cell-like diffuse large B cell lymphoma</div><div class=\"cntnt\"><img style=\"width:539px; height:584px;\" src=\"images/HEME/80736_DLBCLpathogenesisI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse large B cell lymphoma (DLBCL) is a heterogeneous group of tumors derived from germinal center or post-germinal center B cells. Gene expression studies have divided DLBCL based on likely cell of origin. GCB-like tumors contain the (14;18) translocation (IgH/BCL-2 fusion gene) typical of follicular lymphoma and amplifications of the locus on chromosome 2 which codes for the c-Rel oncogene. ABC-like DLBCL is associated with loss of 6q21, trisomy 3, and gains of 3q and 18q21-22. This locus on 6q encodes the tumor suppressor gene PRDM1 (Blimp-1), which is a master regulator in the differentiation of mature B lymphocytes to plasma cells, loss of which may lead to inhibition of terminal differentiation. ABC DLBCL have high expression and constitutive activity of the nuclear factor kappa B (NF-KB) complex involved in the B cell receptor (BCR) signaling pathway. Type III DLBCLs have gene expression profiles that do not resemble either germinal center or post-germinal center B cells. The mechanism of its pathobiology is unknown.</div><div id=\"graphicVersion\">Graphic 80736 Version 4.0</div></div></div>"},"80741":{"type":"graphic_figure","displayName":"Myofascial pelvic pain map","title":"Female myofascial pelvic pain documentation map","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Female myofascial pelvic pain documentation map</div><div class=\"cntnt\"><img style=\"width:517px; height:664px;\" src=\"images/OBGYN/80741_Form_for_pain_map.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 80741 Version 3.0</div></div></div>"},"80742":{"type":"graphic_table","displayName":"Echo pericardial disease","title":"Recommendations for echocardiography in pericardial disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for echocardiography in pericardial disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Class I</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">1. Patients with suspected pericardial disease, including effusion, constriction, or effusive-constrictive process.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"indent1\">2. Patients with suspected bleeding in the pericardial space, eg, trauma, perforation, etc.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"indent1\">3. Follow-up study to evaluate recurrence of effusion or to diagnose early constriction. Repeat studies may be goal directed to answer a specific clinical question.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"indent1\">4. Pericardial friction rub developing in acute myocardial infarction accompanied by symptoms such as persistent pain, hypotension, and nausea.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Class IIa</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">1. Follow-up studies to detect early signs of tamponade in the presence of large or rapidly accumulating effusions. A goal-directed study may be appropriate.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"indent1\">2. Echocardiographic guidance and monitoring of pericardiocentesis.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Class IIb</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">1. Postsurgical pericardial disease, including postpericardiotomy syndrome, with potential for hemodynamic impairment.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"indent1\">2. In the presence of a strong clinical suspicion and nondiagnostic TTE, TEE assessment of pericardial thickness to support a diagnosis of constrictive pericarditis.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Class III</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">1. Routine follow-up of small pericardial effusion in clinically stable patients.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">2. Follow-up studies in patients with cancer or other terminal illness for whom</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">management would not be influenced by echocardiographic findings.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">3. Assessment of pericardial thickness in patients without clinical evidence of constrictive pericarditis.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"indent1\">4. Pericardial friction rub in early uncomplicated myocardial infarction or early postoperative period after cardiac surgery.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">ACC/AHA classification</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td><strong>Class I:</strong> Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"sublist1_start\"><strong>Class II:</strong> Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"sublist1\"><strong> Class IIa:</strong> Weight of evidence/opinion is in favor of usefulness/efficacy.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\"><strong>Class IIb:</strong> Usefulness/efficacy less well established by evidence/opinion.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td><strong>Class III:</strong> Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful and in some cases may be harmful.</td>\n\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003; 108:1146.</div><div id=\"graphicVersion\">Graphic 80742 Version 1.0</div></div></div>"},"80743":{"type":"graphic_figure","displayName":"Pinna embryology","title":"Pinna embryology","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Pinna embryology</div><div class=\"cntnt\"><img style=\"width:508px; height:608px;\" src=\"images/PEDS/80743_Pinna_embryology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The auricle or pinna is formed from the fusion of six raised soft tissue swellings (hillocks) on the surface of the embryo. Three of these hillocks are derived from the first branchial arch (FBA)&nbsp;and three from the second branchial arch (SBA) during the fifth and sixth weeks of intrauterine life. The hillocks of the FBA and SBA flank the first branchial cleft (FBC). The FBA and SBA contribute almost equally to the immature pinna, whereas the mature pinna predominantly originates from the SBA.</div><div class=\"graphic_reference\">Original figure redrawn for this publication. Anson BJ, McVay CB. Surgical anatomy, 6th Edition, Philadelphia: WB Saunders, 1984. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 80743 Version 3.0</div></div></div>"},"80744":{"type":"graphic_picture","displayName":"Neck rotation exercise","title":"Neck rotation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neck rotation</div><div class=\"cntnt\"><img style=\"width:367px; height:276px;\" src=\"images/PC/80744_Neck_rotation_exercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Slowly turn your head to the right. Place tension on your chin with your fingertips. Hold for a few seconds and return to the center. Repeat to the left.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 80744 Version 2.0</div></div></div>"},"80745":{"type":"graphic_picture","displayName":"Lichenification","title":"Lichenification","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichenification</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/80745_Lichenification.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thickened skin with accentuated skin lines&nbsp;is present in this patient who chronically rubbed and scratched this area.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 80745 Version 5.0</div></div></div>"},"80746":{"type":"graphic_table","displayName":"Factors accuracy exercise test","title":"Determinants of sensitivity and specificity in exercise ECG testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Determinants of sensitivity and specificity in exercise ECG testing</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t\t<tr>\n\t\t\t<td class=\"subtitle1_single\">Patient characteristics</td>\n\t\t</tr>\n\t\t<tr>\t\n\t\t\t<td>Prior myocardial infarction</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Abnormal rest ECG</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Degree of coronary stenosis</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Extent of coronary stenosis</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Age</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Gender</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Drugs</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td class=\"subtitle1_single\">Intraobserver variability</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>ECG interpretation</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Angiographic interpretation</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td class=\"subtitle1_single\">Exercise protocol</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Exercise end points</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Patient position</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Exercise lead system</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>ECG criteria for positivity</td>\t\t\t\n\t\t</tr>\n\t</table></div><div id=\"graphicVersion\">Graphic 80746 Version 1.0</div></div></div>"},"80747":{"type":"graphic_table","displayName":"Adverse effects of atypical antipsychotic medications","title":"Selected adverse effects of atypical antipsychotic medications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected adverse effects of atypical antipsychotic medications</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Acute</td> <td class=\"subtitle1\">Chronic</td> </tr> <tr> <td>Clozapine</td> <td>Seizures</td> <td>NMS, Agranulocytosis, Myocarditis</td> </tr> <tr> <td>Risperidone</td> <td>Prolonged QT, dystonia</td> <td>EPS, TD, NMS</td> </tr> <tr> <td>Olanzapine</td> <td>Seizures, dystonia</td> <td>EPS, TD, NMS, Agranulocytosis</td> </tr> <tr> <td>Quetiapine</td> <td>Seizures, dystonia</td> <td>EPS, TD, NMS</td> </tr> <tr> <td>Ziprasidone</td> <td>Prolonged QT, dystonia</td> <td>EPS</td> </tr> <tr> <td>Aripiprazole</td> <td>Gastrointestinal (vomiting)</td> <td>&nbsp;</td> </tr> <tr> <td>Asenapine&nbsp;</td> <td>Hypotension, sedation</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NMS: neuroleptic malignant syndrome; TD: tardive dyskinesia; EPS: extrapyramidal side effects.</div><div id=\"graphicVersion\">Graphic 80747 Version 3.0</div></div></div>"},"80748":{"type":"graphic_picture","displayName":"Proximal biceps tendon rupture","title":"Proximal biceps tendon rupture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proximal biceps tendon rupture</div><div class=\"cntnt\"><img style=\"width:432px; height:300px;\" src=\"images/EM/80748_Biceps_tendon_rupture2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient shows the classic \"Popeye\" deformity associated with a proximal biceps tendon rupture. Note the gap between the contracted biceps muscle and the deltoid. </div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD, and Bryan Dixon, MD.</div><div id=\"graphicVersion\">Graphic 80748 Version 5.0</div></div></div>"},"80752":{"type":"graphic_figure","displayName":"ECG changes with exercise","title":"Spectrum of electrocardiographic changes during exercise testing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spectrum of electrocardiographic changes during exercise testing</div><div class=\"cntnt\"><img style=\"width:422px; height:350px;\" src=\"images/CARD/80752_ECG_changes_with_exercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">A: Normal resting electrocardiogram (lead V5) before exercise; B: Normal J point depression during exercise; C: Upsloping ST depression of subendocardial ischemia; D: Horizontal ST depression of subendocardial ischemia; E: Downsloping ST depression of subendocardial ischemia; F: ST elevation caused by transmural ischemia; G: U wave inversion.</div><div id=\"graphicVersion\">Graphic 80752 Version 1.0</div></div></div>"},"80754":{"type":"graphic_picture","displayName":"Apparent genu varum","title":"Lower-extremity exam","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Lower-extremity exam</div><div class=\"cntnt\"><img style=\"width:471px; height:315px;\" src=\"images/PEDS/80754_Apprnt_genu_vrm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Apparent genu varum.<br />(B) True alignment when patellas are held pointed straight ahead.<br />Greater than 6 cm (2.4 inches)&nbsp;between the medial femoral condyles (arrows) is considered abnormal at any age.</div><div class=\"graphic_reference\">Courtesy of Scott Rosenfeld, MD.</div><div id=\"graphicVersion\">Graphic 80754 Version 2.0</div></div></div>"},"80755":{"type":"graphic_figure","displayName":"GI vascular development","title":"Development of the gastrointestinal vasculature","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Development of the gastrointestinal vasculature</div><div class=\"cntnt\"><img style=\"width:451px; height:433px;\" src=\"images/PEDS/80755_GI_vascular_devel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Embryo during the sixth week of development, showing blood supply to the segments of the gut and formation and rotation of the primary intestinal loop. The superior mesenteric artery forms the axis of this rotation and supplies the midgut. The celiac and inferior mesenteric arteries supply the foregut and hindgut, respectively.</div><div class=\"graphic_reference\">Reproduced with permission from: Sadler T, PhD. Langman's Medical Embryology, Ninth Edition Image Bank. Baltimore: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80755 Version 2.0</div></div></div>"},"80757":{"type":"graphic_table","displayName":"Exposures associated with ILD","title":"Occupational and environmental exposures associated with interstitial lung disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Occupational and environmental exposures associated with interstitial lung disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Inhaled inorganic dust</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Silicates</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Silica (\"silicosis\")</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Asbestos (\"asbestosis\")</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Talc (hydrated Mg silicates; \"talcosis\")</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Kaolin or \"china clay\" (hydrated aluminum silicate)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Diatomaceous earth (Fuller's earth, aluminum silicate\nwith Fe and Mg)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Nepheline (hard rock containing mixed silicates)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Aluminum silicates (sericite, sillimanite, zeolite)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Portland cement</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Mica (principally K and Mg aluminum silicates)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Beryllium (\"berylliosis\")</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Carbon</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Coal dust (\"coal worker's pneumoconiosis\")</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Graphite (\"carbon pneumoconiosis\")</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Metals</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Tin (\"stannosis\")&nbsp;</td>\n\n    </tr>\n\n    <tr><td class=\"sublist2_start\">Aluminum</td></tr><tr>\n\n      <td class=\"sublist2\">Powdered aluminum</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Bauxite (aluminum oxide)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2_start\">Hard metal dusts</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Cadmium&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Titanium oxide</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Tungsten</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Hafnium</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Niobium</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Cobalt</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Vanadium carbides</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Iron (\"siderosis\", \"arc welder's lung\") Barium (powder\nof baryte or BaSO4; \"baritosis\")</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Antimony (oxides and alloys) </td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hematite (mixed dusts of iron oxide, silica and\nsilicates; \"siderosilicosis\") </td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mixed dusts of silver and iron oxide\n(\"argyrosiderosis\") </td>\n\n    </tr>\n\n    <tr>\n\n      <td>CuSO4 neutralized with hydrated lime (Bordeaux mixture;\n\"vineyard sprayer's lung\") </td>\n\n    </tr>\n\n    <tr>\n\n      <td>Rare earths (cerium, scandium, yttrium, lanthanum)</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Crystal, RG. Interstitial lung disease. In: Wyngaarden, JB, Smith, LH, Jr, Bennett, JC, (Eds), Cecil Textbook of Medicine, 19th ed, WB Saunders Co, Philadelphia, 1992.</div><div id=\"graphicVersion\">Graphic 80757 Version 1.0</div></div></div>"},"80758":{"type":"graphic_picture","displayName":"Hürthle cell lesion","title":"Hürthle cell lesion: Appearance on fine-needle aspirate of a thyroid nodule","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hürthle cell lesion: Appearance on fine-needle aspirate of a thyroid nodule</div><div class=\"cntnt\"><img style=\"width:290px; height:470px;\" src=\"images/ENDO/80758_hurthle_cell_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fine-needle aspiration biopsy specimen showing mostly eosinophilic oxyphilic cells with abundant cytoplasm and round oval nuclei with prominent nucleoli.</div><div class=\"graphic_reference\">Courtesy of Stephanie L Lee, MD, PhD.</div><div id=\"graphicVersion\">Graphic 80758 Version 4.0</div></div></div>"},"80761":{"type":"graphic_figure","displayName":"Propranolol after acute MI","title":"Benefit of propranolol after myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Benefit of propranolol after myocardial infarction</div><div class=\"cntnt\"><img style=\"width:482px; height:310px;\" src=\"images/CARD/80761_Propranolol_after_acute_MI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Results of the Beta Blocker Heart Attack Trial which randomized 3837 patients with an acute myocardial infarction to propranolol or placebo. At an average follow-up of 25 months, propranolol significantly reduced total, cardiovascular, and sudden death mortality and reduced the incidence of nonfatal infarction and all coronary events. Benefit occurred in all patient groups, but was more marked in those with heart failure (HF).</div><div class=\"graphic_reference\">Data from Chadda K, Goldstein S, Byington R, et al. Circulation 1986; 73:503.</div><div id=\"graphicVersion\">Graphic 80761 Version 2.0</div></div></div>"},"80762":{"type":"graphic_diagnosticimage","displayName":"Proximal phalanx transverse fracture lateral radiograph","title":"Transverse fracture of the proximal phalanx: Lateral radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse fracture of the proximal phalanx: Lateral radiograph</div><div class=\"cntnt\"><img style=\"width:400px; height:453px;\" src=\"images/EM/80762_Prox_phalanx_trans_fx_lat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse fractures of the proximal phalanx are best seen on lateral radiographs, as shown above (white arrow).</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 80762 Version 3.0</div></div></div>"},"80763":{"type":"graphic_picture","displayName":"Diverticulum with fecolith endoscopy","title":"Diverticulum with nonobstructing fecolith","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diverticulum with nonobstructing fecolith</div><div class=\"cntnt\"><img style=\"width:280px; height:272px;\" src=\"images/GAST/80763_Divertic_with_fecolith_Endo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A nonobstructing fecolith is seen within a large diverticulum.</div><div id=\"graphicVersion\">Graphic 80763 Version 2.0</div></div></div>"},"80765":{"type":"graphic_algorithm","displayName":"Evaluation for LGL","title":"Suggested algorithm for the evaluation of large granular lymphocyte leukemia","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Suggested algorithm for the evaluation of large granular lymphocyte leukemia</div><div class=\"cntnt\"><img style=\"width:507px; height:462px;\" src=\"images/HEME/80765_Evaluation_for_LGL.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LPL: large granular lymphocyte leukemia.<br />* In the case of strong clinical suspicion, phenotyping is recommended as typical LGL phenotype is sometimes observed in the absence of LGL morphology.</div><div class=\"graphic_reference\">Reproduced with permission from: Lamy T, Loughran TP. Large granular lymphocyte leukemia. Cancer Control 1998; 5:25.</div><div id=\"graphicVersion\">Graphic 80765 Version 2.0</div></div></div>"},"80766":{"type":"graphic_figure","displayName":"Reading TST","title":"Measuring a reaction to the tuberculin skin test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Measuring a reaction to the tuberculin skin test</div><div class=\"cntnt\"><img style=\"width:340px; height:462px;\" src=\"images/ID/80766_Reading_TST.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the correct method for measuring a reaction to the tuberculin skin test. The size of the reaction is measured by the width of induration, not erythema. In the example shown, the reaction measures 10 mm.</div><div class=\"graphic_reference\">Redrawn from: Testing for Tuberculosis Infection and Disease. In: Core Curriculum on Tuberculosis: What the Clinician Should Know, Sixth Edition, Centers for Disease Control and Prevention, 2013. Available at: <a href=\"http://www.cdc.gov/tb/education/corecurr/default.htm\" target=\"_blank\">http://www.cdc.gov/tb/education/corecurr/default.htm</a>.</div><div id=\"graphicVersion\">Graphic 80766 Version 4.0</div></div></div>"},"80770":{"type":"graphic_figure","displayName":"Esophageal acid-induced bronchoconstriction","title":"Mechanisms of esophageal acid-induced bronchoconstriction","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Mechanisms of esophageal acid-induced bronchoconstriction</div><div class=\"cntnt\"><img style=\"width:578px; height:316px;\" src=\"images/PULM/80770_Esophageal_acid_induced_bro.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 80770 Version 2.0</div></div></div>"},"80771":{"type":"graphic_table","displayName":"Pediatric oropharyngeal trauma assessment and imaging","title":"Oropharyngeal trauma physical assessment and suggested imaging","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oropharyngeal trauma physical assessment and suggested imaging</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Finding</td> <td class=\"subtitle1\">Minor</td> <td class=\"subtitle1\">Moderate</td> <td class=\"subtitle1\">Severe</td> </tr> <tr> <td>Mechanism</td> <td> <p><strong>Low force:</strong> eg,</p> Fall from sitting with toy in the mouth</td> <td> <p><strong>Intermediate force:</strong> eg,</p> <p>Fall while running with pencil in mouth</p> <p><strong>OR</strong></p> Bicycle accident while eating a popsicle</td> <td> <p><strong>High force:</strong> eg,</p> <p>High speed motor vehicle accident with impaling oropharyngeal object</p> <p><strong>OR</strong></p> Penetrating injury with knife or gunshot wound</td> </tr> <tr> <td>Wound appearance</td> <td> <p>Mucosal laceration &#60;2 cm in length</p> <p><strong>OR</strong></p> Superficial midline puncture wound</td> <td> <p>Submucosal laceration &#62;2 cm in length</p> <p><strong>OR</strong></p> <p>Tonsillar or lateral soft palate deep or indeterminate depth puncture wound</p> <p><strong>OR</strong></p> Protruding or retained foreign body*</td> <td> <p>Large, gaping wound with copious bleeding</p> <p><strong>OR</strong></p> As for moderate injury with associated neurovascular findings</td> </tr> <tr> <td>Associated findings</td> <td>Superficial gum laceration or abrasion</td> <td> <p>Tooth fracture, luxation, or avulsion</p> <p>Tongue laceration</p> Jaw fracture</td> <td>Neurologic abnormality carotid artery bruit on side of injury</td> </tr> <tr> <td>Radiographic imaging</td> <td>Not indicated</td> <td>CTA or contrast enhanced MRA<sup>&#182;</sup></td> <td>Digital subtraction CAA</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CTA: computed tomography angiography; MRA: magnetic resonance angiography; CAA: carotid artery angiogram.<br />* A protruding oropharyngeal foreign body should only be removed in the operating room.<br />¶ Contrast enhanced MRA is preferred if available and if the patient can cooperate with not moving for 30 to 60 minutes.</div><div id=\"graphicVersion\">Graphic 80771 Version 3.0</div></div></div>"},"80772":{"type":"graphic_figure","displayName":"Reflux episodes identified by combined impedance-pH monitoring","title":"Reflux episodes identified by combined impedance-pH monitoring","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Reflux episodes identified by combined impedance-pH monitoring</div><div class=\"cntnt\"><img style=\"width:598px; height:355px;\" src=\"images/GAST/80772_Combined_impedance-pH_monit.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Impedance-measuring segments are located 3, 5, 7, 9, 15, and 17 cm above the lower esophageal sphincter (LES), the esophageal pH sensor 5 cm above the LES (bottom channel). Reflux episodes are detected by the rapid decline in impedance starting in the distal esophagus and over time advancing proximally (ie, retrograde bolus movement). The example on the left (A) is an acid reflux episode as esophageal pH declines from above to below 4.0. Note that the esophageal pH remains below 4.0 longer than the refluxate presence in the esophagus and is later cleared by a swallow. The example on the right (B) is a non-acid reflux episode as the esophageal pH remains above 4.0. Note that this reflux episode would have been missed by conventional pH monitoring alone.</div><div class=\"graphic_reference\">Courtesy of Radu Tutuian, MD, and Donald O. Castell, MD.</div><div id=\"graphicVersion\">Graphic 80772 Version 2.0</div></div></div>"},"80774":{"type":"graphic_picture","displayName":"Forearm fascia flap","title":"Radial forearm pedicled tissue transfer flap","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Radial forearm pedicled tissue transfer flap</div><div class=\"cntnt\"><img style=\"width:588px; height:446px;\" src=\"images/SURG/80774_Forearm_fascia_flap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A radial forearm fascia flap is used for coverage of an electrical injury to the hand. Panel A shows the fascia flap attached to the radial artery. Panel B shows the length of the flap in preparation for coverage of the burned thumb. Panel C shows the pedicled flap covering the burned defect on the thumb.</div><div id=\"graphicVersion\">Graphic 80774 Version 3.0</div></div></div>"},"80775":{"type":"graphic_table","displayName":"Commonly misused drugs PI","title":"Commonly misused prescription drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly misused prescription drugs</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Generic name</td> <td class=\"subtitle1\">US brand names</td> <td class=\"subtitle1\">Prescribed to treat</td> </tr> <tr> <td>Codeine and guaifenesin</td> <td>Robitussin AC</td> <td rowspan=\"2\">Cough</td> </tr> <tr> <td>Hydrocodone and homatropine</td> <td> <p>Hycodan</p> <p>Hydromet</p> </td> </tr> <tr class=\"divider_top\"> <td>Buprenorphine</td> <td> <p>Buprenex</p> <p>Butrans</p> </td> <td rowspan=\"10\">Severe pain</td> </tr> <tr> <td>Codeine</td> <td>&nbsp;</td> </tr> <tr> <td>Codeine and acetaminophen</td> <td>Tylenol with codeine No. 3</td> </tr> <tr> <td>Hydrocodone and acetaminophen</td> <td> <p>Vicodin</p> <p>Lorcet</p> <p>Lortab</p> <p>Others</p> </td> </tr> <tr> <td>Hydromorphone</td> <td> <p>Dilaudid</p> <p>Exalgo</p> </td> </tr> <tr> <td>Methadone</td> <td>Dolophine</td> </tr> <tr> <td>Morphine</td> <td> <p>Avinza</p> <p>Kadian</p> <p>Oramorph SR</p> <p>MS Contin</p> </td> </tr> <tr> <td>Oxycodone</td> <td> <p>Oxecta</p> <p>Oxycontin</p> <p>Roxicodone</p> </td> </tr> <tr> <td>Oxycodone and acetaminophen</td> <td> <p>Endocet</p> <p>Percocet</p> <p>Roxicet</p> <p>Tylox</p> <p>Others</p> </td> </tr> <tr> <td>Oxymorphone</td> <td>Opana</td> </tr> <tr class=\"divider_top\"> <td>Amphetamine and dextroamphetamine</td> <td>Adderall XR</td> <td rowspan=\"3\">Attention deficit hyperactivity disorder (ADHD)</td> </tr> <tr> <td>Methamphetamine</td> <td>Desoxyn</td> </tr> <tr> <td>Methylphenidate</td> <td> <p>Ritalin</p> <p>Concerta</p> <p>Daytrana</p> <p>Others</p> </td> </tr> <tr class=\"divider_top\"> <td>Alprazolam</td> <td>Xanax</td> <td rowspan=\"4\">Anxiety and sleep problems</td> </tr> <tr> <td>Diazepam</td> <td>Valium</td> </tr> <tr> <td>Clonazepam</td> <td>Klonopin</td> </tr> <tr> <td>Lorazepam</td> <td>Ativan</td> </tr> <tr class=\"divider_top\"> <td>Carisoprodol</td> <td>Soma</td> <td>Muscle spasms, back pain</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This list does <STRONG>not </STRONG>include prescription drugs that athletes sometimes misuse to increase muscle growth and do better in sports.</div><div id=\"graphicVersion\">Graphic 80775 Version 3.0</div></div></div>"},"80776":{"type":"graphic_picture","displayName":"Hemoglobin H disease","title":"Hemoglobin H disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemoglobin H disease</div><div class=\"cntnt\"><img style=\"width:395px; height:258px;\" src=\"images/HEME/80776_Hemoglobin_H_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear from a patient with hemoglobin H disease and an intact spleen. The smear shows target cells (blue arrows), microcytic red cells (black arrow), and red cell fragments (yellow arrows).</div><div class=\"graphic_reference\">Courtesy of Stanley Schrier, MD.</div><div id=\"graphicVersion\">Graphic 80776 Version 1.0</div></div></div>"},"80777":{"type":"graphic_table","displayName":"Fungal infx in transplantation","title":"Fungal infections in transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fungal infections in transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Organ transplanted </td> <td class=\"subtitle1\">Estimated incidence (percent) </td> <td class=\"subtitle1\">Mortality <em>Aspergillus</em> (percent) </td> <td class=\"subtitle1\">Mortality <em>Candida </em>(percent) </td> </tr> <tr> <td>Kidney</td> <td>0 to 20 </td> <td>20 to 100</td> <td>23 to 71</td> </tr> <tr> <td>Liver</td> <td>5 to 40 </td> <td>50 to 100</td> <td>6 to 77</td> </tr> <tr> <td>Heart</td> <td>5 to 20</td> <td>78 </td> <td>27</td> </tr> <tr> <td>Lung </td> <td>10 to 36</td> <td>21 to 100</td> <td>27</td> </tr> <tr> <td>Pancreas/pancreas-kidney</td> <td>6 to 38 </td> <td>100</td> <td>20 to 27</td> </tr> <tr> <td>Small bowel </td> <td>33 to 59</td> <td>0 to 100</td> <td>0 to 5</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80777 Version 3.0</div></div></div>"},"80779":{"type":"graphic_diagnosticimage","displayName":"MRI of idiopathic LRPN","title":"MRI of idiopathic lumbosacral radiculoplexus neuropathy","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">MRI of idiopathic lumbosacral radiculoplexus neuropathy</div><div class=\"cntnt\"><img style=\"width:497px; height:396px;\" src=\"images/NEURO/80779_Idiopathic_LS_plexopathy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Coronal view of fat suppressed, gadolinium-enhanced T1-weighted MRI image shows increased signal in the left lumbar plexus.<br />(B) Six months after treatment, the enhancement of the left lumbar plexus disappeared.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Ishii K, Tamaoka A, Shoji S. MRI of idiopathic lumbosacral plexopathy. Neurology 2004; 63:E6. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80779 Version 12.0</div></div></div>"},"80780":{"type":"graphic_algorithm","displayName":"Algorithm for the evaluation of pruritus","title":"Algorithm for the evaluation of pruritus","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Algorithm for the evaluation of pruritus</div><div class=\"cntnt\"><img style=\"width:513px; height:333px;\" src=\"images/DERM/80780_Algorit_evaluation_pruritus.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CBC: complete blood count; LSC: lichen simplex chronicus.</div><div class=\"graphic_reference\">Reproduced with permission from: Yosipovitch G, Dawn AG, Greaves MW. Pathophysiology and clinical aspects of pruritus. In: Fitzpatrick's dermatology in general medicine, 7th ed, Wolff K, Goldsmith LA, Katz SI, et al (Eds), McGraw-Hill Medical 2008. Copyright &copy; 2008 McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 80780 Version 14.0</div></div></div>"},"80781":{"type":"graphic_table","displayName":"Causes congenital NS","title":"Major causes of congenital nephrotic syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of congenital nephrotic syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Congenital nephrotic syndrome of Finnish type</td> </tr> <tr> <td>Diffuse mesangial sclerosis</td> </tr> <tr> <td>Diffuse mesangial sclerosis with Drash syndrome</td> </tr> <tr> <td>Idiopathic nephrotic syndrome</td> </tr> <tr> <td>Pierson syndrome</td> </tr> <tr> <td class=\"sublist1_start\">Other</td> </tr> <tr> <td class=\"sublist1\">Congenital syphilis</td> </tr> <tr> <td class=\"sublist1\">Congenital toxoplasmosis</td> </tr> <tr> <td class=\"sublist1\">Certain viral infections</td> </tr> <tr> <td class=\"sublist1\">Other genetic diseases (eg, Galloway-Mowat syndrome, mitochondrial disorders)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80781 Version 2.0</div></div></div>"},"80782":{"type":"graphic_picture","displayName":"Intragraft stenosis","title":"Intra-graft stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intra-graft stenosis</div><div class=\"cntnt\"><img style=\"width:432px; height:183px;\" src=\"images/NEPH/80782_Intra-graft_stenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intragraft stenosis is shown on the left within a loop graft. Several lesions are present. On the right is the post-therapy appearance after angioplasty.</div><div class=\"graphic_reference\">Courtesy of Gerald Beathard, MD.</div><div id=\"graphicVersion\">Graphic 80782 Version 3.0</div></div></div>"},"80783":{"type":"graphic_diagnosticimage","displayName":"CT Subacute subdural hematoma","title":"Non contrast head CT demonstrates a subacute subdural hematoma over the right cerebral hemisphere","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Non contrast head CT demonstrates a subacute subdural hematoma over the right cerebral hemisphere</div><div class=\"cntnt\"><img style=\"width:396px; height:396px;\" src=\"images/NEURO/80783_CT_right_SDH.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Neuroradiology Department, Thomas Jefferson University, Philadelphia, PA.</div><div id=\"graphicVersion\">Graphic 80783 Version 4.0</div></div></div>"},"80784":{"type":"graphic_figure","displayName":"Etiology renal agenesis","title":"Diagram of normal and abnormal kidney development","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagram of normal and abnormal kidney development</div><div class=\"cntnt\"><img style=\"width:404px; height:396px;\" src=\"images/OBGYN/80784_Etiology_renal_agenesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Uppermost are the precursor structures of a single renal tract, as would be present in a human fetus of 4-5 weeks' gestation; note the mesonephric duct, metanephric mesenchyme (which will form nephrons), and ureteric bud. Solid arrows indicate normal developmental pathways and dotted arrows indicate abnormal pathways. In normal development, the ureteric bud grows into the metanephric mesenchyme and is followed by bud branching and nephron induction and, finally, development of a fully functional, normal kidney containing multiple layers of nephrons. Hypoplastic kidneys contain fewer layers of nephrons than normal but retain a moderated degree of excretory function. Cystic dysplastic kidneys contain malformed tubules and some small cysts but generally retain some excretory function. A discrete renal pelvis (white) is present in normal, hypoplastic and cystic dysplastic kidneys; this feature would appear distended (hydronephrotic) if the kidney was attached to an obstructed lower tract (not shown). The multicystic dysplastic kidney has no useful excretory function and its pelvis is absent or severely disorganized. Aplastic kidneys undergo no primary growth or development; a similar phenotype is seen in the organ remnant left after the spontaneous involution of a multicystic dysplastic kidney. In the most profound type of malformation, agenesis, the first steps of kidney development do not occur and the kidney (and often the ureter) is absent.</div><div class=\"graphic_reference\">Reprinted by permission from MacMillan Publishers Ltd. Kerecuk, L, Schreuder, MF, Woolf, AS. Renal tract malformations: perspectives for nephrologists. Nat Clin Pract Nephrol 2008; 4:312. Copyright &#169;2008.</div><div id=\"graphicVersion\">Graphic 80784 Version 1.0</div></div></div>"},"80788":{"type":"graphic_picture","displayName":"Pediculosis capitis louse","title":"<EM>Pediculus humanus capitis</EM>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Pediculus humanus capitis</EM></div><div class=\"cntnt\"><img style=\"width:432px; height:273px;\" src=\"images/DERM/80788_Pediculosis_capitis_louse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These organisms were combed from the hair of&nbsp;a 10-year-old girl. Note the smallest first instar stage on the far left and the larger second and third stage instar organisms. A nit (top right) is beginning to hatch.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 80788 Version 9.0</div></div></div>"},"80789":{"type":"graphic_figure","displayName":"Insulin injection PI","title":"How to give an insulin shot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">How to give an insulin shot</div><div class=\"cntnt\"><img style=\"width:377px; height:354px;\" src=\"images/PI/80789_Insulin_injection_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><OL>&#xD;&#xA;<LI>Pinch up some skin and quickly insert the needle at a 90° angle (or whatever angle your doctor or nurse tells you). Keep the skin pinched to avoid having the insulin go into the muscle. </LI>&#xD;&#xA;<LI>Push the plunger down all the way. Hold the syringe and needle in place for&nbsp;5 seconds. </LI>&#xD;&#xA;<LI>Let go of the pinched skin and remove the needle from the skin. If blood or clear fluid (insulin) is seen where the shot was given, press on the area for&nbsp;5 to&nbsp;8 seconds, but do not rub. </LI></OL></div><div id=\"graphicVersion\">Graphic 80789 Version 9.0</div></div></div>"},"80791":{"type":"graphic_table","displayName":"Test results for bleeding disorders in children","title":"Expected results of tests for hemostatic function in representative hemorrhagic disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Expected results of tests for hemostatic function in representative hemorrhagic disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"4\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Platelet count</td> <td class=\"subtitle1\">PT</td> <td class=\"subtitle1\">aPTT</td> <td class=\"subtitle1\">Fibrinogen</td> </tr> <tr> <td>Vasculopathies, connective tissue diseases, or collagen disorders affecting skin</td> <td>normal</td> <td>normal</td> <td>normal</td> <td>normal or increased*</td> </tr> <tr> <td>Thrombocytopenia</td> <td>low</td> <td>normal</td> <td>normal</td> <td>normal</td> </tr> <tr> <td>Qualitative platelet abnormalities</td> <td>normal or low<sup>&#182;</sup></td> <td>normal</td> <td>normal</td> <td>normal</td> </tr> <tr> <td>Hemophilia A (factor VIII deficiency)</td> <td>normal</td> <td>normal</td> <td>long</td> <td>normal</td> </tr> <tr> <td>von Willebrand disease</td> <td>normal<sup>&#916;</sup></td> <td>normal</td> <td>normal or long<sup>&#9674;</sup></td> <td>normal</td> </tr> <tr> <td>Disseminated intravascular coagulation</td> <td>low</td> <td>long</td> <td>long</td> <td>low</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PT: prothrombin time; aPTT: activated partial thromboplastin time.<br />* Fibrinogen may be elevated as an acute phase reactant in disorders of inflammation.<br />¶ The platelet count in myeloproliferative disorders is usually high (eg, essential thrombocythemia) and platelets may also be qualitatively abnormal, predisposing to hemorrhagic and thrombotic diatheses.<br />Δ The platelet count may be low in some patients with type 2B von Willebrand disease.<br /><FONT class=lozenge>◊</FONT> The aPTT may be normal in those with Factor VIII activity &gt;40 percent.</div><div id=\"graphicVersion\">Graphic 80791 Version 5.0</div></div></div>"},"80792":{"type":"graphic_diagnosticimage","displayName":"Porcelain gallbladder","title":"Porcelain gallbladder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Porcelain gallbladder</div><div class=\"cntnt\"><img style=\"width:324px; height:312px;\" src=\"images/GAST/80792_Porcelain_gallbladder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain abdominal&nbsp;radiograph of a patient with a porcelain gallbladder revealing a calcified right upper quadrant lesion (arrow).</div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD.</div><div id=\"graphicVersion\">Graphic 80792 Version 3.0</div></div></div>"},"80795":{"type":"graphic_picture","displayName":"Kielland forceps","title":"Kielland forceps","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Kielland forceps</div><div class=\"cntnt\"><img style=\"width:468px; height:224px;\" src=\"images/OBGYN/80795_Kielland_forceps.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kielland forceps have a sliding lock to correct for asynclitism.</div><div class=\"graphic_reference\">Reproduced with permission from: Aron Schuftan, MD. Copyright &#169; Aron Schuftan, MD.</div><div id=\"graphicVersion\">Graphic 80795 Version 3.0</div></div></div>"},"80796":{"type":"graphic_figure","displayName":"Stereotactic headframe","title":"Stereotactic head frame","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Stereotactic head frame</div><div class=\"cntnt\"><img style=\"width:504px; height:454px;\" src=\"images/ONC/80796_Stereotactic_headframe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Model application of a stereotactic head frame. B) Actual application of a stereotactic head frame in preparation for LINAC radiosurgery. The stereotactic head frame is immobilized to the patient by four pins that penetrate the outer skull table (arrows). Typically, the head frame placement is done under local anesthesia. Thin slice CT or MR images are obtained after head frame placement. C) The four posts of the head frame are visualized on the images. Target coordinates are derived based on mathematic calculation of the lesion location relative to axes defined by the head frame posts. The numbers on the lower left panel indicate the dose of radiation delivered to the lesion in cGy.</div><div class=\"graphic_reference\">Courtesy of Massachusetts General Hospital.</div><div id=\"graphicVersion\">Graphic 80796 Version 2.0</div></div></div>"},"80797":{"type":"graphic_diagnosticimage","displayName":"HSV encephalitis MRI","title":"Herpes virus encephalitis magnetic resonance imaging","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Herpes virus encephalitis magnetic resonance imaging</div><div class=\"cntnt\"><img style=\"width:325px; height:396px;\" src=\"images/PEDS/80797_HSV_encephalitis_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2-weighted MR image shows the entire left temporal lobe to be swollen and to show abnormal hyperintensity of cortex and white matter from edema (open arrow). In addition, notice similar but less extensive changes on the right (small arrow).</div><div class=\"graphic_footnotes\">MR: magnetic resonance.</div><div class=\"graphic_reference\">Reproduced with permission from: Wolters Kluwer. Copyright &copy;2008.</div><div id=\"graphicVersion\">Graphic 80797 Version 3.0</div></div></div>"},"80798":{"type":"graphic_diagnosticimage","displayName":"CMC osteoarthritis xray","title":"Carpometacarpal (CMC) osteoarthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Carpometacarpal (CMC) osteoarthritis</div><div class=\"cntnt\"><img style=\"width:260px; height:391px;\" src=\"images/PC/80798_CMC_osteoarthritis_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal width of the articular cartilage should be 2 mm. In this case, the articular cartilage has worn away. The trapezium has also lost its normal saddle shape, and the metacarpal bone has subluxed 2 to 3 mm. These findings are consistent with advanced CMC osteoarthritis.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 80798 Version 2.0</div></div></div>"},"80801":{"type":"graphic_table","displayName":"Carbamazepine interactions with other antiseizure drugs","title":"Some interactions between carbamazepine and other antiseizure drugs*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some interactions between carbamazepine and other antiseizure drugs*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Interacting drugs</td> <td class=\"subtitle1\">Effects (probable mechanism)</td> <td class=\"subtitle1\">Management</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Carbamazepine, with:</td> </tr> <tr class=\"divider_top\"> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Brivaracetam</td> <td>Possible carbamazepine toxicity (decreased metabolism of active epoxide metabolite<sup>&#182;</sup>)</td> <td>Monitor clinical status; reduction of carbamazepine dose may be needed</td> </tr> <tr class=\"divider_bottom\"> <td>Decreased brivaracetam effect (increased metabolism by CYP2C19)</td> <td>Monitor clinical status; brivaracetam dose may need to be adjusted</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Clonazepam</td> <td>Decreased clonazepam effect (increased metabolism by CYP3A4)</td> <td>Monitor clinical status</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Felbamate</td> <td>Possible carbamazepine toxicity (increased concentration of active epoxide metabolite<sup>&#182;</sup>)</td> <td>Monitor clinical status; felbamate and carbamazepine dose may need to be adjusted</td> </tr> <tr class=\"divider_bottom\"> <td>Decreased felbamate effect (increased metabolism by CYP3A4)</td> <td>A reduction in carbamazepine dose is recommended when felbamate is added to carbamazepine therapy. Specific dose adjustment recommendations are provided in the Lexicomp monograph.</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Lamotrigine</td> <td>Carbamazepine toxicity (increased concentration of active epoxide metabolite<sup>&#182;</sup>)</td> <td>Monitor clinical status; serum carbamazepine measurements alone may not predict toxicity</td> </tr> <tr class=\"divider_bottom\"> <td>Decreased lamotrigine effect (increased metabolism; glucuronidation)</td> <td>Monitor clinical status and lamotrigine concentrations; lamotrigine dose may need to be increased. Specific lamotrigine dose adjustment recommendations and provided in the Lexicomp monograph.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" rowspan=\"2\">Levetiracetam</td> <td>Possible increased risk of carbamazepine toxicity (mechanism not established)</td> <td>Monitor for clinical evidence of carbamazepine toxicity</td> </tr> <tr class=\"divider_bottom\"> <td>Possible decreased levetiracetam concentrations&nbsp;(increased metabolism)</td> <td>Monitor clinical effect</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Perampanel</td> <td>Decreased perampanel effect (increased metabolism by CYP3A4)</td> <td>Monitor clinical status; perampanel dosage may need to be adjusted</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Phenytoin</td> <td>Decreased carbamazepine effect (increased metabolism)</td> <td class=\"divider_bottom\" rowspan=\"2\">Monitor clinical status and carbamazepine and phenytoin concentrations</td> </tr> <tr class=\"divider_bottom\"> <td>Altered phenytoin effect may include decreased or increased phenytoin levels (mechanism not established)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tiagabine</td> <td>Decreased tiagabine effect (increased metabolism by CYP3A4)</td> <td>Monitor clinical status</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Topiramate</td> <td>Possible decreased topiramate effect (increased metabolism); possible additive CNS side effects (mechanism not established)</td> <td>Monitor clinical status; may need higher doses of topiramate</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Valproate</td> <td>Decreased valproate effect and possible increased toxicity (increased metabolism by CYP 2C9, 2C19, glucuronidation, and formation of toxic metabolite)</td> <td>Monitor clinical status and valproate concentrations</td> </tr> <tr class=\"divider_bottom\"> <td>Carbamazepine toxicity (increased concentration of active epoxide metabolite<sup>&#182;</sup> and displacement from binding sites)</td> <td>Monitor clinical status, carbamazepine, and carbamazepine epoxide concentrations; carbamazepine dose may need to be adjusted</td> </tr> <tr> <td class=\"indent1\">Zonisamide</td> <td>Decreased zonisamide effect (increased metabolism by CYP3A4)</td> <td>Monitor zonisamide concentrations and clinical status; zonisamide dosage may need to be adjusted</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Carbamazepine is a strong inducer of multiple hepatic enzymes; it can reduce serum concentrations of other drugs, including antiseizure drugs. Carbamazepine is metabolized by CYP3A4 and induces its own metabolism; serum concentrations of carbamazepine fall after first few weeks of initial therapy. Other drugs that are inducers or inhibitors of CYP3A4 can alter serum concentrations of carbamazepine and epoxide active metabolite. A list of CYP3A4 inhibitors and inducers is available in a separate table in UpToDate.</div><div class=\"graphic_footnotes\">CYP: cytochrome P450.<br />* <STRONG>Not all potential interactions are listed.</STRONG> Additional interactions of antiepileptic drugs and management suggestions may be determined by using the drug interactions program included within UpToDate.<br />¶ Routine carbamazepine serum measurements do not assess for accumulation of the active carbamazepine-epoxide metabolite, but this metabolite can be measured as a separate test; refer to accompanying text.</div><div class=\"graphic_reference\">Data from: Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 80801 Version 12.0</div></div></div>"},"80803":{"type":"graphic_table","displayName":"Prog brain mets HER2-pos BC","title":"Prognosis of patients with brain metastases from HER2-positive breast cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prognosis of patients with brain metastases from HER2-positive breast cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">Time period</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Median survival after CNS recurrence</td> </tr> <tr> <td>Tham, et al<sup>[1]</sup></td> <td>1970-1999</td> <td>21</td> <td>~3 months</td> </tr> <tr> <td>Bendell, et al<sup>[2]</sup></td> <td>1998-2000</td> <td>42</td> <td>13 months</td> </tr> <tr> <td>Gori, et al<sup>[3]</sup></td> <td>1999-2005</td> <td>43</td> <td>23 months</td> </tr> <tr> <td>Stemmler, et al<sup>[4]</sup></td> <td>2000-2004</td> <td>42</td> <td>13 months</td> </tr> <tr> <td>Eichler, et al<sup>[5]</sup></td> <td>2001-2005</td> <td>30</td> <td>17 months</td> </tr> <tr> <td>Melisko, et al<sup>[6]</sup></td> <td>1997-2007</td> <td>35</td> <td>23 months</td> </tr> <tr> <td>Brufsky, et al <sup>[7]</sup></td> <td>2003-2009</td> <td>377</td> <td>20.3 months</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Trastuzumab approved by the United States Food and Drug Administration (FDA) for treatment of HER2-positive, metastatic breast cancer in 1998.</div><div class=\"graphic_footnotes\">CNS: central nervous system; HER2: human epidermal growth factor receptor 2.</div><div class=\"graphic_reference\">References:<br> <ol> <li>Tham YL, Sexton K, Kramer R, et al. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006; 107:696. </li> <li>Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97:2972. </li> <li>Gori S, Rimondini S, De Angelis V, et al. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 2007; 12:766. </li> <li>Stemmler HJ, Kahlert S, Siekiera W, et al. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2006; 15:219. </li> <li>Eichler AF, Kuter I, Ryan P, et al. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 2008; 112:2359. </li> <li>Melisko ME, Moore DH, Sneed PK, et al. Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J Neurooncol 2008; 88:359. </li> <li>Brufsky AM, Mayer M, Rugo HS, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 2011; 17:4834. </li> </ol></div><div id=\"graphicVersion\">Graphic 80803 Version 3.0</div></div></div>"},"80805":{"type":"graphic_table","displayName":"Fluid requirements newborns","title":"Fluid requirements (mL/kg per day) in newborns","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fluid requirements (mL/kg per day) in newborns</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Birth weight (g)</td> <td class=\"subtitle1\">Days 1 to 2</td> <td class=\"subtitle1\">Day 3</td> <td class=\"subtitle1\">&#62; Day 3</td> </tr> <tr> <td>&#60;1000</td> <td>90 to 120</td> <td>140</td> <td>150</td> </tr> <tr> <td>1001 to 1250</td> <td>80 to 100</td> <td>120</td> <td>150</td> </tr> <tr> <td>1251 to 1500</td> <td>80</td> <td>100</td> <td>150</td> </tr> <tr> <td>1501 to 2000</td> <td>60 to 80</td> <td>100</td> <td>140 to 160</td> </tr> <tr> <td>&#62;2000</td> <td>60 to 80</td> <td>100</td> <td>140 to 160</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These&nbsp;values are&nbsp;intended as guidelines and should be adjusted according to the infant's clinical status. Adjustments should be made based on monitoring the infant's hydration status, including&nbsp;serial measurements of the&nbsp;infant's weight and serum or plasma sodium levels. <br /><br />Other adjustments include the following:<br /><br /><UL>&#xD;&#xA;<LI>​For very low birth weight (VLBW)&nbsp;infants (BW &lt;1500 g), the above&nbsp;values assume that the infant is being cared for in a humidified incubator with appropriate thermal control, and if respiratory support is provided, humidified gas is used. </LI>&#xD;&#xA;<LI>For&nbsp;VLBW infants&nbsp;cared&nbsp;for&nbsp;in an&nbsp;open warmer or receiving respiratory support with non-humidified gases, the required amount of daily fluid&nbsp;is higher. In this clinical setting, <SPAN style=\"COLOR: black\">fluid administration is started </SPAN><SPAN style=\"COLOR: black\">at the upper end of the normal&nbsp;range and increased in increments of 20 mL/kg per day based on frequent&nbsp;monitoring of hydration status performed at least every eight hours&nbsp;until a&nbsp;stable regimen is established. </SPAN></LI>&#xD;&#xA;<LI>For term infants, fluid adjustments are not needed for those cared for in an open warmer or bassinette if they are adequately wrapped, as they have less fluid skin loss <SPAN style=\"COLOR: black\">than preterm infants&nbsp;due to more mature, thicker skin. </SPAN></LI>&#xD;&#xA;<LI><SPAN style=\"COLOR: black\">For term infants&nbsp;receiving therapeutic hypothermia, many practitioners will restrict fluids to 40 to 60 mL/kg/d if there is evidence of acute kidney injury.</SPAN> </LI>&#xD;&#xA;<LI>For infants receiving conventional phototherapy using fluorescent blue lights, requirements are approximately 10 percent higher (10 to&nbsp;15 mL/kg per day).</LI>&#xD;&#xA;<LI>For&nbsp;infants that receive therapy using LED lights that use high-intensity blue gallium nitride, there is no need for additional adjustment because there is no increased insensible skin losses. </LI></UL></div><div id=\"graphicVersion\">Graphic 80805 Version 4.0</div></div></div>"},"80807":{"type":"graphic_figure","displayName":"Fertility rate and age","title":"Fertility rate in women declines with age","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">Fertility rate in women declines with age</div><div class=\"cntnt\"><img style=\"width:575px; height:302px;\" src=\"images/ENDO/80807_Fertility_rate_and_age.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fertility rates in different groups of women from the 16th to the 20th centuries. The fertility rate declined with age in all the groups.</div><div class=\"graphic_reference\">Data from: Maroulis GB. Seminars Reprod Endocrinol 1991; 9:165.</div><div id=\"graphicVersion\">Graphic 80807 Version 2.0</div></div></div>"},"80808":{"type":"graphic_diagnosticimage","displayName":"CT of mild diverticulitis of the colon ","title":"Mild diverticulitis of the sigmoid colon on CT ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mild diverticulitis of the sigmoid colon on CT </div><div class=\"cntnt\"><img style=\"width:439px; height:357px;\" src=\"images/RADIOL/80808_Mild_diverticulitis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan of the pelvis in a patient with mild acute diverticulitis. There is mild induration of the perisigmoid fat (arrow) and thickening of the sigmoid mesocolon (dashed arrow). Multiple diverticula are noted (arrowheads).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 80808 Version 11.0</div></div></div>"},"80809":{"type":"graphic_figure","displayName":"Parainfluenza gene maps","title":"Parainfluenza gene maps","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Parainfluenza gene maps</div><div class=\"cntnt\"><img style=\"width:530px; height:279px;\" src=\"images/ID/80809_Parainfluenzagenemaps.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gene maps of parainfluenza viruses (PIV), not to exact scale. Each negative-sense genome is drawn 3' to 5', which is the direction of gene transcription. Each encoded messenger RNA (mRNA) is shown as a rectangle; those encoding the envelope-associated proteins are shaded gray. The letter(s) within each rectangle identify the encoded protein(s); for the P gene, the protein encoded by the unedited mRNA is listed first. Nucleotide lengths are under each diagram; those representing extragenic leader (le), trailer (tr), and intergenic regions are underlined. Amino acid lengths are shown above the line.</div><div class=\"graphic_footnotes\">N: nucleocapsid protein; P: phosphoprotein; C: C protein; D: D protein; M: matrix protein; F: fusion glycoprotein; HN: hemagglutinin-neuraminidase glycoprotein; L: polymerase protein.<br> * PIV-3 also encodes a V protein, possibly using ribosome frameshifting.</div><div class=\"graphic_reference\">Modified with permission from: Karron RA, Collins PL. Parainfluenza Viruses. In: Fields Virology, 5th Edition, Knipe D, Howley P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 80809 Version 11.0</div></div></div>"},"80811":{"type":"graphic_table","displayName":"Causes of hemarthrosis","title":"Causes of hemarthrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hemarthrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">1. Trauma</td> </tr> <tr> <td>a. Iatrogenic (traumatic arthrocentesis)</td> </tr> <tr> <td>b. Without bone fracture</td> </tr> <tr> <td>c. With bone fracture (lipohemarthrosis)</td> </tr> <tr> <td>d. Postoperative</td> </tr> <tr> <td class=\"subtitle1_single\">2. Hematological</td> </tr> <tr> <td>a. Drug-induced</td> </tr> <tr> <td>b. Inherited hematologic disorders, ie, coagulation disorders, sickle cell disease</td> </tr> <tr> <td>c. Acquired hematological disorders, ie, myeloproliferative diseases, essential thrombocytosis, and thrombocytopenia</td> </tr> <tr> <td class=\"subtitle1_single\">3. Neurological</td> </tr> <tr> <td>a. Charcot's joint</td> </tr> <tr> <td class=\"subtitle1_single\">4. Tumors</td> </tr> <tr> <td>a. Tenosynovial giant cell tumor (pigmented villonodular synovitis)</td> </tr> <tr> <td class=\"subtitle1_single\">5. Vascular</td> </tr> <tr> <td>a. Hemangioma</td> </tr> <tr> <td>b. Arteriovenous malformation</td> </tr> <tr> <td>c. Aneurysm</td> </tr> <tr> <td>d. Synovial vascular structural abnormalities</td> </tr> <tr> <td class=\"subtitle1_single\">6. Osteoarthritis</td> </tr> <tr> <td>a. Degenerative tear of the meniscus</td> </tr> <tr> <td>b. Osteoarthritis (other)</td> </tr> <tr> <td class=\"subtitle1_single\">7. Crystalline diseases</td> </tr> <tr> <td>a. Gout</td> </tr> <tr> <td>b. Pseudogout</td> </tr> <tr> <td>c. Milwaukee shoulder</td> </tr> <tr> <td class=\"subtitle1_single\">8. Nutritional</td> </tr> <tr> <td>a. Scurvy</td> </tr> <tr> <td class=\"subtitle1_single\">9. Septic arthritis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from Dougados, M. Synovial fluid cell analysis. Bailliere's Clinical Rheumatology 1996; 10:519. and Baker, C. J Med Assoc Georgia 1992; 81:301.</div><div id=\"graphicVersion\">Graphic 80811 Version 3.0</div></div></div>"},"80812":{"type":"graphic_table","displayName":"Evaluation and management of congenital syphilis in neonates","title":"Evaluation and management of neonates (<1 month) born to women with syphilis or history of syphilis*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation and management of neonates (&lt;1 month) born to women with syphilis or history of syphilis*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Initial neonatal evaluation</td> <td class=\"subtitle1\" colspan=\"2\">Maternal treatment</td> <td class=\"subtitle1\" rowspan=\"2\">Subsequent neonatal evaluation</td> <td class=\"subtitle1\" rowspan=\"2\">Treatment of neonate</td> </tr> <tr> <td class=\"subtitle2\">Neonate VDRL/RPR</td> <td class=\"subtitle2\">Neonate evaluation</td> <td class=\"subtitle2\">Timing</td> <td class=\"subtitle2\">Type</td> </tr> <tr class=\"divider_bottom\"> <td>Any result</td> <td><strong>Examination compatible with congenital syphilis or visualization of spirochete in clinical specimen</strong><sup>&#182;</sup></td> <td>Any</td> <td>Any or none</td> <td> <ul> <li>CSF VDRL, cell count, protein </li> <li>CBC with differential and platelet count </li> <li>Additional tests as clinically indicated<sup>&#916;</sup> </li> </ul> </td> <td>10 days of parenteral penicillin<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td><strong>&#8805; Fourfold maternal titer</strong></td> <td>Any</td> <td>Any</td> <td>Any</td> <td> <ul> <li>CSF VDRL, cell count, protein </li> <li>CBC with differential and platelet count </li> <li>Additional tests as clinically indicated<sup>&#916;</sup> </li> </ul> </td> <td>10 days of parenteral penicillin<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>&#60; Fourfold maternal titer</td> <td>Normal physical examination</td> <td>During pregnancy</td> <td>None, inadequate, suboptimal<sup><span style=\"font-size: 13px;\">&#135;</span></sup></td> <td> <ul> <li>CSF VDRL, cell count, protein </li> <li>CBC with differential and platelet count </li> <li>Additional tests as clinically indicated<sup><span style=\"font-size: 13px;\">&#916;</span></sup> </li> </ul> </td> <td> <p>If the entire evaluation is performed and normal<sup><span style=\"font-size: 13px;\">&#134;</span></sup>: Single dose IM benzathine penicillin<sup><span style=\"font-size: 13px;\">&#165;</span></sup>; some experts would treat with 10 days of parenteral penicillin<sup><span style=\"font-size: 13px;\">&#9674;</span></sup></p> If any portion of the evaluation is abnormal, not performed, or not interpretable: 10 days of parenteral penicillin<sup><span style=\"font-size: 13px;\">&#9674;</span></sup></td> </tr> <tr class=\"divider_bottom\"> <td>&#60; Fourfold maternal titer</td> <td>Normal physical examination</td> <td>Before pregnancy</td> <td>Evidence of reinfection or relapse (&#8805; fourfold increase in post-treatment titer)</td> <td> <ul> <li>CSF VDRL, cell count, protein </li> <li>CBC with differential and platelet count </li> <li>Additional tests as clinically indicated<sup><span style=\"font-size: 13px;\">&#916;</span></sup> </li> </ul> </td> <td> <p>If the entire evaluation is performed and normal: Single dose IM benzathine penicillin<sup><span style=\"font-size: 13px;\">&#165;</span></sup></p> If any portion of the evaluation is abnormal, not performed, or not interpretable: 10 days of parenteral penicillin<sup><span style=\"font-size: 13px;\">&#9674;</span></sup></td> </tr> <tr class=\"divider_bottom\"> <td>&#60; Fourfold maternal titer</td> <td>Normal physical examination</td> <td>During pregnancy</td> <td>Adequate<sup><span style=\"font-size: 13px;\">&#167;</span></sup></td> <td>None</td> <td>Single dose IM benzathine penicillin<sup><span style=\"font-size: 13px;\">&#165;</span></sup>; some experts would not treat but provide close serologic follow-up</td> </tr> <tr class=\"divider_bottom\"> <td>&#60; Fourfold maternal titer</td> <td>Normal physical examination</td> <td>Before pregnancy</td> <td>Adequate<sup><span style=\"font-size: 13px;\">&#167;</span></sup></td> <td>None</td> <td>None; some experts would treat with a single dose of IM benzathine penicillin<sup><span style=\"font-size: 13px;\">&#165;</span></sup></td> </tr> <tr class=\"divider_bottom\"> <td>Nonreactive</td> <td>Normal physical examination</td> <td>During pregnancy</td> <td>None, inadequate, suboptimal<sup>&#135;</sup></td> <td>None</td> <td>Single dose IM benzathine penicillin<sup>&#165;</sup></td> </tr> <tr> <td>Nonreactive</td> <td>Normal physical examination</td> <td>During pregnancy</td> <td>Adequate<sup><span style=\"font-size: 13px;\">&#167;</span></sup></td> <td>None</td> <td>None; some experts would treat with a single dose of IM benzathine penicillin<sup><span style=\"font-size: 13px;\">&#165;</span></sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Neonate characteristics in <strong>bold text</strong> indicate proven or highly probable congenital syphilis disease in the infant.</div><div class=\"graphic_footnotes\">VDRL: Venereal Disease Research Laboratory serologic test for syphilis; RPR: rapid plasma reagin serologic test for syphilis; CSF: cerebrospinal fluid; CBC: complete blood count; IM: intramuscular; IV: intravenous.<br />* Mother with reactive nontreponemal (VDRL or RPR) and treponemal (microhemagglutination test for <em>T. pallidum</em> [MHA-TP] or fluorescent treponemal antibody absorption [FTA-ABS]) serologic tests for syphilis. All such infants require clinical and serologic follow-up (see text for details).<br />&#182; Examination findings compatible with early congenital syphilis may include (but are not limited to) hepatomegaly/hepatosplenomegaly; rash; condyloma lata; snuffles; jaundice; pseudoparalysis; anemia; and edema.<br />&Delta; Additional tests may include: Long-bone radiographs, chest radiograph, liver function tests, cranial ultrasonography, ophthalmologic examination, and auditory brainstem response.<br /><span class=\"lozenge\">&loz;</span> There are two alternate regimens: Aqueous penicillin G (50,000 units/kg IV every 12 hours [for infants &le;7 days of age] and every 8 hours [&gt;7 days of age] for a total of 10 days); or procaine penicillin G 50,000 units/kg IM as a single daily dose for 10 days.<br />&sect; Adequate therapy encompasses treatment with penicillin more than four weeks before delivery; appropriate dose for the stage of disease; documentation of treatment response (fourfold decline in titer for early syphilis and titer remained stable or low [VDRL &le;1:2; RPR &le;1:4] for late syphilis); no evidence of reinfection or relapse (fourfold increase in titer after treatment).<br />&yen; Benzathine penicillin G (50,000 units/kg intramuscularly as a single dose).<br />&Dagger; Inadequate or suboptimal maternal therapy encompasses: Treatment with a nonpenicillin antibiotic; treatment less than four weeks before delivery; inappropriate dose for the stage of disease; no documentation of maternal therapy; maternal titers did not decline at least fourfold after treatment for early syphilis or did not remain stable and low [VDRL &le;1:2; RPR &le;1:4] for late syphilis; or maternal titers increased by fourfold after treatment (suggesting reinfection or relapse).<br />&dagger; Normal CSF is generally defined by nonreactive VDRL, CSF WBC &lt;25 cells/microL, and CSF protein &lt;150 mg/dL for term infants and &lt;170 mg/dL for preterm infants; however, some experts define normal CSF WBC as &lt;5 cells/microL and normal CSF protein as &lt;40 mg/dL.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Workowski KA, Bolan GA. Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR Recomm Rep 2015; 64:1.</LI>&#xD;&#xA;<LI>American Academy of Pediatrics. Syphilis. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th, Kimberlin DW.&nbsp; (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.755.</LI>&#xD;&#xA;<LI>Dobson SR, Sanchez PJ. Syphilis. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 7th, Cherry JD, Harrison GJ, Kaplan SL, et al (Eds), Elsevier Saunders, Philadelphia 2014. p.1761.</LI>&#xD;&#xA;<LI>Kollmann TR, Dobson SD. Syphilis. In: Infectious Diseases of the Fetus and Newborn infant, 7th edition, Remington JS, Klein JO, Wilson CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.524.</LI></OL></div><div id=\"graphicVersion\">Graphic 80812 Version 13.0</div></div></div>"},"80813":{"type":"graphic_diagnosticimage","displayName":"Sesamoids of first metatarsal","title":"First metatarsal joint sesamoids (arrows)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">First metatarsal joint sesamoids (arrows)</div><div class=\"cntnt\"><img style=\"width:360px; height:405px;\" src=\"images/SM/80813_1stmcpsesamoidsedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This oblique view shows the two most common foot sesamoids: medial (ie, tibial) and lateral (ie, fibular) sesamoids below the metatarsophalangeal joint of the great toe. A nondisplaced, transverse fracture of the proximal phalanx of the little toe (arrowhead) can also be seen.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 80813 Version 7.0</div></div></div>"},"80814":{"type":"graphic_table","displayName":"MEN1 vs RET tests","title":"Features of MEN1 versus RET germline mutation tests","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features of MEN1 versus RET germline mutation tests</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Test feature</td> <td class=\"subtitle1\">MEN1 gene</td> <td class=\"subtitle1\">RET gene</td> </tr> <tr> <td>Information to patient and clinician</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>Guides intervention to prevent cancer</td> <td>No</td> <td>Yes</td> </tr> <tr> <td>Guides intervention to cure cancer</td> <td>No</td> <td>Yes</td> </tr> <tr> <td>Recommended for child</td> <td>Maybe*</td> <td>Yes</td> </tr> <tr> <td>Chromosomal locus of gene</td> <td>11q13</td> <td>10cen<sup>&#182;</sup></td> </tr> <tr> <td>Mutation type to cause tumor</td> <td>Inactivate</td> <td>Activate</td> </tr> <tr> <td>Genotype/phenotype correlation</td> <td>No</td> <td>Yes</td> </tr> <tr> <td>Mutation test shortcuts</td> <td>No</td> <td>Yes</td> </tr> <tr> <td>False-negative rate</td> <td>10 to 20%</td> <td>2 to 5%</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MEN1: multiple endocrine neoplasia type 1.<br />* Use in child depends partly on philosophy about using a nonessential genetic test in a subject that is not old enough to make an important long-term decision.<br />¶ 10 cen, chromosome 10, centromeric region.</div><div class=\"graphic_reference\">Reproduced with permission from: Brandi, ML, Gagel, RF, Angeli, A, et al. Consensus: Guidelines for diagnosis and therapy of MEN type 2. J Clin Endocrinol Metab 2001; 86:5668. Copyright &copy; 2001 the Endocrine Society.</div><div id=\"graphicVersion\">Graphic 80814 Version 3.0</div></div></div>"},"80815":{"type":"graphic_picture","displayName":"Peutz-Jeghers oral lesions","title":"Oral lesions in Peutz-Jeghers syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oral lesions in Peutz-Jeghers syndrome</div><div class=\"cntnt\"><img style=\"width:279px; height:221px;\" src=\"images/GAST/80815_Peutz_Jeghers_oral_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph shows the characteristic circumoral pigmentation in a patient with the Peutz-Jeghers syndrome. The pigmentation may not be obvious as in this patient, and it should always be sought carefully in young patients presenting with unexplained gastrointestinal bleeding, particularly if there is a family history of such bleeding.</div><div class=\"graphic_reference\">Reprinted with permission from Pounder RE, Allison MC, Dhillon AP. A Colour Atlas of the Digestive System, Wolfe, London 1989&nbsp;p. 118.</div><div id=\"graphicVersion\">Graphic 80815 Version 4.0</div></div></div>"},"80816":{"type":"graphic_diagnosticimage","displayName":"HSG showing submucous fibroids","title":"Hysterosalpingogram showing multiple filling defects due to submucous myomas","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram showing multiple filling defects due to submucous myomas</div><div class=\"cntnt\"><img style=\"width:468px; height:375px;\" src=\"images/OBGYN/80816_HSG_showing_submucous_fibro.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Baramki TA. Hysterosalpingography. Fertil Steril 2005; 83:1595. Copyright © 2005 Elsevier Science, Inc.</div><div id=\"graphicVersion\">Graphic 80816 Version 4.0</div></div></div>"},"80818":{"type":"graphic_table","displayName":"Inherited uncong hyperbili","title":"Principal differential characteristics of inherited unconjugated hyperbilirubinemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Principal differential characteristics of inherited unconjugated hyperbilirubinemia</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">&nbsp;</td>\n<td class=\"subtitle1\">Crigler-Najjar syndrome type I</td>\n<td class=\"subtitle1\">Crigler-Najjar syndrome type II</td>\n<td class=\"subtitle1\">Gilbert's syndrome</td>\n</tr>\n<tr>\n<td>Liver histology</td>\n<td>Normal</td>\n<td>Normal</td>\n<td>Normal</td>\n</tr>\n<tr>\n<td>Serum bilirubin concentration</td>\n<td>20-50 mg/dL</td>\n<td>&#60;20 mg/dL</td>\n<td>Usually &#60;3 mg/dL</td>\n</tr>\n<tr>\n<td>Routine liver function tests</td>\n<td>Normal</td>\n<td>Normal</td>\n<td>Normal</td>\n</tr>\n<tr>\n<td>45-min plasma BSP retention</td>\n<td>Normal</td>\n<td>Normal</td>\n<td>Usually normal; may be elevated</td>\n</tr>\n<tr>\n<td>Bile</td>\n<td>Usually pale; contains small amounts of unconjugated bilirubin </td>\n<td>Increased proportion of bilirubin monoglucuronide </td>\n<td>Increased proportion of bilirubin monoglucuronide</td>\n</tr>\n<tr>\n<td>Hepatic bilirubin UDP- glucuronosyltransferase activity</td>\n<td>Absent</td>\n<td>Markedly reduced</td>\n<td>Reduced</td>\n</tr>\n<tr>\n<td>Effect of phenobarbital on serum bilirubin</td>\n<td>None</td>\n<td>Reduction</td>\n<td>Reduction</td>\n</tr>\n<tr>\n<td>Mode of inheritance</td>\n<td>Autosomal recessive</td>\n<td>Autosomal recessive</td>\n<td>Autosomal recessive</td>\n</tr>\n<tr>\n<td>Prevalence</td>\n<td>Rare</td>\n<td>Rare</td>\n<td>Common (approximately 9 percent of Caucasians are homozygous for a variant TATAA box; 4 to 5 percent have hyperbilirubinemia</td>\n</tr>\n<tr>\n<td>Prognosis</td>\n<td>Kernicterus , unless vigorously treated </td>\n<td>Usually benign, kernicterus occurs rarely</td>\n<td>Benign</td>\n</tr>\n<tr>\n<td>Animal model</td>\n<td>Homozygous Gunn rat </td>\n<td>None</td>\n<td>Bolivian squirrel monkey</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 80818 Version 1.0</div></div></div>"},"80821":{"type":"graphic_diagnosticimage","displayName":"Aging pleural hematoma CT","title":"Loculated pleural hematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Loculated pleural hematoma</div><div class=\"cntnt\"><img style=\"width:360px; height:307px;\" src=\"images/PULM/80821_Aging_pleural_hematoma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Loculated hematoma in left paraspinal location after cardiac transplantation. Low attenuation with several specks of slightly higher attentuation material indicate an aging hematoma.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 80821 Version 2.0</div></div></div>"},"80824":{"type":"graphic_table","displayName":"Modes transmission hepatitis A","title":"Modes of hepatitis A virus transmission*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modes of hepatitis A virus transmission*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Person-to-person contact</td> </tr> <tr> <td class=\"sublist1\">Transmission within households&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Sexual transmission</td> </tr> <tr> <td class=\"sublist1\">Residential institution transmission&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Daycare center transmission</td> </tr> <tr> <td class=\"sublist1\">Transmission among military personnel</td> </tr> <tr> <td>Contact with contaminated food or water</td> </tr> <tr> <td class=\"sublist1\">Consumption of raw or undercooked shellfish, vegetables, or other foods</td> </tr> <tr> <td class=\"sublist1\">Consumption of foods contaminated by infected food handlers</td> </tr> <tr> <td>Blood transfusion</td> </tr> <tr> <td>Illicit drug use</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Hepatitis A virus is usually transmitted via the fecal-oral route, either via person-to-person contact or consumption of contaminated food or water.</div><div id=\"graphicVersion\">Graphic 80824 Version 2.0</div></div></div>"},"80826":{"type":"graphic_table","displayName":"Signs symptoms breast CA recur","title":"Signs and symptoms consistent with breast cancer relapse","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs and symptoms consistent with breast cancer relapse</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Locoregional recurrence</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mass in the ipsilateral breast following breast conserving therapy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mass in the chest wall after mastectomy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Nipple discharge in the treated breast following breast conserving therapy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Rash localized to the treated breast or chest wall</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Axillary, supraclavicular, infraclavicular, or cervical lymph node enlargement</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Systemic recurrence</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Skeletal relapse: localized, progressive bone pain or tenderness</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pulmonary metastasis: pleuritic chest pain, cough, dyspnea</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Liver relapse: right upper quadrant discomfort, fullness, or pain; weight loss; anorexia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>CNS metastasis: persistent headache, mental status changes, new onset seizure, focal motor or sensory loss, bladder or bowel dysfunction</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">CNS: central nervous system.</div><div class=\"graphic_reference\">Reproduced with permission from: Emens LA, Davidson NE. The follow-up of breast cancer. Semin Oncol 2003; 30:338. Copyright &#169; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 80826 Version 2.0</div></div></div>"},"80827":{"type":"graphic_table","displayName":"Changes venous hypertension","title":"Anatomical, histological, and physiological changes associated with venous hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anatomical, histological, and physiological changes associated with venous hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Category</td>\n<td class=\"subtitle1\">Primary abnormality</td>\n<td class=\"subtitle1\">Consequences</td>\n</tr>\n<tr>\n<td>Anatomical</td>\n<td>Valvular incompetence</td>\n<td>Retrograde transmission of pressure and volume into the superficial venous system, increased venous hypertension producing further valvular incompetence</td>\n</tr>\n<tr>\n<td>Histological</td>\n<td>Elongation and dilation of capillary beds, increased capillary surface area, increased basement membrane type IV collagen, formation of pericapillary fibrin cuff, fragmentation and obliteration of cutaneous microlymphatics</td>\n<td>Increased interstitial accumulation of vascular water, red blood cells, fibrin, tissue hypoxia, and formation of a subcutaneous panniculitis (lipodermatosclerosis)</td>\n</tr>\n<tr>\n<td>Physiological</td>\n<td>Loss of reflexive constriction of precapillary arterioles, erythrocyte and leukocyte aggregation</td>\n<td>Increased capillary hydrostatic pressure, reduced oxygen transport, slowed arteriolar circulation, enlarged capillary spaces, leukocyte aggregation and activation, and formation of a subcutaneous panniculitis (lipodermatosclerosis)</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 80827 Version 1.0</div></div></div>"},"80828":{"type":"graphic_diagnosticimage","displayName":"Postpneumonectomy empyema PA","title":"Late postpneumonectomy empyema and bronchopleural fistula","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Late postpneumonectomy empyema and bronchopleural fistula</div><div class=\"cntnt\"><img style=\"width:604px; height:319px;\" src=\"images/PULM/80828_Postpneumonectomy_empyema_P.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph of a patient three months (left) and 12 months (right) after surgery shows a new air-fluid level (arrow) consistent with an empyema and bronchopleural fistula.</div><div class=\"graphic_reference\">Courtesy of Richard Irwin, MD.</div><div id=\"graphicVersion\">Graphic 80828 Version 2.0</div></div></div>"},"80829":{"type":"graphic_waveform","displayName":"ECG Polymorphic VT tutorial","title":"Single lead electrocardiogram (ECG) showing polymorphic ventricular tachycardia (VT)","html":"<div class=\"graphic normal\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Single lead electrocardiogram (ECG) showing polymorphic ventricular tachycardia (VT)</div><div class=\"cntnt\"><img style=\"width:453px; height:150px;\" src=\"images/CARD/80829_Polymorphic_VT_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The QRS complexes in polymorphic VT&nbsp;have markedly differing morphologies due to changes in the direction (vector) of myocardial activation.</div><div id=\"graphicVersion\">Graphic 80829 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"80830":{"type":"graphic_diagnosticimage","displayName":"CMR of eosinophilic endomyocardial fibrosis","title":"Cardiovascular magnetic resonance imaging of eosinophilic endomyocardial fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cardiovascular magnetic resonance imaging of eosinophilic endomyocardial fibrosis</div><div class=\"cntnt\"><img style=\"width:299px; height:442px;\" src=\"images/CARD/80830_CMR_eosino_endo_fibrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Steady state free precession MRI transverse view through both ventricles two minutes after 0.2-mmol/kg Gd-DTPA infusion. Note the apical filling of the left ventricle by thrombus (*) exhibiting lower signal than adjacent myocardium.<br> (B) Delayed enhanced sequence in the same axis 10 minutes after Gd-DTPA infusion. Subendocardium exhibited high signal (arrows) close to the ventricular thrombus (*).</div><div class=\"graphic_reference\">Reproduced with permission from: Genee O, Fichet J, Alison D. Cardiac Magnetic Resonance Imaging and Eosinophilic Endomyocardial Fibrosis. Circulation 2008; 118:e710. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80830 Version 12.0</div></div></div>"},"80832":{"type":"graphic_diagnosticimage","displayName":"Crohn string sign SBFT","title":"String sign in Crohn disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">String sign in Crohn disease</div><div class=\"cntnt\"><img style=\"width:198px; height:360px;\" src=\"images/GAST/80832_Crohns_string_sign_SBFT_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small bowel follow through study shows marked narrowing, irregularity and ulceration in the distal ileum (arrows) in a patient with Crohn disease.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 80832 Version 4.0</div></div></div>"},"80833":{"type":"graphic_figure","displayName":"Crowing rooster maneuver","title":"Crowing rooster maneuver","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Crowing rooster maneuver</div><div class=\"cntnt\"><img style=\"width:320px; height:336px;\" src=\"images/RHEUM/80833_Crowing_rooster_maneuver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The crowing rooster maneuver is performed with the physician standing behind the patient and exerting traction on the upper arms by pulling them backward and slightly superiorly. Both of these maneuvers may be done at the same time as neck extension or rotation.</div><div id=\"graphicVersion\">Graphic 80833 Version 3.0</div></div></div>"},"80834":{"type":"graphic_picture","displayName":"Scaphoid shift test 2","title":"Scaphoid shift test: Step 2","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Scaphoid shift test: Step 2</div><div class=\"cntnt\"><img style=\"width:480px; height:445px;\" src=\"images/EM/80834_Scaphoid_shift_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Next, place your other thumb on the volar side of the scaphoid tubercle. The tubercle is located proximal to the thenar eminence near the wrist crease. Use the hand grasping the metacarpals to repeatedly move the wrist, alternating between ulnar and radial deviation, while lightly palpating with the opposite thumb for the tubercle of the scaphoid. Try to feel if the tubercle protrudes volarly during radial deviation and recedes with ulnar deviation. This preliminary movement helps position you to perform the actual test.</div><div class=\"graphic_reference\">Courtesy of Kevin deWeber, MD, FAAFP, FACSM.</div><div id=\"graphicVersion\">Graphic 80834 Version 2.0</div></div></div>"},"80835":{"type":"graphic_diagnosticimage","displayName":"Porcelain gallbladder US","title":"Porcelain gallbladder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Porcelain gallbladder</div><div class=\"cntnt\"><img style=\"width:288px; height:332px;\" src=\"images/GAST/80835_Porcelain_gallbladder_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound of the abdomen reveals a thickened gallbladder wall with dense calcification and a marked acoustic shadow that could be confused with a large gallstone.</div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD.</div><div id=\"graphicVersion\">Graphic 80835 Version 2.0</div></div></div>"},"80836":{"type":"graphic_waveform","displayName":"Hypothermia tutorial","title":"Hypothermia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypothermia</div><div class=\"cntnt\"><img style=\"width:325px; height:132px;\" src=\"images/CARD/80836_Hypothermia_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">J waves or Osborne waves are characteristic of hypothermia.</div><div id=\"graphicVersion\">Graphic 80836 Version 2.0</div></div></div>"},"80837":{"type":"graphic_figure","displayName":"Pressures aortic stenosis","title":"Pressures in aortic stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pressures in aortic stenosis</div><div class=\"cntnt\"><img style=\"width:441px; height:269px;\" src=\"images/CARD/80837_Pressuresaorticstenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simultaneously recorded pressures from the left ventricle (LV) and aorta (Ao) in a patient with aortic stenosis. There is a systolic pressure gradient (shaded area) in which the LV systolic pressure is greater than that in the aorta. The pressure gradient and systolic ejection period (SEP, in sec/beat) are used in the Gorlin formula to calculate the aortic valve area (aortic valve area = cardiac output ÷ [44.3 x SEP x HR x sq rt mean gradient]).</div><div class=\"graphic_footnotes\">HR: heart rate.</div><div class=\"graphic_reference\">Redrawn from Kern MJ (Ed). Cardiac Catheterization Handbook, 2nd ed. Mosby-Year Book, St. Louis, 1995.</div><div id=\"graphicVersion\">Graphic 80837 Version 3.0</div></div></div>"},"80838":{"type":"graphic_figure","displayName":"Meta-analysis of ACAS and ACST","title":"Meta-analysis of ACAS and ACST","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Meta-analysis of ACAS and ACST</div><div class=\"cntnt\"><img style=\"width:502px; height:298px;\" src=\"images/NEURO/80838_Meta_analys_ACAS_ACST_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The effect of endarterectomy for asymptomatic carotid stenosis on the risk of any stroke and operative death by sex in the ACST and ACAS trials.</div><div class=\"graphic_footnotes\">ACST: Asymptomatic Carotid Surgery Trial; ACAS: Asymptomatic Carotid Atherosclerosis Study;&nbsp;CI: confidence interval; OR: odds ratio.</div><div class=\"graphic_reference\">Reproduced with permission from: Rothwell PM, Goldstein LB. Carotid endarterectomy for asymptomatic carotid stenosis: asymptomatic carotid surgery trial. Stroke 2004; 35:2425. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80838 Version 11.0</div></div></div>"},"80839":{"type":"graphic_figure","displayName":"Kaplan-Meier survival curve metastatic well-differentiated NETs","title":"Kaplan-Meier survival curve of metastatic well-differentiated neuroendocrine tumors of the digestive system","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kaplan-Meier survival curve of metastatic well-differentiated neuroendocrine tumors of the digestive system</div><div class=\"cntnt\"><img style=\"width:307px; height:686px;\" src=\"images/ONC/80839_KM_surv_curve_metast_NETs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier survival curve of metastatic well-differentiated neuroendocrine tumors of the digestive system. There is statistically significant difference in overall survival (A), disease-free survival (B), and progression-free survival (C) between grade 1 (G1) and grade 2 (G2) tumors based upon the highest Ki67 labeling index.</div><div class=\"graphic_reference\">Reproduced with permission from: Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol 2011; 35:853. Copyright © 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80839 Version 5.0</div></div></div>"},"80843":{"type":"graphic_table","displayName":"Diagnostic criteria for cluster headache","title":"Diagnostic criteria for cluster headache","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for cluster headache</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Cluster headache:</strong> Diagnostic criteria for cluster headache require the following:</td> </tr> <tr> <td class=\"indent1\">A. At least five attacks fulfilling criteria B through D</td> </tr> <tr> <td class=\"indent1\">B. Severe or very severe unilateral orbital, supraorbital and/or temporal pain lasting 15 to 180 minutes when untreated; during part (but less than half) of the time-course of cluster headache, attacks may be less severe and/or of shorter or longer duration</td> </tr> <tr> <td class=\"indent1\">C. Either or both of the following:</td> </tr> <tr> <td class=\"sublist3_start\">1. At least one of the following symptoms or signs ipsilateral to the headache:</td> </tr> <tr> <td class=\"sublist3\">a) Conjunctival injection or lacrimation</td> </tr> <tr> <td class=\"sublist3\">b) Nasal congestion and/or rhinorrhea</td> </tr> <tr> <td class=\"sublist3\">c) Eyelid edema</td> </tr> <tr> <td class=\"sublist3\">d) Forehead and facial sweating</td> </tr> <tr> <td class=\"sublist3\">e) Forehead and facial flushing</td> </tr> <tr> <td class=\"sublist3\">f) Sensation of fullness in the ear</td> </tr> <tr> <td class=\"sublist3\">g) Miosis and/or ptosis</td> </tr> <tr> <td class=\"indent2\">2. A sense of restlessness or agitation</td> </tr> <tr> <td class=\"indent1\">D. Attacks have a frequency between one every other day and eight per day for more than half of the time when the disorder is active</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">E. Not better accounted for by another ICHD-3 diagnosis</td> </tr> <tr> <td><strong>Episodic cluster headache:</strong> Diagnostic criteria for episodic cluster headache require the following:</td> </tr> <tr> <td class=\"indent1\">A. Attacks fulfilling criteria for cluster headache and occurring in bouts (cluster periods)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">B. At least two cluster periods lasting from seven days to one year (when untreated) and separated by pain-free remission periods of one month or more</td> </tr> <tr> <td><strong>Chronic cluster headache:</strong> Diagnostic criteria for chronic cluster headache require the following:</td> </tr> <tr> <td class=\"indent1\">A. Attacks fulfilling criteria for cluster headache</td> </tr> <tr> <td class=\"indent1\">B. Attacks occurring without a remission period, or with remissions lasting less than one month, for at least one year</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICHD-3: International Classification of Headache Disorders 3<SUP>rd</SUP> edition.</div><div class=\"graphic_reference\">Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3<SUP>rd</SUP> edition (beta version). Cephalalgia 2013; 33:629.</div><div id=\"graphicVersion\">Graphic 80843 Version 6.0</div></div></div>"},"80844":{"type":"graphic_picture","displayName":"Cafe-au-lait spots","title":"Café-au-lait spots in McCune-Albright syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Café-au-lait spots in McCune-Albright syndrome</div><div class=\"cntnt\"><img style=\"width:387px; height:296px;\" src=\"images/PEDS/80844_Cafe_au_lait_spots.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A typical lesion on the face, chest, and arm of a five-year-old girl with McCune-Albright syndrome, which demonstrates jagged \"coast of Maine\" borders and the tendency for the lesions to both respect the midline and follow the developmental lines of Blaschko (a configuration of skin lesions characterized by arcs on the upper chest, S shapes on the abdomen, and V shapes over the posterior midline, caused by patterns of X-chromosome inactivation).<br />(B) Typical lesions that are often found on the nape of the neck and crease of the buttocks are shown (arrows).</div><div class=\"graphic_reference\">Reproduced from: Dumitrescu CE, Collins MT. McCune-Albright syndrome. Orphanet J Rare Dis 2008; 3:12. Copyright ©2008 BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 80844 Version 6.0</div></div></div>"},"80845":{"type":"graphic_figure","displayName":"Rela incid immunodeficiency","title":"Relative incidence of primary immunodeficiencies","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Relative incidence of primary immunodeficiencies</div><div class=\"cntnt\"><img style=\"width:532px; height:448px;\" src=\"images/PEDS/80845_Rela_incid_immunodeficiency.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 80845 Version 2.0</div></div></div>"},"80847":{"type":"graphic_picture","displayName":"Drug eruption purpura","title":"Maculopapular drug eruption with lower extremity purpura","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Maculopapular drug eruption with lower extremity purpura</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/80847_Drug_eruption_purpura.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Purpuric lesions can occur in sites of nonvasculitic cutaneous inflammation. This is evident on one leg in this patient with a maculopapular drug eruption.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 80847 Version 3.0</div></div></div>"},"80848":{"type":"graphic_picture","displayName":"Oral lichen planus","title":"Oral lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oral lichen planus</div><div class=\"cntnt\"><img style=\"width:432px; height:331px;\" src=\"images/DERM/80848_Oral_lichen_planus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lichen planus. Oral lesions with a white, lacy pattern and an erythematous erosion are present on the buccal mucosa.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80848 Version 1.0</div></div></div>"},"80849":{"type":"graphic_table","displayName":"Lispro insulin and blood glucose","title":"Lispro insulin and blood glucose","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lispro insulin and blood glucose</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Time</td> <td class=\"subtitle1\">Blood glucose level, mg/dL</td> <td class=\"subtitle1\">Lispro insulin, units</td> </tr> <tr> <td>7 AM</td> <td>50 to 250</td> <td>5</td> </tr> <tr> <td>12 PM</td> <td>70 to 200</td> <td>12</td> </tr> <tr> <td>3 PM</td> <td>50 to 250</td> <td>&nbsp;</td> </tr> <tr> <td>6 PM</td> <td>100 to 200</td> <td>15</td> </tr> <tr> <td>Bedtime</td> <td>100 to 200</td> <td>5</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80849 Version 3.0</div></div></div>"},"80850":{"type":"graphic_figure","displayName":"Pulmonary function in pregnancy","title":"Changes in pulmonary function tests during pregnancy","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Changes in pulmonary function tests during pregnancy</div><div class=\"cntnt\"><img style=\"width:552px; height:336px;\" src=\"images/PULM/80850_Pulmonary_function_in_pregn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serial measurements of lung volume compartments during pregnancy. Functional residual capacity decreases approximately 20% during the latter half of pregnancy, due to a decrease in both expiratory reserve volume and residual volume.</div><div class=\"graphic_reference\">Modified from: Prowse CM, Gaensler EA. Respiratory and acid-base changes during pregnancy. Anesthesiology 1965; 26:381.</div><div id=\"graphicVersion\">Graphic 80850 Version 3.0</div></div></div>"},"80851":{"type":"graphic_picture","displayName":"Anhidrotic ectodermal dysplasia","title":"Anhidrotic ectodermal dysplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anhidrotic ectodermal dysplasia</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/80851_Anhidrotic_ectodermal_dyspl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sparse hair is evident in this patient with anhidrotic ectodermal dysplasia.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 80851 Version 4.0</div></div></div>"},"80852":{"type":"graphic_picture","displayName":"Fluorochrome stain of sputum","title":"Fluorochrome stain of sputum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Fluorochrome stain of sputum</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ID/80852_Fluorochromstainofsputum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluorochrome staining of sputum for acid-fast bacilli: Increases sensitivity, decreases examination time versus Ziehl-Neelsen method.</div><div class=\"graphic_reference\">Courtesy of John Bernardo, MD.</div><div id=\"graphicVersion\">Graphic 80852 Version 4.0</div></div></div>"},"80853":{"type":"graphic_table","displayName":"Reoperation following repair of aortic dissection","title":"European Society of Cardiology guidelines: reoperation following repair of aortic dissection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">European Society of Cardiology guidelines: reoperation following repair of aortic dissection</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Recommendation </td>\n\n\n      <td class=\"subtitle1_single\">Class</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">1. Surgical intervention for </td>\n\n\n      <td colspan=\"1\" rowspan=\"3\">I</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Secondary aneurysm in dissected aorta remote from initial repair</td>\n\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Recurrent dissection or aneurysm formation at previous intervention site</td>\n\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>2. Graft replacement for gross dehiscence or infection </td>\n\n\n      <td>I</td>\n\n    </tr>\n\n    <tr>\n\n      <td>3. Use of homografts to replace infected protheses </td>\n\n      <td>I</td>\n\n    </tr>\n\n    <tr>\n\n      <td>4. Endovascular stenting if surgical indication and suitable anatomy</td>\n\n\n      <td>IIa</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">Classification</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\"><strong> Class I:</strong> Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\"><strong> Class II:</strong>\nConditions for which there is conflicting evidence and/or a divergence\nof opinion about the usefulness/efficacy of a procedure or treatment.</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\"><strong> Class IIa:</strong> Weight of evidence/opinion is in favor of usefulness/efficacy.</td>\n\n\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\"><strong>Class IIb:</strong>&nbsp;Usefulness/efficacy less well established by evidence/opinion.</td>\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\"><strong>Class III:</strong>\nConditions for which there is evidence and/or general agreement that\nthe procedure/treatment is not useful and in some cases may be harmful.</td>\n\n\n\n    </tr>\n\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">2.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=4669&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>ESC_reoperation_Ao_dissecti.htm</title></head></div><div class=\"graphic_reference\">Data reproduced with permission from Erbel R, Alfonso F, Boileau C, et al. Eur Heart J 2001; 22:1642.</div><div id=\"graphicVersion\">Graphic 80853 Version 3.0</div></div></div>"},"80854":{"type":"graphic_picture","displayName":"Rheumatoid neutroph dermatitis","title":"Rheumatoid neutrophilic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rheumatoid neutrophilic dermatitis</div><div class=\"cntnt\"><img style=\"width:290px; height:320px;\" src=\"images/RHEUM/80854_Rheumatoid_neutroph_dermati.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules of rheumatoid neutrophilic dermatitis are symmetrically scattered in this patient with rheumatoid arthritis.</div><div class=\"graphic_reference\">Courtesy of Samuel Moschella, MD.</div><div id=\"graphicVersion\">Graphic 80854 Version 1.0</div></div></div>"},"80855":{"type":"graphic_figure","displayName":"Protocol dobutamine stress echo","title":"Protocol for dobutamine stress echocardiography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Protocol for dobutamine stress echocardiography</div><div class=\"cntnt\"><img style=\"width:428px; height:278px;\" src=\"images/CARD/80855_Protocol_dobutamine_stress.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Standard dobutamine infusion protocol for pharmacologic stress testing with echocardiographic imaging. The dobutamine dose is increased every three minutes until the patient achieves at least 85% of maximum predicted heart rate (MPHR). If the heart rate remains &lt;85% MPHR following infusion of dobutamine 40 mcg/kg/min, arm exercise can be performed and/or atropine may be infused in an effort to further increase the heart rate. The echocardiographic images are typically obtained near the end of every three-minute stage, with the peak images obtained at any point once the patient's heart rate exceeds 85% MPHR or the development of symptoms.</div><div id=\"graphicVersion\">Graphic 80855 Version 3.0</div></div></div>"},"80856":{"type":"graphic_picture","displayName":"Pseudoporphyria","title":"Pseudoporphyria","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pseudoporphyria</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/80856_Pseudoporphyria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vesiculation and crusting are present on the dorsal hand.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 80856 Version 1.0</div></div></div>"},"80857":{"type":"graphic_figure","displayName":"Subclavian vein cannulation","title":"Subclavian vein cannulation","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Subclavian vein cannulation</div><div class=\"cntnt\"><img style=\"width:504px; height:524px;\" src=\"images/EM/80857_Subclavian_vein_cannulation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Place the child in the Trendelenberg position with a towel roll under the thoracic spine. <br />(A) Make a small incision at the junction of the medial and distal thirds of the clavicle. Insert the needle and direct it toward the posterior aspect of the sternal notch. Advance the needle along the inferior surface of the clavicle, in the horizontal plane of the chest. Blood will be easily aspirated when the needle enters the vein. <br />(B) Pass a guidewire through the needle. Remove the needle over the guidewire. Pass the catheter over the guidewire. Remove the guidewire. Confirm that blood can be aspirated from each port of the catheter, then flush it with saline. Secure the catheter with a suture and confirm tip placement.</div><div id=\"graphicVersion\">Graphic 80857 Version 3.0</div></div></div>"},"80858":{"type":"graphic_figure","displayName":"Adjective Rating Scale","title":"Adjective Rating Scale for pain assessment","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Adjective Rating Scale for pain assessment</div><div class=\"cntnt\"><img style=\"width:496px; height:104px;\" src=\"images/SURG/80858_Adj_rating_scale.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Adjective Rating Scale allows patients to use descriptive terms to describe the severity of their pain. Scoring can be modified for conversion to a numeric scale.</div><div class=\"graphic_reference\">Original figure modified for this publication. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987; 30:191. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 80858 Version 1.0</div></div></div>"},"80860":{"type":"graphic_table","displayName":"IUD failure rates","title":"Comparison of intrauterine devices","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of intrauterine devices</div><div class=\"cntnt\"><table cellspacing=\"0\"><div class=\"figure\">&nbsp;</div> <div>&nbsp;</div> <tbody> </tbody></table><table style=\"height: 258px; width:93.79%;\" cellspacing=\"0\"> <colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">Type</td> </tr> <tr> <td class=\"subtitle2\">TCu380A IUD</td> <td class=\"subtitle2\">Levonorgestrel IUD (52 mg)</td> <td class=\"subtitle2\"> <p>Levonorgestrel</p> <p>IUD (13.5 mg)</p> </td> </tr> <tr> <td><strong>Duration of therapeutic effect, years</strong></td> <td class=\"centered\">12</td> <td class=\"centered\">7</td> <td class=\"centered\">3&nbsp;</td> </tr> <tr> <td><strong>First year of use pregnancy rate, perfect use, percent</strong></td> <td class=\"centered\">0.6</td> <td class=\"centered\">0.1</td> <td class=\"centered\">0.4&nbsp;</td> </tr> <tr> <td><strong>First year of use pregnancy rate, typical use, percent</strong></td> <td class=\"centered\">0.5 to 0.8</td> <td class=\"centered\">0.1 to 0.2</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Five-year cumulative pregnancy rate, percent</strong></td> <td class=\"centered\">1.4 +/&ndash;0.4</td> <td class=\"centered\">1.1 +/&ndash;0.5</td> <td class=\"centered\">&nbsp;0.9*</td> </tr> <tr> <td><strong>10-year cumulative pregnancy rate, percent</strong></td> <td class=\"centered\">2.2</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>FDA-approved duration of use, years</strong></td> <td class=\"centered\">10</td> <td class=\"centered\">5</td> <td class=\"centered\">3&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FDA:&nbsp;US Food and Drug Administration; IUD: intrauterine device.<br />* Skyla is approved for&nbsp;three years of use. The three-year cumulative pregnancy rate is 0.9 percent. </div><div id=\"graphicVersion\">Graphic 80860 Version 7.0</div></div></div>"},"80861":{"type":"graphic_movie","displayName":"Pertussis infant","title":"Classic pertussis cough in an infant","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Classic pertussis cough in an infant</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/80861_Pertussisinfantvid.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:396px; height:301px;\" src=\"images/CARD/80861_Pertussisinfantedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Sheldon L Kaplan, MD.</div><div id=\"graphicVersion\">Graphic 80861 Version 5.0</div></div></div>"},"80862":{"type":"graphic_picture","displayName":"Hailey Hailey","title":"Vulvar Hailey-Hailey disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar Hailey-Hailey disease</div><div class=\"cntnt\"><img style=\"width:432px; height:313px;\" src=\"images/OBGYN/80862_Hailey_Hailey.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large, erythematous plaque with multiple superficial erosions involving the vulvar and groin area&nbsp;in a patient with Hailey-Hailey disease.</div><div class=\"graphic_reference\">Courtesy of Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 80862 Version 5.0</div></div></div>"},"80863":{"type":"graphic_figure","displayName":"CDC head circumference-for-age boys 0 to 36 months","title":"Head circumference-for-age percentiles, boys birth to 36 months, CDC growth charts","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Head circumference-for-age percentiles, boys birth to 36 months, CDC growth charts</div><div class=\"cntnt\"><img style=\"width:552px; height:756px;\" src=\"images/PEDS/80863_Head_circumference_by_age_b.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 80863 Version 3.0</div></div></div>"},"80864":{"type":"graphic_table","displayName":"Asthma adherence IV","title":"Possible solutions to common problems with taking asthma medications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Possible solutions to common problems with taking asthma medications</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Problem</td> <td class=\"subtitle1\">Solutions</td> </tr> <tr> <td>You were interrupted just before taking your medicine.</td> <td>If you put your medicine down you will be more likely to forget about it. So keep the medicine in your hand until you've taken it.</td> </tr> <tr> <td>You made a planned change in your usual routine and forgot.</td> <td>Think through your day ahead of time and plan when you will take your medicines. Take your medicines with you. Attach a reminder to something you will be using, such as your car keys.</td> </tr> <tr> <td>Your usual routine was unexpectedly changed and you forgot.</td> <td>Keep a small emergency supply of your medicines in your purse or car.</td> </tr> <tr> <td>You ran out of medicine.</td> <td>Use a calendar to remind you to refill medicines. Get prescriptions refilled several days before your are due to run out. Keep a small emergency supply of your medicines. Ask your pharmacist to remind you to get a new prescription when you pick up your last refill.</td> </tr> <tr> <td>You felt so well, you forgot or decided not to take your medicine.</td> <td>Remind yourself that you are feeling well because you have been taking your medicines. Establish the habit of taking your maintenance medicines with activities you do every day. Place your medicines where you will see them easily and frequently. Have someone at home and work remind you that you need to take the medicine.</td> </tr> <tr> <td>You are confused about what, when, or how much medicine to take.</td> <td>Repeat medicine-taking instructions to your doctor. Read the directions on the prescription label. If you don't understand them, ask the pharmacist to write up a schedule for you. Call your pharmacist or doctor and ask questions. Write down the exact instructions for taking each medicine. Keep the instructions with your medicines.</td> </tr> <tr> <td>You became absorbed in an activity and forgot.</td> <td>Plan to take your medicines with activities you do every day. Take your medicines with you. Place your medicines where you can easily see them. Have someone remind you to take your medicines.</td> </tr> <tr> <td>You are worried that if you take the medicine too much you will develop a tolerance to it and it will no longer work as well.</td> <td>Ask your doctor or pharmacist if you can develop a tolerance to the medicine. This cannot happen with most breathing medicines.</td> </tr> <tr> <td>Sometimes you just forget.</td> <td>Use an alarm on a clock, watch, or cell phone as a reminder. Use a pill dispenser. Keep prescriptions filled. Take medicines when you eat, brush your teeth or go to bed. Ask your doctor to make your medicine plan more convenient. Keep your medicine schedule in a handy place as a reminder both at home and at work.</td> </tr> <tr> <td>The medicines are too expensive.</td> <td>Ask your doctor to prescribe generic medicines. Compare costs from several discount drug stores or use a mail order plan. Use your inhaler properly so that medicine is not wasted. (For more tips on reducing costs, visit UpToDate.com and refer to the patient information topic about reducing the cost of medicines.)</td> </tr> <tr> <td>You believe the medicine is not working.</td> <td>Keep taking the medicine until you can discuss this with your doctor. Remember, some medicines will not make you feel better immediately. They require long, continuous treatment to begin working.</td> </tr> <tr> <td>Some side effects are bothering you.</td> <td>Tell your doctor about any side effects. Ask your doctor about trying different brand names. If stomach upset is a problem, ask your doctor if you can take your medicine with meals or milk.</td> </tr> <tr> <td>You have difficulty taking medicines.</td> <td>Take pills with ice cream, juice, jello, or meals. Empty capsules into a drink. Ask for liquid or sprinkle forms of medicines. (DO NOT CRUSH THEOPHYLLINE PILLS). Ask about long-lasting drugs.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80864 Version 4.0</div></div></div>"},"80866":{"type":"graphic_picture","displayName":"Ulcerations and gangrene in thromboangiitis obliterans","title":"Ulcerations and gangrene in thromboangiitis obliterans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ulcerations and gangrene in thromboangiitis obliterans</div><div class=\"cntnt\"><img style=\"width:350px; height:235px;\" src=\"images/SURG/80866_Buergers_gangrene.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Berg D, Worzala K. Atlas of Adult Physical Diagnosis. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 80866 Version 4.0</div></div></div>"},"80867":{"type":"graphic_table","displayName":"PFPS sample phys ther Rx","title":"Sample physical therapy prescription for PFPS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sample physical therapy prescription for PFPS</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Physical therapy prescription </td> </tr> <tr> <td><strong>Dx:</strong> PFPS (Left / Right / Bilateral) ICD9 (719.46)</td> </tr> <tr> <td class=\"subtitle2_left\">Rx: (NOTE: the exercises listed below are examples only and are not intended to limit the physical therapist.) </td> </tr> <tr> <td class=\"indent1\">1. Hip abduction strengthening: (eg, \"monster walks\" - lateral steps with elastic band around [just proximal to] knees: 1 minute x 3 sets; hip hikes: 2 sets of 20 repetitions each side; clamshells (hip abduction&nbsp;against&nbsp;elastic band&nbsp;around [just proximal to]&nbsp;knees while laying on side): 3 sets of 12 repetitions each side). </td> </tr> <tr> <td class=\"indent1\">2. Close chain quadriceps strengthening: (eg, terminal knee extensions with elastic band 3 sets of 15 reps; leg presses 3 sets of 10 repetitions; semi squats 3 sets of 10 repetitions). </td> </tr> <tr> <td class=\"indent1\">3. Pelvic stability training: (eg, standing single leg hip flexion, extension, abduction and adduction with elastic band, 3 sets of 12 repetitions; single leg proprioceptive training; other balance training). </td> </tr> <tr> <td class=\"indent1\">4. Hamstring, quadriceps, and iliotibial band flexibility training. </td> </tr> <tr> <td class=\"indent1\">5. Please instruct in home exercise program. </td> </tr> <tr> <td class=\"indent1\">6. No other treatment modalities other than post-therapy ice prn (unless specifically requested and reviewed with prescribing clinician). </td> </tr> <tr> <td><strong>Frequency:</strong> 2 visits of 45 minutes per week for 6 weeks. (Reassess at 6 weeks or earlier as needed by insurance carrier to represcribe therapy).</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80867 Version 2.0</div></div></div>"},"80868":{"type":"graphic_picture","displayName":"Rhagades","title":"Congenital syphilis: Rhagades","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital syphilis: Rhagades</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PEDS/80868_Rhagades.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph demonstrates rhagades, which are cracks or fissures in the skin around the mouth, in a patient with late congenital syphilis.</div><div class=\"graphic_reference\">Reproduced from: the Public Health Image Library, Centers for Disease Control and Prevention. Photo by Susan Lindsley.</div><div id=\"graphicVersion\">Graphic 80868 Version 2.0</div></div></div>"},"80869":{"type":"graphic_table","displayName":"Nematode characteristics","title":"Nematode characteristics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nematode characteristics</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" rowspan=\"2\"><em>Angiostrongylus costaricensis</em></td> <td class=\"subtitle1\" rowspan=\"2\">Anisakiasis</td> <td class=\"subtitle1\" colspan=\"2\">Capillariasis</td> <td class=\"subtitle1\" colspan=\"3\">Dirofilariasis</td> <td class=\"subtitle1\" rowspan=\"2\">Dracunculiasis</td> <td class=\"subtitle1\" rowspan=\"2\">Trichostrongyliasis</td> </tr> <tr> <td class=\"subtitle2\"><em>C. philippinensis</em></td> <td class=\"subtitle2\"><em>C. hepatica</em></td> <td class=\"subtitle2\"><em>D. immitis</em></td> <td class=\"subtitle2\"><em>D. repens</em></td> <td class=\"subtitle2\"><em>D. tenuis</em></td> </tr> <tr> <td><strong>Mode of acquisition</strong></td> <td>Usually via ingestion of raw snails/slugs or raw produce contaminated with larva-containing slug secretions</td> <td>Ingestion of undercooked or raw fish</td> <td>Ingestion of raw or undercooked fish</td> <td>Ingestion of eggs in contaminated food, water, or soil</td> <td class=\"centered\" colspan=\"3\">Mosquito bite</td> <td>Ingestion of water containing copepods infected with larvae</td> <td>Ingestion of unwashed vegetables fertilized with contaminated manure</td> </tr> <tr class=\"divider_top\"> <td><strong>Main organ system affected</strong></td> <td>Intestine</td> <td>Stomach or intestine</td> <td>Intestine</td> <td>Liver</td> <td>Lung </td> <td class=\"centered\" colspan=\"2\">Subcutaneous nodules</td> <td>Skin</td> <td>Intestine</td> </tr> <tr class=\"divider_top\"> <td><strong>Diagnosis</strong></td> <td>Intestinal biopsy</td> <td>Visualization of worm (in vomitus or at endoscopy)</td> <td>Stool specimen</td> <td>Liver biopsy</td> <td class=\"centered\" colspan=\"3\">Biopsy of involved tissue</td> <td>Clinical</td> <td>Stool</td> </tr> <tr class=\"divider_top\"> <td><strong>Treatment</strong></td> <td>Not required</td> <td>Physical removal of the parasite; possibly albendazole</td> <td class=\"centered\" colspan=\"2\">Albendazole or mebendazole</td> <td class=\"centered\" colspan=\"3\">Extraction/excision</td> <td>Symptomatic only</td> <td>Albendazole or mebendazole</td> </tr> <tr class=\"divider_top\"> <td><strong>Hosts</strong></td> <td> <p>Definitive host: Rats</p> <p>Intermediate host: Snails/slugs</p> </td> <td>Marine mammals, crustaceans, fish/squid</td> <td>Fish-eating birds, fish</td> <td>Rats, mammals</td> <td>Dog</td> <td>Cats</td> <td>Racoons</td> <td>NA</td> <td>Herbivorous mammals, including sheep and cattle</td> </tr> <tr class=\"divider_top\"> <td><strong>Humans</strong></td> <td>Dead-end host</td> <td>Incidental hosts</td> <td class=\"centered\" colspan=\"2\">Incidental hosts</td> <td class=\"centered\" colspan=\"3\">Accidental, dead-end hosts</td> <td>Only known host</td> <td>Incidental hosts</td> </tr> <tr class=\"divider_top\"> <td><strong>Main geographical area</strong></td> <td>Central and South America</td> <td>Japan</td> <td>Thailand, Philippines</td> <td>Worldwide</td> <td class=\"centered\" colspan=\"3\">Mediterranean region</td> <td>Mainly Sudan, also Chad, Ethiopia, Ghana, and Mali</td> <td>Worldwide, especially Middle East and Asia</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Peter Weller, MD, and Karin Leder, MD.</div><div id=\"graphicVersion\">Graphic 80869 Version 2.0</div></div></div>"},"80871":{"type":"graphic_diagnosticimage","displayName":"Aneurysmal bone cyst fibula","title":"Aneurysmal bone cyst of the proximal fibula","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Aneurysmal bone cyst of the proximal fibula</div><div class=\"cntnt\"><img style=\"width:504px; height:288px;\" src=\"images/PEDS/80871_Aneurysmal_bone_cyst_fibula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Frontal (A) and lateral (B) views demonstrate an expanded lesion of the diametaphyseal area of the fibula. The lesion is trabeculated and does not cross the physis. This lesion is radiologically characteristic enough to allow a confident diagnosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Daffner RH. Clinical Radiology: The Essentials, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &#169; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80871 Version 2.0</div></div></div>"},"80873":{"type":"graphic_diagnosticimage","displayName":"Extracranial aneurysm of the internal carotid artery","title":"Extracranial aneurysm of the internal carotid artery","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Extracranial aneurysm of the internal carotid artery</div><div class=\"cntnt\"><img style=\"width:478px; height:470px;\" src=\"images/NEURO/80873_Extracr_aneur_int_car_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arteriography of an extracranial aneurysm of the internal carotid artery at the skull base resulting from carotid dissection in a 34-year-old man.</div><div class=\"graphic_reference\">Reproduced with permission from: Meairs S, Hennerici M. Long-term follow-up of aneurysms developed during extracranial internal carotid artery dissection. Neurology 2000; 54:2190. Copyright © 2000 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 80873 Version 5.0</div></div></div>"},"80874":{"type":"graphic_figure","displayName":"Manual stabilization of the pediatric spine","title":"Manual stabilization of the pediatric spine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Manual stabilization of the pediatric spine</div><div class=\"cntnt\"><img style=\"width:361px; height:465px;\" src=\"images/EM/80874_Pediatric_manual_c-spine.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 80874 Version 5.0</div></div></div>"},"80875":{"type":"graphic_figure","displayName":"Prolonged benefit of nasal CT","title":"Calcitonin chronically preserves bone density","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calcitonin chronically preserves bone density</div><div class=\"cntnt\"><img style=\"width:300px; height:245px;\" src=\"images/ENDO/80875_Prolonged_benefit_of_nasal.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean percent change in lumbar BMD in 87 postmenopausal women treated with 500 mg of calcium/day alone or with intranasal sCT (50 international units/day). Both treatment regimens were given for five days each week. sCT preserved BMD whereas there was a gradual decline with calcium alone.</div><div class=\"graphic_footnotes\">BMD: bone mineral density; sCT: salmon calcitonin.</div><div class=\"graphic_reference\">Data from: Reginster JY, Meurmans L, Deroisy R, et al. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium. Eur J Clin Invest 1994; 24:565.</div><div id=\"graphicVersion\">Graphic 80875 Version 2.0</div></div></div>"},"80877":{"type":"graphic_picture","displayName":"En coup de sabre - face","title":"En coup de sabre","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">En coup de sabre</div><div class=\"cntnt\"><img style=\"width:396px; height:274px;\" src=\"images/DERM/80877_En_coup_de_sabre_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A depressed linear plaque is present on the forehead.</div><div id=\"graphicVersion\">Graphic 80877 Version 2.0</div></div></div>"},"80879":{"type":"graphic_table","displayName":"Evaluation for TB","title":"Guidelines for the evaluation of pulmonary tuberculosis in adults in five clinical scenarios","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for the evaluation of pulmonary tuberculosis in adults in five clinical scenarios</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Patient and setting</td> <td class=\"subtitle1\">Recommended evaluation</td> </tr> <tr> <td>Any patient with a cough of &#8805;2 to 3 weeks' duration, with at least one additional symptom, including fever, night sweats, weight loss, or hemoptysis</td> <td>Chest radiograph: If suggestive of TB*, collect three sputum specimens for AFB smear microscopy and culture. At least one specimen should also be tested using an NAA test.</td> </tr> <tr> <td>Any patient at high risk for TB<sup>&#182;</sup> with an unexplained illness, including respiratory symptoms, of &#8805;2 to 3 weeks' duration</td> <td>Chest radiograph: If suggestive of TB*, collect three sputum specimens for AFB smear microscopy and culture. At least one specimen should also be tested using an NAA test.</td> </tr> <tr> <td>Any patient with HIV infection and unexplained cough and fever</td> <td>Chest radiograph, and collect three sputum specimens for AFB smear microscopy and culture. At least one specimen should also be tested using an NAA test.</td> </tr> <tr> <td>Any patient at high risk for TB<sup>&#182;</sup> with a diagnosis of community-acquired pneumonia who has not improved after seven days of treatment</td> <td>Chest radiograph, and collect three sputum specimens for AFB smear microscopy and culture. At least one specimen should also be tested using an NAA test.</td> </tr> <tr> <td>Any patient at high risk for TB<sup>&#182;</sup> with incidental findings on chest radiograph suggestive of TB even if symptoms are minimal or absent<sup>&#916;</sup></td> <td>Review of previous chest radiographs if available, three sputum specimens for AFB smear microscopy and culture. At least one specimen should also be tested using an NAA test.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TB: tuberculosis; AFB: acid-fast bacilli; NAA: nucleic acid amplification.<br />* Infiltrates with or without cavitation in the upper lobes or the superior segments of the lower lobes.<br />¶ Patients with one of the following characteristics: recent exposure to a person with a case of infectious TB; history of a positive test result for <EM>Mycobacterium tuberculosis</EM>; HIV infection; injection or noninjection drug use; foreign birth and immigration ≤5 years from a region in which incidence is high; residents and employees of high-risk congregate settings; membership in a medically underserved, low-income population; or a medical risk factor for TB (including diabetes mellitus, conditions requiring prolonged corticosteroid and other immunosuppressive therapy, chronic renal failure, certain hematological malignancies and carcinomas, weight &gt;10 percent below ideal body weight, silicosis, gastrectomy, or jejunoileal bypass).<br />Δ Chest radiograph performed for any reason, including targeted testing for latent TB infection and screening for TB disease.</div><div class=\"graphic_reference\">Adapted from: Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, the Infectious Diseases Society of America. MMWR Recomm Rep 2005; 54(RR-12):1. Daley CL, Gotway MB, Jasmer RM. Radiographic manifestations of tuberculosis: a primer for clinicians. San Francisco, CA: Francis J Curry National Tuberculosis Center; 2003: 1-30, and Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep 2009; 58:7.</div><div id=\"graphicVersion\">Graphic 80879 Version 5.0</div></div></div>"},"80881":{"type":"graphic_table","displayName":"Combination chemotherapy STS","title":"Commonly used chemotherapy combinations for patients with soft tissue sarcoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly used chemotherapy combinations for patients with soft tissue sarcoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose (total per cycle)</td> <td class=\"subtitle1\">Schedule</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">AI</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">LeCesne A; 2000</td> <td>Doxorubicin</td> <td>50 or 75 mg/m<sup>2</sup> day 1 (50 to 75 mg/m<sup>2</sup>)</td> <td rowspan=\"3\">Every 3 weeks</td> </tr> <tr> <td>Ifosfamide*</td> <td>5 g/m<sup>2</sup> over 24 hours, day 1 (5 g/m<sup>2</sup>)</td> </tr> <tr> <td>Mesna</td> <td>2.5 g/m<sup>2</sup> mixed with ifosfamide IV over 24 hours; 1.25 g/m<sup>2</sup> IV over 12 hours after ifosfamide<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Worden F; 2005</td> <td>Doxorubicin</td> <td>20 mg/m<sup>2</sup> days 1, 2, 3 (60 mg/m<sup>2</sup>)</td> <td rowspan=\"3\">Every 3 weeks, G-CSF<sup>&#182;</sup></td> </tr> <tr> <td>Ifosfamide*</td> <td>1.5 g/m<sup>2</sup> over 2 hours, days 1 through 4 (6 g/m<sup>2</sup>)</td> </tr> <tr> <td>Mesna</td> <td>225 mg/m<sup>2</sup> IV over 1 hour before ifosfamide, 4 and 8 hours after ifosfamide; G-CSF 5 mcg/kg per day, once daily for 10 days, start on day 5</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"3\">Patel S; 1998</td> <td>Doxorubicin</td> <td>25 mg/m<sup>2</sup> over 24 hours, days 1, 2, 3 (75 mg/m<sup>2</sup>)</td> <td class=\"divider_bottom\" rowspan=\"3\">Every 3 weeks, G-CSF<sup>&#182;</sup></td> </tr> <tr> <td>Ifosfamide*</td> <td>2 g/m<sup>2</sup> over 2 hours, days 1 through 5 (10 g/m<sup>2</sup>)</td> </tr> <tr class=\"divider_bottom\"> <td>Mesna</td> <td>400 mg/m<sup>2</sup> with first dose ifosfamide, then start 1200 mg/m<sup>2</sup> over 24 hours per day, for 5 days</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Epirubicin/ifosfamide</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"3\">Palumbo R; 1999</td> <td>Epirubicin</td> <td>55 mg/m<sup>2</sup> start IV bolus, days 1, 2 (110 mg/m<sup>2</sup>)</td> <td class=\"divider_bottom\" rowspan=\"3\">Every 3 weeks, G-CSF<sup>&#182;</sup></td> </tr> <tr> <td>Ifosfamide*</td> <td>2.5 g/m<sup>2</sup> over 24 hours, days 1 through 4 (10 g/m<sup>2</sup>)</td> </tr> <tr class=\"divider_bottom\"> <td>Mesna</td> <td>2.5 g/m<sup>2</sup> over 24 hours, days 1 through 5</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">AD</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"2\">Antman K; 1993</td> <td>Doxorubicin</td> <td>15 mg/m<sup>2</sup> over 24 hours, days 1 through 4 (60 mg/m<sup>2</sup>)</td> <td class=\"divider_bottom\" rowspan=\"2\">Every 3 weeks</td> </tr> <tr class=\"divider_bottom\"> <td>Dacarbazine</td> <td>250 mg/m<sup>2</sup> over 24 hours, days 1 through 4 (1000 mg/m<sup>2</sup>)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">MAID</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Antman K; 1993, 1998</td> <td>Doxorubicin</td> <td>15 mg/m<sup>2</sup> over 24 hours, days 1 through 4</td> <td rowspan=\"4\">Every 3 weeks</td> </tr> <tr> <td>Ifosfamide*</td> <td>2 g/m<sup>2</sup> over 24 hours, days 1 through 3</td> </tr> <tr> <td>Dacarbazine</td> <td>250 mg/m<sup>2</sup> over 24 hours, days 1 through 4 (mix with doxorubicin)</td> </tr> <tr> <td>Mesna</td> <td>2.5 g/m<sup>2</sup> over 24 hours, days 1 through 4</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"4\">DeLaney T; 2003</td> <td>Doxorubicin</td> <td>20 mg/m<sup>2</sup> over 24 hours, days 1 through 3</td> <td class=\"divider_bottom\" rowspan=\"4\">Every 3 weeks</td> </tr> <tr> <td>Ifosfamide*</td> <td>2 g/m<sup>2</sup> over 24 hours, days 1 through 3</td> </tr> <tr> <td>Dacarbazine</td> <td>250 mg/m<sup>2</sup> over 24 hours, days 1 through 4 (mix with doxorubicin)</td> </tr> <tr class=\"divider_bottom\"> <td>Mesna</td> <td>2.5 g/m<sup>2</sup> over 24 hours, days 1 through 4</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Gemcitabine/docetaxel</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Leu K; 2004</td> <td>Gemcitabine</td> <td>675 mg/m<sup>2</sup> days 1 and 8</td> <td rowspan=\"2\">Every 3 weeks</td> </tr> <tr> <td>Docetaxel</td> <td>100 mg/m<sup>2</sup> day 8</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"2\">Hensley M; 2002</td> <td>Gemcitabine</td> <td>900 mg/m<sup>2</sup> days 1, 8 (675 mg/m<sup>2</sup> days 1 and 8<sup>&#916;</sup>)</td> <td class=\"divider_bottom\" rowspan=\"2\">Every 3 weeks, G-CSF</td> </tr> <tr class=\"divider_bottom\"> <td>Docetaxel</td> <td>100 mg/m<sup>2</sup> day 8 (75 mg/m<sup>2</sup> day 8<sup>&#916;</sup>)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Gemcitabine/vinorelbine</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"2\">Dileo P; 2007</td> <td>Vinorelbine</td> <td>25 mg/m<sup>2</sup> over 10 minutes, days 1 and 8</td> <td class=\"divider_bottom\" rowspan=\"2\">Every 3 weeks</td> </tr> <tr class=\"divider_bottom\"> <td>Gemcitabine</td> <td>800 mg/m<sup>2</sup> over 90 minutes, days 1 and 8</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Gemcitabine/dacarbazine</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Garcia-del Muro X; 2011</td> <td>Gemcitabine</td> <td>1800 mg/m<sup>2</sup>, given by fixed rate infusion (10 mg/m<sup>2</sup> per minute), day 1</td> <td rowspan=\"2\">Every 2 weeks</td> </tr> <tr> <td>Dacarbazine</td> <td>500 mg/m<sup>2</sup>, day 1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">G-CSF: granulocyte colony-stimulating factor.<br />* With Mesna.<br />&para; With routine G-CSF support.<br />&Delta; Lower doses (gemcitabine 675 mg/m<sup>2</sup>, docetaxel 75 mg/m<sup>2</sup>) administered to previously irradiated patients.</div><div id=\"graphicVersion\">Graphic 80881 Version 6.0</div></div></div>"},"80882":{"type":"graphic_diagnosticimage","displayName":"Craniopharyngioma MRI II","title":"Craniopharyngioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Craniopharyngioma</div><div class=\"cntnt\"><img style=\"width:435px; height:268px;\" src=\"images/ONC/80882_Craniopharyngioma_MRI_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Unenhanced and enhanced magnetic resonance imaging of the brain in a 55 year-old patient with decreased vision on the right due to a craniopharygioma. There is a midline, 2.2 cm, enhancing suprasellar mass bordered anteriorly by the optic chiasm, superiorly by the third ventricle, and posteriorly by the interpenduncular cistern. There is no calcification.</div><div class=\"graphic_reference\">Courtesy of Lawrence Recht, MD.</div><div id=\"graphicVersion\">Graphic 80882 Version 2.0</div></div></div>"},"80883":{"type":"graphic_diagnosticimage","displayName":"Right upper lobe atelectasis A","title":"Right upper lobe atelectasis in an adolescent with asthma","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Right upper lobe atelectasis in an adolescent with asthma</div><div class=\"cntnt\"><img style=\"width:548px; height:370px;\" src=\"images/PEDS/80883_Right_upper_lobe_atelectasi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upright frontal and lateral radiographs in 15-year-old with asthma and respiratory distress. The frontal view demonstrates a vague increase in right lung opacity. The right mediastinal border is indistinct, and the right hilum and diaphragm are elevated. On the lateral view, there is a retrosternal curvilinear shadow with increased opacity anteriorly. This represents marked anterior displacement of the major fissure, indicative of the upper lobe volume loss and right upper lobe atelectasis.</div><div id=\"graphicVersion\">Graphic 80883 Version 3.0</div></div></div>"},"80884":{"type":"graphic_picture","displayName":"Linear IgA bullous dermatosis on face","title":"Linear IgA bullous dermatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Linear IgA bullous dermatosis</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/80884_Line_IgA_bull_derma_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple tense vesicles are present on the face.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 80884 Version 3.0</div></div></div>"},"80885":{"type":"graphic_figure","displayName":"Laryngeal inlet anatomy","title":"Laryngeal inlet anatomy","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Laryngeal inlet anatomy</div><div class=\"cntnt\"><img style=\"width:573px; height:412px;\" src=\"images/EM/80885_Laryngealinletanat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superior view of the laryngeal introitus.</div><div class=\"graphic_reference\">Reproduced with permission from: Orebaugh SL. Airway anatomy. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 80885 Version 10.0</div></div></div>"},"80886":{"type":"graphic_diagnosticimage","displayName":"Pancreatic parenchyma EUS","title":"Pancreatic parenchyma seen on endoscopic ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatic parenchyma seen on endoscopic ultrasound</div><div class=\"cntnt\"><img style=\"width:335px; height:613px;\" src=\"images/GAST/80886_Pancreatic_parenchyma_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radial EUS image showing the pancreatic body anterior to the splenic vein (SV). Top: Note the characteristic coarse, grainy &quot;salt and pepper&quot; appearance of the normal pancreatic parenchyma. Bottom: Simplification of top image.</div><div class=\"graphic_reference\">Courtesy of Lyndon V. Hernandez, MD and Manoop S. Bhutani, MD.</div><div id=\"graphicVersion\">Graphic 80886 Version 3.0</div></div></div>"},"80888":{"type":"graphic_figure","displayName":"Mutations in ALA synthase gene","title":"ALAS2 mutations in X-linked sideroblastic anemia","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">ALAS2 mutations in X-linked sideroblastic anemia</div><div class=\"cntnt\"><img style=\"width:491px; height:459px;\" src=\"images/HEME/80888_Mutations_in_ALA_synth_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The location and codon change of distinct mutations in the erythroid 5-aminolevulinate synthase (ALAS2) gene in patients with X-linked sideroblastic anemia are shown here.<SUP>[1-4]</SUP> Two mutations found in the promoter region (c.-206C&gt;G; c.-91_-44del) and four mutations in intron 1 are not indicated.<SUP>[1-3]</SUP> Approximately one-fifth of the mutations occurred in more than one unrelated proband or family; nearly one-third of the probands are female.</div><div class=\"graphic_footnotes\">IRE: iron responsive element; kb: kilobases.<BR>* K391: pyridoxal 5'-phosphate binding lysine.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Bottomley SS. Sideroblastic anemias. In: Wintrobe's Clinical Hematology, 13th ed, Greer JP, Arber DA, Glader B, et al. (Eds), Lippincott Williams and Wilkins, Philadelphia 2014. p.643. </LI>&#xD;&#xA;<LI>Kaneko K, Furuyama K, Fujiwara T, et al. Identification of the novel erythroid-specific enhancer for ALAS2 gene and its loss-of-function mutation associated with congenital sideroblastic anemia. Haematologica 2014; 99:252.</LI>&#xD;&#xA;<LI>Campagna DR, de Bie CI, Schmitz-Abe K, et al. X-linked sideroblastic anemia due to ALAS2 intron 1 enhancer element GATA binding site mutations. Am J Hematol 2014; 89:315.</LI>&#xD;&#xA;<LI>The Human Gene Mutation Database; HGMD®Professional 2012.2 http://www.hgmd.org (Accessed on August 3, 2012). </LI></OL></div><div id=\"graphicVersion\">Graphic 80888 Version 12.0</div></div></div>"},"80891":{"type":"graphic_table","displayName":"Uricemia production","title":"Causes of hyperuricemia due to increased purine biosynthesis and/or urate production","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hyperuricemia due to increased purine biosynthesis and/or urate production</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Inherited enzyme defects leading to purine overproduction (rare monogenic disorders)</td> </tr> <tr> <td>Hypoxanthine-guanine phosphoribosyltransferase deficiency</td> </tr> <tr> <td>Phosphoribosylpyrophosphate synthetase overactivity</td> </tr> <tr> <td>Glucose-6-phosphatase deficiency (glycogen storage disease, type I)</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical disorders leading to purine and/or urate overproduction</td> </tr> <tr> <td>Myeloproliferative disorders</td> </tr> <tr> <td>Lymphoproliferative disorders</td> </tr> <tr> <td>Malignancies</td> </tr> <tr> <td>Hemolytic disorders</td> </tr> <tr> <td>Psoriasis</td> </tr> <tr> <td>Obesity</td> </tr> <tr> <td>Tissue hypoxia</td> </tr> <tr> <td>Down syndrome</td> </tr> <tr> <td>Glycogen storage diseases (types III, V, VII)</td> </tr> <tr> <td class=\"subtitle1_single\">Drug-, diet-, or toxin-induced purine and/or urate overproduction</td> </tr> <tr> <td>Ethanol</td> </tr> <tr> <td>Excessive dietary purine ingestion</td> </tr> <tr> <td>Pancreatic extract</td> </tr> <tr> <td>Fructose</td> </tr> <tr> <td>Vitamin B12 deficiency</td> </tr> <tr> <td>Nicotinic acid</td> </tr> <tr> <td>Ethylamino-1,3,4-thiadiazole</td> </tr> <tr> <td>4-amino-5-imidazole carboxamide riboside</td> </tr> <tr> <td>Cytotoxic drugs</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80891 Version 3.0</div></div></div>"},"80892":{"type":"graphic_picture","displayName":"Chalazion upper eyelid","title":"Chalazion","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Chalazion</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/80892_Chalazion1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A nodular lesion is present on the upper eyelid.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 80892 Version 3.0</div></div></div>"},"80893":{"type":"graphic_algorithm","displayName":"Diagnosis of gastroparesis","title":"Clinical and basic laboratory tests for gastroparesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clinical and basic laboratory tests for gastroparesis</div><div class=\"cntnt\"><img style=\"width:422px; height:490px;\" src=\"images/GAST/80893_Diagnosis_of_gastroparesis.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 80893 Version 3.0</div></div></div>"},"80894":{"type":"graphic_table","displayName":"ACC AHA HRS HCM","title":"ACC/AHA/HRS: Pacing indications for hypertrophic cardiomyopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA/HRS: Pacing indications for hypertrophic cardiomyopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Class I - There is evidence and/or general agreement that permanent pacing is indicated in patients with hypertrophic cardiomyopathy in the following setting:</td> </tr> <tr> <td class=\"indent1\">&#8226; Class I indications for sinus node dysfunction or AV block as previously described. (Level of Evidence: C)</td> </tr> <tr> <td class=\"subtitle1_single\">Class IIb - The evidence or opinion is less well established that permanent pacing in hypertrophic cardiomyopathy is beneficial in the following setting:</td> </tr> <tr> <td class=\"indent1\">&#8226; Medically refractory, symptomatic patients with significant resting or provoked LV outflow tract obstruction (Level of Evidence: A). As for Class I indications, when risk factors for SCD are present, consider a DDD ICD.</td> </tr> <tr> <td class=\"subtitle1_single\">Class III - There is evidence that permanent pacing in hypertrophic cardiomyopathy is not useful and may be harmful in the following settings:</td> </tr> <tr> <td class=\"indent1\">&#8226; Patients who are asymptomatic or whose symptoms are medically controlled. (Level of Evidence: C)</td> </tr> <tr> <td class=\"indent1\">&#8226; Symptomatic patients without evidence of LV outflow tract obstruction. (Level of Evidence: C)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AV: atrioventricular; LV: left ventricular; SCD: sudden cardiac death; ICD: implantable cardioverter defibrillator.</div><div class=\"graphic_reference\">Adapted from: Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.</div><div id=\"graphicVersion\">Graphic 80894 Version 5.0</div></div></div>"},"80895":{"type":"graphic_figure","displayName":"Pulse oximetry light absorption","title":"Principles of pulse oximetry: light absorption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Principles of pulse oximetry: light absorption</div><div class=\"cntnt\"><img style=\"width:389px; height:223px;\" src=\"images/PULM/80895_Pulse_oximetry_light_absorp.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This schematic diagram illustrates light absorption through living tissue. Note that the AC signal is due to the pulsatile component of arterial blood, while the DC signal is comprised of all the nonpulsatile absorbers in the tissue: nonpulsatile arterial blood, venous and capillary blood, and all other tissues.</div><div class=\"graphic_reference\">Redrawn from Ohmeda Pulse Oximeter Model 3700 Service Manual, 1986, p. 22.</div><div id=\"graphicVersion\">Graphic 80895 Version 2.0</div></div></div>"},"80897":{"type":"graphic_picture","displayName":"Leiomyoma uterus A","title":"Hysterectomy specimen showing multiple leiomyomas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hysterectomy specimen showing multiple leiomyomas</div><div class=\"cntnt\"><img style=\"width:396px; height:350px;\" src=\"images/OBGYN/80897_Leiomyoma_uterus_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Aron Schuftan, MD. Copyright &#169; Aron Schuftan, MD.</div><div id=\"graphicVersion\">Graphic 80897 Version 1.0</div></div></div>"},"80898":{"type":"graphic_table","displayName":"Prophylaxis recurrent UTI","title":"Continuous antimicrobial prophylaxis regimens for women with recurrent urinary tract infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Continuous antimicrobial prophylaxis regimens for women with recurrent urinary tract infection</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Regimens\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Expected UTIs per year\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Trimethoprim-sulfamethoxazole 40 mg/200 mg once daily</td>\r\n  \r\n   <td>0 to 0.2</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Trimethoprim-sulfamethoxazole 40 mg/200 mg thrice wkly</td>\r\n  \r\n   <td>0.1</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Trimethoprim 100 mg once daily</td>\r\n  \r\n   <td>0 to 1.5*</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Nitrofurantoin 50 mg once daily</td>\r\n  \r\n   <td>0 to 0.6</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Nitrofurantoin 100 mg once daily</td>\r\n  \r\n   <td>0 to 0.7</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Cefaclor 250 mg once daily</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Cephalexin 125 mg once daily</td>\r\n  \r\n   <td>0.1</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Cephalexin 250 mg once daily</td>\r\n  \r\n   <td>0.2</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Norfloxacin 200 mg once daily</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ciprofloxacin 125 mg once daily</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">* High recurrence rates observed with trimethoprim associated with trimethoprim-resistance.</div><div id=\"graphicVersion\">Graphic 80898 Version 1.0</div></div></div>"},"80899":{"type":"graphic_table","displayName":"Treatment of visceral leishmaniasis","title":"Treatment of visceral leishmaniasis in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of visceral leishmaniasis in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp; </td> <td class=\"subtitle1\">Preferred therapy and duration </td> <td class=\"subtitle1\">Alternative therapy </td> <td class=\"subtitle1\">Other options/issues </td> </tr> <tr> <td>VL in previously immunocompetent patient</td> <td> <p>Liposomal amphotericin B 3 mg/kg IV on days 1 to 5, 14, and 21 to achieve total dose of 20 mg/kg*</p> </td> <td> <p>Miltefosine 2.5 mg/kg/day&nbsp;orally for 28 days<sup>&#182;</sup></p> </td> <td> <p>Nutritional support, treatment of hemorrhagic or infectious complications</p> <p>Sodium stibogluconate<sup>&#916;</sup> 20 mg/kg IV or IM daily&nbsp;for 28 days or amphotericin B lipid complex injection (optimal regimen not established)</p> </td> </tr> <tr> <td rowspan=\"2\">HIV-VL coinfection </td> <td> <p>Liposomal amphotericin B 4 mg/kg on days 1 to 5, 10, 17, 24, 31, and 38 to achieve total dose of 40 mg/kg</p> </td> <td> <p>Combination of liposomal amphotericin B plus miltefosine (optimal regimen not established)</p> </td> <td> <p>ART should be initiated or optimized</p> <p>Alternative regimens for treatment failure: miltefosine 2.5 mg/kg/day&nbsp;orally&nbsp;for 28 days<sup>&#182;</sup> or<br /> sodium stibogluconate<sup>&#916;</sup> 20 mg/kg IV or IM daily&nbsp;for 28 days&nbsp;or amphotericin B lipid complex injection (optimal regimen not established)</p> </td> </tr> <tr> <td>Secondary prophylaxis: Liposomal amphotericin B 4 mg/kg every&nbsp;two to&nbsp;four weeks</td> <td>Secondary prophylaxis: Sodium stibogluconate<sup>&#916;</sup> 20 mg/kg IV or IM every&nbsp;four weeks</td> <td>Secondary prophylaxis: pentamidine-isethionate 4 mg/kg IV in normal saline every four weeks<sup>&#9674;</sup></td> </tr> <tr> <td>Post kala-azar dermal leishmaniasis (PKDL)</td> <td>Miltefosine 2.5 mg/kg/day&nbsp;orally for 12 weeks<sup>&#182;&#167;</sup></td> <td>Sodium stibogluconate<sup>&#916;</sup> 20 mg/kg/day IV or IM&nbsp; for 30 to 120 days (for courses &#8805;60 days, usually given in 20-day courses with 10-day rest periods)</td> <td>Liposomal amphotericin B (optimal regimen not established but most reports achieved total dose of &#8805;30 mg/kg)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">VL: visceral leishmaniasis; IV: intravenous; IM: intramuscular; ART: antiretroviral therapy.<br />* Total dose of 30 mg/kg may be needed for East African VL.<SUP>[1,2]</SUP> First-line treatment in East Africa consists of sodium stibogluconate 20 mg/kg/day plus parenteral paromomycin 15 mg/kg/day for 17 days;<SUP>[3,4]</SUP> parenteral peromomycin is not available in the United States.&nbsp;<br />¶ For patients ≥12 years, weighing ≥30 kg, not pregnant or breastfeeding.<br />Δ Available from the United States Centers for Disease Control and Prevention (CDC) Division of Parasitic Diseases (contact <FONT class=baec5a81-e4d6-4674-97f3-e9220f0136c1 style=\"WHITE-SPACE: nowrap\">404-718-4745<A title=\"Call: 404-718-4745\" style=\"OVERFLOW: hidden; CURSOR: hand; BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; VERTICAL-ALIGN: middle; WHITE-SPACE: nowrap; RIGHT: 0px; BORDER-BOTTOM: medium none; POSITION: static !important; FLOAT: none; LEFT: 0px; MARGIN: 0px; BORDER-LEFT: medium none; DISPLAY: inline; TOP: 0px; BOTTOM: 0px\" href=\"#\"><IMG title=\"Call: 404-718-4745\" style=\"OVERFLOW: hidden; CURSOR: hand; BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; VERTICAL-ALIGN: middle; WHITE-SPACE: nowrap; RIGHT: 0px; BORDER-BOTTOM: medium none; POSITION: static !important; FLOAT: none; LEFT: 0px; MARGIN: 0px; BORDER-LEFT: medium none; DISPLAY: inline; TOP: 0px; BOTTOM: 0px\" src=\"data:image/png;base64,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\"></A></FONT>; email parasites@cdc.gov), CDC Drug Service (<FONT class=baec5a81-e4d6-4674-97f3-e9220f0136c1 style=\"WHITE-SPACE: nowrap\">404-639-3670<A title=\"Call: 404-639-3670\" style=\"OVERFLOW: hidden; CURSOR: hand; BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; VERTICAL-ALIGN: middle; WHITE-SPACE: nowrap; RIGHT: 0px; BORDER-BOTTOM: medium none; POSITION: static !important; FLOAT: none; LEFT: 0px; MARGIN: 0px; BORDER-LEFT: medium none; DISPLAY: inline; TOP: 0px; BOTTOM: 0px\" href=\"#\"><IMG title=\"Call: 404-639-3670\" style=\"OVERFLOW: hidden; CURSOR: hand; BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; VERTICAL-ALIGN: middle; WHITE-SPACE: nowrap; RIGHT: 0px; BORDER-BOTTOM: medium none; POSITION: static !important; FLOAT: none; LEFT: 0px; MARGIN: 0px; BORDER-LEFT: medium none; DISPLAY: inline; TOP: 0px; BOTTOM: 0px\" src=\"data:image/png;base64,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\"></A></FONT>), or for emergencies outside of business hours, CDC Emergency Operations Center (<FONT class=baec5a81-e4d6-4674-97f3-e9220f0136c1 style=\"WHITE-SPACE: nowrap\">770-488-7100<A title=\"Call: 770-488-7100\" style=\"OVERFLOW: hidden; CURSOR: hand; BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; VERTICAL-ALIGN: middle; WHITE-SPACE: nowrap; RIGHT: 0px; BORDER-BOTTOM: medium none; POSITION: static !important; FLOAT: none; LEFT: 0px; MARGIN: 0px; BORDER-LEFT: medium none; DISPLAY: inline; TOP: 0px; BOTTOM: 0px\" href=\"#\"><IMG title=\"Call: 770-488-7100\" style=\"OVERFLOW: hidden; CURSOR: hand; BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; VERTICAL-ALIGN: middle; WHITE-SPACE: nowrap; RIGHT: 0px; BORDER-BOTTOM: medium none; POSITION: static !important; FLOAT: none; LEFT: 0px; MARGIN: 0px; BORDER-LEFT: medium none; DISPLAY: inline; TOP: 0px; BOTTOM: 0px\" src=\"data:image/png;base64,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\"></A></FONT>).<br />◊ Data for East African VL-HIV coinfection only.<SUP>[5]</SUP><br />§ Stated regimen is first-line treatment for PKDL in the Indian subcontinent; however, increasing failure rates have been reported.<SUP>[6,7]</SUP>&nbsp;Conventional treatment for East African PKDL consists of sodium stibogluconate 20 mg/kg/day for 30 to 60 days, but data suggest sodium stibogluconate (30 mg/kg/day for a minimum of 17 days) plus paromomycin (15 mg sulphate/kg/day for 17 days) may have higher efficacy.<SUP>[8]</SUP>&nbsp;&nbsp;</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Salih NA, van Griensven J, Chappuis F, et al. Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: How effective is treatment for this neglected disease?&nbsp;Trop&nbsp;Med Int Health&nbsp;2014; 19:146.</LI>&#xD;&#xA;<LI>Mueller YK, Kolaczinski JH, Koech T, et al. Clinical epidemiology, diagnosis and treatment of visceral leishmaniasis in the Pokot endemic area of Uganda and Kenya. Am J Med Hyg 2014; 90:33</LI>&#xD;&#xA;<LI>Musa A, Khalil E, Hailu A, et al. Sodium stibogluconate (SSG) &amp; paromomycin combination compared to SSG for visceral leishmaniasis in East Africa:&nbsp;A randomised controlled trial. PLoS Negl Trop Dis 2012; 6:e1674.</LI>&#xD;&#xA;<LI>Sundar S, Singh A. Recent developments and future prospects in the treatment of visceral leishmaniasis. Ther Adv Infect Dis 2016; 3:98. </LI>&#xD;&#xA;<LI>Diro E, Ritmeijer K, Boelaert M, et al. Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients, the first twelve months of a prospective cohort study. PLoS Negl Trop Dis 2015; 9:e0004087.</LI>&#xD;&#xA;<LI>Ramesh V, Singh R, Avishek K, et al. Decline in clinical efficacy of oral miltefosine in treatment of post kala-azar dermal leishmaniasis (PKDL) in India. PLoS Negl Trop Dis 2015; 9:e0004093.</LI>&#xD;&#xA;<LI>Ghosh S, Das NK, Mukherjee S, et al. Inadequacy of 12-Week miltefosine treatment for Indian post-kala-azar dermal leishmaniasis. Am J Trop Med Hyg 2015; 93:767.</LI>&#xD;&#xA;<LI>Abongomera C, Gatluak F, Buyze J, Ritmeijer K. A comparison of the effectiveness of sodium stibogluconate monotherapy to sodium stibogluconate and paromomycin combination for the treatment of severe post kala azar dermal leishmaniasis in South Sudan - A retrospective cohort study. PloS One 2016; 11:e0163047.</LI></OL></div><div id=\"graphicVersion\">Graphic 80899 Version 6.0</div></div></div>"},"80900":{"type":"graphic_picture","displayName":"Vulvar lichen sclerosus with purpura 1","title":"Lichen sclerosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen sclerosus</div><div class=\"cntnt\"><img style=\"width:287px; height:432px;\" src=\"images/OBGYN/80900_LS_purp_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is loss of all vulvar architecture so the vulva is flat. A white plaque of&nbsp;lichen sclerosus&nbsp;surrounds the vulva with areas of purpura and small erosions from scratching.</div><div class=\"graphic_reference\">Reproduced with permission from: F William Danby, MD, FRCPC, FAAD,&nbsp;and Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 80900 Version 8.0</div></div></div>"},"80901":{"type":"graphic_figure","displayName":"J-curve systolic HTN","title":"Lack of true J-shaped curve in systolic pressure","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Lack of true J-shaped curve in systolic pressure</div><div class=\"cntnt\"><img style=\"width:525px; height:449px;\" src=\"images/NEPH/80901_J_curve_systolic_HTN.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Age- and sex-adjusted mortality rates (per 1000 patient-years, bars show the 95 percent confidence intervals) according to achieved systolic pressure in active treatment and control groups in a meta-analysis of seven randomized clinical trials of hypertensive patients. The number of events is shown below each bar. Among treated patients, cardiovascular mortality initially falls at achieved systolic pressures below 180 mmHg and then rises again at low systolic pressures (upper right panel). However, a similar relationship is seen with noncardiovascular mortality (bottom right panel) and in the control groups (left panels). Thus, the increase in mortality at low diastolic pressures probably reflects underlying poor health rather than an adverse effect of antihypertensive therapy.</div><div class=\"graphic_reference\">Data from Boutitie, F, Gueyffier, F, Pocock, S, et al, Ann Intern Med 2002; 136:438.</div><div id=\"graphicVersion\">Graphic 80901 Version 2.0</div></div></div>"},"80902":{"type":"graphic_table","displayName":"Neuro vs vasc claudication","title":"Comparison of symptoms in neurogenic and vascular claudication","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of symptoms in neurogenic and vascular claudication</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Symptoms</td>\n\t\t\t\t\t<td class=\"subtitle1\">Neurogenic</td>\n\t\t\t\t\t<td class=\"subtitle1\">Vascular</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2\">Quality</td>\n\t\t\t\t\t<td class=\"subtitle2\">Pain/numbness/tingling</td>\n\t\t\t\t\t<td class=\"subtitle2\">Cramping/tightness</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Increased with walking</td>\n\t\t\t\t\t<td>Yes</td>\n\t\t\t\t\t<td>Yes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Relieved walking flexed with a cart</td>\n\t\t\t\t\t<td>Yes</td>\n\t\t\t\t\t<td>No</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Relieved standing erect</td>\n\t\t\t\t\t<td>No</td>\n\t\t\t\t\t<td>Yes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Relieved sitting/lying</td>\n\t\t\t\t\t<td>Within minutes</td>\n\t\t\t\t\t<td>Immediate</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Increased walking uphill/upstairs</td>\n\t\t\t\t\t<td>No/less</td>\n\t\t\t\t\t<td>Yes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Increased walking downhill</td>\n\t\t\t\t\t<td>Yes/more</td>\n\t\t\t\t\t<td>Yes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Increased biking/back flexed</td>\n\t\t\t\t\t<td>No</td>\n\t\t\t\t\t<td>Yes</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Increased biking/back extended</td>\n\t\t\t\t\t<td>Yes</td>\n\t\t\t\t\t<td>Yes</td>\n\t\t\t\t</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 80902 Version 1.0</div></div></div>"},"80903":{"type":"graphic_picture","displayName":"ALK gene FISH probe","title":"Fluorescence in situ hybridization (FISH) for ALK gene","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fluorescence in situ hybridization (FISH) for ALK gene</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/ONC/80903_ALK_gene_FISH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluorescence microscopy image using ALK break apart probes of cells from a NSCLC tumor, demonstrating an ALK gene rearrangement. The red and green probes hybridize to regions that flank the highly conserved translocation breakpoint within the ALK gene. Arrow: In the setting of an ALK rearrangement, these probes are separated, and splitting of the red and green signals is observed. In the wild-type intact ALK gene, the closely apposed red and green probes result in a yellow signal.</div><div id=\"graphicVersion\">Graphic 80903 Version 2.0</div></div></div>"},"80906":{"type":"graphic_figure","displayName":"Iron needs during adolescence","title":"Iron needs during adolescence","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Iron needs during adolescence</div><div class=\"cntnt\"><img style=\"width:567px; height:317px;\" src=\"images/PEDS/80906_Iron_needs_during_adolescen.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure on the left is based on a representative boy whose peak adolescent growth is at 13.5 years, near the average in the USA. Iron needs peak sharply during the growth spurt but decline rapidly thereafter. Sexual maturation (progression from Tanner stages 2 to 5) begins about 2 years before peak growth; this signals the period of greatest iron needs. The figure on the right is based on a representative girl whose peak growth is at 11.5 years, near the average in the USA. Although iron needs in girls rise to a maximum during peak growth, they remain high subsequently, since the need to replace menstrual iron loss begins about&nbsp;one&nbsp;year after peak growth.&nbsp;Because of the ongoing iron loss, the total&nbsp;iron requirement during adolescence is higher for girls than for boys.&nbsp;<br />​</div><div class=\"graphic_reference\">Data from Dallman, PR. Changing iron needs from birth through adolescence. In: Nutritional anemias, Fomon, SJ, Zlotkin, S (Ed), Nestle Nutrition Workshop Series, vol 30, Nestec, Ltd. Vevey/Raven Press, Ltd, New York 1992. p. 34.</div><div id=\"graphicVersion\">Graphic 80906 Version 3.0</div></div></div>"},"80908":{"type":"graphic_table","displayName":"Initiating Rx 0 to 4 years","title":"Classifying asthma severity and initiating treatment in children 0 to 4 years of age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classifying asthma severity and initiating treatment in children 0 to 4 years of age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"5\" width=\"18%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\" colspan=\"2\">Components of severity</td> <td class=\"subtitle1\" colspan=\"4\">Classification of asthma severity (0 to 4 years of age)</td> </tr> <tr> <td class=\"subtitle2\" rowspan=\"2\">Intermittent</td> <td class=\"subtitle2\" colspan=\"4\">Persistent</td> </tr> <tr> <td class=\"subtitle3\">Mild</td> <td class=\"subtitle3\">Moderate</td> <td class=\"subtitle3\">Severe</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Impairment</td> <td>Symptoms</td> <td>&#8804;2 days/week</td> <td>&#62;2 days/week but not daily</td> <td>Daily</td> <td>Throughout the day</td> </tr> <tr> <td>Nighttime awakenings</td> <td>0</td> <td>1 to 2 times/month</td> <td>3 to 4 times/month</td> <td>&#62;1 time/week</td> </tr> <tr> <td>Short-acting beta<sub>2 </sub>agonist use for symptom control (not prevention of EIB)</td> <td>&#8804;2 days/week</td> <td>&#62;2 days/week but not daily</td> <td>Daily</td> <td>Several times per day</td> </tr> <tr class=\"divider_bottom\"> <td>Interference with normal activity</td> <td>None</td> <td>Minor limitation</td> <td>Some limitation</td> <td>Extremely limited</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Risk</td> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Exacerbations requiring oral systemic glucocorticoids</strong></td> <td><strong>0 to 1/year</strong></td> <td colspan=\"3\"><strong>&#8805;2 exacerbations in six months requiring oral systemic glucocorticoids, or &#8805;4 wheezing episodes/one year lasting &#62;1 day AND risk factors for persistent asthma</strong></td> </tr> <tr> <td colspan=\"4\"><strong>Consider severity and interval since last exacerbation</strong></td> </tr> <tr> <td colspan=\"4\"><strong>Frequency and severity may fluctuate over time</strong></td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Exacerbations of any severity may occur in patients in any severity category</strong></td> </tr> <tr> <td rowspan=\"2\" colspan=\"2\">Recommended step for initiating treatment</td> <td>Step 1</td> <td>Step 2</td> <td colspan=\"2\">Step 3 and consider short course of oral systemic glucocorticoids</td> </tr> <tr> <td colspan=\"4\">In two to six weeks, depending on severity, evaluate level of asthma control that is achieved. If no clear benefit is observed in four to six weeks, consider adjusting therapy or alternative diagnoses.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>Assessing severity and initiating therapy in children who are not currently taking long-term control medication.</strong> The stepwise approach is meant to assist, not replace, the clinical decision-making required to meet individual patient needs. Level of severity is determined by both impairment and risk. Assess impairment domain by patient's/caregiver's recall of previous two to four weeks. Symptom assessment for longer periods should reflect a global assessment, such as inquiring whether the patient's asthma is better or worse since the last visit. Assign severity to the most severe category in which any feature occurs. At present, data are inadequate to correlate frequencies of exacerbations with different levels of asthma severity. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic glucocorticoids in the past six months, or &ge;4 wheezing episodes in the past year, and who have risk factors for persistent asthma may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.</div><div class=\"graphic_footnotes\">EIB: exercise-induced bronchospasm.</div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 80908 Version 8.0</div></div></div>"},"80911":{"type":"graphic_figure","displayName":"Mechanisms of CVT","title":"Mechanisms of cerebral venous thrombosis","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Mechanisms of cerebral venous thrombosis</div><div class=\"cntnt\"><img style=\"width:467px; height:486px;\" src=\"images/NEURO/80911_Mechanisms_of_CVT.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid.</div><div id=\"graphicVersion\">Graphic 80911 Version 3.0</div></div></div>"},"80912":{"type":"graphic_table","displayName":"BRCA2 mutations male breast CA","title":"BRCA2 mutations in male breast cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">BRCA2 mutations in male breast cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Author; year</td> <td class=\"subtitle1\">Men tested</td> <td class=\"subtitle1\">Men with BRCA2 mutations</td> <td class=\"subtitle1\">Percent of men with BRCA2 mutations</td> <td class=\"subtitle1\">Percent of men with positive family history</td> </tr> <tr> <td>Couch, FJ; 1996</td> <td>50</td> <td>7</td> <td>14</td> <td>80</td> </tr> <tr> <td>Thorlacius, S; 1996</td> <td>30</td> <td>12</td> <td>40</td> <td>25</td> </tr> <tr> <td>Friedman, LS; 1997</td> <td>54</td> <td>2</td> <td>4</td> <td>17</td> </tr> <tr> <td>Mavraki, E; 1997</td> <td>28</td> <td>3</td> <td>11</td> <td>36</td> </tr> <tr> <td>Haraldsson, K; 1998</td> <td>34</td> <td>7</td> <td>21</td> <td>13</td> </tr> <tr> <td>Csokay, B; 1999</td> <td>18</td> <td>6</td> <td>33</td> <td>0</td> </tr> <tr> <td>Diez, O; 2000</td> <td>17</td> <td>3</td> <td>18</td> <td>53</td> </tr> <tr> <td>Sverdlov, R; 2000</td> <td>31</td> <td>1</td> <td>3</td> <td>35</td> </tr> <tr> <td>Kwiatkowska, E; 2001</td> <td>37</td> <td>4</td> <td>11</td> <td>13</td> </tr> <tr> <td>Basham, V; 2002</td> <td>94</td> <td>3</td> <td>8</td> <td>20</td> </tr> <tr> <td>Frank, TS; 2002</td> <td>76</td> <td>14</td> <td>18</td> <td>36</td> </tr> <tr> <td>Ottini, L; 2003</td> <td>25</td> <td>4</td> <td>16</td> <td>28</td> </tr> <tr> <td>Ding, Y; 2011</td> <td>115</td> <td>18</td> <td>16</td> <td>22</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80912 Version 3.0</div></div></div>"},"80913":{"type":"graphic_table","displayName":"Recommended nutritional supplementation after bariatric surgery","title":"Recommended nutritional supplementation after bariatric surgery in adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended nutritional supplementation after bariatric surgery in adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Gastric bypass</td> </tr> <tr> <td>Standard multivitamin with folate and iron, or prenatal vitamin if female*</td> </tr> <tr> <td>Vitamin B12 500 micrograms orally daily, or 1000 micrograms intramuscularly monthly</td> </tr> <tr> <td>Calcium 1200 mg to 1500 mg daily with 800 units vitamin D<sup>&#182;</sup></td> </tr> <tr> <td>Supplemental iron if iron deficient*</td> </tr> <tr> <td class=\"subtitle1_single\">Adjustable banding</td> </tr> <tr> <td>Standard multivitamin with folate and iron* or prenatal vitamin if female*</td> </tr> <tr> <td>Vitamin B12, iron, calcium with vitamin D as indicated clinically</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Additional iron and folate may be necessary in pregnant females.<br />¶ Calcium citrate may be better absorbed.</div><div id=\"graphicVersion\">Graphic 80913 Version 6.0</div></div></div>"},"80915":{"type":"graphic_diagnosticimage","displayName":"Acromioclavicular injury Type IV","title":"Acromioclavicular injury Type IV","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acromioclavicular injury Type IV</div><div class=\"cntnt\"><img style=\"width:289px; height:515px;\" src=\"images/EM/80915_AC_type_IV_XR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Type IV AC injuries are uncommon and involve forceful posterior displacement of the distal clavicle (arrow) from the acromion (arrowhead). The injury and posterior displacement are easier to see on this axillary view. The humeral head and glenoid are in normal anatomic position.</div><div class=\"graphic_footnotes\">AC: acromioclavicular.</div><div class=\"graphic_reference\">Courtesy of Scott M Koehler, MD.</div><div id=\"graphicVersion\">Graphic 80915 Version 4.0</div></div></div>"},"80916":{"type":"graphic_figure","displayName":"Carcinogenesis in Barretts","title":"Carcinogenesis in Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Carcinogenesis in Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:251px; height:251px;\" src=\"images/GAST/80916_Carcinogenesis_in_Barretts.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 80916 Version 1.0</div></div></div>"},"80921":{"type":"graphic_algorithm","displayName":"Management corneal abrasions","title":"Management of corneal abrasions*","html":"<div class=\"graphic\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Management of corneal abrasions*</div><div class=\"cntnt\"><img style=\"width:704px; height:615px;\" src=\"images/PC/80921_Mgmt_corneal_abrasions.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Refer to UpToDate topics on corneal abrasion.</div><div id=\"graphicVersion\">Graphic 80921 Version 5.0</div></div></div>"},"80922":{"type":"graphic_figure","displayName":"Partial mainstem bronchial obs","title":"Partially occluded right mainstem bronchus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Partially occluded right mainstem bronchus</div><div class=\"cntnt\"><img style=\"width:193px; height:149px;\" src=\"images/PULM/80922_Partial_mainstem_bronchial.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Maximal expiratory and inspiratory flow-volume loops before (green, 6mm) and after (blue, 9mm) laser treatment in a patient with a right mainstem bronchial obstruction in addition to complete obstruction of the left mainstem bronchus. The diameter of the orifice at the site of maximal obstruction of the mainstem bronchus both before and after treatment is shown in relation to the corresponding flow-volume loop. Note the relatively parallel rightward shift of the descending limb of the maximal expiratory flow-volume curve after treatment.</div><div id=\"graphicVersion\">Graphic 80922 Version 1.0</div></div></div>"},"80925":{"type":"graphic_figure","displayName":"Termination of Rx in RA","title":"Frequent termination of therapy in rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Frequent termination of therapy in rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:446px; height:412px;\" src=\"images/RHEUM/80925_Termination_of_Rx_in_RA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative termination incidence of therapy with gold, penicillamine, or sulphasalazine in patients with rheumatoid arthritis. Ninety-two percent of patients were no longer taking gold after five years, and the median time to treatment termination was six to seven months. Similar findings were seen with the other two drugs.</div><div class=\"graphic_reference\">Data from Situnayake, RD, Grindulis, KA, McConkey, B, Ann Rheum Dis 1987; 46:177.</div><div id=\"graphicVersion\">Graphic 80925 Version 1.0</div></div></div>"},"80926":{"type":"graphic_figure","displayName":"Thrombocytopenia","title":"Thrombocytopenia","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Thrombocytopenia</div><div class=\"cntnt\"><img style=\"width:593px; height:273px;\" src=\"images/SURG/80926_Thrombocytopenia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Citrated rapid-TEG reflecting thrombocytopenia.The red line is a normal tracing.<br> This study shows a normal ACT, R time, K time, and LY30; low alpha angle, MA, and G, reflecting platelet hypocoagulability.</div><div class=\"graphic_footnotes\">R (reaction time): time from sample placement or activation until the tracing amplitude reaches 2 mm; K (clot formation time): time elapsed between the R-time and the point where the tracing amplitude reaches 20 mm; alpha angle: angle between the middle line of the tracing and a tangential line to the developing &quot;body&quot; of the tracing; MA (maximal amplitude): the maximal amplitude reached after clot initiation; G: a calculated measure of total clot strength based on amplitude; LY30: the amount of clot lysis detected 30 minutes after the maximal amplitute (MA) is reached; SP (split point): time from sample placement (or activation with an exogenous procoagulant) until the earliest detectable resistance.</div><div id=\"graphicVersion\">Graphic 80926 Version 3.0</div></div></div>"},"80928":{"type":"graphic_figure","displayName":"Basic decision tree","title":"Decision tree","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Decision tree</div><div class=\"cntnt\"><img style=\"width:266px; height:220px;\" src=\"images/PC/80928_Basic_decision_tree.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A decision tree starts with a decision node (square), which represents the decision to be made, followed by chance nodes (circles), which represent the possible events given the choices. Each outcome is associated with a probability (p<sub>1</sub> through p<sub>4</sub>) that represents its likelihood of occurring. Each branch eventually ends in a terminal node or outcome (boxes) representing the value of that outcome.</div><div id=\"graphicVersion\">Graphic 80928 Version 1.0</div></div></div>"},"80931":{"type":"graphic_table","displayName":"Rush VIT - Three-day protocol","title":"Three-day rush schedule for Hymenoptera venom immunotherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Three-day rush schedule for Hymenoptera venom immunotherapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Day</td> <td class=\"subtitle1\">Volume (mL)</td> <td class=\"subtitle1\">Concentration (micrograms/mL)</td> <td class=\"subtitle1\">Dose (micrograms)</td> </tr> <tr> <td>1</td> <td>0.05</td> <td>1</td> <td>0.05</td> </tr> <tr> <td>1</td> <td>0.1</td> <td>1</td> <td>0.1</td> </tr> <tr> <td>1</td> <td>0.2</td> <td>1</td> <td>0.2</td> </tr> <tr> <td>1</td> <td>0.4</td> <td>1</td> <td>0.4</td> </tr> <tr> <td>1</td> <td>0.8</td> <td>1</td> <td>0.8</td> </tr> <tr> <td>1</td> <td>0.2</td> <td>10</td> <td>2</td> </tr> <tr> <td>1</td> <td>0.5</td> <td>10</td> <td>5</td> </tr> <tr> <td>1</td> <td>1</td> <td>10</td> <td>10</td> </tr> <tr> <td>1</td> <td>0.2</td> <td>100</td> <td>20</td> </tr> <tr> <td>1</td> <td>0.2</td> <td>100</td> <td>20</td> </tr> <tr> <td>2</td> <td>0.2</td> <td>100</td> <td>20</td> </tr> <tr> <td>2</td> <td>0.3</td> <td>100</td> <td>30</td> </tr> <tr> <td>2</td> <td>0.5</td> <td>100</td> <td>50</td> </tr> <tr> <td>3</td> <td>1</td> <td>100</td> <td>100</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">1</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=88683&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">The time interval between doses on days&nbsp;1 and&nbsp;2 is 15 minutes. Once the maintenance dose of 100 micrograms is reached, it is then given at one-week intervals for two doses, then two-week intervals for two doses, then three-week intervals for two doses, and then monthly thereafter.</div><div class=\"graphic_reference\">Reproduced from: Goldberg A, Confino-Cohen R. Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy. Ann Allergy Asthma Immunol 2003; 91:405. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 80931 Version 9.0</div></div></div>"},"80932":{"type":"graphic_table","displayName":"Anticoagulant trials AF","title":"Trials of warfarin versus newer anticoagulants in AF*<sup>¶</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Trials of warfarin versus newer anticoagulants in AF*<sup>&para;</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"7\">Baseline characteristics</td> </tr> <tr> <td class=\"subtitle2\">Study drug and dose</td> <td class=\"subtitle2\">Mean CHADS<sub>2</sub> score</td> <td class=\"subtitle2\">Percent on aspirin</td> <td class=\"subtitle2\" colspan=\"2\">Primary outcome</td> <td class=\"subtitle2\" colspan=\"2\">Major bleeding definition</td> </tr> <tr class=\"divider_bottom\"> <td><strong>RE-LY</strong></td> <td>Dabigatran<br /> 110 mg twice per day<br /> 150 mg twice per day</td> <td>2.1</td> <td>40</td> <td colspan=\"2\">All stroke and systemic embolism</td> <td colspan=\"2\">Reduction in hemoglobin of at least 2 g/dL [20 g/L] or symptomatic bleeding in critical organ</td> </tr> <tr class=\"divider_bottom\"> <td><strong>ROCKET-AF</strong></td> <td>Rivaroxaban<br /> 20 mg once per day<sup>&#916;</sup></td> <td>3.5</td> <td>36</td> <td colspan=\"2\">All stroke and systemic embolism</td> <td colspan=\"2\">Major and non-major clinically relevant bleeding</td> </tr> <tr class=\"divider_bottom\"> <td><strong>ARISTOTLE</strong></td> <td>Apixaban<br /> 5 mg twice per day<sup>&#9674;</sup></td> <td>2.1</td> <td>31</td> <td colspan=\"2\">All stroke and systemic embolism</td> <td colspan=\"2\">Overt bleeding plus fall in hemoglobin of at least 2 g/dL [20 g/L] or transfusion of 2 units of packed red blood cells, occurring at a critical site, or resulting in death</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist_other\" colspan=\"8\">&nbsp;</td> </tr> <tr> <td class=\"subtitle1\" rowspan=\"2\" colspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"6\">Outcome event rates (percent/yr)<br /> (new agent/warfarin)</td> </tr> <tr> <td class=\"subtitle2\">Primary outcome</td> <td class=\"subtitle2\">Major bleeding</td> <td class=\"subtitle2\">Death</td> <td class=\"subtitle2\">Stroke (all)</td> <td class=\"subtitle2\">Stroke (hemorrhagic)</td> <td class=\"subtitle2\">Percent time in INR range</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>RE-LY</strong></td> <td>110 mg</td> <td>1.53/1.69 (A)</td> <td>2.71/3.36 (C)</td> <td>3.75/4.13</td> <td>1.44/1.57</td> <td>0.12/0.38 (C)</td> <td>64</td> </tr> <tr class=\"divider_bottom\"> <td>150 mg</td> <td>1.11/1.69 (B)</td> <td>3.11/3.36</td> <td>3.64/4.13</td> <td>1.01/1.57 (C)</td> <td>0.10/0.38 (C)</td> <td>64</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>ROCKET-AF</strong></td> <td>As treated analysis</td> <td>1.70/2.20 (A)</td> <td>3.60/3.40</td> <td>1.90/2.20</td> <td>2.61/3.12</td> <td>0.50/0.70 (C)</td> <td>55</td> </tr> <tr class=\"divider_bottom\"> <td>Intention to treat analysis</td> <td>2.10/2.40 (A)</td> <td>---</td> <td>4.50/4.90</td> <td>---</td> <td>---</td> <td>---</td> </tr> <tr> <td colspan=\"2\"><strong>ARISTOTLE</strong></td> <td>1.27/1.60 (B)</td> <td>2.13/3.09 (B)</td> <td>3.52/3.94 (B)</td> <td>1.19/1.51</td> <td>0.24/0.47 (C)</td> <td>62</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CHADS<sub>2</sub>: estimate of stroke risk; (A): statistically significant for noninferiority; (B): statistically significant for superiority; (C): statistically significant.<br />* Target INR 2.0 to 3.0 in each study.<br />&para; Mean follow-up of approximately two years in each study.<br />&Delta; Dose of rivaroxaban adjusted to 15 mg per day for renal insufficiency (creatinine clearance 30 to 49 mL/minute [0.5 to 0.82 mL/second]).<br /><span class=\"lozenge\">&loz;</span> Dose of apixaban adjusted to 2.5 mg twice per day with two or more of: age &ge;80 years, body weight &le;60 kg, or renal insufficiency (serum creatinine level &ge;1.5 mg/dL [133 &micro;mol/L]).</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Connolly SJ, Ezekowitz MD, Eikelbloom YS, et al. Dabigatran versus warfarin in patients with atrial fibrillation; N Engl J Med 2009; 361:1139. </li>&#xD;&#xA;    <li>Patel MR, Mahaffey KE, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation; N Engl J Med 2011; 365:883. </li>&#xD;&#xA;    <li>Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation; N Engl J Med 2011; 365:981. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 80932 Version 12.0</div></div></div>"},"80934":{"type":"graphic_table","displayName":"Medical hx chronic diarrhea","title":"Implications of some aspects of the medical history in patients with chronic diarrhea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Implications of some aspects of the medical history in patients with chronic diarrhea</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Line of questioning</td> <td class=\"subtitle1\">Clinical implication</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Onset</td> </tr> <tr> <td class=\"sublist1\">Congenital</td> <td class=\"sublist_other\">Chloridorrhea, Na+ malabsorption</td> </tr> <tr> <td class=\"sublist1\">Abrupt</td> <td class=\"sublist_other\">Infections, idiopathic secretory diarrhea</td> </tr> <tr> <td class=\"sublist1\">Gradual</td> <td class=\"sublist_other\">Everything else</td> </tr> <tr> <td>Family history</td> <td>Congenital absorptive defects, IBD, celiac disease, multiple endocrine neoplasia</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Dietary history</td> </tr> <tr> <td class=\"sublist1\">\"Sugar-free\" foods</td> <td class=\"sublist_other\">Sorbitol, mannitol ingestion</td> </tr> <tr> <td class=\"sublist1\">Raw milk</td> <td class=\"sublist_other\">Brainerd diarrhea</td> </tr> <tr> <td>Exposure to potentially impure water source</td> <td>Chronic bacterial infections (eg, Aeromonas), giardiasis, cryptosporidiosis, Brainerd diarrhea</td> </tr> <tr> <td>Travel history</td> <td>Infectious diarrhea, chronic idiopathic secretory diarrhea</td> </tr> <tr> <td>Weight loss</td> <td>Malabsorption, pancreatic exocrine insufficiency, neoplasm, anorexia</td> </tr> <tr> <td>Previous therapeutic interventions (drugs, radiation, surgery, antibiotics)</td> <td>Drug side effects, radiation enteritis, postsurgical status, pseudomembranous colitis, post-cholecystectomy diarrhea</td> </tr> <tr> <td>Secondary gain from illness</td> <td>Laxative abuse</td> </tr> <tr> <td>Systemic illness symptoms</td> <td>Hyperthyroidism, diabetes, vasculitis tumors, Whipple's disease, inflammatory bowel syndrome, tuberculosis, mastocytosis</td> </tr> <tr> <td>Intravenous drug abuse, sexual promiscuity</td> <td>AIDS</td> </tr> <tr> <td>Immune problems</td> <td>AIDS, immunoglobulin deficiencies</td> </tr> <tr> <td>Abdominal pain</td> <td>Mesenteric vascular insufficiency, obstruction, irritable bowel syndrome</td> </tr> <tr> <td>Excessive flatus</td> <td>Carbohydrate malabsorption</td> </tr> <tr> <td>Leakage of stool</td> <td>Fecal incontinence</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Stool characteristics</td> </tr> <tr> <td class=\"sublist1\">Blood</td> <td class=\"sublist_other\">Malignancy, inflammatory bowel disease</td> </tr> <tr> <td class=\"sublist1\">Oil/food particles</td> <td class=\"sublist_other\">Malabsorption, maldigestion</td> </tr> <tr> <td class=\"sublist1\">White/tan color</td> <td class=\"sublist_other\">Celiac disease, absence of bile</td> </tr> <tr> <td class=\"sublist1\">Nocturnal diarrhea</td> <td class=\"sublist_other\">Organic etiology</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">6</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=19727&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Reprinted with permission from: Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999; 116:1464.</div><div id=\"graphicVersion\">Graphic 80934 Version 3.0</div></div></div>"},"80937":{"type":"graphic_figure","displayName":"Classification of biliary cysts","title":"Classification of biliary cysts according to Todani and colleagues","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Classification of biliary cysts according to Todani and colleagues</div><div class=\"cntnt\"><img style=\"width:405px; height:307px;\" src=\"images/GAST/80937_Classification_chole_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(IA) common type; (IB) segmental dilatation; (IC) diffuse dilatation; (II) diverticulum; (III) choledochocele; (IVA) multiple cysts (intra- and extrahepatic); (IVB) multiple cysts (extrahepatic); (V) single or multiple dilatations of the intrahepatic ducts.</div><div class=\"graphic_reference\">From: Savader SJ, Benenati JF, Venbrux AC, et al. Choledochal cysts: Classification and cholangiographic appearance.&nbsp;Am J Roentgenol 1991; 156:327. Reprinted with permission from the American Journal of Roentgenology.</div><div id=\"graphicVersion\">Graphic 80937 Version 13.0</div></div></div>"},"80939":{"type":"graphic_waveform","displayName":"RNS pre and post exercise normal subject","title":"Repetitive nerve stimulation pre and post exercise in a normal subject","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Repetitive nerve stimulation pre and post exercise in a normal subject</div><div class=\"cntnt\"><img style=\"width:456px; height:681px;\" src=\"images/NEURO/80939_RNS_pre_post_ex_norm_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Repetitive nerve stimulation (3 Hz) before and after exercise in a normal subject.<BR>(A) Baseline before exercise.<BR>(B) 30 seconds after 1 minute of isometric exercise.<BR>(C) Two minutes after exercise.<BR>(D) Three minutes after exercise.<BR>(E) Four minutes after exercise.</div><div class=\"graphic_reference\">Courtesy of David Weinberg, MD.</div><div id=\"graphicVersion\">Graphic 80939 Version 2.0</div></div></div>"},"80944":{"type":"graphic_picture","displayName":"Biopsy in advanced RPC","title":"Biopsy in advanced relapsing polychondritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Biopsy in advanced relapsing polychondritis</div><div class=\"cntnt\"><img style=\"width:360px; height:243px;\" src=\"images/RHEUM/80944_Biopsy_in_advanced_RPC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Biopsy in advanced relapsing polychondritis showing chronic inflammation with granulation tissue invading and destroying cartilage.</div><div class=\"graphic_reference\">Courtesy of Jerome H Herman, MD.</div><div id=\"graphicVersion\">Graphic 80944 Version 1.0</div></div></div>"},"80945":{"type":"graphic_figure","displayName":"Fasting and postprandial gastrointestinal motility","title":"Fasting and postprandial gastrointestinal motility","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Fasting and postprandial gastrointestinal motility</div><div class=\"cntnt\"><img style=\"width:453px; height:257px;\" src=\"images/GAST/80945_Postprandial_GI_motility.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gastroduodenal manometry shows the normal interdigestive motor complex (left panel), in contrast to the irregular persistent phasic pressure activity seen postprandially (right panel).</div><div class=\"graphic_reference\">Reproduced from: Manometric Diagnosis of Gastrointestinal Motility Disorders, Malagelada JR, Camilleri M, Stanghellini M (Eds), Thieme Inc, New York 1986.</div><div id=\"graphicVersion\">Graphic 80945 Version 3.0</div></div></div>"},"80946":{"type":"graphic_picture","displayName":"Ligasure division","title":"LigaSure™ division","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">LigaSure&#8482; division</div><div class=\"cntnt\"><img style=\"width:412px; height:314px;\" src=\"images/SURG/80946_Ligasure_division.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ileocolic artery after division with LigaSure&#8482; device.</div><div class=\"graphic_reference\">Courtesy of Jon Gould, MD.</div><div id=\"graphicVersion\">Graphic 80946 Version 3.0</div></div></div>"},"80947":{"type":"graphic_diagnosticimage","displayName":"VSD gradient CW Doppler","title":"VSD gradient CW Doppler","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">VSD gradient CW Doppler</div><div class=\"cntnt\"><img style=\"width:572px; height:431px;\" src=\"images/CARD/80947_VSD_gradient_CW_Doppler_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Echocardiographic still frame demonstrating the Doppler determination of pressure gradient across a membranous ventricular septal defect (VSD). The dotted cursor line denotes the angle of the continuous wave Doppler beam used to obtain the velocity across the ventricular septal defect. The velocity (v) is 3.6 m/sec and based upon the modified Bernoulli equation (pressure = 4 [v]<sup>2</sup>), and the gradient between the left and right ventricles is 53 mmHg. Note that this envelope is m-shaped, and the use of a mean or end systolic gradient may be more appropriate in this patient.</div><div id=\"graphicVersion\">Graphic 80947 Version 6.0</div></div></div>"},"80948":{"type":"graphic_table","displayName":"Personnel and facility requirements","title":"ACCF/AHA/SCAI expert consensus document personnel and facility requirements for PCI","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACCF/AHA/SCAI expert consensus document personnel and facility requirements for PCI</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Experienced nursing and technical laboratory staff with training in interventional laboratories. Personnel must be comfortable treating acutely ill patients with hemodynamic and electrical instability.</td> </tr> <tr> <td>On-call schedule with operation of laboratory 24 h/d, 365 d/y*</td> </tr> <tr> <td>Experienced coronary care unit nursing staff comfortable with invasive hemodynamic monitoring, operation of temporary pacemaker, and management of IABP. Personnel capable of endotracheal intubation and ventilator management both on-site and during transfer if necessary.</td> </tr> <tr> <td>Full support from hospital administration in fulfilling the necessary institutional requirements, including appropriate support services (eg, respiratory care, blood bank)</td> </tr> <tr> <td>Written agreements for emergency transfer of patients to a facility with cardiac surgery. Transport protocols should be developed and tested a minimum of&nbsp;two times per year.</td> </tr> <tr> <td>Well-equipped and maintained cardiac catheterization laboratory with high-resolution digital imaging capability and IABP equipment compatible with transport vehicles. The capability for real-time transfer of images and hemodynamic data (via T-1 transmission line) as well as audio and video images to review terminals for consultation at the facility providing surgical backup support is ideal.</td> </tr> <tr> <td>Appropriate inventory of interventional equipment, including guide catheters, balloons, and stents in multiple sizes; thrombectomy and distal protection devices; covered stents; temporary pacemakers; and pericardiocentesis trays. Pressure wire device and IVUS equipment are optimal but not mandatory. Rotational or other atherectomy devices should be used cautiously in these facilities because of the greater risk of perforation.</td> </tr> <tr> <td>Meticulous clinical and angiographic selection criteria for PCI</td> </tr> <tr> <td>Performance of primary PCI as the treatment of first choice for STEMI to ensure streamlined care paths and increased case volumes. Door-to-balloon times should be tracked, and &#60;90 min outlier cases should be carefully reviewed for process improvement opportunities.</td> </tr> <tr> <td>On-site rigorous data collection, outcomes analysis, benchmarking, quality improvement, and formalized periodic case review</td> </tr> <tr> <td>Participation in a national data registry where available, such as the ACC NCDR in the United States</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACC: American College of Cardiology; IABP: intra-aortic balloon pump; IVUS: intravascular ultrasound; NCDR: National Cardiovascular Data Registry; PCI: percutaneous coronary intervention; SCAI: Society for Cardiovascular Angiography and Interventions; STEMI: ST-elevation myocardial infarction.<br> * Required for US facilities but may not be possible for all facilities worldwide.</div><div class=\"graphic_reference\">From: Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58:e44. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 80948 Version 1.0</div></div></div>"},"80949":{"type":"graphic_picture","displayName":"CJD pathology low power","title":"Low power photomicrograph of classic CJD showing fine vacuolation distributed throughout the cortical gray matter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Low power photomicrograph of classic CJD showing fine vacuolation distributed throughout the cortical gray matter</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/NEURO/80949_Classic_CJD_low_power.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Henry G Brown, MD, PhD.</div><div id=\"graphicVersion\">Graphic 80949 Version 2.0</div></div></div>"},"80952":{"type":"graphic_picture","displayName":"Pseudoxanthoma elasticum neck 1","title":"Pseudoxanthoma elasticum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudoxanthoma elasticum</div><div class=\"cntnt\"><img style=\"width:370px; height:504px;\" src=\"images/DERM/80952_PXE_neck_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This woman with pseudoxanthoma elasticum has numerous yellow asymptomatic papules on her neck and upper chest.</div><div class=\"graphic_reference\">Copyright © Yahia Albaili, DO, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 80952 Version 7.0</div></div></div>"},"80955":{"type":"graphic_picture","displayName":"Nodular melanoma","title":"Nodular melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nodular melanoma</div><div class=\"cntnt\"><img style=\"width:288px; height:193px;\" src=\"images/PC/80955_Nodular_melanoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodular melanomas present a discrete nodule, usually with dark pigmentation, although they may be amelanotic, as depicted above.</div><div class=\"graphic_reference\">Courtesy of James C Shaw, MD.</div><div id=\"graphicVersion\">Graphic 80955 Version 5.0</div></div></div>"},"80958":{"type":"graphic_table","displayName":"Predictors shunt outcome","title":"Predictors of improvement after shunting for normal pressure hydrocephalus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predictors of improvement after shunting for normal pressure hydrocephalus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Favorable indicators*</td> </tr> <tr> <td class=\"indent1\">Early appearance of gait disorder</td> </tr> <tr> <td class=\"indent1\">Gait disorder most prominent symptom</td> </tr> <tr> <td class=\"indent1\">Shorter duration of symptoms (&#60;6 months)</td> </tr> <tr> <td class=\"indent1\">Identified etiology of NPH</td> </tr> <tr> <td class=\"sublist2_start\">Clinical response to CSF removal (tap test, lumbar drain)</td> </tr> <tr> <td class=\"subtitle1_single\">Unfavorable indicators*</td> </tr> <tr> <td class=\"indent1\">Early appearance of dementia</td> </tr> <tr> <td class=\"indent1\">Moderate to severe dementia</td> </tr> <tr> <td class=\"indent1\">Dementia present for more than two years</td> </tr> <tr> <td class=\"indent1\">Gait disorder absent or appearing after dementia</td> </tr> <tr> <td class=\"indent1\">Alcoholism</td> </tr> <tr> <td class=\"sublist2_start\">MRI findings:</td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Marked white matter disease </li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Diffuse sulcal enlargement </li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Medial temporal atrophy </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NPH: normal pressure hydrocephalus; CSF: cerebrospinal fluid; MRI: magnetic resonance imaging.<br />* Any one factor is not decisive in selecting patients for surgery.</div><div id=\"graphicVersion\">Graphic 80958 Version 4.0</div></div></div>"},"80960":{"type":"graphic_figure","displayName":"Chest tube suction","title":"Chest tube drainage system","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Chest tube drainage system</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/SURG/80960_Chesttubesuction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three functional chambers are generally a part of most chest tube collection devices. From right to left, the first chamber (ie, collection chamber, depicted with three subsections) accepts air and fluid from the patient via the chest tube; the fluid accumulates in this chamber. The air rises and enters the second chamber (ie, water seal chamber), which contains water at the bottom. Air from the patient enters this chamber below the water level, bubbling through the water seal and&nbsp;preventing return of air to the patient. The air enters the third chamber (ie, suction chamber) connected to wall suction and is discharged through the hospital collection system. The height of water in the suction chamber indicates the amount of suction applied. Suction pressures are typically between -10 and -40 mmHg. An atmospheric vent prevents the application of excessive suction; manual venting through a pressure relief valve rapidly equilibrates the collection chamber with atmospheric pressure. Modern devices vary in appearance, method of suction regulation, and volume of the fluid collection chambers; this basic design in common to most. </div><div id=\"graphicVersion\">Graphic 80960 Version 3.0</div></div></div>"},"80961":{"type":"graphic_picture","displayName":"Cytokeratin stain Merkel cell","title":"Immunohistochemistry of Merkel cell skin cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Immunohistochemistry of Merkel cell skin cancer</div><div class=\"cntnt\"><img style=\"width:400px; height:255px;\" src=\"images/ONC/80961_Cytokeratin_stain_Merkel_ce.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power photomicrograph of a hematoxylin and eosin-stained section of a skin biopsy, immunostained for cytokeratin expression (CK 20). CK 20-positive cells have conspicious brown-stained paranuclear dots.</div><div class=\"graphic_reference\">Reproduced with permission from: Mosby-Wolfe, Times Mirror International Medical Publishers, from: McKee PH, Pathology of the skin, 2nd ed, 1996. Copyright © 1996 Harcourt Publishers Ltd.</div><div id=\"graphicVersion\">Graphic 80961 Version 3.0</div></div></div>"},"80966":{"type":"graphic_table","displayName":"Diff dx headache with fever","title":"Differential diagnosis of headache with fever","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of headache with fever</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Intracranial infection</td> </tr> <tr> <td class=\"sublist1_start\">Meningitis</td> </tr> <tr> <td class=\"sublist1\">Bacterial</td> </tr> <tr> <td class=\"sublist1\">Fungal</td> </tr> <tr> <td class=\"sublist1\">Viral</td> </tr> <tr> <td class=\"sublist1\">Lymphocytic</td> </tr> <tr> <td>Encephalitis</td> </tr> <tr> <td>Brain abscess</td> </tr> <tr> <td>Subdural empyema</td> </tr> <tr> <td class=\"subtitle1_single\">Systemic infection</td> </tr> <tr> <td>Bacterial infection</td> </tr> <tr> <td>Viral infection</td> </tr> <tr> <td>HIV/AIDS</td> </tr> <tr> <td>Other systemic infection</td> </tr> <tr> <td class=\"subtitle1_single\">Other causes</td> </tr> <tr> <td>Familial hemiplegic migraine</td> </tr> <tr> <td>Pituitary apoplexy</td> </tr> <tr> <td>Rhinosinusitis</td> </tr> <tr> <td>Subarachnoid hemorrhage</td> </tr> <tr> <td>Malignancy of central nervous system</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 80966 Version 3.0</div></div></div>"},"80967":{"type":"graphic_picture","displayName":"Palpation sacroiliac joint","title":"Palpation of the sacroiliac joint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palpation of the sacroiliac joint</div><div class=\"cntnt\"><img style=\"width:331px; height:304px;\" src=\"images/EM/80967_Palpation_sacroiliac_joint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sacroiliac joint is palpated for local tenderness in patients in whom an intrinsic hip condition is unlikely but who complain of posterior hip pain. The sacroiliac joint is located 1 inch medial and 1 inch inferior to the posterior superior iliac spine. The patient is placed in the prone position. Firm to hard pressure is placed directly over the upper portion of the sacroiliac joint. Sacroiliac strain and sacroiliitis cause focal tenderness, approximately the size of a half dollar. Diffuse tenderness extending over a wide area is seen with severe paraspinal muscle spasm. Local tenderness that does not conform to the typical area of the joint should suggest involvement of the adjacent bone.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 80967 Version 2.0</div></div></div>"},"80968":{"type":"graphic_picture","displayName":"ECD lesion biopsy","title":"Erdheim-Chester disease lesion biopsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erdheim-Chester disease lesion biopsy</div><div class=\"cntnt\"><img style=\"width:440px; height:440px;\" src=\"images/HEME/80968_ECD_lesion_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure demonstrates a representative hematoxylin/eosin-stained ECD lesion biopsy sample from a retroperitoneal, perinephric infiltrate (400x magnification). It shows the bland histiocytic infiltrate with foamy (xanthomatous) cytoplasm and interspersed inflammatory cells.</div><div class=\"graphic_reference\">Reproduced with permission of the American Society of Hematology, from Allen CE, McClain KL, Erdheim-Chester: beyond the lesion, Blood 2011; 117:2745, Copyright © 2011; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 80968 Version 13.0</div></div></div>"},"80969":{"type":"graphic_figure","displayName":"Venoarterial ECMO","title":"Veno-arterial (VA) ECMO for cardiac and/or respiratory failure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Veno-arterial (VA) ECMO for cardiac and/or respiratory failure</div><div class=\"cntnt\"><img style=\"width:360px; height:454px;\" src=\"images/PULM/80969_Venoarterial_ECMO.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Demonstrated here with right internal jugular vein drainage and right carotid artery infusion.</div><div class=\"graphic_reference\">Reproduced from: Van Meurs, K, Lally, KP, Peek, G, Zwischenberger, JB. ECMO: Extracorporeal Cardiopulmonary Support in critical care, Extracorporeal Life Support Organization, Ann Arbor 2005.</div><div id=\"graphicVersion\">Graphic 80969 Version 1.0</div></div></div>"},"80970":{"type":"graphic_diagnosticimage","displayName":"Tracheal stenosis in GPA","title":"Tracheal stenosis in granulomatosis with polyangiitis (Wegener's)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tracheal stenosis in granulomatosis with polyangiitis (Wegener's)</div><div class=\"cntnt\"><img style=\"width:238px; height:412px;\" src=\"images/PULM/80970_Wegeners_tomogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Conventional tomogram shows moderate cervical tracheal stenosis due to granulomatosis with polyangiitis (Wegener's).</div><div id=\"graphicVersion\">Graphic 80970 Version 4.0</div></div></div>"},"80971":{"type":"graphic_table","displayName":"Dosing of antiviral medications for genital HSV","title":"Dosing of antiviral medications for adults with genital herpes simplex virus infection in persons with HIV","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosing of antiviral medications for adults with genital herpes simplex virus infection in persons with HIV</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical setting</td> <td class=\"subtitle1\">Acyclovir*</td> <td class=\"subtitle1\">Valacyclovir</td> <td class=\"subtitle1\">Famciclovir</td> </tr> <tr> <td>First episode or recurrence</td> <td>400 mg orally three times daily for 5 to 10 days<sup>&#182;</sup></td> <td>1 gram orally twice daily for 5 to10 days<sup>&#182;</sup></td> <td> <p>500 mg orally twice daily for 5 to10 days<sup>&#182;</sup></p> </td> </tr> <tr> <td>Suppression</td> <td>400 to 800 mg orally twice daily or three times daily</td> <td>500 mg orally twice daily</td> <td>500 mg orally twice daily</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; HSV: herpes simplex virus.<br />* Intravenous (IV) acyclovir therapy should be provided for patients who have severe HSV disease or complications that necessitate hospitalization.<br />¶ Length of therapy dependent upon resolution of lesions. Therapy should be continued for longer than 10 days if lesions persist.</div><div class=\"graphic_reference\">Reproduced from: Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59(RR-12):23-4.</div><div id=\"graphicVersion\">Graphic 80971 Version 3.0</div></div></div>"},"80972":{"type":"graphic_table","displayName":"Obesity and obstetric complications","title":"Results of multivariable logistic regression analysis showing the relation between obesity and selected maternal outcomes, singleton deliveries, Nova Scotia, 1988 to 2002","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Results of multivariable logistic regression analysis showing the relation between obesity and selected maternal outcomes, singleton deliveries, Nova Scotia, 1988 to 2002</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Maternal morbidity</td> <td class=\"subtitle1\" colspan=\"2\">Moderate obesity (n = 9355)</td> </tr> <tr> <td class=\"subtitle2\">Adjusted OR*</td> <td class=\"subtitle2\">95% CI</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antepartum</td> </tr> <tr> <td class=\"indent1\">PIH</td> <td class=\"centered\">2.38</td> <td class=\"centered\">2.24-2.52</td> </tr> <tr> <td class=\"indent1\">Severe PIH (including HELLP)</td> <td class=\"centered\">1.56</td> <td class=\"centered\">1.35-1.8</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Gestational diabetes</td> <td class=\"centered\">2.8</td> <td class=\"centered\">2.54-3.08</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Intrapartum</td> </tr> <tr> <td class=\"indent1\">Very PTB (&#60;32 weeks)</td> <td class=\"centered\">0.89</td> <td class=\"centered\">0.7-1.12</td> </tr> <tr> <td class=\"indent1\">PTB (&#60;37 weeks)</td> <td class=\"centered\">0.96</td> <td class=\"centered\">0.87-1.05</td> </tr> <tr> <td class=\"indent1\">Post-term (&#62;41 weeks)</td> <td class=\"centered\">1.18</td> <td class=\"centered\">1.08-1.28</td> </tr> <tr> <td class=\"indent1\">Labor induction</td> <td class=\"centered\">1.94</td> <td class=\"centered\">1.86-2.04</td> </tr> <tr> <td class=\"indent1\">Cesarean delivery</td> <td class=\"centered\">1.6</td> <td class=\"centered\">1.53-1.67</td> </tr> <tr> <td class=\"indent1\">Anesthesia complications</td> <td class=\"centered\">1.18</td> <td class=\"centered\">1-1.39</td> </tr> <tr> <td class=\"indent1\">Augmentation</td> <td class=\"centered\">1.25</td> <td class=\"centered\">1.18-1.33</td> </tr> <tr> <td class=\"indent1\">Prolonged second stage (&#62;3 hours)</td> <td class=\"centered\">0.96</td> <td class=\"centered\">0.88-1.05</td> </tr> <tr> <td class=\"indent1\">Shoulder dystocia</td> <td class=\"centered\">1.51</td> <td class=\"centered\">1.32-1.74</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Third- or fourth-degree laceration<sup>&#182;</sup></td> <td class=\"centered\">0.9</td> <td class=\"centered\">0.72-1.11</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Postpartum</td> </tr> <tr> <td class=\"indent1\">Postpartum hemorrhage</td> <td class=\"centered\">1.12</td> <td class=\"centered\">1.02-1.22</td> </tr> <tr> <td class=\"indent1\">Pyrexia</td> <td class=\"centered\">1.07</td> <td class=\"centered\">0.95-1.19</td> </tr> <tr> <td class=\"indent1\">Puerperal morbidity</td> <td class=\"centered\">1.12</td> <td class=\"centered\">0.9-1.4</td> </tr> <tr> <td class=\"indent1\">Endometritis</td> <td class=\"centered\">1.04</td> <td class=\"centered\">0.77-1.42</td> </tr> <tr> <td class=\"indent1\">Urinary tract infection</td> <td class=\"centered\">1.15</td> <td class=\"centered\">0.95-1.39</td> </tr> <tr> <td class=\"indent1\">Wound infection</td> <td class=\"centered\">1.67</td> <td class=\"centered\">1.38-2</td> </tr> <tr> <td class=\"indent1\">Wound dehiscence</td> <td class=\"centered\">1.85</td> <td class=\"centered\">1.1-3.11</td> </tr> <tr> <td class=\"indent1\">Prolonged hospital stay (&#62;3 days)</td> <td class=\"centered\">0.89</td> <td class=\"centered\">0.85-0.93</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Comparison group = 79,005 non-obese women.</div><div class=\"graphic_footnotes\">OR: odds ratio; PIH: pregnancy-induced hypertension; HELLP: syndrome of hemolysis, elevated liver enzymes, and low platelets; PTB: preterm birth.<br />* Adjusted for maternal age, marital status, smoking, parity, and socioeconomic status.<br />¶ Third- or fourth-degree laceration limited to those delivered vaginally.</div><div class=\"graphic_reference\">Data from: Robinson HE, O'Connell CM, Joseph KS, McLeod NL. Maternal outcomes in pregnancies complicated by obesity. Obstet Gynecol 2005; 106:1357.</div><div id=\"graphicVersion\">Graphic 80972 Version 6.0</div></div></div>"},"80973":{"type":"graphic_figure","displayName":"Carpal bone angles","title":"Carpal bone angles","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Carpal bone angles</div><div class=\"cntnt\"><img style=\"width:532px; height:639px;\" src=\"images/PEDS/80973_Carpal_bone_angles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Measurement of the carpal bone angles helps to indentify carpal instability. The normal angle is depicted in the left image of each group. The drawing on the right depicts abnormal angles when there is a dorsal intercalation scaphoid pattern of carpal instability. A scapholunate angle of &gt;80° indicates scapholunate dissociation or volarly displaced scaphoid fracture. The capitolunate angle is usually less than 15°. The radiolunate angle is normally &lt;15°.</div><div id=\"graphicVersion\">Graphic 80973 Version 3.0</div></div></div>"},"80975":{"type":"graphic_diagnosticimage","displayName":"Meconium peritonitis","title":"Meconium peritonitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Meconium peritonitis</div><div class=\"cntnt\"><img style=\"width:396px; height:374px;\" src=\"images/OBGYN/80975_Meconium_peritonitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Meconium peritonitis with calcifications outlining the liver. Sagittal view of the fetal torso at 18 weeks of gestation shows punctuate calcifications lining the liver in this fetus with meconium peritonitis.</div><div class=\"graphic_footnotes\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 80975 Version 3.0</div></div></div>"},"80980":{"type":"graphic_figure","displayName":"Minimum-dose heparin in HD","title":"Schematic diagram showing minimum-dose heparin regimen in hemodialysis","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Schematic diagram showing minimum-dose heparin regimen in hemodialysis</div><div class=\"cntnt\"><img style=\"width:528px; height:427px;\" src=\"images/NEPH/80980_Minimum_dose_heparin_in_HD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic diagram illustrating the minimum-dose heparin regimen for anticoagulation during hemodialysis.</div><div id=\"graphicVersion\">Graphic 80980 Version 5.0</div></div></div>"},"80982":{"type":"graphic_picture","displayName":"Thumb spica cast 4","title":"Thumb spica cast: Step 4","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thumb spica cast: Step 4</div><div class=\"cntnt\"><img style=\"width:432px; height:330px;\" src=\"images/EM/80982_Thumb_spica_cast_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After placing the covered thumb through the hole in the stockinette, be sure all the material is as smooth as possible before beginning to apply the webril or other synthetic cast underpadding.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 80982 Version 5.0</div></div></div>"},"80984":{"type":"graphic_diagnosticimage","displayName":"Interscalene block ultrasound","title":"Interscalene block ultrasound","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Interscalene block ultrasound</div><div class=\"cntnt\"><img style=\"width:516px; height:268px;\" src=\"images/SURG/80984_Interscalene_block_US_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With an ultrasound-guided technique, the probe is placed in a transverse position just above the clavicle. The nerves of the brachial plexus appear lateral to the subclavian artery and are traced cephalad. At the C6 level, the nerves of the brachial plexus are visualized in a vertical orientation within the interscalene groove (ie, between the anterior and middle scalene muscles).</div><div class=\"graphic_footnotes\">m.: muscle.</div><div id=\"graphicVersion\">Graphic 80984 Version 6.0</div></div></div>"},"80985":{"type":"graphic_figure","displayName":"Outcome liver TPL in HDV","title":"Higher survival after liver transplantation with hepatitis D virus than hepatitis B virus","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Higher survival after liver transplantation with hepatitis D virus than hepatitis B virus</div><div class=\"cntnt\"><img style=\"width:452px; height:391px;\" src=\"images/GAST/80985_Outcome_liver_TPL_in_HDV.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Actuarial survival according to initial type of hepatitis in a large cohort of European patients undergoing liver transplantation. Survival was better in patients with cirrhosis infected with HDV (top curve) than with HBV (bottom curve).</div><div class=\"graphic_footnotes\">HDV-C, HDV-related cirrhosis; F-HBV, fulminant HBV; F-HDV, fulminant HDV; HBV-C, HBV-related cirrhosis.</div><div class=\"graphic_reference\">Data from Samuel, D, Muller, Alexander, G, et al, N Engl J Med 1993; 329:1842.</div><div id=\"graphicVersion\">Graphic 80985 Version 2.0</div></div></div>"},"80987":{"type":"graphic_diagnosticimage","displayName":"Spinal cord myxopapillary ependymoma","title":"Spinal cord myxopapillary ependymoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spinal cord myxopapillary ependymoma</div><div class=\"cntnt\"><img style=\"width:360px; height:250px;\" src=\"images/ONC/80987_Spinal_cord_myxopap_epend_M.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal and axial contrast-enhanced magnetic resonance imaging study of a small, cauda equine lesion (arrow) found in a 49-year-old woman with left buttock and leg pain. Complete resection was performed and the diagnosis of myxopapillary ependymoma was confirmed.</div><div class=\"graphic_reference\">Courtesy of William Welch, MD.</div><div id=\"graphicVersion\">Graphic 80987 Version 3.0</div></div></div>"},"80989":{"type":"graphic_diagnosticimage","displayName":"Rickets wrist","title":"Anteroposterior radiograph of the wrist and hand in a child with rickets","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Anteroposterior radiograph of the wrist and hand in a child with rickets</div><div class=\"cntnt\"><img style=\"width:598px; height:339px;\" src=\"images/RADIOL/80989_Rickets_wrist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Rickets. Anteroposterior radiograph of the wrist and hand in a 3-year-old child with nutritional rickets. The child had been put on a strict diet without dairy products. Note the widening, cupping, and fraying of the distal radius (arrowhead) and ulna metaphyses with an associated increase in the thickness of the growth plate (arrow). These changes are the consequence of disordered endochondral growth.<br />(B) Normal. Radiograph of the hand of a healthy 3-year-old child, without rickets.</div><div class=\"graphic_reference\">Panel A reproduced with permission from: Rao SB, Crawford AH. Traumatic and Acquired Wrist Disorders in Children. In: The Wrist and its Disorders, Lichtman DM, Alexander AH (Eds), WB Saunders, 1999. Copyright &copy; 1999 Elsevier.<br />Panel B courtesy of: Lachlan Smith, MD.</div><div id=\"graphicVersion\">Graphic 80989 Version 6.0</div></div></div>"},"80991":{"type":"graphic_picture","displayName":"Optic disc Frisen grade 1","title":"Optic disc Frisén Grade I","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Optic disc Fris&#233;n Grade I</div><div class=\"cntnt\"><img style=\"width:450px; height:422px;\" src=\"images/NEURO/80991_Optic_disc_Frisen_grade_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fris&#233;n Grade I showing the C-shaped halo of disc edema with a temporal gap.</div><div class=\"graphic_reference\">Courtesy of Michael Wall, MD.</div><div id=\"graphicVersion\">Graphic 80991 Version 1.0</div></div></div>"},"80993":{"type":"graphic_picture","displayName":"Recipro gait orthosis","title":"Reciprocating gait orthosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reciprocating gait orthosis</div><div class=\"cntnt\"><img style=\"width:350px; height:451px;\" src=\"images/PEDS/80993_Recipro_gait_orthosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A child with myelomeningocele using a reciprocating gait orthosis.</div><div class=\"graphic_reference\">Courtesy of: Drs. Vineeta Swaroop and Luciano Dias.</div><div id=\"graphicVersion\">Graphic 80993 Version 2.0</div></div></div>"},"80994":{"type":"graphic_figure","displayName":"Lower leg fasciotomy landmarks","title":"Incisions for four compartment lower extremity fasciotomy","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Incisions for four compartment lower extremity fasciotomy</div><div class=\"cntnt\"><img style=\"width:495px; height:573px;\" src=\"images/SURG/80994_Right-leg-fasciotomy-landmarks.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The two incision four-compartment fasciotomy uses medial and lateral longitudinal incisions that are 12 to 20 cm in length. The lateral incision is centered between the fibular shaft and the spine of the tibia. The medial incision is placed 1 to 2 cm medial to the tibial margin. A single incision fasciotomy uses the lateral of these incisions.</div><div id=\"graphicVersion\">Graphic 80994 Version 3.0</div></div></div>"},"80995":{"type":"graphic_figure","displayName":"Jugular venous pulse in constrictive pericarditis","title":"Jugular venous pulse in constrictive pericarditis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Jugular venous pulse in constrictive pericarditis</div><div class=\"cntnt\"><img style=\"width:400px; height:339px;\" src=\"images/CARD/80995_Jugular_venous_pulse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal jugular venous pulse waveform is represented in blue. In comparison, the jugular venous pulse waveform in a patient with constrictive pericarditis (CP) is shown in red. Note the sharp, prominent y descent in CP, which represents rapid passive filling during early diastole that abruptly stops when the ventricular volume reaches the maximal capacity allowed by the stiff, thickened pericardium.</div><div id=\"graphicVersion\">Graphic 80995 Version 2.0</div></div></div>"},"80996":{"type":"graphic_waveform","displayName":"Atrial fibrillation WPW","title":"Episode of atrial fibrillation with rapid conduction to the ventricle via the accessory pathway in patient with Wolff-Parkinson-White syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Episode of atrial fibrillation with rapid conduction to the ventricle via the accessory pathway in patient with Wolff-Parkinson-White syndrome</div><div class=\"cntnt\"><img style=\"width:348px; height:236px;\" src=\"images/PEDS/80996_Atrial_fibrillation_WPW.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 80996 Version 2.0</div></div></div>"},"80997":{"type":"graphic_figure","displayName":"Exercise testing in IPF","title":"Exercise testing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Exercise testing</div><div class=\"cntnt\"><img style=\"width:410px; height:271px;\" src=\"images/PULM/80997_Exercise_testing_in_IPF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Exercise test in a woman who presented for evaluation of dyspnea on running and a dry cough of 18 months duration. She did not smoke or have a history of lung disease. The chest x-ray and lung function tests were normal. Her resting room air arterial blood gases (elevation 5000 feet) revealed PO2: 78; PCO2: 34; pH: 7.43; Sat: 94 percent; AaO2: 3.8. The patient performed an exercise test on a cycle ergometer. The work rate was increased 10 watts per minute to her symptom limited maximum. Blood was sampled every minute from an indwelling catheter. Her resting and exercise ECG was normal. The patient achieved 94 watts (65 percent of predicted workload). The PO2 decreased, AaO2 increased, and minute ventilation (Ve) increased systematically with increasing work rate (shown as the percent of predicted maximal VO2). The study was stopped because of mild shortness of breath and leg fatigue. Lung biopsy revealed UIP.</div><div id=\"graphicVersion\">Graphic 80997 Version 1.0</div></div></div>"},"80998":{"type":"graphic_picture","displayName":"Erythema annulare centrifugum - light skin","title":"Superficial erythema annulare centrifugum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial erythema annulare centrifugum</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/80998_Eryth_ann_cent_light_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular, erythematous plaques with \"trailing scale\" are classic features of superficial erythema annulare centrifugum.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 80998 Version 4.0</div></div></div>"},"80999":{"type":"graphic_table","displayName":"Hamstring injury prevention program","title":"Hamstring injury prevention program","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hamstring injury prevention program</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td colspan=\"3\">This table outlines a hamstring injury prevention program for athletes at high-risk for recurrent strain.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"3\">3 days per week maintenance and prevention:</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Warm-up: Stationary bike or light jogging, 5 minutes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Exercises</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">1. Side shuffle: 30 m, 3 x 1 min</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">2. Grapevine jog: 30 m, 3 x 1 min</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">3. Boxer shuffle: 30 m, 3 x 1 min</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">4. Advanced skipping: A hop-step forward movement that alternates from leg to leg and mimics arm position in running. During the hop, the opposite knee is lifted in a flexed position. Then the opposite knee extends prior to hip extension, recreating the terminal swing phase of running. The leg is then pulled backward in a pawing type action.</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">5. Forward-backward accelerations, 3 x 1 min, start at 10 m, progress to 20 m</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">6. Rotating body bridge, 5 second hold each side, 2 x 10 reps. Advance to performing with dumbbells as able.</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">a. Begin in push-up extended position, then rotate to side plank position with arm extended, hold for 5 seconds, then rotate torso placing weight on opposite arm in side plank position on this side and repeat</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">7. Supine single-limb chair bridge, 3 x 15 reps</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">8. Single-limb balance windmill touches, 3 x 15. Advance to performing with dumbbells as able.</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">a. Balance on 1 leg, rotate trunk to touch cone alternating right and left hands, twisting at torso</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Eccentric hamstring strengthening</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Include in the prevention program a progression of eccentric hamstring strengthening exercises, such as the following:</td> </tr> <tr> <td class=\"subtitle3_single\" colspan=\"3\">Nordic hamstring exercise (\"Nordic lowers\"):</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">1. Kneel on the ground and stabilize your lower legs by having a partner push down firmly on the back of your ankles or by wedging your feet or ankles under a heavy object</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">2. While keeping your body perfectly straight from your knees to the top of your head, and with your hands placed just in front of your chest, slowly lower your torso until your hands touch the ground</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">3. Push yourself back up to the kneeling position and repeat for suggested number of repetitions</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">Note that this exercise is challenging; progress slowly</td> </tr> <tr class=\"divider_top\"> <td colspan=\"3\">The following schedule can be used for the Nordic hamstring exercise:</td> </tr> <tr> <td>&nbsp;</td> <td><strong>Sessions per week</strong></td> <td><strong>Sets and repetitions</strong></td> </tr> <tr> <td>Week 1:</td> <td>1</td> <td>2 x 5</td> </tr> <tr> <td>Week 2:</td> <td>2</td> <td>2 x 6</td> </tr> <tr> <td>Week 3:</td> <td>3</td> <td>3 x 6-8</td> </tr> <tr> <td>Week 4:</td> <td>3</td> <td>3 x 8-10</td> </tr> <tr> <td>Week 5 (and thereafter):</td> <td>3</td> <td>1 x 12, 1 x 10, 1 x 8</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:<br> <ol> <li>Heiderscheit BC, Sherry MA, Silder A, et al. Hamstring strain injuries: recommendations for diagnosis, rehabilitation, and injury prevention. J Orthop Sports Phys Ther 2010; 40:67. </li> <li>Mj&#248;lsnes R, Arnason A, &#216;sthagen T, et al. A 10-week randomized trial comparing eccentric vs. concentric hamstring strength training in well-trained soccer players. Scand J Med Sci Sports 2004; 14:311. </li> <li>Arnason A, Andersen TE, Holme I, et al. Prevention of hamstring strains in elite soccer: an intervention study. Scand J Med Sci Sports 2008; 18:40. </li> </ol></div><div id=\"graphicVersion\">Graphic 80999 Version 2.0</div></div></div>"}};